<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="0" size="11" family="Times" color="#ffffff"/>
	<fontspec id="1" size="26" family="Times" color="#0e2a52"/>
	<fontspec id="2" size="9" family="Times" color="#000000"/>
	<fontspec id="3" size="9" family="Times" color="#4c4c4c"/>
	<fontspec id="4" size="9" family="Times" color="#327eb1"/>
	<fontspec id="5" size="6" family="Times" color="#000000"/>
	<fontspec id="6" size="6" family="Times" color="#327eb1"/>
	<fontspec id="7" size="8" family="Times" color="#000000"/>
	<fontspec id="8" size="8" family="Times" color="#327eb1"/>
	<fontspec id="9" size="5" family="Times" color="#000000"/>
<text top="142" left="161" width="428" height="17" font="0">CLINICAL PRACTICE GUIDELINE: EXECUTIVE SUMMARY</text>
<text top="185" left="159" width="458" height="25" font="1">2018 AHA/ACC Guideline for the</text>
<text top="221" left="159" width="393" height="25" font="1">Management of Adults With</text>
<text top="257" left="159" width="358" height="25" font="1">Congenital Heart Disease:</text>
<text top="293" left="159" width="276" height="25" font="1">Executive Summary</text>
<text top="342" left="161" width="421" height="12" font="2">A Report of the American College of Cardiology/American Heart Association</text>
<text top="360" left="161" width="232" height="12" font="2">Task Force on Clinical Practice Guidelines</text>
<text top="389" left="161" width="525" height="12" font="3">Developed in Collaboration with the American Association for Thoracic Surgery, American Society of</text>
<text top="408" left="161" width="520" height="12" font="3">Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease,</text>
<text top="428" left="161" width="482" height="12" font="3">Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons</text>
<text top="502" left="57" width="40" height="12" font="3">Writing</text>
<text top="520" left="57" width="60" height="12" font="3">Committee</text>
<text top="538" left="57" width="51" height="12" font="3"><a href="">Members</a></text>
<text top="538" left="107" width="6" height="12" font="4"><a href="">*</a></text>
<text top="502" left="161" width="183" height="12" font="2">Karen K. Stout, MD, FACC, <a href="">Chair</a></text>
<text top="501" left="343" width="5" height="15" font="4"><a href="">y</a></text>
<text top="520" left="161" width="170" height="12" font="2">Curt J. Daniels, MD, Vice <a href="">Chair</a></text>
<text top="520" left="331" width="5" height="12" font="4"><a href="">*</a></text>
<text top="518" left="337" width="10" height="15" font="4"><a href="">yz</a></text>
<text top="556" left="161" width="212" height="12" font="2">Jamil A. Aboulhosn, MD, FACC, <a href="">FSCAI</a></text>
<text top="556" left="373" width="5" height="12" font="4"><a href="">*</a></text>
<text top="554" left="379" width="5" height="15" font="4"><a href="">x</a></text>
<text top="574" left="161" width="129" height="12" font="2">Biykem Bozkurt, MD, P</text>
<text top="577" left="290" width="6" height="8" font="5">H</text>
<text top="574" left="297" width="86" height="12" font="2">D, FACC, FAHA</text>
<text top="572" left="383" width="6" height="15" font="4"><a href="">k</a></text>
<text top="592" left="161" width="153" height="12" font="2">Craig S. Broberg, MD, FACC</text>
<text top="592" left="314" width="5" height="12" font="4"><a href="">*</a></text>
<text top="590" left="319" width="5" height="15" font="4"><a href="">y</a></text>
<text top="610" left="161" width="152" height="12" font="2">Jack M. Colman, MD, FACC</text>
<text top="608" left="313" width="5" height="15" font="4"><a href="">y</a></text>
<text top="628" left="161" width="171" height="12" font="2">Stephen R. Crumb, DNP, <a href="">AACC</a></text>
<text top="626" left="332" width="5" height="15" font="4"><a href="">y</a></text>
<text top="646" left="161" width="164" height="12" font="2">Joseph A. Dearani, MD, FACC</text>
<text top="644" left="325" width="7" height="15" font="4"><a href="">{</a></text>
<text top="664" left="161" width="180" height="12" font="2">Stephanie Fuller, MD, MS, FACC</text>
<text top="664" left="341" width="7" height="12" font="4"><a href="">#</a></text>
<text top="682" left="161" width="155" height="12" font="2">Michelle Gurvitz, MD, <a href="">FACC</a></text>
<text top="682" left="316" width="11" height="12" font="4"><a href="">**</a></text>
<text top="700" left="161" width="105" height="12" font="2">Paul Khairy, MD, P</text>
<text top="702" left="266" width="6" height="8" font="5">H</text>
<text top="700" left="272" width="8" height="12" font="2"><a href="">D</a></text>
<text top="700" left="280" width="5" height="12" font="4"><a href="">*</a></text>
<text top="698" left="286" width="5" height="15" font="4"><a href="">y</a></text>
<text top="718" left="161" width="181" height="12" font="2">Michael J. Landzberg, MD, <a href="">FACC</a></text>
<text top="718" left="342" width="5" height="12" font="4"><a href="">*</a></text>
<text top="716" left="348" width="5" height="15" font="4"><a href="">y</a></text>
<text top="735" left="161" width="154" height="12" font="2">Arwa Saidi, MB, BCH, <a href="">FACC</a></text>
<text top="735" left="315" width="5" height="12" font="4"><a href="">*</a></text>
<text top="734" left="321" width="5" height="15" font="4"><a href="">y</a></text>
<text top="502" left="488" width="251" height="12" font="2">Anne Marie Valente, MD, FACC, FAHA, FASE</text>
<text top="501" left="739" width="10" height="15" font="4"><a href="">yy</a></text>
<text top="520" left="488" width="173" height="12" font="2">George F. Van Hare, MD, FACC</text>
<text top="518" left="661" width="10" height="15" font="4"><a href="">zz</a></text>
<text top="571" left="488" width="298" height="9" font="5">*Writing committee members are required to recuse themselves from</text>
<text top="585" left="488" width="164" height="9" font="5">voting on sections to which their speci</text>
<text top="584" left="652" width="149" height="12" font="5">ﬁc relationships with industry may</text>
<text top="600" left="488" width="43" height="9" font="5">apply; see</text>
<text top="600" left="534" width="48" height="9" font="6"><a href="">Appendix 1</a></text>
<text top="600" left="584" width="101" height="9" font="5">for recusal information.</text>
<text top="598" left="687" width="114" height="12" font="5"><a href="">y</a>ACC/AHA Representative.</text>
<text top="612" left="488" width="313" height="12" font="5"><a href="">z</a>International Society for Adult Congenital Heart Disease Representative.</text>
<text top="626" left="488" width="252" height="12" font="5"><a href="">x</a>Society for Cardiovascular Angiography and Interventions</text>
<text top="642" left="488" width="67" height="9" font="5">Representative.</text>
<text top="641" left="558" width="228" height="12" font="5"><a href="">k</a>ACC/AHA Task Force on Clinical Practice Guidelines</text>
<text top="656" left="488" width="33" height="9" font="5">Liaison.</text>
<text top="655" left="524" width="247" height="12" font="5"><a href="">{Society </a>of Thoracic Surgeons Representative. #American</text>
<text top="670" left="488" width="309" height="9" font="5">Association for Thoracic Surgery Representative. **ACC/AHA Task Force</text>
<text top="685" left="488" width="147" height="9" font="5">on Performance Measures Liaison.</text>
<text top="683" left="638" width="93" height="12" font="5"><a href="">yy</a>American Society of</text>
<text top="699" left="488" width="146" height="9" font="5">Echocardiography Representative.</text>
<text top="697" left="637" width="102" height="12" font="5"><a href="">zzHeart </a>Rhythm Society</text>
<text top="713" left="488" width="67" height="9" font="5">Representative.</text>
<text top="1120" left="57" width="108" height="9" font="7">ISSN 0735-1097/$36.00</text>
<text top="1120" left="613" width="188" height="9" font="8"><a href="https://doi.org/10.1016/j.jacc.2018.08.1028">https://doi.org/10.1016/j.jacc.2018.08.1028</a></text>
<text top="925" left="170" width="631" height="9" font="5">This document was approved by the American College of Cardiology Clinical Policy Approval Committee in May 2018, the American Heart Association</text>
<text top="939" left="161" width="568" height="9" font="5">Science Advisory and Coordinating Committee in June 2018, and the American Heart Association Executive Committee in July 2018.</text>
<text top="953" left="170" width="631" height="9" font="5">The American College of Cardiology requests that this document be cited as follows: Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS,</text>
<text top="967" left="161" width="640" height="9" font="5">Colman JM, Crumb SR, Dearani JA, Fuller S, Gurvitz M, Khairy P, Landzberg MJ, Saidi A, Valente AM, Van Hare GF. 2018 AHA/ACC guideline for the</text>
<text top="982" left="161" width="640" height="9" font="5">management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology/American Heart Association</text>
<text top="996" left="161" width="316" height="9" font="5">Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;73:1494</text>
<text top="994" left="477" width="22" height="12" font="5">–563.</text>
<text top="1010" left="170" width="206" height="9" font="5">This article has been copublished in Circulation.</text>
<text top="1024" left="170" width="450" height="9" font="5">Copies: This document is available on the World Wide Web sites of the American College of Cardiology <a href="http://www.acc.org">(</a></text>
<text top="1024" left="620" width="55" height="9" font="6"><a href="http://www.acc.org">www.acc.org</a></text>
<text top="1024" left="675" width="126" height="9" font="5">) and the American Heart As-</text>
<text top="1038" left="161" width="45" height="9" font="5">sociation (</text>
<text top="1038" left="206" width="93" height="9" font="6"><a href="http://professional.heart.org">professional.heart.org</a></text>
<text top="1038" left="298" width="503" height="9" font="5">). For copies of this document, please contact the Elsevier Inc. Reprint Department via fax (212-633-3820) or e-mail</text>
<text top="1053" left="161" width="3" height="9" font="5">(</text>
<text top="1053" left="164" width="95" height="9" font="6"><a href="mailto:reprints@elsevier.com">reprints@elsevier.com</a></text>
<text top="1053" left="259" width="6" height="9" font="5">).</text>
<text top="1067" left="170" width="152" height="9" font="5">Permissions: Multiple copies, modi</text>
<text top="1065" left="321" width="480" height="12" font="5">ﬁcation, alteration, enhancement, and/or distribution of this document are not permitted without the express</text>
<text top="1081" left="161" width="464" height="9" font="5">permission of the American College of Cardiology. Requests may be completed online via the Elsevier site <a href="https://www.elsevier.com/about/policies/copyright/permissions">(</a></text>
<text top="1081" left="624" width="177" height="9" font="6"><a href="https://www.elsevier.com/about/policies/copyright/permissions">https://www.elsevier.com/about/policies/</a></text>
<text top="1095" left="161" width="95" height="9" font="6"><a href="https://www.elsevier.com/about/policies/copyright/permissions">copyright/permissions</a></text>
<text top="1095" left="256" width="6" height="9" font="5"><a href="https://www.elsevier.com/about/policies/copyright/permissions">).</a></text>
<text top="54" left="161" width="256" height="7" font="9">J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y</text>
<text top="54" left="703" width="99" height="7" font="9">V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="67" left="161" width="272" height="7" font="9">© 2 0 1 9 B Y T H E A M E R I C A N H E A R T A S S O C I A T I O N , I N C . , A N D</text>
<text top="81" left="161" width="239" height="7" font="9">A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N .</text>
<text top="94" left="161" width="113" height="7" font="9">P U B L I S H E D B Y E L S E V I E R</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="10" size="11" family="Times" color="#e3202b"/>
	<fontspec id="11" size="8" family="Times" color="#e3202b"/>
	<fontspec id="12" size="9" family="Times" color="#0e2a52"/>
	<fontspec id="13" size="7" family="Times" color="#000000"/>
<text top="143" left="63" width="80" height="12" font="3">ACC/AHA Task</text>
<text top="161" left="63" width="84" height="12" font="3">Force Members</text>
<text top="143" left="167" width="231" height="12" font="2">Glenn N. Levine, MD, FACC, FAHA, Chair</text>
<text top="161" left="167" width="65" height="12" font="2">Patrick T. O</text>
<text top="159" left="232" width="204" height="15" font="2">’Gara, MD, MACC, FAHA, Chair-Elect</text>
<text top="179" left="167" width="224" height="12" font="2">Jonathan L. Halperin, MD, FACC, FAHA,</text>
<text top="197" left="167" width="118" height="12" font="2">Immediate Past Chair</text>
<text top="233" left="167" width="104" height="12" font="2">Nancy M. Albert, P</text>
<text top="235" left="271" width="6" height="8" font="5">H</text>
<text top="233" left="277" width="72" height="12" font="2">D, RN, FAHA</text>
<text top="231" left="350" width="10" height="15" font="4"><a href="">xx</a></text>
<text top="250" left="167" width="238" height="12" font="2">Sana M. Al-Khatib, MD, MHS, FACC, FAHA</text>
<text top="268" left="167" width="199" height="12" font="2">Joshua A. Beckman, MD, MS, FAHA</text>
<text top="286" left="167" width="100" height="12" font="2">Kim K. Birtcher, P</text>
<text top="289" left="267" width="25" height="8" font="5">HARM</text>
<text top="286" left="292" width="71" height="12" font="2">D, MS, AACC</text>
<text top="304" left="167" width="129" height="12" font="2">Biykem Bozkurt, MD, P</text>
<text top="307" left="296" width="6" height="8" font="5">H</text>
<text top="304" left="302" width="86" height="12" font="2">D, FACC, <a href="">FAHA</a></text>
<text top="302" left="388" width="10" height="15" font="4"><a href="">xx</a></text>
<text top="322" left="167" width="192" height="12" font="2">Ralph G. Brindis, MD, MPH, MACC</text>
<text top="320" left="359" width="10" height="15" font="4"><a href="">xx</a></text>
<text top="340" left="167" width="172" height="12" font="2">Joaquin E. Cigarroa, MD, FACC</text>
<text top="358" left="167" width="102" height="12" font="2">Lesley H. Curtis, P</text>
<text top="361" left="269" width="6" height="8" font="5">H</text>
<text top="358" left="275" width="48" height="12" font="2">D, <a href="">FAHA</a></text>
<text top="356" left="323" width="10" height="15" font="4"><a href="">xx</a></text>
<text top="376" left="167" width="211" height="12" font="2">Anita Deswal, MD, MPH, FACC, FAHA</text>
<text top="394" left="167" width="187" height="12" font="2">Lee A. Fleisher, MD, FACC, FAHA</text>
<text top="412" left="167" width="155" height="12" font="2">Federico Gentile, MD, FACC</text>
<text top="430" left="167" width="168" height="12" font="2">Samuel S. Gidding, MD, <a href="">FAHA</a></text>
<text top="428" left="334" width="10" height="15" font="4"><a href="">xx</a></text>
<text top="143" left="469" width="252" height="12" font="2">Zachary D. Goldberger, MD, MS, FACC, FAHA</text>
<text top="161" left="469" width="148" height="12" font="2">Mark A. Hlatky, MD, FACC</text>
<text top="178" left="469" width="133" height="12" font="2">John Ikonomidis, MD, P</text>
<text top="181" left="602" width="6" height="8" font="5">H</text>
<text top="178" left="608" width="48" height="12" font="2">D, FAHA</text>
<text top="196" left="469" width="164" height="12" font="2">José Joglar, MD, FACC, FAHA</text>
<text top="214" left="469" width="202" height="12" font="2">Richard J. Kovacs, MD, FACC, <a href="">FAHA</a></text>
<text top="213" left="670" width="10" height="15" font="4"><a href="">xx</a></text>
<text top="232" left="469" width="118" height="12" font="2">Laura Mauri, MD, MS</text>
<text top="235" left="587" width="5" height="8" font="5">C</text>
<text top="232" left="592" width="40" height="12" font="2">, FAHA</text>
<text top="250" left="469" width="166" height="12" font="2">E. Magnus Ohman, MD, FACC</text>
<text top="248" left="635" width="10" height="15" font="4"><a href="">xx</a></text>
<text top="268" left="469" width="134" height="12" font="2">Mariann R. Piano, RN, P</text>
<text top="271" left="603" width="6" height="8" font="5">H</text>
<text top="268" left="609" width="88" height="12" font="2">D, FAHA, FAAN</text>
<text top="286" left="469" width="106" height="12" font="2">Susan J. Pressler, P</text>
<text top="289" left="575" width="6" height="8" font="5">H</text>
<text top="286" left="581" width="72" height="12" font="2">D, RN, <a href="">FAHA</a></text>
<text top="284" left="653" width="10" height="15" font="4"><a href="">xx</a></text>
<text top="304" left="469" width="94" height="12" font="2">Barbara Riegel, P</text>
<text top="307" left="563" width="6" height="8" font="5">H</text>
<text top="304" left="569" width="72" height="12" font="2">D, RN, FAHA</text>
<text top="322" left="469" width="191" height="12" font="2">Frank W. Sellke, MD, FACC, FAHA</text>
<text top="320" left="660" width="10" height="15" font="4"><a href="">xx</a></text>
<text top="340" left="469" width="197" height="12" font="2">Win-Kuang Shen, MD, FACC, <a href="">FAHA</a></text>
<text top="338" left="666" width="10" height="15" font="4"><a href="">xx</a></text>
<text top="358" left="469" width="187" height="12" font="2">Duminda N. Wijeysundera, MD, P</text>
<text top="361" left="656" width="6" height="8" font="5">H</text>
<text top="358" left="662" width="8" height="12" font="2">D</text>
<text top="407" left="469" width="249" height="12" font="5"><a href="">xx</a>Former Task Force member; current member during the</text>
<text top="423" left="469" width="60" height="9" font="5">writing effort.</text>
<text top="499" left="63" width="160" height="17" font="10">TABLE OF CONTENTS</text>
<text top="541" left="63" width="66" height="14" font="11">PREAMBLE</text>
<text top="541" left="131" width="235" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="542" left="371" width="25" height="11" font="2">1496</text>
<text top="573" left="67" width="106" height="14" font="11">1. INTRODUCTION</text>
<text top="573" left="178" width="189" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="574" left="371" width="25" height="11" font="2">1498</text>
<text top="599" left="80" width="218" height="12" font="12">1.1. Methodology and Evidence Review</text>
<text top="598" left="305" width="62" height="14" font="7">. . . . . . . . . .</text>
<text top="599" left="371" width="25" height="11" font="2">1498</text>
<text top="624" left="78" width="240" height="12" font="12">1.2. Organization of the Writing Committee</text>
<text top="623" left="325" width="42" height="14" font="7">. . . . . . .</text>
<text top="624" left="371" width="25" height="11" font="2">1499</text>
<text top="649" left="78" width="203" height="12" font="12">1.3. Document Review and Approval</text>
<text top="648" left="285" width="82" height="14" font="7">. . . . . . . . . . . . .</text>
<text top="649" left="371" width="25" height="11" font="2">1499</text>
<text top="674" left="77" width="150" height="12" font="12">1.4. Scope of the Guideline</text>
<text top="673" left="232" width="135" height="14" font="7">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="674" left="371" width="25" height="11" font="2">1499</text>
<text top="699" left="78" width="99" height="12" font="12">1.5. Abbreviations</text>
<text top="698" left="186" width="182" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="699" left="371" width="25" height="11" font="2">1500</text>
<text top="738" left="65" width="257" height="14" font="11">2. BACKGROUND AND PATHOPHYSIOLOGY</text>
<text top="738" left="331" width="36" height="14" font="7">. . . . . .</text>
<text top="739" left="373" width="23" height="11" font="2">1502</text>
<text top="764" left="78" width="215" height="12" font="12">2.1. Anatomic and Physiological Terms</text>
<text top="763" left="299" width="69" height="14" font="7">. . . . . . . . . . .</text>
<text top="764" left="373" width="23" height="11" font="2">1502</text>
<text top="789" left="77" width="121" height="12" font="12">2.2. Severity of ACHD</text>
<text top="788" left="206" width="162" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="789" left="373" width="23" height="11" font="2">1502</text>
<text top="814" left="77" width="136" height="12" font="12">2.3. The ACHD AP Classi</text>
<text top="812" left="214" width="41" height="15" font="12">ﬁcation</text>
<text top="813" left="259" width="109" height="14" font="7">. . . . . . . . . . . . . . . . .</text>
<text top="814" left="373" width="23" height="11" font="2">1502</text>
<text top="850" left="65" width="146" height="14" font="11">3. GENERAL PRINCIPLES</text>
<text top="850" left="218" width="149" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="851" left="372" width="25" height="11" font="2">1504</text>
<text top="875" left="85" width="106" height="12" font="12">3.1. ACHD Program</text>
<text top="875" left="199" width="169" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="876" left="372" width="25" height="11" font="2">1504</text>
<text top="900" left="84" width="104" height="12" font="12">3.2. Access to Care</text>
<text top="900" left="192" width="175" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="901" left="373" width="23" height="11" font="2">1505</text>
<text top="925" left="84" width="113" height="12" font="12">3.3. Delivery of Care</text>
<text top="925" left="206" width="162" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="926" left="373" width="23" height="11" font="2">1505</text>
<text top="950" left="82" width="256" height="12" font="12">3.4. Evaluation of Suspected and Known CHD</text>
<text top="950" left="345" width="22" height="14" font="7">. . . .</text>
<text top="951" left="373" width="23" height="11" font="2">1507</text>
<text top="971" left="110" width="133" height="12" font="2">3.4.1. Electrocardiogram</text>
<text top="970" left="249" width="115" height="14" font="7">. . . . . . . . . . . . . . . . . .</text>
<text top="971" left="373" width="23" height="11" font="2">1507</text>
<text top="991" left="109" width="193" height="12" font="2">3.4.2. Ionizing Radiation Principles</text>
<text top="990" left="309" width="56" height="14" font="7">. . . . . . . . .</text>
<text top="991" left="372" width="24" height="11" font="2">1508</text>
<text top="1011" left="109" width="132" height="12" font="2">3.4.3. Echocardiography</text>
<text top="1011" left="249" width="115" height="14" font="7">. . . . . . . . . . . . . . . . . .</text>
<text top="1012" left="372" width="24" height="11" font="2">1508</text>
<text top="1032" left="108" width="109" height="12" font="2">3.4.4. CMR Imaging</text>
<text top="1031" left="223" width="142" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1032" left="372" width="24" height="11" font="2">1508</text>
<text top="1052" left="109" width="210" height="12" font="2">3.4.5. Cardiac Computed Tomography</text>
<text top="1051" left="323" width="42" height="14" font="7">. . . . . . .</text>
<text top="1052" left="372" width="24" height="11" font="2">1509</text>
<text top="1072" left="108" width="163" height="12" font="2">3.4.6. Cardiac Catheterization</text>
<text top="1072" left="276" width="89" height="14" font="7">. . . . . . . . . . . . . .</text>
<text top="1073" left="372" width="24" height="11" font="2">1509</text>
<text top="1093" left="109" width="124" height="12" font="2">3.4.7. Exercise Testing</text>
<text top="1092" left="236" width="135" height="14" font="7">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="1093" left="374" width="22" height="11" font="2">1510</text>
<text top="538" left="444" width="140" height="12" font="12">3.5. Transition Education</text>
<text top="538" left="592" width="135" height="14" font="7">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="539" left="734" width="22" height="11" font="2">1510</text>
<text top="563" left="443" width="134" height="12" font="12">3.6. Exercise and Sports</text>
<text top="562" left="579" width="149" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="563" left="734" width="22" height="11" font="2">1510</text>
<text top="588" left="444" width="247" height="12" font="12">3.7. Mental Health and Neurodevelopmental</text>
<text top="603" left="468" width="34" height="12" font="12">Issues</text>
<text top="602" left="506" width="222" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="603" left="734" width="22" height="11" font="2">1510</text>
<text top="628" left="443" width="158" height="12" font="12">3.8. Endocarditis Prevention</text>
<text top="627" left="606" width="122" height="14" font="7">. . . . . . . . . . . . . . . . . . .</text>
<text top="628" left="736" width="20" height="11" font="2">1511</text>
<text top="653" left="443" width="161" height="12" font="12">3.9. Concomitant Syndromes</text>
<text top="652" left="612" width="115" height="14" font="7">. . . . . . . . . . . . . . . . . .</text>
<text top="653" left="736" width="20" height="11" font="2">1511</text>
<text top="678" left="438" width="177" height="12" font="12">3.10. Noncardiac Medical Issues</text>
<text top="677" left="619" width="109" height="14" font="7">. . . . . . . . . . . . . . . . .</text>
<text top="678" left="735" width="21" height="11" font="2">1512</text>
<text top="703" left="440" width="136" height="12" font="12">3.11. Noncardiac Surgery</text>
<text top="702" left="579" width="149" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="703" left="735" width="21" height="11" font="2">1512</text>
<text top="728" left="439" width="278" height="12" font="12">3.12. Pregnancy, Reproduction, and Sexual Health</text>
<text top="727" left="719" width="9" height="14" font="7">. .</text>
<text top="728" left="735" width="21" height="11" font="2">1513</text>
<text top="748" left="469" width="94" height="12" font="2">3.12.1. Pregnancy</text>
<text top="748" left="570" width="162" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="749" left="735" width="21" height="11" font="2">1513</text>
<text top="769" left="468" width="115" height="12" font="2">3.12.2. Contraception</text>
<text top="768" left="590" width="142" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="769" left="735" width="21" height="11" font="2">1513</text>
<text top="795" left="439" width="190" height="12" font="12">3.13. Heart Failure and Transplant</text>
<text top="794" left="632" width="95" height="14" font="7">. . . . . . . . . . . . . . .</text>
<text top="795" left="735" width="21" height="11" font="2">1513</text>
<text top="815" left="469" width="109" height="12" font="2">3.13.1. Heart Failure</text>
<text top="815" left="583" width="149" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="816" left="735" width="21" height="11" font="2">1513</text>
<text top="836" left="468" width="131" height="12" font="2">3.13.2. Heart Transplant</text>
<text top="835" left="603" width="129" height="14" font="7">. . . . . . . . . . . . . . . . . . . .</text>
<text top="836" left="734" width="22" height="11" font="2">1514</text>
<text top="862" left="438" width="109" height="12" font="12">3.14. Palliative Care</text>
<text top="861" left="553" width="175" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="862" left="734" width="22" height="11" font="2">1514</text>
<text top="887" left="439" width="78" height="12" font="12">3.15. Cyanosis</text>
<text top="886" left="519" width="208" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="887" left="734" width="22" height="11" font="2">1514</text>
<text top="912" left="438" width="225" height="12" font="12">3.16. Pharmacological Therapy for ACHD</text>
<text top="911" left="672" width="56" height="14" font="7">. . . . . . . . .</text>
<text top="912" left="735" width="21" height="11" font="2">1515</text>
<text top="950" left="424" width="125" height="14" font="11">4. SPECIFIC LESIONS</text>
<text top="950" left="558" width="169" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="951" left="735" width="21" height="11" font="2">1515</text>
<text top="976" left="440" width="102" height="12" font="12">4.1. Shunt Lesions</text>
<text top="975" left="546" width="182" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="976" left="735" width="21" height="11" font="2">1515</text>
<text top="996" left="466" width="138" height="12" font="2">4.1.1. Atrial Septal Defect</text>
<text top="995" left="612" width="115" height="14" font="7">. . . . . . . . . . . . . . . . . .</text>
<text top="996" left="735" width="21" height="11" font="2">1515</text>
<text top="1016" left="465" width="204" height="12" font="2">4.1.2. Anomalous Pulmonary Venous</text>
<text top="1031" left="498" width="68" height="12" font="2">Connections</text>
<text top="1030" left="572" width="155" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1031" left="735" width="21" height="11" font="2">1517</text>
<text top="1051" left="465" width="170" height="12" font="2">4.1.3. Ventricular Septal Defect</text>
<text top="1051" left="639" width="89" height="14" font="7">. . . . . . . . . . . . . .</text>
<text top="1052" left="734" width="22" height="11" font="2">1518</text>
<text top="1072" left="464" width="198" height="12" font="2">4.1.4. Atrioventricular Septal Defect</text>
<text top="1071" left="666" width="62" height="14" font="7">. . . . . . . . . .</text>
<text top="1072" left="733" width="23" height="11" font="2">1520</text>
<text top="1092" left="465" width="170" height="12" font="2">4.1.5. Patent Ductus Arteriosus</text>
<text top="1091" left="639" width="89" height="14" font="7">. . . . . . . . . . . . . .</text>
<text top="1092" left="733" width="23" height="11" font="2">1520</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="788" width="20" height="9" font="5">1495</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="14" size="9" family="Times" color="#e3202b"/>
<text top="143" left="123" width="195" height="12" font="12">4.2. Left-Sided Obstructive Lesions</text>
<text top="142" left="324" width="89" height="14" font="7">. . . . . . . . . . . . . .</text>
<text top="143" left="420" width="21" height="11" font="2">1521</text>
<text top="163" left="151" width="118" height="12" font="2">4.2.1. Cor Triatriatum</text>
<text top="162" left="277" width="135" height="14" font="7">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="163" left="420" width="21" height="11" font="2">1521</text>
<text top="183" left="150" width="178" height="12" font="2">4.2.2. Congenital Mitral Stenosis</text>
<text top="183" left="337" width="76" height="14" font="7">. . . . . . . . . . . .</text>
<text top="184" left="419" width="22" height="11" font="2">1522</text>
<text top="204" left="150" width="134" height="12" font="2">4.2.3. Subaortic Stenosis</text>
<text top="203" left="290" width="122" height="14" font="7">. . . . . . . . . . . . . . . . . . .</text>
<text top="204" left="419" width="22" height="11" font="2">1522</text>
<text top="224" left="149" width="230" height="12" font="2">4.2.4. Congenital Valvular Aortic Stenosis</text>
<text top="223" left="383" width="29" height="14" font="7">. . . . .</text>
<text top="224" left="419" width="22" height="11" font="2">1523</text>
<text top="241" left="184" width="133" height="11" font="2">4.2.4.1. Turner Syndrome</text>
<text top="240" left="325" width="89" height="14" font="7">. . . . . . . . . . . . . .</text>
<text top="241" left="419" width="22" height="11" font="2">1523</text>
<text top="261" left="150" width="196" height="12" font="2">4.2.5. Supravalvular Aortic Stenosis</text>
<text top="260" left="350" width="62" height="14" font="7">. . . . . . . . . .</text>
<text top="262" left="418" width="23" height="11" font="2">1524</text>
<text top="282" left="149" width="168" height="12" font="2">4.2.6. Coarctation of the Aorta</text>
<text top="281" left="323" width="89" height="14" font="7">. . . . . . . . . . . . . .</text>
<text top="282" left="419" width="22" height="11" font="2">1525</text>
<text top="309" left="123" width="135" height="12" font="12">4.3. Right-Sided Lesions</text>
<text top="309" left="264" width="149" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="310" left="418" width="23" height="11" font="2">1526</text>
<text top="330" left="151" width="192" height="12" font="2">4.3.1. Valvular Pulmonary Stenosis</text>
<text top="329" left="350" width="62" height="14" font="7">. . . . . . . . . .</text>
<text top="330" left="418" width="23" height="11" font="2">1526</text>
<text top="347" left="184" width="198" height="11" font="2">4.3.1.1. Isolated PR After Repair of PS</text>
<text top="346" left="385" width="29" height="14" font="7">. . . . .</text>
<text top="347" left="418" width="23" height="11" font="2">1526</text>
<text top="367" left="150" width="221" height="12" font="2">4.3.2. Branch and Peripheral Pulmonary</text>
<text top="382" left="183" width="45" height="12" font="2">Stenosis</text>
<text top="381" left="237" width="175" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="382" left="418" width="23" height="11" font="2">1528</text>
<text top="402" left="150" width="227" height="12" font="2">4.3.3. Double-Chambered Right Ventricle</text>
<text top="402" left="383" width="29" height="14" font="7">. . . . .</text>
<text top="403" left="418" width="23" height="11" font="2">1528</text>
<text top="423" left="149" width="129" height="12" font="2">4.3.4. Ebstein Anomaly</text>
<text top="422" left="284" width="129" height="14" font="7">. . . . . . . . . . . . . . . . . . . .</text>
<text top="423" left="418" width="23" height="11" font="2">1529</text>
<text top="443" left="150" width="136" height="12" font="2">4.3.5. Tetralogy of Fallot</text>
<text top="442" left="290" width="122" height="14" font="7">. . . . . . . . . . . . . . . . . . .</text>
<text top="443" left="417" width="23" height="11" font="2">1530</text>
<text top="463" left="149" width="235" height="12" font="2">4.3.6. Right Ventricle-to-Pulmonary Artery</text>
<text top="478" left="183" width="44" height="12" font="2">Conduit</text>
<text top="478" left="230" width="182" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="479" left="419" width="22" height="11" font="2">1533</text>
<text top="506" left="122" width="120" height="12" font="12">4.4. Complex Lesions</text>
<text top="506" left="251" width="162" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="507" left="418" width="23" height="11" font="2">1534</text>
<text top="527" left="151" width="226" height="12" font="2">4.4.1. Transposition of the Great Arteries</text>
<text top="526" left="383" width="29" height="14" font="7">. . . . .</text>
<text top="527" left="418" width="23" height="11" font="2">1534</text>
<text top="543" left="186" width="223" height="11" font="2">4.4.1.1. Transposition of the Great Arteries</text>
<text top="558" left="228" width="94" height="11" font="2">With Atrial Switch</text>
<text top="557" left="326" width="89" height="14" font="7">. . . . . . . . . . . . . .</text>
<text top="558" left="418" width="23" height="11" font="2">1534</text>
<text top="575" left="185" width="224" height="11" font="2">4.4.1.2. Transposition of the Great Arteries</text>
<text top="590" left="228" width="104" height="11" font="2">With Arterial Switch</text>
<text top="589" left="339" width="76" height="14" font="7">. . . . . . . . . . . .</text>
<text top="590" left="419" width="22" height="11" font="2">1535</text>
<text top="606" left="185" width="235" height="11" font="2">4.4.1.3. Congenitally Corrected Transposition</text>
<text top="621" left="228" width="108" height="11" font="2">of the Great Arteries</text>
<text top="620" left="339" width="76" height="14" font="7">. . . . . . . . . . . .</text>
<text top="621" left="418" width="23" height="11" font="2">1536</text>
<text top="642" left="150" width="235" height="12" font="2">4.4.2. Fontan Palliation of Single Ventricle</text>
<text top="657" left="184" width="239" height="12" font="2">Physiology (Including Tricuspid Atresia and</text>
<text top="672" left="184" width="151" height="12" font="2">Double Inlet Left Ventricle)</text>
<text top="671" left="343" width="69" height="14" font="7">. . . . . . . . . . .</text>
<text top="672" left="419" width="22" height="11" font="2">1537</text>
<text top="692" left="150" width="198" height="12" font="2">4.4.3. Double Outlet Right Ventricle</text>
<text top="691" left="357" width="56" height="14" font="7">. . . . . . . . .</text>
<text top="692" left="418" width="23" height="11" font="2">1538</text>
<text top="712" left="149" width="200" height="12" font="2">4.4.4. Severe PAH and Eisenmenger</text>
<text top="727" left="184" width="56" height="12" font="2">Syndrome</text>
<text top="727" left="244" width="169" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="728" left="418" width="23" height="11" font="2">1538</text>
<text top="744" left="186" width="104" height="11" font="2">4.4.4.1. Severe PAH</text>
<text top="743" left="293" width="122" height="14" font="7">. . . . . . . . . . . . . . . . . . .</text>
<text top="744" left="418" width="23" height="11" font="2">1538</text>
<text top="760" left="185" width="167" height="11" font="2">4.4.4.2. Eisenmenger Syndrome</text>
<text top="759" left="359" width="56" height="14" font="7">. . . . . . . . .</text>
<text top="760" left="418" width="23" height="11" font="2">1539</text>
<text top="781" left="150" width="147" height="12" font="2">4.4.5. Coronary Anomalies</text>
<text top="780" left="304" width="109" height="14" font="7">. . . . . . . . . . . . . . . . .</text>
<text top="781" left="416" width="25" height="11" font="2">1540</text>
<text top="798" left="186" width="187" height="11" font="2">4.4.5.1. Anomalous Coronary Artery</text>
<text top="813" left="229" width="54" height="11" font="2">Evaluation</text>
<text top="812" left="286" width="122" height="14" font="7">. . . . . . . . . . . . . . . . . . .</text>
<text top="813" left="416" width="25" height="11" font="2">1540</text>
<text top="829" left="185" width="236" height="11" font="2">4.4.5.2. Anomalous Aortic Origin of Coronary</text>
<text top="844" left="229" width="32" height="11" font="2">Artery</text>
<text top="843" left="266" width="149" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="844" left="419" width="22" height="11" font="2">1541</text>
<text top="861" left="185" width="228" height="11" font="2">4.4.5.3. Anomalous Coronary Artery Arising</text>
<text top="875" left="229" width="66" height="11" font="2">From the PA</text>
<text top="874" left="300" width="115" height="14" font="7">. . . . . . . . . . . . . . . . . .</text>
<text top="875" left="418" width="23" height="11" font="2">1542</text>
<text top="906" left="109" width="274" height="14" font="11">5. EVIDENCE GAPS AND FUTURE DIRECTIONS</text>
<text top="906" left="389" width="22" height="14" font="7">. . . .</text>
<text top="907" left="418" width="23" height="11" font="2">1542</text>
<text top="940" left="108" width="80" height="14" font="11">REFERENCES</text>
<text top="940" left="196" width="215" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="941" left="417" width="24" height="11" font="2">1544</text>
<text top="976" left="108" width="71" height="14" font="11">APPENDIX 1</text>
<text top="1001" left="122" width="222" height="12" font="12">Author Relationships With Industry and</text>
<text top="1016" left="122" width="137" height="12" font="12">Other Entities (Relevant)</text>
<text top="1016" left="264" width="149" height="14" font="7">. . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1017" left="419" width="22" height="11" font="2">1557</text>
<text top="1052" left="108" width="73" height="14" font="11">APPENDIX 2</text>
<text top="1077" left="122" width="235" height="12" font="12">Reviewer Relationships With Industry and</text>
<text top="1092" left="122" width="174" height="12" font="12">Other Entities (Comprehensive)</text>
<text top="1091" left="304" width="109" height="14" font="7">. . . . . . . . . . . . . . . . .</text>
<text top="1092" left="418" width="23" height="11" font="2">1559</text>
<text top="141" left="468" width="73" height="16" font="14">PREAMBLE</text>
<text top="178" left="468" width="333" height="12" font="2">Since 1980, the American College of Cardiology (ACC)</text>
<text top="196" left="468" width="333" height="12" font="2">and American Heart Association (AHA) have translated</text>
<text top="214" left="468" width="38" height="12" font="2">scienti</text>
<text top="213" left="506" width="295" height="15" font="2">ﬁc evidence into clinical practice guidelines</text>
<text top="232" left="468" width="333" height="12" font="2">(guidelines) with recommendations to improve cardio-</text>
<text top="250" left="468" width="333" height="12" font="2">vascular health. These guidelines, which are based on</text>
<text top="268" left="468" width="333" height="12" font="2">systematic methods to evaluate and classify evidence,</text>
<text top="286" left="468" width="333" height="12" font="2">provide a cornerstone for quality cardiovascular care. The</text>
<text top="304" left="468" width="333" height="12" font="2">ACC and AHA sponsor the development and publication</text>
<text top="322" left="468" width="333" height="12" font="2">of guidelines without commercial support, and members</text>
<text top="340" left="468" width="333" height="12" font="2">of each organization volunteer their time to the writing</text>
<text top="358" left="468" width="223" height="12" font="2">and review efforts. Guidelines are of</text>
<text top="356" left="691" width="110" height="15" font="2">ﬁcial policy of the</text>
<text top="376" left="468" width="84" height="12" font="2">ACC and AHA.</text>
<text top="408" left="468" width="71" height="11" font="12">Intended Use</text>
<text top="430" left="468" width="333" height="12" font="2">Practice guidelines provide recommendations applicable</text>
<text top="447" left="468" width="333" height="12" font="2">to patients with or at risk of developing cardiovascular</text>
<text top="465" left="468" width="333" height="12" font="2">disease. The focus is on medical practice in the United</text>
<text top="483" left="468" width="333" height="12" font="2">States, but guidelines developed in collaboration with</text>
<text top="501" left="468" width="333" height="12" font="2">other organizations can have a global impact. Although</text>
<text top="519" left="468" width="333" height="12" font="2">guidelines may be used to inform regulatory or payer</text>
<text top="537" left="468" width="285" height="12" font="2">decisions, they are intended to improve patients</text>
<text top="535" left="753" width="48" height="15" font="2">’ quality</text>
<text top="555" left="468" width="182" height="12" font="2">of care and align with patients</text>
<text top="553" left="650" width="151" height="15" font="2">’ interests. Guidelines are</text>
<text top="573" left="468" width="83" height="12" font="2">intended to de</text>
<text top="571" left="552" width="249" height="15" font="2">ﬁne practices meeting the needs of patients</text>
<text top="591" left="468" width="333" height="12" font="2">in most, but not all, circumstances and should not replace</text>
<text top="609" left="468" width="105" height="12" font="2">clinical judgment.</text>
<text top="641" left="468" width="126" height="11" font="12">Clinical Implementation</text>
<text top="663" left="468" width="333" height="12" font="2">Management in accordance with guideline recommen-</text>
<text top="681" left="468" width="333" height="12" font="2">dations is effective only when followed by both practi-</text>
<text top="699" left="468" width="333" height="12" font="2">tioners and patients. Adherence to recommendations</text>
<text top="716" left="468" width="333" height="12" font="2">can be enhanced by shared decision making between</text>
<text top="734" left="468" width="333" height="12" font="2">clinicians and patients, with patient engagement in</text>
<text top="752" left="468" width="51" height="12" font="2">selecting</text>
<text top="752" left="531" width="78" height="12" font="2">interventions</text>
<text top="752" left="621" width="14" height="12" font="2">on</text>
<text top="752" left="648" width="19" height="12" font="2">the</text>
<text top="752" left="678" width="28" height="12" font="2">basis</text>
<text top="752" left="719" width="11" height="12" font="2">of</text>
<text top="752" left="742" width="59" height="12" font="2">individual</text>
<text top="770" left="468" width="333" height="12" font="2">values, preferences, and associated conditions and</text>
<text top="788" left="468" width="83" height="12" font="2">comorbidities.</text>
<text top="820" left="468" width="174" height="11" font="12">Methodology and Modernization</text>
<text top="842" left="468" width="333" height="12" font="2">The ACC/AHA Task Force on Clinical Practice Guidelines</text>
<text top="860" left="468" width="313" height="12" font="2">(Task Force) continuously reviews, updates, and modi</text>
<text top="858" left="781" width="20" height="15" font="2">ﬁes</text>
<text top="878" left="468" width="333" height="12" font="2">guideline methodology on the basis of published stan-</text>
<text top="896" left="468" width="333" height="12" font="2">dards from organizations, including the Institute of</text>
<text top="914" left="468" width="53" height="12" font="2">Medicine</text>
<text top="914" left="525" width="52" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">(P-1, P-2)</a></text>
<text top="914" left="578" width="223" height="12" font="2">, and on the basis of internal reevalu-</text>
<text top="932" left="468" width="334" height="12" font="2">ation. Similarly, the presentation and delivery of guide-</text>
<text top="950" left="468" width="201" height="12" font="2">lines are reevaluated and modi</text>
<text top="948" left="670" width="132" height="15" font="2">ﬁed on the basis of</text>
<text top="968" left="468" width="333" height="12" font="2">evolving technologies and other factors to facilitate</text>
<text top="985" left="468" width="333" height="12" font="2">optimal dissemination of information to healthcare</text>
<text top="1003" left="468" width="196" height="12" font="2">professionals at the point of care.</text>
<text top="1021" left="483" width="318" height="12" font="2">Toward this goal, this guideline continues the intro-</text>
<text top="1039" left="468" width="333" height="12" font="2">duction of an evolved format of presenting guideline</text>
<text top="1057" left="468" width="275" height="12" font="2">recommendations and associated text called the</text>
<text top="1055" left="746" width="55" height="15" font="2">“modular</text>
<text top="1075" left="468" width="156" height="12" font="2">knowledge chunk format.</text>
<text top="1073" left="625" width="177" height="15" font="2">” Each modular “chunk” in-</text>
<text top="1093" left="468" width="333" height="12" font="2">cludes a table of related recommendations, a brief</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="20" height="9" font="5">1496</text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="192" height="12" font="2">synopsis, recommendation-speci</text>
<text top="141" left="255" width="141" height="15" font="2">ﬁc supportive text, and</text>
<text top="161" left="63" width="110" height="12" font="2">when appropriate,</text>
<text top="159" left="180" width="216" height="15" font="2">ﬂow diagrams or additional tables.</text>
<text top="178" left="63" width="333" height="12" font="2">References are provided at the end of the document in</text>
<text top="196" left="63" width="333" height="12" font="2">their respective sections. Additionally, this format will</text>
<text top="214" left="63" width="333" height="12" font="2">facilitate seamless updating of guidelines with focused</text>
<text top="232" left="63" width="333" height="12" font="2">updates as new evidence is published, as well as content</text>
<text top="250" left="63" width="333" height="12" font="2">tagging for rapid electronic retrieval of related recom-</text>
<text top="268" left="63" width="333" height="12" font="2">mendations on a topic of interest. This evolved approach</text>
<text top="286" left="63" width="333" height="12" font="2">format was instituted when this guideline was near</text>
<text top="304" left="63" width="333" height="12" font="2">completion; therefore, the present document represents a</text>
<text top="322" left="63" width="333" height="12" font="2">transitional format that best suits the text as written.</text>
<text top="340" left="63" width="333" height="12" font="2">Future guidelines will fully implement this format,</text>
<text top="358" left="63" width="333" height="12" font="2">including provisions for limiting the amount of text in a</text>
<text top="376" left="63" width="58" height="12" font="2">guideline.</text>
<text top="394" left="78" width="219" height="12" font="2">Recognizing the importance of cost</text>
<text top="392" left="298" width="99" height="15" font="2">–value consider-</text>
<text top="412" left="63" width="333" height="12" font="2">ations in certain guidelines, when appropriate and</text>
<text top="430" left="63" width="333" height="12" font="2">feasible, an analysis of the value of a drug, device, or</text>
<text top="447" left="63" width="333" height="12" font="2">intervention may be performed in accordance with the</text>
<text top="465" left="63" width="135" height="12" font="2">ACC/AHA methodology</text>
<text top="465" left="202" width="27" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">(P-3)</a></text>
<text top="465" left="229" width="3" height="12" font="2">.</text>
<text top="483" left="78" width="318" height="12" font="2">To ensure that guideline recommendations remain</text>
<text top="501" left="63" width="333" height="12" font="2">current, new data are reviewed on an ongoing basis, with</text>
<text top="519" left="63" width="333" height="12" font="2">full guideline revisions commissioned in approximately</text>
<text top="537" left="63" width="333" height="12" font="2">6-year cycles. Publication of new, potentially practice-</text>
<text top="555" left="63" width="333" height="12" font="2">changing study results that are relevant to an existing or</text>
<text top="573" left="63" width="333" height="12" font="2">new drug, device, or management strategy will prompt</text>
<text top="591" left="63" width="333" height="12" font="2">evaluation by the Task Force, in consultation with</text>
<text top="609" left="63" width="333" height="12" font="2">the relevant guideline writing committee, to determine</text>
<text top="627" left="63" width="333" height="12" font="2">whether a focused update should be commissioned. For</text>
<text top="645" left="63" width="333" height="12" font="2">additional information and policies regarding guideline</text>
<text top="663" left="63" width="333" height="12" font="2">development, we encourage readers to consult the ACC/</text>
<text top="681" left="63" width="227" height="12" font="2">AHA guideline methodology manual</text>
<text top="681" left="298" width="28" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">(P-4)</a></text>
<text top="681" left="335" width="61" height="12" font="2">and other</text>
<text top="698" left="63" width="122" height="12" font="2">methodology articles</text>
<text top="698" left="189" width="22" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">(P-5</a></text>
<text top="697" left="212" width="29" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">–P-8)</a></text>
<text top="698" left="241" width="3" height="12" font="2">.</text>
<text top="737" left="63" width="221" height="11" font="12">Selection of Writing Committee Members</text>
<text top="758" left="63" width="333" height="12" font="2">The Task Force strives to avoid bias by selecting experts</text>
<text top="776" left="63" width="333" height="12" font="2">from a broad array of backgrounds. Writing committee</text>
<text top="794" left="63" width="333" height="12" font="2">members represent different geographic regions, sexes,</text>
<text top="812" left="63" width="333" height="12" font="2">ethnicities, races, intellectual perspectives/biases, and</text>
<text top="830" left="63" width="333" height="12" font="2">scopes of clinical practice. The Task Force may also invite</text>
<text top="848" left="63" width="333" height="12" font="2">organizations and professional societies with related</text>
<text top="866" left="63" width="333" height="12" font="2">interests and expertise to participate as partners, collab-</text>
<text top="884" left="63" width="125" height="12" font="2">orators, or endorsers.</text>
<text top="919" left="63" width="248" height="11" font="12">Relationships With Industry and Other Entities</text>
<text top="941" left="63" width="333" height="12" font="2">The ACC and AHA have rigorous policies and methods to</text>
<text top="959" left="63" width="333" height="12" font="2">ensure that guidelines are developed without bias or</text>
<text top="977" left="63" width="74" height="12" font="2">improper in</text>
<text top="975" left="137" width="259" height="15" font="2">ﬂuence. The complete relationships with</text>
<text top="995" left="63" width="333" height="12" font="2">industry and other entities (RWI) policy can be found</text>
<text top="1013" left="63" width="37" height="12" font="4"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">online</a></text>
<text top="1013" left="100" width="3" height="12" font="2"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">.</a></text>
<text top="1013" left="108" width="65" height="12" font="4"><a href="">Appendix 1</a></text>
<text top="1013" left="177" width="219" height="12" font="2">of the present document lists writing</text>
<text top="1031" left="63" width="123" height="12" font="2">committee members</text>
<text top="1029" left="186" width="210" height="15" font="2">’ relevant RWI. For the purposes</text>
<text top="143" left="423" width="11" height="12" font="2">of</text>
<text top="143" left="447" width="20" height="12" font="2">full</text>
<text top="143" left="479" width="79" height="12" font="2">transparency,</text>
<text top="143" left="571" width="42" height="12" font="2">writing</text>
<text top="143" left="625" width="62" height="12" font="2">committee</text>
<text top="143" left="700" width="53" height="12" font="2">members</text>
<text top="141" left="753" width="3" height="15" font="2">’</text>
<text top="161" left="423" width="290" height="12" font="2">comprehensive disclosure information is available</text>
<text top="161" left="716" width="37" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Exec_Summ_and_Full_Text_Comp_RWI_Table_08-02-18.pdf">online</a></text>
<text top="161" left="753" width="3" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Exec_Summ_and_Full_Text_Comp_RWI_Table_08-02-18.pdf">.</a></text>
<text top="178" left="423" width="333" height="12" font="2">Comprehensive disclosure information for the Task</text>
<text top="196" left="423" width="125" height="12" font="2">Force is also available</text>
<text top="196" left="551" width="37" height="12" font="4"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/guidelines-and-documents-task-forces">online</a></text>
<text top="196" left="588" width="3" height="12" font="2">.</text>
<text top="232" left="423" width="272" height="11" font="12">Evidence Review and Evidence Review Committees</text>
<text top="253" left="423" width="333" height="12" font="2">In developing recommendations, the writing committee</text>
<text top="271" left="423" width="333" height="12" font="2">uses evidence-based methodologies that are based on all</text>
<text top="289" left="423" width="85" height="12" font="2">available data</text>
<text top="289" left="516" width="23" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">(P-4</a></text>
<text top="287" left="540" width="28" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">–P-7)</a></text>
<text top="289" left="568" width="188" height="12" font="2">. Literature searches focus on</text>
<text top="307" left="423" width="333" height="12" font="2">randomized controlled trials but also include registries,</text>
<text top="325" left="423" width="333" height="12" font="2">nonrandomized comparative and descriptive studies,</text>
<text top="343" left="423" width="333" height="12" font="2">case series, cohort studies, systematic reviews, and expert</text>
<text top="361" left="423" width="226" height="12" font="2">opinion. Only key references are cited.</text>
<text top="379" left="438" width="318" height="12" font="2">An independent evidence review committee (ERC) is</text>
<text top="397" left="423" width="333" height="12" font="2">commissioned when there are 1 or more questions</text>
<text top="415" left="423" width="333" height="12" font="2">deemed of utmost clinical importance that merit formal</text>
<text top="433" left="423" width="333" height="12" font="2">systematic review. The systematic review will determine</text>
<text top="451" left="423" width="237" height="12" font="2">which patients are most likely to bene</text>
<text top="449" left="661" width="96" height="15" font="2">ﬁt from a drug,</text>
<text top="469" left="423" width="333" height="12" font="2">device, or treatment strategy and to what degree.</text>
<text top="486" left="423" width="333" height="12" font="2">Criteria for commissioning an ERC and formal systematic</text>
<text top="504" left="423" width="333" height="12" font="2">review include: a) the absence of a current authoritative</text>
<text top="522" left="423" width="272" height="12" font="2">systematic review, b) the feasibility of de</text>
<text top="520" left="695" width="61" height="15" font="2">ﬁning the</text>
<text top="540" left="423" width="28" height="12" font="2">bene</text>
<text top="538" left="451" width="305" height="15" font="2">ﬁt and risk in a time frame consistent with</text>
<text top="558" left="423" width="333" height="12" font="2">the writing of a guideline, c) the relevance to a sub-</text>
<text top="576" left="423" width="333" height="12" font="2">stantial number of patients, and d) the likelihood</text>
<text top="594" left="423" width="52" height="12" font="2">that the</text>
<text top="592" left="485" width="272" height="15" font="2">ﬁndings can be translated into actionable</text>
<text top="612" left="423" width="333" height="12" font="2">recommendations. ERC members may include method-</text>
<text top="630" left="423" width="333" height="12" font="2">ologists, epidemiologists, healthcare providers, and bio-</text>
<text top="648" left="423" width="333" height="12" font="2">statisticians. The recommendations developed by the</text>
<text top="666" left="423" width="333" height="12" font="2">writing committee on the basis of the systematic review</text>
<text top="684" left="423" width="98" height="12" font="2">are marked with</text>
<text top="682" left="526" width="31" height="15" font="2">“SR”.</text>
<text top="719" left="423" width="242" height="11" font="12">Guideline-Directed Management and Therapy</text>
<text top="741" left="423" width="333" height="12" font="2">The term guideline-directed management and therapy</text>
<text top="759" left="423" width="333" height="12" font="2">(GDMT) encompasses clinical evaluation, diagnostic</text>
<text top="776" left="423" width="333" height="12" font="2">testing, and pharmacological and procedural treatments.</text>
<text top="794" left="423" width="333" height="12" font="2">For these and all recommended drug treatment regi-</text>
<text top="812" left="423" width="35" height="12" font="2">mens,</text>
<text top="812" left="470" width="18" height="12" font="2">the</text>
<text top="812" left="501" width="37" height="12" font="2">reader</text>
<text top="812" left="551" width="39" height="12" font="2">should</text>
<text top="812" left="602" width="21" height="12" font="2">con</text>
<text top="811" left="623" width="133" height="15" font="2">ﬁrm the dosage by</text>
<text top="830" left="423" width="333" height="12" font="2">reviewing product insert material and evaluate the</text>
<text top="848" left="423" width="57" height="12" font="2">treatment</text>
<text top="848" left="495" width="47" height="12" font="2">regimen</text>
<text top="848" left="557" width="16" height="12" font="2">for</text>
<text top="848" left="588" width="101" height="12" font="2">contraindications</text>
<text top="848" left="704" width="21" height="12" font="2">and</text>
<text top="848" left="741" width="16" height="12" font="2">in-</text>
<text top="866" left="423" width="333" height="12" font="2">teractions. The recommendations are limited to drugs,</text>
<text top="884" left="423" width="333" height="12" font="2">devices, and treatments approved for clinical use in the</text>
<text top="902" left="423" width="83" height="12" font="2">United States.</text>
<text top="937" left="423" width="258" height="11" font="12">Class of Recommendation and Level of Evidence</text>
<text top="959" left="423" width="333" height="12" font="2">The Class of Recommendation (COR) indicates the</text>
<text top="977" left="423" width="333" height="12" font="2">strength of the recommendation, encompassing the esti-</text>
<text top="995" left="423" width="227" height="12" font="2">mated magnitude and certainty of bene</text>
<text top="993" left="650" width="106" height="15" font="2">ﬁt in proportion to</text>
<text top="1013" left="423" width="333" height="12" font="2">risk. The Level of Evidence (LOE) rates the quality of</text>
<text top="1031" left="423" width="38" height="12" font="2">scienti</text>
<text top="1029" left="461" width="295" height="15" font="2">ﬁc evidence that supports the intervention on the</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="788" width="19" height="9" font="5">1497</text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="15" size="8" family="Times" color="#ffffff"/>
	<fontspec id="16" size="8" family="Times" color="#0e2a52"/>
<text top="962" left="108" width="334" height="12" font="2">basis of the type, quantity, and consistency of data from</text>
<text top="980" left="108" width="191" height="12" font="2">clinical trials and other sources (</text>
<text top="981" left="299" width="40" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#5">Table 1</a></text>
<text top="980" left="339" width="4" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#5">)</a></text>
<text top="980" left="347" width="23" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">(P-4</a></text>
<text top="978" left="371" width="29" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">–P-6)</a></text>
<text top="980" left="400" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#51">.</a></text>
<text top="998" left="123" width="318" height="12" font="2">The reader is encouraged to consult the full-text</text>
<text top="1016" left="108" width="54" height="12" font="2">guideline</text>
<text top="1016" left="166" width="27" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">(P-9)</a></text>
<text top="1016" left="198" width="243" height="12" font="2">for additional guidance and details about</text>
<text top="1034" left="108" width="333" height="12" font="2">adult congenital heart disease because this executive</text>
<text top="1052" left="108" width="286" height="12" font="2">summary contains mainly the recommendations.</text>
<text top="1074" left="242" width="199" height="12" font="2">Glenn N. Levine, MD, FACC, FAHA</text>
<text top="1092" left="125" width="316" height="12" font="2">Chair, ACC/AHA Task Force on Clinical Practice Guidelines</text>
<text top="960" left="468" width="120" height="16" font="14">1. INTRODUCTION</text>
<text top="998" left="468" width="208" height="11" font="12">1.1. Methodology and Evidence Review</text>
<text top="1020" left="468" width="333" height="12" font="2">The recommendations listed in this guideline are,</text>
<text top="1038" left="468" width="333" height="12" font="2">whenever possible, evidence-based. An initial extensive</text>
<text top="1056" left="468" width="333" height="12" font="2">evidence review, which included literature derived from</text>
<text top="1074" left="468" width="333" height="12" font="2">research involving human subjects, published in English,</text>
<text top="1092" left="468" width="333" height="12" font="2">and indexed in MEDLINE (through PubMed), EMBASE,</text>
<text top="156" left="116" width="46" height="10" font="15">T A B L E 1</text>
<text top="149" left="179" width="571" height="10" font="16">Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments,</text>
<text top="163" left="179" width="328" height="10" font="16">or Diagnostic Testing in Patient Care* (Updated August 2015)</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="20" height="9" font="5">1498</text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="333" height="12" font="2">the Cochrane Library, the Agency for Healthcare Research</text>
<text top="161" left="63" width="333" height="12" font="2">and Quality, and other selected databases relevant to this</text>
<text top="178" left="63" width="333" height="12" font="2">guideline, was conducted from April 2014 to November</text>
<text top="196" left="63" width="333" height="12" font="2">2014. Key search words included but were not limited to</text>
<text top="214" left="63" width="333" height="12" font="2">the following: adult congenital heart disease, anesthesia,</text>
<text top="232" left="63" width="333" height="12" font="2">aortic aneurysm, aortic stenosis, atrial septal defect, arte-</text>
<text top="250" left="63" width="333" height="12" font="2">rial switch operation, bradycardia, bicuspid aortic valve,</text>
<text top="268" left="63" width="333" height="12" font="2">cardiac catheterization, cardiac imaging, cardiovascular</text>
<text top="286" left="63" width="333" height="12" font="2">magnetic resonance, cardiac reoperation, cardiovascular</text>
<text top="304" left="63" width="333" height="12" font="2">surgery, chest x-ray, cirrhosis, coarctation of the aorta,</text>
<text top="322" left="63" width="333" height="12" font="2">congenital heart defects, congenitally corrected trans-</text>
<text top="340" left="63" width="333" height="12" font="2">position of the great arteries, contraception, coronary</text>
<text top="358" left="63" width="333" height="12" font="2">artery abnormalities, cyanotic congenital heart disease,</text>
<text top="376" left="63" width="333" height="12" font="2">dextro-transposition of the great arteries, double inlet left</text>
<text top="394" left="63" width="53" height="12" font="2">ventricle,</text>
<text top="394" left="127" width="41" height="12" font="2">Ebstein</text>
<text top="394" left="180" width="53" height="12" font="2">anomaly,</text>
<text top="394" left="245" width="105" height="12" font="2">echocardiography,</text>
<text top="394" left="362" width="34" height="12" font="2">Eisen-</text>
<text top="412" left="63" width="333" height="12" font="2">menger syndrome, electrocardiogram, endocarditis, exer-</text>
<text top="430" left="63" width="333" height="12" font="2">cise test, Fontan, heart catheterization, heart defect, heart</text>
<text top="447" left="63" width="333" height="12" font="2">failure, infertility, l-transposition of the great arteries,</text>
<text top="465" left="63" width="44" height="12" font="2">medical</text>
<text top="465" left="120" width="48" height="12" font="2">therapy,</text>
<text top="465" left="182" width="64" height="12" font="2">myocardial</text>
<text top="465" left="259" width="60" height="12" font="2">infarction,</text>
<text top="465" left="333" width="63" height="12" font="2">noncardiac</text>
<text top="483" left="63" width="333" height="12" font="2">surgery, patent ductus arteriosus, perioperative care,</text>
<text top="501" left="63" width="333" height="12" font="2">physical activity, postoperative complications, pregnancy,</text>
<text top="519" left="63" width="333" height="12" font="2">preoperative assessment, psychosocial, pulmonary arterial</text>
<text top="537" left="63" width="333" height="12" font="2">hypertension, hypoplastic left heart syndrome, pulmonary</text>
<text top="555" left="63" width="77" height="12" font="2">regurgitation,</text>
<text top="555" left="154" width="62" height="12" font="2">pulmonary</text>
<text top="555" left="230" width="47" height="12" font="2">stenosis,</text>
<text top="555" left="291" width="62" height="12" font="2">pulmonary</text>
<text top="555" left="366" width="30" height="12" font="2">valve</text>
<text top="573" left="63" width="333" height="12" font="2">replacement, right heart obstruction, right ventricle to</text>
<text top="591" left="63" width="333" height="12" font="2">pulmonary artery conduit, single ventricle, supravalvular</text>
<text top="609" left="63" width="333" height="12" font="2">pulmonary stenosis, surgical therapy, tachyarrhythmia,</text>
<text top="627" left="63" width="333" height="12" font="2">tachycardia, tetralogy of Fallot, transplantation, tricuspid</text>
<text top="645" left="63" width="333" height="12" font="2">atresia, Turner syndrome, and ventricular septal defect.</text>
<text top="663" left="63" width="333" height="12" font="2">Additional relevant studies published through January</text>
<text top="681" left="63" width="333" height="12" font="2">2018, during the guideline writing process, were also</text>
<text top="698" left="63" width="333" height="12" font="2">considered by the writing committee, and added to</text>
<text top="716" left="63" width="248" height="12" font="2">the evidence tables when appropriate. The</text>
<text top="715" left="315" width="81" height="15" font="2">ﬁnal evidence</text>
<text top="734" left="63" width="131" height="12" font="2">tables, included in the</text>
<text top="734" left="198" width="143" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement</a></text>
<text top="734" left="342" width="55" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">, </a>summa-</text>
<text top="752" left="63" width="333" height="12" font="2">rize the evidence used by the writing committee to</text>
<text top="770" left="63" width="333" height="12" font="2">formulate recommendations. References selected and</text>
<text top="788" left="63" width="333" height="12" font="2">published in this document are representative and not</text>
<text top="806" left="63" width="75" height="12" font="2">all-inclusive.</text>
<text top="824" left="78" width="318" height="12" font="2">As noted in the preamble, an independent ERC was</text>
<text top="842" left="63" width="333" height="12" font="2">commissioned to perform a formal systematic review of</text>
<text top="860" left="63" width="333" height="12" font="2">critical clinical questions related to adult congenital heart</text>
<text top="878" left="63" width="333" height="12" font="2">disease (ACHD), the results of which were considered by</text>
<text top="896" left="63" width="333" height="12" font="2">the writing committee for incorporation into this guide-</text>
<text top="914" left="63" width="333" height="12" font="2">line. Concurrent with this process, writing committee</text>
<text top="932" left="63" width="333" height="12" font="2">members evaluated study data relevant to the rest of the</text>
<text top="950" left="63" width="84" height="12" font="2">guideline. The</text>
<text top="948" left="152" width="244" height="15" font="2">ﬁndings of the ERC and the writing com-</text>
<text top="967" left="63" width="333" height="12" font="2">mittee members were formally presented and discussed,</text>
<text top="985" left="63" width="333" height="12" font="2">and then recommendations were developed. The sys-</text>
<text top="1003" left="63" width="150" height="12" font="2">tematic review reports on</text>
<text top="1002" left="217" width="179" height="15" font="2">“Medical Therapy for Systemic</text>
<text top="1021" left="63" width="333" height="12" font="2">Right Ventricles: A Systematic Review (Part 1) for the 2018</text>
<text top="1039" left="63" width="333" height="12" font="2">AHA/ACC Guideline for the Management of Adults With</text>
<text top="1057" left="63" width="153" height="12" font="2">Congenital Heart Disease</text>
<text top="1055" left="216" width="6" height="15" font="2">”</text>
<text top="1057" left="230" width="40" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">(S1.1-1)</a></text>
<text top="1057" left="277" width="21" height="12" font="2">and</text>
<text top="1055" left="307" width="89" height="15" font="2">“Interventional</text>
<text top="1075" left="63" width="333" height="12" font="2">Therapy Versus Medical Therapy for Secundum Atrial</text>
<text top="143" left="423" width="333" height="12" font="2">Septal Defect: A Systematic Review (Part 2) for the 2018</text>
<text top="161" left="423" width="333" height="12" font="2">AHA/ACC Guideline for the Management of Adults With</text>
<text top="178" left="423" width="158" height="12" font="2">Congenital Heart Disease</text>
<text top="177" left="582" width="6" height="15" font="2">”</text>
<text top="178" left="598" width="41" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">(S1.1-2)</a></text>
<text top="178" left="649" width="107" height="12" font="2">are published in</text>
<text top="196" left="423" width="187" height="12" font="2">conjunction with this guideline.</text>
<text top="235" left="423" width="231" height="11" font="12">1.2. Organization of the Writing Committee</text>
<text top="256" left="423" width="333" height="12" font="2">The writing committee consisted of pediatric and adult</text>
<text top="274" left="423" width="60" height="12" font="2">congenital</text>
<text top="274" left="495" width="77" height="12" font="2">cardiologists,</text>
<text top="274" left="585" width="83" height="12" font="2">interventional</text>
<text top="274" left="679" width="77" height="12" font="2">cardiologists,</text>
<text top="292" left="423" width="333" height="12" font="2">electrophysiologists, surgeons, and an advance practice</text>
<text top="310" left="423" width="333" height="12" font="2">nurse. The writing committee included representatives</text>
<text top="328" left="423" width="333" height="12" font="2">from the ACC, AHA, and American Association for</text>
<text top="346" left="423" width="333" height="12" font="2">Thoracic Surgery (AATS), American Society of Echocardi-</text>
<text top="364" left="423" width="333" height="12" font="2">ography (ASE), Heart Rhythm Society (HRS), International</text>
<text top="382" left="423" width="333" height="12" font="2">Society for Adult Congenital Heart Disease (ISACHD), So-</text>
<text top="400" left="423" width="333" height="12" font="2">ciety for Cardiovascular Angiography and Interventions</text>
<text top="418" left="423" width="298" height="12" font="2">(SCAI), and the Society of Thoracic Surgeons (STS).</text>
<text top="456" left="423" width="193" height="11" font="12">1.3. Document Review and Approval</text>
<text top="478" left="423" width="214" height="12" font="2">This document was reviewed by 3 of</text>
<text top="476" left="638" width="119" height="15" font="2">ﬁcial reviewers each</text>
<text top="495" left="423" width="333" height="12" font="2">nominated by the ACC and AHA, and 1 to 2 reviewers each</text>
<text top="513" left="423" width="333" height="12" font="2">from the AATS, ASE, HRS, ISACHD, SCAI, STS; and 32 in-</text>
<text top="531" left="423" width="226" height="12" font="2">dividual content reviewers. Reviewers</text>
<text top="530" left="650" width="107" height="15" font="2">’ RWI information</text>
<text top="549" left="423" width="333" height="12" font="2">was distributed to the writing committee and is published</text>
<text top="567" left="423" width="107" height="12" font="2">in this document (</text>
<text top="567" left="531" width="66" height="12" font="4"><a href="">Appendix 2</a></text>
<text top="567" left="597" width="8" height="12" font="2">).</text>
<text top="585" left="438" width="318" height="12" font="2">This document was approved for publication by the</text>
<text top="603" left="423" width="333" height="12" font="2">governing bodies of the ACC and the AHA and endorsed</text>
<text top="621" left="423" width="281" height="12" font="2">by the AATS, ASE, HRS, ISACHD, SCAI, and STS.</text>
<text top="659" left="423" width="144" height="11" font="12">1.4. Scope of the Guideline</text>
<text top="681" left="423" width="293" height="12" font="2">The 2018 ACHD guideline is a full revision of the</text>
<text top="679" left="721" width="35" height="15" font="2">“2008</text>
<text top="699" left="423" width="333" height="12" font="2">ACC/AHA Guidelines for the Management of Adults with</text>
<text top="717" left="423" width="150" height="12" font="2">Congenital Heart Disease</text>
<text top="715" left="574" width="6" height="15" font="2">”</text>
<text top="717" left="587" width="42" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">(S1.4-1)</a></text>
<text top="717" left="629" width="98" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#51">, </a>which was the</text>
<text top="715" left="734" width="23" height="15" font="2">ﬁrst</text>
<text top="735" left="423" width="333" height="12" font="2">U.S. guideline to be published on the topic. This revision</text>
<text top="753" left="423" width="333" height="12" font="2">uses the 2008 ACHD guideline as a framework and in-</text>
<text top="771" left="423" width="333" height="12" font="2">corporates new data and growing ACHD expertise to</text>
<text top="789" left="423" width="333" height="12" font="2">develop recommendations. Congenital heart disease</text>
<text top="806" left="423" width="333" height="12" font="2">(CHD) encompasses a range of structural cardiac abnor-</text>
<text top="824" left="423" width="333" height="12" font="2">malities present before birth attributable to abnormal</text>
<text top="842" left="423" width="333" height="12" font="2">fetal cardiac development but does not include inherited</text>
<text top="860" left="423" width="333" height="12" font="2">disorders that may have cardiac manifestations such as</text>
<text top="878" left="423" width="333" height="12" font="2">Marfan syndrome or hypertrophic cardiomyopathy. Also</text>
<text top="896" left="423" width="333" height="12" font="2">not included are anatomic variants such as patent fora-</text>
<text top="914" left="423" width="333" height="12" font="2">men ovale. Valvular heart disease (VHD) may be congen-</text>
<text top="932" left="423" width="233" height="12" font="2">ital, so management overlaps with the</text>
<text top="930" left="663" width="94" height="15" font="2">“2014 AHA/ACC</text>
<text top="950" left="423" width="333" height="12" font="2">Guidelines for the Management of Patients With Valvular</text>
<text top="968" left="423" width="82" height="12" font="2">Heart Disease</text>
<text top="966" left="505" width="6" height="15" font="2">”</text>
<text top="968" left="518" width="43" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-2)</a></text>
<text top="968" left="561" width="195" height="12" font="2">, particularly for bicuspid aortic</text>
<text top="986" left="423" width="333" height="12" font="2">valve (BAV) disease. Where overlap exists, this document</text>
<text top="1004" left="423" width="333" height="12" font="2">focuses on the diagnosis and treatment of congenital</text>
<text top="1022" left="423" width="333" height="12" font="2">valve disease when it differs from acquired valve disease,</text>
<text top="1040" left="423" width="333" height="12" font="2">whether because of anatomic differences, presence of</text>
<text top="1058" left="423" width="333" height="12" font="2">concomitant lesions, or differences to consider given the</text>
<text top="1075" left="423" width="333" height="12" font="2">relatively young age of patients with ACHD. This</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="787" width="20" height="9" font="5">1499</text>
</page>
<page number="7" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="277" height="12" font="2">guideline is not intended to apply to children (</text>
<text top="141" left="385" width="56" height="15" font="2">&lt;18 years</text>
<text top="161" left="108" width="333" height="12" font="2">of age) with CHD or adults with acquired VHD, heart</text>
<text top="178" left="108" width="260" height="12" font="2">failure (HF), or other cardiovascular disease.</text>
<text top="196" left="123" width="318" height="12" font="2">The prevalence of ACHD is growing because of the</text>
<text top="214" left="108" width="333" height="12" font="2">success of pediatric cardiology and congenital cardiac</text>
<text top="232" left="108" width="333" height="12" font="2">surgery in diagnosing and treating congenital heart de-</text>
<text top="250" left="108" width="333" height="12" font="2">fects in children. Improved survival to adulthood is most</text>
<text top="268" left="108" width="333" height="12" font="2">striking for those with the most severe disease, with</text>
<text top="286" left="108" width="333" height="12" font="2">survival to age 18 years now expected for 90% of children</text>
<text top="304" left="108" width="161" height="12" font="2">diagnosed with severe CHD</text>
<text top="304" left="273" width="38" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">(S1.4-3</a></text>
<text top="302" left="312" width="44" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">–S1.4-5)</a></text>
<text top="304" left="356" width="85" height="12" font="2">. Patients with</text>
<text top="322" left="108" width="333" height="12" font="2">ACHD are a heterogeneous population, both in underlying</text>
<text top="340" left="108" width="333" height="12" font="2">anatomy and physiology, as well as surgical repair or</text>
<text top="358" left="108" width="333" height="12" font="2">palliation. Consequently, although the prevalence of</text>
<text top="376" left="108" width="333" height="12" font="2">ACHD is increasing, the population of patients with a</text>
<text top="394" left="108" width="229" height="12" font="2">given congenital abnormality or speci</text>
<text top="392" left="337" width="104" height="15" font="2">ﬁc repair may be</text>
<text top="412" left="108" width="90" height="12" font="2">relatively small</text>
<text top="412" left="201" width="81" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">(S1.4-3, S1.4-6</a></text>
<text top="410" left="283" width="45" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">–S1.4-8)</a></text>
<text top="412" left="329" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#51">.</a></text>
<text top="430" left="123" width="318" height="12" font="2">Patients with CHD are not cured of their disease after</text>
<text top="447" left="108" width="333" height="12" font="2">successful treatment in childhood. Almost all patients</text>
<text top="465" left="108" width="333" height="12" font="2">with ACHD will have sequelae of either their native CHD</text>
<text top="483" left="108" width="333" height="12" font="2">or its surgical repair or palliation, although these sequelae</text>
<text top="501" left="108" width="333" height="12" font="2">can take decades to manifest. The heterogeneity of the</text>
<text top="519" left="108" width="333" height="12" font="2">population and the long symptom-free intervals constrain</text>
<text top="537" left="108" width="333" height="12" font="2">the ability to generate data applicable across the popula-</text>
<text top="555" left="108" width="212" height="12" font="2">tion of ACHD or to adults with speci</text>
<text top="553" left="320" width="121" height="15" font="2">ﬁc lesions or repairs.</text>
<text top="573" left="108" width="94" height="12" font="2">Despite the dif</text>
<text top="571" left="202" width="239" height="15" font="2">ﬁculty in studying ACHD populations,</text>
<text top="591" left="108" width="333" height="12" font="2">there is a growing body of high-quality data in these pa-</text>
<text top="609" left="108" width="242" height="12" font="2">tients to guide the care of this relatively</text>
<text top="607" left="355" width="86" height="15" font="2">“new” popula-</text>
<text top="627" left="108" width="333" height="12" font="2">tion, and whenever feasible, these data were used to</text>
<text top="645" left="108" width="333" height="12" font="2">develop recommendations. Recommendations are made</text>
<text top="663" left="108" width="333" height="12" font="2">based on the available data; however, when important</text>
<text top="681" left="108" width="157" height="12" font="2">clinical issues lacked data,</text>
<text top="679" left="270" width="171" height="15" font="2">ﬁrst principles, extrapolation</text>
<text top="698" left="108" width="333" height="12" font="2">from data in other populations, and expert consensus are</text>
<text top="716" left="108" width="333" height="12" font="2">used to guide care. Patients with ACHD may have</text>
<text top="734" left="108" width="333" height="12" font="2">concomitant disease to which other existing guidelines</text>
<text top="752" left="108" width="333" height="12" font="2">apply, such as coronary artery disease, HF, and arrhyth-</text>
<text top="770" left="108" width="333" height="12" font="2">mias. The data from acquired heart disease populations</text>
<text top="788" left="108" width="333" height="12" font="2">may apply to some patients with ACHD, and those cir-</text>
<text top="806" left="108" width="333" height="12" font="2">cumstances are acknowledged in these recommendations</text>
<text top="824" left="108" width="163" height="12" font="2">and referenced accordingly.</text>
<text top="842" left="123" width="318" height="12" font="2">Patients with ACHD who are cared for in ACHD centers</text>
<text top="860" left="108" width="333" height="12" font="2">have better outcomes than those cared for in centers</text>
<text top="878" left="108" width="152" height="12" font="2">without ACHD expertise</text>
<text top="878" left="269" width="43" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#51">(S1.4-9)</a></text>
<text top="878" left="312" width="129" height="12" font="2">, and this need for</text>
<text top="896" left="108" width="334" height="12" font="2">specialized care is noted throughout the guideline. These</text>
<text top="914" left="108" width="333" height="12" font="2">recommendations are intended to provide guidance to a</text>
<text top="932" left="108" width="333" height="12" font="2">wide variety of providers caring for patients with ACHD,</text>
<text top="950" left="108" width="333" height="12" font="2">including general, pediatric, and ACHD cardiologists, as</text>
<text top="967" left="108" width="333" height="12" font="2">well as surgeons, primary care providers, and other</text>
<text top="985" left="108" width="124" height="12" font="2">healthcare providers.</text>
<text top="1003" left="123" width="318" height="12" font="2">In developing the 2018 ACHD guideline, the writing</text>
<text top="1021" left="108" width="333" height="12" font="2">committee reviewed previously published guidelines and</text>
<text top="1039" left="108" width="85" height="12" font="2">related scienti</text>
<text top="1037" left="193" width="88" height="15" font="2">ﬁc statements.</text>
<text top="1040" left="287" width="43" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#8">Table 2</a></text>
<text top="1039" left="337" width="104" height="12" font="2">contains a list of</text>
<text top="143" left="468" width="141" height="12" font="2">publications and scienti</text>
<text top="141" left="609" width="192" height="15" font="2">ﬁc statements deemed pertinent</text>
<text top="161" left="468" width="333" height="12" font="2">to this writing effort; it is intended for use as a resource</text>
<text top="178" left="468" width="333" height="12" font="2">and does not repeat existing guideline recommendations.</text>
<text top="214" left="468" width="95" height="11" font="12">1.5. Abbreviations</text>
<text top="266" left="468" width="60" height="9" font="13">Abbreviation</text>
<text top="266" left="644" width="75" height="9" font="13">Meaning/Phrase</text>
<text top="286" left="468" width="30" height="9" font="13">AAOCA</text>
<text top="286" left="563" width="194" height="9" font="13">anomalous aortic origin of the coronary artery</text>
<text top="305" left="468" width="24" height="9" font="13">ACHD</text>
<text top="305" left="563" width="126" height="9" font="13">adult congenital heart disease</text>
<text top="324" left="468" width="11" height="9" font="13">AP</text>
<text top="324" left="563" width="113" height="9" font="13">anatomic and physiological</text>
<text top="343" left="468" width="12" height="9" font="13">AR</text>
<text top="343" left="563" width="81" height="9" font="13">aortic regurgitation</text>
<text top="362" left="468" width="17" height="9" font="13">ASD</text>
<text top="362" left="563" width="79" height="9" font="13">atrial septal defect</text>
<text top="382" left="468" width="23" height="9" font="13">AVSD</text>
<text top="382" left="563" width="121" height="9" font="13">atrioventricular septal defect</text>
<text top="401" left="468" width="18" height="9" font="13">BAV</text>
<text top="401" left="563" width="86" height="9" font="13">bicuspid aortic valve</text>
<text top="420" left="468" width="16" height="9" font="13">CCT</text>
<text top="420" left="563" width="128" height="9" font="13">cardiac computed tomography</text>
<text top="439" left="468" width="28" height="9" font="13">CCTGA</text>
<text top="439" left="563" width="238" height="9" font="13">congenitally corrected transposition of the great arteries</text>
<text top="458" left="468" width="18" height="9" font="13">CHD</text>
<text top="458" left="563" width="102" height="9" font="13">congenital heart disease</text>
<text top="478" left="468" width="19" height="9" font="13">CMR</text>
<text top="478" left="563" width="145" height="9" font="13">cardiovascular magnetic resonance</text>
<text top="497" left="468" width="17" height="9" font="13">CoA</text>
<text top="497" left="563" width="100" height="9" font="13">coarctation of the aorta</text>
<text top="516" left="468" width="22" height="9" font="13">CPET</text>
<text top="516" left="563" width="125" height="9" font="13">cardiopulmonary exercise test</text>
<text top="535" left="468" width="11" height="9" font="13">CT</text>
<text top="535" left="563" width="96" height="9" font="13">computed tomography</text>
<text top="554" left="468" width="17" height="9" font="13">CTA</text>
<text top="554" left="563" width="150" height="9" font="13">computed tomography angiography</text>
<text top="574" left="468" width="27" height="9" font="13">d-TGA</text>
<text top="574" left="563" width="173" height="9" font="13">dextro-transposition of the great arteries</text>
<text top="593" left="468" width="17" height="9" font="13">ECG</text>
<text top="593" left="563" width="76" height="9" font="13">electrocardiogram</text>
<text top="612" left="468" width="17" height="9" font="13">ERC</text>
<text top="612" left="563" width="119" height="9" font="13">Evidence Review Committee</text>
<text top="631" left="468" width="26" height="9" font="13">GDMT</text>
<text top="631" left="563" width="186" height="9" font="13">guideline-directed management and therapy</text>
<text top="650" left="468" width="12" height="9" font="13">HF</text>
<text top="650" left="563" width="51" height="9" font="13">heart failure</text>
<text top="670" left="468" width="14" height="9" font="13">ICD</text>
<text top="670" left="563" width="117" height="9" font="13">implantable cardioverter-de</text>
<text top="668" left="679" width="39" height="12" font="13">ﬁbrillator</text>
<text top="689" left="468" width="8" height="9" font="13">IE</text>
<text top="689" left="563" width="89" height="9" font="13">infective endocarditis</text>
<text top="708" left="468" width="11" height="9" font="13">LV</text>
<text top="708" left="563" width="62" height="9" font="13">left ventricular</text>
<text top="727" left="468" width="23" height="9" font="13">LVOT</text>
<text top="727" left="563" width="79" height="9" font="13">left ventricular out</text>
<text top="726" left="642" width="41" height="12" font="13">ﬂow tract</text>
<text top="746" left="468" width="11" height="9" font="13">PA</text>
<text top="746" left="563" width="72" height="9" font="13">pulmonary artery</text>
<text top="766" left="468" width="18" height="9" font="13">PAH</text>
<text top="766" left="563" width="134" height="9" font="13">pulmonary arterial hypertension</text>
<text top="785" left="468" width="18" height="9" font="13">PDA</text>
<text top="785" left="563" width="102" height="9" font="13">patent ductus arteriosus</text>
<text top="804" left="468" width="11" height="9" font="13">PR</text>
<text top="804" left="563" width="102" height="9" font="13">pulmonary regurgitation</text>
<text top="823" left="468" width="10" height="9" font="13">PS</text>
<text top="823" left="563" width="81" height="9" font="13">pulmonary stenosis</text>
<text top="842" left="468" width="25" height="9" font="13">Qp:Qs</text>
<text top="842" left="563" width="44" height="9" font="13">pulmonary</text>
<text top="841" left="607" width="111" height="12" font="13">–systemic blood ﬂow ratio</text>
<text top="862" left="468" width="12" height="9" font="13">RV</text>
<text top="862" left="563" width="67" height="9" font="13">right ventricular</text>
<text top="881" left="468" width="23" height="9" font="13">RVOT</text>
<text top="881" left="563" width="84" height="9" font="13">right ventricular out</text>
<text top="879" left="647" width="41" height="12" font="13">ﬂow tract</text>
<text top="900" left="468" width="17" height="9" font="13">SCD</text>
<text top="900" left="563" width="89" height="9" font="13">sudden cardiac death</text>
<text top="919" left="468" width="16" height="9" font="13">TEE</text>
<text top="919" left="563" width="145" height="9" font="13">transesophageal echocardiography</text>
<text top="939" left="468" width="17" height="9" font="13">TGA</text>
<text top="939" left="563" width="142" height="9" font="13">transposition of the great arteries</text>
<text top="958" left="468" width="17" height="9" font="13">TOF</text>
<text top="958" left="563" width="77" height="9" font="13">tetralogy of Fallot</text>
<text top="977" left="468" width="11" height="9" font="13">TR</text>
<text top="977" left="563" width="93" height="9" font="13">tricuspid regurgitation</text>
<text top="996" left="468" width="16" height="9" font="13">TTE</text>
<text top="996" left="563" width="131" height="9" font="13">transthoracic echocardiography</text>
<text top="1015" left="468" width="19" height="9" font="13">VHD</text>
<text top="1015" left="563" width="91" height="9" font="13">valvular heart disease</text>
<text top="1035" left="468" width="17" height="9" font="13">VSD</text>
<text top="1035" left="563" width="102" height="9" font="13">ventricular septal defect</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="21" height="9" font="5">1500</text>
</page>
<page number="8" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="17" size="7" family="Times" color="#0e2a52"/>
	<fontspec id="18" size="7" family="Times" color="#327eb1"/>
<text top="149" left="71" width="47" height="10" font="15">T A B L E 2</text>
<text top="149" left="135" width="202" height="10" font="16">Associated Guidelines and Statements</text>
<text top="185" left="63" width="21" height="9" font="13">Title</text>
<text top="185" left="528" width="59" height="9" font="13">Organization</text>
<text top="173" left="669" width="76" height="9" font="13">Publication Year</text>
<text top="185" left="679" width="55" height="9" font="13">(Reference)</text>
<text top="204" left="63" width="45" height="9" font="17">Guidelines</text>
<text top="224" left="63" width="35" height="9" font="13">Syncope</text>
<text top="224" left="527" width="60" height="9" font="13">ACC/AHA/HRS</text>
<text top="224" left="676" width="20" height="9" font="13">2017</text>
<text top="224" left="699" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#51">(S1.4-10)</a></text>
<text top="243" left="63" width="118" height="9" font="13">Supraventricular tachycardia</text>
<text top="243" left="527" width="60" height="9" font="13">ACC/AHA/HRS</text>
<text top="243" left="677" width="20" height="9" font="13">2015</text>
<text top="243" left="701" width="35" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#51">(S1.4-11)</a></text>
<text top="262" left="63" width="276" height="9" font="13">Cardiopulmonary resuscitation and emergency cardiovascular care</text>
<text top="260" left="339" width="36" height="12" font="13">—Part 8:</text>
<text top="274" left="78" width="95" height="9" font="13">postcardiac arrest care</text>
<text top="262" left="548" width="18" height="9" font="13">AHA</text>
<text top="262" left="677" width="20" height="9" font="13">2015</text>
<text top="262" left="700" width="37" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#51">(S1.4-12)</a></text>
<text top="293" left="63" width="186" height="9" font="13">Non-ST-elevation acute coronary syndromes</text>
<text top="293" left="538" width="39" height="9" font="13">AHA/ACC</text>
<text top="293" left="677" width="21" height="9" font="13">2014</text>
<text top="293" left="701" width="36" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#51">(S1.4-13)</a></text>
<text top="312" left="63" width="264" height="9" font="13">Perioperative cardiovascular evaluation and noncardiac surgery</text>
<text top="312" left="538" width="39" height="9" font="13">ACC/AHA</text>
<text top="312" left="676" width="21" height="9" font="13">2014</text>
<text top="312" left="700" width="37" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#51">(S1.4-14)</a></text>
<text top="332" left="63" width="23" height="9" font="13">Atrial</text>
<text top="330" left="88" width="43" height="12" font="13">ﬁbrillation</text>
<text top="332" left="527" width="60" height="9" font="13">AHA/ACC/HRS</text>
<text top="332" left="677" width="21" height="9" font="13">2014</text>
<text top="332" left="700" width="37" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#51">(S1.4-15)</a></text>
<text top="351" left="63" width="122" height="9" font="13">Stable ischemic heart disease</text>
<text top="351" left="480" width="153" height="9" font="13">ACC/AHA/ACP/AATS/PCNA/SCAI/STS</text>
<text top="351" left="675" width="21" height="9" font="13">2014</text>
<text top="351" left="699" width="37" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#51">(S1.4-16)</a></text>
<text top="351" left="736" width="3" height="9" font="13">,</text>
<text top="363" left="677" width="20" height="9" font="13">2012</text>
<text top="363" left="700" width="36" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#51">(S1.4-17)</a></text>
<text top="382" left="63" width="140" height="9" font="13">Assessment of cardiovascular risk</text>
<text top="382" left="538" width="39" height="9" font="13">ACC/AHA</text>
<text top="382" left="676" width="21" height="9" font="13">2014</text>
<text top="382" left="700" width="37" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#51">(S1.4-18)</a></text>
<text top="401" left="63" width="300" height="9" font="13">Blood cholesterol to reduce atherosclerotic cardiovascular risk in adults</text>
<text top="401" left="538" width="39" height="9" font="13">ACC/AHA</text>
<text top="401" left="676" width="21" height="9" font="13">2014</text>
<text top="401" left="700" width="37" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-19)</a></text>
<text top="420" left="63" width="139" height="9" font="13">Overweight and obesity in adults</text>
<text top="420" left="528" width="59" height="9" font="13">AHA/ACC/TOS</text>
<text top="420" left="675" width="21" height="9" font="13">2014</text>
<text top="420" left="699" width="39" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-20)</a></text>
<text top="440" left="63" width="215" height="9" font="13">Lifestyle management to reduce cardiovascular risk</text>
<text top="440" left="538" width="39" height="9" font="13">AHA/ACC</text>
<text top="440" left="677" width="21" height="9" font="13">2014</text>
<text top="440" left="700" width="37" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-21)</a></text>
<text top="459" left="63" width="92" height="9" font="13">Valvular heart disease</text>
<text top="459" left="538" width="39" height="9" font="13">AHA/ACC</text>
<text top="459" left="676" width="20" height="9" font="13">2017</text>
<text top="459" left="699" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-22)</a></text>
<text top="478" left="63" width="124" height="9" font="13">High blood pressure in adults</text>
<text top="478" left="464" width="186" height="9" font="13">ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/</text>
<text top="490" left="528" width="73" height="9" font="13">ASPC/NMA/PCNA</text>
<text top="478" left="676" width="20" height="9" font="13">2017</text>
<text top="478" left="700" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-23)</a></text>
<text top="509" left="63" width="137" height="9" font="13">Aortic valve and ascending aorta</text>
<text top="509" left="550" width="15" height="9" font="13">STS</text>
<text top="509" left="676" width="20" height="9" font="13">2013</text>
<text top="509" left="699" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-24)</a></text>
<text top="528" left="63" width="143" height="9" font="13">ST-elevation myocardial infarction</text>
<text top="528" left="538" width="39" height="9" font="13">ACC/AHA</text>
<text top="528" left="676" width="20" height="9" font="13">2013</text>
<text top="528" left="700" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-25)</a></text>
<text top="548" left="63" width="53" height="9" font="13">Heart failure</text>
<text top="548" left="525" width="65" height="9" font="13">ACC/AHA/HFSA</text>
<text top="548" left="676" width="20" height="9" font="13">2017</text>
<text top="548" left="699" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-26)</a></text>
<text top="567" left="63" width="230" height="9" font="13">Device-based therapy for cardiac rhythm abnormalities</text>
<text top="567" left="527" width="60" height="9" font="13">ACC/AHA/HRS</text>
<text top="567" left="676" width="20" height="9" font="13">2012</text>
<text top="567" left="700" width="37" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-27)</a></text>
<text top="586" left="63" width="154" height="9" font="13">Coronary artery bypass graft surgery</text>
<text top="586" left="538" width="39" height="9" font="13">ACC/AHA</text>
<text top="586" left="676" width="19" height="9" font="13">2011</text>
<text top="586" left="699" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-28)</a></text>
<text top="605" left="63" width="149" height="9" font="13">Percutaneous coronary intervention</text>
<text top="605" left="526" width="62" height="9" font="13">ACC/AHA/SCAI</text>
<text top="605" left="676" width="19" height="9" font="13">2011</text>
<text top="605" left="699" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-29)</a></text>
<text top="624" left="63" width="204" height="9" font="13">Secondary prevention and risk reduction therapy</text>
<text top="624" left="538" width="39" height="9" font="13">AHA/ACC</text>
<text top="624" left="676" width="19" height="9" font="13">2011</text>
<text top="624" left="698" width="39" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-30)</a></text>
<text top="644" left="63" width="138" height="9" font="13">Cardiovascular disease in women</text>
<text top="644" left="538" width="39" height="9" font="13">AHA/ACC</text>
<text top="644" left="677" width="19" height="9" font="13">2011</text>
<text top="644" left="700" width="36" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-31)</a></text>
<text top="663" left="63" width="146" height="9" font="13">Grown-up congenital heart disease</text>
<text top="663" left="549" width="16" height="9" font="13">ESC</text>
<text top="663" left="676" width="22" height="9" font="13">2010</text>
<text top="663" left="700" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-32)</a></text>
<text top="682" left="63" width="95" height="9" font="13">Thoracic aortic disease</text>
<text top="682" left="463" width="188" height="9" font="13">ACC/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/</text>
<text top="694" left="555" width="19" height="9" font="13">SVM</text>
<text top="682" left="676" width="22" height="9" font="13">2010</text>
<text top="682" left="700" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-33)</a></text>
<text top="713" left="63" width="127" height="9" font="13">Adult congenital heart disease</text>
<text top="713" left="549" width="16" height="9" font="13">CCS</text>
<text top="713" left="675" width="22" height="9" font="13">2010</text>
<text top="713" left="700" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-34)</a></text>
<text top="732" left="63" width="90" height="9" font="13">Infective endocarditis</text>
<text top="732" left="549" width="16" height="9" font="13">ESC</text>
<text top="732" left="675" width="24" height="9" font="13">2009</text>
<text top="732" left="701" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-35)</a></text>
<text top="752" left="63" width="28" height="9" font="17">Scienti</text>
<text top="750" left="91" width="62" height="12" font="17">ﬁc statements</text>
<text top="771" left="63" width="251" height="9" font="13">Imaging for patients with transposition of the great arteries</text>
<text top="771" left="549" width="16" height="9" font="13">ASE</text>
<text top="771" left="676" width="21" height="9" font="13">2016</text>
<text top="771" left="700" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-36)</a></text>
<text top="790" left="63" width="98" height="9" font="13">Cardiac chamber quanti</text>
<text top="788" left="161" width="121" height="12" font="13">ﬁcation by echocardiography</text>
<text top="790" left="549" width="16" height="9" font="13">ASE</text>
<text top="790" left="676" width="20" height="9" font="13">2015</text>
<text top="790" left="700" width="37" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-37)</a></text>
<text top="809" left="63" width="200" height="9" font="13">Consensus on arrhythmia management in ACHD</text>
<text top="809" left="533" width="48" height="9" font="13">PACES/HRS</text>
<text top="809" left="676" width="21" height="9" font="13">2014</text>
<text top="809" left="700" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-38)</a></text>
<text top="828" left="63" width="224" height="9" font="13">Imaging for patients with repaired tetralogy of Fallot</text>
<text top="828" left="549" width="16" height="9" font="13">ASE</text>
<text top="828" left="676" width="21" height="9" font="13">2014</text>
<text top="828" left="700" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-39)</a></text>
<text top="848" left="63" width="95" height="9" font="13">Thoracic aortic disease</text>
<text top="848" left="549" width="16" height="9" font="13">CCS</text>
<text top="848" left="675" width="21" height="9" font="13">2014</text>
<text top="848" left="699" width="40" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-40)</a></text>
<text top="867" left="63" width="266" height="9" font="13">Promotion of physical activity for children and adults with CHD</text>
<text top="867" left="548" width="18" height="9" font="13">AHA</text>
<text top="867" left="677" width="20" height="9" font="13">2013</text>
<text top="867" left="700" width="37" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-41)</a></text>
<text top="886" left="63" width="221" height="9" font="13">Neurodevelopmental outcomes in children with CHD</text>
<text top="886" left="548" width="18" height="9" font="13">AHA</text>
<text top="886" left="676" width="20" height="9" font="13">2012</text>
<text top="886" left="699" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-42)</a></text>
<text top="905" left="63" width="167" height="9" font="13">Pregnancy in women with heart disease</text>
<text top="905" left="549" width="16" height="9" font="13">ESC</text>
<text top="905" left="677" width="19" height="9" font="13">2011</text>
<text top="905" left="699" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-43)</a></text>
<text top="924" left="63" width="209" height="9" font="13">Transition to adulthood for adolescents with CHD</text>
<text top="924" left="548" width="18" height="9" font="13">AHA</text>
<text top="924" left="676" width="19" height="9" font="13">2011</text>
<text top="924" left="698" width="39" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-44)</a></text>
<text top="944" left="63" width="102" height="9" font="13">Pulmonary hypertension</text>
<text top="944" left="538" width="39" height="9" font="13">ACC/AHA</text>
<text top="944" left="674" width="24" height="9" font="13">2009</text>
<text top="944" left="701" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-45)</a></text>
<text top="963" left="63" width="149" height="9" font="13">Prevention of infective endocarditis</text>
<text top="963" left="548" width="18" height="9" font="13">AHA</text>
<text top="963" left="675" width="22" height="9" font="13">2007</text>
<text top="963" left="700" width="39" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#52">(S1.4-46)</a></text>
<text top="986" left="63" width="694" height="8" font="5">AATS indicates American Association for Thoracic Surgery; ABC, Association of Black Cardiologists; ACC, American College of Cardiology; ACHD, adult congenital heart disease; ACP,</text>
<text top="998" left="63" width="694" height="8" font="5">American College of Physicians; ACPM, American College of Preventive Medicine; ACR, American College of Radiology; AGS, American Geriatrics Society; AHA, American Heart As-</text>
<text top="1010" left="63" width="694" height="8" font="5">sociation; APhA, American Pharmacists Association; ASA, American Stroke Association; ASE, American Society of Echocardiography; ASH, American Society of Hypertension; ASPC,</text>
<text top="1022" left="63" width="694" height="8" font="5">American Society of Preventive Cardiology; CCS, Canadian Cardiovascular Society; CHD, congenital heart disease; ESC, European Society of Cardiology; HFSA, Heart Failure Society of</text>
<text top="1034" left="63" width="694" height="8" font="5">America; HRS, Heart Rhythm Society; NMA, National Medical Association; PACES, Pediatric and Congenital Electrophysiology Society; PCNA, Preventive Cardiovascular Nurses As-</text>
<text top="1046" left="63" width="694" height="8" font="5">sociation; SCA, Society of Cardiovascular Anesthesiologists; SCAI, Society for Cardiovascular Angiography and Interventions; SIR, Society of Interventional Radiology; STS, Society of</text>
<text top="1058" left="63" width="333" height="8" font="5">Thoracic Surgeons; SVM, Society for Vascular Medicine; and TOS, The Obesity Society.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="789" width="18" height="9" font="5">1501</text>
</page>
<page number="9" position="absolute" top="0" left="0" height="1160" width="864">
<text top="141" left="108" width="289" height="16" font="14">2. BACKGROUND AND PATHOPHYSIOLOGY</text>
<text top="179" left="108" width="205" height="11" font="12">2.1. Anatomic and Physiological Terms</text>
<text top="200" left="108" width="333" height="12" font="2">The International Society for Nomenclature of Pediatric</text>
<text top="218" left="108" width="333" height="12" font="2">and Congenital Heart Disease (also known as the</text>
<text top="236" left="108" width="206" height="12" font="2">Nomenclature Working Group) de</text>
<text top="234" left="314" width="127" height="15" font="2">ﬁned, codiﬁed, map-</text>
<text top="254" left="108" width="333" height="12" font="2">ped, and archived examples of nomenclatures and</text>
<text top="272" left="108" width="218" height="12" font="2">developed standards for terminology</text>
<text top="272" left="331" width="36" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#52">(S2.1-1</a></text>
<text top="270" left="367" width="43" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#52">–S2.1-5)</a></text>
<text top="272" left="411" width="30" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#52">. </a>The</text>
<text top="290" left="108" width="333" height="12" font="2">International Paediatric and Congenital Cardiac Code</text>
<text top="308" left="108" width="333" height="12" font="2">(IPCCC) nomenclature for anatomic lesions and repairs is</text>
<text top="326" left="108" width="135" height="12" font="2">used in this guideline (</text>
<text top="326" left="243" width="90" height="12" font="4"><a href="http://ipccc.net/">http://ipccc.net</a></text>
<text top="326" left="333" width="4" height="12" font="2"><a href="http://ipccc.net/">)</a></text>
<text top="326" left="341" width="42" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#53">(S2.1-6)</a></text>
<text top="326" left="384" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#53">.</a></text>
<text top="366" left="108" width="116" height="11" font="12">2.2. Severity of ACHD</text>
<text top="387" left="108" width="333" height="12" font="2">In a patient with CHD, severity of disease is determined</text>
<text top="405" left="108" width="333" height="12" font="2">by native anatomy, surgical repair, and current physi-</text>
<text top="423" left="108" width="333" height="12" font="2">ology. Prior documents, including the 2008 ACHD guide-</text>
<text top="441" left="108" width="22" height="12" font="2">line</text>
<text top="441" left="135" width="42" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#53">(S2.2-1)</a></text>
<text top="441" left="177" width="215" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#53">, </a>relied primarily on anatomic classi</text>
<text top="439" left="392" width="49" height="15" font="2">ﬁcations</text>
<text top="459" left="108" width="333" height="12" font="2">to rank severity of disease. However, patients with the</text>
<text top="477" left="108" width="333" height="12" font="2">same underlying anatomy may have very different repairs</text>
<text top="495" left="108" width="333" height="12" font="2">and experienced variable physiological consequences of</text>
<text top="513" left="108" width="333" height="12" font="2">those repairs. For example, a patient with tetralogy of</text>
<text top="531" left="108" width="333" height="12" font="2">Fallot (TOF) after a valve-sparing primary repair may have</text>
<text top="549" left="108" width="333" height="12" font="2">excellent biventricular function with normal exercise ca-</text>
<text top="567" left="108" width="333" height="12" font="2">pacity and no arrhythmias, whereas another patient of the</text>
<text top="585" left="108" width="333" height="12" font="2">same age with TOF may have had palliative shunting</text>
<text top="602" left="108" width="333" height="12" font="2">followed by a transannular patch repair resulting in se-</text>
<text top="620" left="108" width="333" height="12" font="2">vere pulmonary regurgitation (PR) with right ventricular</text>
<text top="638" left="108" width="333" height="12" font="2">(RV) enlargement, biventricular dysfunction, and ven-</text>
<text top="656" left="108" width="333" height="12" font="2">tricular tachycardia. To categorize disease severity in CHD</text>
<text top="674" left="108" width="333" height="12" font="2">in a more comprehensive way, the writing committee</text>
<text top="692" left="108" width="333" height="12" font="2">developed an ACHD Anatomic and Physiological (AP)</text>
<text top="710" left="108" width="31" height="12" font="2">classi</text>
<text top="708" left="139" width="94" height="15" font="2">ﬁcation system (</text>
<text top="710" left="234" width="79" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="710" left="313" width="128" height="12" font="2">) that incorporates the</text>
<text top="728" left="108" width="333" height="12" font="2">previously described CHD anatomic variables as well as</text>
<text top="746" left="108" width="334" height="12" font="2">physiological variables, many of which have prognostic</text>
<text top="764" left="108" width="170" height="12" font="2">value in patients with ACHD.</text>
<text top="799" left="108" width="129" height="11" font="12">2.3. The ACHD AP Classi</text>
<text top="797" left="237" width="39" height="15" font="12">ﬁcation</text>
<text top="821" left="108" width="116" height="12" font="2">The ACHD AP classi</text>
<text top="819" left="224" width="52" height="15" font="2">ﬁcation (</text>
<text top="821" left="277" width="84" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="821" left="360" width="80" height="12" font="2">), newly elab-</text>
<text top="839" left="108" width="333" height="12" font="2">orated in this guideline, is intended to capture the</text>
<text top="857" left="108" width="333" height="12" font="2">complexity of ACHD anatomy and physiology, which are</text>
<text top="875" left="108" width="333" height="12" font="2">not always correlated. Certain anatomic abnormalities of</text>
<text top="893" left="108" width="333" height="12" font="2">clinical importance are shared across diagnoses (e.g.,</text>
<text top="910" left="108" width="333" height="12" font="2">aortic enlargement), which may be found in patients with</text>
<text top="928" left="108" width="333" height="12" font="2">BAV, coarctation of the aorta (CoA), transposition of the</text>
<text top="946" left="108" width="333" height="12" font="2">great arteries, and TOF, amongst others. In every patient,</text>
<text top="964" left="108" width="333" height="12" font="2">anatomic and physiological variables should be consid-</text>
<text top="982" left="108" width="79" height="12" font="2">ered. In using</text>
<text top="982" left="189" width="79" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="982" left="269" width="150" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#11">, </a>a patient should be classi</text>
<text top="980" left="419" width="22" height="15" font="2">ﬁed</text>
<text top="1000" left="108" width="73" height="12" font="2">based on the</text>
<text top="998" left="184" width="257" height="15" font="2">“highest” relevant anatomic or physiological</text>
<text top="1018" left="108" width="333" height="12" font="2">feature. For example, a normotensive patient with</text>
<text top="1036" left="108" width="333" height="12" font="2">repaired CoA, normal exercise capacity, and normal end-</text>
<text top="1054" left="108" width="261" height="12" font="2">organ function would be ACHD AP classi</text>
<text top="1052" left="369" width="72" height="15" font="2">ﬁcation IIA,</text>
<text top="1072" left="108" width="333" height="12" font="2">whereas an otherwise similar patient with ascending</text>
<text top="1090" left="108" width="290" height="12" font="2">aortic diameter of 4.0 cm would be ACHD AP classi</text>
<text top="1088" left="398" width="43" height="15" font="2">ﬁcation</text>
<text top="143" left="468" width="333" height="12" font="2">IIB, and if moderate aortic stenosis were also present, the</text>
<text top="161" left="468" width="89" height="12" font="2">ACHD AP classi</text>
<text top="159" left="557" width="125" height="15" font="2">ﬁcation would be IIC.</text>
<text top="178" left="483" width="318" height="12" font="2">Patients with ACHD may have baseline exercise limi-</text>
<text top="196" left="468" width="333" height="12" font="2">tations, cyanosis, end-organ dysfunction, or other clini-</text>
<text top="214" left="468" width="333" height="12" font="2">cally important comorbidities related to their CHD. They</text>
<text top="232" left="468" width="333" height="12" font="2">are also at risk of HF, arrhythmias, sudden cardiac death</text>
<text top="250" left="468" width="333" height="12" font="2">(SCD), and development or progression of cardiac symp-</text>
<text top="268" left="468" width="333" height="12" font="2">toms such as dyspnea, chest pain, and exercise intoler-</text>
<text top="286" left="468" width="333" height="12" font="2">ance. Concomitant valvular disease or aortic pathology</text>
<text top="304" left="468" width="333" height="12" font="2">may be present. There are growing data regarding the</text>
<text top="322" left="468" width="333" height="12" font="2">prognostic implications of these variables in patients with</text>
<text top="340" left="468" width="333" height="12" font="2">ACHD, but not the abundance of data available for pa-</text>
<text top="358" left="468" width="198" height="12" font="2">tients with acquired heart disease</text>
<text top="358" left="670" width="37" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#53">(S2.3-1</a></text>
<text top="356" left="708" width="50" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#53">–S2.3-16)</a></text>
<text top="358" left="758" width="3" height="12" font="2">.</text>
<text top="376" left="483" width="293" height="12" font="2">The variables forming part of the ACHD AP classi</text>
<text top="374" left="776" width="25" height="15" font="2">ﬁca-</text>
<text top="394" left="468" width="31" height="12" font="2">tion (</text>
<text top="394" left="499" width="40" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#10">Table 3</a></text>
<text top="394" left="540" width="262" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#10">) </a>were selected because data exist suggesting</text>
<text top="412" left="468" width="333" height="12" font="2">their importance in prognosis, management, or quality of</text>
<text top="430" left="468" width="333" height="12" font="2">life. As new data become available, we expect changes in</text>
<text top="447" left="468" width="333" height="12" font="2">the relative weights attributed to the components of the</text>
<text top="465" left="468" width="95" height="12" font="2">ACHD AP classi</text>
<text top="464" left="563" width="238" height="15" font="2">ﬁcation and perhaps new components,</text>
<text top="483" left="468" width="333" height="12" font="2">resulting in a scheme that ever more precisely tracks</text>
<text top="501" left="468" width="333" height="12" font="2">overall severity of disease and need for more or less</text>
<text top="519" left="468" width="223" height="12" font="2">intensive follow-up and management.</text>
<text top="537" left="483" width="318" height="12" font="2">Similar to the New York Heart Association (NYHA)</text>
<text top="555" left="468" width="31" height="12" font="2">classi</text>
<text top="553" left="499" width="302" height="15" font="2">ﬁcation of functional status, patients may move</text>
<text top="573" left="468" width="147" height="12" font="2">from one ACHD AP classi</text>
<text top="571" left="615" width="186" height="15" font="2">ﬁcation to another over time. If</text>
<text top="591" left="468" width="193" height="12" font="2">clinical status worsens, the classi</text>
<text top="589" left="662" width="140" height="15" font="2">ﬁcation will change to a</text>
<text top="609" left="468" width="333" height="12" font="2">higher severity group, but improvement in status, for</text>
<text top="627" left="468" width="333" height="12" font="2">example after an intervention such as valve replacement</text>
<text top="645" left="468" width="333" height="12" font="2">or control of arrhythmia, can result in change to a lower</text>
<text top="663" left="468" width="82" height="12" font="2">severity classi</text>
<text top="661" left="551" width="250" height="15" font="2">ﬁcation. Such movement among classes is</text>
<text top="681" left="468" width="211" height="12" font="2">unlike the AHA HF A to D classi</text>
<text top="679" left="679" width="43" height="15" font="2">ﬁcation</text>
<text top="681" left="730" width="48" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#53">(S2.3-17)</a></text>
<text top="681" left="779" width="22" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#53">, </a>in</text>
<text top="698" left="468" width="333" height="12" font="2">which patients move in only one direction. This ACHD</text>
<text top="716" left="468" width="56" height="12" font="2">AP classi</text>
<text top="715" left="524" width="277" height="15" font="2">ﬁcation is used throughout this document,</text>
<text top="734" left="468" width="333" height="12" font="2">particularly when considering follow-up visits and need</text>
<text top="752" left="468" width="232" height="12" font="2">for testing. As the ACHD AP classi</text>
<text top="751" left="700" width="101" height="15" font="2">ﬁcation worsens</text>
<text top="770" left="468" width="333" height="12" font="2">because of changes in physiology (e.g., development of</text>
<text top="788" left="468" width="333" height="12" font="2">arrhythmias, HF, end-organ disease), the nature and</text>
<text top="806" left="468" width="333" height="12" font="2">frequency of recommended follow-up visits and testing</text>
<text top="824" left="468" width="263" height="12" font="2">will also change, adapting to the patient</text>
<text top="822" left="731" width="70" height="15" font="2">’s changing</text>
<text top="842" left="468" width="333" height="12" font="2">circumstance instead of depending solely on a descrip-</text>
<text top="860" left="468" width="333" height="12" font="2">tion of anatomic disease, which may not adequately</text>
<text top="878" left="468" width="333" height="12" font="2">discriminate physiological changes that alter severity</text>
<text top="896" left="468" width="60" height="12" font="2">over time.</text>
<text top="914" left="483" width="319" height="12" font="2">Some patients with ACHD may have substantial</text>
<text top="932" left="468" width="333" height="12" font="2">acquired comorbidities unrelated to CHD, and as a conse-</text>
<text top="950" left="468" width="333" height="12" font="2">quence, their follow-up strategies might be more appro-</text>
<text top="967" left="468" width="333" height="12" font="2">priately be based on other existing guidelines for acquired</text>
<text top="985" left="468" width="333" height="12" font="2">heart disease. For example, an 80-year-old patient who</text>
<text top="1003" left="468" width="333" height="12" font="2">has a small atrial septal defect (ASD), but whose symptoms</text>
<text top="1021" left="468" width="333" height="12" font="2">are related to diastolic HF, chronic kidney disease caused</text>
<text top="1039" left="468" width="333" height="12" font="2">by hypertension and diabetes mellitus, and moderate</text>
<text top="1057" left="468" width="333" height="12" font="2">aortic stenosis is well-suited to be followed according to</text>
<text top="1075" left="468" width="333" height="12" font="2">existing guidelines for those diseases, rather than ac-</text>
<text top="1093" left="468" width="200" height="12" font="2">cording to the ACHD AP classi</text>
<text top="1091" left="668" width="133" height="15" font="2">ﬁcation for the ASD.</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="20" height="9" font="5">1502</text>
</page>
<page number="10" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="19" size="5" family="Times" color="#999999"/>
<text top="149" left="71" width="47" height="10" font="15">T A B L E 3</text>
<text top="149" left="135" width="266" height="10" font="16">Physiological Variables as Used in ACHD AP Classi</text>
<text top="147" left="401" width="39" height="14" font="16">ﬁcation</text>
<text top="173" left="63" width="38" height="9" font="13">Variable</text>
<text top="173" left="463" width="53" height="9" font="13">Description</text>
<text top="192" left="63" width="48" height="9" font="13">Aortopathy</text>
<text top="192" left="226" width="521" height="9" font="13">Aortic enlargement is common in some types of CHD and after some repairs. Aortic enlargement may be progressive over a</text>
<text top="204" left="237" width="458" height="9" font="13">lifetime. There is no universally accepted threshold for repair, nor is the role of indexing to body size clearly de</text>
<text top="203" left="695" width="61" height="12" font="13">ﬁned in adults,</text>
<text top="216" left="237" width="417" height="9" font="13">as is done in pediatric populations. For purposes of categorization and timing of follow-up imaging</text>
<text top="216" left="657" width="30" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#53">(S2.2-2</a></text>
<text top="215" left="687" width="35" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#53">–S2.2-4)</a></text>
<text top="216" left="722" width="3" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#53">:</a></text>
<text top="228" left="227" width="6" height="10" font="9">n</text>
<text top="229" left="241" width="130" height="9" font="13">Mild aortic enlargement is de</text>
<text top="227" left="371" width="173" height="12" font="13">ﬁned as maximum diameter 3.5–3.9 cm</text>
<text top="240" left="227" width="6" height="10" font="9">n</text>
<text top="240" left="241" width="153" height="9" font="13">Moderate aortic enlargement is de</text>
<text top="239" left="394" width="175" height="12" font="13">ﬁned as maximum diameter 4.0–4.9 cm</text>
<text top="251" left="227" width="6" height="10" font="9">n</text>
<text top="252" left="241" width="140" height="9" font="13">Severe aortic enlargement is de</text>
<text top="250" left="381" width="163" height="12" font="13">ﬁned as maximum diameter $5.0 cm</text>
<text top="271" left="63" width="48" height="9" font="13">Arrhythmia</text>
<text top="271" left="226" width="483" height="9" font="13">Arrhythmias are very common in patients with ACHD and may be both the cause and consequence of deteriorating</text>
<text top="283" left="237" width="518" height="9" font="13">hemodynamics, valvular dysfunction, or ventricular dysfunction. Arrhythmias are associated with symptoms, outcomes, and</text>
<text top="295" left="237" width="40" height="9" font="13">prognosis</text>
<text top="295" left="281" width="30" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#53">(S2.2-5</a></text>
<text top="293" left="310" width="35" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#53">–S2.2-8)</a></text>
<text top="295" left="345" width="290" height="9" font="13">, thus are categorized based on presence and response to treatment.</text>
<text top="307" left="227" width="6" height="10" font="9">n</text>
<text top="307" left="241" width="63" height="9" font="13">No arrhythmia</text>
<text top="306" left="304" width="324" height="12" font="13">–No documented clinically relevant atrial or ventricular tachyarrhythmias</text>
<text top="318" left="227" width="6" height="10" font="9">n</text>
<text top="319" left="241" width="157" height="9" font="13">Arrhythmia not requiring treatment</text>
<text top="317" left="398" width="305" height="12" font="13">–Bradyarrhythmia, atrial or ventricular tachyarrhythmia not requiring</text>
<text top="329" left="241" width="220" height="9" font="13">antiarrhythmic therapy, cardioversion, or ablation</text>
<text top="339" left="227" width="6" height="10" font="9">n</text>
<text top="340" left="241" width="160" height="9" font="13">Arrhythmia controlled with therapy:</text>
<text top="350" left="249" width="6" height="10" font="19">n</text>
<text top="351" left="263" width="225" height="9" font="13">Bradyarrhythmia requiring pacemaker implantation</text>
<text top="362" left="249" width="6" height="10" font="19">n</text>
<text top="362" left="263" width="428" height="9" font="13">Atrial or ventricular tachyarrhythmia requiring antiarrhythmic therapy, cardioversion, or ablation</text>
<text top="373" left="249" width="6" height="10" font="19">n</text>
<text top="374" left="263" width="172" height="9" font="13">AF and controlled ventricular response</text>
<text top="384" left="249" width="6" height="10" font="19">n</text>
<text top="385" left="263" width="90" height="9" font="13">Patients with an ICD</text>
<text top="395" left="227" width="6" height="10" font="9">n</text>
<text top="396" left="241" width="104" height="9" font="13">Refractory arrhythmias:</text>
<text top="406" left="249" width="6" height="10" font="19">n</text>
<text top="407" left="263" width="493" height="9" font="13">Atrial or ventricular tachyarrhythmia currently unresponsive to or refractory to antiarrhythmic therapy or ablation</text>
<text top="426" left="63" width="76" height="9" font="13">Concomitant VHD</text>
<text top="426" left="226" width="47" height="9" font="13">Severity de</text>
<text top="425" left="273" width="180" height="12" font="13">ﬁned according to the 2014 VHD guideline</text>
<text top="426" left="456" width="33" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#53">(S2.2-2)</a></text>
<text top="426" left="489" width="3" height="9" font="13">.</text>
<text top="441" left="227" width="6" height="10" font="9">n</text>
<text top="442" left="241" width="42" height="9" font="13">Mild VHD</text>
<text top="452" left="227" width="6" height="10" font="9">n</text>
<text top="453" left="241" width="64" height="9" font="13">Moderate VHD</text>
<text top="464" left="227" width="6" height="10" font="9">n</text>
<text top="465" left="241" width="52" height="9" font="13">Severe VHD</text>
<text top="484" left="63" width="97" height="9" font="13">End-organ dysfunction</text>
<text top="484" left="226" width="256" height="9" font="13">Clinical and/or laboratory evidence of end-organ dysfunction</text>
<text top="484" left="485" width="31" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#53">(S2.2-9</a></text>
<text top="482" left="516" width="37" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#53">–S2.2-11)</a></text>
<text top="484" left="556" width="38" height="9" font="13">including</text>
<text top="499" left="227" width="6" height="10" font="9">n</text>
<text top="499" left="241" width="63" height="9" font="13">Renal (kidney)</text>
<text top="510" left="227" width="6" height="10" font="9">n</text>
<text top="511" left="241" width="63" height="9" font="13">Hepatic (liver)</text>
<text top="521" left="227" width="6" height="10" font="9">n</text>
<text top="522" left="241" width="77" height="9" font="13">Pulmonary (lung)</text>
<text top="541" left="63" width="73" height="9" font="13">Exercise capacity</text>
<text top="541" left="226" width="530" height="9" font="13">Patients with ACHD are often asymptomatic notwithstanding exercise limitations demonstrated as diminished exercise capacity</text>
<text top="553" left="237" width="114" height="9" font="13">when evaluated objectively</text>
<text top="553" left="355" width="34" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#53">(S2.2-12</a></text>
<text top="551" left="389" width="39" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#53">–S2.2-14)</a></text>
<text top="553" left="427" width="299" height="9" font="13">. Thus, assessment of both subjective and objective exercise capacity is</text>
<text top="565" left="237" width="114" height="9" font="13">important (see NYHA classi</text>
<text top="563" left="351" width="292" height="12" font="13">ﬁcation system below). Exercise capacity is associated with prognosis</text>
<text top="565" left="646" width="34" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#53">(S2.2-15</a></text>
<text top="563" left="680" width="38" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#53">–S2.2-17)</a></text>
<text top="565" left="717" width="3" height="9" font="13">.</text>
<text top="577" left="227" width="6" height="10" font="9">n</text>
<text top="578" left="241" width="238" height="9" font="13">Abnormal objective cardiac limitation to exercise is de</text>
<text top="576" left="479" width="277" height="12" font="13">ﬁned as an exercise maximum ventilatory equivalent of oxygen</text>
<text top="588" left="241" width="174" height="9" font="13">below the range expected for the speci</text>
<text top="586" left="416" width="120" height="12" font="13">ﬁc CHD anatomic diagnosis</text>
<text top="588" left="539" width="40" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#53">(S2.2-18)</a></text>
<text top="588" left="579" width="3" height="9" font="13">.</text>
<text top="598" left="227" width="6" height="10" font="9">n</text>
<text top="599" left="241" width="463" height="9" font="13">Expected norms for CPET values should take into account age, sex, and underlying congenital diagnosis. Published</text>
<text top="609" left="241" width="117" height="9" font="13">studies with institution-speci</text>
<text top="608" left="358" width="395" height="12" font="13">ﬁc norms can be used as guides, bearing in mind variability among institutional norms and ranges.</text>
<text top="628" left="63" width="124" height="9" font="13">Hypoxemia/hypoxia/cyanosis</text>
<text top="628" left="226" width="15" height="9" font="13">See</text>
<text top="628" left="244" width="50" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#21">Section 3.15</a></text>
<text top="628" left="294" width="68" height="9" font="13">. for detailed de</text>
<text top="627" left="362" width="81" height="12" font="13">ﬁnition of cyanosis.</text>
<text top="643" left="227" width="6" height="10" font="9">n</text>
<text top="644" left="241" width="72" height="9" font="13">Hypoxemia is de</text>
<text top="643" left="314" width="312" height="12" font="13">ﬁned as oxygen saturation measured by pulse oximetry at rest #90%.</text>
<text top="655" left="227" width="6" height="10" font="9">n</text>
<text top="655" left="241" width="103" height="9" font="13">Severe hypoxemia is de</text>
<text top="654" left="345" width="182" height="12" font="13">ﬁned as oxygen saturation at rest &lt;85%.</text>
<text top="666" left="227" width="6" height="10" font="9">n</text>
<text top="667" left="241" width="515" height="9" font="13">In patients with normal or high hemoglobin concentrations, severe hypoxemia will be associated with visible cyanosis</text>
<text top="677" left="241" width="68" height="9" font="13">(which requires</text>
<text top="675" left="312" width="226" height="12" font="13">$5g/L desaturated hemoglobin to be appreciated).</text>
<text top="687" left="227" width="6" height="10" font="9">n</text>
<text top="688" left="241" width="515" height="9" font="13">The terms cyanosis and hypoxemia (or hypoxia) are sometimes used interchangeably. Such interchangeability would</text>
<text top="698" left="241" width="471" height="9" font="13">not apply; however, in the presence of anemia, severe hypoxemia can be present without visible cyanosis.</text>
<text top="718" left="63" width="97" height="9" font="13">NYHA functional classi</text>
<text top="716" left="160" width="31" height="12" font="13">ﬁcation</text>
<text top="729" left="78" width="30" height="9" font="13">system</text>
<text top="729" left="111" width="37" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#53">(S2.3-31)</a></text>
<text top="718" left="226" width="108" height="9" font="13">Class Functional Capacity</text>
<text top="733" left="231" width="526" height="9" font="13">I Patients with cardiac disease but resulting in no limitation of physical activity. Ordinary physical activity does not cause</text>
<text top="743" left="238" width="232" height="9" font="13">undue fatigue, palpitation, dyspnea, or anginal pain.</text>
<text top="755" left="228" width="528" height="9" font="13">II Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary</text>
<text top="765" left="238" width="320" height="9" font="13">physical activity results in fatigue, palpitation, dyspnea, or anginal pain.</text>
<text top="776" left="223" width="533" height="9" font="13">III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than</text>
<text top="786" left="236" width="309" height="9" font="13">ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.</text>
<text top="797" left="223" width="534" height="9" font="13">IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of HF</text>
<text top="808" left="236" width="503" height="9" font="13">or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort increases.</text>
<text top="827" left="63" width="105" height="9" font="13">Pulmonary hypertension</text>
<text top="827" left="226" width="530" height="9" font="13">Pulmonary hypertension is a broad term that encompasses pulmonary arterial hypertension, which is pulmonary hypertension with</text>
<text top="839" left="237" width="244" height="9" font="13">increased pulmonary vascular resistance. This document de</text>
<text top="837" left="481" width="245" height="12" font="13">ﬁnes PH and PAH as they are used in the ﬁeld of pulmonary</text>
<text top="851" left="237" width="57" height="9" font="13">hypertension.</text>
<text top="863" left="226" width="122" height="9" font="13">Pulmonary hypertension is de</text>
<text top="861" left="348" width="35" height="12" font="13">ﬁned as:</text>
<text top="875" left="227" width="6" height="10" font="9">n</text>
<text top="876" left="241" width="213" height="9" font="13">Mean PA pressure by right heart catheterization</text>
<text top="874" left="457" width="56" height="12" font="13">$25 mm Hg.</text>
<text top="887" left="226" width="41" height="9" font="13">PAH is de</text>
<text top="886" left="267" width="35" height="12" font="13">ﬁned as:</text>
<text top="899" left="227" width="6" height="10" font="9">n</text>
<text top="900" left="241" width="213" height="9" font="13">Mean PA pressure by right heart catheterization</text>
<text top="898" left="457" width="298" height="12" font="13">$25 mm Hg and a pulmonary capillary wedge pressure #15 mm Hg</text>
<text top="910" left="241" width="152" height="9" font="13">and pulmonary vascular resistance</text>
<text top="909" left="397" width="66" height="12" font="13">$3 Wood units</text>
<text top="910" left="466" width="42" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#53">(S2.2-20)</a></text>
<text top="930" left="63" width="129" height="9" font="13">Shunt (hemodynamically signi</text>
<text top="928" left="191" width="24" height="12" font="13">ﬁcant</text>
<text top="942" left="78" width="27" height="9" font="13">shunt)</text>
<text top="930" left="226" width="196" height="9" font="13">An intracardiac shunt is hemodynamically signi</text>
<text top="928" left="422" width="35" height="12" font="13">ﬁcant if:</text>
<text top="944" left="227" width="6" height="10" font="9">n</text>
<text top="945" left="241" width="274" height="9" font="13">There is evidence of chamber enlargement distal to the shunt</text>
<text top="956" left="227" width="6" height="10" font="9">n</text>
<text top="956" left="241" width="159" height="9" font="13">And/or evidence of sustained Qp:Qs</text>
<text top="955" left="403" width="27" height="12" font="13">$1.5:1</text>
<text top="967" left="227" width="6" height="10" font="9">n</text>
<text top="968" left="241" width="381" height="9" font="13">An intracardiac shunt not meeting these criteria would be described as small or trivial</text>
<text top="987" left="63" width="121" height="9" font="13">Venous and arterial stenosis</text>
<text top="990" left="227" width="6" height="10" font="9">n</text>
<text top="991" left="241" width="161" height="9" font="13">Aortic recoarctation after CoA repair</text>
<text top="1001" left="227" width="6" height="10" font="9">n</text>
<text top="1002" left="241" width="142" height="9" font="13">Supravalvular aortic obstruction</text>
<text top="1012" left="227" width="6" height="10" font="9">n</text>
<text top="1013" left="241" width="49" height="9" font="13">Venous baf</text>
<text top="1011" left="290" width="65" height="12" font="13">ﬂe obstruction</text>
<text top="1023" left="227" width="6" height="10" font="9">n</text>
<text top="1024" left="241" width="149" height="9" font="13">Supravalvular pulmonary stenosis</text>
<text top="1035" left="227" width="6" height="10" font="9">n</text>
<text top="1035" left="241" width="84" height="9" font="13">Branch PA stenosis</text>
<text top="1046" left="227" width="6" height="10" font="9">n</text>
<text top="1047" left="241" width="170" height="9" font="13">Stenosis of cavopulmonary connection</text>
<text top="1057" left="227" width="6" height="10" font="9">n</text>
<text top="1058" left="241" width="107" height="9" font="13">Pulmonary vein stenosis</text>
<text top="1082" left="63" width="212" height="8" font="5">ACHD indicates adult congenital heart disease; AF, atrial</text>
<text top="1080" left="277" width="479" height="11" font="5">ﬁbrillation; AP, anatomic and physiologic; CHD, congenital heart disease; CoA, coarctation of the aorta; CPET, cardiopulmonary</text>
<text top="1093" left="63" width="248" height="8" font="5">exercise test; HF, heart failure; ICD, implantable cardioverter-de</text>
<text top="1092" left="311" width="445" height="11" font="5">ﬁbrillator; NYHA, New York Heart Association; PA, pulmonary artery; PAH, pulmonary arterial hypertension; Qp:Qs,</text>
<text top="1105" left="63" width="41" height="8" font="5">pulmonary</text>
<text top="1104" left="104" width="233" height="11" font="5">–systemic blood ﬂow ratio; and VHD, valvular heart disease.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="788" width="19" height="9" font="5">1503</text>
</page>
<page number="11" position="absolute" top="0" left="0" height="1160" width="864">
<text top="561" left="468" width="79" height="12" font="2">Nevertheless,</text>
<text top="561" left="560" width="19" height="12" font="2">the</text>
<text top="561" left="592" width="36" height="12" font="2">added</text>
<text top="561" left="641" width="82" height="12" font="2">hemodynamic</text>
<text top="561" left="737" width="65" height="12" font="2">complexity</text>
<text top="579" left="468" width="244" height="12" font="2">brought by the ASD must be kept in mind.</text>
<text top="597" left="483" width="275" height="12" font="2">Throughout this document, the ACHD AP classi</text>
<text top="595" left="758" width="43" height="15" font="2">ﬁcation</text>
<text top="615" left="468" width="333" height="12" font="2">is used to help guide resource utilization, including ACHD</text>
<text top="633" left="468" width="257" height="12" font="2">consultation and routine diagnostic studies.</text>
<text top="675" left="468" width="166" height="16" font="14">3. GENERAL PRINCIPLES</text>
<text top="713" left="468" width="20" height="12" font="2">See</text>
<text top="713" left="492" width="195" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplements 1 and 2</a></text>
<text top="713" left="692" width="109" height="12" font="2">for additional data</text>
<text top="731" left="468" width="138" height="12" font="2">supporting this section.</text>
<text top="766" left="468" width="102" height="11" font="12">3.1. ACHD Program</text>
<text top="788" left="468" width="333" height="12" font="2">Patients with complex CHD have generally better out-</text>
<text top="806" left="468" width="333" height="12" font="2">comes when cared for in an integrated, collaborative, and</text>
<text top="824" left="468" width="154" height="12" font="2">multidisciplinary program</text>
<text top="824" left="627" width="41" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#53">(S3.1-1)</a></text>
<text top="824" left="668" width="133" height="12" font="2">. Many medical issues</text>
<text top="842" left="468" width="333" height="12" font="2">in patients with ACHD involve cardiac sequelae, and</text>
<text top="860" left="468" width="333" height="12" font="2">the diagnosis and management may require cardiac an-</text>
<text top="878" left="468" width="333" height="12" font="2">esthesiologists, electrophysiologists, and interventional</text>
<text top="896" left="468" width="333" height="12" font="2">cardiologists; imaging services such as cardiovascular</text>
<text top="913" left="468" width="333" height="12" font="2">magnetic resonance (CMR)/cardiac computed tomogra-</text>
<text top="931" left="468" width="333" height="12" font="2">phy (CCT); and pulmonary hypertension services with</text>
<text top="949" left="468" width="120" height="12" font="2">expertise in ACHD <a href="1-s2.0-S0735109718368451-main.html#12">(</a></text>
<text top="950" left="588" width="43" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#12">Table 5</a></text>
<text top="949" left="632" width="170" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#12">). </a>Appropriate specialty care</text>
<text top="967" left="468" width="333" height="12" font="2">must be available to address pregnancy, acquired car-</text>
<text top="985" left="468" width="66" height="12" font="2">diovascular</text>
<text top="985" left="548" width="46" height="12" font="2">disease,</text>
<text top="985" left="607" width="21" height="12" font="2">and</text>
<text top="985" left="642" width="31" height="12" font="2">acute</text>
<text top="985" left="687" width="64" height="12" font="2">noncardiac</text>
<text top="985" left="764" width="37" height="12" font="2">illness</text>
<text top="1003" left="468" width="333" height="12" font="2">complicating CHD, management of which is frequently</text>
<text top="1021" left="468" width="243" height="12" font="2">more complicated in patients with ACHD.</text>
<text top="1039" left="483" width="318" height="12" font="2">Although individual providers may be community-</text>
<text top="1057" left="468" width="51" height="12" font="2">based af</text>
<text top="1055" left="520" width="281" height="15" font="2">ﬁliates, ACHD programs are inpatient, outpa-</text>
<text top="1075" left="468" width="219" height="12" font="2">tient, and hospital-based with staf</text>
<text top="1073" left="687" width="114" height="15" font="2">ﬁng and expertise</text>
<text top="1093" left="468" width="264" height="12" font="2">available on-site or accessible when needed (</text>
<text top="1093" left="732" width="41" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#12">Table 5</a></text>
<text top="1093" left="773" width="8" height="12" font="2">).</text>
<text top="156" left="114" width="48" height="10" font="15">T A B L E 4</text>
<text top="149" left="179" width="82" height="10" font="16">ACHD AP Classi</text>
<text top="147" left="261" width="132" height="14" font="16">ﬁcation (CHD Anatomy þ</text>
<text top="163" left="179" width="103" height="10" font="16">Physiological Stage</text>
<text top="161" left="286" width="137" height="14" font="16">¼ ACHD AP Classiﬁcation)</text>
<text top="187" left="107" width="64" height="9" font="13">CHD Anato<a href="1-s2.0-S0735109718368451-main.html#11">my</a></text>
<text top="187" left="171" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#11">*</a></text>
<text top="207" left="107" width="37" height="9" font="13">I: Simple</text>
<text top="226" left="107" width="62" height="9" font="13">Native disease</text>
<text top="241" left="107" width="6" height="10" font="9">n</text>
<text top="242" left="122" width="83" height="9" font="13">Isolated small ASD</text>
<text top="252" left="107" width="6" height="10" font="9">n</text>
<text top="253" left="122" width="83" height="9" font="13">Isolated small VSD</text>
<text top="263" left="107" width="6" height="10" font="9">n</text>
<text top="264" left="122" width="139" height="9" font="13">Mild isolated pulmonic stenosis</text>
<text top="276" left="107" width="85" height="9" font="13">Repaired conditions</text>
<text top="291" left="107" width="6" height="10" font="9">n</text>
<text top="292" left="122" width="213" height="9" font="13">Previously ligated or occluded ductus arteriosus</text>
<text top="302" left="107" width="6" height="10" font="9">n</text>
<text top="303" left="122" width="275" height="9" font="13">Repaired secundum ASD or sinus venosus defect without signi</text>
<text top="301" left="397" width="24" height="12" font="13">ﬁcant</text>
<text top="313" left="122" width="174" height="9" font="13">residual shunt or chamber enlargement</text>
<text top="323" left="107" width="6" height="10" font="9">n</text>
<text top="324" left="122" width="120" height="9" font="13">Repaired VSD without signi</text>
<text top="323" left="242" width="143" height="12" font="13">ﬁcant residual shunt or chamber</text>
<text top="335" left="122" width="55" height="9" font="13">enlargement</text>
<text top="354" left="107" width="103" height="9" font="13">II: Moderate Complexity</text>
<text top="373" left="107" width="146" height="9" font="13">Repaired or unrepaired conditions</text>
<text top="388" left="107" width="6" height="10" font="9">n</text>
<text top="389" left="122" width="95" height="9" font="13">Aorto-left ventricular</text>
<text top="387" left="220" width="27" height="12" font="13">ﬁstula</text>
<text top="399" left="107" width="6" height="10" font="9">n</text>
<text top="400" left="122" width="255" height="9" font="13">Anomalous pulmonary venous connection, partial or total</text>
<text top="410" left="107" width="6" height="10" font="9">n</text>
<text top="411" left="122" width="273" height="9" font="13">Anomalous coronary artery arising from the pulmonary artery</text>
<text top="421" left="107" width="6" height="10" font="9">n</text>
<text top="422" left="122" width="305" height="9" font="13">Anomalous aortic origin of a coronary artery from the opposite sinus</text>
<text top="433" left="107" width="6" height="10" font="9">n</text>
<text top="433" left="122" width="223" height="9" font="13">AVSD (partial or complete, including primum ASD)</text>
<text top="444" left="107" width="6" height="10" font="9">n</text>
<text top="445" left="122" width="137" height="9" font="13">Congenital aortic valve disease</text>
<text top="455" left="107" width="6" height="10" font="9">n</text>
<text top="456" left="122" width="138" height="9" font="13">Congenital mitral valve disease</text>
<text top="466" left="107" width="6" height="10" font="9">n</text>
<text top="467" left="122" width="106" height="9" font="13">Coarctation of the aorta</text>
<text top="477" left="107" width="6" height="10" font="9">n</text>
<text top="478" left="122" width="319" height="9" font="13">Ebstein anomaly (disease spectrum includes mild, moderate, and severe</text>
<text top="489" left="122" width="46" height="9" font="13">variations)</text>
<text top="499" left="107" width="6" height="10" font="9">n</text>
<text top="500" left="122" width="146" height="9" font="13">Infundibular right ventricular out</text>
<text top="498" left="268" width="73" height="12" font="13">ﬂow obstruction</text>
<text top="510" left="107" width="6" height="10" font="9">n</text>
<text top="511" left="122" width="88" height="9" font="13">Ostium primum ASD</text>
<text top="521" left="107" width="6" height="10" font="9">n</text>
<text top="522" left="122" width="205" height="9" font="13">Moderate and large unrepaired secundum ASD</text>
<text top="532" left="107" width="6" height="10" font="9">n</text>
<text top="533" left="122" width="253" height="9" font="13">Moderate and large persistently patent ductus arteriosus</text>
<text top="544" left="107" width="6" height="10" font="9">n</text>
<text top="545" left="122" width="234" height="9" font="13">Pulmonary valve regurgitation (moderate or greater)</text>
<text top="555" left="107" width="6" height="10" font="9">n</text>
<text top="556" left="122" width="212" height="9" font="13">Pulmonary valve stenosis (moderate or greater)</text>
<text top="566" left="107" width="6" height="10" font="9">n</text>
<text top="567" left="122" width="133" height="9" font="13">Peripheral pulmonary stenosis</text>
<text top="577" left="107" width="6" height="10" font="9">n</text>
<text top="578" left="122" width="74" height="9" font="13">Sinus of Valsalva</text>
<text top="576" left="200" width="73" height="12" font="13">ﬁstula/aneurysm</text>
<text top="589" left="107" width="6" height="10" font="9">n</text>
<text top="589" left="122" width="92" height="9" font="13">Sinus venosus defect</text>
<text top="600" left="107" width="6" height="10" font="9">n</text>
<text top="601" left="122" width="313" height="9" font="13">Subvalvar aortic stenosis (excluding HCM; HCM not addressed in these</text>
<text top="611" left="122" width="48" height="9" font="13">guidelines)</text>
<text top="621" left="107" width="6" height="10" font="9">n</text>
<text top="622" left="122" width="118" height="9" font="13">Supravalvar aortic stenosis</text>
<text top="632" left="107" width="6" height="10" font="9">n</text>
<text top="633" left="122" width="143" height="9" font="13">Straddling atrioventricular valve</text>
<text top="644" left="107" width="6" height="10" font="9">n</text>
<text top="644" left="122" width="123" height="9" font="13">Repaired tetralogy of Fallot</text>
<text top="655" left="107" width="6" height="10" font="9">n</text>
<text top="656" left="122" width="298" height="9" font="13">VSD with associated abnormality and/or moderate or greater shunt</text>
<text top="675" left="107" width="147" height="9" font="13">III: Great Complexity (or Complex)</text>
<text top="697" left="107" width="6" height="10" font="9">n</text>
<text top="698" left="122" width="301" height="9" font="13">Cyanotic congenital heart defect (unrepaired or palliated, all forms)</text>
<text top="708" left="107" width="6" height="10" font="9">n</text>
<text top="709" left="122" width="104" height="9" font="13">Double-outlet ventricle</text>
<text top="719" left="107" width="6" height="10" font="9">n</text>
<text top="720" left="122" width="78" height="9" font="13">Fontan procedure</text>
<text top="731" left="107" width="6" height="10" font="9">n</text>
<text top="731" left="122" width="100" height="9" font="13">Interrupted aortic arch</text>
<text top="742" left="107" width="6" height="10" font="9">n</text>
<text top="743" left="122" width="58" height="9" font="13">Mitral atresia</text>
<text top="753" left="107" width="6" height="10" font="9">n</text>
<text top="754" left="122" width="312" height="9" font="13">Single ventricle (including double inlet left ventricle, tricuspid atresia,</text>
<text top="764" left="122" width="273" height="9" font="13">hypoplastic left heart, any other anatomic abnormality with a</text>
<text top="774" left="121" width="127" height="9" font="13">functionally single ventricle)</text>
<text top="785" left="107" width="6" height="10" font="9">n</text>
<text top="785" left="122" width="129" height="9" font="13">Pulmonary atresia (all forms)</text>
<text top="796" left="107" width="6" height="10" font="9">n</text>
<text top="797" left="122" width="177" height="9" font="13">TGA (classic or d-TGA; CCTGA or l-TGA)</text>
<text top="807" left="107" width="6" height="10" font="9">n</text>
<text top="808" left="122" width="81" height="9" font="13">Truncus arteriosus</text>
<text top="818" left="107" width="6" height="10" font="9">n</text>
<text top="819" left="122" width="269" height="9" font="13">Other abnormalities of atrioventricular and ventriculoarterial</text>
<text top="829" left="122" width="300" height="9" font="13">connection (i.e., crisscross heart, isomerism, heterotaxy syndromes,</text>
<text top="840" left="122" width="94" height="9" font="13">ventricular inversion)</text>
<text top="859" left="107" width="83" height="9" font="13">Physiological Stage</text>
<text top="878" left="107" width="6" height="9" font="13">A</text>
<text top="900" left="107" width="6" height="10" font="9">n</text>
<text top="901" left="122" width="94" height="9" font="13">NYHA FC I symptoms</text>
<text top="911" left="107" width="6" height="10" font="9">n</text>
<text top="912" left="122" width="173" height="9" font="13">No hemodynamic or anatomic sequelae</text>
<text top="922" left="107" width="6" height="10" font="9">n</text>
<text top="923" left="122" width="67" height="9" font="13">No arrhythmias</text>
<text top="934" left="107" width="6" height="10" font="9">n</text>
<text top="935" left="122" width="110" height="9" font="13">Normal exercise capacity</text>
<text top="945" left="107" width="6" height="10" font="9">n</text>
<text top="946" left="122" width="184" height="9" font="13">Normal renal/hepatic/pulmonary function</text>
<text top="965" left="107" width="6" height="9" font="13">B</text>
<text top="986" left="107" width="6" height="10" font="9">n</text>
<text top="986" left="122" width="96" height="9" font="13">NYHA FC II symptoms</text>
<text top="997" left="107" width="6" height="10" font="9">n</text>
<text top="998" left="122" width="314" height="9" font="13">Mild hemodynamic sequelae (mild aortic enlargement, mild ventricular</text>
<text top="1008" left="122" width="190" height="9" font="13">enlargement, mild ventricular dysfunction)</text>
<text top="1018" left="107" width="6" height="10" font="9">n</text>
<text top="1019" left="122" width="92" height="9" font="13">Mild valvular disease</text>
<text top="1029" left="107" width="6" height="10" font="9">n</text>
<text top="1030" left="122" width="219" height="9" font="13">Trivial or small shunt (not hemodynamically signi</text>
<text top="1029" left="341" width="28" height="12" font="13">ﬁcant)</text>
<text top="1041" left="107" width="6" height="10" font="9">n</text>
<text top="1041" left="122" width="157" height="9" font="13">Arrhythmia not requiring treatment</text>
<text top="1052" left="107" width="6" height="10" font="9">n</text>
<text top="1053" left="122" width="216" height="9" font="13">Abnormal objective cardiac limitation to exercise</text>
<text top="1073" left="329" width="112" height="8" font="5">Continued in the next column</text>
<text top="1074" left="321" width="121" height="9" font="13">Continued in the next column</text>
<text top="148" left="475" width="48" height="10" font="15">T A B L E 4</text>
<text top="148" left="540" width="53" height="10" font="16">Continued</text>
<text top="168" left="468" width="61" height="9" font="13">CHD <a href="1-s2.0-S0735109718368451-main.html#11">Anatomy</a></text>
<text top="168" left="528" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#11">*</a></text>
<text top="188" left="468" width="5" height="9" font="13">C</text>
<text top="210" left="468" width="6" height="10" font="9">n</text>
<text top="211" left="483" width="99" height="9" font="13">NYHA FC III symptoms</text>
<text top="221" left="468" width="6" height="10" font="9">n</text>
<text top="222" left="483" width="21" height="9" font="13">Signi</text>
<text top="220" left="504" width="293" height="12" font="13">ﬁcant (moderate or greater) valvular disease; moderate or greater</text>
<text top="232" left="483" width="236" height="9" font="13">ventricular dysfunction (systemic, pulmonic, or both)</text>
<text top="242" left="468" width="6" height="10" font="9">n</text>
<text top="243" left="483" width="129" height="9" font="13">Moderate aortic enlargement</text>
<text top="254" left="468" width="6" height="10" font="9">n</text>
<text top="254" left="483" width="118" height="9" font="13">Venous or arterial stenosis</text>
<text top="265" left="468" width="6" height="10" font="9">n</text>
<text top="266" left="483" width="168" height="9" font="13">Mild or moderate hypoxemia/cyanosis</text>
<text top="276" left="468" width="6" height="10" font="9">n</text>
<text top="277" left="483" width="101" height="9" font="13">Hemodynamically signi</text>
<text top="275" left="584" width="52" height="12" font="13">ﬁcant shunt</text>
<text top="287" left="468" width="6" height="10" font="9">n</text>
<text top="288" left="483" width="172" height="9" font="13">Arrhythmias controlled with treatment</text>
<text top="298" left="468" width="6" height="10" font="9">n</text>
<text top="299" left="483" width="189" height="9" font="13">Pulmonary hypertension (less than severe)</text>
<text top="310" left="468" width="6" height="10" font="9">n</text>
<text top="310" left="483" width="200" height="9" font="13">End-organ dysfunction responsive to therapy</text>
<text top="330" left="468" width="6" height="9" font="13">D</text>
<text top="352" left="468" width="6" height="10" font="9">n</text>
<text top="353" left="483" width="100" height="9" font="13">NYHA FC IV symptoms</text>
<text top="363" left="468" width="6" height="10" font="9">n</text>
<text top="364" left="483" width="116" height="9" font="13">Severe aortic enlargement</text>
<text top="374" left="468" width="6" height="10" font="9">n</text>
<text top="375" left="483" width="160" height="9" font="13">Arrhythmias refractory to treatment</text>
<text top="385" left="468" width="6" height="10" font="9">n</text>
<text top="386" left="483" width="264" height="9" font="13">Severe hypoxemia (almost always associated with cyanosis)</text>
<text top="397" left="468" width="6" height="10" font="9">n</text>
<text top="397" left="483" width="140" height="9" font="13">Severe pulmonary hypertension</text>
<text top="408" left="468" width="6" height="10" font="9">n</text>
<text top="409" left="483" width="102" height="9" font="13">Eisenmenger syndrome</text>
<text top="419" left="468" width="6" height="10" font="9">n</text>
<text top="420" left="483" width="150" height="9" font="13">Refractory end-organ dysfunction</text>
<text top="444" left="468" width="333" height="8" font="5">*This list is not meant to be comprehensive; other conditions may be important in in-</text>
<text top="455" left="468" width="66" height="8" font="5">dividual patients.</text>
<text top="470" left="476" width="325" height="8" font="5">ACHD indicates adult congenital heart disease; AP, anatomic and physiological; ASD,</text>
<text top="482" left="468" width="333" height="8" font="5">atrial septal defect; AVSD, atrioventricular septal defect; CCTGA, congenitally corrected</text>
<text top="494" left="468" width="333" height="8" font="5">transposition of the great arteries; CHD, congenital heart disease; d-TGA, dextro-</text>
<text top="505" left="468" width="333" height="8" font="5">transposition of the great arteries; FC, functional class; HCM, hypertrophic cardiomy-</text>
<text top="517" left="468" width="333" height="8" font="5">opathy; l-TGA, levo-transposition of the great arteries; NYHA, New York Heart Asso-</text>
<text top="529" left="468" width="322" height="8" font="5">ciation; TGA, transposition of the great arteries; and VSD, ventricular septal defect.</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="20" height="9" font="5">1504</text>
</page>
<page number="12" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="20" size="9" family="Times" color="#ffffff"/>
<text top="696" left="63" width="101" height="11" font="12">3.2. Access to Care</text>
<text top="881" left="63" width="109" height="11" font="12">3.3. Delivery of Care</text>
<text top="728" left="63" width="201" height="11" font="20">Recommendation for Access to Care</text>
<text top="742" left="63" width="407" height="11" font="20">Referenced studies that support the recommendation are summarized in</text>
<text top="742" left="474" width="146" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 3</a></text>
<text top="742" left="620" width="3" height="11" font="20">.</text>
<text top="783" left="89" width="19" height="10" font="13">COR</text>
<text top="783" left="161" width="18" height="10" font="13">LOE</text>
<text top="783" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="821" left="97" width="3" height="9" font="5">I</text>
<text top="813" left="160" width="21" height="9" font="5">B-NR</text>
<text top="808" left="234" width="566" height="11" font="12">1. Physicians caring for patients with ACHD should support access to care by a) assuring smooth transitions</text>
<text top="823" left="246" width="350" height="11" font="12">for adolescents and young adults from pediatric to adult providers</text>
<text top="823" left="599" width="81" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#53">(S3.2-1, S3.2-2)</a></text>
<text top="823" left="684" width="116" height="11" font="12">(Level of Evidence: B-</text>
<text top="839" left="246" width="514" height="11" font="12">NR); and b) promoting awareness of the need for lifelong specialized care through outreach and</text>
<text top="855" left="246" width="259" height="11" font="12">educational programs (Level of Evidence: C-EO).</text>
<text top="829" left="160" width="20" height="9" font="5">C-EO</text>
<text top="923" left="63" width="216" height="11" font="20">Recommendations for Delivery of Care</text>
<text top="938" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="938" left="457" width="204" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplements 3, 4, and 5</a></text>
<text top="938" left="662" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="979" left="89" width="19" height="10" font="13">COR</text>
<text top="979" left="161" width="18" height="10" font="13">LOE</text>
<text top="979" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="1016" left="97" width="3" height="9" font="5">I</text>
<text top="1016" left="160" width="21" height="9" font="5">B-NR</text>
<text top="1003" left="234" width="165" height="11" font="12">1. Patients with ACHD AP classi</text>
<text top="1001" left="399" width="160" height="15" font="12">ﬁcation IB-D, IIA-D, and IIIA-D</text>
<text top="1003" left="560" width="5" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#12">*</a></text>
<text top="1003" left="568" width="231" height="11" font="12">should be managed in collaboration with an</text>
<text top="1019" left="246" width="96" height="11" font="12">ACHD cardiologist</text>
<text top="1019" left="347" width="41" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.3-1)</a></text>
<text top="1019" left="388" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#54">.</a></text>
<text top="1063" left="97" width="3" height="9" font="5">I</text>
<text top="1063" left="160" width="20" height="9" font="5">C-LD</text>
<text top="1051" left="234" width="565" height="11" font="12">2. Cardiac surgery, catheter-based interventional cardiac procedures, and electrophysiological procedures</text>
<text top="1067" left="248" width="552" height="11" font="12">involving congenital heart lesions in patients with ACHD should be performed by operators with expertise</text>
<text top="1083" left="248" width="353" height="11" font="12">in CHD procedures and in collaboration with an ACHD cardiologist</text>
<text top="1083" left="604" width="82" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.3-1, S3.3-2)</a></text>
<text top="1083" left="686" width="3" height="11" font="12">.</text>
<text top="1108" left="63" width="17" height="8" font="5">*See</text>
<text top="1108" left="83" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="1108" left="144" width="224" height="8" font="5">for details on the ACHD Anatomic and Physiological classi</text>
<text top="1106" left="368" width="61" height="11" font="5">ﬁcation system.</text>
<text top="149" left="71" width="47" height="10" font="15">T A B L E 5</text>
<text top="149" left="135" width="334" height="10" font="16">Key Personnel and Services Recommended for ACHD Programs</text>
<text top="173" left="63" width="46" height="9" font="13">Personnel</text>
<text top="192" left="63" width="135" height="9" font="13">ACHD board-eligible/board-certi</text>
<text top="191" left="198" width="71" height="12" font="13">ﬁed cardiologists</text>
<text top="212" left="63" width="117" height="9" font="13">Congenital cardiac surgeons</text>
<text top="231" left="63" width="195" height="9" font="13">Nurses/physician assistants/nurse practitioners</text>
<text top="250" left="63" width="224" height="9" font="13">Cardiac anesthesiologists with CHD training/expertise</text>
<text top="269" left="63" width="99" height="9" font="13">Multidisciplinary teams:</text>
<text top="284" left="63" width="6" height="10" font="9">n</text>
<text top="285" left="77" width="86" height="9" font="13">High-risk obstetrics</text>
<text top="295" left="63" width="6" height="10" font="9">n</text>
<text top="296" left="77" width="107" height="9" font="13">Pulmonary hypertension</text>
<text top="307" left="63" width="6" height="10" font="9">n</text>
<text top="307" left="77" width="61" height="9" font="13">HF/transplant</text>
<text top="318" left="63" width="6" height="10" font="9">n</text>
<text top="319" left="77" width="37" height="9" font="13">Genetics</text>
<text top="329" left="63" width="6" height="10" font="9">n</text>
<text top="330" left="77" width="51" height="9" font="13">Hepatology</text>
<text top="340" left="63" width="6" height="10" font="9">n</text>
<text top="341" left="77" width="80" height="9" font="13">Cardiac pathology</text>
<text top="351" left="63" width="6" height="10" font="9">n</text>
<text top="352" left="77" width="99" height="9" font="13">Rehabilitation services</text>
<text top="363" left="63" width="6" height="10" font="9">n</text>
<text top="363" left="77" width="64" height="9" font="13">Social services</text>
<text top="374" left="63" width="6" height="10" font="9">n</text>
<text top="375" left="77" width="98" height="9" font="13">Psychological services</text>
<text top="385" left="63" width="6" height="10" font="9">n</text>
<text top="386" left="77" width="89" height="9" font="13">Financial counselors</text>
<text top="405" left="63" width="35" height="9" font="13">Services</text>
<text top="424" left="63" width="235" height="9" font="13">Echocardiography, including TEE and intraoperative <a href="1-s2.0-S0735109718368451-main.html#12">TEE</a></text>
<text top="424" left="298" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#12">*</a></text>
<text top="443" left="63" width="208" height="9" font="13">CHD diagnostic and interventional <a href="1-s2.0-S0735109718368451-main.html#12">catheterization</a></text>
<text top="443" left="271" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#12">*</a></text>
<text top="463" left="63" width="200" height="9" font="13">CHD electrophysiology/pacing/ICD implantation</text>
<text top="463" left="263" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#12">*</a></text>
<text top="463" left="267" width="3" height="9" font="13">:</text>
<text top="478" left="63" width="6" height="10" font="9">n</text>
<text top="478" left="77" width="70" height="9" font="13">Exercise testing</text>
<text top="489" left="63" width="6" height="10" font="9">n</text>
<text top="490" left="77" width="80" height="9" font="13">Echocardiographic</text>
<text top="500" left="63" width="6" height="10" font="9">n</text>
<text top="501" left="77" width="56" height="9" font="13">Radionuclide</text>
<text top="511" left="63" width="6" height="10" font="9">n</text>
<text top="512" left="77" width="75" height="9" font="13">Cardiopulmonary</text>
<text top="531" left="63" width="109" height="9" font="13">Cardiac imaging/radiology</text>
<text top="531" left="172" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#12">*</a></text>
<text top="531" left="176" width="3" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#12">:</a></text>
<text top="546" left="63" width="6" height="10" font="9">n</text>
<text top="547" left="77" width="20" height="9" font="13">CMR</text>
<text top="557" left="63" width="6" height="10" font="9">n</text>
<text top="558" left="77" width="17" height="9" font="13">CCT</text>
<text top="568" left="63" width="6" height="10" font="9">n</text>
<text top="569" left="77" width="76" height="9" font="13">Nuclear medicine</text>
<text top="589" left="63" width="101" height="9" font="13">Information technology:</text>
<text top="603" left="63" width="6" height="10" font="9">n</text>
<text top="604" left="77" width="66" height="9" font="13">Data collection</text>
<text top="615" left="63" width="6" height="10" font="9">n</text>
<text top="615" left="77" width="77" height="9" font="13">Database support</text>
<text top="626" left="63" width="6" height="10" font="9">n</text>
<text top="627" left="77" width="162" height="9" font="13">Quality assessment review/protocols</text>
<text top="650" left="63" width="451" height="8" font="5">*These modalities must be supervised/performed and interpreted by clinicians with expertise and/or training in CHD.</text>
<text top="664" left="71" width="686" height="8" font="5">ACHD indicates adult congenital heart disease; CCT, cardiac computed tomography; CHD, congenital heart disease; CMR, cardiovascular magnetic resonance; HF, heart failure; ICD,</text>
<text top="676" left="63" width="106" height="8" font="5">implantable cardioverter-de</text>
<text top="675" left="169" width="210" height="11" font="5">ﬁbrillator; and TEE, transesophageal echocardiography.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="788" width="20" height="9" font="5">1505</text>
</page>
<page number="13" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="41" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#13">Table 6</a></text>
<text top="143" left="152" width="289" height="12" font="2">addresses delivery of care where circumstances of</text>
<text top="161" left="108" width="281" height="12" font="2">ACHD expertise may improve patient outcomes.</text>
<text top="192" left="115" width="48" height="10" font="15">T A B L E 6</text>
<text top="192" left="179" width="421" height="10" font="16">Delivery of Care: Circumstances Where ACHD Expertise May Improve Outcomes</text>
<text top="216" left="108" width="61" height="9" font="13">Circumstance</text>
<text top="216" left="272" width="80" height="9" font="13">Possible Solution</text>
<text top="216" left="488" width="44" height="9" font="13">Rationale</text>
<text top="216" left="689" width="39" height="9" font="13">Example</text>
<text top="236" left="108" width="94" height="9" font="13">Care of patients in the</text>
<text top="247" left="123" width="69" height="9" font="13">lowest ACHD AP</text>
<text top="259" left="123" width="22" height="9" font="13">classi</text>
<text top="258" left="145" width="49" height="12" font="13">ﬁcation (IA)</text>
<text top="259" left="194" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#14">*</a></text>
<text top="236" left="221" width="148" height="9" font="13">1. Face-to-face consultation with</text>
<text top="247" left="232" width="96" height="9" font="13">an ACHD cardiologist.</text>
<text top="266" left="222" width="134" height="9" font="13">2. Collaborative care planning</text>
<text top="277" left="234" width="114" height="9" font="13">between an ACHD patient</text>
<text top="275" left="349" width="7" height="12" font="13">’s</text>
<text top="288" left="234" width="137" height="9" font="13">general cardiologist or primary</text>
<text top="299" left="234" width="91" height="9" font="13">care provider and an</text>
<text top="310" left="234" width="83" height="9" font="13">ACHD cardiologist.</text>
<text top="236" left="412" width="129" height="9" font="13">1. Patients in ACHD AP classi</text>
<text top="235" left="541" width="45" height="12" font="13">ﬁcation IA</text>
<text top="236" left="586" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#14">*</a></text>
<text top="236" left="594" width="13" height="9" font="13">are</text>
<text top="247" left="424" width="186" height="9" font="13">likely to be asymptomatic and not require</text>
<text top="258" left="424" width="180" height="9" font="13">frequent routine congenital cardiac care.</text>
<text top="274" left="411" width="192" height="9" font="13">2. The very long-term outcomes of patients</text>
<text top="285" left="424" width="87" height="9" font="13">with ACHD AP classi</text>
<text top="284" left="511" width="44" height="12" font="13">ﬁcation IA</text>
<text top="285" left="555" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#14">*</a></text>
<text top="285" left="562" width="30" height="9" font="13">lesions</text>
<text top="296" left="424" width="172" height="9" font="13">have not been well described, although</text>
<text top="307" left="424" width="178" height="9" font="13">available data suggest that patients with</text>
<text top="319" left="424" width="180" height="9" font="13">simple CHD have higher cardiac mortality</text>
<text top="330" left="424" width="183" height="9" font="13">in long-term follow-up than age-matched</text>
<text top="341" left="424" width="36" height="9" font="13">controls</text>
<text top="341" left="462" width="35" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.3-3)</a></text>
<text top="341" left="497" width="3" height="9" font="13">.</text>
<text top="356" left="411" width="188" height="9" font="13">3. Consultation with an ACHD cardiologist</text>
<text top="368" left="424" width="161" height="9" font="13">should help to accurately assess the</text>
<text top="379" left="424" width="31" height="9" font="13">patient</text>
<text top="377" left="455" width="114" height="12" font="13">’s ACHD AP class, provide</text>
<text top="390" left="424" width="167" height="9" font="13">information regarding potential long-</text>
<text top="401" left="424" width="156" height="9" font="13">term outcomes, and reinforce signs</text>
<text top="412" left="424" width="153" height="9" font="13">and symptoms that should prompt</text>
<text top="423" left="424" width="83" height="9" font="13">further evaluation.</text>
<text top="236" left="616" width="185" height="9" font="13">Patients with small VSDs are thought to have</text>
<text top="247" left="631" width="161" height="9" font="13">excellent long-term survival, although</text>
<text top="259" left="631" width="163" height="9" font="13">complications (double-chamber RV, IE,</text>
<text top="271" left="631" width="132" height="9" font="13">aortic valve prolapse and aortic</text>
<text top="283" left="631" width="127" height="9" font="13">regurgitation) may manifest in</text>
<text top="295" left="631" width="164" height="9" font="13">adulthood; consequently, patients with</text>
<text top="307" left="631" width="160" height="9" font="13">small VSDs warrant lifelong follow-up</text>
<text top="319" left="631" width="34" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.3-4)</a></text>
<text top="319" left="665" width="3" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#54">.</a></text>
<text top="445" left="108" width="66" height="9" font="13">Cardiac imaging</text>
<text top="457" left="123" width="45" height="9" font="13">of patients</text>
<text top="469" left="123" width="46" height="9" font="13">with ACHD</text>
<text top="445" left="219" width="157" height="9" font="13">Imaging studies should be performed</text>
<text top="457" left="234" width="147" height="9" font="13">and interpreted by individuals with</text>
<text top="469" left="234" width="109" height="9" font="13">expertise in CHD imaging.</text>
<text top="446" left="412" width="194" height="9" font="13">1. The complexity and variability of lesions,</text>
<text top="457" left="424" width="171" height="9" font="13">repairs, and sequelae in CHD constrain</text>
<text top="468" left="424" width="167" height="9" font="13">the use of standard protocols and se-</text>
<text top="479" left="424" width="141" height="9" font="13">quences and often require modi</text>
<text top="478" left="564" width="32" height="12" font="13">ﬁcation</text>
<text top="490" left="424" width="179" height="9" font="13">of plans during acquisition of images, as</text>
<text top="502" left="424" width="186" height="9" font="13">well as specialized skills in interpretation.</text>
<text top="513" left="424" width="150" height="9" font="13">Thus, CHD expertise is helpful for</text>
<text top="524" left="424" width="150" height="9" font="13">optimal quality and interpretation</text>
<text top="535" left="424" width="118" height="9" font="13">of cardiac imaging studies.</text>
<text top="551" left="411" width="186" height="9" font="13">2. Use of a multimodality cardiac imaging</text>
<text top="562" left="424" width="173" height="9" font="13">approach can be used for patients with</text>
<text top="573" left="424" width="156" height="9" font="13">ACHD, accounting for patient-speci</text>
<text top="571" left="580" width="10" height="12" font="13">ﬁc</text>
<text top="584" left="424" width="185" height="9" font="13">considerations, strengths and weaknesses</text>
<text top="595" left="424" width="181" height="9" font="13">of each modality, institutional resources,</text>
<text top="606" left="424" width="62" height="9" font="13">and expertise.</text>
<text top="622" left="411" width="184" height="9" font="13">3. ACHD programs need a dedicated CMR</text>
<text top="633" left="424" width="179" height="9" font="13">service, and CMR expertise is integral to</text>
<text top="644" left="424" width="159" height="9" font="13">an ACHD program, as is expertise in</text>
<text top="655" left="424" width="45" height="9" font="13">ACHD CCT</text>
<text top="655" left="472" width="70" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.3-5, S3.3-6)</a></text>
<text top="655" left="542" width="3" height="9" font="13">.</text>
<text top="445" left="616" width="185" height="9" font="13">Although imaging of a patient with TOF may</text>
<text top="457" left="631" width="151" height="9" font="13">seem straightforward because many</text>
<text top="469" left="631" width="164" height="9" font="13">have familiar chamber and great vessel</text>
<text top="481" left="631" width="145" height="9" font="13">relationships, there are nuances to</text>
<text top="493" left="631" width="157" height="9" font="13">echocardiographic imaging of RV size</text>
<text top="505" left="631" width="139" height="9" font="13">and function, PR severity, and/or</text>
<text top="517" left="631" width="130" height="9" font="13">location of right ventricular out</text>
<text top="515" left="761" width="40" height="12" font="13">ﬂow tract</text>
<text top="529" left="631" width="165" height="9" font="13">obstruction that affect clinical care and</text>
<text top="541" left="631" width="117" height="9" font="13">are thus best carried out by</text>
<text top="553" left="631" width="159" height="9" font="13">sonographers and echocardiographers</text>
<text top="565" left="631" width="154" height="9" font="13">with appropriate expertise. Similarly,</text>
<text top="577" left="631" width="170" height="9" font="13">expertise in congenital CMR is important</text>
<text top="589" left="631" width="161" height="9" font="13">in evaluating patients with TOF, as RV</text>
<text top="601" left="631" width="124" height="9" font="13">volumes and function are key</text>
<text top="613" left="631" width="164" height="9" font="13">components in evaluation for timing of</text>
<text top="625" left="631" width="124" height="9" font="13">pulmonary valve replacement</text>
<text top="625" left="758" width="32" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.3-7,</a></text>
<text top="637" left="631" width="31" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#54">S3.3-8)</a></text>
<text top="637" left="662" width="3" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#54">.</a></text>
<text top="677" left="108" width="84" height="9" font="13">Electrophysiological</text>
<text top="689" left="123" width="66" height="9" font="13">care of patients</text>
<text top="701" left="123" width="46" height="9" font="13">with ACHD</text>
<text top="677" left="219" width="170" height="9" font="13">Perform procedures in electrophysiology</text>
<text top="689" left="234" width="120" height="9" font="13">laboratories equipped for 3D</text>
<text top="701" left="234" width="143" height="9" font="13">mapping and ablation and involve</text>
<text top="713" left="234" width="123" height="9" font="13">specialists experienced in the</text>
<text top="725" left="234" width="129" height="9" font="13">management of arrhythmias in</text>
<text top="737" left="234" width="85" height="9" font="13">patients with ACHD.</text>
<text top="677" left="409" width="161" height="9" font="13">Examples of diagnostic questions best</text>
<text top="689" left="424" width="168" height="9" font="13">answered by electrophysiological study:</text>
<text top="702" left="412" width="174" height="9" font="13">a) evaluation of the conduction system</text>
<text top="713" left="425" width="151" height="9" font="13">in cases of suspected postsurgical</text>
<text top="724" left="425" width="111" height="9" font="13">conduction abnormalities</text>
<text top="740" left="411" width="111" height="9" font="13">b) evaluation of syncope</text>
<text top="756" left="412" width="148" height="9" font="13">c) diagnosis of the mechanism of</text>
<text top="767" left="425" width="137" height="9" font="13">supraventricular tachycardia or</text>
<text top="778" left="425" width="114" height="9" font="13">wide complex tachycardia</text>
<text top="793" left="411" width="171" height="9" font="13">d) programmed ventricular stimulation</text>
<text top="805" left="425" width="143" height="9" font="13">particularly in patients following</text>
<text top="816" left="425" width="126" height="9" font="13">repair of TOF and its variants</text>
<text top="827" left="425" width="3" height="9" font="13">(</text>
<text top="827" left="428" width="56" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#41">Section 4.4.1</a></text>
<text top="827" left="485" width="109" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#41">.) </a>as well as preoperative</text>
<text top="838" left="425" width="180" height="9" font="13">assessment of arrhythmia substrates that</text>
<text top="849" left="425" width="187" height="9" font="13">may be amenable to operative intervention,</text>
<text top="860" left="425" width="182" height="9" font="13">such as an atrial maze procedure for atrial</text>
<text top="871" left="425" width="156" height="9" font="13">arrhythmias. The latter procedure is</text>
<text top="882" left="425" width="180" height="9" font="13">commonly used at the time of conversion</text>
<text top="893" left="425" width="165" height="9" font="13">of atriopulmonary connection Fontan,</text>
<text top="905" left="425" width="163" height="9" font="13">and may also be useful in other forms</text>
<text top="916" left="425" width="154" height="9" font="13">of repaired CHD with postoperative</text>
<text top="927" left="425" width="134" height="9" font="13">atrial arrhythmias such as TOF.</text>
<text top="677" left="616" width="178" height="9" font="13">Bradyarrhythmia and tachyarrhythmias are</text>
<text top="689" left="631" width="142" height="9" font="13">common in TGA with atrial switch</text>
<text top="701" left="631" width="97" height="9" font="13">patients and may seem</text>
<text top="711" left="631" width="142" height="12" font="13">“straightforward,” but the altered</text>
<text top="725" left="631" width="136" height="9" font="13">anatomy adds complexity to the</text>
<text top="737" left="631" width="170" height="9" font="13">procedures and emphasizes the need for</text>
<text top="749" left="631" width="164" height="9" font="13">specialized equipment and expertise to</text>
<text top="761" left="631" width="160" height="9" font="13">ensure the best chance for procedural</text>
<text top="773" left="631" width="149" height="9" font="13">success. For example: 1) pacemaker</text>
<text top="785" left="631" width="158" height="9" font="13">placement in a patient with TGA with</text>
<text top="797" left="631" width="169" height="9" font="13">atrial switch can be challenging because</text>
<text top="809" left="631" width="140" height="9" font="13">of the altered atrial anatomy and</text>
<text top="821" left="631" width="57" height="9" font="13">interatrial baf</text>
<text top="819" left="688" width="98" height="12" font="13">ﬂe that will necessitate</text>
<text top="833" left="631" width="141" height="9" font="13">placement of an atrial lead in the</text>
<text top="845" left="631" width="169" height="9" font="13">anatomic left atrium, often scarred such</text>
<text top="857" left="631" width="149" height="9" font="13">that tissue amenable to pacing is dif</text>
<text top="855" left="780" width="21" height="12" font="13">ﬁcult</text>
<text top="869" left="631" width="9" height="9" font="13">to</text>
<text top="867" left="643" width="158" height="12" font="13">ﬁnd; and 2) atrial ﬂutter is a common</text>
<text top="881" left="631" width="170" height="9" font="13">arrhythmia in TGA with atrial switch, but</text>
<text top="893" left="631" width="14" height="9" font="13">the</text>
<text top="891" left="647" width="154" height="12" font="13">ﬂutter circuit may be on the systemic</text>
<text top="904" left="631" width="102" height="9" font="13">side of the interatrial baf</text>
<text top="903" left="733" width="68" height="12" font="13">ﬂe and thus may</text>
<text top="916" left="631" width="46" height="9" font="13">require baf</text>
<text top="915" left="677" width="110" height="12" font="13">ﬂe puncture or retrograde</text>
<text top="928" left="631" width="170" height="9" font="13">approach to effectively ablate the circuit.</text>
<text top="947" left="108" width="62" height="9" font="13">Diagnostic and</text>
<text top="959" left="123" width="58" height="9" font="13">interventional</text>
<text top="971" left="123" width="81" height="9" font="13">cardiac procedures,</text>
<text top="983" left="123" width="38" height="9" font="13">including</text>
<text top="995" left="123" width="74" height="9" font="13">electrophysiology</text>
<text top="1007" left="123" width="46" height="9" font="13">procedures</text>
<text top="948" left="223" width="113" height="9" font="13">1. Perform procedure in a</text>
<text top="959" left="234" width="120" height="9" font="13">hospital with cardiologists,</text>
<text top="970" left="234" width="124" height="9" font="13">anesthesiologists, surgeons,</text>
<text top="981" left="234" width="153" height="9" font="13">and other providers with expertise</text>
<text top="993" left="234" width="137" height="9" font="13">in the management of patients</text>
<text top="1004" left="234" width="50" height="9" font="13">with ACHD.</text>
<text top="1019" left="222" width="158" height="9" font="13">2. Consultation with providers with</text>
<text top="1030" left="234" width="157" height="9" font="13">ACHD expertise may be substituted</text>
<text top="1042" left="234" width="136" height="9" font="13">if the procedure is urgent such</text>
<text top="1053" left="234" width="155" height="9" font="13">that timely transfer is not feasible.</text>
<text top="948" left="412" width="189" height="9" font="13">1. Patients with ACHD often have complex</text>
<text top="959" left="424" width="141" height="9" font="13">underlying cardiac anatomy and</text>
<text top="970" left="424" width="50" height="9" font="13">physiology.</text>
<text top="986" left="411" width="191" height="9" font="13">2. The data obtained and the interventions</text>
<text top="997" left="424" width="188" height="9" font="13">performed during ACHD cardiac procedures</text>
<text top="1008" left="424" width="28" height="9" font="13">are dif</text>
<text top="1007" left="452" width="160" height="12" font="13">ﬁcult to sort out without specialized</text>
<text top="1019" left="424" width="103" height="9" font="13">knowledge of the CHD.</text>
<text top="1035" left="411" width="192" height="9" font="13">3. An ACHD program has additional resources</text>
<text top="1046" left="424" width="188" height="9" font="13">such as cardiac anesthesia, congenital cardiac</text>
<text top="1057" left="424" width="188" height="9" font="13">surgery, and specialty cardiac imaging, should</text>
<text top="1068" left="424" width="176" height="9" font="13">the need for those services arise during or</text>
<text top="1079" left="424" width="83" height="9" font="13">after the procedure.</text>
<text top="947" left="616" width="158" height="9" font="13">In patients with CHD, the presence of</text>
<text top="959" left="631" width="162" height="9" font="13">anatomic and physiological complexity</text>
<text top="971" left="631" width="61" height="9" font="13">from the speci</text>
<text top="970" left="692" width="86" height="12" font="13">ﬁc defect or surgical</text>
<text top="983" left="631" width="163" height="9" font="13">palliation, may change the overall care</text>
<text top="995" left="631" width="157" height="9" font="13">plan and procedural decision-making.</text>
<text top="1007" left="631" width="111" height="9" font="13">Procedures that may seem</text>
<text top="1019" left="631" width="149" height="9" font="13">straightforward, such as pacemaker</text>
<text top="1031" left="631" width="154" height="9" font="13">implantation or ASD closure, may be</text>
<text top="1043" left="631" width="165" height="9" font="13">more complex when accounting for the</text>
<text top="1055" left="631" width="111" height="9" font="13">nuances imparted by CHD.</text>
<text top="1103" left="690" width="112" height="8" font="5">Continued in the next column</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="20" height="9" font="5">1506</text>
</page>
<page number="14" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="21" size="4" family="Times" color="#000000"/>
<text top="736" left="63" width="243" height="11" font="12">3.4. Evaluation of Suspected and Known CHD</text>
<text top="758" left="63" width="127" height="11" font="2">3.4.1. Electrocardiogram</text>
<text top="780" left="63" width="47" height="12" font="2">See also</text>
<text top="780" left="114" width="41" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#15">Table 7</a></text>
<text top="780" left="155" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#15">.</a></text>
<text top="148" left="70" width="48" height="10" font="15">T A B L E 6</text>
<text top="148" left="135" width="53" height="10" font="16">Continued</text>
<text top="171" left="63" width="57" height="9" font="13">Circumstance</text>
<text top="171" left="227" width="80" height="9" font="13">Possible Solution</text>
<text top="171" left="444" width="44" height="9" font="13">Rationale</text>
<text top="171" left="644" width="39" height="9" font="13">Example</text>
<text top="191" left="63" width="73" height="9" font="13">Administration of</text>
<text top="203" left="78" width="59" height="9" font="13">anesthesia for</text>
<text top="215" left="78" width="82" height="9" font="13">invasive procedures</text>
<text top="227" left="78" width="65" height="9" font="13">in patients with</text>
<text top="238" left="78" width="39" height="9" font="13">ACHD AP</text>
<text top="250" left="78" width="22" height="9" font="13">classi</text>
<text top="249" left="100" width="55" height="12" font="13">ﬁcation IB-D,</text>
<text top="262" left="78" width="69" height="9" font="13">IIA-D, and <a href="1-s2.0-S0735109718368451-main.html#14">IIIA-D</a></text>
<text top="262" left="147" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#14">*</a></text>
<text top="191" left="178" width="159" height="9" font="13">1. Performed by, or in collaboration</text>
<text top="202" left="189" width="133" height="9" font="13">with, an anesthesiologist with</text>
<text top="214" left="189" width="141" height="9" font="13">expertise in the management of</text>
<text top="225" left="189" width="89" height="9" font="13">patients with ACHD.</text>
<text top="240" left="177" width="178" height="9" font="13">2. If clinical urgency precludes transfer,</text>
<text top="251" left="189" width="165" height="9" font="13">consultation with an anesthesiologist</text>
<text top="263" left="189" width="147" height="9" font="13">with ACHD expertise would be of</text>
<text top="274" left="189" width="21" height="9" font="13">bene</text>
<text top="272" left="211" width="136" height="12" font="13">ﬁt to on-site providers who do</text>
<text top="285" left="189" width="113" height="9" font="13">not have ACHD expertise.</text>
<text top="191" left="367" width="63" height="9" font="13">1. ACHD-speci</text>
<text top="190" left="431" width="90" height="12" font="13">ﬁc issues need to be</text>
<text top="202" left="379" width="177" height="9" font="13">addressed when considering anesthesia,</text>
<text top="214" left="379" width="175" height="9" font="13">including underlying cardiac physiology</text>
<text top="225" left="379" width="170" height="9" font="13">and hemodynamics, and the effects of</text>
<text top="236" left="379" width="171" height="9" font="13">anesthetic medications and ventilation</text>
<text top="247" left="379" width="46" height="9" font="13">strategies.</text>
<text top="263" left="366" width="169" height="9" font="13">2. Many patients with ACHD have had</text>
<text top="274" left="379" width="167" height="9" font="13">surgeries in the past, which may have</text>
<text top="285" left="379" width="73" height="9" font="13">created or identi</text>
<text top="283" left="452" width="99" height="12" font="13">ﬁed airway or vascular</text>
<text top="296" left="379" width="163" height="9" font="13">access concerns. Patients with ACHD</text>
<text top="307" left="379" width="157" height="9" font="13">can also have underlying restrictive</text>
<text top="318" left="379" width="161" height="9" font="13">and/or obstructive lung disease that</text>
<text top="329" left="379" width="94" height="9" font="13">should be considered</text>
<text top="329" left="476" width="75" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.3-9, S3.3-10)</a></text>
<text top="329" left="551" width="3" height="9" font="13">.</text>
<text top="191" left="571" width="137" height="9" font="13">The application of anesthesia for</text>
<text top="203" left="586" width="131" height="9" font="13">laparoscopic procedures can be</text>
<text top="215" left="586" width="170" height="9" font="13">especially challenging in Fontan patients.</text>
<text top="227" left="586" width="20" height="9" font="13">Signi</text>
<text top="225" left="606" width="150" height="12" font="13">ﬁcant cardiovascular and respiratory</text>
<text top="238" left="586" width="148" height="9" font="13">alterations may occur as a result of</text>
<text top="250" left="586" width="165" height="9" font="13">increased intra-abdominal pressure and</text>
<text top="262" left="586" width="153" height="9" font="13">decreased venous return. Abdominal</text>
<text top="274" left="586" width="20" height="9" font="13">insuf</text>
<text top="273" left="606" width="141" height="12" font="13">ﬂation may lead to lower preload</text>
<text top="286" left="586" width="170" height="9" font="13">and hypotension, while at the same time</text>
<text top="298" left="586" width="159" height="9" font="13">elevating systemic vascular resistance</text>
<text top="310" left="586" width="143" height="9" font="13">and compromising cardiac output.</text>
<text top="322" left="586" width="138" height="9" font="13">Elevations in pulmonary vascular</text>
<text top="334" left="586" width="157" height="9" font="13">resistance attributable to hypercarbia</text>
<text top="346" left="586" width="158" height="9" font="13">can be caused by either direct carbon</text>
<text top="358" left="586" width="157" height="9" font="13">dioxide absorption or hypoventilation</text>
<text top="370" left="586" width="36" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.3-11)</a></text>
<text top="370" left="622" width="3" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#54">.</a></text>
<text top="389" left="63" width="82" height="9" font="13">Patients with ACHD</text>
<text top="401" left="78" width="63" height="9" font="13">and pulmonary</text>
<text top="413" left="78" width="54" height="9" font="13">hypertension</text>
<text top="390" left="176" width="136" height="9" font="13">1. Consultation with experts in</text>
<text top="401" left="188" width="155" height="9" font="13">pulmonary hypertension and ACHD</text>
<text top="412" left="188" width="142" height="9" font="13">to assist in the interpretation of</text>
<text top="423" left="188" width="137" height="9" font="13">diagnostic and invasive studies</text>
<text top="434" left="188" width="147" height="9" font="13">and determine the best course of</text>
<text top="445" left="188" width="60" height="9" font="13">management.</text>
<text top="390" left="366" width="190" height="9" font="13">1. PAH imparts a poor prognosis compared</text>
<text top="401" left="377" width="154" height="9" font="13">with CHD without PAH. Because of</text>
<text top="412" left="377" width="163" height="9" font="13">the complexity of PAH in the setting</text>
<text top="423" left="377" width="148" height="9" font="13">of CHD, patients with ACHD bene</text>
<text top="422" left="526" width="9" height="12" font="13">ﬁt</text>
<text top="434" left="377" width="146" height="9" font="13">from the expertise of both ACHD</text>
<text top="445" left="377" width="171" height="9" font="13">providers and pulmonary hypertension</text>
<text top="457" left="377" width="41" height="9" font="13">providers</text>
<text top="457" left="422" width="36" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.3-12</a></text>
<text top="455" left="458" width="42" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#54">–S3.3-20)</a></text>
<text top="457" left="500" width="3" height="9" font="13">.</text>
<text top="389" left="571" width="185" height="9" font="13">Management of PAH in patients with shunts</text>
<text top="401" left="586" width="42" height="9" font="13">can be dif</text>
<text top="399" left="628" width="129" height="12" font="13">ﬁcult. For example, in patients</text>
<text top="413" left="586" width="169" height="9" font="13">for whom PAH treatment is expected to</text>
<text top="425" left="586" width="155" height="9" font="13">allow subsequent closure of a shunt,</text>
<text top="437" left="586" width="170" height="9" font="13">cohort series demonstrate progression of</text>
<text top="449" left="586" width="156" height="9" font="13">pulmonary vascular resistance or late</text>
<text top="461" left="586" width="148" height="9" font="13">mortality if defects with associated</text>
<text top="473" left="586" width="167" height="9" font="13">pulmonary vascular resistance elevation</text>
<text top="485" left="586" width="103" height="9" font="13">beyond 2.5 Wood units (</text>
<text top="483" left="690" width="40" height="12" font="13">$4 Wood</text>
<text top="497" left="586" width="20" height="9" font="13">units</text>
<text top="495" left="607" width="15" height="12" font="13">m</text>
<text top="495" left="622" width="4" height="6" font="21">2</text>
<text top="497" left="625" width="43" height="9" font="13">) or Qp:Qs</text>
<text top="495" left="672" width="66" height="12" font="13">$3 were closed</text>
<text top="509" left="586" width="74" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.3-21, S3.3-22)</a></text>
<text top="509" left="660" width="86" height="9" font="13">. The utility of acute</text>
<text top="521" left="586" width="168" height="9" font="13">administration of pulmonary vasodilator</text>
<text top="533" left="586" width="158" height="9" font="13">therapy as a marker of reversibility of</text>
<text top="545" left="586" width="161" height="9" font="13">pulmonary vascular resistance remains</text>
<text top="557" left="586" width="41" height="9" font="13">uncertain.</text>
<text top="555" left="631" width="114" height="12" font="13">“Treat-to-repair” strategies</text>
<text top="568" left="586" width="166" height="9" font="13">involving use of PAH therapies to bring</text>
<text top="580" left="586" width="153" height="9" font="13">pulmonary vascular resistance into a</text>
<text top="592" left="586" width="158" height="9" font="13">range where repair can be considered</text>
<text top="604" left="586" width="170" height="9" font="13">have been applied, but the utility of such</text>
<text top="616" left="586" width="140" height="9" font="13">strategies also remains uncertain.</text>
<text top="640" left="63" width="17" height="8" font="5">*See</text>
<text top="640" left="83" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="640" left="144" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="638" left="273" width="60" height="11" font="5">ﬁcation system.</text>
<text top="654" left="71" width="686" height="8" font="5">3D indicates 3-dimensional; ACHD, adult congenital heart disease; AP, anatomic and physiological; ASD, atrial septal defect; CCT, cardiac computed tomography; CHD, congenital</text>
<text top="666" left="63" width="657" height="8" font="5">heart disease; CMR, cardiovascular magnetic resonance; IE, infective endocarditis; PAH, pulmonary arterial hypertension; PR, pulmonary regurgitation; Qp:Qs, pulmonary</text>
<text top="665" left="720" width="37" height="11" font="5">–systemic</text>
<text top="678" left="63" width="22" height="8" font="5">blood</text>
<text top="676" left="88" width="507" height="11" font="5">ﬂow ratio; RV, right ventricle; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; and VSD, ventricular septal defect.</text>
<text top="817" left="63" width="228" height="11" font="20">Recommendations for Electrocardiogram</text>
<text top="858" left="89" width="19" height="10" font="13">COR</text>
<text top="858" left="161" width="18" height="10" font="13">LOE</text>
<text top="858" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="895" left="97" width="3" height="9" font="5">I</text>
<text top="895" left="160" width="20" height="9" font="5">C-EO</text>
<text top="883" left="234" width="564" height="11" font="12">1. A standard 12-lead electrocardiogram (ECG) is recommended in adults with CHD with serial assessment</text>
<text top="899" left="246" width="124" height="11" font="12">depending on the speci</text>
<text top="897" left="371" width="347" height="15" font="12">ﬁc ACHD AP classiﬁcation or when symptoms develop or worsen.</text>
<text top="952" left="97" width="3" height="9" font="5">I</text>
<text top="952" left="160" width="20" height="9" font="5">C-EO</text>
<text top="940" left="234" width="566" height="11" font="12">2. Ambulatory electrocardiographic monitoring should be performed in patients with CHD who are at risk of</text>
<text top="956" left="248" width="525" height="11" font="12">tachyarrhythmia, bradyarrhythmia or heart block, or when symptoms possibly of arrhythmic origin</text>
<text top="971" left="248" width="45" height="11" font="12">develop.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="788" width="19" height="9" font="5">1507</text>
</page>
<page number="15" position="absolute" top="0" left="0" height="1160" width="864">
<text top="346" left="108" width="180" height="11" font="2">3.4.2. Ionizing Radiation Principles</text>
<text top="540" left="108" width="126" height="11" font="2">3.4.3. Echocardiography</text>
<text top="785" left="108" width="104" height="11" font="2">3.4.4. CMR Imaging</text>
<text top="807" left="108" width="47" height="12" font="2">See also</text>
<text top="807" left="158" width="83" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#16">Tables 8 </a>and <a href="1-s2.0-S0735109718368451-main.html#16">9</a></text>
<text top="807" left="242" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#16">.</a></text>
<text top="149" left="116" width="47" height="10" font="15">T A B L E 7</text>
<text top="149" left="179" width="169" height="10" font="16">Use of ECGs in ACHD Evaluation</text>
<text top="174" left="112" width="6" height="10" font="9">n</text>
<text top="175" left="126" width="25" height="9" font="13">Identi</text>
<text top="173" left="152" width="649" height="12" font="13">ﬁcation of sinus bradycardia or junctional rhythm in patients at risk of sinus node dysfunction (especially after the Mustard, Senning, Glenn, or Fontan</text>
<text top="186" left="126" width="48" height="9" font="13">procedure)</text>
<text top="196" left="112" width="6" height="10" font="9">n</text>
<text top="197" left="126" width="25" height="9" font="13">Identi</text>
<text top="196" left="152" width="441" height="12" font="13">ﬁcation of clinically inapparent intra-atrial re-entry tachycardia in patients who have had atriotomy</text>
<text top="208" left="112" width="6" height="10" font="9">n</text>
<text top="208" left="126" width="25" height="9" font="13">Identi</text>
<text top="207" left="152" width="585" height="12" font="13">ﬁcation of atrioventricular block in patients at risk for progression of atrioventricular conduction system disease (especially CCTGA)</text>
<text top="219" left="112" width="6" height="10" font="9">n</text>
<text top="220" left="126" width="220" height="9" font="13">Evaluation of rhythm in patients with pacemakers</text>
<text top="230" left="112" width="6" height="10" font="9">n</text>
<text top="231" left="126" width="403" height="9" font="13">Measurement of QRS duration in patients after repair of TOF and as part of CRT evaluation</text>
<text top="241" left="112" width="6" height="10" font="9">n</text>
<text top="242" left="126" width="500" height="9" font="13">Preoperatively to compare with postoperative ECGs in patients undergoing heart surgery and noncardiac surgery</text>
<text top="252" left="112" width="6" height="10" font="9">n</text>
<text top="253" left="126" width="343" height="9" font="13">Postoperatively to identify arrhythmias (e.g., atrial ectopic tachycardia, atrial</text>
<text top="252" left="473" width="288" height="12" font="13">ﬂutter, AF, junctional ectopic tachycardia, atrioventricular block)</text>
<text top="264" left="112" width="6" height="10" font="9">n</text>
<text top="264" left="126" width="353" height="9" font="13">Diagnosis of Wolff-Parkinson-White Syndrome in patients with Ebstein anomaly</text>
<text top="275" left="112" width="6" height="10" font="9">n</text>
<text top="276" left="126" width="253" height="9" font="13">Initial evaluation of suspected acute coronary syndromes</text>
<text top="299" left="108" width="218" height="8" font="5">ACHD indicates adult congenital heart disease; AF, atrial</text>
<text top="298" left="328" width="473" height="11" font="5">ﬁbrillation; CCTGA, congenitally corrected transposition of the great arteries; CRT, cardiac resynchronization therapy; ECG,</text>
<text top="311" left="108" width="186" height="8" font="5">electrocardiogram; and TOF, tetralogy of Fallot.</text>
<text top="380" left="63" width="280" height="11" font="20">Recommendation for Ionizing Radiation Principles</text>
<text top="394" left="63" width="407" height="11" font="20">Referenced studies that support the recommendation are summarized in</text>
<text top="394" left="474" width="147" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 6</a></text>
<text top="394" left="621" width="3" height="11" font="20">.</text>
<text top="435" left="89" width="19" height="10" font="13">COR</text>
<text top="435" left="161" width="18" height="10" font="13">LOE</text>
<text top="435" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="472" left="97" width="3" height="9" font="5">I</text>
<text top="472" left="160" width="21" height="9" font="5">B-NR</text>
<text top="460" left="234" width="551" height="11" font="12">1. Strategies to limit and monitor radiation exposure are recommended during imaging of patients with</text>
<text top="475" left="246" width="433" height="11" font="12">ACHD, with studies not involving ionizing radiation chosen whenever appropriate</text>
<text top="475" left="683" width="47" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.4.2-1</a></text>
<text top="473" left="731" width="55" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#54">–S3.4.2-4)</a></text>
<text top="475" left="786" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#54">.</a></text>
<text top="578" left="63" width="225" height="11" font="20">Recommendations for Echocardiography</text>
<text top="593" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="593" left="457" width="146" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 7</a></text>
<text top="593" left="604" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="633" left="89" width="19" height="10" font="13">COR</text>
<text top="633" left="161" width="18" height="10" font="13">LOE</text>
<text top="633" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="670" left="97" width="3" height="9" font="5">I</text>
<text top="670" left="160" width="21" height="9" font="5">B-NR</text>
<text top="658" left="234" width="421" height="11" font="12">1. Intraoperative TEE is recommended to guide surgical repair of CHD in adults</text>
<text top="658" left="658" width="51" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.4.3-1)</a></text>
<text top="658" left="710" width="3" height="11" font="12">.</text>
<text top="719" left="97" width="3" height="9" font="5">I</text>
<text top="719" left="160" width="20" height="9" font="5">C-EO</text>
<text top="707" left="234" width="556" height="11" font="12">2. Patients with ACHD should undergo transthoracic echocardiography (TTE) for initial assessment, with</text>
<text top="723" left="248" width="493" height="11" font="12">timing of serial assessment based on anatomic and physiological severity and clinical status.</text>
<text top="872" left="63" width="199" height="11" font="20">Recommendations for CMR Imaging</text>
<text top="886" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="886" left="457" width="147" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 8</a></text>
<text top="886" left="605" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="927" left="89" width="19" height="10" font="13">COR</text>
<text top="927" left="161" width="18" height="10" font="13">LOE</text>
<text top="927" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="964" left="97" width="3" height="9" font="5">I</text>
<text top="964" left="160" width="21" height="9" font="5">B-NR</text>
<text top="952" left="234" width="566" height="11" font="12">1. In patients with ACHD who have or who are at risk of developing RV enlargement and dysfunction, serial</text>
<text top="967" left="246" width="393" height="11" font="12">CMR is recommended for quantitative assessment of RV size and function</text>
<text top="967" left="644" width="48" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.4.4-1</a></text>
<text top="965" left="692" width="54" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#54">–S3.4.4-3)</a></text>
<text top="967" left="747" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#54">.</a></text>
<text top="1021" left="94" width="10" height="9" font="5">IIa</text>
<text top="1021" left="160" width="20" height="9" font="5">C-LD</text>
<text top="1008" left="234" width="566" height="11" font="12">2. CMR can be useful in the initial evaluation and serial assessment of selected patients with CHD based on</text>
<text top="1024" left="248" width="210" height="11" font="12">anatomic complexity and clinical status</text>
<text top="1024" left="462" width="153" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.4.4-1, S3.4.4-2, S3.4.4-4</a></text>
<text top="1022" left="615" width="61" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#54">–S3.4.4-10)</a></text>
<text top="1024" left="677" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#54">.</a></text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="20" height="9" font="5">1508</text>
</page>
<page number="16" position="absolute" top="0" left="0" height="1160" width="864">
<text top="571" left="63" width="198" height="11" font="2">3.4.5. Cardiac Computed Tomography</text>
<text top="762" left="63" width="155" height="11" font="2">3.4.6. Cardiac Catheterization</text>
<text top="350" left="70" width="48" height="10" font="15">T A B L E 9</text>
<text top="350" left="135" width="325" height="10" font="16">Comparison of Imaging Modalities Useful in ACHD Evaluation</text>
<text top="375" left="177" width="44" height="9" font="13">Radiation</text>
<text top="387" left="178" width="43" height="9" font="13">Exposure</text>
<text top="375" left="245" width="38" height="9" font="13">Relative</text>
<text top="387" left="254" width="20" height="9" font="13">Cost</text>
<text top="375" left="300" width="99" height="9" font="13">Ventricular Volumes/</text>
<text top="387" left="330" width="40" height="9" font="13">Function</text>
<text top="375" left="419" width="90" height="9" font="13">Valvular Structure/</text>
<text top="387" left="443" width="40" height="9" font="13">Function</text>
<text top="375" left="524" width="107" height="9" font="13">Coronary Anatomy and</text>
<text top="387" left="562" width="31" height="9" font="13">Course</text>
<text top="375" left="648" width="100" height="9" font="13">Extracardiac Vascular</text>
<text top="387" left="677" width="41" height="9" font="13">Anatomy</text>
<text top="406" left="63" width="74" height="9" font="13">Echocardiography</text>
<text top="406" left="193" width="12" height="9" font="13">No</text>
<text top="406" left="262" width="5" height="9" font="13">$</text>
<text top="404" left="343" width="14" height="12" font="13">þþ</text>
<text top="404" left="453" width="22" height="12" font="13">þþþ</text>
<text top="404" left="570" width="15" height="12" font="13">þ/-</text>
<text top="404" left="690" width="15" height="12" font="13">þ/-</text>
<text top="425" left="63" width="19" height="9" font="13">CMR</text>
<text top="425" left="193" width="12" height="9" font="13">No</text>
<text top="425" left="259" width="10" height="9" font="13">$$</text>
<text top="423" left="339" width="22" height="12" font="13">þþþ</text>
<text top="423" left="456" width="14" height="12" font="13">þþ</text>
<text top="423" left="568" width="14" height="12" font="13">þþ</text>
<text top="425" left="583" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#16">*</a></text>
<text top="423" left="687" width="22" height="12" font="13">þþþ</text>
<text top="444" left="63" width="16" height="9" font="13">CCT</text>
<text top="444" left="192" width="14" height="9" font="13">Yes</text>
<text top="444" left="259" width="10" height="9" font="13">$$</text>
<text top="443" left="344" width="7" height="12" font="13"><a href="1-s2.0-S0735109718368451-main.html#16">þ</a></text>
<text top="444" left="351" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#16">*</a></text>
<text top="443" left="460" width="7" height="12" font="13">þ</text>
<text top="443" left="567" width="22" height="12" font="13">þþþ</text>
<text top="443" left="687" width="22" height="12" font="13">þþþ</text>
<text top="463" left="63" width="95" height="9" font="13">Cardiac catheterization</text>
<text top="463" left="192" width="14" height="9" font="13">Yes</text>
<text top="463" left="259" width="10" height="9" font="13">$$</text>
<text top="462" left="346" width="7" height="12" font="13">þ</text>
<text top="462" left="456" width="14" height="12" font="13">þþ</text>
<text top="462" left="567" width="22" height="12" font="13">þþþ</text>
<text top="462" left="691" width="14" height="12" font="13">þþ</text>
<text top="487" left="63" width="182" height="8" font="5">$ indicates less expensive; $$, more expensive;</text>
<text top="485" left="247" width="257" height="11" font="5">þ/-, possible value; þ, good; þþ, very good; and þþþ, excellent.</text>
<text top="499" left="63" width="33" height="8" font="5">*In speci</text>
<text top="497" left="96" width="108" height="11" font="5">ﬁc gated imaging protocols.</text>
<text top="513" left="71" width="502" height="8" font="5">ACHD indicates adult congenital heart disease; CCT, cardiac computed tomography; and CMR, cardiovascular magnetic resonance.</text>
<text top="606" left="63" width="294" height="11" font="20">Recommendation for Cardiac Computed Tomography</text>
<text top="621" left="63" width="407" height="11" font="20">Referenced studies that support the recommendation are summarized in</text>
<text top="621" left="474" width="147" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 9</a></text>
<text top="621" left="621" width="3" height="11" font="20">.</text>
<text top="662" left="89" width="19" height="10" font="13">COR</text>
<text top="662" left="161" width="18" height="10" font="13">LOE</text>
<text top="662" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="699" left="94" width="10" height="9" font="5">IIa</text>
<text top="699" left="160" width="20" height="9" font="5">C-LD</text>
<text top="686" left="234" width="522" height="11" font="12">1. CCT imaging can be useful in patients with ACHD when information that cannot be obtained by</text>
<text top="702" left="246" width="492" height="11" font="12">other diagnostic modalities is important enough to justify the exposure to ionizing radiation</text>
<text top="702" left="742" width="51" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.4.5-1,</a></text>
<text top="718" left="246" width="49" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#54">S3.4.5-2)</a></text>
<text top="718" left="295" width="3" height="11" font="12">.</text>
<text top="808" left="63" width="256" height="11" font="20">Recommendations for Cardiac Catheterization</text>
<text top="822" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="822" left="457" width="153" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 10</a></text>
<text top="822" left="610" width="3" height="11" font="20">.</text>
<text top="863" left="89" width="19" height="10" font="13">COR</text>
<text top="863" left="161" width="18" height="10" font="13">LOE</text>
<text top="863" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="900" left="97" width="3" height="9" font="5">I</text>
<text top="900" left="160" width="20" height="9" font="5">C-LD</text>
<text top="887" left="234" width="494" height="11" font="12">1. Cardiac catheterization (hemodynamic and/or angiographic) in patients with ACHD AP classi</text>
<text top="885" left="728" width="71" height="15" font="12">ﬁcation II and</text>
<text top="903" left="246" width="403" height="11" font="12">III, or interventional cardiac catheterization in patients with ACHD AP classi</text>
<text top="901" left="650" width="131" height="15" font="12">ﬁcation I to III should be</text>
<text top="919" left="246" width="406" height="11" font="12">performed by, or in collaboration with, cardiologists with expertise in ACHD</text>
<text top="919" left="657" width="48" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.4.6-1</a></text>
<text top="917" left="705" width="56" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#54">–S3.4.6-4)</a></text>
<text top="919" left="761" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#54">.</a></text>
<text top="960" left="94" width="10" height="9" font="5">IIa</text>
<text top="960" left="160" width="21" height="9" font="5">B-NR</text>
<text top="948" left="234" width="554" height="11" font="12">2. In patients with a low or intermediate pretest probability of coronary artery disease (CAD), use of CT</text>
<text top="964" left="248" width="276" height="11" font="12">coronary angiography is reasonable to exclude signi</text>
<text top="962" left="524" width="275" height="15" font="12">ﬁcant obstructive CAD when cardiac catheterization</text>
<text top="979" left="248" width="46" height="11" font="12">has signi</text>
<text top="977" left="294" width="230" height="15" font="12">ﬁcant risk or because of patient preference</text>
<text top="979" left="528" width="49" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">(S3.4.6-5</a></text>
<text top="977" left="578" width="56" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">–S3.4.6-9)</a></text>
<text top="979" left="634" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#55">.</a></text>
<text top="149" left="70" width="48" height="10" font="15">T A B L E 8</text>
<text top="149" left="135" width="490" height="10" font="16">Circumstances Where CMR, CCT, TEE, and/or Cardiac Catheterization May be Superior to TTE</text>
<text top="174" left="67" width="6" height="10" font="9">n</text>
<text top="175" left="81" width="664" height="9" font="13">Assessment of RV size and function in repaired TOF, systemic right ventricles, and other conditions associated with RV volume and pressure overload</text>
<text top="188" left="77" width="87" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.4.4-1, S3.4.4-3)</a></text>
<text top="202" left="67" width="6" height="10" font="9">n</text>
<text top="202" left="81" width="25" height="9" font="13">Identi</text>
<text top="201" left="107" width="235" height="12" font="13">ﬁcation of anomalous pulmonary venous connections</text>
<text top="202" left="346" width="48" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.4.4-11)</a></text>
<text top="213" left="85" width="6" height="10" font="19">n</text>
<text top="213" left="99" width="577" height="9" font="13">Serial assessment of thoracic aortic aneurysms, especially when the dilation might extend beyond the echocardiographic windows</text>
<text top="213" left="679" width="44" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#54">(S3.4.4-7)</a></text>
<text top="224" left="67" width="6" height="10" font="9">n</text>
<text top="225" left="81" width="315" height="9" font="13">Accurate assessment of PA pressure and pulmonary vascular resistance</text>
<text top="235" left="67" width="6" height="10" font="9">n</text>
<text top="236" left="81" width="185" height="9" font="13">Assessment for recoarctation of the aorta</text>
<text top="246" left="67" width="6" height="10" font="9">n</text>
<text top="247" left="81" width="97" height="9" font="13">Sinus venosus defects</text>
<text top="258" left="67" width="6" height="10" font="9">n</text>
<text top="258" left="81" width="62" height="9" font="13">Vascular rings</text>
<text top="269" left="67" width="6" height="10" font="9">n</text>
<text top="270" left="81" width="147" height="9" font="13">Evaluation of coronary anomalies</text>
<text top="280" left="67" width="6" height="10" font="9">n</text>
<text top="281" left="81" width="29" height="9" font="13">Quanti</text>
<text top="279" left="111" width="144" height="12" font="13">ﬁcation of valvular regurgitation</text>
<text top="304" left="63" width="694" height="8" font="5">CCT indicates cardiac computed tomography; CMR, cardiovascular magnetic resonance; PA, pulmonary artery; RV, right ventricular; TEE, transesophageal echocardiography; and TOF,</text>
<text top="316" left="63" width="73" height="8" font="5">tetralogy of Fallot.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="787" width="20" height="9" font="5">1509</text>
</page>
<page number="17" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="117" height="11" font="2">3.4.7. Exercise Testing</text>
<text top="384" left="108" width="132" height="11" font="12">3.5. Transition Education</text>
<text top="567" left="108" width="129" height="11" font="12">3.6. Exercise and Sports</text>
<text top="849" left="108" width="274" height="11" font="12">3.7. Mental Health and Neurodevelopmental Issues</text>
<text top="185" left="63" width="217" height="11" font="20">Recommendations for Exercise Testing</text>
<text top="199" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="199" left="457" width="150" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 11</a></text>
<text top="199" left="608" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="240" left="89" width="19" height="10" font="13">COR</text>
<text top="240" left="161" width="18" height="10" font="13">LOE</text>
<text top="240" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="277" left="94" width="10" height="9" font="5">IIa</text>
<text top="277" left="160" width="21" height="9" font="5">B-NR</text>
<text top="265" left="234" width="552" height="11" font="12">1. In patients with ACHD, cardiopulmonary exercise testing (CPET) can be useful for baseline functional</text>
<text top="280" left="246" width="156" height="11" font="12">assessment and serial testing</text>
<text top="280" left="407" width="102" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">(S3.4.7-1, S3.4.7-2)</a></text>
<text top="280" left="509" width="3" height="11" font="12">.</text>
<text top="334" left="94" width="10" height="9" font="5">IIa</text>
<text top="334" left="160" width="20" height="9" font="5">C-LD</text>
<text top="322" left="234" width="564" height="11" font="12">2. In symptomatic patients with ACHD, a 6-minute walk test can be useful to objectively assess symptom</text>
<text top="337" left="248" width="287" height="11" font="12">severity, functional capacity, and response to therapy</text>
<text top="337" left="539" width="105" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">(S3.4.7-3, S3.4.7-4)</a></text>
<text top="337" left="643" width="3" height="11" font="12">.</text>
<text top="418" left="63" width="235" height="11" font="20">Recommendation for Transition Education</text>
<text top="432" left="63" width="407" height="11" font="20">Referenced studies that support the recommendation are summarized in</text>
<text top="432" left="474" width="151" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 12</a></text>
<text top="432" left="625" width="3" height="11" font="20">.</text>
<text top="473" left="89" width="19" height="10" font="13">COR</text>
<text top="473" left="161" width="18" height="10" font="13">LOE</text>
<text top="473" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="510" left="97" width="3" height="9" font="5">I</text>
<text top="510" left="160" width="21" height="9" font="5">B-NR</text>
<text top="498" left="234" width="565" height="11" font="12">1. Clinicians caring for patients with CHD should deliver developmentally appropriate transition education</text>
<text top="513" left="246" width="440" height="11" font="12">to adolescent and young patients with CHD, and to their families/support network</text>
<text top="513" left="691" width="82" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">(S3.5-1, S3.5-2)</a></text>
<text top="513" left="773" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#55">.</a></text>
<text top="608" left="63" width="236" height="11" font="20">Recommendations for Exercise and Sports</text>
<text top="622" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="622" left="457" width="151" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 13</a></text>
<text top="622" left="609" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="663" left="89" width="19" height="10" font="13">COR</text>
<text top="663" left="161" width="18" height="10" font="13">LOE</text>
<text top="663" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="700" left="97" width="3" height="9" font="5">I</text>
<text top="700" left="160" width="20" height="9" font="5">C-LD</text>
<text top="688" left="234" width="552" height="11" font="12">1. Clinicians should assess activity levels at regular intervals and counsel patients with ACHD about the</text>
<text top="704" left="246" width="348" height="11" font="12">types and intensity of exercise appropriate to their clinical status</text>
<text top="704" left="599" width="37" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">(S3.6-1</a></text>
<text top="702" left="637" width="45" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">–S3.6-9)</a></text>
<text top="704" left="682" width="3" height="11" font="12">.</text>
<text top="757" left="94" width="10" height="9" font="5">IIa</text>
<text top="757" left="160" width="20" height="9" font="5">C-LD</text>
<text top="745" left="234" width="432" height="11" font="12">2. CPET can be useful to guide activity recommendations for patients with ACHD</text>
<text top="745" left="670" width="95" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">(S3.6-10, S3.6-11)</a></text>
<text top="745" left="765" width="3" height="11" font="12">.</text>
<text top="806" left="94" width="10" height="9" font="5">IIa</text>
<text top="806" left="160" width="21" height="9" font="5">B-NR</text>
<text top="793" left="234" width="437" height="11" font="12">3. Cardiac rehabilitation can be useful to increase exercise capacity in patients with ACHD</text>
<text top="793" left="674" width="95" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">(S3.6-12, S3.6-13)</a></text>
<text top="793" left="770" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#55">.</a></text>
<text top="888" left="63" width="388" height="11" font="20">Recommendations for Mental Health and Neurodevelopmental Issues</text>
<text top="902" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="902" left="457" width="152" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 14</a></text>
<text top="902" left="610" width="3" height="11" font="20">.</text>
<text top="943" left="89" width="19" height="10" font="13">COR</text>
<text top="943" left="161" width="18" height="10" font="13">LOE</text>
<text top="943" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="980" left="97" width="3" height="9" font="5">I</text>
<text top="980" left="160" width="21" height="9" font="5">B-NR</text>
<text top="968" left="234" width="374" height="11" font="12">1. Patients with ACHD should be evaluated for depression and anxiety</text>
<text top="968" left="611" width="36" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">(S3.7-1</a></text>
<text top="966" left="648" width="43" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">–S3.7-3)</a></text>
<text top="1028" left="94" width="10" height="9" font="5">IIa</text>
<text top="1028" left="160" width="21" height="9" font="5">B-NR</text>
<text top="1015" left="234" width="479" height="11" font="12">2. Referral for mental health evaluation and treatment is reasonable in patients with ACHD</text>
<text top="1015" left="716" width="36" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">(S3.7-1</a></text>
<text top="1013" left="752" width="44" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">–S3.7-4)</a></text>
<text top="1015" left="796" width="3" height="11" font="12">.</text>
<text top="1076" left="94" width="10" height="9" font="5">IIb</text>
<text top="1076" left="160" width="21" height="9" font="5">B-NR</text>
<text top="1064" left="234" width="542" height="11" font="12">3. Neurodevelopmental or neuropsychological testing may be considered in some patients with ACHD to guide</text>
<text top="1080" left="248" width="410" height="11" font="12">therapies that enhance academic, behavioral, psychosocial, and adaptive functioning</text>
<text top="1080" left="661" width="34" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">(S3.7-5</a></text>
<text top="1078" left="695" width="40" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">–S3.7-9)</a></text>
<text top="1080" left="735" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#55">.</a></text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="18" height="9" font="5">1510</text>
</page>
<page number="18" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="151" height="11" font="12">3.8. Endocarditis Prevention</text>
<text top="164" left="63" width="333" height="12" font="2">Patients with ACHD have an increased risk of developing</text>
<text top="182" left="63" width="150" height="12" font="2">infective endocarditis (IE)</text>
<text top="182" left="217" width="85" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">(S3.8-1, S3.8-2)</a></text>
<text top="182" left="303" width="94" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#55">. </a>The most com-</text>
<text top="200" left="63" width="333" height="12" font="2">mon pathogens responsible for IE include Streptococcus</text>
<text top="218" left="63" width="333" height="12" font="2">viridans, Staphylococcus species, and Enterococcus spe-</text>
<text top="236" left="63" width="333" height="12" font="2">cies. Despite advances in antimicrobial therapy and sur-</text>
<text top="254" left="63" width="333" height="12" font="2">gical techniques, IE remains a condition associated with</text>
<text top="272" left="63" width="27" height="12" font="2">signi</text>
<text top="270" left="91" width="306" height="15" font="2">ﬁcant morbidity and mortality. Numerous guidelines</text>
<text top="290" left="63" width="333" height="12" font="2">are available with recommendations on the prevention</text>
<text top="308" left="63" width="125" height="12" font="2">and diagnosis of IE</text>
<text top="308" left="196" width="39" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">(S3.8-3</a></text>
<text top="306" left="236" width="45" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">–S3.8-5)</a></text>
<text top="308" left="281" width="115" height="12" font="2">. These guidelines</text>
<text top="326" left="63" width="333" height="12" font="2">include consistent descriptions of the patients at highest</text>
<text top="344" left="63" width="333" height="12" font="2">risk of adverse effects from endocarditis. Antibiotic pro-</text>
<text top="362" left="63" width="333" height="12" font="2">phylaxis continues to be recommended for patients with</text>
<text top="380" left="63" width="333" height="12" font="2">high-risk characteristics, which are often found in patients</text>
<text top="398" left="63" width="64" height="12" font="2">with ACHD</text>
<text top="398" left="130" width="44" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">(S3.8-2)</a></text>
<text top="398" left="174" width="142" height="12" font="2">. These patients include:</text>
<text top="144" left="427" width="6" height="10" font="9">n</text>
<text top="143" left="440" width="139" height="12" font="2">Those with previous IE;</text>
<text top="162" left="427" width="6" height="10" font="9">n</text>
<text top="161" left="440" width="316" height="12" font="2">Patients with prosthetic valves (biological and me-</text>
<text top="178" left="436" width="216" height="12" font="2">chanical, surgical and transcatheter);</text>
<text top="198" left="427" width="6" height="10" font="9">n</text>
<text top="196" left="440" width="316" height="12" font="2">Patients within 6 months of placement of prosthetic</text>
<text top="214" left="436" width="52" height="12" font="2">material;</text>
<text top="233" left="427" width="6" height="10" font="9">n</text>
<text top="232" left="440" width="316" height="12" font="2">Patients with residual intracardiac shunts at the site of</text>
<text top="250" left="436" width="320" height="12" font="2">or adjacent to previous repair with prosthetic material</text>
<text top="268" left="436" width="79" height="12" font="2">or devices; or</text>
<text top="287" left="427" width="6" height="10" font="9">n</text>
<text top="286" left="440" width="288" height="12" font="2">Patients with uncorrected cyanotic heart disease.</text>
<text top="313" left="438" width="20" height="12" font="2">See</text>
<text top="313" left="462" width="158" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 15</a></text>
<text top="313" left="624" width="132" height="12" font="2">for referenced studies.</text>
<text top="348" left="423" width="153" height="11" font="12">3.9. Concomitant Syndromes</text>
<text top="370" left="423" width="47" height="12" font="2">See also</text>
<text top="370" left="474" width="48" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#18">Table 10</a></text>
<text top="370" left="522" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#18">.</a></text>
<text top="432" left="63" width="255" height="11" font="20">Recommendation for Concomitant Syndromes</text>
<text top="446" left="63" width="407" height="11" font="20">Referenced studies that support the recommendation are summarized in</text>
<text top="446" left="474" width="152" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 16</a></text>
<text top="446" left="627" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="487" left="89" width="19" height="10" font="13">COR</text>
<text top="487" left="161" width="18" height="10" font="13">LOE</text>
<text top="487" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="524" left="94" width="10" height="9" font="5">IIa</text>
<text top="524" left="160" width="21" height="9" font="5">B-NR</text>
<text top="512" left="234" width="515" height="11" font="12">1. Genetic testing for 22q11 deletions is reasonable for patients with conotruncal cardiac defects</text>
<text top="512" left="753" width="41" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">(S3.9-1,</a></text>
<text top="527" left="246" width="39" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#55">S3.9-2)</a></text>
<text top="527" left="286" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#55">.</a></text>
<text top="606" left="67" width="54" height="10" font="15">T A B L E 1 0</text>
<text top="606" left="135" width="337" height="10" font="16">Underlying Genetic Syndromes Commonly Associated With CHD</text>
<text top="606" left="475" width="83" height="10" font="8"><a href="1-s2.0-S0735109718368451-main.html#55">(S3.9-3, S3.9-4)</a></text>
<text top="630" left="63" width="46" height="9" font="13">Syndrome</text>
<text top="630" left="189" width="96" height="9" font="13">Genetic Abnormality</text>
<text top="630" left="395" width="77" height="9" font="13">Clinical Features</text>
<text top="630" left="605" width="119" height="9" font="13">Common Cardiac Findings</text>
<text top="650" left="63" width="82" height="9" font="13">DiGeorge syndrome</text>
<text top="661" left="78" width="68" height="9" font="13">(velocardiofacial</text>
<text top="673" left="78" width="44" height="9" font="13">syndrome)</text>
<text top="650" left="180" width="68" height="9" font="13">22q11.2 deletion</text>
<text top="650" left="299" width="196" height="9" font="13">Thymic and parathyroid hypoplasia, immunode</text>
<text top="648" left="495" width="34" height="12" font="13">ﬁciency,</text>
<text top="661" left="314" width="203" height="9" font="13">low-set ears, hypocalcemia, speech and learning</text>
<text top="673" left="314" width="192" height="9" font="13">disorders, renal anomalies, psychiatric disease</text>
<text top="685" left="299" width="19" height="9" font="13">25%</text>
<text top="684" left="318" width="182" height="12" font="13">–75% have CHD, depending on age studied</text>
<text top="697" left="314" width="68" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.9-5, S3.9-6)</a></text>
<text top="650" left="572" width="176" height="9" font="13">IAA type B, aortic arch anomalies, truncus</text>
<text top="661" left="587" width="63" height="9" font="13">arteriosus, TOF</text>
<text top="717" left="63" width="68" height="9" font="13">Down syndrome</text>
<text top="717" left="180" width="45" height="9" font="13">Trisomy 21</text>
<text top="717" left="299" width="229" height="9" font="13">Developmental disability, characteristic facial features,</text>
<text top="728" left="314" width="105" height="9" font="13">hypotonia, palmar crease</text>
<text top="740" left="299" width="21" height="9" font="13">40%</text>
<text top="739" left="320" width="69" height="12" font="13">–50% have CHD</text>
<text top="717" left="572" width="91" height="9" font="13">ASD, VSD, AVSD, TOF</text>
<text top="760" left="63" width="18" height="9" font="13">Holt</text>
<text top="758" left="81" width="71" height="12" font="13">–Oram syndrome</text>
<text top="772" left="78" width="34" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.9-7)</a></text>
<text top="760" left="180" width="22" height="9" font="13">TBX5</text>
<text top="760" left="299" width="141" height="9" font="13">Upper limb skeletal abnormalities</text>
<text top="772" left="299" width="63" height="9" font="13">75% have CHD</text>
<text top="760" left="572" width="93" height="9" font="13">ASD, VSD, MV disease</text>
<text top="791" left="63" width="88" height="9" font="13">Klinefelter syndrome</text>
<text top="791" left="180" width="31" height="9" font="13">47 XXY</text>
<text top="791" left="299" width="206" height="9" font="13">Tall stature, hypoplastic testes, delayed puberty,</text>
<text top="803" left="314" width="102" height="9" font="13">developmental disability</text>
<text top="815" left="299" width="64" height="9" font="13">50% have CHD</text>
<text top="791" left="572" width="99" height="9" font="13">PDA, ASD, MV prolapse</text>
<text top="834" left="63" width="76" height="9" font="13">Noonan syndrome</text>
<text top="846" left="78" width="35" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.9-8)</a></text>
<text top="834" left="180" width="84" height="9" font="13">PTPN11, KRAS, SOS1</text>
<text top="846" left="195" width="80" height="9" font="13">RAF1, NRAS, BRAF,</text>
<text top="858" left="195" width="34" height="9" font="13">MAP2K1</text>
<text top="834" left="299" width="203" height="9" font="13">Facial anomalies, webbed neck, chest deformity,</text>
<text top="846" left="314" width="201" height="9" font="13">short stature, lymphatic abnormalities, bleeding</text>
<text top="858" left="314" width="56" height="9" font="13">abnormalities</text>
<text top="870" left="299" width="65" height="9" font="13">80% have CHD</text>
<text top="834" left="572" width="59" height="9" font="13">PS, ASD, HCM</text>
<text top="889" left="63" width="71" height="9" font="13">Turner syndrome</text>
<text top="889" left="180" width="17" height="9" font="13">45X</text>
<text top="889" left="299" width="212" height="9" font="13">Short stature, webbed neck, lymphedema, primary</text>
<text top="901" left="314" width="49" height="9" font="13">amenorrhea</text>
<text top="913" left="299" width="64" height="9" font="13">30% have CHD</text>
<text top="925" left="299" width="99" height="9" font="13">Risk of aortic dissection</text>
<text top="889" left="572" width="139" height="9" font="13">Coarctation, BAV, aortic stenosis,</text>
<text top="901" left="587" width="137" height="9" font="13">hypoplastic left heart, ascending</text>
<text top="913" left="587" width="46" height="9" font="13">aortopathy</text>
<text top="944" left="63" width="79" height="9" font="13">Williams syndrome</text>
<text top="944" left="180" width="68" height="9" font="13">7q11.23 deletion</text>
<text top="944" left="299" width="8" height="9" font="13">El</text>
<text top="942" left="307" width="168" height="12" font="13">ﬁn face, social personality, hearing loss,</text>
<text top="956" left="314" width="190" height="9" font="13">developmental delay, infantile hypercalcemia</text>
<text top="968" left="299" width="20" height="9" font="13">50%</text>
<text top="966" left="319" width="69" height="12" font="13">–80% have CHD</text>
<text top="944" left="572" width="173" height="9" font="13">Supravalvar aortic stenosis, peripheral PS</text>
<text top="992" left="63" width="694" height="8" font="5">ASD indicates atrial septal defect; AVSD, atrioventricular septal defect; BAV, bicuspid aortic valve; CHD, congenital heart disease; HCM, hypertrophic cardiomyopathy; IAA, interrupted</text>
<text top="1004" left="63" width="561" height="8" font="5">aortic arch; MV, mitral valve; PDA, patent ductus arteriosus; PS, pulmonary stenosis; TOF, tetralogy of Fallot; and VSD, ventricular septal defect.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="791" width="16" height="9" font="5">1511</text>
</page>
<page number="19" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="168" height="11" font="12">3.10. Noncardiac Medical Issues</text>
<text top="328" left="108" width="130" height="11" font="12">3.11. Noncardiac Surgery</text>
<text top="350" left="108" width="47" height="12" font="2">See also</text>
<text top="350" left="158" width="45" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#19">Table 11</a></text>
<text top="350" left="204" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#19">.</a></text>
<text top="175" left="63" width="266" height="11" font="20">Recommendation for Noncardiac Medical Issues</text>
<text top="189" left="63" width="407" height="11" font="20">Referenced studies that support the recommendation are summarized in</text>
<text top="189" left="474" width="152" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 18</a></text>
<text top="189" left="627" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="230" left="89" width="19" height="10" font="13">COR</text>
<text top="230" left="161" width="18" height="10" font="13">LOE</text>
<text top="230" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="267" left="97" width="3" height="9" font="5">I</text>
<text top="267" left="160" width="20" height="9" font="5">C-LD</text>
<text top="255" left="234" width="566" height="11" font="12">1. Patients with ACHD at risk for hepatitis C should be screened and vaccinated for viral hepatitis and treated</text>
<text top="271" left="246" width="76" height="11" font="12">as appropriate</text>
<text top="271" left="327" width="47" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.10-1)</a></text>
<text top="271" left="374" width="3" height="11" font="12">.</text>
<text top="377" left="63" width="234" height="11" font="20">Recommendations for Noncardiac Surgery</text>
<text top="392" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="392" left="457" width="152" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 18</a></text>
<text top="392" left="610" width="3" height="11" font="20">.</text>
<text top="433" left="89" width="19" height="10" font="13">COR</text>
<text top="433" left="161" width="18" height="10" font="13">LOE</text>
<text top="433" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="470" left="97" width="3" height="9" font="5">I</text>
<text top="470" left="160" width="20" height="9" font="5">C-LD</text>
<text top="457" left="234" width="566" height="11" font="12">1. Optimization before and close surveillance after invasive procedures, regardless of the complexity of the</text>
<text top="473" left="246" width="241" height="11" font="12">anatomic defect or type of procedure is bene</text>
<text top="471" left="488" width="152" height="15" font="12">ﬁcial for patients with ACHD</text>
<text top="473" left="644" width="40" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.11-1</a></text>
<text top="471" left="684" width="48" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">–S3.11-4)</a></text>
<text top="473" left="732" width="3" height="11" font="12">.</text>
<text top="518" left="97" width="3" height="9" font="5">I</text>
<text top="518" left="160" width="21" height="9" font="5">B-NR</text>
<text top="505" left="234" width="183" height="11" font="12">2. In patients with ACHD AP classi</text>
<text top="503" left="417" width="162" height="15" font="12">ﬁcation IB-D, IIA-D, and IIIA-D</text>
<text top="505" left="579" width="5" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#19">*</a></text>
<text top="505" left="588" width="203" height="11" font="12">noncardiac surgical and interventional</text>
<text top="521" left="248" width="552" height="11" font="12">procedures should be performed in a hospital with or in consultation with experts in ACHD when possible</text>
<text top="537" left="248" width="129" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.11-1, S3.11-3, S3.11-5</a></text>
<text top="535" left="378" width="48" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">–S3.11-9)</a></text>
<text top="537" left="426" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#56">.</a></text>
<text top="562" left="63" width="17" height="8" font="5">*See</text>
<text top="562" left="83" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="562" left="144" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="560" left="273" width="60" height="11" font="5">ﬁcation system.</text>
<text top="609" left="113" width="51" height="10" font="15">T A B L E 1 1</text>
<text top="609" left="179" width="264" height="10" font="16">ACHD Management Issues for Noncardiac Surgery</text>
<text top="633" left="108" width="100" height="9" font="13">Clarify CHD diagnosis</text>
<text top="650" left="108" width="411" height="12" font="13">➢ Clarify prior procedures, residua, sequelae, and current status, including ACHD AP classiﬁcation</text>
<text top="670" left="108" width="404" height="12" font="13">➢ Be aware that history obtained from only the patient and family may be faulty or incomplete</text>
<text top="689" left="108" width="443" height="12" font="13">➢ Obtain and review old records to ensure accurate understanding of past procedures and clinical course</text>
<text top="708" left="108" width="333" height="12" font="13">➢ Complete additional investigations required to deﬁne ACHD AP classiﬁcation</text>
<text top="727" left="108" width="313" height="12" font="13">➢ Develop management strategies to minimize risk and optimize outcome</text>
<text top="748" left="108" width="339" height="9" font="13">Factors associated with increased risk of perioperative morbidity and mortality</text>
<text top="748" left="449" width="41" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.11-10)</a></text>
<text top="748" left="491" width="3" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#56">:</a></text>
<text top="763" left="112" width="6" height="10" font="9">n</text>
<text top="764" left="126" width="38" height="9" font="13">Cyanosis</text>
<text top="774" left="112" width="6" height="10" font="9">n</text>
<text top="775" left="126" width="64" height="9" font="13">Congestive HF</text>
<text top="785" left="112" width="6" height="10" font="9">n</text>
<text top="786" left="126" width="87" height="9" font="13">Poor general health</text>
<text top="797" left="112" width="6" height="10" font="9">n</text>
<text top="797" left="126" width="55" height="9" font="13">Younger age</text>
<text top="808" left="112" width="6" height="10" font="9">n</text>
<text top="809" left="126" width="107" height="9" font="13">Pulmonary hypertension</text>
<text top="819" left="112" width="6" height="10" font="9">n</text>
<text top="820" left="126" width="226" height="9" font="13">Operations on the respiratory and nervous systems</text>
<text top="830" left="112" width="6" height="10" font="9">n</text>
<text top="831" left="126" width="60" height="9" font="13">Complex CHD</text>
<text top="841" left="112" width="6" height="10" font="9">n</text>
<text top="842" left="126" width="134" height="9" font="13">Urgent/emergency procedures</text>
<text top="861" left="108" width="79" height="9" font="13">Issues to consider:</text>
<text top="876" left="112" width="6" height="10" font="9">n</text>
<text top="877" left="126" width="108" height="9" font="13">Endocarditis prophylaxis</text>
<text top="888" left="112" width="6" height="10" font="9">n</text>
<text top="888" left="126" width="227" height="9" font="13">Complications related to underlying hemodynamics</text>
<text top="899" left="112" width="6" height="10" font="9">n</text>
<text top="900" left="126" width="347" height="9" font="13">Abnormal venous and/or arterial anatomy affecting venous and arterial access</text>
<text top="910" left="112" width="6" height="10" font="9">n</text>
<text top="911" left="126" width="76" height="9" font="13">Persistent shunts</text>
<text top="921" left="112" width="6" height="10" font="9">n</text>
<text top="922" left="126" width="71" height="9" font="13">Valvular disease</text>
<text top="932" left="112" width="6" height="10" font="9">n</text>
<text top="933" left="126" width="180" height="9" font="13">Arrhythmias, including bradyarrhythmias</text>
<text top="944" left="112" width="6" height="10" font="9">n</text>
<text top="944" left="126" width="63" height="9" font="13">Erythrocytosis</text>
<text top="955" left="112" width="6" height="10" font="9">n</text>
<text top="956" left="126" width="121" height="9" font="13">Pulmonary vascular disease</text>
<text top="966" left="112" width="6" height="10" font="9">n</text>
<text top="967" left="126" width="164" height="9" font="13">Meticulous line care (also consider air</text>
<text top="965" left="293" width="510" height="12" font="13">ﬁlters for intravenous lines) to reduce risk of paradoxic embolus in patients who are cyanotic because of right-to-left</text>
<text top="977" left="127" width="29" height="9" font="13">shunts</text>
<text top="987" left="112" width="6" height="10" font="9">n</text>
<text top="988" left="126" width="385" height="9" font="13">Adjustment of anticoagulant volume in tubes for some blood work in cyanotic patients</text>
<text top="999" left="112" width="6" height="10" font="9">n</text>
<text top="999" left="126" width="146" height="9" font="13">Prevention of venous thrombosis</text>
<text top="1010" left="112" width="6" height="10" font="9">n</text>
<text top="1011" left="126" width="167" height="9" font="13">Monitoring of renal and liver function</text>
<text top="1021" left="112" width="6" height="10" font="9">n</text>
<text top="1022" left="126" width="133" height="9" font="13">Periprocedure anticoagulation</text>
<text top="1032" left="112" width="6" height="10" font="9">n</text>
<text top="1033" left="126" width="209" height="9" font="13">Possible need for nonconventional drug dosing</text>
<text top="1043" left="112" width="6" height="10" font="9">n</text>
<text top="1044" left="126" width="463" height="9" font="13">Increased prevalence of hepatitis C infection because of prior procedures and remote blood transfusions</text>
<text top="1055" left="112" width="6" height="10" font="9">n</text>
<text top="1055" left="126" width="110" height="9" font="13">Developmental disability</text>
<text top="1079" left="108" width="512" height="8" font="5">ACHD indicates adult congenital heart disease; AP, anatomic and physiological; CHD, congenital heart disease; and HF, heart failure.</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="17" height="9" font="5">1512</text>
</page>
<page number="20" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="266" height="11" font="12">3.12. Pregnancy, Reproduction, and Sexual Health</text>
<text top="165" left="63" width="90" height="11" font="2">3.12.1. Pregnancy</text>
<text top="729" left="63" width="111" height="11" font="2">3.12.2. Contraception</text>
<text top="942" left="63" width="181" height="11" font="12">3.13. Heart Failure and Transplant</text>
<text top="957" left="63" width="104" height="11" font="2">3.13.1. Heart Failure</text>
<text top="193" left="63" width="184" height="11" font="20">Recommendations for Pregnancy</text>
<text top="207" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="207" left="457" width="152" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 19</a></text>
<text top="207" left="610" width="3" height="11" font="20">.</text>
<text top="248" left="89" width="19" height="10" font="13">COR</text>
<text top="248" left="161" width="18" height="10" font="13">LOE</text>
<text top="248" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="285" left="97" width="3" height="9" font="5">I</text>
<text top="285" left="160" width="20" height="9" font="5">C-LD</text>
<text top="273" left="234" width="542" height="11" font="12">1. Women with CHD should receive prepregnancy counseling with input from an ACHD cardiologist to</text>
<text top="289" left="246" width="530" height="11" font="12">determine maternal cardiac, obstetrical and fetal risks, and potential long-term risks to the mother</text>
<text top="305" left="246" width="50" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.12.1-1</a></text>
<text top="303" left="297" width="57" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">–S3.12.1-4)</a></text>
<text top="305" left="355" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#56">.</a></text>
<text top="342" left="97" width="3" height="9" font="5">I</text>
<text top="342" left="160" width="20" height="9" font="5">C-LD</text>
<text top="329" left="234" width="566" height="11" font="12">2. An individualized plan of care that addresses expectations and contingencies should be developed for and</text>
<text top="345" left="248" width="552" height="11" font="12">with women with CHD who are pregnant or who may become pregnant and shared with the patient and all</text>
<text top="361" left="248" width="54" height="11" font="12">caregivers</text>
<text top="361" left="306" width="110" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.12.1-2, S3.12.1-3)</a></text>
<text top="361" left="416" width="3" height="11" font="12">.</text>
<text top="402" left="97" width="3" height="9" font="5">I</text>
<text top="402" left="160" width="21" height="9" font="5">B-NR</text>
<text top="390" left="234" width="563" height="11" font="12">3. Women with CHD receiving chronic anticoagulation should be counseled, ideally before conception, on</text>
<text top="406" left="248" width="97" height="11" font="12">the risks and bene</text>
<text top="404" left="345" width="252" height="15" font="12">ﬁts of speciﬁc anticoagulants during pregnancy</text>
<text top="406" left="602" width="111" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.12.1-5, S3.12.1-6)</a></text>
<text top="406" left="713" width="3" height="11" font="12">.</text>
<text top="452" left="97" width="3" height="9" font="5">I</text>
<text top="452" left="160" width="21" height="9" font="5">B-NR</text>
<text top="440" left="234" width="166" height="11" font="12">4. Women with ACHD AP classi</text>
<text top="438" left="400" width="162" height="15" font="12">ﬁcation IB-D, IIA-D, and IIIA-D</text>
<text top="440" left="562" width="5" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#20">*</a></text>
<text top="440" left="571" width="224" height="11" font="12">should be managed collaboratively during</text>
<text top="455" left="249" width="482" height="11" font="12">pregnancy by ACHD cardiologists, obstetricians, and anesthesiologists experienced in ACHD</text>
<text top="455" left="735" width="55" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.12.1-2,</a></text>
<text top="471" left="249" width="107" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">S3.12.1-7, S3.12.1-8)</a></text>
<text top="471" left="355" width="3" height="11" font="12">.</text>
<text top="506" left="97" width="3" height="9" font="5">I</text>
<text top="506" left="160" width="20" height="9" font="5">C-EO</text>
<text top="494" left="234" width="557" height="11" font="12">5. In collaboration with an ACHD cardiologist to ensure accurate assessment of pregnancy risk, patients at high risk of</text>
<text top="510" left="248" width="552" height="11" font="12">maternal morbidity or mortality, including women with pulmonary arterial hypertension (PAH), Eisenmenger syndrome,</text>
<text top="526" left="248" width="464" height="11" font="12">severe systemic ventricular dysfunction, severe left-sided obstructive lesions, and/or ACHD AP classi</text>
<text top="524" left="712" width="88" height="15" font="12">ﬁcation ID, IID, and</text>
<text top="541" left="248" width="16" height="11" font="12">I<a href="1-s2.0-S0735109718368451-main.html#20">IID</a></text>
<text top="541" left="264" width="5" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#20">*</a></text>
<text top="541" left="273" width="523" height="11" font="12">should be counseled against becoming pregnant or be given the option of terminating pregnancy.</text>
<text top="577" left="97" width="3" height="9" font="5">I</text>
<text top="577" left="160" width="21" height="9" font="5">B-NR</text>
<text top="565" left="234" width="551" height="11" font="12">6. Men and women of childbearing age with CHD should be counseled on the risk of CHD recurrence in</text>
<text top="580" left="249" width="48" height="11" font="12">offspring</text>
<text top="580" left="301" width="57" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.12.1-9)</a></text>
<text top="580" left="358" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#56">.</a></text>
<text top="626" left="94" width="10" height="9" font="5">IIa</text>
<text top="626" left="160" width="21" height="9" font="5">B-NR</text>
<text top="614" left="234" width="440" height="11" font="12">7. Exercise testing can be useful for risk assessment in women with ACHD AP classi</text>
<text top="612" left="674" width="126" height="15" font="12">ﬁcation IC-D, IIA-D, and</text>
<text top="630" left="247" width="31" height="11" font="12">I<a href="1-s2.0-S0735109718368451-main.html#20">IIA-D</a></text>
<text top="630" left="278" width="5" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#20">*</a></text>
<text top="630" left="288" width="166" height="11" font="12">who are considering pregnancy</text>
<text top="630" left="457" width="120" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.12.1-10, S3.12.1-11)</a></text>
<text top="630" left="578" width="3" height="11" font="12">.</text>
<text top="675" left="94" width="10" height="9" font="5">IIa</text>
<text top="675" left="160" width="21" height="9" font="5">B-NR</text>
<text top="663" left="234" width="439" height="11" font="12">8. When either parent has CHD, it is reasonable to perform fetal echocardiography</text>
<text top="663" left="676" width="120" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.12.1-12, S3.12.1-13)</a></text>
<text top="663" left="796" width="3" height="11" font="12">.</text>
<text top="710" left="63" width="17" height="8" font="5">*See</text>
<text top="710" left="83" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="710" left="144" width="88" height="8" font="5">for the ACHD AP classi</text>
<text top="709" left="232" width="61" height="11" font="5">ﬁcation system.</text>
<text top="755" left="63" width="204" height="11" font="20">Recommendations for Contraception</text>
<text top="769" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="769" left="457" width="154" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 20</a></text>
<text top="769" left="612" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="810" left="89" width="19" height="10" font="13">COR</text>
<text top="810" left="161" width="18" height="10" font="13">LOE</text>
<text top="810" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="847" left="97" width="3" height="9" font="5">I</text>
<text top="847" left="160" width="20" height="9" font="5">C-LD</text>
<text top="835" left="234" width="556" height="11" font="12">1. Women of childbearing potential with CHD should be counseled about the risks associated with preg-</text>
<text top="850" left="246" width="238" height="11" font="12">nancy and appropriate contraceptive options</text>
<text top="850" left="489" width="51" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.12.2-1</a></text>
<text top="848" left="541" width="58" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">–S3.12.2-3)</a></text>
<text top="850" left="599" width="3" height="11" font="12">.</text>
<text top="895" left="81" width="35" height="9" font="5">III: Harm</text>
<text top="895" left="160" width="21" height="9" font="5">B-NR</text>
<text top="883" left="234" width="564" height="11" font="12">2. Estrogen-containing contraceptives are potentially harmful for women with CHD at high risk of throm-</text>
<text top="898" left="248" width="549" height="11" font="12">boembolic events (e.g., cyanosis, Fontan physiology, mechanical valves, prior thrombotic events, PAH)</text>
<text top="914" left="248" width="114" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.12.2-4, S3.12.2-5)</a></text>
<text top="914" left="362" width="3" height="11" font="12">.</text>
<text top="994" left="63" width="193" height="11" font="20">Recommendation for Heart Failure</text>
<text top="1008" left="63" width="407" height="11" font="20">Referenced studies that support the recommendation are summarized in</text>
<text top="1008" left="474" width="152" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 22</a></text>
<text top="1008" left="627" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="1049" left="89" width="19" height="10" font="13">COR</text>
<text top="1049" left="161" width="18" height="10" font="13">LOE</text>
<text top="1049" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="1086" left="97" width="3" height="9" font="5">I</text>
<text top="1086" left="160" width="20" height="9" font="5">C-LD</text>
<text top="1074" left="234" width="553" height="11" font="12">1. Consultation with ACHD and HF specialists is recommended for patients with ACHD and HF or severe</text>
<text top="1090" left="246" width="123" height="11" font="12">ventricular dysfunction</text>
<text top="1090" left="373" width="50" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.13.1-1</a></text>
<text top="1088" left="424" width="57" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">–S3.13.1-4)</a></text>
<text top="1090" left="481" width="3" height="11" font="12">.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="790" width="17" height="9" font="5">1513</text>
</page>
<page number="21" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="125" height="11" font="2">3.13.2. Heart Transplant</text>
<text top="164" left="108" width="333" height="12" font="2">Because of the prevalence of HF among patients with</text>
<text top="182" left="108" width="333" height="12" font="2">CHD, heart transplantation is increasingly being consid-</text>
<text top="200" left="108" width="333" height="12" font="2">ered as a therapeutic option. Data on proper timing of</text>
<text top="218" left="108" width="333" height="12" font="2">transplantation are limited, particularly for individual</text>
<text top="236" left="108" width="333" height="12" font="2">lesions. Larger studies based on transplant databases do</text>
<text top="254" left="108" width="271" height="12" font="2">not allow for analysis based on the type of CHD</text>
<text top="254" left="382" width="53" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.13.2-1</a></text>
<text top="252" left="436" width="5" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">–</a></text>
<text top="272" left="108" width="55" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">S3.13.2-4)</a></text>
<text top="272" left="163" width="278" height="12" font="2">. Currently, patients with ACHD may have fewer</text>
<text top="290" left="108" width="333" height="12" font="2">mechanical circulatory devices (e.g., ventricular-assist</text>
<text top="308" left="108" width="333" height="12" font="2">devices), which may lower their listing status and hence</text>
<text top="326" left="108" width="154" height="12" font="2">potential for organ receipt</text>
<text top="326" left="266" width="169" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.13.2-1, S3.13.2-2, S3.13.2-4</a></text>
<text top="324" left="436" width="5" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">–</a></text>
<text top="344" left="108" width="54" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">S3.13.2-7)</a></text>
<text top="344" left="162" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#56">.</a></text>
<text top="362" left="123" width="91" height="12" font="2">Although speci</text>
<text top="360" left="214" width="227" height="15" font="2">ﬁc criteria for timing of referral for</text>
<text top="380" left="108" width="333" height="12" font="2">transplantation are desirable, universal recommendations</text>
<text top="398" left="108" width="333" height="12" font="2">cannot be made based on current data. Generally, pub-</text>
<text top="415" left="108" width="333" height="12" font="2">lished data show that immediate and early post-</text>
<text top="433" left="108" width="333" height="12" font="2">transplantation risk is higher in ACHD than in acquired</text>
<text top="451" left="108" width="333" height="12" font="2">heart disease because of increased perioperative mortal-</text>
<text top="469" left="108" width="15" height="12" font="2">ity</text>
<text top="469" left="129" width="58" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.13.2-2)</a></text>
<text top="469" left="187" width="254" height="12" font="2">. However, once beyond the perioperative</text>
<text top="487" left="108" width="333" height="12" font="2">period, patients with ACHD do as well as or better than</text>
<text top="505" left="108" width="333" height="12" font="2">those with acquired heart disease, with expected 10-year</text>
<text top="523" left="108" width="333" height="12" font="2">survival equivalent to or better than that of patients</text>
<text top="541" left="108" width="84" height="12" font="2">without ACHD</text>
<text top="541" left="196" width="186" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.13.2-2-4, S3.13.2-6, S3.13.2-7)</a></text>
<text top="541" left="383" width="58" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#56">. </a>Risks for</text>
<text top="143" left="468" width="26" height="12" font="2">poor</text>
<text top="143" left="508" width="56" height="12" font="2">outcomes</text>
<text top="143" left="578" width="43" height="12" font="2">include</text>
<text top="143" left="634" width="34" height="12" font="2">single</text>
<text top="143" left="682" width="51" height="12" font="2">ventricle</text>
<text top="143" left="747" width="54" height="12" font="2">anatomy,</text>
<text top="161" left="468" width="333" height="12" font="2">anatomic complexity, protein-losing enteropathy, or high</text>
<text top="178" left="468" width="204" height="12" font="2">titers of panel reactive antibodies</text>
<text top="178" left="678" width="120" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#56">(S3.13.2-8, S3.13.2-9)</a></text>
<text top="178" left="798" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#56">.</a></text>
<text top="196" left="468" width="333" height="12" font="2">The current allocation system puts patients with ACHD at</text>
<text top="214" left="468" width="333" height="12" font="2">a disadvantage. Rather than priority dictated by the usual</text>
<text top="232" left="468" width="333" height="12" font="2">accepted risk markers, patients with ACHD are often lis-</text>
<text top="250" left="468" width="35" height="12" font="2">ted by</text>
<text top="248" left="507" width="295" height="15" font="2">“exception,” a process that requires the clinician to</text>
<text top="268" left="468" width="333" height="12" font="2">argue that the patient warrants higher priority than would</text>
<text top="286" left="468" width="333" height="12" font="2">be evident by applying the used risk markers. There is</text>
<text top="304" left="468" width="54" height="12" font="2">also signi</text>
<text top="302" left="522" width="279" height="15" font="2">ﬁcant mortality for patients with ACHD while on</text>
<text top="322" left="468" width="65" height="12" font="2">the waitlist</text>
<text top="322" left="536" width="126" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S3.13.2-10, S3.13.2-11)</a></text>
<text top="322" left="662" width="139" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#57">. </a>Surgical alternatives to</text>
<text top="340" left="468" width="333" height="12" font="2">transplantation exist for some patients with CHD (e.g.,</text>
<text top="358" left="468" width="333" height="12" font="2">valve replacement, shunt closure), but these patients are</text>
<text top="376" left="468" width="216" height="12" font="2">at high risk of perioperative mortality</text>
<text top="376" left="687" width="64" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S3.13.2-12)</a></text>
<text top="376" left="751" width="50" height="12" font="2">. Ideally,</text>
<text top="394" left="468" width="333" height="12" font="2">providers will consider early referral to a transplant cen-</text>
<text top="412" left="468" width="333" height="12" font="2">ter with expertise in ACHD transplantation when trans-</text>
<text top="430" left="468" width="333" height="12" font="2">plantation becomes a relevant clinical consideration.</text>
<text top="447" left="468" width="333" height="12" font="2">Additionally, it is advisable to consider options for</text>
<text top="465" left="468" width="333" height="12" font="2">transplantation or ventricular assist device as a backup</text>
<text top="483" left="468" width="243" height="12" font="2">before other high-risk surgery is pursued.</text>
<text top="501" left="483" width="20" height="12" font="2">See</text>
<text top="501" left="507" width="159" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 23</a></text>
<text top="501" left="670" width="132" height="12" font="2">for referenced studies.</text>
<text top="536" left="468" width="106" height="11" font="12">3.14. Palliative Care</text>
<text top="581" left="63" width="201" height="11" font="20">Recommendation for Palliative Care</text>
<text top="595" left="63" width="407" height="11" font="20">Referenced studies that support the recommendation are summarized in</text>
<text top="595" left="474" width="153" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 24</a></text>
<text top="595" left="628" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="636" left="89" width="19" height="10" font="13">COR</text>
<text top="636" left="161" width="18" height="10" font="13">LOE</text>
<text top="636" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="673" left="94" width="10" height="9" font="5">IIa</text>
<text top="673" left="160" width="21" height="9" font="5">B-NR</text>
<text top="661" left="234" width="371" height="11" font="12">1. Discussion of end-of-life issues and advance directives can be bene</text>
<text top="659" left="605" width="195" height="15" font="12">ﬁcial for patients with ACHD or their</text>
<text top="677" left="246" width="56" height="11" font="12">surrogates</text>
<text top="677" left="306" width="42" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S3.14-1</a></text>
<text top="675" left="349" width="49" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">–S3.14-3)</a></text>
<text top="677" left="398" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#57">.</a></text>
<text top="728" left="108" width="74" height="11" font="12">3.15. Cyanosis</text>
<text top="750" left="108" width="46" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#21">Table 12</a></text>
<text top="749" left="154" width="3" height="12" font="2">.</text>
<text top="777" left="113" width="52" height="10" font="15">T A B L E 1 2</text>
<text top="776" left="179" width="27" height="10" font="16">Speci</text>
<text top="775" left="207" width="229" height="14" font="16">ﬁc Management Practices for Cyanotic CHD</text>
<text top="802" left="108" width="6" height="10" font="9">n</text>
<text top="802" left="122" width="199" height="9" font="13">Recording clinical oxygen saturation at rest (</text>
<text top="801" left="322" width="405" height="12" font="13">&gt;5 min) rather than immediately after effort (e.g., walking into a clinic examination room).</text>
<text top="813" left="108" width="6" height="10" font="9">n</text>
<text top="814" left="122" width="448" height="9" font="13">Meticulous intravenous care to avoid air or particulate matter, which may include use of air/particulate</text>
<text top="812" left="573" width="228" height="12" font="13">ﬁlters on all intravenous access lines, when feasible,</text>
<text top="824" left="123" width="145" height="9" font="13">and careful de-airing of all lines.</text>
<text top="834" left="108" width="6" height="10" font="9">n</text>
<text top="835" left="122" width="539" height="9" font="13">Cerebral imaging for any new headache or neurologic sign to assess for possible cerebral abscess, hemorrhage, or stroke.</text>
<text top="845" left="108" width="6" height="10" font="9">n</text>
<text top="846" left="122" width="438" height="9" font="13">Measurement of serum uric acid and treatment with allopurinol in a patient with a history of gout.</text>
<text top="857" left="108" width="6" height="10" font="9">n</text>
<text top="857" left="122" width="666" height="9" font="13">Supplemental oxygen as needed for symptom relief but not to a target oxygen saturation level and not if there is no demonstrable symptomatic bene</text>
<text top="856" left="789" width="12" height="12" font="13">ﬁt.</text>
<text top="868" left="108" width="6" height="10" font="9">n</text>
<text top="869" left="122" width="308" height="9" font="13">Avoidance of or cautious use of therapies that may reduce the patient</text>
<text top="867" left="431" width="370" height="12" font="13">’s hypoxia-mediated drive to ventilation, such as narcotics or, in rare circumstances,</text>
<text top="879" left="123" width="126" height="9" font="13">excess supplemental oxygen</text>
<text top="879" left="252" width="38" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#57">(S3.15-1)</a></text>
<text top="879" left="290" width="3" height="9" font="13">.</text>
<text top="889" left="108" width="6" height="10" font="9">n</text>
<text top="890" left="122" width="462" height="9" font="13">Anesthesia by providers with expertise in anesthesia for patients with ACHD for any noncardiac surgery.</text>
<text top="900" left="108" width="6" height="10" font="9">n</text>
<text top="901" left="122" width="60" height="9" font="13">Non-estrogen</text>
<text top="900" left="183" width="612" height="12" font="13">–containing birth control for women of child-bearing potential (intrauterine device may be a preferred option). Avoidance of birth control</text>
<text top="911" left="123" width="176" height="9" font="13">entirely is not a safe acceptable option.</text>
<text top="922" left="108" width="6" height="10" font="9">n</text>
<text top="923" left="122" width="300" height="9" font="13">Patients can travel safely on commercial airlines without undue risk</text>
<text top="923" left="426" width="39" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#57">(S3.15-2)</a></text>
<text top="923" left="465" width="20" height="9" font="13">. Pre</text>
<text top="921" left="486" width="298" height="12" font="13">ﬂight simulation testing or mandated supplemental oxygen are not</text>
<text top="933" left="123" width="327" height="9" font="13">usually indicated, although adequate hydration and movement during the</text>
<text top="931" left="453" width="97" height="12" font="13">ﬂight are appropriate.</text>
<text top="943" left="108" width="6" height="10" font="9">n</text>
<text top="944" left="122" width="674" height="9" font="13">Measurement of coagulation parameters (e.g., activated partial thromboplastin time, international normalized ratio, thrombin time) in a patient with an</text>
<text top="954" left="123" width="89" height="9" font="13">elevated hematocrit</text>
<text top="953" left="215" width="583" height="12" font="13">&gt;55% requires adjustment of anticoagulant volume in the blood collection vials to account for reduced plasma volume in the draw</text>
<text top="965" left="118" width="39" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#57">(S3.15-3)</a></text>
<text top="965" left="157" width="3" height="9" font="13">.</text>
<text top="988" left="108" width="13" height="8" font="5">See</text>
<text top="988" left="124" width="106" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 25</a></text>
<text top="988" left="233" width="87" height="8" font="5">for referenced studies.</text>
<text top="1002" left="116" width="315" height="8" font="5">ACHD indicates adult congenital heart disease and CHD, congenital heart disease.</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="18" height="9" font="5">1514</text>
</page>
<page number="22" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="217" height="11" font="12">3.16. Pharmacological Therapy for ACHD</text>
<text top="164" left="63" width="333" height="12" font="2">Patients with ACHD are commonly excluded from clinical</text>
<text top="182" left="63" width="333" height="12" font="2">trials, and there are few data to guide pharmacological</text>
<text top="200" left="63" width="333" height="12" font="2">therapies. Although it may be tempting to extrapolate</text>
<text top="218" left="63" width="333" height="12" font="2">from management guidelines developed for patients</text>
<text top="236" left="63" width="206" height="12" font="2">without CHD (e.g., HF guidelines)</text>
<text top="236" left="275" width="48" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S3.16-1)</a></text>
<text top="236" left="323" width="73" height="12" font="2">, treatments</text>
<text top="254" left="63" width="184" height="12" font="2">may not have the same bene</text>
<text top="252" left="247" width="149" height="15" font="2">ﬁt in the heterogeneous</text>
<text top="272" left="63" width="333" height="12" font="2">population of patients with ACHD and in some cases may</text>
<text top="290" left="63" width="333" height="12" font="2">cause harm. The evaluation of new symptoms in a patient</text>
<text top="308" left="63" width="263" height="12" font="2">with ACHD must be tailored to the patient</text>
<text top="306" left="326" width="70" height="15" font="2">’s anatomy,</text>
<text top="326" left="63" width="333" height="12" font="2">surgical repair, and physiology. Before considering phar-</text>
<text top="344" left="63" width="333" height="12" font="2">macological therapies, evaluation for residual shunts,</text>
<text top="362" left="63" width="18" height="12" font="2">baf</text>
<text top="360" left="81" width="315" height="15" font="2">ﬂe stenosis, valvular or conduit dysfunction, and</text>
<text top="380" left="63" width="333" height="12" font="2">collateral vessels, any of which may be amenable to in-</text>
<text top="398" left="63" width="251" height="12" font="2">terventions, is an important consideration.</text>
<text top="415" left="78" width="318" height="12" font="2">The literature documenting pharmacological therapies</text>
<text top="433" left="63" width="333" height="12" font="2">for patients with ACHD is limited to small studies with</text>
<text top="451" left="63" width="333" height="12" font="2">limited duration of drug administration and follow-up.</text>
<text top="469" left="63" width="333" height="12" font="2">Additionally, the endpoints used are often surrogate</text>
<text top="487" left="63" width="333" height="12" font="2">markers that have not been validated for clinical decision-</text>
<text top="505" left="63" width="333" height="12" font="2">making, and studies are also often underpowered. How-</text>
<text top="523" left="63" width="333" height="12" font="2">ever, studies in patients with ACHD do exist and evaluate</text>
<text top="541" left="63" width="333" height="12" font="2">conventional pharmacological therapy, especially for HF</text>
<text top="559" left="63" width="333" height="12" font="2">and for arrhythmia, including beta blockers, angiotensin-</text>
<text top="577" left="63" width="62" height="12" font="2">converting</text>
<text top="577" left="140" width="45" height="12" font="2">enzyme</text>
<text top="577" left="200" width="60" height="12" font="2">inhibitors,</text>
<text top="577" left="275" width="121" height="12" font="2">angiotensin-receptor</text>
<text top="595" left="63" width="333" height="12" font="2">blockers, and aldosterone antagonists, although results</text>
<text top="613" left="63" width="25" height="12" font="2">vary</text>
<text top="613" left="92" width="44" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S3.16-2</a></text>
<text top="611" left="137" width="51" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">–S3.16-9)</a></text>
<text top="613" left="188" width="3" height="12" font="2">.</text>
<text top="631" left="78" width="318" height="12" font="2">Pharmacological therapies in patients with ACHD are</text>
<text top="649" left="63" width="128" height="12" font="2">often directed to speci</text>
<text top="647" left="191" width="205" height="15" font="2">ﬁc conditions (i.e., beta blockers for</text>
<text top="667" left="63" width="333" height="12" font="2">arrhythmia treatment). However, there are limited data</text>
<text top="684" left="63" width="116" height="12" font="2">examining the bene</text>
<text top="683" left="179" width="217" height="15" font="2">ﬁts of beta blockers in speciﬁc ACHD</text>
<text top="702" left="63" width="333" height="12" font="2">populations. Results from a small study indicate that</text>
<text top="143" left="423" width="333" height="12" font="2">beta-blocker therapy may have potential to improve</text>
<text top="161" left="423" width="333" height="12" font="2">functional class in patients with a systemic right ventricle</text>
<text top="178" left="423" width="21" height="12" font="2">and</text>
<text top="178" left="458" width="6" height="12" font="2">a</text>
<text top="178" left="478" width="62" height="12" font="2">pacemaker</text>
<text top="178" left="553" width="49" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S3.16-2)</a></text>
<text top="178" left="603" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#57">.</a></text>
<text top="178" left="619" width="137" height="12" font="2">Angiotensin-converting</text>
<text top="196" left="423" width="333" height="12" font="2">enzyme inhibitors and angiotensin-receptor blockers</text>
<text top="214" left="423" width="282" height="12" font="2">have also been assessed in small studies in speci</text>
<text top="213" left="705" width="51" height="15" font="2">ﬁc ACHD</text>
<text top="232" left="423" width="171" height="12" font="2">populations in which no signi</text>
<text top="230" left="595" width="162" height="15" font="2">ﬁcant beneﬁt on ventricular</text>
<text top="250" left="423" width="277" height="12" font="2">function or exercise capacity has been proven</text>
<text top="250" left="705" width="45" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S3.16-6</a></text>
<text top="248" left="751" width="5" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">–</a></text>
<text top="268" left="423" width="45" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">S3.16-8)</a></text>
<text top="268" left="469" width="288" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#57">. </a>Data from 1 small trial with a short follow-up</text>
<text top="286" left="423" width="333" height="12" font="2">interval in patients with a systemic right ventricle sug-</text>
<text top="304" left="423" width="333" height="12" font="2">gest that eplerenone may be associated with reduced</text>
<text top="322" left="423" width="64" height="12" font="2">myocardial</text>
<text top="320" left="491" width="184" height="15" font="2">ﬁbrosis, as assessed by imaging</text>
<text top="322" left="679" width="49" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S3.16-3)</a></text>
<text top="322" left="729" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#57">.</a></text>
<text top="340" left="438" width="319" height="12" font="2">Some pharmacological therapies affecting the pulmo-</text>
<text top="358" left="423" width="333" height="12" font="2">nary vasculature (e.g., endothelin-receptor antagonists</text>
<text top="376" left="423" width="333" height="12" font="2">and phosphodiesterase type-5 [PDE-5] inhibitors) have a</text>
<text top="394" left="423" width="28" height="12" font="2">bene</text>
<text top="392" left="451" width="305" height="15" font="2">ﬁcial effect on long-term outcomes in patients with</text>
<text top="412" left="423" width="140" height="12" font="2">Eisenmenger syndrome</text>
<text top="412" left="571" width="55" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S3.16-10)</a></text>
<text top="412" left="627" width="130" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#57">. </a>Similarly, there are</text>
<text top="430" left="423" width="333" height="12" font="2">limited data on the use of pulmonary vasodilator therapy</text>
<text top="447" left="423" width="333" height="12" font="2">in Fontan patients, in whom the pulmonary vascular</text>
<text top="465" left="423" width="167" height="12" font="2">resistance may be abnormal</text>
<text top="465" left="596" width="49" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S3.16-11</a></text>
<text top="464" left="645" width="55" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">–S3.16-13)</a></text>
<text top="465" left="701" width="56" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#57">. </a>Because</text>
<text top="483" left="423" width="333" height="12" font="2">of the lack of data, clinical recommendations regarding</text>
<text top="501" left="423" width="333" height="12" font="2">pharmacological therapy for patients with ACHD are un-</text>
<text top="519" left="423" width="333" height="12" font="2">supported. Individualized care is needed, recognizing the</text>
<text top="537" left="423" width="87" height="12" font="2">potential bene</text>
<text top="535" left="510" width="246" height="15" font="2">ﬁts and risks of the therapy relative to</text>
<text top="555" left="423" width="75" height="12" font="2">patient-speci</text>
<text top="553" left="499" width="220" height="15" font="2">ﬁc anatomic and physiological issues.</text>
<text top="573" left="438" width="20" height="12" font="2">See</text>
<text top="573" left="462" width="159" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 23</a></text>
<text top="573" left="625" width="132" height="12" font="2">for referenced studies.</text>
<text top="616" left="423" width="142" height="16" font="14">4. SPECIFIC LESIONS</text>
<text top="654" left="423" width="97" height="11" font="12">4.1. Shunt Lesions</text>
<text top="676" left="423" width="133" height="11" font="2">4.1.1. Atrial Septal Defect</text>
<text top="697" left="423" width="47" height="12" font="2">See also</text>
<text top="697" left="474" width="119" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#23">Table 13 </a>and <a href="1-s2.0-S0735109718368451-main.html#24">Figure 1</a></text>
<text top="697" left="593" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#24">.</a></text>
<text top="737" left="63" width="237" height="11" font="20">Recommendations for Atrial Septal Defect</text>
<text top="751" left="63" width="393" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="751" left="460" width="154" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 26</a></text>
<text top="751" left="619" width="173" height="11" font="20">and the ERC systematic review</text>
<text top="765" left="63" width="35" height="11" font="20">report</text>
<text top="765" left="102" width="51" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S4.1.1-1)</a></text>
<text top="765" left="153" width="3" height="11" font="20">.</text>
<text top="806" left="89" width="19" height="10" font="13">COR</text>
<text top="806" left="161" width="18" height="10" font="13">LOE</text>
<text top="806" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="833" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="878" left="97" width="3" height="9" font="5">I</text>
<text top="878" left="160" width="20" height="9" font="5">C-EO</text>
<text top="866" left="234" width="560" height="11" font="12">1. Pulse oximetry at rest and during exercise is recommended for evaluation of adults with unrepaired or</text>
<text top="881" left="246" width="475" height="11" font="12">repaired ASD with residual shunt to determine the direction and magnitude of the shunt.</text>
<text top="927" left="97" width="3" height="9" font="5">I</text>
<text top="927" left="160" width="21" height="9" font="5">B-NR</text>
<text top="915" left="234" width="512" height="11" font="12">2. CMR, CCT, and/or TEE are useful to evaluate pulmonary venous connections in adults with ASD</text>
<text top="915" left="748" width="46" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S4.1.1-2</a></text>
<text top="913" left="794" width="5" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">–</a></text>
<text top="931" left="248" width="46" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">S4.1.1-4)</a></text>
<text top="931" left="295" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#57">.</a></text>
<text top="977" left="97" width="3" height="9" font="5">I</text>
<text top="977" left="160" width="21" height="9" font="5">B-NR</text>
<text top="965" left="234" width="438" height="11" font="12">3. Echocardiographic imaging is recommended to guide percutaneous ASD closure</text>
<text top="965" left="675" width="100" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S4.1.1-5, S4.1.1-6)</a></text>
<text top="965" left="776" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#57">.</a></text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="790" width="17" height="9" font="5">1515</text>
</page>
<page number="23" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="22" size="3" family="Times" color="#000000"/>
<text top="173" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="217" left="97" width="3" height="9" font="5">I</text>
<text top="217" left="156" width="21" height="9" font="5">B-NR</text>
<text top="215" left="177" width="8" height="6" font="22">SR</text>
<text top="205" left="234" width="535" height="11" font="12">4. In adults with isolated secundum ASD causing impaired functional capacity, right atrial and/or RV</text>
<text top="221" left="249" width="237" height="11" font="12">enlargement, and net left-to-right shunt suf</text>
<text top="219" left="486" width="276" height="15" font="12">ﬁciently large to cause physiological sequelae (e.g.,</text>
<text top="236" left="249" width="56" height="11" font="12">pulmonary</text>
<text top="234" left="305" width="493" height="15" font="12">–systemic blood ﬂow ratio [Qp:Qs] ‡1.5:1) without cyanosis at rest or during exercise, trans-</text>
<text top="252" left="249" width="525" height="11" font="12">catheter or surgical closure to reduce RV volume and improve exercise tolerance is recommended,</text>
<text top="268" left="249" width="551" height="11" font="12">provided that systolic PA pressure is less than 50% of systolic systemic pressure and pulmonary vascular</text>
<text top="283" left="249" width="358" height="11" font="12">resistance is less than one third of the systemic vascular resistance</text>
<text top="283" left="611" width="45" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S4.1.1-7</a></text>
<text top="281" left="657" width="56" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">–S4.1.1-12)</a></text>
<text top="283" left="713" width="3" height="11" font="12">.</text>
<text top="322" left="97" width="3" height="9" font="5">I</text>
<text top="322" left="160" width="21" height="9" font="5">B-NR</text>
<text top="310" left="234" width="546" height="11" font="12">5. Adults with primum ASD, sinus venosus defect or coronary sinus defect causing impaired functional</text>
<text top="325" left="248" width="402" height="11" font="12">capacity, right atrial and/or RV enlargement and net left-to-right shunt suf</text>
<text top="323" left="650" width="121" height="15" font="12">ﬁciently large to cause</text>
<text top="341" left="248" width="187" height="11" font="12">physiological sequelae (e.g., Qp:Qs</text>
<text top="339" left="439" width="359" height="15" font="12">‡1.5:1) without cyanosis at rest or during exercise, should be surgi-</text>
<text top="357" left="248" width="552" height="11" font="12">cally repaired unless precluded by comorbidities, provided that systolic PA pressure is less than 50% of</text>
<text top="373" left="248" width="530" height="11" font="12">systemic pressure and pulmonary vascular resistance is less than one third of the systemic vascular</text>
<text top="388" left="248" width="53" height="11" font="12">resistance</text>
<text top="388" left="305" width="110" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S4.1.1-13, S4.1.1-14)</a></text>
<text top="388" left="415" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#57">.</a></text>
<text top="427" left="94" width="10" height="9" font="5">IIa</text>
<text top="427" left="157" width="20" height="9" font="5">C-LD</text>
<text top="425" left="176" width="8" height="6" font="22">SR</text>
<text top="415" left="234" width="562" height="11" font="12">6. In asymptomatic adults with isolated secundum ASD, right atrial and RV enlargement, and net left-to-</text>
<text top="430" left="249" width="78" height="11" font="12">right shunt suf</text>
<text top="428" left="328" width="449" height="15" font="12">ﬁciently large to cause physiological sequelae (e.g., Qp:Qs 1.5:1 or greater), without</text>
<text top="446" left="249" width="550" height="11" font="12">cyanosis at rest or during exercise, transcatheter or surgical closure is reasonable to reduce RV volume</text>
<text top="462" left="249" width="533" height="11" font="12">and/or improve functional capacity, provided that systolic PA pressure is less than 50% of systemic</text>
<text top="477" left="249" width="445" height="11" font="12">pressure and pulmonary vascular resistance is less than one third systemic resistance</text>
<text top="477" left="697" width="45" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S4.1.1-7</a></text>
<text top="475" left="743" width="57" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">–S4.1.1-10,</a></text>
<text top="493" left="249" width="51" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">S4.1.1-12)</a></text>
<text top="493" left="300" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#57">.</a></text>
<text top="531" left="94" width="10" height="9" font="5">IIa</text>
<text top="531" left="160" width="20" height="9" font="5">C-LD</text>
<text top="519" left="234" width="553" height="11" font="12">7. Surgical closure of a secundum ASD in adults is reasonable when a concomitant surgical procedure is</text>
<text top="535" left="247" width="308" height="11" font="12">being performed and there is a net left-to-right shunt suf</text>
<text top="533" left="555" width="244" height="15" font="12">ﬁciently large to cause physiological sequelae</text>
<text top="551" left="247" width="531" height="11" font="12">(e.g., Qp:Qs 1.5:1 or greater) and right atrial and RV enlargement without cyanosis at rest or during</text>
<text top="566" left="247" width="42" height="11" font="12">exercise</text>
<text top="566" left="294" width="51" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">(S4.1.1-15</a></text>
<text top="564" left="345" width="57" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#57">–S4.1.1-18)</a></text>
<text top="566" left="403" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#57">.</a></text>
<text top="606" left="94" width="10" height="9" font="5">IIb</text>
<text top="606" left="160" width="21" height="9" font="5">B-NR</text>
<text top="594" left="234" width="555" height="11" font="12">8. Percutaneous or surgical closure may be considered for adults with ASD when net left-to-right shunt</text>
<text top="610" left="249" width="539" height="11" font="12">(Qp:Qs) is 1.5:1 or greater, PA systolic pressure is 50% or more of systemic arterial systolic pressure,</text>
<text top="626" left="249" width="475" height="11" font="12">and/or pulmonary vascular resistance is greater than one third of the systemic resistance</text>
<text top="626" left="728" width="55" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.1-19,</a></text>
<text top="641" left="249" width="54" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">S4.1.1-20)</a></text>
<text top="641" left="303" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#58">.</a></text>
<text top="681" left="81" width="35" height="9" font="5">III: Harm</text>
<text top="681" left="160" width="20" height="9" font="5">C-LD</text>
<text top="669" left="234" width="556" height="11" font="12">9. ASD closure should not be performed in adults with PA systolic pressure greater than two thirds sys-</text>
<text top="685" left="249" width="550" height="11" font="12">temic, pulmonary vascular resistance greater than two thirds systemic, and/or a net right-to-left shunt</text>
<text top="700" left="249" width="111" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.1-21, S4.1.1-22)</a></text>
<text top="700" left="360" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#58">.</a></text>
<text top="149" left="69" width="61" height="10" font="15">(continued)</text>
<text top="770" left="113" width="52" height="10" font="15">T A B L E 1 3</text>
<text top="770" left="179" width="244" height="10" font="16">ASD: Routine Follow-Up and Testing Intervals</text>
<text top="794" left="108" width="100" height="9" font="13">Frequency of Routine</text>
<text top="806" left="108" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="794" left="311" width="61" height="9" font="13">Physiological</text>
<text top="806" left="308" width="36" height="9" font="13">Stage A</text>
<text top="806" left="344" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#23">*</a></text>
<text top="806" left="352" width="22" height="9" font="13">(mo)</text>
<text top="794" left="453" width="61" height="9" font="13">Physiological</text>
<text top="806" left="451" width="35" height="9" font="13">Stage B</text>
<text top="806" left="487" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#23">*</a></text>
<text top="806" left="495" width="22" height="9" font="13">(mo)</text>
<text top="794" left="595" width="61" height="9" font="13">Physiological</text>
<text top="806" left="593" width="35" height="9" font="13">Stage C</text>
<text top="806" left="629" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#23">*</a></text>
<text top="806" left="636" width="22" height="9" font="13">(mo)</text>
<text top="794" left="738" width="61" height="9" font="13">Physiological</text>
<text top="806" left="735" width="36" height="9" font="13">Stage D</text>
<text top="806" left="771" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#23">*</a></text>
<text top="806" left="779" width="22" height="9" font="13">(mo)</text>
<text top="825" left="108" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="825" left="328" width="11" height="9" font="13">36</text>
<text top="823" left="338" width="16" height="12" font="13">–60</text>
<text top="825" left="479" width="11" height="9" font="13">24</text>
<text top="825" left="616" width="6" height="9" font="13">6</text>
<text top="823" left="622" width="13" height="12" font="13">–12</text>
<text top="825" left="761" width="5" height="9" font="13">3</text>
<text top="823" left="766" width="10" height="12" font="13">–6</text>
<text top="844" left="108" width="17" height="9" font="13">ECG</text>
<text top="844" left="328" width="11" height="9" font="13">36</text>
<text top="843" left="338" width="16" height="12" font="13">–60</text>
<text top="844" left="479" width="11" height="9" font="13">24</text>
<text top="844" left="621" width="9" height="9" font="13">12</text>
<text top="844" left="764" width="9" height="9" font="13">12</text>
<text top="863" left="108" width="16" height="9" font="13">TTE</text>
<text top="863" left="328" width="11" height="9" font="13">36</text>
<text top="862" left="338" width="16" height="12" font="13">–60</text>
<text top="863" left="479" width="11" height="9" font="13">24</text>
<text top="863" left="621" width="9" height="9" font="13">12</text>
<text top="863" left="764" width="9" height="9" font="13">12</text>
<text top="883" left="108" width="62" height="9" font="13">Pulse oximetry</text>
<text top="883" left="319" width="44" height="9" font="13">As needed</text>
<text top="883" left="462" width="44" height="9" font="13">As needed</text>
<text top="883" left="606" width="40" height="9" font="13">Each visit</text>
<text top="883" left="748" width="40" height="9" font="13">Each visit</text>
<text top="902" left="108" width="53" height="9" font="13">Exercise test</text>
<text top="900" left="161" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#23">†</a></text>
<text top="902" left="319" width="44" height="9" font="13">As needed</text>
<text top="902" left="462" width="44" height="9" font="13">As needed</text>
<text top="902" left="614" width="9" height="9" font="13">12</text>
<text top="900" left="623" width="15" height="12" font="13">–24</text>
<text top="902" left="759" width="6" height="9" font="13">6</text>
<text top="900" left="765" width="13" height="12" font="13">–12</text>
<text top="926" left="108" width="17" height="8" font="5">*See</text>
<text top="926" left="128" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="926" left="189" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="924" left="318" width="60" height="11" font="5">ﬁcation system.</text>
<text top="936" left="108" width="257" height="11" font="5">†6-minute walk test or CPET, depending on the clinical indication.</text>
<text top="952" left="116" width="577" height="8" font="5">ACHD indicates adult congenital heart disease; CPET, cardiopulmonary exercise test; ECG, electrocardiogram; and TTE, transthoracic echocardiogram.</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="18" height="9" font="5">1516</text>
</page>
<page number="24" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="23" size="6" family="Times" color="#e3202b"/>
	<fontspec id="24" size="6" family="Times" color="#0e2a52"/>
	<fontspec id="25" size="7" family="Times" color="#000000"/>
<text top="729" left="63" width="258" height="11" font="2">4.1.2. Anomalous Pulmonary Venous Connections</text>
<text top="775" left="63" width="368" height="11" font="20">Recommendations for Anomalous Pulmonary Venous Connections</text>
<text top="790" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="790" left="457" width="152" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 27</a></text>
<text top="790" left="610" width="3" height="11" font="20">.</text>
<text top="831" left="89" width="19" height="10" font="13">COR</text>
<text top="831" left="161" width="18" height="10" font="13">LOE</text>
<text top="831" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="858" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="902" left="97" width="3" height="9" font="5">I</text>
<text top="902" left="160" width="21" height="9" font="5">B-NR</text>
<text top="890" left="234" width="512" height="11" font="12">1. CMR or CTA is recommended for evaluation of partial anomalous pulmonary venous connection</text>
<text top="890" left="748" width="46" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.2-1</a></text>
<text top="888" left="794" width="5" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">–</a></text>
<text top="906" left="246" width="48" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">S4.1.2-4)</a></text>
<text top="906" left="295" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#58">.</a></text>
<text top="952" left="94" width="10" height="9" font="5">IIa</text>
<text top="952" left="160" width="21" height="9" font="5">B-NR</text>
<text top="940" left="234" width="565" height="11" font="12">2. Cardiac catheterization can be useful in adults with partial anomalous pulmonary venous connection to</text>
<text top="955" left="248" width="54" height="11" font="12">further de</text>
<text top="953" left="302" width="101" height="15" font="12">ﬁne hemodynamics</text>
<text top="955" left="407" width="103" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.2-5, S4.1.2-6)</a></text>
<text top="955" left="510" width="3" height="11" font="12">.</text>
<text top="996" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="1040" left="97" width="3" height="9" font="5">I</text>
<text top="1040" left="160" width="21" height="9" font="5">B-NR</text>
<text top="1028" left="234" width="563" height="11" font="12">3. Surgical repair is recommended for patients with partial anomalous pulmonary venous connection when</text>
<text top="1044" left="248" width="509" height="11" font="12">functional capacity is impaired and RV enlargement is present, there is a net left-to-right shunt suf</text>
<text top="1042" left="757" width="42" height="15" font="12">ﬁciently</text>
<text top="1060" left="248" width="262" height="11" font="12">large to cause physiological sequelae (e.g., Qp:Qs</text>
<text top="1058" left="513" width="286" height="15" font="12">‡1.5:1), PA systolic pressure is less than 50% systemic</text>
<text top="1075" left="248" width="464" height="11" font="12">pressure and pulmonary vascular resistance is less than one third of systemic resistance</text>
<text top="1075" left="715" width="52" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.2-5)</a></text>
<text top="1075" left="767" width="3" height="11" font="12">.</text>
<text top="154" left="80" width="44" height="11" font="23">FIGURE 1</text>
<text top="155" left="132" width="66" height="9" font="24">Secundum ASD</text>
<text top="198" left="370" width="66" height="10" font="13">Secundum ASD</text>
<text top="243" left="391" width="27" height="10" font="13">Shunt </text>
<text top="254" left="385" width="35" height="10" font="13">direction</text>
<text top="320" left="269" width="47" height="10" font="13">Left-to-right</text>
<text top="414" left="159" width="82" height="10" font="13">Pulmonary vascular</text>
<text top="425" left="131" width="142" height="10" font="13">resistance &lt;1/3 systemic vascular </text>
<text top="437" left="120" width="163" height="10" font="13">resistance, PASP &lt;50% systemic, right </text>
<text top="448" left="125" width="152" height="10" font="13">heart enlargement, <b>AND </b>shunt large </text>
<text top="459" left="121" width="160" height="10" font="13">enough to cause physiologic sequelae </text>
<text top="470" left="160" width="80" height="10" font="13">(e.g.,Qp:Qs ≥1.5:1)</text>
<text top="574" left="138" width="47" height="10" font="13">Surgical or </text>
<text top="585" left="131" width="61" height="10" font="13">device closure </text>
<text top="596" left="143" width="35" height="10" font="13">(Class I)</text>
<text top="513" left="353" width="74" height="10" font="13">Consultation with </text>
<text top="524" left="342" width="93" height="10" font="13">ACHD and PH  experts</text>
<text top="574" left="367" width="47" height="10" font="13">Surgical or </text>
<text top="585" left="359" width="61" height="10" font="13">device closure </text>
<text top="596" left="368" width="42" height="10" font="13">(Class IIb)</text>
<text top="550" left="178" width="16" height="10" font="13">Yes</text>
<text top="422" left="348" width="83" height="10" font="13">Pulmonary vascular </text>
<text top="433" left="338" width="104" height="10" font="13">resistance &gt;1/3 systemic </text>
<text top="444" left="348" width="84" height="10" font="13">vascular resistance, </text>
<text top="455" left="344" width="93" height="10" font="25"><b>AND/OR </b>PASP ≥50% </text>
<text top="467" left="371" width="36" height="10" font="13">systemic</text>
<text top="574" left="218" width="47" height="10" font="13">Surgical or </text>
<text top="585" left="210" width="61" height="10" font="13">device closure </text>
<text top="596" left="219" width="42" height="10" font="13">(Class IIa)</text>
<text top="506" left="179" width="46" height="10" font="13">Functional </text>
<text top="517" left="177" width="46" height="10" font="13">impairment</text>
<text top="550" left="211" width="12" height="10" font="13">No</text>
<text top="372" left="468" width="98" height="10" font="13">Confirm PAH diagnosis </text>
<text top="383" left="468" width="100" height="10" font="13">(often requiring  invasive </text>
<text top="395" left="487" width="60" height="10" font="13">hemodynamic </text>
<text top="406" left="490" width="53" height="10" font="13">assessment)</text>
<text top="417" left="499" width="35" height="10" font="13">(Class I)</text>
<text top="360" left="627" width="67" height="10" font="13">PDE-5 inhibitors</text>
<text top="371" left="640" width="42" height="10" font="13">(Class IIa)</text>
<text top="319" left="642" width="39" height="10" font="13">Bosentan</text>
<text top="330" left="643" width="35" height="10" font="13">(Class I)</text>
<text top="397" left="635" width="55" height="10" font="13">Combination </text>
<text top="408" left="643" width="35" height="10" font="13">therapy*</text>
<text top="419" left="640" width="42" height="10" font="13">(Class IIa)</text>
<text top="378" left="263" width="62" height="10" font="13">Hemodynamic </text>
<text top="390" left="268" width="49" height="10" font="13">assessment</text>
<text top="447" left="639" width="44" height="10" font="13">No closure</text>
<text top="458" left="628" width="68" height="10" font="13">(Class III: Harm)</text>
<text top="395" left="577" width="16" height="10" font="13">Yes</text>
<text top="309" left="492" width="51" height="10" font="13">Right-to-left </text>
<text top="320" left="477" width="81" height="10" font="13">(e.g., Eisenmenger </text>
<text top="331" left="494" width="44" height="10" font="13">syndrome)</text>
<text top="631" left="80" width="655" height="9" font="13">*Combination therapy with bosentan and PDE-5 inhibitor if symptomatic improvement does not occur with either alone. ACHD indicates adult congenital</text>
<text top="646" left="80" width="656" height="9" font="13">heart disease; ASD, atrial septal defect; PAH, pulmonary artery hypertension; PASP, pulmonary artery systolic pressure; PDE-5, phosphodiesterase type-5</text>
<text top="661" left="80" width="268" height="9" font="13">inhibitors; PH, pulmonary hypertension; and Qp:Qs, pulmonary</text>
<text top="659" left="348" width="115" height="12" font="13">–systemic blood ﬂow ratio.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="791" width="17" height="9" font="5">1517</text>
</page>
<page number="25" position="absolute" top="0" left="0" height="1160" width="864">
<text top="483" left="108" width="163" height="11" font="2">4.1.3. Ventricular Septal Defect</text>
<text top="504" left="108" width="47" height="12" font="2">See also</text>
<text top="505" left="158" width="121" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#26">Table 14 </a>and <a href="1-s2.0-S0735109718368451-main.html#26">Figure 2</a></text>
<text top="504" left="280" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#26">.</a></text>
<text top="202" left="97" width="3" height="9" font="5">I</text>
<text top="202" left="160" width="21" height="9" font="5">B-NR</text>
<text top="190" left="234" width="560" height="11" font="12">4. Repair of partial anomalous pulmonary venous connection is recommended at the time of closure of a</text>
<text top="205" left="249" width="150" height="11" font="12">sinus venosus defect or ASD</text>
<text top="205" left="403" width="51" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.2-7)</a></text>
<text top="205" left="454" width="3" height="11" font="12">.</text>
<text top="251" left="97" width="3" height="9" font="5">I</text>
<text top="251" left="160" width="21" height="9" font="5">B-NR</text>
<text top="239" left="234" width="566" height="11" font="12">5. Repair of a scimitar vein is recommended in adults when functional capacity is impaired, evidence of RV</text>
<text top="255" left="248" width="345" height="11" font="12">volume overload is present, there is a net left-to-right shunt suf</text>
<text top="253" left="593" width="194" height="15" font="12">ﬁciently large to cause physiological</text>
<text top="270" left="248" width="113" height="11" font="12">sequelae (e.g., Qp:Qs</text>
<text top="268" left="365" width="422" height="15" font="12">‡1.5:1), PA systolic pressure is less than 50% systemic pressure and pulmonary</text>
<text top="286" left="248" width="265" height="11" font="12">vascular resistance is less than one third systemic</text>
<text top="286" left="517" width="154" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.2-5, S4.1.2-8, S4.1.2-9)</a></text>
<text top="286" left="672" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#58">.</a></text>
<text top="332" left="94" width="10" height="9" font="5">IIa</text>
<text top="332" left="160" width="21" height="9" font="5">B-NR</text>
<text top="320" left="234" width="529" height="11" font="12">6. Surgery can be useful for right- or left-sided partial anomalous pulmonary venous connection in</text>
<text top="336" left="249" width="396" height="11" font="12">asymptomatic adults with RV volume overload, net left-to-right shunt suf</text>
<text top="334" left="645" width="121" height="15" font="12">ﬁciently large to cause</text>
<text top="351" left="249" width="185" height="11" font="12">physiological sequelae (e.g., Qp:Qs</text>
<text top="349" left="438" width="362" height="15" font="12">‡1.5:1), pulmonary pressures less than 50% systemic and pulmonary</text>
<text top="367" left="249" width="253" height="11" font="12">vascular resistance less than one third systemic</text>
<text top="367" left="506" width="52" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.2-5)</a></text>
<text top="367" left="558" width="3" height="11" font="12">.</text>
<text top="413" left="94" width="10" height="9" font="5">IIa</text>
<text top="413" left="160" width="21" height="9" font="5">B-NR</text>
<text top="401" left="234" width="562" height="11" font="12">7. Surgery can be useful for repair of a scimitar vein in adults with evidence of RV volume overload, with</text>
<text top="416" left="247" width="116" height="11" font="12">Qp:Qs 1.5:1 or greater</text>
<text top="416" left="367" width="103" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.2-5, S4.1.2-9)</a></text>
<text top="416" left="471" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#58">.</a></text>
<text top="149" left="69" width="61" height="10" font="15">(continued)</text>
<text top="549" left="63" width="268" height="11" font="20">Recommendations for Ventricular Septal Defect</text>
<text top="563" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="563" left="457" width="153" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 28</a></text>
<text top="563" left="611" width="3" height="11" font="20">.</text>
<text top="604" left="89" width="19" height="10" font="13">COR</text>
<text top="604" left="161" width="18" height="10" font="13">LOE</text>
<text top="604" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="631" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="676" left="97" width="3" height="9" font="5">I</text>
<text top="676" left="160" width="21" height="9" font="5">B-NR</text>
<text top="664" left="234" width="521" height="11" font="12">1. Adults with a VSD and evidence of left ventricular volume overload and hemodynamically signi</text>
<text top="662" left="755" width="29" height="15" font="12">ﬁcant</text>
<text top="679" left="246" width="74" height="11" font="12">shunts (Qp:Qs</text>
<text top="677" left="325" width="475" height="15" font="12">‡1.5:1) should undergo VSD closure, if PA systolic pressure is less than 50% systemic and</text>
<text top="695" left="246" width="326" height="11" font="12">pulmonary vascular resistance is less than one third systemic</text>
<text top="695" left="576" width="50" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.3-1)</a></text>
<text top="695" left="626" width="3" height="11" font="12">.</text>
<text top="741" left="94" width="10" height="9" font="5">IIa</text>
<text top="741" left="160" width="20" height="9" font="5">C-LD</text>
<text top="729" left="234" width="566" height="11" font="12">2. Surgical closure of perimembranous or supracristal VSD is reasonable in adults when there is worsening</text>
<text top="744" left="248" width="212" height="11" font="12">aortic regurgitation (AR) caused by VSD</text>
<text top="744" left="464" width="100" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.3-1, S4.1.3-2)</a></text>
<text top="744" left="565" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#58">.</a></text>
<text top="790" left="94" width="10" height="9" font="5">IIb</text>
<text top="790" left="160" width="20" height="9" font="5">C-LD</text>
<text top="778" left="234" width="566" height="11" font="12">3. Surgical closure of a VSD may be reasonable in adults with a history of IE caused by VSD if not otherwise</text>
<text top="794" left="248" width="82" height="11" font="12">contraindicated</text>
<text top="794" left="334" width="51" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.3-3)</a></text>
<text top="794" left="386" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#58">.</a></text>
<text top="840" left="94" width="10" height="9" font="5">IIb</text>
<text top="840" left="160" width="20" height="9" font="5">C-LD</text>
<text top="828" left="234" width="478" height="11" font="12">4. Closure of a VSD may be considered in the presence of a net left-to-right shunt (Qp:Qs</text>
<text top="826" left="715" width="84" height="15" font="12">‡1.5:1) when PA</text>
<text top="843" left="249" width="551" height="11" font="12">systolic pressure is 50% or more than systemic and/or pulmonary vascular resistance is greater than one</text>
<text top="859" left="249" width="75" height="11" font="12">third systemic</text>
<text top="859" left="327" width="48" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.3-4</a></text>
<text top="857" left="375" width="53" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">–S4.1.3-6)</a></text>
<text top="859" left="429" width="3" height="11" font="12">.</text>
<text top="905" left="81" width="35" height="9" font="5">III: Harm</text>
<text top="905" left="160" width="20" height="9" font="5">C-LD</text>
<text top="893" left="234" width="563" height="11" font="12">5. VSD closure should not be performed in adults with severe PAH with PA systolic pressure greater than</text>
<text top="908" left="248" width="552" height="11" font="12">two thirds systemic, pulmonary vascular resistance greater than two thirds systemic and/or a net right-</text>
<text top="924" left="248" width="68" height="11" font="12">to-left shunt</text>
<text top="924" left="320" width="47" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.3-7</a></text>
<text top="922" left="367" width="53" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">–S4.1.3-9)</a></text>
<text top="924" left="421" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#58">.</a></text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="18" height="9" font="5">1518</text>
</page>
<page number="26" position="absolute" top="0" left="0" height="1160" width="864">
<text top="448" left="80" width="45" height="11" font="23">FIGURE 2</text>
<text top="449" left="134" width="102" height="9" font="24">Hemodynamically Signi</text>
<text top="447" left="236" width="132" height="12" font="24">ﬁcant Ventricular Level Shunt</text>
<text top="485" left="340" width="120" height="10" font="13">Hemodynamically significant </text>
<text top="497" left="354" width="90" height="10" font="13">ventricular level shunt</text>
<text top="627" left="274" width="48" height="10" font="13">Left-to-right</text>
<text top="730" left="176" width="69" height="10" font="13">LV enlargement </text>
<text top="742" left="180" width="58" height="10" font="13">Qp:Qs ≥1.5:1,</text>
<text top="753" left="162" width="96" height="10" font="13">PASP &lt;50% systemic, </text>
<text top="764" left="157" width="107" height="10" font="25"><b>AND </b>pulmonary vascular </text>
<text top="775" left="158" width="102" height="10" font="13">resistance &lt;1/3 systemic</text>
<text top="803" left="173" width="16" height="10" font="13">Yes</text>
<text top="803" left="225" width="12" height="10" font="13">No</text>
<text top="828" left="206" width="86" height="10" font="13">Progressive AR due </text>
<text top="839" left="208" width="83" height="10" font="13">to perimembranous </text>
<text top="851" left="208" width="80" height="10" font="13">or supracristal VSD</text>
<text top="874" left="217" width="16" height="10" font="13">Yes</text>
<text top="874" left="263" width="12" height="10" font="13">No</text>
<text top="800" left="350" width="82" height="10" font="13">Consult with ACHD </text>
<text top="812" left="357" width="64" height="10" font="13">and PH experts</text>
<text top="823" left="372" width="35" height="10" font="13">(Class I)</text>
<text top="854" left="367" width="48" height="10" font="13">Surgical or </text>
<text top="865" left="360" width="62" height="10" font="13">device closure </text>
<text top="877" left="368" width="43" height="10" font="13">(Class IIb)</text>
<text top="617" left="489" width="51" height="10" font="13">Right-to-left </text>
<text top="628" left="474" width="81" height="10" font="13">(e.g., Eisenmenger </text>
<text top="639" left="491" width="44" height="10" font="13">syndrome)</text>
<text top="760" left="641" width="47" height="10" font="13">No closure </text>
<text top="771" left="629" width="68" height="10" font="13">(Class III: Harm)</text>
<text top="681" left="465" width="98" height="10" font="13">Confirm PAH diagnosis </text>
<text top="692" left="463" width="101" height="10" font="13">(often requiring invasive </text>
<text top="703" left="456" width="114" height="10" font="13">hemodynamic assessment)</text>
<text top="715" left="496" width="35" height="10" font="13">(Class I)</text>
<text top="672" left="630" width="68" height="10" font="13">PDE-5 inhibitors</text>
<text top="683" left="642" width="43" height="10" font="13">(Class IIa)</text>
<text top="631" left="645" width="39" height="10" font="13">Bosentan</text>
<text top="642" left="646" width="35" height="10" font="13">(Class I)</text>
<text top="711" left="638" width="55" height="10" font="13">Combination </text>
<text top="722" left="647" width="35" height="10" font="13">therapy*</text>
<text top="733" left="643" width="43" height="10" font="13">(Class IIa)</text>
<text top="544" left="387" width="27" height="10" font="13">Shunt </text>
<text top="556" left="382" width="35" height="10" font="13">direction</text>
<text top="693" left="268" width="60" height="10" font="13">Hemodynamic</text>
<text top="704" left="273" width="50" height="10" font="13">assessment</text>
<text top="724" left="346" width="83" height="10" font="13">Pulmonary vascular </text>
<text top="736" left="355" width="66" height="10" font="13">resistance &gt;1/3 </text>
<text top="747" left="367" width="39" height="10" font="13">systemic,</text>
<text top="758" left="341" width="94" height="10" font="25"><b>AND/OR </b>PASP ≥50% </text>
<text top="769" left="369" width="36" height="10" font="13">systemic</text>
<text top="829" left="131" width="47" height="10" font="13">Surgical or </text>
<text top="841" left="123" width="62" height="10" font="13">device closure </text>
<text top="852" left="136" width="35" height="10" font="13">(Class I)</text>
<text top="899" left="183" width="48" height="10" font="13">Surgical or </text>
<text top="911" left="176" width="62" height="10" font="13">device closure </text>
<text top="922" left="185" width="43" height="10" font="13">(Class IIa)</text>
<text top="911" left="262" width="51" height="10" font="13">History of IE</text>
<text top="953" left="264" width="16" height="10" font="13">Yes</text>
<text top="978" left="315" width="45" height="10" font="13">Continued </text>
<text top="989" left="318" width="37" height="10" font="13">follow-up</text>
<text top="953" left="298" width="12" height="10" font="13">No</text>
<text top="972" left="221" width="48" height="10" font="13">Surgical or </text>
<text top="983" left="214" width="62" height="10" font="13">device closure </text>
<text top="994" left="222" width="43" height="10" font="13">(Class IIb)</text>
<text top="697" left="579" width="16" height="10" font="13">Yes</text>
<text top="1036" left="80" width="658" height="9" font="13">*Combination therapy with bosentan and PDE-5 inhibitor, if symptomatic improvement does not occur with either alone. ACHD indicates adult congenital</text>
<text top="1051" left="80" width="658" height="9" font="13">heart disease; AR, aortic regurgitation; IE, infective endocarditis; LV, left ventricular; PAH, pulmonary artery hypertension; PASP, pulmonary artery systolic</text>
<text top="1066" left="80" width="429" height="9" font="13">pressure; PDE-5, phosphodiesterase type-5 inhibitors; PH, pulmonary hypertension; Qp:Qs, pulmonary</text>
<text top="1065" left="509" width="229" height="12" font="13">–systemic blood ﬂow ratio; and VSD, ventricular septal</text>
<text top="1081" left="80" width="30" height="9" font="13">defect.</text>
<text top="149" left="67" width="53" height="10" font="15">T A B L E 1 4</text>
<text top="149" left="135" width="243" height="10" font="16">VSD: Routine Follow-Up and Testing Intervals</text>
<text top="173" left="63" width="100" height="9" font="13">Frequency of Routine</text>
<text top="185" left="63" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="173" left="266" width="61" height="9" font="13">Physiological</text>
<text top="185" left="263" width="36" height="9" font="13">Stage <a href="1-s2.0-S0735109718368451-main.html#26">A</a></text>
<text top="185" left="299" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#26">*</a></text>
<text top="185" left="307" width="22" height="9" font="13">(mo)</text>
<text top="173" left="408" width="61" height="9" font="13">Physiological</text>
<text top="185" left="406" width="35" height="9" font="13">Stage B</text>
<text top="185" left="442" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#26">*</a></text>
<text top="185" left="450" width="22" height="9" font="13">(mo)</text>
<text top="173" left="550" width="61" height="9" font="13">Physiological</text>
<text top="185" left="549" width="35" height="9" font="13">Stage C</text>
<text top="185" left="584" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#26">*</a></text>
<text top="185" left="592" width="22" height="9" font="13">(mo)</text>
<text top="173" left="693" width="61" height="9" font="13">Physiological</text>
<text top="185" left="690" width="36" height="9" font="13">Stage <a href="1-s2.0-S0735109718368451-main.html#26">D</a></text>
<text top="185" left="726" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#26">*</a></text>
<text top="185" left="734" width="22" height="9" font="13">(mo)</text>
<text top="204" left="63" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="204" left="291" width="11" height="9" font="13">36</text>
<text top="204" left="434" width="11" height="9" font="13">24</text>
<text top="204" left="572" width="6" height="9" font="13">6</text>
<text top="203" left="577" width="13" height="12" font="13">–12</text>
<text top="204" left="716" width="5" height="9" font="13">3</text>
<text top="203" left="721" width="10" height="12" font="13">–6</text>
<text top="224" left="63" width="17" height="9" font="13">ECG</text>
<text top="224" left="291" width="11" height="9" font="13">36</text>
<text top="224" left="434" width="11" height="9" font="13">24</text>
<text top="224" left="577" width="9" height="9" font="13">12</text>
<text top="224" left="719" width="9" height="9" font="13">12</text>
<text top="243" left="63" width="16" height="9" font="13">TTE</text>
<text top="243" left="291" width="11" height="9" font="13">36</text>
<text top="243" left="434" width="11" height="9" font="13">24</text>
<text top="243" left="577" width="9" height="9" font="13">12</text>
<text top="243" left="719" width="9" height="9" font="13">12</text>
<text top="262" left="63" width="62" height="9" font="13">Pulse oximetry</text>
<text top="262" left="275" width="44" height="9" font="13">As needed</text>
<text top="262" left="417" width="44" height="9" font="13">As needed</text>
<text top="262" left="561" width="40" height="9" font="13">Each visit</text>
<text top="262" left="704" width="40" height="9" font="13">Each visit</text>
<text top="281" left="63" width="53" height="9" font="13">Exercise test</text>
<text top="280" left="116" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#26">†</a></text>
<text top="281" left="275" width="44" height="9" font="13">As needed</text>
<text top="281" left="417" width="44" height="9" font="13">As needed</text>
<text top="281" left="569" width="9" height="9" font="13">12</text>
<text top="280" left="578" width="15" height="12" font="13">–24</text>
<text top="281" left="714" width="6" height="9" font="13">6</text>
<text top="280" left="720" width="13" height="12" font="13">–12</text>
<text top="305" left="63" width="17" height="8" font="5">*See</text>
<text top="305" left="83" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="305" left="144" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="303" left="273" width="60" height="11" font="5">ﬁcation system.</text>
<text top="315" left="63" width="269" height="11" font="5">†6-minute walk test or CPET, depending on the clinical circumstance.</text>
<text top="331" left="71" width="684" height="8" font="5">ACHD indicates adult congenital heart disease; CPET, cardiopulmonary exercise test; ECG, electrocardiogram; TTE, transthoracic echocardiogram; and VSD, ventricular septal defect.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="790" width="18" height="9" font="5">1519</text>
</page>
<page number="27" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="188" height="11" font="2">4.1.4. Atrioventricular Septal Defect</text>
<text top="164" left="108" width="47" height="12" font="2">See also</text>
<text top="165" left="158" width="46" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#27">Table 15</a></text>
<text top="164" left="205" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#27">.</a></text>
<text top="922" left="108" width="162" height="11" font="2">4.1.5. Patent Ductus Arteriosus</text>
<text top="937" left="108" width="47" height="12" font="2">See also</text>
<text top="937" left="158" width="47" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#28">Table 16</a></text>
<text top="937" left="206" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#28">.</a></text>
<text top="197" left="63" width="295" height="11" font="20">Recommendations for Atrioventricular Septal Defect</text>
<text top="211" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="211" left="457" width="153" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 29</a></text>
<text top="211" left="611" width="3" height="11" font="20">.</text>
<text top="252" left="89" width="19" height="10" font="13">COR</text>
<text top="252" left="161" width="18" height="10" font="13">LOE</text>
<text top="252" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="279" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="324" left="94" width="10" height="9" font="5">IIa</text>
<text top="324" left="160" width="20" height="9" font="5">C-EO</text>
<text top="312" left="234" width="559" height="11" font="12">1. Cardiac catheterization can be useful in adults with atrioventricular septal defect when pulmonary hy-</text>
<text top="327" left="246" width="128" height="11" font="12">pertension is suspected.</text>
<text top="358" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="403" left="97" width="3" height="9" font="5">I</text>
<text top="403" left="160" width="20" height="9" font="5">C-LD</text>
<text top="391" left="234" width="553" height="11" font="12">2. Surgery for severe left atrioventricular valve regurgitation is recommended per GDMT indications for</text>
<text top="406" left="248" width="104" height="11" font="12">mitral regurgitation</text>
<text top="406" left="356" width="47" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.4-1</a></text>
<text top="404" left="403" width="54" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">–S4.1.4-4)</a></text>
<text top="406" left="458" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#58">.</a></text>
<text top="452" left="97" width="3" height="9" font="5">I</text>
<text top="452" left="160" width="20" height="9" font="5">C-EO</text>
<text top="440" left="234" width="557" height="11" font="12">3. Surgery for primary repair of atrioventricular septal defect or closure of residual shunts in adults with repaired</text>
<text top="456" left="248" width="456" height="11" font="12">atrioventricular septal defect is recommended when there is a net left-to-right shunt (Qp:Qs</text>
<text top="454" left="707" width="92" height="15" font="12">‡1.5:1), PA systolic</text>
<text top="471" left="248" width="478" height="11" font="12">pressure less than 50% systemic and pulmonary vascular resistance less than one third systemic.</text>
<text top="510" left="94" width="10" height="9" font="5">IIa</text>
<text top="510" left="160" width="20" height="9" font="5">C-EO</text>
<text top="498" left="234" width="566" height="11" font="12">4. Operation for discrete LVOT obstruction in adults with atrioventricular septal defect is reasonable with a</text>
<text top="513" left="249" width="507" height="11" font="12">maximum gradient of 50 mm Hg or greater, a lesser gradient if HF symptoms are present, or if</text>
<text top="529" left="249" width="311" height="11" font="12">concomitant moderate-to-severe mitral or AR are present.</text>
<text top="568" left="94" width="10" height="9" font="5">IIb</text>
<text top="568" left="160" width="20" height="9" font="5">C-EO</text>
<text top="555" left="234" width="559" height="11" font="12">5. Surgery for primary repair of atrioventricular septal defect or closure of residual shunts in adults with</text>
<text top="571" left="248" width="540" height="11" font="12">repaired atrioventricular septal defect may be considered in the presence of a net left-to-right shunt</text>
<text top="587" left="248" width="36" height="11" font="12">(Qp:Qs</text>
<text top="585" left="288" width="512" height="15" font="12">‡1.5:1), if PA systolic pressure is 50% or more systemic, and/or pulmonary vascular resistance is</text>
<text top="602" left="248" width="171" height="11" font="12">greater than one third systemic.</text>
<text top="641" left="81" width="35" height="9" font="5">III: Harm</text>
<text top="641" left="160" width="20" height="9" font="5">C-LD</text>
<text top="629" left="234" width="560" height="11" font="12">6. Surgery for primary repair of atrioventricular septal defect or closure of residual shunts in adults with</text>
<text top="644" left="249" width="547" height="11" font="12">repaired atrioventricular septal defect should not be performed with PA systolic pressure greater than</text>
<text top="660" left="249" width="549" height="11" font="12">two thirds systemic, pulmonary vascular resistance greater than two thirds systemic, or a net right-to-</text>
<text top="676" left="249" width="52" height="11" font="12">left shunt</text>
<text top="676" left="305" width="104" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.4-5, S4.1.4-6)</a></text>
<text top="676" left="409" width="3" height="11" font="12">.</text>
<text top="709" left="113" width="52" height="10" font="15">T A B L E 1 5</text>
<text top="709" left="179" width="251" height="10" font="16">AVSD: Routine Follow-Up and Testing Intervals</text>
<text top="733" left="108" width="100" height="9" font="13">Frequency of Routine</text>
<text top="745" left="108" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="733" left="311" width="61" height="9" font="13">Physiological</text>
<text top="745" left="308" width="36" height="9" font="13">Stage A</text>
<text top="745" left="344" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#27">*</a></text>
<text top="745" left="352" width="22" height="9" font="13">(mo)</text>
<text top="733" left="453" width="61" height="9" font="13">Physiological</text>
<text top="745" left="451" width="35" height="9" font="13">Stage B</text>
<text top="745" left="487" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#27">*</a></text>
<text top="745" left="495" width="22" height="9" font="13">(mo)</text>
<text top="733" left="595" width="61" height="9" font="13">Physiological</text>
<text top="745" left="593" width="35" height="9" font="13">Stage C</text>
<text top="745" left="629" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#27">*</a></text>
<text top="745" left="636" width="22" height="9" font="13">(mo)</text>
<text top="733" left="738" width="61" height="9" font="13">Physiological</text>
<text top="745" left="735" width="36" height="9" font="13">Stage D</text>
<text top="745" left="771" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#27">*</a></text>
<text top="745" left="779" width="22" height="9" font="13">(mo)</text>
<text top="764" left="108" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="764" left="328" width="11" height="9" font="13">24</text>
<text top="763" left="339" width="15" height="12" font="13">–36</text>
<text top="764" left="479" width="11" height="9" font="13">24</text>
<text top="764" left="616" width="6" height="9" font="13">6</text>
<text top="763" left="622" width="13" height="12" font="13">–12</text>
<text top="764" left="761" width="5" height="9" font="13">3</text>
<text top="763" left="766" width="10" height="12" font="13">–6</text>
<text top="783" left="108" width="17" height="9" font="13">ECG</text>
<text top="783" left="328" width="11" height="9" font="13">24</text>
<text top="782" left="339" width="15" height="12" font="13">–36</text>
<text top="783" left="479" width="11" height="9" font="13">24</text>
<text top="783" left="621" width="9" height="9" font="13">12</text>
<text top="783" left="764" width="9" height="9" font="13">12</text>
<text top="803" left="108" width="16" height="9" font="13">TTE</text>
<text top="803" left="328" width="11" height="9" font="13">24</text>
<text top="801" left="339" width="15" height="12" font="13">–36</text>
<text top="803" left="479" width="11" height="9" font="13">24</text>
<text top="803" left="621" width="9" height="9" font="13">12</text>
<text top="803" left="764" width="9" height="9" font="13">12</text>
<text top="822" left="108" width="62" height="9" font="13">Pulse oximetry</text>
<text top="822" left="319" width="44" height="9" font="13">As needed</text>
<text top="822" left="462" width="44" height="9" font="13">As needed</text>
<text top="822" left="606" width="40" height="9" font="13">Each visit</text>
<text top="822" left="748" width="40" height="9" font="13">Each visit</text>
<text top="841" left="108" width="53" height="9" font="13">Exercise test</text>
<text top="839" left="161" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#27">†</a></text>
<text top="841" left="319" width="44" height="9" font="13">As needed</text>
<text top="841" left="462" width="44" height="9" font="13">As needed</text>
<text top="841" left="614" width="9" height="9" font="13">12</text>
<text top="839" left="623" width="15" height="12" font="13">–24</text>
<text top="841" left="759" width="6" height="9" font="13">6</text>
<text top="839" left="765" width="13" height="12" font="13">–12</text>
<text top="865" left="108" width="17" height="8" font="5">*See</text>
<text top="865" left="128" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="865" left="189" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="863" left="318" width="60" height="11" font="5">ﬁcation system.</text>
<text top="875" left="108" width="257" height="11" font="5">†6-minute walk test or CPET, depending on the clinical indication.</text>
<text top="891" left="116" width="686" height="8" font="5">ACHD indicates adult congenital heart disease; AVSD, atrioventricular septal defect; CPET, cardiopulmonary exercise test; ECG, electrocardiogram; and TTE, transthoracic</text>
<text top="903" left="108" width="63" height="8" font="5">echocardiogram.</text>
<text top="960" left="62" width="267" height="11" font="20">Recommendations for Patent Ductus Arteriosus</text>
<text top="974" left="62" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="974" left="457" width="154" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 30</a></text>
<text top="974" left="611" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="1015" left="89" width="19" height="10" font="13">COR</text>
<text top="1015" left="161" width="18" height="10" font="13">LOE</text>
<text top="1015" left="232" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="1042" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="1087" left="97" width="3" height="9" font="5">I</text>
<text top="1087" left="159" width="20" height="9" font="5">C-EO</text>
<text top="1075" left="233" width="566" height="11" font="12">1. Measurement of oxygen saturation should be performed in feet and both hands in adults with a PDA to</text>
<text top="1090" left="246" width="262" height="11" font="12">assess for the presence of right-to-left shunting.</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="20" height="9" font="5">1520</text>
</page>
<page number="28" position="absolute" top="0" left="0" height="1160" width="864">
<text top="712" left="63" width="188" height="11" font="12">4.2. Left-Sided Obstructive Lesions</text>
<text top="734" left="63" width="111" height="11" font="2">4.2.1. Cor Triatriatum</text>
<text top="149" left="69" width="61" height="10" font="15">(continued)</text>
<text top="203" left="94" width="10" height="9" font="5">IIa</text>
<text top="203" left="160" width="20" height="9" font="5">C-EO</text>
<text top="191" left="234" width="562" height="11" font="12">2. In addition to the standard diagnostic tools, cardiac catheterization can be useful in patients with PDA</text>
<text top="207" left="248" width="217" height="11" font="12">and suspected pulmonary hypertension (</text>
<text top="207" left="465" width="59" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#17">Section 3.5</a></text>
<text top="207" left="524" width="7" height="11" font="12">).</text>
<text top="243" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="287" left="97" width="3" height="9" font="5">I</text>
<text top="287" left="160" width="20" height="9" font="5">C-LD</text>
<text top="275" left="234" width="566" height="11" font="12">3. PDA closure in adults is recommended if left atrial or LV enlargement is present and attributable to PDA</text>
<text top="291" left="248" width="521" height="11" font="12">with net left-to-right shunt, PA systolic pressure less than 50% systemic and pulmonary vascular</text>
<text top="307" left="248" width="206" height="11" font="12">resistance less than one third systemic</text>
<text top="307" left="458" width="46" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.5-1</a></text>
<text top="305" left="504" width="52" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">–S4.1.5-3)</a></text>
<text top="307" left="557" width="3" height="11" font="12">.</text>
<text top="352" left="94" width="10" height="9" font="5">IIb</text>
<text top="352" left="160" width="21" height="9" font="5">B-NR</text>
<text top="340" left="234" width="539" height="11" font="12">4. PDA closure in adults may be considered in the presence of a net left-to-right shunt if PA systolic</text>
<text top="356" left="249" width="533" height="11" font="12">pressure is 50% or greater systemic, and/or pulmonary vascular resistance is greater than one third</text>
<text top="372" left="249" width="45" height="11" font="12">systemic</text>
<text top="372" left="298" width="103" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.5-3, S4.1.5-4)</a></text>
<text top="372" left="401" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#58">.</a></text>
<text top="418" left="81" width="35" height="9" font="5">III: Harm</text>
<text top="418" left="160" width="20" height="9" font="5">C-LD</text>
<text top="406" left="234" width="559" height="11" font="12">5. PDA closure should not be performed in adults with a net right-to-left shunt and PA systolic pressure</text>
<text top="421" left="248" width="531" height="11" font="12">greater than two thirds systemic or pulmonary vascular resistance greater than two thirds systemic</text>
<text top="437" left="248" width="52" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.1.5-5)</a></text>
<text top="437" left="300" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#58">.</a></text>
<text top="495" left="67" width="53" height="10" font="15">T A B L E 1 6</text>
<text top="495" left="135" width="244" height="10" font="16">PDA: Routine Follow-Up and Testing Intervals</text>
<text top="519" left="63" width="100" height="9" font="13">Frequency of Routine</text>
<text top="531" left="63" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="519" left="266" width="61" height="9" font="13">Physiological</text>
<text top="531" left="263" width="36" height="9" font="13">Stage A</text>
<text top="531" left="300" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#28">*</a></text>
<text top="531" left="307" width="22" height="9" font="13">(mo)</text>
<text top="519" left="409" width="61" height="9" font="13">Physiological</text>
<text top="531" left="406" width="35" height="9" font="13">Stage B</text>
<text top="531" left="442" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#28">*</a></text>
<text top="531" left="450" width="22" height="9" font="13">(mo)</text>
<text top="519" left="551" width="61" height="9" font="13">Physiological</text>
<text top="531" left="549" width="35" height="9" font="13">Stage C</text>
<text top="531" left="584" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#28">*</a></text>
<text top="531" left="592" width="22" height="9" font="13">(mo)</text>
<text top="519" left="693" width="61" height="9" font="13">Physiological</text>
<text top="531" left="691" width="36" height="9" font="13">Stage D</text>
<text top="531" left="727" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#28">*</a></text>
<text top="531" left="735" width="22" height="9" font="13">(mo)</text>
<text top="550" left="63" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="550" left="283" width="11" height="9" font="13">36</text>
<text top="549" left="294" width="16" height="12" font="13">–60</text>
<text top="550" left="434" width="11" height="9" font="13">24</text>
<text top="550" left="572" width="6" height="9" font="13">6</text>
<text top="549" left="578" width="13" height="12" font="13">–12</text>
<text top="550" left="716" width="5" height="9" font="13">3</text>
<text top="549" left="721" width="10" height="12" font="13">–6</text>
<text top="570" left="63" width="17" height="9" font="13">ECG</text>
<text top="570" left="283" width="11" height="9" font="13">36</text>
<text top="568" left="294" width="16" height="12" font="13">–60</text>
<text top="570" left="434" width="11" height="9" font="13">24</text>
<text top="570" left="577" width="9" height="9" font="13">12</text>
<text top="570" left="719" width="9" height="9" font="13">12</text>
<text top="589" left="63" width="16" height="9" font="13">TTE</text>
<text top="589" left="283" width="11" height="9" font="13">36</text>
<text top="587" left="294" width="16" height="12" font="13">–60</text>
<text top="589" left="434" width="11" height="9" font="13">24</text>
<text top="589" left="577" width="9" height="9" font="13">12</text>
<text top="589" left="719" width="9" height="9" font="13">12</text>
<text top="608" left="63" width="62" height="9" font="13">Pulse oximetry</text>
<text top="606" left="125" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#28">†</a></text>
<text top="608" left="275" width="44" height="9" font="13">As needed</text>
<text top="608" left="417" width="44" height="9" font="13">As needed</text>
<text top="608" left="561" width="40" height="9" font="13">Each visit</text>
<text top="608" left="704" width="40" height="9" font="13">Each visit</text>
<text top="627" left="63" width="53" height="9" font="13">Exercise test</text>
<text top="626" left="116" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#28">‡</a></text>
<text top="627" left="275" width="44" height="9" font="13">As needed</text>
<text top="627" left="417" width="44" height="9" font="13">As needed</text>
<text top="627" left="569" width="9" height="9" font="13">12</text>
<text top="626" left="578" width="15" height="12" font="13">–24</text>
<text top="627" left="714" width="6" height="9" font="13">6</text>
<text top="626" left="720" width="13" height="12" font="13">–12</text>
<text top="651" left="63" width="17" height="8" font="5">*See</text>
<text top="651" left="83" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="651" left="144" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="649" left="273" width="60" height="11" font="5">ﬁcation system.</text>
<text top="661" left="63" width="111" height="11" font="5">†Upper and lower extremity.</text>
<text top="673" left="63" width="257" height="11" font="5">‡6-minute walk test or CPET, depending on the clinical indication.</text>
<text top="689" left="71" width="686" height="8" font="5">ACHD indicates adult congenital heart disease; CPET, cardiopulmonary exercise test; ECG, electrocardiogram; PDA, patent ductus arteriosus; and TTE, transthoracic echocardiogram.</text>
<text top="777" left="63" width="212" height="11" font="20">Recommendations for Cor Triatriatum</text>
<text top="791" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="791" left="457" width="151" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 31</a></text>
<text top="791" left="609" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="832" left="89" width="19" height="10" font="13">COR</text>
<text top="832" left="161" width="18" height="10" font="13">LOE</text>
<text top="832" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="859" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="904" left="97" width="3" height="9" font="5">I</text>
<text top="904" left="160" width="21" height="9" font="5">B-NR</text>
<text top="891" left="234" width="559" height="11" font="12">1. Adults presenting with cor triatriatum sinister should be evaluated for other congenital abnormalities,</text>
<text top="907" left="246" width="365" height="11" font="12">particularly ASD, VSD, and anomalous pulmonary venous connection</text>
<text top="907" left="615" width="50" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.2.1-1)</a></text>
<text top="907" left="666" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#58">.</a></text>
<text top="953" left="94" width="10" height="9" font="5">IIa</text>
<text top="953" left="160" width="21" height="9" font="5">B-NR</text>
<text top="941" left="234" width="566" height="11" font="12">2. In adults with prior repair of cor triatriatum sinister and recurrent symptoms, it is reasonable to evaluate</text>
<text top="957" left="248" width="148" height="11" font="12">for pulmonary vein stenosis</text>
<text top="957" left="400" width="52" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.2.1-2)</a></text>
<text top="957" left="451" width="3" height="11" font="12">.</text>
<text top="993" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="1037" left="97" width="3" height="9" font="5">I</text>
<text top="1037" left="160" width="21" height="9" font="5">B-NR</text>
<text top="1025" left="234" width="541" height="11" font="12">3. Surgical repair is indicated for adults with cor triatriatum sinister for symptoms attributable to the</text>
<text top="1041" left="248" width="312" height="11" font="12">obstruction or a substantial gradient across the membrane</text>
<text top="1041" left="564" width="51" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.2.1-3)</a></text>
<text top="1073" left="63" width="13" height="8" font="5">See</text>
<text top="1073" left="78" width="42" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#12">Section 3.3</a></text>
<text top="1073" left="122" width="453" height="8" font="5">for recommendations on who should perform surgeries, cardiac catheterization, and other procedures in these patients;</text>
<text top="1073" left="578" width="42" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="1073" left="622" width="179" height="8" font="5">for recommendations on diagnostic evaluation.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="790" width="17" height="9" font="5">1521</text>
</page>
<page number="29" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="170" height="11" font="2">4.2.2. Congenital Mitral Stenosis</text>
<text top="164" left="108" width="47" height="12" font="2">See also</text>
<text top="165" left="158" width="46" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#29">Table 17</a></text>
<text top="164" left="205" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#29">.</a></text>
<text top="562" left="108" width="129" height="11" font="2">4.2.3. Subaortic Stenosis</text>
<text top="583" left="108" width="47" height="12" font="2">See also</text>
<text top="583" left="158" width="47" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#30">Table 18</a></text>
<text top="583" left="206" width="3" height="12" font="2">.</text>
<text top="210" left="63" width="268" height="11" font="20">Recommendation for Congenital Mitral Stenosis</text>
<text top="224" left="63" width="407" height="11" font="20">Referenced studies that support the recommendation are summarized in</text>
<text top="224" left="474" width="152" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 32</a></text>
<text top="224" left="627" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="266" left="89" width="19" height="10" font="13">COR</text>
<text top="266" left="161" width="18" height="10" font="13">LOE</text>
<text top="266" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="302" left="97" width="3" height="9" font="5">I</text>
<text top="302" left="160" width="21" height="9" font="5">B-NR</text>
<text top="290" left="234" width="566" height="11" font="12">1. Adults with congenital mitral stenosis or a parachute mitral valve should be evaluated for other left-sided</text>
<text top="306" left="246" width="100" height="11" font="12">obstructive lesions</text>
<text top="306" left="350" width="103" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.2.2-1, S4.2.2-2)</a></text>
<text top="306" left="454" width="3" height="11" font="12">.</text>
<text top="363" left="113" width="52" height="10" font="15">T A B L E 1 7</text>
<text top="363" left="179" width="362" height="10" font="16">Congenital Mitral Stenosis: Routine Follow-Up and Testing Intervals</text>
<text top="388" left="108" width="100" height="9" font="13">Frequency of Routine</text>
<text top="400" left="108" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="388" left="311" width="61" height="9" font="13">Physiological</text>
<text top="400" left="308" width="36" height="9" font="13">Stage A</text>
<text top="400" left="344" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#29">*</a></text>
<text top="400" left="352" width="22" height="9" font="13">(mo)</text>
<text top="388" left="453" width="61" height="9" font="13">Physiological</text>
<text top="400" left="451" width="35" height="9" font="13">Stage B</text>
<text top="400" left="487" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#29">*</a></text>
<text top="400" left="495" width="22" height="9" font="13">(mo)</text>
<text top="388" left="595" width="61" height="9" font="13">Physiological</text>
<text top="400" left="593" width="35" height="9" font="13">Stage C</text>
<text top="400" left="629" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#29">*</a></text>
<text top="400" left="636" width="22" height="9" font="13">(mo)</text>
<text top="388" left="738" width="61" height="9" font="13">Physiological</text>
<text top="400" left="735" width="36" height="9" font="13">Stage D</text>
<text top="400" left="771" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#29">*</a></text>
<text top="400" left="779" width="22" height="9" font="13">(mo)</text>
<text top="419" left="108" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="419" left="336" width="11" height="9" font="13">24</text>
<text top="419" left="479" width="11" height="9" font="13">24</text>
<text top="419" left="616" width="6" height="9" font="13">6</text>
<text top="417" left="622" width="13" height="12" font="13">–12</text>
<text top="419" left="761" width="5" height="9" font="13">3</text>
<text top="417" left="766" width="10" height="12" font="13">–6</text>
<text top="438" left="108" width="17" height="9" font="13">ECG</text>
<text top="438" left="336" width="11" height="9" font="13">24</text>
<text top="438" left="479" width="11" height="9" font="13">24</text>
<text top="438" left="621" width="9" height="9" font="13">12</text>
<text top="438" left="764" width="9" height="9" font="13">12</text>
<text top="457" left="108" width="16" height="9" font="13">TTE</text>
<text top="457" left="336" width="11" height="9" font="13">24</text>
<text top="457" left="479" width="11" height="9" font="13">24</text>
<text top="457" left="621" width="9" height="9" font="13">12</text>
<text top="457" left="764" width="9" height="9" font="13">12</text>
<text top="476" left="108" width="53" height="9" font="13">Exercise test</text>
<text top="475" left="161" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#29">†</a></text>
<text top="476" left="319" width="44" height="9" font="13">As needed</text>
<text top="476" left="479" width="11" height="9" font="13">24</text>
<text top="476" left="621" width="11" height="9" font="13">24</text>
<text top="476" left="764" width="9" height="9" font="13">12</text>
<text top="500" left="108" width="17" height="8" font="5">*See</text>
<text top="500" left="128" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="500" left="189" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="498" left="318" width="60" height="11" font="5">ﬁcation system.</text>
<text top="510" left="108" width="257" height="11" font="5">†6-minute walk test or CPET, depending on the clinical indication.</text>
<text top="526" left="116" width="577" height="8" font="5">ACHD indicates adult congenital heart disease; CPET, cardiopulmonary exercise test; ECG, electrocardiogram; and TTE, transthoracic echocardiogram.</text>
<text top="628" left="63" width="229" height="11" font="20">Recommendations for Subaortic Stenosis</text>
<text top="642" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="642" left="457" width="152" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 33</a></text>
<text top="642" left="610" width="3" height="11" font="20">.</text>
<text top="683" left="89" width="19" height="10" font="13">COR</text>
<text top="683" left="161" width="18" height="10" font="13">LOE</text>
<text top="683" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="710" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="755" left="94" width="10" height="9" font="5">IIb</text>
<text top="755" left="160" width="20" height="9" font="5">C-LD</text>
<text top="742" left="234" width="558" height="11" font="12">1. Stress testing for adults with LVOT obstruction to determine exercise capacity, symptoms, electrocar-</text>
<text top="758" left="246" width="553" height="11" font="12">diographic changes, or arrhythmias may be reasonable in the presence of otherwise equivocal indications</text>
<text top="774" left="246" width="84" height="11" font="12">for intervention</text>
<text top="774" left="334" width="103" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.2.3-1, S4.2.3-2)</a></text>
<text top="774" left="438" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#58">.</a></text>
<text top="810" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="854" left="97" width="3" height="9" font="5">I</text>
<text top="854" left="160" width="20" height="9" font="5">C-EO</text>
<text top="842" left="234" width="566" height="11" font="12">2. Surgical intervention is recommended for adults with subAS, a maximum gradient 50 mm Hg or more and</text>
<text top="858" left="248" width="196" height="11" font="12">symptoms attributable to the subAS.</text>
<text top="904" left="97" width="3" height="9" font="5">I</text>
<text top="904" left="160" width="20" height="9" font="5">C-LD</text>
<text top="892" left="234" width="566" height="11" font="12">3. Surgical intervention is recommended for adults with subAS and less than 50 mm Hg maximum gradient</text>
<text top="908" left="248" width="446" height="11" font="12">and HF or ischemic symptoms, and/or LV systolic dysfunction attributable to subAS</text>
<text top="908" left="698" width="53" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.2.3-3)</a></text>
<text top="908" left="751" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#58">.</a></text>
<text top="953" left="94" width="10" height="9" font="5">IIb</text>
<text top="953" left="160" width="20" height="9" font="5">C-LD</text>
<text top="941" left="234" width="566" height="11" font="12">4. To prevent the progression of AR, surgical intervention may be considered for asymptomatic adults with</text>
<text top="957" left="249" width="400" height="11" font="12">subAS and at least mild AR and a maximum gradient of 50 mm Hg or more</text>
<text top="957" left="652" width="49" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.2.3-4</a></text>
<text top="955" left="702" width="55" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">–S4.2.3-6)</a></text>
<text top="957" left="757" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#58">.</a></text>
<text top="989" left="63" width="13" height="8" font="5">See</text>
<text top="989" left="78" width="42" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#12">Section 3.3</a></text>
<text top="989" left="122" width="453" height="8" font="5">for recommendations on who should perform surgeries, cardiac catheterization, and other procedures in these patients;</text>
<text top="989" left="578" width="42" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="989" left="622" width="179" height="8" font="5">for recommendations on diagnostic evaluation;</text>
<text top="1001" left="63" width="14" height="8" font="5">and</text>
<text top="1001" left="80" width="34" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#30">Table 18</a></text>
<text top="1001" left="116" width="166" height="8" font="5">for routine testing and follow-up intervals.</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="18" height="9" font="5">1522</text>
</page>
<page number="30" position="absolute" top="0" left="0" height="1160" width="864">
<text top="352" left="63" width="217" height="11" font="2">4.2.4. Congenital Valvular Aortic Stenosis</text>
<text top="373" left="63" width="47" height="12" font="2">See also</text>
<text top="374" left="114" width="47" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#30">Table 19</a></text>
<text top="373" left="161" width="3" height="12" font="2">.</text>
<text top="898" left="63" width="139" height="12" font="3">4.2.4.1. Turner Syndrome</text>
<text top="149" left="67" width="53" height="10" font="15">T A B L E 1 8</text>
<text top="149" left="135" width="320" height="10" font="16">Subaortic Stenosis: Routine Follow-Up and Testing Intervals</text>
<text top="173" left="63" width="100" height="9" font="13">Frequency of Routine</text>
<text top="185" left="63" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="173" left="266" width="61" height="9" font="13">Physiological</text>
<text top="185" left="263" width="36" height="9" font="13">Stage <a href="1-s2.0-S0735109718368451-main.html#30">A</a></text>
<text top="185" left="299" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#30">*</a></text>
<text top="185" left="307" width="22" height="9" font="13">(mo)</text>
<text top="173" left="408" width="61" height="9" font="13">Physiological</text>
<text top="185" left="406" width="35" height="9" font="13">Stage B</text>
<text top="185" left="442" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#30">*</a></text>
<text top="185" left="450" width="22" height="9" font="13">(mo)</text>
<text top="173" left="550" width="61" height="9" font="13">Physiological</text>
<text top="185" left="549" width="35" height="9" font="13">Stage C</text>
<text top="185" left="584" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#30">*</a></text>
<text top="185" left="592" width="22" height="9" font="13">(mo)</text>
<text top="173" left="693" width="61" height="9" font="13">Physiological</text>
<text top="185" left="690" width="36" height="9" font="13">Stage <a href="1-s2.0-S0735109718368451-main.html#30">D</a></text>
<text top="185" left="726" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#30">*</a></text>
<text top="185" left="734" width="22" height="9" font="13">(mo)</text>
<text top="204" left="63" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="204" left="291" width="11" height="9" font="13">24</text>
<text top="204" left="434" width="11" height="9" font="13">24</text>
<text top="204" left="572" width="6" height="9" font="13">6</text>
<text top="203" left="577" width="13" height="12" font="13">–12</text>
<text top="204" left="716" width="5" height="9" font="13">3</text>
<text top="203" left="721" width="10" height="12" font="13">–6</text>
<text top="224" left="63" width="17" height="9" font="13">ECG</text>
<text top="224" left="291" width="11" height="9" font="13">24</text>
<text top="224" left="434" width="11" height="9" font="13">24</text>
<text top="224" left="577" width="9" height="9" font="13">12</text>
<text top="224" left="719" width="9" height="9" font="13">12</text>
<text top="243" left="63" width="16" height="9" font="13">TTE</text>
<text top="243" left="291" width="11" height="9" font="13">24</text>
<text top="243" left="434" width="11" height="9" font="13">24</text>
<text top="243" left="577" width="9" height="9" font="13">12</text>
<text top="243" left="719" width="9" height="9" font="13">12</text>
<text top="262" left="63" width="53" height="9" font="13">Exercise test</text>
<text top="260" left="116" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#30">†</a></text>
<text top="262" left="275" width="44" height="9" font="13">As needed</text>
<text top="262" left="434" width="11" height="9" font="13">24</text>
<text top="262" left="576" width="11" height="9" font="13">24</text>
<text top="262" left="719" width="9" height="9" font="13">12</text>
<text top="286" left="63" width="17" height="8" font="5">*See</text>
<text top="286" left="83" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="286" left="144" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="284" left="273" width="60" height="11" font="5">ﬁcation system.</text>
<text top="296" left="63" width="257" height="11" font="5">†6-minute walk test or CPET, depending on the clinical indication.</text>
<text top="312" left="71" width="577" height="8" font="5">ACHD indicates adult congenital heart disease; CPET, cardiopulmonary exercise test; ECG, electrocardiogram; and TTE, transthoracic echocardiogram.</text>
<text top="395" left="63" width="324" height="11" font="20">Recommendations for Congenital Valvular Aortic Stenosis</text>
<text top="410" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="410" left="457" width="153" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 34</a></text>
<text top="410" left="611" width="3" height="11" font="20">.</text>
<text top="451" left="89" width="19" height="10" font="13">COR</text>
<text top="451" left="161" width="18" height="10" font="13">LOE</text>
<text top="451" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="478" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="522" left="97" width="3" height="9" font="5">I</text>
<text top="522" left="160" width="21" height="9" font="5">B-NR</text>
<text top="510" left="234" width="566" height="11" font="12">1. Adults with bicuspid aortic valve should be evaluated for coarctation of the aorta by clinical examination</text>
<text top="526" left="246" width="106" height="11" font="12">and imaging studies</text>
<text top="526" left="356" width="52" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#58">(S4.2.4-1)</a></text>
<text top="526" left="409" width="3" height="11" font="12">.</text>
<text top="572" left="94" width="10" height="9" font="5">IIa</text>
<text top="572" left="160" width="21" height="9" font="5">B-NR</text>
<text top="560" left="234" width="148" height="11" font="12">2. It is reasonable to screen</text>
<text top="558" left="385" width="414" height="15" font="12">ﬁrst-degree relatives of patients with bicuspid aortic valve or unicuspid aortic</text>
<text top="575" left="248" width="331" height="11" font="12">valve with echocardiography for valve disease and aortopathy</text>
<text top="575" left="583" width="49" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.4-2</a></text>
<text top="573" left="633" width="55" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">–S4.2.4-4)</a></text>
<text top="575" left="688" width="3" height="11" font="12">.</text>
<text top="611" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="656" left="94" width="10" height="9" font="5">IIb</text>
<text top="656" left="160" width="21" height="9" font="5">B-NR</text>
<text top="644" left="234" width="323" height="11" font="12">3. In adults with bicuspid aortic valve stenosis and a noncalci</text>
<text top="642" left="557" width="242" height="15" font="12">ﬁed valve with no more than mild AR meeting</text>
<text top="659" left="248" width="202" height="11" font="12">indications for intervention per GDMT</text>
<text top="659" left="453" width="54" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.4-5)</a></text>
<text top="659" left="507" width="281" height="11" font="12">, it may be reasonable to treat with balloon valvulo-</text>
<text top="675" left="248" width="32" height="11" font="12">plasty</text>
<text top="675" left="284" width="55" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.4-6)</a></text>
<text top="675" left="339" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#59">.</a></text>
<text top="700" left="63" width="13" height="8" font="5">See</text>
<text top="700" left="79" width="43" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="700" left="125" width="198" height="8" font="5">for recommendations on diagnostic evaluation; and</text>
<text top="700" left="326" width="33" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#30">Table 19</a></text>
<text top="700" left="362" width="166" height="8" font="5">for routine testing and follow-up intervals.</text>
<text top="734" left="67" width="53" height="10" font="15">T A B L E 1 9</text>
<text top="734" left="135" width="363" height="10" font="16">Congenital Aortic Stenosis: Routine Follow-Up and Testing Intervals</text>
<text top="734" left="498" width="5" height="10" font="8"><a href="1-s2.0-S0735109718368451-main.html#30">*</a></text>
<text top="758" left="63" width="26" height="9" font="13">Stage</text>
<text top="758" left="580" width="138" height="9" font="13">Frequency of Echocardiogram</text>
<text top="777" left="63" width="90" height="9" font="13">Progressive (Stage B)</text>
<text top="777" left="542" width="31" height="9" font="13">Every 3</text>
<text top="776" left="573" width="163" height="12" font="13">–5 y (mild severity, Vmax 2.0–2.9 m/s)</text>
<text top="789" left="542" width="30" height="9" font="13">Every 1</text>
<text top="788" left="572" width="184" height="12" font="13">–2 y (moderate severity, Vmax 3.0–3.9 m/s)</text>
<text top="809" left="63" width="69" height="9" font="13">Severe (Stage C)</text>
<text top="809" left="542" width="32" height="9" font="13">Every 6</text>
<text top="807" left="574" width="106" height="12" font="13">–12 mo (Vmax $4.0 m/s)</text>
<text top="828" left="63" width="59" height="9" font="13">Aortic dilation</text>
<text top="826" left="125" width="36" height="12" font="13">&gt;4.5 cm</text>
<text top="828" left="542" width="175" height="9" font="13">Every 12 mo (echocardiogram, MRI or CT)</text>
<text top="851" left="63" width="23" height="8" font="5">*Modi</text>
<text top="850" left="86" width="195" height="11" font="5">ﬁed from existing GDMT for valvular heart disease</text>
<text top="851" left="284" width="39" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.4-5)</a></text>
<text top="851" left="322" width="2" height="8" font="5">.</text>
<text top="866" left="71" width="599" height="8" font="5">CT indicates computed tomography; GDMT, guideline-directed management and therapy; MRI, magnetic resonance imaging; and Vmax, maximum velocity.</text>
<text top="952" left="63" width="222" height="11" font="20">Recommendations for Turner Syndrome</text>
<text top="966" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="966" left="457" width="152" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 35</a></text>
<text top="966" left="610" width="3" height="11" font="20">.</text>
<text top="1007" left="89" width="19" height="10" font="13">COR</text>
<text top="1007" left="161" width="18" height="10" font="13">LOE</text>
<text top="1007" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="1034" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="1079" left="97" width="3" height="9" font="5">I</text>
<text top="1079" left="160" width="21" height="9" font="5">B-NR</text>
<text top="1067" left="234" width="566" height="11" font="12">1. Women with Turner syndrome should be evaluated for bicuspid aortic valve, coarctation of the aorta, and</text>
<text top="1082" left="246" width="191" height="11" font="12">enlargement of the ascending aorta</text>
<text top="1082" left="441" width="61" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.4.1-1)</a></text>
<text top="1082" left="502" width="3" height="11" font="12">.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="789" width="18" height="9" font="5">1523</text>
</page>
<page number="31" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="26" size="5" family="Times" color="#0e2a52"/>
<text top="287" left="108" width="185" height="11" font="2">4.2.5. Supravalvular Aortic Stenosis</text>
<text top="309" left="108" width="47" height="12" font="2">See also</text>
<text top="309" left="158" width="49" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#31">Table 20</a></text>
<text top="309" left="208" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#31">.</a></text>
<text top="149" left="69" width="61" height="10" font="15">(continued)</text>
<text top="178" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="223" left="94" width="10" height="9" font="5">IIa</text>
<text top="223" left="160" width="21" height="9" font="5">B-NR</text>
<text top="211" left="234" width="531" height="11" font="12">2. Prophylactic replacement of the aortic root or ascending aorta in adults with Turner syndrome is</text>
<text top="226" left="248" width="261" height="11" font="12">reasonable when the aortic diameter is 2.5 cm/m</text>
<text top="224" left="509" width="5" height="7" font="26">2</text>
<text top="226" left="518" width="53" height="11" font="12">or greater</text>
<text top="226" left="575" width="62" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.4.1-2)</a></text>
<text top="226" left="637" width="3" height="11" font="12">.</text>
<text top="351" left="63" width="291" height="11" font="20">Recommendations for Supravalvular Aortic Stenosis</text>
<text top="365" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="365" left="457" width="152" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 37</a></text>
<text top="365" left="610" width="3" height="11" font="20">.</text>
<text top="406" left="89" width="19" height="10" font="13">COR</text>
<text top="406" left="161" width="18" height="10" font="13">LOE</text>
<text top="406" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="433" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="478" left="97" width="3" height="9" font="5">I</text>
<text top="478" left="160" width="20" height="9" font="5">C-LD</text>
<text top="466" left="234" width="566" height="11" font="12">1. Aortic imaging using TTE, TEE, CMR, or CTA is recommended in adults with Williams syndrome or patients</text>
<text top="481" left="246" width="262" height="11" font="12">suspected of having supravalvular aortic stenosis</text>
<text top="481" left="513" width="52" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.5-1)</a></text>
<text top="481" left="564" width="3" height="11" font="12">.</text>
<text top="527" left="97" width="3" height="9" font="5">I</text>
<text top="527" left="160" width="20" height="9" font="5">C-LD</text>
<text top="515" left="234" width="566" height="11" font="12">2. Coronary imaging is recommended in patients with Williams syndrome and supravalvular aortic stenosis</text>
<text top="531" left="248" width="255" height="11" font="12">presenting with symptoms of coronary ischemia</text>
<text top="531" left="507" width="49" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.5-2</a></text>
<text top="529" left="556" width="55" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">–S4.2.5-4)</a></text>
<text top="531" left="611" width="3" height="11" font="12">.</text>
<text top="567" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="611" left="97" width="3" height="9" font="5">I</text>
<text top="611" left="160" width="21" height="9" font="5">B-NR</text>
<text top="599" left="234" width="552" height="11" font="12">3. Surgical repair is recommended for adults with supravalvular aortic stenosis (discrete or diffuse) and</text>
<text top="615" left="248" width="441" height="11" font="12">symptoms or decreased LV systolic function deemed secondary to aortic obstruction</text>
<text top="615" left="692" width="49" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.5-5</a></text>
<text top="613" left="741" width="55" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">–S4.2.5-8)</a></text>
<text top="615" left="796" width="3" height="11" font="12">.</text>
<text top="661" left="97" width="3" height="9" font="5">I</text>
<text top="661" left="160" width="20" height="9" font="5">C-LD</text>
<text top="649" left="234" width="564" height="11" font="12">4. Coronary artery revascularization is recommended in symptomatic adults with supravalvular aortic ste-</text>
<text top="664" left="249" width="179" height="11" font="12">nosis and coronary ostial stenosis</text>
<text top="664" left="432" width="106" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.5-4, S4.2.5-9)</a></text>
<text top="664" left="538" width="3" height="11" font="12">.</text>
<text top="696" left="63" width="13" height="8" font="5">See</text>
<text top="696" left="78" width="42" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#12">Section 3.3</a></text>
<text top="696" left="122" width="453" height="8" font="5">for recommendations on who should perform surgeries, cardiac catheterization, and other procedures in these patients;</text>
<text top="696" left="578" width="42" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="696" left="622" width="179" height="8" font="5">for recommendations on diagnostic evaluation;</text>
<text top="708" left="63" width="14" height="8" font="5">and</text>
<text top="708" left="80" width="35" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#31">Table 20</a></text>
<text top="708" left="117" width="166" height="8" font="5">for routine testing and follow-up intervals.</text>
<text top="766" left="112" width="55" height="10" font="15">T A B L E 2 0</text>
<text top="766" left="179" width="379" height="10" font="16">Supravalvular Aortic Stenosis: Routine Follow-Up and Testing Intervals</text>
<text top="790" left="108" width="100" height="9" font="13">Frequency of Routine</text>
<text top="802" left="108" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="790" left="311" width="61" height="9" font="13">Physiological</text>
<text top="802" left="308" width="36" height="9" font="13">Stage A</text>
<text top="802" left="344" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#31">*</a></text>
<text top="802" left="352" width="22" height="9" font="13">(mo)</text>
<text top="790" left="453" width="61" height="9" font="13">Physiological</text>
<text top="802" left="451" width="35" height="9" font="13">Stage B</text>
<text top="802" left="487" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#31">*</a></text>
<text top="802" left="495" width="22" height="9" font="13">(mo)</text>
<text top="790" left="595" width="61" height="9" font="13">Physiological</text>
<text top="802" left="593" width="35" height="9" font="13">Stage C</text>
<text top="802" left="629" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#31">*</a></text>
<text top="802" left="636" width="22" height="9" font="13">(mo)</text>
<text top="790" left="738" width="61" height="9" font="13">Physiological</text>
<text top="802" left="735" width="36" height="9" font="13">Stage D</text>
<text top="802" left="771" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#31">*</a></text>
<text top="802" left="779" width="22" height="9" font="13">(mo)</text>
<text top="821" left="108" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="821" left="336" width="11" height="9" font="13">24</text>
<text top="821" left="479" width="11" height="9" font="13">24</text>
<text top="821" left="616" width="6" height="9" font="13">6</text>
<text top="819" left="622" width="13" height="12" font="13">–12</text>
<text top="821" left="761" width="5" height="9" font="13">3</text>
<text top="819" left="766" width="10" height="12" font="13">–6</text>
<text top="840" left="108" width="17" height="9" font="13">ECG</text>
<text top="840" left="336" width="11" height="9" font="13">24</text>
<text top="840" left="479" width="11" height="9" font="13">24</text>
<text top="840" left="621" width="9" height="9" font="13">12</text>
<text top="840" left="764" width="9" height="9" font="13">12</text>
<text top="860" left="108" width="16" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#31">TTE</a></text>
<text top="858" left="123" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#31">†</a></text>
<text top="860" left="336" width="11" height="9" font="13">24</text>
<text top="860" left="479" width="11" height="9" font="13">24</text>
<text top="860" left="621" width="9" height="9" font="13">12</text>
<text top="860" left="764" width="9" height="9" font="13">12</text>
<text top="879" left="108" width="19" height="9" font="13">CMR</text>
<text top="877" left="127" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#31">‡</a></text>
<text top="879" left="131" width="20" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#31">/CCT</a></text>
<text top="879" left="151" width="5" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#31">§</a></text>
<text top="879" left="328" width="11" height="9" font="13">36</text>
<text top="877" left="338" width="16" height="12" font="13">–60</text>
<text top="879" left="470" width="11" height="9" font="13">36</text>
<text top="877" left="481" width="16" height="12" font="13">–60</text>
<text top="879" left="612" width="11" height="9" font="13">36</text>
<text top="877" left="623" width="16" height="12" font="13">–60</text>
<text top="879" left="755" width="11" height="9" font="13">36</text>
<text top="877" left="765" width="16" height="12" font="13">–60</text>
<text top="898" left="108" width="53" height="9" font="13">Exercise test</text>
<text top="896" left="161" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#31">k</a></text>
<text top="898" left="319" width="44" height="9" font="13">As needed</text>
<text top="898" left="479" width="11" height="9" font="13">24</text>
<text top="898" left="621" width="11" height="9" font="13">24</text>
<text top="898" left="764" width="9" height="9" font="13">12</text>
<text top="922" left="108" width="17" height="8" font="5">*See</text>
<text top="922" left="128" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="922" left="189" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="920" left="318" width="60" height="11" font="5">ﬁcation system.</text>
<text top="932" left="108" width="471" height="11" font="5">†Routine TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise.</text>
<text top="944" left="108" width="694" height="11" font="5">‡CMR may be indicated for assessment of aortic anatomy. Baseline study is recommended with periodic follow-up CMR, with frequency of repeat imaging determined by anatomic and</text>
<text top="957" left="108" width="50" height="8" font="5">physiological</text>
<text top="956" left="160" width="33" height="11" font="5">ﬁndings.</text>
<text top="969" left="108" width="393" height="8" font="5">§If CCT is used instead of CMR imaging, the frequency should be weighed against radiation exposure.</text>
<text top="980" left="108" width="257" height="11" font="5"><a href="1-s2.0-S0735109718368451-main.html#11">k6-minute </a>walk test or CPET, depending on the clinical indication.</text>
<text top="996" left="116" width="686" height="8" font="5">ACHD indicates adult congenital heart disease; CCT, cardiac computed tomography; CMR, cardiovascular magnetic resonance; CPET, cardiopulmonary exercise test; ECG, electro-</text>
<text top="1007" left="108" width="201" height="8" font="5">cardiogram; and TTE, transthoracic echocardiogram.</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="19" height="9" font="5">1524</text>
</page>
<page number="32" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="162" height="11" font="2">4.2.6. Coarctation of the Aorta</text>
<text top="164" left="63" width="47" height="12" font="2">See also</text>
<text top="165" left="114" width="46" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#32">Table 21</a></text>
<text top="164" left="160" width="3" height="12" font="2">.</text>
<text top="193" left="63" width="263" height="11" font="20">Recommendations for Coarctation of the Aorta</text>
<text top="207" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="207" left="457" width="153" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 38</a></text>
<text top="207" left="611" width="3" height="11" font="20">.</text>
<text top="248" left="89" width="19" height="10" font="13">COR</text>
<text top="248" left="161" width="18" height="10" font="13">LOE</text>
<text top="248" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="276" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="320" left="97" width="3" height="9" font="5">I</text>
<text top="320" left="160" width="21" height="9" font="5">B-NR</text>
<text top="308" left="234" width="566" height="11" font="12">1. Initial and follow-up aortic imaging using CMR or CTA is recommended in adults with coarctation of the</text>
<text top="324" left="246" width="370" height="11" font="12">aorta, including those who have had surgical or catheter intervention</text>
<text top="324" left="621" width="48" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.6-1</a></text>
<text top="322" left="669" width="55" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">–S4.2.6-3)</a></text>
<text top="324" left="724" width="3" height="11" font="12">.</text>
<text top="370" left="97" width="3" height="9" font="5">I</text>
<text top="370" left="160" width="20" height="9" font="5">C-EO</text>
<text top="357" left="234" width="566" height="11" font="12">2. Resting blood pressure should be measured in upper and lower extremities in all adults with coarctation</text>
<text top="373" left="248" width="67" height="11" font="12">of the aorta.</text>
<text top="419" left="94" width="10" height="9" font="5">IIa</text>
<text top="419" left="160" width="20" height="9" font="5">C-LD</text>
<text top="407" left="234" width="566" height="11" font="12">3. Ambulatory blood pressure monitoring in adults with coarctation of the aorta can be useful for diagnosis</text>
<text top="423" left="248" width="179" height="11" font="12">and management of hypertension</text>
<text top="423" left="431" width="55" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.6-4)</a></text>
<text top="423" left="486" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#59">.</a></text>
<text top="468" left="94" width="10" height="9" font="5">IIb</text>
<text top="468" left="160" width="21" height="9" font="5">B-NR</text>
<text top="456" left="234" width="561" height="11" font="12">4. Screening for intracranial aneurysms by magnetic resonance angiography or CTA may be reasonable in</text>
<text top="472" left="249" width="190" height="11" font="12">adults with coarctation of the aorta</text>
<text top="472" left="443" width="108" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.6-5, S4.2.6-6)</a></text>
<text top="472" left="551" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#59">.</a></text>
<text top="518" left="94" width="10" height="9" font="5">IIb</text>
<text top="518" left="160" width="20" height="9" font="5">C-LD</text>
<text top="506" left="234" width="564" height="11" font="12">5. Exercise testing to evaluate for exercise-induced hypertension may be reasonable in adults with coarc-</text>
<text top="522" left="248" width="171" height="11" font="12">tation of the aorta who exercise</text>
<text top="522" left="423" width="107" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.6-4, S4.2.6-7)</a></text>
<text top="522" left="530" width="3" height="11" font="12">.</text>
<text top="562" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="606" left="97" width="3" height="9" font="5">I</text>
<text top="606" left="160" width="21" height="9" font="5">B-NR</text>
<text top="594" left="234" width="535" height="11" font="12">6. Surgical repair or catheter-based stenting is recommended for adults with hypertension and signi</text>
<text top="592" left="769" width="29" height="15" font="12">ﬁcant</text>
<text top="610" left="249" width="231" height="11" font="12">native or recurrent coarctation of the aorta</text>
<text top="610" left="483" width="155" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.6-1, S4.2.6-2, S4.2.6-8</a></text>
<text top="608" left="638" width="60" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">–S4.2.6-12)</a></text>
<text top="610" left="699" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#59">.</a></text>
<text top="656" left="97" width="3" height="9" font="5">I</text>
<text top="656" left="160" width="20" height="9" font="5">C-EO</text>
<text top="644" left="234" width="541" height="11" font="12">7. GDMT is recommended for treatment of hypertension in patients with coarctation of the aorta</text>
<text top="660" left="247" width="59" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.6-13)</a></text>
<text top="660" left="307" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#59">.</a></text>
<text top="714" left="94" width="10" height="9" font="5">IIb</text>
<text top="714" left="160" width="21" height="9" font="5">B-NR</text>
<text top="701" left="234" width="560" height="11" font="12">8. Balloon angioplasty for adults with native and recurrent coarctation of the aorta may be considered if</text>
<text top="717" left="249" width="389" height="11" font="12">stent placement is not feasible and surgical intervention is not an option</text>
<text top="717" left="642" width="60" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.2.6-14)</a></text>
<text top="717" left="702" width="3" height="11" font="12">.</text>
<text top="749" left="63" width="13" height="8" font="5">See</text>
<text top="749" left="78" width="42" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#12">Section 3.3</a></text>
<text top="749" left="122" width="453" height="8" font="5">for recommendations on who should perform surgeries, cardiac catheterization, and other procedures in these patients;</text>
<text top="749" left="578" width="42" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="749" left="622" width="179" height="8" font="5">for recommendations on diagnostic evaluation;</text>
<text top="761" left="63" width="14" height="8" font="5">and</text>
<text top="761" left="80" width="33" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#32">Table 21</a></text>
<text top="761" left="115" width="166" height="8" font="5">for routine testing and follow-up intervals.</text>
<text top="813" left="68" width="52" height="10" font="15">T A B L E 2 1</text>
<text top="813" left="135" width="243" height="10" font="16">CoA: Routine Follow-Up and Testing Intervals</text>
<text top="837" left="63" width="100" height="9" font="13">Frequency of Routine</text>
<text top="849" left="63" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="837" left="261" width="61" height="9" font="13">Physiological</text>
<text top="849" left="260" width="36" height="9" font="13">Stage A</text>
<text top="849" left="296" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#32">*</a></text>
<text top="849" left="301" width="22" height="9" font="13">(mo)</text>
<text top="837" left="405" width="61" height="9" font="13">Physiological</text>
<text top="849" left="405" width="35" height="9" font="13">Stage B</text>
<text top="849" left="440" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#32">*</a></text>
<text top="849" left="445" width="22" height="9" font="13">(mo)</text>
<text top="837" left="549" width="61" height="9" font="13">Physiological</text>
<text top="849" left="549" width="35" height="9" font="13">Stage C</text>
<text top="849" left="584" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#32">*</a></text>
<text top="849" left="589" width="22" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#32">(mo)</a></text>
<text top="837" left="694" width="61" height="9" font="13">Physiological</text>
<text top="849" left="693" width="36" height="9" font="13">Stage D</text>
<text top="849" left="729" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#32">*</a></text>
<text top="849" left="734" width="22" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#32">(mo)</a></text>
<text top="868" left="63" width="72" height="9" font="13">Outpatient ACHD</text>
<text top="880" left="78" width="48" height="9" font="13">cardiologist</text>
<text top="868" left="286" width="11" height="9" font="13">24</text>
<text top="868" left="430" width="11" height="9" font="13">24</text>
<text top="868" left="571" width="6" height="9" font="13">6</text>
<text top="866" left="576" width="13" height="12" font="13">–12</text>
<text top="868" left="717" width="5" height="9" font="13">3</text>
<text top="866" left="722" width="10" height="12" font="13">–6</text>
<text top="899" left="63" width="17" height="9" font="13">ECG</text>
<text top="899" left="286" width="11" height="9" font="13">24</text>
<text top="899" left="430" width="11" height="9" font="13">24</text>
<text top="899" left="576" width="9" height="9" font="13">12</text>
<text top="899" left="720" width="9" height="9" font="13">12</text>
<text top="918" left="63" width="16" height="9" font="13">TTE</text>
<text top="917" left="79" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#32">†</a></text>
<text top="918" left="286" width="11" height="9" font="13">24</text>
<text top="918" left="430" width="11" height="9" font="13">24</text>
<text top="918" left="576" width="9" height="9" font="13">12</text>
<text top="918" left="720" width="9" height="9" font="13">12</text>
<text top="938" left="63" width="19" height="9" font="13">CMR</text>
<text top="936" left="82" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#32">‡</a></text>
<text top="938" left="87" width="20" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#32">/CCT</a></text>
<text top="938" left="106" width="5" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#32">§</a></text>
<text top="938" left="278" width="11" height="9" font="13">36</text>
<text top="936" left="289" width="16" height="12" font="13">–60</text>
<text top="938" left="422" width="11" height="9" font="13">36</text>
<text top="936" left="433" width="16" height="12" font="13">–60</text>
<text top="938" left="568" width="9" height="9" font="13">12</text>
<text top="936" left="577" width="15" height="12" font="13">–24</text>
<text top="938" left="712" width="9" height="9" font="13">12</text>
<text top="936" left="721" width="15" height="12" font="13">–24</text>
<text top="957" left="63" width="53" height="9" font="13">Exercise test</text>
<text top="955" left="116" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#32">k</a></text>
<text top="957" left="286" width="11" height="9" font="13">36</text>
<text top="957" left="430" width="11" height="9" font="13">24</text>
<text top="957" left="575" width="11" height="9" font="13">24</text>
<text top="957" left="720" width="9" height="9" font="13">12</text>
<text top="980" left="63" width="17" height="8" font="5">*See</text>
<text top="980" left="83" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="980" left="144" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="979" left="273" width="60" height="11" font="5">ﬁcation system.</text>
<text top="991" left="63" width="471" height="11" font="5">†Routine TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise.</text>
<text top="1003" left="63" width="694" height="11" font="5">‡CMR may be indicated for assessment of aortic size and aortic arch/coarctation repair site anatomy. Baseline study is recommended with periodic follow-up CMR, with frequency of</text>
<text top="1016" left="63" width="224" height="8" font="5">repeat imaging determined by anatomic and physiological</text>
<text top="1015" left="289" width="33" height="11" font="5">ﬁndings.</text>
<text top="1028" left="63" width="342" height="8" font="5">§CCT may be used if CMR is not feasible and to evaluate cross-sectional imaging status</text>
<text top="1027" left="404" width="352" height="11" font="5">–post-stent therapy for coarctation of the aorta; the frequency should be weighed against</text>
<text top="1040" left="63" width="74" height="8" font="5">radiation exposure.</text>
<text top="1051" left="63" width="257" height="11" font="5"><a href="1-s2.0-S0735109718368451-main.html#11">k</a>6-minute walk test or CPET, depending on the clinical indication.</text>
<text top="1066" left="71" width="686" height="8" font="5">ACHD indicates adult congenital heart disease; CCT, cardiac computed tomography; CMR, cardiovascular magnetic resonance imaging; CoA, coarctation of the aorta; CPET, car-</text>
<text top="1078" left="63" width="340" height="8" font="5">diopulmonary exercise; ECG, electrocardiogram; and TTE, transthoracic echocardiogram.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="789" width="18" height="9" font="5">1525</text>
</page>
<page number="33" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="129" height="11" font="12">4.3. Right-Sided Lesions</text>
<text top="165" left="108" width="180" height="11" font="2">4.3.1. Valvular Pulmonary Stenosis</text>
<text top="186" left="108" width="47" height="12" font="2">See also</text>
<text top="187" left="158" width="94" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#33">Tables 22 </a>and <a href="1-s2.0-S0735109718368451-main.html#33">23</a></text>
<text top="186" left="253" width="3" height="12" font="2">.</text>
<text top="854" left="108" width="208" height="12" font="3">4.3.1.1. Isolated PR After Repair of PS</text>
<text top="221" left="63" width="286" height="11" font="20">Recommendations for Valvular Pulmonary Stenosis</text>
<text top="235" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="235" left="457" width="153" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 39</a></text>
<text top="235" left="611" width="3" height="11" font="20">.</text>
<text top="276" left="89" width="19" height="10" font="13">COR</text>
<text top="276" left="161" width="18" height="10" font="13">LOE</text>
<text top="276" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="313" left="97" width="3" height="9" font="5">I</text>
<text top="313" left="160" width="21" height="9" font="5">B-NR</text>
<text top="301" left="234" width="565" height="11" font="12">1. In adults with moderate or severe valvular pulmonary stenosis and otherwise unexplained symptoms of</text>
<text top="317" left="246" width="551" height="11" font="12">HF, cyanosis from interatrial right-to-left communication, and/or exercise intolerance, balloon valvulo-</text>
<text top="332" left="246" width="122" height="11" font="12">plasty is recommended</text>
<text top="332" left="373" width="46" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.3.1-1</a></text>
<text top="330" left="419" width="53" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">–S4.3.1-4)</a></text>
<text top="332" left="473" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#59">.</a></text>
<text top="371" left="97" width="3" height="9" font="5">I</text>
<text top="371" left="160" width="21" height="9" font="5">B-NR</text>
<text top="359" left="234" width="566" height="11" font="12">2. In adults with moderate or severe valvular pulmonary stenosis and otherwise unexplained symptoms of</text>
<text top="374" left="248" width="532" height="11" font="12">HF, cyanosis, and/or exercise intolerance who are ineligible for or who failed balloon valvuloplasty,</text>
<text top="390" left="248" width="166" height="11" font="12">surgical repair is recommended</text>
<text top="390" left="418" width="96" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.3.1-1, S4.3.1-5</a></text>
<text top="388" left="514" width="53" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">–S4.3.1-8)</a></text>
<text top="430" left="94" width="10" height="9" font="5">IIa</text>
<text top="430" left="160" width="20" height="9" font="5">C-EO</text>
<text top="418" left="234" width="505" height="11" font="12">3. In asymptomatic adults with severe valvular pulmonary stenosis, intervention is reasonable.</text>
<text top="465" left="63" width="13" height="8" font="5">See</text>
<text top="465" left="78" width="42" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#12">Section 3.3</a></text>
<text top="465" left="122" width="453" height="8" font="5">for recommendations on who should perform surgeries, cardiac catheterization, and other procedures in these patients;</text>
<text top="465" left="578" width="42" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="465" left="622" width="179" height="8" font="5">for recommendations on diagnostic evaluation;</text>
<text top="477" left="63" width="34" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#33">Table 23</a></text>
<text top="477" left="99" width="183" height="8" font="5">for routine testing and follow-up intervals; and</text>
<text top="477" left="285" width="32" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#34">Figure 3</a></text>
<text top="477" left="320" width="290" height="8" font="5">for a diagnostic and treatment algorithm for isolated PR after repair of PS.</text>
<text top="515" left="112" width="53" height="10" font="15">T A B L E 2 2</text>
<text top="515" left="179" width="157" height="10" font="16">Severity of RVOT Obstruction</text>
<text top="537" left="108" width="18" height="9" font="13">Mild</text>
<text top="537" left="476" width="57" height="9" font="13">Peak gradient</text>
<text top="535" left="536" width="150" height="12" font="13">&lt;36 mm Hg (peak velocity &lt;3 m/s)</text>
<text top="556" left="108" width="40" height="9" font="13">Moderate</text>
<text top="556" left="476" width="71" height="9" font="13">Peak gradient 36</text>
<text top="555" left="547" width="151" height="12" font="13">–64 mm Hg (peak velocity 3–4 m/s)</text>
<text top="576" left="108" width="28" height="9" font="13">Severe</text>
<text top="576" left="476" width="167" height="9" font="13">Peak gradient 64 mm Hg (peak velocity</text>
<text top="574" left="646" width="155" height="12" font="13">&gt;4 m/s); mean gradient &gt;35 mm Hg</text>
<text top="599" left="108" width="694" height="8" font="5">Estimations of RV systolic pressure by TR velocity is part of the echocardiographic assessment of RV obstruction, as Doppler measurements across the RV obstruction itself may be</text>
<text top="611" left="108" width="40" height="8" font="5">unreliable.</text>
<text top="625" left="116" width="222" height="8" font="5">RV indicates right ventricular; RVOT, right ventricular out</text>
<text top="624" left="337" width="163" height="11" font="5">ﬂow tract; and TR, tricuspid regurgitation.</text>
<text top="664" left="112" width="53" height="10" font="15">T A B L E 2 3</text>
<text top="664" left="179" width="283" height="10" font="16">Valvular PS: Routine Follow-Up and Testing Intervals</text>
<text top="688" left="108" width="100" height="9" font="13">Frequency of Routine</text>
<text top="700" left="108" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="688" left="311" width="61" height="9" font="13">Physiological</text>
<text top="700" left="308" width="36" height="9" font="13">Stage A</text>
<text top="700" left="344" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#33">*</a></text>
<text top="700" left="352" width="22" height="9" font="13">(mo)</text>
<text top="688" left="453" width="61" height="9" font="13">Physiological</text>
<text top="700" left="451" width="35" height="9" font="13">Stage B</text>
<text top="700" left="487" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#33">*</a></text>
<text top="700" left="495" width="22" height="9" font="13">(mo)</text>
<text top="688" left="595" width="61" height="9" font="13">Physiological</text>
<text top="700" left="593" width="35" height="9" font="13">Stage C</text>
<text top="700" left="629" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#33">*</a></text>
<text top="700" left="636" width="22" height="9" font="13">(mo)</text>
<text top="688" left="738" width="61" height="9" font="13">Physiological</text>
<text top="700" left="735" width="36" height="9" font="13">Stage D</text>
<text top="700" left="771" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#33">*</a></text>
<text top="700" left="779" width="22" height="9" font="13">(mo)</text>
<text top="719" left="108" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="719" left="328" width="11" height="9" font="13">36</text>
<text top="717" left="338" width="16" height="12" font="13">–60</text>
<text top="719" left="479" width="11" height="9" font="13">24</text>
<text top="719" left="616" width="6" height="9" font="13">6</text>
<text top="717" left="622" width="13" height="12" font="13">–12</text>
<text top="719" left="761" width="5" height="9" font="13">3</text>
<text top="717" left="766" width="10" height="12" font="13">–6</text>
<text top="738" left="108" width="17" height="9" font="13">ECG</text>
<text top="738" left="328" width="11" height="9" font="13">36</text>
<text top="737" left="338" width="16" height="12" font="13">–60</text>
<text top="738" left="479" width="11" height="9" font="13">24</text>
<text top="738" left="621" width="9" height="9" font="13">12</text>
<text top="738" left="764" width="9" height="9" font="13">12</text>
<text top="758" left="108" width="16" height="9" font="13">TTE</text>
<text top="758" left="328" width="11" height="9" font="13">36</text>
<text top="756" left="338" width="16" height="12" font="13">–60</text>
<text top="758" left="479" width="11" height="9" font="13">24</text>
<text top="758" left="621" width="9" height="9" font="13">12</text>
<text top="758" left="764" width="9" height="9" font="13">12</text>
<text top="777" left="108" width="53" height="9" font="13">Exercise test</text>
<text top="775" left="161" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#33">†</a></text>
<text top="777" left="319" width="44" height="9" font="13">As needed</text>
<text top="777" left="479" width="11" height="9" font="13">24</text>
<text top="777" left="621" width="11" height="9" font="13">24</text>
<text top="777" left="764" width="9" height="9" font="13">12</text>
<text top="800" left="108" width="17" height="8" font="5">*See</text>
<text top="800" left="128" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="800" left="189" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="799" left="318" width="60" height="11" font="5">ﬁcation system.</text>
<text top="811" left="108" width="241" height="11" font="5">†6-minute walk test or CPET, depending on clinical indication.</text>
<text top="827" left="116" width="672" height="8" font="5">ACHD indicates adult congenital heart disease; CPET, cardiopulmonary exercise test; ECG, electrocardiogram; PS, pulmonary stenosis; and TTE, transthoracic echocardiogram.</text>
<text top="897" left="63" width="392" height="11" font="20">Recommendations for Isolated PR After Repair of Pulmonary Stenosis</text>
<text top="938" left="89" width="19" height="10" font="13">COR</text>
<text top="938" left="161" width="18" height="10" font="13">LOE</text>
<text top="938" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="975" left="97" width="3" height="9" font="5">I</text>
<text top="975" left="160" width="20" height="9" font="5">C-EO</text>
<text top="962" left="234" width="566" height="11" font="12">1. In symptomatic patients with moderate or greater PR resulting from treated isolated pulmonary stenosis,</text>
<text top="978" left="246" width="443" height="11" font="12">with RV dilation or RV dysfunction, pulmonary valve replacement is recommended.</text>
<text top="1023" left="97" width="3" height="9" font="5">I</text>
<text top="1023" left="160" width="20" height="9" font="5">C-EO</text>
<text top="1010" left="234" width="566" height="11" font="12">2. For asymptomatic patients with residual PR resulting from treatment of isolated pulmonary stenosis with</text>
<text top="1026" left="248" width="311" height="11" font="12">a dilated right ventricle, serial follow-up is recommended.</text>
<text top="1072" left="94" width="10" height="9" font="5">IIb</text>
<text top="1072" left="160" width="20" height="9" font="5">C-EO</text>
<text top="1060" left="234" width="562" height="11" font="12">3. In asymptomatic patients with moderate or greater PR resulting from treatment of isolated pulmonary</text>
<text top="1076" left="248" width="527" height="11" font="12">stenosis with progressive RV dilation and/or RV dysfunction, pulmonary valve replacement may be</text>
<text top="1091" left="248" width="61" height="11" font="12">reasonable.</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="19" height="9" font="5">1526</text>
</page>
<page number="34" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="27" size="10" family="Times" color="#000000"/>
<text top="153" left="80" width="45" height="11" font="23">FIGURE 3</text>
<text top="154" left="134" width="134" height="9" font="24">Isolated PR After Repair of PS</text>
<text top="195" left="240" width="165" height="14" font="27">Isolated PR after repair of PS</text>
<text top="268" left="282" width="86" height="14" font="27">Assessment of </text>
<text top="283" left="278" width="93" height="14" font="27">PR severity and </text>
<text top="299" left="277" width="92" height="14" font="27">RV size/function</text>
<text top="483" left="381" width="67" height="14" font="27">Symptoms†</text>
<text top="561" left="302" width="97" height="14" font="27">Pulmonary valve </text>
<text top="576" left="314" width="73" height="14" font="27">replacement </text>
<text top="591" left="325" width="47" height="14" font="27">(Class I)</text>
<text top="526" left="365" width="22" height="14" font="27">Yes</text>
<text top="576" left="435" width="108" height="14" font="27">Imaging and CPET</text>
<text top="526" left="450" width="16" height="14" font="27">No</text>
<text top="676" left="421" width="136" height="14" font="27">Progressive RV dilation </text>
<text top="692" left="425" width="125" height="14" font="27">and/or RV dysfunction</text>
<text top="707" left="407" width="165" height="14" font="27">and/or progressive decrease </text>
<text top="722" left="432" width="111" height="14" font="27">in exercise capacity</text>
<text top="808" left="359" width="97" height="14" font="27">Pulmonary valve </text>
<text top="824" left="371" width="70" height="14" font="27">replacement</text>
<text top="839" left="377" width="58" height="14" font="27">(Class IIb)</text>
<text top="772" left="440" width="22" height="14" font="27">Yes</text>
<text top="772" left="518" width="16" height="14" font="27">No</text>
<text top="816" left="509" width="125" height="14" font="27">Interval follow-up with </text>
<text top="831" left="519" width="103" height="14" font="27">ACHD cardiologist</text>
<text top="475" left="187" width="96" height="14" font="27">Interval follow-up</text>
<text top="490" left="211" width="47" height="14" font="27">(Class I)</text>
<text top="385" left="381" width="73" height="14" font="27">Moderate or </text>
<text top="400" left="372" width="90" height="14" font="27">greater PR and </text>
<text top="415" left="367" width="97" height="14" font="27">RV enlargement*</text>
<text top="392" left="200" width="73" height="14" font="27">Mild PR and </text>
<text top="407" left="187" width="97" height="14" font="27">RV enlargement*</text>
<text top="890" left="80" width="25" height="9" font="13">*Signi</text>
<text top="888" left="105" width="633" height="12" font="13">ﬁcant PR causes RV dilation. If a patient has moderate or greater PR and normal RV size, most likely the estimation of PR severity is inaccurate or there</text>
<text top="905" left="80" width="329" height="9" font="13">may be restrictive RV physiology, which would warrant further investigation.</text>
<text top="903" left="412" width="312" height="12" font="13">†Symptoms may include dyspnea, chest pain, and/or exercise intolerance</text>
<text top="919" left="80" width="658" height="9" font="13">referable to PR or otherwise unexplained. ACHD indicates adult congenital heart disease; CPET, cardiopulmonary exercise test; PR, pulmonary regurgitation;</text>
<text top="934" left="80" width="212" height="9" font="13">PS, pulmonary stenosis; and RV, right ventricular.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="790" width="18" height="9" font="5">1527</text>
</page>
<page number="35" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="254" height="11" font="2">4.3.2. Branch and Peripheral Pulmonary Stenosis</text>
<text top="164" left="108" width="47" height="12" font="2">See also</text>
<text top="165" left="158" width="49" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#35">Table 24</a></text>
<text top="164" left="207" width="3" height="12" font="2">.</text>
<text top="779" left="108" width="215" height="11" font="2">4.3.3. Double-Chambered Right Ventricle</text>
<text top="800" left="108" width="47" height="12" font="2">See also</text>
<text top="801" left="158" width="48" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#36">Table 25</a></text>
<text top="800" left="206" width="3" height="12" font="2">.</text>
<text top="198" left="63" width="268" height="11" font="20">Recommendations for Branch and Peripheral PS</text>
<text top="212" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="212" left="457" width="155" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 40</a></text>
<text top="212" left="613" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="253" left="89" width="19" height="10" font="13">COR</text>
<text top="253" left="161" width="18" height="10" font="13">LOE</text>
<text top="253" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="280" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="324" left="97" width="3" height="9" font="5">I</text>
<text top="324" left="160" width="21" height="9" font="5">B-NR</text>
<text top="312" left="234" width="430" height="11" font="12">1. For adults with peripheral or branch PS, ongoing surveillance is recommended</text>
<text top="312" left="668" width="103" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.3.2-1, S4.3.2-2)</a></text>
<text top="312" left="771" width="3" height="11" font="12">.</text>
<text top="363" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="408" left="94" width="10" height="9" font="5">IIa</text>
<text top="408" left="160" width="21" height="9" font="5">B-NR</text>
<text top="395" left="234" width="443" height="11" font="12">2. In adults with peripheral or branch PA stenosis, PA dilation and stenting can be useful</text>
<text top="395" left="680" width="104" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.3.2-2, S4.3.2-3)</a></text>
<text top="395" left="785" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#59">.</a></text>
<text top="443" left="63" width="13" height="8" font="5">See</text>
<text top="443" left="78" width="42" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#12">Section 3.3</a></text>
<text top="443" left="122" width="453" height="8" font="5">for recommendations on who should perform surgeries, cardiac catheterization, and other procedures in these patients;</text>
<text top="443" left="578" width="42" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="443" left="622" width="179" height="8" font="5">for recommendations on diagnostic evaluation;</text>
<text top="455" left="63" width="14" height="8" font="5">and</text>
<text top="455" left="80" width="34" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#35">Table 24</a></text>
<text top="455" left="117" width="166" height="8" font="5">for routine testing and follow-up intervals.</text>
<text top="489" left="112" width="54" height="10" font="15">T A B L E 2 4</text>
<text top="489" left="179" width="357" height="10" font="16">Branch and Peripheral PS: Routine Follow-Up and Testing Intervals</text>
<text top="514" left="108" width="100" height="9" font="13">Frequency of Routine</text>
<text top="526" left="108" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="514" left="311" width="61" height="9" font="13">Physiological</text>
<text top="526" left="308" width="36" height="9" font="13">Stage A</text>
<text top="526" left="344" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#35">*</a></text>
<text top="526" left="352" width="22" height="9" font="13">(mo)</text>
<text top="514" left="453" width="61" height="9" font="13">Physiological</text>
<text top="526" left="451" width="35" height="9" font="13">Stage B</text>
<text top="526" left="487" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#35">*</a></text>
<text top="526" left="495" width="22" height="9" font="13">(mo)</text>
<text top="514" left="595" width="61" height="9" font="13">Physiological</text>
<text top="526" left="593" width="35" height="9" font="13">Stage C</text>
<text top="526" left="629" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#35">*</a></text>
<text top="526" left="636" width="22" height="9" font="13">(mo)</text>
<text top="514" left="738" width="61" height="9" font="13">Physiological</text>
<text top="526" left="735" width="36" height="9" font="13">Stage D</text>
<text top="526" left="771" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#35">*</a></text>
<text top="526" left="779" width="22" height="9" font="13">(mo)</text>
<text top="545" left="108" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="545" left="328" width="11" height="9" font="13">24</text>
<text top="543" left="339" width="15" height="12" font="13">–36</text>
<text top="545" left="479" width="11" height="9" font="13">24</text>
<text top="545" left="616" width="6" height="9" font="13">6</text>
<text top="543" left="622" width="13" height="12" font="13">–12</text>
<text top="545" left="761" width="5" height="9" font="13">3</text>
<text top="543" left="766" width="10" height="12" font="13">–6</text>
<text top="564" left="108" width="17" height="9" font="13">ECG</text>
<text top="564" left="328" width="11" height="9" font="13">24</text>
<text top="562" left="339" width="15" height="12" font="13">–36</text>
<text top="564" left="479" width="11" height="9" font="13">24</text>
<text top="564" left="621" width="9" height="9" font="13">12</text>
<text top="564" left="764" width="9" height="9" font="13">12</text>
<text top="583" left="108" width="16" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#35">TTE</a></text>
<text top="581" left="123" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#35">†</a></text>
<text top="583" left="328" width="11" height="9" font="13">24</text>
<text top="581" left="339" width="15" height="12" font="13">–36</text>
<text top="583" left="479" width="11" height="9" font="13">24</text>
<text top="583" left="621" width="9" height="9" font="13">12</text>
<text top="583" left="764" width="9" height="9" font="13">12</text>
<text top="602" left="108" width="19" height="9" font="13">CMR</text>
<text top="601" left="127" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#35">‡</a></text>
<text top="602" left="131" width="20" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#35">/CCT</a></text>
<text top="602" left="151" width="5" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#35">§</a></text>
<text top="602" left="328" width="11" height="9" font="13">36</text>
<text top="601" left="338" width="16" height="12" font="13">–60</text>
<text top="602" left="470" width="11" height="9" font="13">36</text>
<text top="601" left="481" width="16" height="12" font="13">–60</text>
<text top="602" left="613" width="11" height="9" font="13">24</text>
<text top="601" left="624" width="15" height="12" font="13">–36</text>
<text top="602" left="755" width="11" height="9" font="13">24</text>
<text top="601" left="766" width="15" height="12" font="13">–36</text>
<text top="622" left="108" width="53" height="9" font="13">Exercise test</text>
<text top="620" left="161" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#35">k</a></text>
<text top="622" left="336" width="11" height="9" font="13">36</text>
<text top="622" left="479" width="11" height="9" font="13">24</text>
<text top="622" left="621" width="11" height="9" font="13">24</text>
<text top="622" left="764" width="9" height="9" font="13">12</text>
<text top="645" left="108" width="17" height="8" font="5">*See</text>
<text top="645" left="128" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="645" left="189" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="644" left="318" width="60" height="11" font="5">ﬁcation system.</text>
<text top="656" left="108" width="471" height="11" font="5">†Routine TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise.</text>
<text top="668" left="108" width="694" height="11" font="5">‡CMR may be indicated for assessment of branch PS. Baseline study is recommended with periodic follow-up CMR, with frequency of repeat imaging determined by anatomic and</text>
<text top="681" left="108" width="50" height="8" font="5">physiological</text>
<text top="680" left="160" width="33" height="11" font="5">ﬁndings.</text>
<text top="693" left="108" width="694" height="8" font="5">§CCT may be used if CMR is not feasible and to evaluate cross-sectional imaging status and post-stent therapy for peripheral PS; the frequency should be weighed against radiation</text>
<text top="705" left="108" width="37" height="8" font="5">exposure.</text>
<text top="715" left="108" width="337" height="11" font="5"><a href="1-s2.0-S0735109718368451-main.html#11">k6-minute </a>walk test or cardiopulmonary exercise test, depending on clinical indication.</text>
<text top="731" left="116" width="686" height="8" font="5">ACHD indicates adult congenital heart disease; CCT, cardiac computed tomography; CMR, cardiovascular magnetic resonance imaging; ECG, electrocardiogram; PS, pulmonary</text>
<text top="743" left="108" width="189" height="8" font="5">stenosis; and TTE, transthoracic echocardiogram.</text>
<text top="845" left="63" width="320" height="11" font="20">Recommendations for Double-Chambered Right Ventricle</text>
<text top="859" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="859" left="457" width="152" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 41</a></text>
<text top="859" left="610" width="3" height="11" font="20">.</text>
<text top="900" left="89" width="19" height="10" font="13">COR</text>
<text top="900" left="161" width="18" height="10" font="13">LOE</text>
<text top="900" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="937" left="97" width="3" height="9" font="5">I</text>
<text top="937" left="160" width="20" height="9" font="5">C-LD</text>
<text top="925" left="234" width="511" height="11" font="12">1. Surgical repair for adults with double-chambered right ventricle and moderate or greater out</text>
<text top="923" left="745" width="23" height="15" font="12">ﬂow</text>
<text top="941" left="246" width="544" height="11" font="12">obstruction is recommended in patients with otherwise unexplained symptoms of HF, cyanosis, or ex-</text>
<text top="956" left="246" width="85" height="11" font="12">ercise limitation</text>
<text top="956" left="336" width="47" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.3.3-1</a></text>
<text top="954" left="383" width="54" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">–S4.3.3-3)</a></text>
<text top="956" left="441" width="4" height="11" font="12">(</text>
<text top="956" left="445" width="45" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#33">Table 22</a></text>
<text top="956" left="491" width="7" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#33">).</a></text>
<text top="1001" left="94" width="10" height="9" font="5">IIb</text>
<text top="1001" left="160" width="20" height="9" font="5">C-LD</text>
<text top="989" left="234" width="564" height="11" font="12">2. Surgical repair for adults with double-chambered right ventricle with a severe gradient may be consid-</text>
<text top="1004" left="248" width="161" height="11" font="12">ered in asymptomatic patients</text>
<text top="1004" left="413" width="105" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#59">(S4.3.3-3, S4.3.3-4)</a></text>
<text top="1004" left="522" width="4" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#33">(</a></text>
<text top="1004" left="526" width="45" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#33">Table 22</a></text>
<text top="1004" left="572" width="7" height="11" font="12">).</text>
<text top="1036" left="63" width="13" height="8" font="5">See</text>
<text top="1036" left="78" width="42" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#12">Section 3.3</a></text>
<text top="1036" left="122" width="453" height="8" font="5">for recommendations on who should perform surgeries, cardiac catheterization, and other procedures in these patients;</text>
<text top="1036" left="578" width="42" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="1036" left="622" width="179" height="8" font="5">for recommendations on diagnostic evaluation;</text>
<text top="1048" left="63" width="14" height="8" font="5">and</text>
<text top="1048" left="80" width="34" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#36">Table 25</a></text>
<text top="1048" left="116" width="166" height="8" font="5">for routine testing and follow-up intervals.</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="19" height="9" font="5">1528</text>
</page>
<page number="36" position="absolute" top="0" left="0" height="1160" width="864">
<text top="352" left="63" width="122" height="11" font="2">4.3.4. Ebstein Anomaly</text>
<text top="373" left="63" width="47" height="12" font="2">See also</text>
<text top="374" left="114" width="48" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#37">Table 26</a></text>
<text top="373" left="162" width="3" height="12" font="2">.</text>
<text top="149" left="67" width="53" height="10" font="15">T A B L E 2 5</text>
<text top="149" left="135" width="407" height="10" font="16">Double-Chambered Right Ventricle: Routine Follow-Up and Testing Intervals</text>
<text top="173" left="63" width="100" height="9" font="13">Frequency of Routine</text>
<text top="185" left="63" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="173" left="266" width="61" height="9" font="13">Physiological</text>
<text top="185" left="263" width="36" height="9" font="13">Stage <a href="1-s2.0-S0735109718368451-main.html#36">A</a></text>
<text top="185" left="299" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#36">*</a></text>
<text top="185" left="307" width="22" height="9" font="13">(mo)</text>
<text top="173" left="408" width="61" height="9" font="13">Physiological</text>
<text top="185" left="406" width="35" height="9" font="13">Stage B</text>
<text top="185" left="442" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#36">*</a></text>
<text top="185" left="450" width="22" height="9" font="13">(mo)</text>
<text top="173" left="550" width="61" height="9" font="13">Physiological</text>
<text top="185" left="549" width="35" height="9" font="13">Stage C</text>
<text top="185" left="584" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#36">*</a></text>
<text top="185" left="592" width="22" height="9" font="13">(mo)</text>
<text top="173" left="693" width="61" height="9" font="13">Physiological</text>
<text top="185" left="690" width="36" height="9" font="13">Stage <a href="1-s2.0-S0735109718368451-main.html#36">D</a></text>
<text top="185" left="726" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#36">*</a></text>
<text top="185" left="734" width="22" height="9" font="13">(mo)</text>
<text top="204" left="63" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="204" left="284" width="11" height="9" font="13">24</text>
<text top="203" left="294" width="15" height="12" font="13">–36</text>
<text top="204" left="434" width="11" height="9" font="13">24</text>
<text top="204" left="572" width="6" height="9" font="13">6</text>
<text top="203" left="577" width="13" height="12" font="13">–12</text>
<text top="204" left="716" width="5" height="9" font="13">3</text>
<text top="203" left="721" width="10" height="12" font="13">–6</text>
<text top="224" left="63" width="17" height="9" font="13">ECG</text>
<text top="224" left="284" width="11" height="9" font="13">24</text>
<text top="222" left="294" width="15" height="12" font="13">–36</text>
<text top="224" left="434" width="11" height="9" font="13">24</text>
<text top="224" left="577" width="9" height="9" font="13">12</text>
<text top="224" left="719" width="9" height="9" font="13">12</text>
<text top="243" left="63" width="16" height="9" font="13">TTE</text>
<text top="243" left="284" width="11" height="9" font="13">24</text>
<text top="241" left="294" width="15" height="12" font="13">–36</text>
<text top="243" left="434" width="11" height="9" font="13">24</text>
<text top="243" left="577" width="9" height="9" font="13">12</text>
<text top="243" left="719" width="9" height="9" font="13">12</text>
<text top="262" left="63" width="53" height="9" font="13">Exercise test</text>
<text top="260" left="116" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#36">†</a></text>
<text top="262" left="275" width="44" height="9" font="13">As needed</text>
<text top="262" left="434" width="11" height="9" font="13">24</text>
<text top="262" left="576" width="11" height="9" font="13">24</text>
<text top="262" left="719" width="9" height="9" font="13">12</text>
<text top="286" left="63" width="17" height="8" font="5">*See</text>
<text top="286" left="83" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="286" left="144" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="284" left="273" width="60" height="11" font="5">ﬁcation system.</text>
<text top="296" left="63" width="241" height="11" font="5">†6-minute walk test or CPET, depending on clinical indication.</text>
<text top="312" left="71" width="577" height="8" font="5">ACHD indicates adult congenital heart disease; CPET, cardiopulmonary exercise test; ECG, electrocardiogram; and TTE, transthoracic echocardiogram.</text>
<text top="402" left="63" width="220" height="11" font="20">Recommendations for Ebstein Anomaly</text>
<text top="416" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="416" left="457" width="154" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 42</a></text>
<text top="416" left="611" width="3" height="11" font="20">.</text>
<text top="457" left="89" width="19" height="10" font="13">COR</text>
<text top="457" left="161" width="18" height="10" font="13">LOE</text>
<text top="457" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="484" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="529" left="94" width="10" height="9" font="5">IIa</text>
<text top="529" left="160" width="21" height="9" font="5">B-NR</text>
<text top="517" left="234" width="560" height="11" font="12">1. In adults with Ebstein anomaly, CMR can be useful to determine anatomy, RV dimensions, and systolic</text>
<text top="532" left="246" width="44" height="11" font="12">function</text>
<text top="532" left="294" width="104" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.4-1, S4.3.4-2)</a></text>
<text top="532" left="399" width="3" height="11" font="12">.</text>
<text top="578" left="94" width="10" height="9" font="5">IIa</text>
<text top="578" left="160" width="21" height="9" font="5">B-NR</text>
<text top="566" left="234" width="566" height="11" font="12">2. In adults with Ebstein anomaly, TEE can be useful for surgical planning if TTE images are inadequate to</text>
<text top="582" left="248" width="265" height="11" font="12">evaluate tricuspid valve morphology and function</text>
<text top="582" left="517" width="52" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.4-1)</a></text>
<text top="582" left="569" width="3" height="11" font="12">.</text>
<text top="628" left="94" width="10" height="9" font="5">IIa</text>
<text top="628" left="160" width="21" height="9" font="5">B-NR</text>
<text top="616" left="234" width="566" height="11" font="12">3. Electrophysiological study with or without catheter ablation can be useful in the diagnostic evaluation of</text>
<text top="631" left="248" width="529" height="11" font="12">adults with Ebstein anomaly and ventricular preexcitation but without supraventricular tachycardia</text>
<text top="647" left="248" width="107" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.4-3, S4.3.4-4)</a></text>
<text top="647" left="355" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#60">.</a></text>
<text top="693" left="94" width="10" height="9" font="5">IIa</text>
<text top="693" left="160" width="21" height="9" font="5">B-NR</text>
<text top="681" left="234" width="522" height="11" font="12">4. In adults with Ebstein anomaly, electrophysiological study (and catheter ablation, if needed) is</text>
<text top="696" left="249" width="541" height="11" font="12">reasonable before surgical intervention on the tricuspid valve even in the absence of preexcitation or</text>
<text top="712" left="249" width="150" height="11" font="12">supraventricular tachycardia</text>
<text top="712" left="403" width="54" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.4-5)</a></text>
<text top="712" left="457" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#60">.</a></text>
<text top="753" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="797" left="97" width="3" height="9" font="5">I</text>
<text top="797" left="160" width="21" height="9" font="5">B-NR</text>
<text top="785" left="234" width="396" height="11" font="12">5. Surgical repair or reoperation for adults with Ebstein anomaly and signi</text>
<text top="783" left="630" width="170" height="15" font="12">ﬁcant TR is recommended when</text>
<text top="801" left="248" width="544" height="11" font="12">one or more of the following are present: HF symptoms, objective evidence of worsening exercise ca-</text>
<text top="816" left="248" width="385" height="11" font="12">pacity, progressive RV systolic dysfunction by echocardiography or CMR</text>
<text top="816" left="637" width="50" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.4-6</a></text>
<text top="814" left="687" width="61" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">–S4.3.4-10)</a></text>
<text top="816" left="749" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#60">.</a></text>
<text top="862" left="97" width="3" height="9" font="5">I</text>
<text top="862" left="160" width="20" height="9" font="5">C-LD</text>
<text top="850" left="234" width="566" height="11" font="12">6. Catheter ablation is recommended for adults with Ebstein anomaly and high-risk pathway conduction or</text>
<text top="866" left="249" width="152" height="11" font="12">multiple accessory pathways</text>
<text top="866" left="405" width="167" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.4-3, S4.3.4-11, S4.3.4-12)</a></text>
<text top="866" left="572" width="3" height="11" font="12">.</text>
<text top="912" left="94" width="10" height="9" font="5">IIa</text>
<text top="912" left="160" width="21" height="9" font="5">B-NR</text>
<text top="900" left="234" width="393" height="11" font="12">7. Surgical repair or reoperation for adults with Ebstein anomaly and signi</text>
<text top="898" left="627" width="173" height="15" font="12">ﬁcant TR can be beneﬁcial in the</text>
<text top="915" left="247" width="537" height="11" font="12">presence of progressive RV enlargement, systemic desaturation from right-to-left atrial shunt, para-</text>
<text top="931" left="247" width="261" height="11" font="12">doxical embolism, and/or atrial tachyarrhythmias</text>
<text top="931" left="513" width="173" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.4-11, S4.3.4-13, S4.3.4-14)</a></text>
<text top="931" left="685" width="3" height="11" font="12">.</text>
<text top="977" left="94" width="10" height="9" font="5">IIb</text>
<text top="977" left="160" width="21" height="9" font="5">B-NR</text>
<text top="965" left="234" width="549" height="11" font="12">8. Bidirectional superior cavopulmonary (Glenn) anastomosis at time of Ebstein anomaly repair may be</text>
<text top="980" left="249" width="551" height="11" font="12">considered for adults when severe RV dilation or severe RV systolic dysfunction is present, LV function is</text>
<text top="996" left="249" width="432" height="11" font="12">preserved, and left atrial pressure and LV end diastolic pressure are not elevated</text>
<text top="996" left="684" width="112" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.4-6, S4.3.4-15)</a></text>
<text top="996" left="796" width="3" height="11" font="12">.</text>
<text top="1021" left="63" width="13" height="8" font="5">See</text>
<text top="1021" left="78" width="42" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#12">Section 3.3</a></text>
<text top="1021" left="122" width="453" height="8" font="5">for recommendations on who should perform surgeries, cardiac catheterization, and other procedures in these patients;</text>
<text top="1021" left="578" width="42" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="1021" left="622" width="179" height="8" font="5">for recommendations on diagnostic evaluation;</text>
<text top="1033" left="63" width="14" height="8" font="5">and</text>
<text top="1033" left="80" width="34" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#37">Table 26</a></text>
<text top="1033" left="117" width="166" height="8" font="5">for routine testing and follow-up intervals.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="788" width="19" height="9" font="5">1529</text>
</page>
<page number="37" position="absolute" top="0" left="0" height="1160" width="864">
<text top="472" left="108" width="132" height="11" font="2">4.3.5. Tetralogy of Fallot</text>
<text top="493" left="108" width="47" height="12" font="2">See also</text>
<text top="493" left="158" width="47" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#38">Table 27</a></text>
<text top="493" left="206" width="3" height="12" font="2">.</text>
<text top="149" left="112" width="54" height="10" font="15">T A B L E 2 6</text>
<text top="149" left="179" width="334" height="10" font="16">Ebstein Anomaly: Routine and Follow-Up and Testing Intervals</text>
<text top="173" left="108" width="100" height="9" font="13">Frequency of Routine</text>
<text top="185" left="108" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="173" left="311" width="61" height="9" font="13">Physiological</text>
<text top="185" left="308" width="36" height="9" font="13">Stage A</text>
<text top="185" left="344" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#37">*</a></text>
<text top="185" left="352" width="22" height="9" font="13">(mo)</text>
<text top="173" left="453" width="61" height="9" font="13">Physiological</text>
<text top="185" left="451" width="35" height="9" font="13">Stage B</text>
<text top="185" left="487" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#37">*</a></text>
<text top="185" left="495" width="22" height="9" font="13">(mo)</text>
<text top="173" left="595" width="61" height="9" font="13">Physiological</text>
<text top="185" left="593" width="35" height="9" font="13">Stage C</text>
<text top="185" left="629" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#37">*</a></text>
<text top="185" left="636" width="22" height="9" font="13">(mo)</text>
<text top="173" left="738" width="61" height="9" font="13">Physiological</text>
<text top="185" left="735" width="36" height="9" font="13">Stage D</text>
<text top="185" left="771" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#37">*</a></text>
<text top="185" left="779" width="22" height="9" font="13">(mo)</text>
<text top="204" left="108" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="204" left="329" width="9" height="9" font="13">12</text>
<text top="203" left="338" width="15" height="12" font="13">–24</text>
<text top="204" left="479" width="9" height="9" font="13">12</text>
<text top="204" left="616" width="6" height="9" font="13">6</text>
<text top="203" left="622" width="13" height="12" font="13">–12</text>
<text top="204" left="761" width="5" height="9" font="13">3</text>
<text top="203" left="766" width="10" height="12" font="13">–6</text>
<text top="224" left="108" width="17" height="9" font="13">ECG</text>
<text top="224" left="329" width="9" height="9" font="13">12</text>
<text top="222" left="338" width="15" height="12" font="13">–24</text>
<text top="224" left="479" width="9" height="9" font="13">12</text>
<text top="224" left="621" width="9" height="9" font="13">12</text>
<text top="224" left="764" width="9" height="9" font="13">12</text>
<text top="243" left="108" width="17" height="9" font="13">CXR</text>
<text top="243" left="319" width="44" height="9" font="13">As needed</text>
<text top="243" left="462" width="44" height="9" font="13">As needed</text>
<text top="243" left="614" width="9" height="9" font="13">12</text>
<text top="241" left="623" width="15" height="12" font="13">–24</text>
<text top="243" left="756" width="9" height="9" font="13">12</text>
<text top="241" left="765" width="15" height="12" font="13">–24</text>
<text top="262" left="108" width="16" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#37">TTE</a></text>
<text top="260" left="123" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#37">†</a></text>
<text top="262" left="329" width="9" height="9" font="13">12</text>
<text top="260" left="338" width="15" height="12" font="13">–24</text>
<text top="262" left="472" width="9" height="9" font="13">12</text>
<text top="260" left="481" width="15" height="12" font="13">–24</text>
<text top="262" left="621" width="9" height="9" font="13">12</text>
<text top="262" left="764" width="9" height="9" font="13">12</text>
<text top="281" left="108" width="62" height="9" font="13">Pulse oximetry</text>
<text top="281" left="336" width="11" height="9" font="13">24</text>
<text top="281" left="479" width="9" height="9" font="13">12</text>
<text top="281" left="606" width="40" height="9" font="13">Each visit</text>
<text top="281" left="748" width="40" height="9" font="13">Each visit</text>
<text top="300" left="108" width="62" height="9" font="13">Holter monitor</text>
<text top="300" left="319" width="44" height="9" font="13">As needed</text>
<text top="300" left="462" width="44" height="9" font="13">As needed</text>
<text top="300" left="621" width="11" height="9" font="13">24</text>
<text top="300" left="756" width="9" height="9" font="13">12</text>
<text top="299" left="765" width="15" height="12" font="13">–24</text>
<text top="320" left="108" width="19" height="9" font="13">CMR</text>
<text top="318" left="127" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#37">‡</a></text>
<text top="320" left="131" width="20" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#37">/CCT</a></text>
<text top="320" left="151" width="5" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#37">§</a></text>
<text top="320" left="335" width="12" height="9" font="13">60</text>
<text top="320" left="478" width="11" height="9" font="13">36</text>
<text top="320" left="613" width="11" height="9" font="13">24</text>
<text top="318" left="624" width="15" height="12" font="13">–36</text>
<text top="320" left="756" width="9" height="9" font="13">12</text>
<text top="318" left="765" width="15" height="12" font="13">–24</text>
<text top="339" left="108" width="53" height="9" font="13">Exercise test</text>
<text top="337" left="161" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#37">k</a></text>
<text top="339" left="336" width="11" height="9" font="13">36</text>
<text top="339" left="471" width="11" height="9" font="13">24</text>
<text top="337" left="482" width="15" height="12" font="13">–36</text>
<text top="339" left="621" width="11" height="9" font="13">24</text>
<text top="339" left="764" width="9" height="9" font="13">12</text>
<text top="363" left="108" width="17" height="8" font="5">*See</text>
<text top="363" left="128" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="363" left="189" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="361" left="318" width="60" height="11" font="5">ﬁcation system.</text>
<text top="373" left="108" width="471" height="11" font="5">†Routine TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise.</text>
<text top="385" left="108" width="694" height="11" font="5">‡CMR may be indicated for assessment of right ventricular size and function. Baseline study is recommended with periodic follow-up CMR, with frequency of repeat imaging</text>
<text top="398" left="108" width="163" height="8" font="5">determined by anatomic and physiological</text>
<text top="397" left="274" width="33" height="11" font="5">ﬁndings.</text>
<text top="410" left="108" width="398" height="8" font="5">§CCT may be used if CMR is not feasible; the frequency should be weighed against radiation exposure.</text>
<text top="421" left="108" width="241" height="11" font="5"><a href="1-s2.0-S0735109718368451-main.html#11">k6-minute </a>walk test or CPET, depending on clinical indication.</text>
<text top="436" left="116" width="686" height="8" font="5">ACHD indicates adult congenital heart disease; CCT, cardiac computed tomography; CMR, cardiovascular magnetic resonance imaging; CPET, cardiopulmonary exercise test; CXR,</text>
<text top="448" left="108" width="296" height="8" font="5">chest x ray; ECG, electrocardiogram; and TTE, transthoracic echocardiogram.</text>
<text top="521" left="63" width="148" height="11" font="20">Recommendations for TOF</text>
<text top="535" left="63" width="393" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="535" left="461" width="155" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 43</a></text>
<text top="535" left="616" width="31" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">. </a>(See</text>
<text top="535" left="652" width="73" height="11" font="4"><a href="">Section 4.3.6</a></text>
<text top="535" left="726" width="67" height="11" font="20"><a href="">. </a>for recom-</text>
<text top="550" left="63" width="385" height="11" font="20">mendations regarding evaluation and management of right ventricle</text>
<text top="548" left="448" width="96" height="15" font="20">–to-PA conduits.)</text>
<text top="591" left="89" width="19" height="10" font="13">COR</text>
<text top="591" left="161" width="18" height="10" font="13">LOE</text>
<text top="591" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="618" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="662" left="97" width="3" height="9" font="5">I</text>
<text top="662" left="160" width="21" height="9" font="5">B-NR</text>
<text top="650" left="234" width="545" height="11" font="12">1. CMR is useful to quantify ventricular size and function, pulmonary valve function, pulmonary artery</text>
<text top="666" left="246" width="358" height="11" font="12">anatomy and left heart abnormalities in patients with repaired TOF</text>
<text top="666" left="608" width="51" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.5-1)</a></text>
<text top="666" left="660" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#60">.</a></text>
<text top="712" left="97" width="3" height="9" font="5">I</text>
<text top="712" left="160" width="21" height="9" font="5">B-NR</text>
<text top="700" left="234" width="390" height="11" font="12">2. Coronary artery compression testing is indicated before right ventricle</text>
<text top="698" left="624" width="141" height="15" font="12">–to-PA conduit stenting or</text>
<text top="715" left="248" width="247" height="11" font="12">transcatheter valve placement in repaired TOF</text>
<text top="715" left="499" width="53" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.5-2)</a></text>
<text top="715" left="552" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#60">.</a></text>
<text top="761" left="94" width="10" height="9" font="5">IIa</text>
<text top="761" left="160" width="21" height="9" font="5">B-NR</text>
<text top="749" left="234" width="551" height="11" font="12">3. Programmed ventricular stimulation can be useful to risk stratify adults with TOF and additional risk</text>
<text top="765" left="248" width="81" height="11" font="12">factors for SCD</text>
<text top="765" left="333" width="48" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.5-3</a></text>
<text top="763" left="381" width="55" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">–S4.3.5-8)</a></text>
<text top="765" left="436" width="3" height="11" font="12">.</text>
<text top="811" left="94" width="10" height="9" font="5">IIa</text>
<text top="811" left="160" width="20" height="9" font="5">C-EO</text>
<text top="798" left="234" width="554" height="11" font="12">4. In patients with repaired TOF, cardiac catheterization with angiography, if indicated, is reasonable to</text>
<text top="814" left="249" width="516" height="11" font="12">assess hemodynamics when adequate data cannot be obtained noninvasively in the setting of an</text>
<text top="830" left="249" width="537" height="11" font="12">arrhythmia, HF, unexplained ventricular dysfunction, suspected pulmonary hypertension or cyanosis.</text>
<text top="866" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="911" left="97" width="3" height="9" font="5">I</text>
<text top="911" left="160" width="21" height="9" font="5">B-NR</text>
<text top="898" left="234" width="549" height="11" font="12">5. Pulmonary valve replacement (surgical or percutaneous) for relief of symptoms is recommended for</text>
<text top="914" left="248" width="536" height="11" font="12">patients with repaired TOF and moderate or greater PR with cardiovascular symptoms not otherwise</text>
<text top="930" left="248" width="51" height="11" font="12">explained</text>
<text top="930" left="303" width="49" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.5-9</a></text>
<text top="928" left="352" width="57" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">–S4.3.5-11)</a></text>
<text top="930" left="410" width="3" height="11" font="12">.</text>
<text top="976" left="94" width="10" height="9" font="5">IIa</text>
<text top="976" left="160" width="21" height="9" font="5">B-NR</text>
<text top="964" left="234" width="566" height="11" font="12">6. Pulmonary valve replacement (surgical or percutaneous) is reasonable for preservation of ventricular size</text>
<text top="979" left="249" width="551" height="11" font="12">and function in asymptomatic patients with repaired TOF and ventricular enlargement or dysfunction and</text>
<text top="995" left="249" width="125" height="11" font="12">moderate or greater PR</text>
<text top="995" left="378" width="157" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.5-1, S4.3.5-9, S4.3.5-12</a></text>
<text top="993" left="535" width="60" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">–S4.3.5-14)</a></text>
<text top="995" left="595" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#60">.</a></text>
<text top="1041" left="94" width="10" height="9" font="5">IIa</text>
<text top="1041" left="160" width="21" height="9" font="5">B-NR</text>
<text top="1029" left="234" width="521" height="11" font="12">7. Primary prevention ICD therapy is reasonable in adults with TOF and multiple risk factors for SCD</text>
<text top="1029" left="757" width="42" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.5-</a></text>
<text top="1045" left="247" width="11" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">15</a></text>
<text top="1042" left="259" width="58" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">–S4.3.5-17)</a></text>
<text top="1045" left="318" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#60">.</a></text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="19" height="9" font="5">1530</text>
</page>
<page number="38" position="absolute" top="0" left="0" height="1160" width="864">
<text top="206" left="94" width="10" height="9" font="5">IIb</text>
<text top="206" left="160" width="20" height="9" font="5">C-EO</text>
<text top="194" left="234" width="566" height="11" font="12">8. Surgical pulmonary valve replacement may be reasonable for adults with repaired TOF and moderate or</text>
<text top="210" left="249" width="329" height="11" font="12">greater PR with other lesions requiring surgical interventions.</text>
<text top="256" left="94" width="10" height="9" font="5">IIb</text>
<text top="256" left="160" width="20" height="9" font="5">C-EO</text>
<text top="244" left="234" width="566" height="11" font="12">9. Pulmonary valve replacement, in addition to arrhythmia management, may be considered for adults with</text>
<text top="260" left="249" width="398" height="11" font="12">repaired TOF and moderate or greater PR and ventricular tachyarrhythmia.</text>
<text top="291" left="63" width="13" height="8" font="5">See</text>
<text top="291" left="78" width="42" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#12">Section 3.3</a></text>
<text top="291" left="122" width="453" height="8" font="5">for recommendations on who should perform surgeries, cardiac catheterization, and other procedures in these patients;</text>
<text top="291" left="578" width="42" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="291" left="622" width="179" height="8" font="5">for recommendations on diagnostic evaluation;</text>
<text top="303" left="63" width="33" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#39">Figure 4</a></text>
<text top="303" left="99" width="309" height="8" font="5">for a diagnostic and treatment algorithm for repaired TOF with residual PR; and</text>
<text top="303" left="411" width="34" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#38">Table 27</a></text>
<text top="303" left="447" width="166" height="8" font="5">for routine testing and follow-up intervals.</text>
<text top="149" left="69" width="61" height="10" font="15">(continued)</text>
<text top="352" left="67" width="53" height="10" font="15">T A B L E 2 7</text>
<text top="352" left="135" width="243" height="10" font="16">TOF: Routine Follow-Up and Testing Intervals</text>
<text top="376" left="63" width="100" height="9" font="13">Frequency of Routine</text>
<text top="388" left="63" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="376" left="266" width="61" height="9" font="13">Physiological</text>
<text top="388" left="263" width="36" height="9" font="13">Stage <a href="1-s2.0-S0735109718368451-main.html#38">A</a></text>
<text top="388" left="299" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#38">*</a></text>
<text top="388" left="307" width="22" height="9" font="13">(mo)</text>
<text top="376" left="408" width="61" height="9" font="13">Physiological</text>
<text top="388" left="406" width="35" height="9" font="13">Stage B</text>
<text top="388" left="442" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#38">*</a></text>
<text top="388" left="450" width="22" height="9" font="13">(mo)</text>
<text top="376" left="550" width="61" height="9" font="13">Physiological</text>
<text top="388" left="549" width="35" height="9" font="13">Stage C</text>
<text top="388" left="584" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#38">*</a></text>
<text top="388" left="592" width="22" height="9" font="13">(mo)</text>
<text top="376" left="693" width="61" height="9" font="13">Physiological</text>
<text top="388" left="690" width="36" height="9" font="13">Stage <a href="1-s2.0-S0735109718368451-main.html#38">D</a></text>
<text top="388" left="726" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#38">*</a></text>
<text top="388" left="734" width="22" height="9" font="13">(mo)</text>
<text top="407" left="63" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="407" left="284" width="9" height="9" font="13">12</text>
<text top="405" left="293" width="15" height="12" font="13">–24</text>
<text top="407" left="435" width="9" height="9" font="13">12</text>
<text top="407" left="572" width="6" height="9" font="13">6</text>
<text top="405" left="577" width="13" height="12" font="13">–12</text>
<text top="407" left="716" width="5" height="9" font="13">3</text>
<text top="405" left="721" width="10" height="12" font="13">–6</text>
<text top="426" left="63" width="17" height="9" font="13">ECG</text>
<text top="426" left="291" width="11" height="9" font="13">24</text>
<text top="426" left="435" width="9" height="9" font="13">12</text>
<text top="426" left="577" width="9" height="9" font="13">12</text>
<text top="426" left="719" width="9" height="9" font="13">12</text>
<text top="445" left="63" width="16" height="9" font="13">TTE</text>
<text top="444" left="79" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#38">†</a></text>
<text top="445" left="291" width="11" height="9" font="13">24</text>
<text top="445" left="427" width="9" height="9" font="13">12</text>
<text top="444" left="436" width="15" height="12" font="13">–24</text>
<text top="445" left="577" width="9" height="9" font="13">12</text>
<text top="445" left="714" width="6" height="9" font="13">6</text>
<text top="444" left="720" width="13" height="12" font="13">–12</text>
<text top="465" left="63" width="62" height="9" font="13">Pulse oximetry</text>
<text top="465" left="275" width="44" height="9" font="13">As needed</text>
<text top="465" left="417" width="44" height="9" font="13">As needed</text>
<text top="465" left="561" width="40" height="9" font="13">Each visit</text>
<text top="465" left="704" width="40" height="9" font="13">Each visit</text>
<text top="484" left="63" width="62" height="9" font="13">Holter monitor</text>
<text top="484" left="275" width="44" height="9" font="13">As needed</text>
<text top="484" left="417" width="44" height="9" font="13">As needed</text>
<text top="484" left="569" width="9" height="9" font="13">12</text>
<text top="482" left="578" width="15" height="12" font="13">–24</text>
<text top="484" left="712" width="9" height="9" font="13">12</text>
<text top="482" left="720" width="15" height="12" font="13">–24</text>
<text top="503" left="63" width="19" height="9" font="13">CMR</text>
<text top="501" left="82" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#38">‡</a></text>
<text top="503" left="87" width="20" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#38">/CCT</a></text>
<text top="503" left="106" width="5" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#38">§</a></text>
<text top="503" left="291" width="11" height="9" font="13">36</text>
<text top="503" left="426" width="11" height="9" font="13">24</text>
<text top="501" left="437" width="15" height="12" font="13">–36</text>
<text top="503" left="569" width="9" height="9" font="13">12</text>
<text top="501" left="578" width="15" height="12" font="13">–24</text>
<text top="503" left="712" width="9" height="9" font="13">12</text>
<text top="501" left="720" width="15" height="12" font="13">–24</text>
<text top="522" left="63" width="53" height="9" font="13">Exercise test</text>
<text top="521" left="116" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#38">k</a></text>
<text top="522" left="283" width="11" height="9" font="13">36</text>
<text top="521" left="294" width="16" height="12" font="13">–60</text>
<text top="522" left="425" width="11" height="9" font="13">24</text>
<text top="521" left="436" width="16" height="12" font="13">–60</text>
<text top="522" left="569" width="9" height="9" font="13">12</text>
<text top="521" left="578" width="15" height="12" font="13">–24</text>
<text top="522" left="712" width="9" height="9" font="13">12</text>
<text top="521" left="720" width="15" height="12" font="13">–24</text>
<text top="546" left="63" width="17" height="8" font="5">*See</text>
<text top="546" left="83" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="546" left="144" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="544" left="273" width="60" height="11" font="5">ﬁcation system.</text>
<text top="556" left="63" width="471" height="11" font="5">†Routine TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise.</text>
<text top="568" left="63" width="694" height="11" font="5">‡CMR may be indicated for assessment of right ventricular size and function, pulmonary valve function, pulmonary artery anatomy and left heart abnormalities. Baseline study is</text>
<text top="582" left="63" width="469" height="8" font="5">recommended with periodic follow-up CMR, with frequency of repeat imaging determined by anatomic and physiological</text>
<text top="580" left="534" width="33" height="11" font="5">ﬁndings.</text>
<text top="594" left="63" width="503" height="8" font="5">§CCT may be used if CMR is not feasible and to evaluate origin and course of the coronary arteries, and cross-sectional imaging status</text>
<text top="592" left="566" width="191" height="11" font="5">—post-stent therapy. If cardiac CCT is used instead</text>
<text top="606" left="63" width="303" height="8" font="5">of CMR imaging, the frequency should be weighed against radiation exposure.</text>
<text top="616" left="63" width="241" height="11" font="5"><a href="1-s2.0-S0735109718368451-main.html#11">k</a>6-minute walk test or CPET, depending on clinical indication.</text>
<text top="632" left="71" width="686" height="8" font="5">ACHD indicates adult congenital heart disease; CCT, cardiac computed tomography; CMR, cardiovascular magnetic resonance imaging; CPET, cardiopulmonary exercise test; ECG,</text>
<text top="644" left="63" width="324" height="8" font="5">electrocardiogram; TOF, tetralogy of Fallot; and TTE, transthoracic echocardiogram.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="790" width="17" height="9" font="5">1531</text>
</page>
<page number="39" position="absolute" top="0" left="0" height="1160" width="864">
<text top="153" left="125" width="46" height="11" font="23">FIGURE 4</text>
<text top="154" left="179" width="295" height="9" font="24">Pulmonary Valve Replacement in Patients With TOF Repair and PR</text>
<text top="585" left="473" width="5" height="10" font="5">≥</text>
<text top="916" left="125" width="658" height="9" font="13">*Symptoms may included dyspnea, chest pain, and/or exercise intolerance referable to PR or otherwise unexplained. ACHD indicates adult congenital heart</text>
<text top="931" left="125" width="658" height="9" font="13">disease; HF, heart failure; LV, left ventricular; LVEDV, left ventricular end diastolic volume; PR, pulmonary regurgitation; RV, right ventricular; RVEDV, right</text>
<text top="946" left="125" width="647" height="9" font="13">ventricular end diastolic volume; RVEDVI, right ventricular end diastolic volume index; RVESVI, right ventricular end systolic volume index; RVOT, right</text>
<text top="961" left="125" width="62" height="9" font="13">ventricular out</text>
<text top="959" left="187" width="596" height="12" font="13">ﬂow tract; RVSP, right ventricular systolic pressure; and TOF, tetralogy of Fallot. †See recommendation 6 supporting text in the full text of the</text>
<text top="974" left="125" width="409" height="12" font="13">“2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease” (P-9).</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="18" height="9" font="5">1532</text>
</page>
<page number="40" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="112" height="11" font="2">4.3.6. Right Ventricle</text>
<text top="141" left="175" width="156" height="15" font="2">–to-Pulmonary Artery Conduit</text>
<text top="164" left="63" width="47" height="12" font="2">See also</text>
<text top="165" left="114" width="49" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#40">Table 28</a></text>
<text top="164" left="163" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#40">.</a></text>
<text top="211" left="63" width="210" height="11" font="20">Recommendations for Right Ventricle</text>
<text top="209" left="274" width="84" height="15" font="20">–to-PA Conduit</text>
<text top="225" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="225" left="457" width="155" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 44</a></text>
<text top="225" left="612" width="3" height="11" font="20">.</text>
<text top="266" left="89" width="19" height="10" font="13">COR</text>
<text top="266" left="161" width="18" height="10" font="13">LOE</text>
<text top="266" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="294" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="338" left="97" width="3" height="9" font="5">I</text>
<text top="338" left="160" width="21" height="9" font="5">B-NR</text>
<text top="326" left="234" width="566" height="11" font="12">1. Coronary artery compression testing with simultaneous coronary angiography and high-pressure balloon</text>
<text top="342" left="246" width="300" height="11" font="12">dilation in the conduit is indicated before right ventricle</text>
<text top="340" left="547" width="248" height="15" font="12">–to-PA conduit stenting or transcatheter valve</text>
<text top="357" left="246" width="55" height="11" font="12">placement</text>
<text top="357" left="306" width="105" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.6-1, S4.3.6-2)</a></text>
<text top="357" left="411" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#60">.</a></text>
<text top="403" left="97" width="3" height="9" font="5">I</text>
<text top="403" left="160" width="21" height="9" font="5">B-NR</text>
<text top="391" left="234" width="221" height="11" font="12">2. In patients with stented right ventricle</text>
<text top="389" left="455" width="341" height="15" font="12">–to-PA conduits and worsening PS or PR, evaluation for conduit</text>
<text top="407" left="248" width="244" height="11" font="12">complications should be performed, including</text>
<text top="405" left="496" width="303" height="15" font="12">ﬂuoroscopy to evaluate for stent fracture and blood cul-</text>
<text top="422" left="248" width="112" height="11" font="12">tures to assess for IE</text>
<text top="422" left="364" width="107" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.6-3, S4.3.6-4)</a></text>
<text top="422" left="471" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#60">.</a></text>
<text top="468" left="94" width="10" height="9" font="5">IIa</text>
<text top="468" left="160" width="20" height="9" font="5">C-LD</text>
<text top="456" left="234" width="167" height="11" font="12">3. In adults with right ventricle</text>
<text top="454" left="401" width="379" height="15" font="12">–to-PA conduit and arrhythmia, congestive HF, unexplained ventricular</text>
<text top="472" left="248" width="478" height="11" font="12">dysfunction or cyanosis cardiac catheterization is reasonable to assess the hemodynamics</text>
<text top="472" left="729" width="53" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.6-5,</a></text>
<text top="488" left="248" width="50" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">S4.3.6-6)</a></text>
<text top="488" left="298" width="3" height="11" font="12">.</text>
<text top="524" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="568" left="94" width="10" height="9" font="5">IIa</text>
<text top="568" left="160" width="21" height="9" font="5">B-NR</text>
<text top="556" left="234" width="92" height="11" font="12">4. Right ventricle</text>
<text top="554" left="326" width="474" height="15" font="12">–to-PA conduit intervention is reasonable for adults with right ventricle–to-PA conduit and</text>
<text top="572" left="249" width="306" height="11" font="12">moderate or greater PR or moderate or greater stenosis (</text>
<text top="572" left="555" width="45" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#33">Table 22</a></text>
<text top="572" left="600" width="197" height="11" font="12">) with reduced functional capacity or</text>
<text top="588" left="249" width="57" height="11" font="12">arrhythmia</text>
<text top="588" left="310" width="49" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">(S4.3.6-7</a></text>
<text top="586" left="359" width="58" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#60">–S4.3.6-11)</a></text>
<text top="588" left="418" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#60">.</a></text>
<text top="633" left="94" width="10" height="9" font="5">IIb</text>
<text top="633" left="160" width="21" height="9" font="5">B-NR</text>
<text top="621" left="234" width="92" height="11" font="12">5. Right ventricle</text>
<text top="619" left="326" width="441" height="15" font="12">–to-PA conduit intervention may be reasonable for asymptomatic adults with right</text>
<text top="637" left="248" width="46" height="11" font="12">ventricle</text>
<text top="635" left="294" width="505" height="15" font="12">–to-PA conduit and severe stenosis or severe regurgitation with reduced RV ejection fraction or</text>
<text top="653" left="248" width="58" height="11" font="12">RV dilation</text>
<text top="653" left="310" width="54" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.3.6-12</a></text>
<text top="651" left="365" width="61" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">–S4.3.6-14)</a></text>
<text top="653" left="426" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#61">.</a></text>
<text top="678" left="63" width="13" height="8" font="5">See</text>
<text top="678" left="78" width="42" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#12">Section 3.3</a></text>
<text top="678" left="122" width="453" height="8" font="5">for recommendations on who should perform surgeries, cardiac catheterization, and other procedures in these patients;</text>
<text top="678" left="578" width="42" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="678" left="622" width="179" height="8" font="5">for recommendations on diagnostic evaluation;</text>
<text top="690" left="63" width="14" height="8" font="5">and</text>
<text top="690" left="80" width="35" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#40">Table 28</a></text>
<text top="690" left="117" width="166" height="8" font="5">for routine testing and follow-up intervals.</text>
<text top="754" left="67" width="54" height="10" font="15">T A B L E 2 8</text>
<text top="754" left="135" width="80" height="10" font="16">Right Ventricle</text>
<text top="752" left="215" width="302" height="14" font="16">–to-PA Conduit: Routine Follow-Up and Testing Intervals</text>
<text top="778" left="63" width="100" height="9" font="13">Frequency of Routine</text>
<text top="790" left="63" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="778" left="266" width="61" height="9" font="13">Physiological</text>
<text top="790" left="264" width="36" height="9" font="13">Stage A</text>
<text top="790" left="300" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#40">*</a></text>
<text top="790" left="308" width="22" height="9" font="13">(mo)</text>
<text top="778" left="409" width="61" height="9" font="13">Physiological</text>
<text top="790" left="407" width="35" height="9" font="13">Stage <a href="1-s2.0-S0735109718368451-main.html#40">B</a></text>
<text top="790" left="442" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#40">*</a></text>
<text top="790" left="450" width="22" height="9" font="13">(mo)</text>
<text top="778" left="551" width="61" height="9" font="13">Physiological</text>
<text top="790" left="549" width="35" height="9" font="13">Stage <a href="1-s2.0-S0735109718368451-main.html#40">C</a></text>
<text top="790" left="584" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#40">*</a></text>
<text top="790" left="592" width="22" height="9" font="13">(mo)</text>
<text top="778" left="694" width="61" height="9" font="13">Physiological</text>
<text top="790" left="692" width="36" height="9" font="13">Stage D</text>
<text top="790" left="728" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#40">*</a></text>
<text top="790" left="736" width="22" height="9" font="13">(mo)</text>
<text top="809" left="63" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="809" left="285" width="9" height="9" font="13">12</text>
<text top="808" left="294" width="15" height="12" font="13">–24</text>
<text top="809" left="435" width="9" height="9" font="13">12</text>
<text top="809" left="572" width="6" height="9" font="13">6</text>
<text top="808" left="578" width="13" height="12" font="13">–12</text>
<text top="809" left="717" width="5" height="9" font="13">3</text>
<text top="808" left="722" width="10" height="12" font="13">–6</text>
<text top="828" left="63" width="17" height="9" font="13">ECG</text>
<text top="828" left="285" width="9" height="9" font="13">12</text>
<text top="827" left="294" width="15" height="12" font="13">–24</text>
<text top="828" left="435" width="9" height="9" font="13">12</text>
<text top="828" left="578" width="9" height="9" font="13">12</text>
<text top="828" left="720" width="9" height="9" font="13">12</text>
<text top="848" left="63" width="16" height="9" font="13">TTE</text>
<text top="846" left="79" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#40">†</a></text>
<text top="848" left="285" width="9" height="9" font="13">12</text>
<text top="846" left="294" width="15" height="12" font="13">–24</text>
<text top="848" left="435" width="9" height="9" font="13">12</text>
<text top="848" left="578" width="9" height="9" font="13">12</text>
<text top="848" left="720" width="9" height="9" font="13">12</text>
<text top="867" left="63" width="19" height="9" font="13">CMR</text>
<text top="865" left="82" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#40">‡</a></text>
<text top="867" left="87" width="20" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#40">/CCT</a></text>
<text top="867" left="106" width="5" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#40">§</a></text>
<text top="867" left="283" width="11" height="9" font="13">36</text>
<text top="865" left="294" width="16" height="12" font="13">–60</text>
<text top="867" left="426" width="11" height="9" font="13">36</text>
<text top="865" left="437" width="16" height="12" font="13">–60</text>
<text top="867" left="570" width="9" height="9" font="13">12</text>
<text top="865" left="579" width="15" height="12" font="13">–24</text>
<text top="867" left="713" width="9" height="9" font="13">12</text>
<text top="865" left="722" width="15" height="12" font="13">–24</text>
<text top="886" left="63" width="53" height="9" font="13">Exercise test</text>
<text top="884" left="116" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#40">k</a></text>
<text top="886" left="275" width="44" height="9" font="13">As needed</text>
<text top="886" left="418" width="44" height="9" font="13">As needed</text>
<text top="886" left="570" width="9" height="9" font="13">12</text>
<text top="884" left="579" width="15" height="12" font="13">–24</text>
<text top="886" left="713" width="9" height="9" font="13">12</text>
<text top="884" left="722" width="15" height="12" font="13">–24</text>
<text top="910" left="63" width="17" height="8" font="5">*See</text>
<text top="910" left="83" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="910" left="144" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="908" left="273" width="60" height="11" font="5">ﬁcation system.</text>
<text top="920" left="63" width="471" height="11" font="5">†Routine TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise.</text>
<text top="932" left="63" width="695" height="11" font="5">‡CMR may be indicated for assessment of right ventricular size and function and valvular function, conduit anatomy and pulmonary artery anatomy. Baseline study is recommended</text>
<text top="946" left="63" width="411" height="8" font="5">with periodic follow-up CMR, with frequency of repeat imaging determined by anatomic and physiological</text>
<text top="944" left="477" width="33" height="11" font="5">ﬁndings.</text>
<text top="958" left="63" width="335" height="8" font="5">§CCT may be used if CMR is not feasible and to evaluate cross-sectional imaging status</text>
<text top="956" left="398" width="360" height="11" font="5">–post-stent therapy. If CCT is used instead of CMR imaging, the frequency should be weighed</text>
<text top="970" left="63" width="104" height="8" font="5">against radiation exposure.</text>
<text top="980" left="63" width="241" height="11" font="5"><a href="1-s2.0-S0735109718368451-main.html#11">k</a>6-minute walk test or CPET, depending on clinical indication.</text>
<text top="996" left="71" width="687" height="8" font="5">ACHD indicates adult congenital heart disease; CCT, cardiac computed tomography; CMR, cardiovascular magnetic resonance; CPET, cardiopulmonary exercise test; ECG, electro-</text>
<text top="1008" left="63" width="288" height="8" font="5">cardiogram; PA, pulmonary artery; and TTE, transthoracic echocardiogram.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="789" width="18" height="9" font="5">1533</text>
</page>
<page number="41" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="114" height="11" font="12">4.4. Complex Lesions</text>
<text top="165" left="108" width="214" height="11" font="2">4.4.1. Transposition of the Great Arteries</text>
<text top="186" left="108" width="333" height="12" font="3">4.4.1.1. Transposition of the Great Arteries With Atrial Switch</text>
<text top="208" left="108" width="47" height="12" font="2">See also</text>
<text top="208" left="158" width="49" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#41">Table 29</a></text>
<text top="208" left="207" width="3" height="12" font="2">.</text>
<text top="257" left="63" width="266" height="11" font="20">Recommendations for d-TGA With Atrial Switch</text>
<text top="271" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="271" left="457" width="154" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 45</a></text>
<text top="271" left="611" width="3" height="11" font="20">.</text>
<text top="312" left="89" width="19" height="10" font="13">COR</text>
<text top="312" left="161" width="18" height="10" font="13">LOE</text>
<text top="312" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="339" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="384" left="97" width="3" height="9" font="5">I</text>
<text top="384" left="160" width="20" height="9" font="5">C-EO</text>
<text top="372" left="234" width="566" height="11" font="12">1. Ambulatory monitoring for bradycardia or sinus node dysfunction is recommended for adults with d-TGA</text>
<text top="387" left="246" width="468" height="11" font="12">with atrial switch, especially if treated with beta blockers or other rate-slowing agents.</text>
<text top="433" left="97" width="3" height="9" font="5">I</text>
<text top="433" left="160" width="20" height="9" font="5">C-EO</text>
<text top="421" left="234" width="566" height="11" font="12">2. Adults with d-TGA with atrial switch repair should undergo annual imaging with either echocardiography</text>
<text top="437" left="248" width="413" height="11" font="12">or CMR to evaluate for common long-term complications of the atrial switch.</text>
<text top="483" left="94" width="10" height="9" font="5">IIa</text>
<text top="483" left="160" width="20" height="9" font="5">C-LD</text>
<text top="471" left="234" width="327" height="11" font="12">3. Assessment for a communication through the interatrial baf</text>
<text top="469" left="561" width="239" height="15" font="12">ﬂe or venous stenosis is reasonable for adults</text>
<text top="486" left="248" width="546" height="11" font="12">with d-TGA with atrial switch, particularly if transvenous pacemaker/ICD implantation is considered or</text>
<text top="502" left="248" width="134" height="11" font="12">leads are already present</text>
<text top="502" left="386" width="59" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.1.1-1)</a></text>
<text top="502" left="446" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#61">.</a></text>
<text top="539" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="584" left="97" width="3" height="9" font="5">I</text>
<text top="584" left="160" width="21" height="9" font="5">B-NR</text>
<text top="571" left="234" width="521" height="11" font="12">4. GDMT with appropriate attention to the need for anticoagulation is recommended to promptly</text>
<text top="587" left="249" width="540" height="11" font="12">restore sinus rhythm for adults with d-TGA with atrial switch repair presenting with atrial arrhythmia</text>
<text top="603" left="249" width="61" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.1.1-2)</a></text>
<text top="603" left="310" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#61">.</a></text>
<text top="628" left="63" width="13" height="8" font="5">See</text>
<text top="628" left="78" width="42" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#12">Section 3.3</a></text>
<text top="628" left="122" width="453" height="8" font="5">for recommendations on who should perform surgeries, cardiac catheterization, and other procedures in these patients;</text>
<text top="628" left="578" width="42" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="628" left="622" width="179" height="8" font="5">for recommendations on diagnostic evaluation;</text>
<text top="640" left="63" width="34" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#41">Table 29</a></text>
<text top="640" left="100" width="183" height="8" font="5">for routine testing and follow-up intervals; and</text>
<text top="640" left="286" width="106" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 25</a></text>
<text top="640" left="395" width="87" height="8" font="5">for referenced studies.</text>
<text top="693" left="112" width="54" height="10" font="15">T A B L E 2 9</text>
<text top="693" left="179" width="355" height="10" font="16">d-TGA With Atrial Switch: Routine Follow-Up and Testing Intervals</text>
<text top="717" left="108" width="100" height="9" font="13">Frequency of Routine</text>
<text top="729" left="108" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="717" left="311" width="61" height="9" font="13">Physiological</text>
<text top="729" left="308" width="36" height="9" font="13">Stage A</text>
<text top="729" left="344" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#41">*</a></text>
<text top="729" left="352" width="22" height="9" font="13">(mo)</text>
<text top="717" left="453" width="61" height="9" font="13">Physiological</text>
<text top="729" left="451" width="35" height="9" font="13">Stage B</text>
<text top="729" left="487" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#41">*</a></text>
<text top="729" left="495" width="22" height="9" font="13">(mo)</text>
<text top="717" left="595" width="61" height="9" font="13">Physiological</text>
<text top="729" left="593" width="35" height="9" font="13">Stage C</text>
<text top="729" left="629" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#41">*</a></text>
<text top="729" left="636" width="22" height="9" font="13">(mo)</text>
<text top="717" left="738" width="61" height="9" font="13">Physiological</text>
<text top="729" left="735" width="36" height="9" font="13">Stage D</text>
<text top="729" left="771" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#41">*</a></text>
<text top="729" left="779" width="22" height="9" font="13">(mo)</text>
<text top="748" left="108" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="748" left="337" width="9" height="9" font="13">12</text>
<text top="748" left="479" width="9" height="9" font="13">12</text>
<text top="748" left="616" width="6" height="9" font="13">6</text>
<text top="746" left="622" width="13" height="12" font="13">–12</text>
<text top="748" left="761" width="5" height="9" font="13">3</text>
<text top="746" left="766" width="10" height="12" font="13">–6</text>
<text top="767" left="108" width="17" height="9" font="13">ECG</text>
<text top="767" left="337" width="9" height="9" font="13">12</text>
<text top="767" left="479" width="9" height="9" font="13">12</text>
<text top="767" left="616" width="6" height="9" font="13">6</text>
<text top="766" left="622" width="13" height="12" font="13">–12</text>
<text top="767" left="759" width="6" height="9" font="13">6</text>
<text top="766" left="765" width="13" height="12" font="13">–12</text>
<text top="786" left="108" width="16" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#41">TTE</a></text>
<text top="785" left="123" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#41">†</a></text>
<text top="786" left="329" width="9" height="9" font="13">12</text>
<text top="785" left="338" width="15" height="12" font="13">–24</text>
<text top="786" left="472" width="9" height="9" font="13">12</text>
<text top="785" left="481" width="15" height="12" font="13">–24</text>
<text top="786" left="621" width="9" height="9" font="13">12</text>
<text top="786" left="764" width="9" height="9" font="13">12</text>
<text top="806" left="108" width="62" height="9" font="13">Pulse oximetry</text>
<text top="806" left="337" width="9" height="9" font="13">12</text>
<text top="806" left="479" width="9" height="9" font="13">12</text>
<text top="806" left="606" width="40" height="9" font="13">Each visit</text>
<text top="806" left="748" width="40" height="9" font="13">Each visit</text>
<text top="825" left="108" width="62" height="9" font="13">Holter monitor</text>
<text top="825" left="336" width="11" height="9" font="13">24</text>
<text top="825" left="479" width="11" height="9" font="13">24</text>
<text top="825" left="621" width="9" height="9" font="13">12</text>
<text top="825" left="764" width="9" height="9" font="13">12</text>
<text top="844" left="108" width="19" height="9" font="13">CMR</text>
<text top="842" left="127" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#41">‡</a></text>
<text top="844" left="131" width="20" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#41">/CCT</a></text>
<text top="844" left="151" width="5" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#41">§</a></text>
<text top="844" left="328" width="11" height="9" font="13">24</text>
<text top="842" left="339" width="15" height="12" font="13">–36</text>
<text top="844" left="479" width="11" height="9" font="13">24</text>
<text top="844" left="614" width="9" height="9" font="13">12</text>
<text top="842" left="623" width="15" height="12" font="13">–24</text>
<text top="844" left="756" width="9" height="9" font="13">12</text>
<text top="842" left="765" width="15" height="12" font="13">–24</text>
<text top="863" left="108" width="53" height="9" font="13">Exercise test</text>
<text top="862" left="161" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#41">k</a></text>
<text top="863" left="336" width="11" height="9" font="13">36</text>
<text top="863" left="478" width="11" height="9" font="13">36</text>
<text top="863" left="621" width="11" height="9" font="13">24</text>
<text top="863" left="764" width="9" height="9" font="13">12</text>
<text top="887" left="108" width="17" height="8" font="5">*See</text>
<text top="887" left="128" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="887" left="189" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="885" left="318" width="60" height="11" font="5">ﬁcation system.</text>
<text top="897" left="108" width="471" height="11" font="5">†Routine TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise.</text>
<text top="909" left="108" width="694" height="11" font="5">‡CMR may be indicated for assessment of ventricular size and function, systemic and venous bafﬂe obstruction and leaks, and valvular function. Baseline study is recommended with</text>
<text top="923" left="108" width="379" height="8" font="5">periodic follow-up CMR, with frequency of repeat imaging determined anatomic and physiological</text>
<text top="921" left="490" width="33" height="11" font="5">ﬁndings.</text>
<text top="935" left="108" width="335" height="8" font="5">§CCT may be used if CMR is not feasible and to evaluate cross-sectional imaging status</text>
<text top="933" left="442" width="359" height="11" font="5">–post-stent therapy. If CCT is used instead of CMR imaging, the frequency should be weighed</text>
<text top="947" left="108" width="104" height="8" font="5">against radiation exposure.</text>
<text top="957" left="108" width="349" height="11" font="5"><a href="1-s2.0-S0735109718368451-main.html#11">k6-minute </a>exercise test or cardiopulmonary exercise test, depending on clinical indication.</text>
<text top="973" left="116" width="686" height="8" font="5">ACHD indicates adult congenital heart disease; CCT, cardiac computed tomography; CMR, cardiovascular magnetic resonance imaging; d-TGA, dextro-transposition of the great</text>
<text top="985" left="108" width="282" height="8" font="5">arteries; ECG, electrocardiogram; and TTE, transthoracic echocardiogram.</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="19" height="9" font="5">1534</text>
</page>
<page number="42" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="310" height="12" font="3">4.4.1.2. Transposition of the Great Arteries With Arterial</text>
<text top="161" left="107" width="36" height="12" font="3">Switch</text>
<text top="183" left="63" width="47" height="12" font="2">See also</text>
<text top="183" left="114" width="49" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#42">Table 30</a></text>
<text top="183" left="163" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#42">.</a></text>
<text top="227" left="63" width="278" height="11" font="20">Recommendations for d-TGA With Arterial Switch</text>
<text top="242" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="242" left="457" width="155" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 46</a></text>
<text top="242" left="612" width="3" height="11" font="20">.</text>
<text top="283" left="89" width="19" height="10" font="13">COR</text>
<text top="283" left="161" width="18" height="10" font="13">LOE</text>
<text top="283" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="310" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="354" left="97" width="3" height="9" font="5">I</text>
<text top="354" left="160" width="20" height="9" font="5">C-LD</text>
<text top="342" left="234" width="566" height="11" font="12">1. Baseline and serial imaging with either echocardiography or CMR should be performed in adults with d-</text>
<text top="358" left="246" width="548" height="11" font="12">TGA with arterial switch who have neoaortic dilation, valve dysfunction or PA or branch PA stenosis or</text>
<text top="373" left="246" width="123" height="11" font="12">ventricular dysfunction</text>
<text top="373" left="373" width="56" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.1.2-1</a></text>
<text top="371" left="430" width="63" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">–S4.4.1.2-3)</a></text>
<text top="373" left="493" width="3" height="11" font="12">.</text>
<text top="419" left="97" width="3" height="9" font="5">I</text>
<text top="419" left="160" width="20" height="9" font="5">C-EO</text>
<text top="407" left="234" width="566" height="11" font="12">2. Coronary revascularization for adults with d-TGA with arterial switch should be planned by surgeons or</text>
<text top="423" left="248" width="548" height="11" font="12">interventional cardiologists with expertise in revascularization in collaboration with ACHD providers to</text>
<text top="439" left="248" width="341" height="11" font="12">ensure coronary and pulmonary artery anatomy are understood.</text>
<text top="484" left="94" width="10" height="9" font="5">IIa</text>
<text top="484" left="160" width="21" height="9" font="5">B-NR</text>
<text top="472" left="234" width="566" height="11" font="12">3. It is reasonable to perform anatomic evaluation of coronary artery patency (catheter angiography, or CT</text>
<text top="488" left="248" width="404" height="11" font="12">or MR angiography) in asymptomatic adults with d-TGA with arterial switch</text>
<text top="488" left="656" width="124" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.1.2-4, S4.4.1.2-5)</a></text>
<text top="488" left="780" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#61">.</a></text>
<text top="534" left="94" width="10" height="9" font="5">IIa</text>
<text top="534" left="160" width="20" height="9" font="5">C-EO</text>
<text top="522" left="234" width="541" height="11" font="12">4. Physiological tests of myocardial perfusion for adults with d-TGA after arterial switch can be bene</text>
<text top="520" left="775" width="25" height="15" font="12">ﬁcial</text>
<text top="538" left="249" width="316" height="11" font="12">for assessing symptoms suggestive of myocardial ischemia.</text>
<text top="583" left="94" width="10" height="9" font="5">IIa</text>
<text top="583" left="160" width="20" height="9" font="5">C-EO</text>
<text top="571" left="234" width="555" height="11" font="12">5. GDMT is reasonable to determine the need for coronary revascularization for adults with d-TGA after</text>
<text top="587" left="248" width="76" height="11" font="12">arterial switch</text>
<text top="587" left="328" width="59" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.1.2-6</a></text>
<text top="585" left="387" width="64" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">–S4.4.1.2-8)</a></text>
<text top="587" left="451" width="3" height="11" font="12">.</text>
<text top="623" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="668" left="94" width="10" height="9" font="5">IIa</text>
<text top="668" left="160" width="20" height="9" font="5">C-EO</text>
<text top="656" left="234" width="552" height="11" font="12">6. GDMT is reasonable to determine indications for aortic valve replacement in adults with d-TGA after</text>
<text top="671" left="249" width="299" height="11" font="12">arterial switch with severe neoaortic valve regurgitation</text>
<text top="671" left="552" width="63" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.1.2-6)</a></text>
<text top="671" left="616" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#61">.</a></text>
<text top="717" left="94" width="10" height="9" font="5">IIa</text>
<text top="717" left="160" width="20" height="9" font="5">C-EO</text>
<text top="705" left="234" width="547" height="11" font="12">7. Catheter or surgical intervention for PS is reasonable in adults with d-TGA after arterial switch with</text>
<text top="721" left="247" width="355" height="11" font="12">symptoms of HF or decreased exercise capacity attributable to PS.</text>
<text top="752" left="63" width="13" height="8" font="5">See</text>
<text top="752" left="78" width="42" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#12">Section 3.3</a></text>
<text top="752" left="122" width="453" height="8" font="5">for recommendations on who should perform surgeries, cardiac catheterization, and other procedures in these patients;</text>
<text top="752" left="578" width="42" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="752" left="622" width="179" height="8" font="5">for recommendations on diagnostic evaluation;</text>
<text top="764" left="63" width="14" height="8" font="5">and</text>
<text top="764" left="80" width="35" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#42">Table 30</a></text>
<text top="764" left="117" width="166" height="8" font="5">for routine testing and follow-up intervals.</text>
<text top="810" left="67" width="55" height="10" font="15">T A B L E 3 0</text>
<text top="810" left="135" width="366" height="10" font="16">d-TGA With Arterial Switch: Routine Follow-Up and Testing Intervals</text>
<text top="834" left="63" width="100" height="9" font="13">Frequency of Routine</text>
<text top="846" left="63" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="834" left="266" width="61" height="9" font="13">Physiological</text>
<text top="846" left="263" width="36" height="9" font="13">Stage <a href="1-s2.0-S0735109718368451-main.html#42">A</a></text>
<text top="846" left="299" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#42">*</a></text>
<text top="846" left="307" width="22" height="9" font="13">(mo)</text>
<text top="834" left="408" width="61" height="9" font="13">Physiological</text>
<text top="846" left="406" width="35" height="9" font="13">Stage B</text>
<text top="846" left="442" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#42">*</a></text>
<text top="846" left="450" width="22" height="9" font="13">(mo)</text>
<text top="834" left="550" width="61" height="9" font="13">Physiological</text>
<text top="846" left="549" width="35" height="9" font="13">Stage C</text>
<text top="846" left="584" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#42">*</a></text>
<text top="846" left="592" width="22" height="9" font="13">(mo)</text>
<text top="834" left="693" width="61" height="9" font="13">Physiological</text>
<text top="846" left="690" width="36" height="9" font="13">Stage <a href="1-s2.0-S0735109718368451-main.html#42">D</a></text>
<text top="846" left="726" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#42">*</a></text>
<text top="846" left="734" width="22" height="9" font="13">(mo)</text>
<text top="865" left="63" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="865" left="284" width="9" height="9" font="13">12</text>
<text top="864" left="293" width="15" height="12" font="13">–24</text>
<text top="865" left="435" width="9" height="9" font="13">12</text>
<text top="865" left="572" width="6" height="9" font="13">6</text>
<text top="864" left="577" width="13" height="12" font="13">–12</text>
<text top="865" left="716" width="5" height="9" font="13">3</text>
<text top="864" left="721" width="10" height="12" font="13">–6</text>
<text top="885" left="63" width="17" height="9" font="13">ECG</text>
<text top="885" left="284" width="9" height="9" font="13">12</text>
<text top="883" left="293" width="15" height="12" font="13">–24</text>
<text top="885" left="427" width="9" height="9" font="13">12</text>
<text top="883" left="436" width="15" height="12" font="13">–24</text>
<text top="885" left="577" width="9" height="9" font="13">12</text>
<text top="885" left="720" width="6" height="9" font="13">6</text>
<text top="904" left="63" width="16" height="9" font="13">TTE</text>
<text top="902" left="79" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#42">†</a></text>
<text top="904" left="284" width="9" height="9" font="13">12</text>
<text top="902" left="293" width="15" height="12" font="13">–24</text>
<text top="904" left="427" width="9" height="9" font="13">12</text>
<text top="902" left="436" width="15" height="12" font="13">–24</text>
<text top="904" left="577" width="9" height="9" font="13">12</text>
<text top="904" left="719" width="9" height="9" font="13">12</text>
<text top="923" left="63" width="19" height="9" font="13">CMR</text>
<text top="921" left="82" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#42">‡</a></text>
<text top="923" left="87" width="20" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#42">/CCT</a></text>
<text top="923" left="106" width="5" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#42">§</a></text>
<text top="923" left="283" width="11" height="9" font="13">36</text>
<text top="921" left="294" width="16" height="12" font="13">–60</text>
<text top="923" left="426" width="11" height="9" font="13">24</text>
<text top="921" left="437" width="15" height="12" font="13">–36</text>
<text top="923" left="569" width="9" height="9" font="13">12</text>
<text top="921" left="578" width="15" height="12" font="13">–24</text>
<text top="923" left="712" width="9" height="9" font="13">12</text>
<text top="921" left="720" width="15" height="12" font="13">–24</text>
<text top="942" left="63" width="53" height="9" font="13">Exercise test</text>
<text top="941" left="116" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#42">k</a></text>
<text top="942" left="283" width="11" height="9" font="13">36</text>
<text top="941" left="294" width="16" height="12" font="13">–60</text>
<text top="942" left="425" width="11" height="9" font="13">36</text>
<text top="941" left="436" width="16" height="12" font="13">–60</text>
<text top="942" left="568" width="11" height="9" font="13">24</text>
<text top="941" left="579" width="15" height="12" font="13">–36</text>
<text top="942" left="712" width="9" height="9" font="13">12</text>
<text top="941" left="720" width="15" height="12" font="13">–24</text>
<text top="966" left="63" width="79" height="8" font="5">*See ACHD AP classi</text>
<text top="964" left="142" width="28" height="11" font="5">ﬁcation</text>
<text top="966" left="173" width="30" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#11">Table 4</a></text>
<text top="966" left="203" width="2" height="8" font="5"><a href="1-s2.0-S0735109718368451-main.html#11">.</a></text>
<text top="976" left="63" width="471" height="11" font="5">†Routine TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise.</text>
<text top="988" left="63" width="694" height="11" font="5">‡CMR may be indicated for assessment of neoaortic size, the origin and proximal course of the coronary arteries, branch pulmonary arteries, ventricular function and valvular function.</text>
<text top="1002" left="63" width="536" height="8" font="5">Baseline study is recommended with periodic follow-up CMR, with frequency of repeat imaging determined by anatomic and physiological</text>
<text top="1000" left="601" width="33" height="11" font="5">ﬁndings.</text>
<text top="1014" left="63" width="694" height="8" font="5">§CCT or catheterization once to establish knowledge of coronary artery anatomy and then as warranted by clinical condition. CCT may be used if CMR is not feasible and to evaluate</text>
<text top="1026" left="63" width="694" height="8" font="5">coronary artery anatomy and cross-sectional imaging status-post stent therapy. If CCT is used instead of CMR imaging, the frequency should be weighed against radiation exposure.</text>
<text top="1036" left="63" width="254" height="11" font="5"><a href="1-s2.0-S0735109718368451-main.html#11">k</a>6-minute exercise test or CPET, depending on clinical indication.</text>
<text top="1052" left="71" width="686" height="8" font="5">ACHD indicates adult congenital heart disease; CCT, cardiac computed tomography; CMR, cardiovascular magnetic resonance imaging; CPET, cardiopulmonary exercise test; d-TGA,</text>
<text top="1064" left="63" width="413" height="8" font="5">dextro-transposition of the great arteries; ECG, electrocardiogram; and TTE, transthoracic echocardiogram.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="789" width="18" height="9" font="5">1535</text>
</page>
<page number="43" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="284" height="12" font="3">4.4.1.3. Congenitally Corrected Transposition of the</text>
<text top="161" left="152" width="77" height="12" font="3">Great Arteries</text>
<text top="183" left="108" width="47" height="12" font="2">See also</text>
<text top="183" left="158" width="46" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#43">Table 31</a></text>
<text top="183" left="205" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#43">.</a></text>
<text top="220" left="63" width="455" height="11" font="20">Recommendations for Congenitally Corrected Transposition of the Great Arteries</text>
<text top="234" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="234" left="457" width="154" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 47</a></text>
<text top="234" left="611" width="3" height="11" font="20">.</text>
<text top="275" left="89" width="19" height="10" font="13">COR</text>
<text top="275" left="161" width="18" height="10" font="13">LOE</text>
<text top="275" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="302" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="347" left="94" width="10" height="9" font="5">IIa</text>
<text top="347" left="160" width="20" height="9" font="5">C-LD</text>
<text top="335" left="234" width="544" height="11" font="12">1. CMR is reasonable in adults with CCTGA to determine systemic RV dimensions and systolic function</text>
<text top="350" left="246" width="122" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.1.3-1, S4.4.1.3-2)</a></text>
<text top="350" left="368" width="3" height="11" font="12">.</text>
<text top="387" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="432" left="97" width="3" height="9" font="5">I</text>
<text top="432" left="160" width="21" height="9" font="5">B-NR</text>
<text top="420" left="234" width="554" height="11" font="12">2. Tricuspid valve replacement is recommended for symptomatic adults with CCTGA and severe TR, and</text>
<text top="435" left="248" width="319" height="11" font="12">preserved or mildly depressed systemic ventricular function</text>
<text top="435" left="571" width="124" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.1.3-3, S4.4.1.3-4)</a></text>
<text top="435" left="695" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#61">.</a></text>
<text top="481" left="94" width="10" height="9" font="5">IIa</text>
<text top="481" left="160" width="20" height="9" font="5">C-LD</text>
<text top="469" left="234" width="542" height="11" font="12">3. Tricuspid valve replacement is reasonable for asymptomatic adults with CCTGA and severe TR with</text>
<text top="485" left="248" width="283" height="11" font="12">dilation or mild dysfunction of the systemic ventricle</text>
<text top="485" left="535" width="62" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.1.3-3)</a></text>
<text top="485" left="597" width="3" height="11" font="12">.</text>
<text top="531" left="94" width="10" height="9" font="5">IIb</text>
<text top="531" left="160" width="21" height="9" font="5">B-NR</text>
<text top="519" left="234" width="543" height="11" font="12">4. Conduit intervention/replacement may be considered for adults with CCTGA and symptomatic sub-</text>
<text top="534" left="249" width="129" height="11" font="12">pulmonary left ventricle</text>
<text top="532" left="378" width="395" height="15" font="12">–to-PA conduit dysfunction, recognizing that unloading the subpulmonary</text>
<text top="550" left="249" width="447" height="11" font="12">ventricle may have a detrimental impact on systemic atrioventricular valve function</text>
<text top="550" left="699" width="62" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.1.3-5)</a></text>
<text top="550" left="762" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#61">.</a></text>
<text top="575" left="63" width="13" height="8" font="5">See</text>
<text top="575" left="78" width="42" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#12">Section 3.3</a></text>
<text top="575" left="122" width="453" height="8" font="5">for recommendations on who should perform surgeries, cardiac catheterization, and other procedures in these patients;</text>
<text top="575" left="578" width="42" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="575" left="622" width="179" height="8" font="5">for recommendations on diagnostic evaluation;</text>
<text top="587" left="63" width="14" height="8" font="5">and</text>
<text top="587" left="80" width="33" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#43">Table 31</a></text>
<text top="587" left="115" width="166" height="8" font="5">for routine testing and follow-up intervals.</text>
<text top="704" left="113" width="52" height="10" font="15">T A B L E 3 1</text>
<text top="704" left="179" width="257" height="10" font="16">CCTGA: Routine Follow-Up and Testing Intervals</text>
<text top="728" left="108" width="100" height="9" font="13">Frequency of Routine</text>
<text top="740" left="108" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="728" left="311" width="61" height="9" font="13">Physiological</text>
<text top="740" left="308" width="36" height="9" font="13">Stage <a href="1-s2.0-S0735109718368451-main.html#43">A</a></text>
<text top="740" left="344" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#43">*</a></text>
<text top="740" left="352" width="22" height="9" font="13">(mo)</text>
<text top="728" left="453" width="61" height="9" font="13">Physiological</text>
<text top="740" left="451" width="35" height="9" font="13">Stage B</text>
<text top="740" left="487" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#43">*</a></text>
<text top="740" left="495" width="22" height="9" font="13">(mo)</text>
<text top="728" left="596" width="61" height="9" font="13">Physiological</text>
<text top="740" left="594" width="35" height="9" font="13">Stage C</text>
<text top="740" left="629" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#43">*</a></text>
<text top="740" left="637" width="22" height="9" font="13">(mo)</text>
<text top="728" left="738" width="61" height="9" font="13">Physiological</text>
<text top="740" left="736" width="36" height="9" font="13">Stage D</text>
<text top="740" left="772" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#43">*</a></text>
<text top="740" left="780" width="22" height="9" font="13">(mo)</text>
<text top="759" left="108" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="759" left="337" width="9" height="9" font="13">12</text>
<text top="759" left="480" width="9" height="9" font="13">12</text>
<text top="759" left="617" width="6" height="9" font="13">6</text>
<text top="758" left="623" width="13" height="12" font="13">–12</text>
<text top="759" left="761" width="5" height="9" font="13">3</text>
<text top="758" left="766" width="10" height="12" font="13">–6</text>
<text top="779" left="108" width="17" height="9" font="13">ECG</text>
<text top="779" left="337" width="9" height="9" font="13">12</text>
<text top="779" left="480" width="9" height="9" font="13">12</text>
<text top="779" left="622" width="9" height="9" font="13">12</text>
<text top="779" left="764" width="9" height="9" font="13">12</text>
<text top="798" left="108" width="16" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#43">TTE</a></text>
<text top="796" left="123" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#43">†</a></text>
<text top="798" left="329" width="9" height="9" font="13">12</text>
<text top="796" left="338" width="15" height="12" font="13">–24</text>
<text top="798" left="480" width="9" height="9" font="13">12</text>
<text top="798" left="622" width="9" height="9" font="13">12</text>
<text top="798" left="764" width="9" height="9" font="13">12</text>
<text top="817" left="108" width="62" height="9" font="13">Pulse oximetry</text>
<text top="817" left="319" width="44" height="9" font="13">As needed</text>
<text top="817" left="462" width="44" height="9" font="13">As needed</text>
<text top="817" left="606" width="40" height="9" font="13">Each visit</text>
<text top="817" left="749" width="40" height="9" font="13">Each visit</text>
<text top="836" left="108" width="62" height="9" font="13">Holter monitor</text>
<text top="836" left="329" width="9" height="9" font="13">12</text>
<text top="835" left="338" width="16" height="12" font="13">–60</text>
<text top="836" left="471" width="9" height="9" font="13">12</text>
<text top="835" left="480" width="16" height="12" font="13">–60</text>
<text top="836" left="614" width="9" height="9" font="13">12</text>
<text top="835" left="623" width="15" height="12" font="13">–36</text>
<text top="836" left="764" width="9" height="9" font="13">12</text>
<text top="855" left="108" width="19" height="9" font="13">CMR</text>
<text top="854" left="127" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#43">‡</a></text>
<text top="855" left="131" width="20" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#43">/CCT</a></text>
<text top="855" left="151" width="5" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#43">§</a></text>
<text top="855" left="328" width="11" height="9" font="13">36</text>
<text top="854" left="338" width="16" height="12" font="13">–60</text>
<text top="855" left="471" width="11" height="9" font="13">36</text>
<text top="854" left="481" width="16" height="12" font="13">–60</text>
<text top="855" left="614" width="9" height="9" font="13">12</text>
<text top="854" left="623" width="15" height="12" font="13">–24</text>
<text top="855" left="764" width="9" height="9" font="13">12</text>
<text top="875" left="108" width="53" height="9" font="13">Exercise test</text>
<text top="873" left="161" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#43">k</a></text>
<text top="875" left="328" width="11" height="9" font="13">36</text>
<text top="873" left="338" width="16" height="12" font="13">–60</text>
<text top="875" left="471" width="11" height="9" font="13">36</text>
<text top="873" left="481" width="16" height="12" font="13">–60</text>
<text top="875" left="614" width="9" height="9" font="13">12</text>
<text top="873" left="623" width="15" height="12" font="13">–24</text>
<text top="875" left="764" width="9" height="9" font="13">12</text>
<text top="898" left="108" width="17" height="8" font="5">*See</text>
<text top="898" left="128" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="898" left="189" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="897" left="318" width="60" height="11" font="5">ﬁcation system.</text>
<text top="909" left="108" width="471" height="11" font="5">†Routine TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise.</text>
<text top="921" left="108" width="694" height="11" font="5">‡CMR may be indicated for assessment of ventricular size and function and valvular function. Baseline study is recommended with periodic follow-up CMR, with frequency of repeat</text>
<text top="934" left="108" width="196" height="8" font="5">imaging determined by anatomic and physiological</text>
<text top="933" left="307" width="33" height="11" font="5">ﬁndings.</text>
<text top="946" left="108" width="550" height="8" font="5">§CCT may be used if CMR is not feasible. If CCT is used instead of CMR imaging, the frequency should be weighed against radiation exposure.</text>
<text top="957" left="108" width="241" height="11" font="5"><a href="1-s2.0-S0735109718368451-main.html#11">k6-minute </a>walk test or CPET, depending on clinical indication.</text>
<text top="972" left="116" width="686" height="8" font="5">ACHD indicates adult congenital heart disease; CCT, cardiac computed tomography; CCTGA, congenitally corrected transposition of the great arteries; CMR, cardiovascular magnetic</text>
<text top="984" left="108" width="471" height="8" font="5">resonance imaging; CPET, cardiopulmonary exercise test; ECG, electrocardiogram; and TTE, transthoracic echocardiogram.</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="19" height="9" font="5">1536</text>
</page>
<page number="44" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="333" height="11" font="2">4.4.2. Fontan Palliation of Single Ventricle Physiology (Including</text>
<text top="161" left="98" width="256" height="11" font="2">Tricuspid Atresia and Double Inlet Left Ventricle)</text>
<text top="182" left="63" width="47" height="12" font="2">See also</text>
<text top="183" left="114" width="47" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#45">Table 32</a></text>
<text top="182" left="161" width="3" height="12" font="2">.</text>
<text top="212" left="63" width="395" height="11" font="20">Recommendations for Fontan Palliation of Single Ventricle Physiology</text>
<text top="227" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="227" left="457" width="155" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 48</a></text>
<text top="227" left="612" width="3" height="11" font="20">.</text>
<text top="268" left="89" width="19" height="10" font="13">COR</text>
<text top="268" left="161" width="18" height="10" font="13">LOE</text>
<text top="268" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="295" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="339" left="97" width="3" height="9" font="5">I</text>
<text top="339" left="160" width="20" height="9" font="5">C-LD</text>
<text top="327" left="234" width="538" height="11" font="12">1. New presentation of an atrial tachyarrhythmia in adults with Fontan palliation should be managed</text>
<text top="343" left="246" width="553" height="11" font="12">promptly and include prevention of thromboembolic events and consultation with an electrophysiologist</text>
<text top="359" left="246" width="102" height="11" font="12">with CHD expertise</text>
<text top="359" left="353" width="105" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.2-1, S4.4.2-2)</a></text>
<text top="359" left="458" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#61">.</a></text>
<text top="397" left="97" width="3" height="9" font="5">I</text>
<text top="397" left="160" width="20" height="9" font="5">C-EO</text>
<text top="385" left="234" width="538" height="11" font="12">2. Adults after Fontan palliation should be evaluated annually with either echocardiography or CMR.</text>
<text top="446" left="97" width="3" height="9" font="5">I</text>
<text top="446" left="160" width="20" height="9" font="5">C-EO</text>
<text top="434" left="234" width="566" height="11" font="12">3. Cardiac catheterization should be performed in adults before initial Fontan surgery or revision of a prior</text>
<text top="449" left="248" width="525" height="11" font="12">Fontan connection to assess suitability of preintervention hemodynamics for Fontan physiology or</text>
<text top="465" left="248" width="201" height="11" font="12">revision of a prior Fontan connection.</text>
<text top="511" left="97" width="3" height="9" font="5">I</text>
<text top="511" left="160" width="20" height="9" font="5">C-EO</text>
<text top="499" left="234" width="557" height="11" font="12">4. New onset or worsening atrial tachyarrhythmias in adults with single ventricle after Fontan palliation</text>
<text top="514" left="249" width="551" height="11" font="12">should prompt a search for potential hemodynamic abnormalities, which may necessitate imaging and/or</text>
<text top="530" left="249" width="124" height="11" font="12">cardiac catheterization.</text>
<text top="568" left="94" width="10" height="9" font="5">IIa</text>
<text top="568" left="163" width="15" height="9" font="5">B-R</text>
<text top="556" left="234" width="566" height="11" font="12">5. In adults with Fontan palliation, it is reasonable to encourage a regular exercise program appropriate to</text>
<text top="572" left="248" width="70" height="11" font="12">their abilities</text>
<text top="572" left="322" width="49" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.2-3</a></text>
<text top="570" left="371" width="55" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">–S4.4.2-5)</a></text>
<text top="572" left="426" width="3" height="11" font="12">.</text>
<text top="618" left="94" width="10" height="9" font="5">IIa</text>
<text top="618" left="160" width="20" height="9" font="5">C-LD</text>
<text top="606" left="234" width="520" height="11" font="12">6. Imaging of the liver (ultrasonography, CMR, CT) and laboratory evaluation of liver function for</text>
<text top="604" left="758" width="41" height="15" font="12">ﬁbrosis,</text>
<text top="622" left="249" width="478" height="11" font="12">cirrhosis, and/or hepatocellular carcinoma are reasonable in adults after Fontan palliation</text>
<text top="622" left="731" width="55" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.2-6)</a></text>
<text top="622" left="786" width="3" height="11" font="12">.</text>
<text top="667" left="94" width="10" height="9" font="5">IIa</text>
<text top="667" left="160" width="20" height="9" font="5">C-EO</text>
<text top="655" left="234" width="566" height="11" font="12">7. In adults after Fontan palliation, it is reasonable to perform biochemical and hematological testing on an</text>
<text top="671" left="247" width="272" height="11" font="12">annual basis especially for liver and renal function.</text>
<text top="717" left="94" width="10" height="9" font="5">IIa</text>
<text top="717" left="160" width="20" height="9" font="5">C-LD</text>
<text top="705" left="234" width="544" height="11" font="12">8. Cardiac catheterization can be useful to evaluate a symptomatic adult after Fontan palliation when</text>
<text top="721" left="249" width="144" height="11" font="12">noninvasive testing is insuf</text>
<text top="718" left="394" width="125" height="15" font="12">ﬁcient to guide therapy</text>
<text top="721" left="523" width="107" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.2-7, S4.4.2-8)</a></text>
<text top="721" left="630" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#61">.</a></text>
<text top="766" left="94" width="10" height="9" font="5">IIa</text>
<text top="766" left="160" width="20" height="9" font="5">C-LD</text>
<text top="754" left="234" width="537" height="11" font="12">9. Evaluation for cardiac transplantation is reasonable in adults with Fontan palliation and signs and</text>
<text top="770" left="249" width="216" height="11" font="12">symptoms of protein-losing enteropathy</text>
<text top="770" left="469" width="50" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.2-9</a></text>
<text top="768" left="520" width="60" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">–S4.4.2-12)</a></text>
<text top="770" left="580" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#61">.</a></text>
<text top="816" left="94" width="10" height="9" font="5">IIb</text>
<text top="816" left="160" width="20" height="9" font="5">C-EO</text>
<text top="804" left="234" width="543" height="11" font="12">10. It may be reasonable to perform catheterization in asymptomatic adults after Fontan palliation to</text>
<text top="819" left="254" width="545" height="11" font="12">evaluate hemodynamics, oxygenation and cardiac function to guide optimal medical, interventional and/</text>
<text top="835" left="254" width="104" height="11" font="12">or surgical therapy.</text>
<text top="859" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="904" left="97" width="3" height="9" font="5">I</text>
<text top="904" left="160" width="20" height="9" font="5">C-EO</text>
<text top="892" left="234" width="546" height="11" font="12">11. Anticoagulation with a vitamin K antagonist is recommended for adults with Fontan palliation with</text>
<text top="907" left="251" width="539" height="11" font="12">known or suspected thrombus, thromboembolic events, or prior atrial arrhythmia, and no contraindi-</text>
<text top="923" left="251" width="142" height="11" font="12">cations to anticoagulation.</text>
<text top="969" left="94" width="10" height="9" font="5">IIa</text>
<text top="969" left="160" width="20" height="9" font="5">C-LD</text>
<text top="957" left="234" width="566" height="11" font="12">12. Catheter ablation can be useful in adults after Fontan palliation with intra-atrial reentrant tachycardia or</text>
<text top="973" left="253" width="121" height="11" font="12">focal atrial tachycardia</text>
<text top="973" left="378" width="54" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.2-13</a></text>
<text top="971" left="433" width="60" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">–S4.4.2-15)</a></text>
<text top="973" left="493" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#61">.</a></text>
<text top="1018" left="94" width="10" height="9" font="5">IIa</text>
<text top="1018" left="160" width="20" height="9" font="5">C-LD</text>
<text top="1006" left="234" width="565" height="11" font="12">13. Fontan revision surgery, including arrhythmia surgery as indicated, is reasonable for adults with atrio-</text>
<text top="1022" left="253" width="533" height="11" font="12">pulmonary Fontan connections with recurrent atrial tachyarrhythmias refractory to pharmacological</text>
<text top="1038" left="253" width="547" height="11" font="12">therapy and catheter ablation who have preserved systolic ventricular function and severe atrial dilation</text>
<text top="1053" left="253" width="55" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.2-16</a></text>
<text top="1051" left="308" width="61" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">–S4.4.2-18)</a></text>
<text top="1053" left="369" width="3" height="11" font="12">.</text>
<text top="1092" left="94" width="10" height="9" font="5">IIa</text>
<text top="1092" left="163" width="15" height="9" font="5">B-R</text>
<text top="1080" left="234" width="270" height="11" font="12">14. Pulmonary vasoactive medications can be bene</text>
<text top="1078" left="504" width="296" height="15" font="12">ﬁcial to improve exercise capacity in adults with Fontan</text>
<text top="1095" left="254" width="30" height="11" font="12">repair</text>
<text top="1095" left="288" width="55" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">(S4.4.2-19</a></text>
<text top="1093" left="344" width="61" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#61">–S4.4.2-25)</a></text>
<text top="1095" left="405" width="3" height="11" font="12">.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="790" width="18" height="9" font="5">1537</text>
</page>
<page number="45" position="absolute" top="0" left="0" height="1160" width="864">
<text top="720" left="108" width="190" height="11" font="2">4.4.3. Double Outlet Right Ventricle</text>
<text top="741" left="108" width="333" height="12" font="2">Double outlet right ventricle is an anatomic descriptor</text>
<text top="759" left="108" width="333" height="12" font="2">that includes abnormalities similar to TOF in some pa-</text>
<text top="777" left="108" width="333" height="12" font="2">tients (when the aorta is closely related to the VSD) and</text>
<text top="795" left="108" width="333" height="12" font="2">similar to d-TGA with a VSD in others (when the PA is</text>
<text top="813" left="108" width="333" height="12" font="2">more closely related to the VSD than the aorta). Repairs</text>
<text top="831" left="108" width="333" height="12" font="2">are predicated on the underlying anatomy and may</text>
<text top="849" left="108" width="311" height="12" font="2">involve VSD closure with relief of PS, right ventricle</text>
<text top="847" left="419" width="22" height="15" font="2">–to-</text>
<text top="867" left="108" width="333" height="12" font="2">PA conduit, or Rastelli-type repair. In severe cases, single-</text>
<text top="884" left="108" width="333" height="12" font="2">ventricle physiology may be present. Consequently, rec-</text>
<text top="902" left="108" width="333" height="12" font="2">ommendations for the management of a patient with</text>
<text top="719" left="468" width="333" height="12" font="2">double outlet right ventricle can generally be inferred in</text>
<text top="737" left="468" width="333" height="12" font="2">the recommendations for the lesion with the most similar</text>
<text top="755" left="468" width="333" height="12" font="2">anatomy and physiology (e.g., TOF can reasonably be</text>
<text top="773" left="468" width="206" height="12" font="2">based on the recommendations in</text>
<text top="773" left="680" width="76" height="12" font="4"><a href="1-s2.0-S0735109718368451-main.html#41">Section 4.4.1</a></text>
<text top="773" left="756" width="45" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#41">, </a>recog-</text>
<text top="791" left="468" width="333" height="12" font="2">nizing that a patient with double outlet right ventricle is</text>
<text top="809" left="468" width="278" height="12" font="2">more likely to have residual LVOT obstruction).</text>
<text top="844" left="468" width="244" height="11" font="2">4.4.4. Severe PAH and Eisenmenger Syndrome</text>
<text top="866" left="468" width="110" height="12" font="3">4.4.4.1. Severe PAH</text>
<text top="888" left="468" width="47" height="12" font="2">See also</text>
<text top="888" left="519" width="48" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#46">Table 33</a></text>
<text top="888" left="567" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#46">.</a></text>
<text top="149" left="68" width="61" height="10" font="15">(continued)</text>
<text top="210" left="94" width="10" height="9" font="5">IIb</text>
<text top="210" left="160" width="21" height="9" font="5">B-NR</text>
<text top="198" left="234" width="560" height="11" font="12">15. Antiplatelet therapy or anticoagulation with a vitamin K antagonist may be considered in adults after</text>
<text top="214" left="253" width="541" height="11" font="12">Fontan palliation without known or suspected thrombus, thromboembolic events, or prior arrhythmia</text>
<text top="229" left="253" width="61" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">(S4.4.2-26)</a></text>
<text top="229" left="314" width="3" height="11" font="12">.</text>
<text top="275" left="94" width="10" height="9" font="5">IIb</text>
<text top="275" left="160" width="20" height="9" font="5">C-LD</text>
<text top="263" left="234" width="553" height="11" font="12">16. Reoperation or intervention for structural/anatomic abnormalities in a Fontan palliated patient with</text>
<text top="279" left="254" width="373" height="11" font="12">symptoms or with failure of the Fontan circulation may be considered</text>
<text top="279" left="631" width="60" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">(S4.4.2-27)</a></text>
<text top="279" left="691" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#62">.</a></text>
<text top="311" left="63" width="13" height="8" font="5">See</text>
<text top="311" left="79" width="42" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#12">Section 3.3</a></text>
<text top="311" left="123" width="452" height="8" font="5">for recommendations on who should perform surgeries, cardiac catheterization and other procedures in these patients;</text>
<text top="311" left="577" width="42" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="311" left="622" width="179" height="8" font="5">for recommendations on diagnostic evaluation;</text>
<text top="323" left="63" width="14" height="8" font="5">and</text>
<text top="323" left="80" width="34" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#45">Table 32</a></text>
<text top="323" left="116" width="166" height="8" font="5">for routine testing and follow-up intervals.</text>
<text top="363" left="112" width="53" height="10" font="15">T A B L E 3 2</text>
<text top="363" left="179" width="313" height="10" font="16">Fontan Palliation: Routine Follow-Up and Testing Intervals</text>
<text top="388" left="108" width="100" height="9" font="13">Frequency of Routine</text>
<text top="400" left="108" width="105" height="9" font="13">Follow-Up and Testing</text>
<text top="388" left="311" width="61" height="9" font="13">Physiological</text>
<text top="400" left="308" width="36" height="9" font="13">Stage A</text>
<text top="400" left="344" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#45">*</a></text>
<text top="400" left="352" width="22" height="9" font="13">(mo)</text>
<text top="388" left="453" width="61" height="9" font="13">Physiological</text>
<text top="400" left="451" width="35" height="9" font="13">Stage B</text>
<text top="400" left="487" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#45">*</a></text>
<text top="400" left="495" width="22" height="9" font="13">(mo)</text>
<text top="388" left="595" width="61" height="9" font="13">Physiological</text>
<text top="400" left="593" width="35" height="9" font="13">Stage C</text>
<text top="400" left="629" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#45">*</a></text>
<text top="400" left="636" width="22" height="9" font="13">(mo)</text>
<text top="388" left="738" width="61" height="9" font="13">Physiological</text>
<text top="400" left="735" width="36" height="9" font="13">Stage D</text>
<text top="400" left="771" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#45">*</a></text>
<text top="400" left="779" width="22" height="9" font="13">(mo)</text>
<text top="419" left="108" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="419" left="337" width="9" height="9" font="13">12</text>
<text top="419" left="479" width="9" height="9" font="13">12</text>
<text top="419" left="623" width="6" height="9" font="13">6</text>
<text top="419" left="761" width="5" height="9" font="13">3</text>
<text top="417" left="766" width="10" height="12" font="13">–6</text>
<text top="438" left="108" width="17" height="9" font="13">ECG</text>
<text top="438" left="337" width="9" height="9" font="13">12</text>
<text top="438" left="479" width="9" height="9" font="13">12</text>
<text top="438" left="616" width="6" height="9" font="13">6</text>
<text top="436" left="622" width="13" height="12" font="13">–12</text>
<text top="438" left="765" width="6" height="9" font="13">6</text>
<text top="457" left="108" width="16" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#45">TTE</a></text>
<text top="455" left="123" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#45">†</a></text>
<text top="457" left="337" width="9" height="9" font="13">12</text>
<text top="457" left="479" width="9" height="9" font="13">12</text>
<text top="457" left="621" width="9" height="9" font="13">12</text>
<text top="457" left="764" width="9" height="9" font="13">12</text>
<text top="476" left="108" width="62" height="9" font="13">Pulse oximetry</text>
<text top="476" left="337" width="9" height="9" font="13">12</text>
<text top="476" left="479" width="9" height="9" font="13">12</text>
<text top="476" left="606" width="40" height="9" font="13">Each visit</text>
<text top="476" left="748" width="40" height="9" font="13">Each visit</text>
<text top="496" left="108" width="62" height="9" font="13">Holter monitor</text>
<text top="496" left="337" width="9" height="9" font="13">12</text>
<text top="496" left="479" width="9" height="9" font="13">12</text>
<text top="496" left="621" width="9" height="9" font="13">12</text>
<text top="496" left="764" width="9" height="9" font="13">12</text>
<text top="515" left="108" width="19" height="9" font="13">CMR</text>
<text top="513" left="127" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#45">‡</a></text>
<text top="515" left="131" width="20" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#45">/CCT</a></text>
<text top="515" left="151" width="5" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#45">§</a></text>
<text top="515" left="336" width="11" height="9" font="13">36</text>
<text top="515" left="479" width="11" height="9" font="13">24</text>
<text top="515" left="621" width="11" height="9" font="13">24</text>
<text top="515" left="763" width="11" height="9" font="13">24</text>
<text top="534" left="108" width="53" height="9" font="13">Exercise test</text>
<text top="532" left="161" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#45">k</a></text>
<text top="534" left="336" width="11" height="9" font="13">36</text>
<text top="534" left="479" width="11" height="9" font="13">24</text>
<text top="534" left="621" width="9" height="9" font="13">12</text>
<text top="534" left="764" width="9" height="9" font="13">12</text>
<text top="558" left="108" width="17" height="8" font="5">*See</text>
<text top="558" left="128" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="558" left="189" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="556" left="318" width="60" height="11" font="5">ﬁcation system.</text>
<text top="568" left="108" width="471" height="11" font="5">†Routine TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise.</text>
<text top="580" left="108" width="694" height="11" font="5">‡CMR may be indicated for assessment of the long-term sequelae of Fontan palliation: thrombosis, right-to-left shunts (e.g., fenestration. intrapulmonary atrioventricular malfor-</text>
<text top="594" left="108" width="694" height="8" font="5">mation), obstructive lesion, systemic atrioventricular valve dysfunction, ventricular size and function, collateral burden, and branch pulmonary artery obstruction. Baseline study is</text>
<text top="605" left="108" width="469" height="8" font="5">recommended with periodic follow-up CMR, with frequency of repeat imaging determined by anatomic and physiological</text>
<text top="604" left="579" width="33" height="11" font="5">ﬁndings.</text>
<text top="617" left="108" width="694" height="8" font="5">§CCT may be used if CMR is not feasible and to evaluate cross-sectional imaging status-post stent therapy. CCT with contrast injection in Fontan patients can be misleading; therefore,</text>
<text top="629" left="108" width="694" height="8" font="5">it should be done only when clinically indicated and when it can be appropriately protocoled and interpreted. If CCT is used instead of CMR imaging, the frequency should be weighed</text>
<text top="641" left="108" width="104" height="8" font="5">against radiation exposure.</text>
<text top="652" left="108" width="241" height="11" font="5"><a href="1-s2.0-S0735109718368451-main.html#11">k6-minute </a>walk test or CPET, depending on clinical indication.</text>
<text top="667" left="116" width="686" height="8" font="5">ACHD indicates adult congenital heart disease; CCT, cardiac computed tomography; CMR, cardiovascular magnetic resonance imaging; CPET, cardiopulmonary exercise test; ECG,</text>
<text top="679" left="108" width="228" height="8" font="5">electrocardiogram; and TTE, transthoracic echocardiogram.</text>
<text top="934" left="63" width="191" height="11" font="20">Recommendations for Severe PAH</text>
<text top="949" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="949" left="457" width="155" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 49</a></text>
<text top="949" left="612" width="3" height="11" font="20">.</text>
<text top="990" left="89" width="19" height="10" font="13">COR</text>
<text top="990" left="161" width="18" height="10" font="13">LOE</text>
<text top="990" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="1017" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="1061" left="97" width="3" height="9" font="5">I</text>
<text top="1061" left="160" width="21" height="9" font="5">B-NR</text>
<text top="1049" left="234" width="457" height="11" font="12">1. Patients with ACHD with pulmonary vascular resistance 2.5 Wood units or greater (</text>
<text top="1047" left="691" width="97" height="15" font="12">‡4 Wood units3m</text>
<text top="1047" left="788" width="5" height="7" font="26">2</text>
<text top="1049" left="793" width="4" height="11" font="12">)</text>
<text top="1065" left="246" width="553" height="11" font="12">should be assessed collaboratively by an ACHD cardiologist and an expert in pulmonary hypertension to</text>
<text top="1080" left="246" width="151" height="11" font="12">develop a management plan</text>
<text top="1080" left="401" width="57" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">(S4.4.4.1-1</a></text>
<text top="1078" left="459" width="69" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">–S4.4.4.1-17)</a></text>
<text top="1080" left="527" width="3" height="11" font="12">.</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="19" height="9" font="5">1538</text>
</page>
<page number="46" position="absolute" top="0" left="0" height="1160" width="864">
<text top="744" left="63" width="175" height="12" font="3">4.4.4.2. Eisenmenger Syndrome</text>
<text top="149" left="69" width="61" height="10" font="15">(continued)</text>
<text top="199" left="97" width="3" height="9" font="5">I</text>
<text top="199" left="160" width="21" height="9" font="5">B-NR</text>
<text top="187" left="234" width="566" height="11" font="12">2. Adults with septal or great artery shunts should undergo periodic screening for pulmonary hypertension</text>
<text top="202" left="248" width="47" height="11" font="12">with TTE</text>
<text top="202" left="299" width="57" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">(S4.4.4.1-1</a></text>
<text top="200" left="356" width="70" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">–S4.4.4.1-18)</a></text>
<text top="202" left="426" width="3" height="11" font="12">.</text>
<text top="248" left="97" width="3" height="9" font="5">I</text>
<text top="248" left="160" width="21" height="9" font="5">B-NR</text>
<text top="236" left="234" width="551" height="11" font="12">3. Cardiac catheterization to assess pulmonary vascular hemodynamics is recommended for adults with</text>
<text top="252" left="248" width="427" height="11" font="12">septal or great artery shunts and clinical symptoms, signs, or echocardiographic</text>
<text top="250" left="679" width="117" height="15" font="12">ﬁndings suggestive of</text>
<text top="268" left="248" width="128" height="11" font="12">pulmonary hypertension</text>
<text top="268" left="379" width="421" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">(S4.4.4.1-1, S4.4.4.1-2, S4.4.4.1-4, S4.4.4.1-6, S4.4.4.1-7, S4.4.4.1-11, S4.4.4.1-</a></text>
<text top="283" left="248" width="78" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">12, S4.4.4.1-15</a></text>
<text top="281" left="326" width="70" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">–S4.4.4.1-18)</a></text>
<text top="283" left="396" width="3" height="11" font="12">.</text>
<text top="323" left="97" width="3" height="9" font="5">I</text>
<text top="323" left="160" width="21" height="9" font="5">B-NR</text>
<text top="311" left="234" width="546" height="11" font="12">4. In adults with septal or great artery shunts, cardiac catheterization with hemodynamics (performed</text>
<text top="327" left="249" width="193" height="11" font="12">before or at time of closure) is bene</text>
<text top="325" left="442" width="194" height="15" font="12">ﬁcial to assess suitability for closure</text>
<text top="327" left="640" width="57" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">(S4.4.4.1-1</a></text>
<text top="325" left="697" width="69" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">–S4.4.4.1-17)</a></text>
<text top="327" left="766" width="3" height="11" font="12">.</text>
<text top="373" left="97" width="3" height="9" font="5">I</text>
<text top="373" left="160" width="20" height="9" font="5">C-EO</text>
<text top="361" left="234" width="551" height="11" font="12">5. BNP, chest x-ray, 6-minute walk test, and cardiac catheterization are useful for initial and follow-up</text>
<text top="376" left="248" width="235" height="11" font="12">evaluation of patients with ACHD with PAH.</text>
<text top="408" left="63" width="13" height="8" font="5">See</text>
<text top="408" left="78" width="42" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#12">Section 3.3</a></text>
<text top="408" left="122" width="453" height="8" font="5">for recommendations on who should perform surgeries, cardiac catheterization, and other procedures in these patients;</text>
<text top="408" left="578" width="42" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="408" left="622" width="179" height="8" font="5">for recommendations on diagnostic evaluation;</text>
<text top="420" left="63" width="14" height="8" font="5">and</text>
<text top="420" left="80" width="34" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#46">Table 33</a></text>
<text top="420" left="116" width="166" height="8" font="5">for routine testing and follow-up intervals.</text>
<text top="453" left="67" width="53" height="10" font="15">T A B L E 3 3</text>
<text top="453" left="135" width="505" height="10" font="16">Pulmonary Hypertension and Eisenmenger Syndrome: Routine Follow-Up and Testing Intervals</text>
<text top="477" left="63" width="208" height="9" font="13">Frequency of Routine Follow-Up and Testing</text>
<text top="477" left="384" width="99" height="9" font="13">Physiological Stage C</text>
<text top="477" left="483" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#46">*</a></text>
<text top="477" left="491" width="22" height="9" font="13">(mo)</text>
<text top="477" left="626" width="100" height="9" font="13">Physiological Stage <a href="1-s2.0-S0735109718368451-main.html#46">D</a></text>
<text top="477" left="726" width="4" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#46">*</a></text>
<text top="477" left="734" width="22" height="9" font="13">(mo)</text>
<text top="496" left="63" width="124" height="9" font="13">Outpatient ACHD cardiologist</text>
<text top="496" left="439" width="6" height="9" font="13">6</text>
<text top="495" left="445" width="13" height="12" font="13">–12</text>
<text top="496" left="684" width="5" height="9" font="13">3</text>
<text top="495" left="689" width="10" height="12" font="13">–6</text>
<text top="515" left="63" width="17" height="9" font="13">ECG</text>
<text top="515" left="444" width="9" height="9" font="13">12</text>
<text top="515" left="687" width="9" height="9" font="13">12</text>
<text top="535" left="63" width="16" height="9" font="13">TTE</text>
<text top="533" left="79" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#46">†</a></text>
<text top="535" left="444" width="9" height="9" font="13">12</text>
<text top="535" left="687" width="9" height="9" font="13">12</text>
<text top="554" left="63" width="62" height="9" font="13">Pulse oximetry</text>
<text top="554" left="429" width="40" height="9" font="13">Each visit</text>
<text top="554" left="671" width="40" height="9" font="13">Each visit</text>
<text top="573" left="63" width="19" height="9" font="13">CMR</text>
<text top="571" left="82" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#46">‡</a></text>
<text top="573" left="427" width="44" height="9" font="13">As needed</text>
<text top="573" left="669" width="44" height="9" font="13">As needed</text>
<text top="592" left="63" width="53" height="9" font="13">Exercise test</text>
<text top="592" left="116" width="5" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#46">§</a></text>
<text top="592" left="439" width="6" height="9" font="13">6</text>
<text top="591" left="445" width="13" height="12" font="13">–12</text>
<text top="592" left="682" width="6" height="9" font="13">6</text>
<text top="591" left="687" width="13" height="12" font="13">–12</text>
<text top="611" left="63" width="95" height="9" font="13">Cardiac <a href="1-s2.0-S0735109718368451-main.html#46">catheterization</a></text>
<text top="610" left="158" width="5" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#46">k</a></text>
<text top="611" left="427" width="44" height="9" font="13">As needed</text>
<text top="611" left="669" width="44" height="9" font="13">As needed</text>
<text top="635" left="63" width="17" height="8" font="5">*See</text>
<text top="635" left="83" width="58" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#10">Tables 3 </a>and <a href="1-s2.0-S0735109718368451-main.html#11">4</a></text>
<text top="635" left="144" width="129" height="8" font="5">for details on the ACHD AP classi</text>
<text top="634" left="273" width="60" height="11" font="5">ﬁcation system.</text>
<text top="646" left="63" width="471" height="11" font="5">†Routine TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise.</text>
<text top="657" left="63" width="694" height="11" font="5">‡CMR may be indicated for assessment of right ventricular function and CHD anatomy not clariﬁed with TTE. Baseline study is recommended with periodic follow-up CMR, with</text>
<text top="671" left="63" width="275" height="8" font="5">frequency of repeat imaging determined by anatomic and physiological</text>
<text top="669" left="341" width="33" height="11" font="5">ﬁndings.</text>
<text top="683" left="63" width="241" height="8" font="5">§6-minute walk test or CPET, depending on clinical indication.</text>
<text top="693" left="63" width="281" height="11" font="5"><a href="1-s2.0-S0735109718368451-main.html#11">k</a>Cardiac catheterization should be performed at baseline and as needed.</text>
<text top="709" left="71" width="686" height="8" font="5">ACHD indicates adult congenital heart disease; CMR, cardiovascular magnetic resonance; CPET, cardiopulmonary exercise test; ECG, electrocardiogram; and TTE, transthoracic</text>
<text top="721" left="63" width="63" height="8" font="5">echocardiogram.</text>
<text top="790" left="63" width="257" height="11" font="20">Recommendations for Eisenmenger Syndrome</text>
<text top="805" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="805" left="457" width="154" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 50</a></text>
<text top="805" left="612" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="846" left="89" width="19" height="10" font="13">COR</text>
<text top="846" left="161" width="18" height="10" font="13">LOE</text>
<text top="846" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="873" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="917" left="97" width="3" height="9" font="5">I</text>
<text top="917" left="160" width="20" height="9" font="5">C-EO</text>
<text top="905" left="234" width="465" height="11" font="12">1. When evaluating adults with presumed Eisenmenger syndrome, clinicians should con</text>
<text top="903" left="699" width="100" height="15" font="12">ﬁrm diagnostic im-</text>
<text top="921" left="246" width="553" height="11" font="12">aging and cardiac catheterization data accuracy and exclude other potential contributors to right-to-left</text>
<text top="936" left="246" width="197" height="11" font="12">shunting or pulmonary hypertension.</text>
<text top="973" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="1017" left="97" width="3" height="9" font="5">I</text>
<text top="1017" left="168" width="6" height="9" font="5">A</text>
<text top="1005" left="234" width="105" height="11" font="12">2. Bosentan is bene</text>
<text top="1003" left="338" width="393" height="15" font="12">ﬁcial in symptomatic adults with Eisenmenger syndrome with ASD or VSD</text>
<text top="1005" left="735" width="59" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">(S4.4.4.2-1</a></text>
<text top="1003" left="794" width="5" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">–</a></text>
<text top="1021" left="248" width="60" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">S4.4.4.2-3)</a></text>
<text top="1021" left="308" width="3" height="11" font="12">.</text>
<text top="1067" left="94" width="10" height="9" font="5">IIa</text>
<text top="1067" left="163" width="15" height="9" font="5">B-R</text>
<text top="1054" left="234" width="551" height="11" font="12">3. In symptomatic adults with Eisenmenger syndrome, bosentan and PDE-5 inhibitors are reasonable in</text>
<text top="1070" left="248" width="461" height="11" font="12">combination if symptomatic improvement does not occur with either medication alone</text>
<text top="1070" left="713" width="62" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">(S4.4.4.2-1,</a></text>
<text top="1086" left="248" width="56" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">S4.4.4.2-4</a></text>
<text top="1084" left="304" width="66" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">–S4.4.4.2-6)</a></text>
<text top="1086" left="371" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#62">.</a></text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="789" width="19" height="9" font="5">1539</text>
</page>
<page number="47" position="absolute" top="0" left="0" height="1160" width="864">
<text top="374" left="108" width="138" height="11" font="2">4.4.5. Coronary Anomalies</text>
<text top="396" left="108" width="49" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#47">Table 34</a></text>
<text top="396" left="156" width="3" height="12" font="2">.</text>
<text top="833" left="108" width="257" height="12" font="3">4.4.5.1. Anomalous Coronary Artery Evaluation</text>
<text top="855" left="108" width="49" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#47">Table 34</a></text>
<text top="855" left="156" width="3" height="12" font="2">.</text>
<text top="149" left="69" width="61" height="10" font="15">(continued)</text>
<text top="199" left="94" width="10" height="9" font="5">IIa</text>
<text top="193" left="160" width="20" height="9" font="5">C-EO</text>
<text top="191" left="234" width="566" height="11" font="12">4. Bosentan is a reasonable therapy to treat symptomatic adults with Eisenmenger syndrome with 1 of the</text>
<text top="206" left="249" width="551" height="11" font="12">following: shunts other than ASD/VSD (e.g., PDA, aortopulmonary window) (Level of Evidence C-EO), or</text>
<text top="222" left="249" width="175" height="11" font="12">complex congenital heart lesions</text>
<text top="222" left="428" width="126" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">(S4.4.4.2-1, S4.4.4.2-7)</a></text>
<text top="222" left="558" width="100" height="11" font="12">or Down syndrome</text>
<text top="222" left="662" width="127" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">(S4.4.4.2-4, S4.4.4.2-5,</a></text>
<text top="238" left="249" width="57" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">S4.4.4.2-8</a></text>
<text top="236" left="305" width="72" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">–S4.4.4.2-10)</a></text>
<text top="238" left="381" width="137" height="11" font="12">(Level of Evidence B-NR).</text>
<text top="210" left="160" width="21" height="9" font="5">B-NR</text>
<text top="293" left="94" width="10" height="9" font="5">IIa</text>
<text top="293" left="160" width="21" height="9" font="5">B-NR</text>
<text top="281" left="234" width="295" height="11" font="12">5. It is reasonable to use PDE-5 inhibitors (e.g., sildena</text>
<text top="279" left="529" width="245" height="15" font="12">ﬁl, tadalaﬁl) to treat symptomatic adults with</text>
<text top="297" left="248" width="323" height="11" font="12">Eisenmenger syndrome with ASD, VSD, or great artery shunt</text>
<text top="297" left="575" width="125" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">(S4.4.4.2-1, S4.4.4.2-11</a></text>
<text top="295" left="700" width="71" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#62">–S4.4.4.2-16)</a></text>
<text top="297" left="772" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#62">.</a></text>
<text top="329" left="63" width="13" height="8" font="5">See</text>
<text top="329" left="78" width="42" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#12">Section 3.3</a></text>
<text top="329" left="122" width="453" height="8" font="5">for recommendations on who should perform surgeries, cardiac catheterization, and other procedures in these patients;</text>
<text top="329" left="578" width="42" height="8" font="6"><a href="">Section 3.4</a></text>
<text top="329" left="622" width="179" height="8" font="5">for recommendations on diagnostic evaluation;</text>
<text top="341" left="63" width="14" height="8" font="5">and</text>
<text top="341" left="80" width="34" height="8" font="6"><a href="1-s2.0-S0735109718368451-main.html#46">Table 33</a></text>
<text top="341" left="116" width="166" height="8" font="5">for routine testing and follow-up intervals.</text>
<text top="423" left="112" width="54" height="10" font="15">T A B L E 3 4</text>
<text top="423" left="179" width="413" height="10" font="16">Factors That May Relate to the Clinical Importance of AAOCA and Risk of SCD</text>
<text top="445" left="108" width="16" height="9" font="13">Age</text>
<text top="445" left="227" width="279" height="9" font="13">AAOCA is more commonly invoked as the cause of SCD in patients</text>
<text top="444" left="510" width="288" height="12" font="13">&lt;35 y of age than in patients &gt;35 y of age, in whom atherosclerotic</text>
<text top="457" left="242" width="559" height="9" font="13">coronary disease becomes a more prevalent cause. However, death has been attributed to AAOCA in patients of all ages; there does not</text>
<text top="469" left="242" width="555" height="9" font="13">seem to be an age beyond which the AAOCA may not be relevant, even in the setting of atherosclerotic coronary disease and other</text>
<text top="481" left="242" width="98" height="9" font="13">concomitant conditions</text>
<text top="481" left="343" width="82" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#62">(S4.4.5-1, S4.4.5-2)</a></text>
<text top="481" left="425" width="3" height="9" font="13">.</text>
<text top="500" left="108" width="88" height="9" font="13">Anatomy of coronary</text>
<text top="512" left="123" width="46" height="9" font="13">ostium and</text>
<text top="524" left="123" width="75" height="9" font="13">proximal coronary</text>
<text top="536" left="123" width="27" height="9" font="13">course</text>
<text top="500" left="227" width="35" height="9" font="13">Slit-like/</text>
<text top="499" left="263" width="531" height="12" font="13">ﬁsh-mouth-shaped oriﬁce, acute angle takeoff, intramural course, interarterial course and hypoplasia of the proximal coronary</text>
<text top="512" left="242" width="467" height="9" font="13">artery have all been proposed as reasons for symptoms, ischemia and SCD in patients with AAOCA. The slit-like ori</text>
<text top="511" left="709" width="92" height="12" font="13">ﬁce is more commonly</text>
<text top="524" left="242" width="383" height="9" font="13">seen in anomalous right coronary artery arising from the left sinus. Each of these anatomic</text>
<text top="523" left="628" width="149" height="12" font="13">ﬁndings offers a pathophysiological</text>
<text top="536" left="242" width="559" height="9" font="13">mechanism for intermittent ischemia, particularly at times of high cardiac output and/or increased aortic wall tension, such as during</text>
<text top="548" left="242" width="33" height="9" font="13">exercise</text>
<text top="548" left="279" width="39" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#62">(S4.4.5-3</a></text>
<text top="546" left="317" width="44" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#62">–S4.4.5-6)</a></text>
<text top="548" left="361" width="3" height="9" font="13">.</text>
<text top="567" left="108" width="73" height="9" font="13">Anomalous origin</text>
<text top="567" left="227" width="574" height="9" font="13">Left coronary artery arising from the right cusp is less common than the right coronary artery arising from the left cusp but is more often</text>
<text top="579" left="242" width="127" height="9" font="13">found in autopsy series of SCD</text>
<text top="579" left="372" width="123" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#62">(S4.4.5-1, S4.4.5-7, S4.4.5-8)</a></text>
<text top="579" left="495" width="306" height="9" font="13">. This suggests that anomalous origin of the left coronary artery from the</text>
<text top="591" left="242" width="559" height="9" font="13">right cusp is more likely to cause SCD than anomalous origin of the right coronary artery from the left cusp. This may be due either to</text>
<text top="603" left="242" width="550" height="9" font="13">anatomic features that make anomalous aortic origin of the left coronary artery prone to coronary compromise or because a larger</text>
<text top="615" left="242" width="312" height="9" font="13">proportion of myocardium is supplied by the left coronary artery, or both.</text>
<text top="634" left="108" width="34" height="9" font="13">Exercise</text>
<text top="634" left="227" width="401" height="9" font="13">Autopsy series suggest most patients die during, or in close temporal association with, exercise</text>
<text top="634" left="632" width="40" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#63">(S4.4.5-8</a></text>
<text top="633" left="671" width="48" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#63">–S4.4.5-10)</a></text>
<text top="634" left="719" width="3" height="9" font="13">.</text>
<text top="654" left="108" width="36" height="9" font="13">Ischemia</text>
<text top="654" left="227" width="163" height="9" font="13">Autopsy series demonstrate myocardial</text>
<text top="652" left="394" width="408" height="12" font="13">ﬁbrosis in a signiﬁcant number of patients whose deaths were attributed to AAOCA, particularly in</text>
<text top="666" left="242" width="300" height="9" font="13">patients with anomalous left coronary artery arising from the right cusp</text>
<text top="666" left="545" width="47" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#63">(S4.4.5-10)</a></text>
<text top="666" left="592" width="209" height="9" font="13">. Surgical series describe patients with ischemia or</text>
<text top="677" left="242" width="489" height="9" font="13">MI before surgical repair in the absence of other CAD, suggesting a relation of the coronary anomaly to the ischemia</text>
<text top="677" left="734" width="45" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#63">(S4.4.5-11)</a></text>
<text top="677" left="779" width="22" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#63">. </a>This</text>
<text top="689" left="242" width="477" height="9" font="13">suggests that had perfusion imaging been obtained before SCD, ischemia would have been found in such patients</text>
<text top="689" left="723" width="79" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#63">(S4.4.5-12, S4.4.5-</a></text>
<text top="701" left="242" width="12" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#63">13)</a></text>
<text top="701" left="254" width="547" height="9" font="13">. However, other data indicate that a normal stress test does not preclude a SCD event, with the proviso that most of those studies</text>
<text top="713" left="242" width="257" height="9" font="13">used only stress ECG, rather than the more sensitive and speci</text>
<text top="712" left="499" width="302" height="12" font="13">ﬁc modalities of nuclear perfusion imaging or stress echocardiography. In</text>
<text top="725" left="242" width="550" height="9" font="13">addition, postoperative studies have shown that ischemia may be found after surgical repair in the distribution not supplied by the</text>
<text top="737" left="242" width="268" height="9" font="13">abnormal coronary artery and may not persist on repeat testing</text>
<text top="737" left="514" width="47" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#63">(S4.4.5-14)</a></text>
<text top="737" left="560" width="3" height="9" font="13">.</text>
<text top="756" left="108" width="44" height="9" font="13">Symptoms</text>
<text top="756" left="227" width="154" height="9" font="13">In autopsy and surgical series, a signi</text>
<text top="755" left="382" width="375" height="12" font="13">ﬁcant number of patients reported cardiovascular symptoms, including before SCD events</text>
<text top="756" left="759" width="42" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#63">(S4.4.5-9,</a></text>
<text top="768" left="242" width="39" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#63">S4.4.5-15</a></text>
<text top="767" left="282" width="48" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#63">–S4.4.5-18)</a></text>
<text top="768" left="329" width="472" height="9" font="13">. Symptoms are more commonly reported in patients in whom the left coronary artery arises from the right sinus.</text>
<text top="780" left="242" width="325" height="9" font="13">Surgical series have described improvement in symptoms after surgical repair</text>
<text top="780" left="570" width="82" height="9" font="18"><a href="1-s2.0-S0735109718368451-main.html#63">(S4.4.5-6, S4.4.5-8</a></text>
<text top="779" left="652" width="139" height="12" font="18"><a href="1-s2.0-S0735109718368451-main.html#63">–S4.4.5-10, S4.4.5-15, S4.4.5-16)</a></text>
<text top="780" left="791" width="3" height="9" font="13"><a href="1-s2.0-S0735109718368451-main.html#63">.</a></text>
<text top="804" left="108" width="686" height="8" font="5">AAOCA indicates anomalous aortic origin of the coronary artery; CAD, coronary artery disease; ECG, electrocardiogram; MI, myocardial infarction; and SCD, sudden cardiac death.</text>
<text top="889" left="63" width="345" height="11" font="20">Recommendations for Anomalous Coronary Artery Evaluation</text>
<text top="904" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="904" left="457" width="151" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 51</a></text>
<text top="904" left="609" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="945" left="89" width="19" height="10" font="13">COR</text>
<text top="945" left="161" width="18" height="10" font="13">LOE</text>
<text top="945" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="972" left="404" width="53" height="11" font="12">Diagnostic</text>
<text top="1016" left="97" width="3" height="9" font="5">I</text>
<text top="1016" left="160" width="20" height="9" font="5">C-LD</text>
<text top="1004" left="234" width="563" height="11" font="12">1. Coronary angiography, using catheterization, CT, or CMR, is recommended for evaluation of anomalous</text>
<text top="1020" left="246" width="81" height="11" font="12">coronary artery</text>
<text top="1020" left="332" width="56" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#63">(S4.4.5.1-1</a></text>
<text top="1018" left="389" width="63" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#63">–S4.4.5.1-3)</a></text>
<text top="1020" left="452" width="3" height="11" font="12">.</text>
<text top="1066" left="97" width="3" height="9" font="5">I</text>
<text top="1066" left="160" width="20" height="9" font="5">C-LD</text>
<text top="1054" left="234" width="565" height="11" font="12">2. Anatomic and physiological evaluation should be performed in patients with anomalous aortic origin of</text>
<text top="1069" left="248" width="421" height="11" font="12">the left coronary from the right sinus and/or right coronary from the left sinus</text>
<text top="1069" left="673" width="58" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#63">(S4.4.5.1-4</a></text>
<text top="1067" left="732" width="64" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#63">–S4.4.5.1-9)</a></text>
<text top="1069" left="796" width="3" height="11" font="12">.</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="20" height="9" font="5">1540</text>
</page>
<page number="48" position="absolute" top="0" left="0" height="1160" width="864">
<text top="712" left="63" width="287" height="12" font="3">4.4.5.2. Anomalous Aortic Origin of Coronary Artery</text>
<text top="735" left="63" width="46" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#48">Figure 5</a></text>
<text top="734" left="109" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#48">.</a></text>
<text top="153" left="80" width="46" height="11" font="23">FIGURE 5</text>
<text top="154" left="134" width="213" height="9" font="24">Anomalous Aortic Origin of the Coronary Artery</text>
<text top="193" left="237" width="164" height="13" font="2">Anomalous aortic origin of the </text>
<text top="207" left="276" width="81" height="13" font="2">coronary artery</text>
<text top="359" left="405" width="52" height="13" font="2">Ischemic </text>
<text top="373" left="368" width="124" height="13" font="2">symptoms or ischemia </text>
<text top="388" left="383" width="96" height="13" font="2">during diagnostic </text>
<text top="402" left="411" width="36" height="13" font="2">testing</text>
<text top="479" left="135" width="47" height="13" font="2">Surgical </text>
<text top="494" left="124" width="67" height="13" font="2">intervention*</text>
<text top="509" left="135" width="45" height="13" font="2">(Class I)</text>
<text top="452" left="176" width="21" height="13" font="2">Yes</text>
<text top="479" left="237" width="47" height="13" font="2">Surgical </text>
<text top="493" left="225" width="68" height="13" font="2">Intervention*</text>
<text top="508" left="232" width="55" height="13" font="2">(Class IIa)</text>
<text top="452" left="220" width="16" height="13" font="2">No</text>
<text top="359" left="182" width="51" height="13" font="2">Ischemic </text>
<text top="373" left="146" width="124" height="13" font="2">symptoms or ischemia </text>
<text top="388" left="160" width="96" height="13" font="2">during diagnostic </text>
<text top="402" left="188" width="36" height="13" font="2">testing</text>
<text top="479" left="348" width="47" height="13" font="2">Surgical </text>
<text top="493" left="336" width="67" height="13" font="2">intervention*</text>
<text top="508" left="347" width="45" height="13" font="2">(Class I)</text>
<text top="452" left="397" width="20" height="13" font="2">Yes</text>
<text top="459" left="638" width="47" height="13" font="2">Surgical </text>
<text top="473" left="626" width="68" height="13" font="2">Intervention*</text>
<text top="488" left="632" width="55" height="13" font="2">(Class IIb)</text>
<text top="496" left="465" width="62" height="13" font="2">Ventricular </text>
<text top="511" left="462" width="63" height="13" font="2">arrhythmias</text>
<text top="452" left="454" width="16" height="13" font="2">No</text>
<text top="556" left="483" width="21" height="13" font="2">Yes</text>
<text top="587" left="472" width="47" height="13" font="2">Surgical </text>
<text top="601" left="460" width="71" height="13" font="2">intervention* </text>
<text top="616" left="466" width="55" height="13" font="2">(Class IIa)</text>
<text top="280" left="147" width="122" height="13" font="2">Left coronary from the </text>
<text top="295" left="179" width="55" height="13" font="2">right sinus</text>
<text top="280" left="365" width="127" height="13" font="2">Right coronary from the</text>
<text top="295" left="405" width="48" height="13" font="2">left sinus</text>
<text top="522" left="632" width="59" height="13" font="2">Continued </text>
<text top="537" left="629" width="63" height="13" font="2">observation</text>
<text top="552" left="632" width="55" height="13" font="2">(Class IIb)</text>
<text top="504" left="565" width="16" height="13" font="2">No</text>
<text top="664" left="80" width="166" height="9" font="13">*Surgical intervention to involve unroo</text>
<text top="662" left="246" width="350" height="12" font="13">ﬁng or coronary revascularization for patients with concomitant ﬁxed obstruction.</text>
<text top="760" left="63" width="373" height="11" font="20">Recommendations for Anomalous Aortic Origin of Coronary Artery</text>
<text top="774" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="774" left="457" width="151" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 51</a></text>
<text top="774" left="609" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="815" left="89" width="19" height="10" font="13">COR</text>
<text top="815" left="161" width="18" height="10" font="13">LOE</text>
<text top="815" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="842" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="887" left="97" width="3" height="9" font="5">I</text>
<text top="887" left="160" width="21" height="9" font="5">B-NR</text>
<text top="875" left="234" width="565" height="11" font="12">1. Surgery is recommended for AAOCA from the left sinus or AAOCA from the right sinus for symptoms or</text>
<text top="890" left="246" width="538" height="11" font="12">diagnostic evidence consistent with coronary ischemia attributable to the anomalous coronary artery</text>
<text top="906" left="246" width="58" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#63">(S4.4.5.2-1</a></text>
<text top="904" left="305" width="64" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#63">–S4.4.5.2-3)</a></text>
<text top="906" left="369" width="3" height="11" font="12">.</text>
<text top="952" left="94" width="10" height="9" font="5">IIa</text>
<text top="952" left="160" width="20" height="9" font="5">C-LD</text>
<text top="940" left="234" width="564" height="11" font="12">2. Surgery is reasonable for anomalous aortic origin of the left coronary artery from the right sinus in the</text>
<text top="955" left="248" width="179" height="11" font="12">absence of symptoms or ischemia</text>
<text top="955" left="431" width="60" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#63">(S4.4.5.2-4</a></text>
<text top="953" left="491" width="65" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#63">–S4.4.5.2-6)</a></text>
<text top="955" left="557" width="3" height="11" font="12"><a href="1-s2.0-S0735109718368451-main.html#63">.</a></text>
<text top="1001" left="94" width="10" height="9" font="5">IIa</text>
<text top="1001" left="160" width="20" height="9" font="5">C-EO</text>
<text top="989" left="234" width="409" height="11" font="12">3. Surgery for AAOCA is reasonable in the setting of ventricular arrhythmias.</text>
<text top="1050" left="94" width="10" height="9" font="5">IIb</text>
<text top="1050" left="160" width="21" height="9" font="5">B-NR</text>
<text top="1038" left="234" width="566" height="11" font="12">4. Surgery or continued observation may be reasonable for asymptomatic patients with an anomalous left</text>
<text top="1054" left="249" width="546" height="11" font="12">coronary artery arising from the right sinus or right coronary artery arising from the left sinus without</text>
<text top="1069" left="249" width="524" height="11" font="12">ischemia or anatomic or physiological evaluation suggesting potential for compromise of coronary</text>
<text top="1085" left="249" width="181" height="11" font="12">perfusion (e.g., intramural course,</text>
<text top="1083" left="434" width="210" height="15" font="12">ﬁsh-mouth-shaped oriﬁce, acute angle)</text>
<text top="1085" left="648" width="60" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#63">(S4.4.5.2-4</a></text>
<text top="1083" left="708" width="66" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#63">–S4.4.5.2-6)</a></text>
<text top="1085" left="774" width="3" height="11" font="12">.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="790" width="18" height="9" font="5">1541</text>
</page>
<page number="49" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="313" height="12" font="3">4.4.5.3. Anomalous Coronary Artery Arising From the PA</text>
<text top="476" left="108" width="308" height="16" font="14">5. EVIDENCE GAPS AND FUTURE DIRECTIONS</text>
<text top="514" left="108" width="48" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#49">Table 35</a></text>
<text top="514" left="156" width="3" height="12" font="2"><a href="1-s2.0-S0735109718368451-main.html#49">.</a></text>
<text top="195" left="63" width="400" height="11" font="20">Recommendations for Anomalous Coronary Artery Arising From the PA</text>
<text top="209" left="63" width="391" height="11" font="20">Referenced studies that support recommendations are summarized in</text>
<text top="209" left="457" width="151" height="11" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">Online Data Supplement 51</a></text>
<text top="209" left="609" width="3" height="11" font="20"><a href="http://jaccjacc.acc.org/Clinical_Document/ACHD_Guideline_ES-FT_Data_Supplements_08-02-18.pdf">.</a></text>
<text top="250" left="89" width="19" height="10" font="13">COR</text>
<text top="250" left="161" width="18" height="10" font="13">LOE</text>
<text top="250" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="278" left="401" width="60" height="11" font="12">Therapeutic</text>
<text top="322" left="97" width="3" height="9" font="5">I</text>
<text top="322" left="160" width="21" height="9" font="5">B-NR</text>
<text top="310" left="234" width="400" height="11" font="12">1. Surgery is recommended for anomalous left coronary artery from the PA</text>
<text top="310" left="638" width="58" height="11" font="4"><a href="1-s2.0-S0735109718368451-main.html#63">(S4.4.5.3-1</a></text>
<text top="308" left="696" width="64" height="15" font="4"><a href="1-s2.0-S0735109718368451-main.html#63">–S4.4.5.3-7)</a></text>
<text top="310" left="760" width="3" height="11" font="12">.</text>
<text top="371" left="97" width="3" height="9" font="5">I</text>
<text top="371" left="160" width="20" height="9" font="5">C-EO</text>
<text top="358" left="234" width="565" height="11" font="12">2. In a symptomatic adult with anomalous right coronary artery from the PA with symptoms attributed to</text>
<text top="374" left="248" width="269" height="11" font="12">the anomalous coronary, surgery is recommended.</text>
<text top="420" left="94" width="10" height="9" font="5">IIa</text>
<text top="420" left="160" width="20" height="9" font="5">C-EO</text>
<text top="408" left="234" width="556" height="11" font="12">3. Surgery for anomalous right coronary artery from the PA is reasonable in an asymptomatic adult with</text>
<text top="424" left="248" width="552" height="11" font="12">ventricular dysfunction or with myocardial ischemia attributed to anomalous right coronary artery from</text>
<text top="439" left="248" width="39" height="11" font="12">the PA.</text>
<text top="538" left="112" width="53" height="10" font="15">T A B L E 3 5</text>
<text top="538" left="179" width="219" height="10" font="16">High-Impact Research Questions in ACHD</text>
<text top="560" left="108" width="33" height="9" font="17">General</text>
<text top="579" left="108" width="69" height="9" font="13">Pathophysiology</text>
<text top="582" left="244" width="6" height="10" font="9">n</text>
<text top="583" left="258" width="383" height="9" font="13">What are the mechanisms of heart failure that can be prevented, reversed, or treated?</text>
<text top="593" left="244" width="6" height="10" font="9">n</text>
<text top="594" left="258" width="189" height="9" font="13">Why does the systemic right ventricle fail?</text>
<text top="605" left="244" width="6" height="10" font="9">n</text>
<text top="605" left="258" width="482" height="9" font="13">Will all patients with Fontan physiology develop clinically important cirrhosis, and how can we prevent this?</text>
<text top="616" left="244" width="6" height="10" font="9">n</text>
<text top="617" left="258" width="196" height="9" font="13">Who is at risk of aortic rupture and dilation?</text>
<text top="627" left="244" width="6" height="10" font="9">n</text>
<text top="628" left="258" width="520" height="9" font="13">Are patients with manipulated coronary arteries (e.g., ASO, Ross repair) at risk of premature coronary artery disease?</text>
<text top="638" left="244" width="6" height="10" font="9">n</text>
<text top="639" left="258" width="278" height="9" font="13">What is the impact of radiation exposure on long-term health?</text>
<text top="649" left="244" width="6" height="10" font="9">n</text>
<text top="650" left="258" width="385" height="9" font="13">Can we predict who will develop pulmonary hypertension/pulmonary vascular disease?</text>
<text top="669" left="108" width="128" height="9" font="13">Medical and surgical treatment</text>
<text top="672" left="244" width="6" height="10" font="9">n</text>
<text top="673" left="258" width="525" height="9" font="13">How can we modify current CHD surgical procedures to prevent or reduce later development of heart failure and/or arrhythmias?</text>
<text top="684" left="244" width="6" height="10" font="9">n</text>
<text top="684" left="258" width="360" height="9" font="13">Which patients with ACHD can use direct oral anticoagulants instead of warfarin?</text>
<text top="695" left="244" width="6" height="10" font="9">n</text>
<text top="696" left="258" width="238" height="9" font="13">What is the best algorithm for contraception choices?</text>
<text top="706" left="244" width="6" height="10" font="9">n</text>
<text top="707" left="258" width="250" height="9" font="13">Beyond those with severe PAH, which patients will bene</text>
<text top="705" left="509" width="103" height="12" font="13">ﬁt from PAH therapies?</text>
<text top="717" left="244" width="6" height="10" font="9">n</text>
<text top="718" left="258" width="270" height="9" font="13">Do patients with ACHD with systemic right ventricles and HF bene</text>
<text top="716" left="528" width="257" height="12" font="13">ﬁt from standard therapies (beta blockers, ACE inhibitors/ARBs,</text>
<text top="728" left="258" width="159" height="9" font="13">aldosterone antagonist)? Which one(s)?</text>
<text top="739" left="244" width="6" height="10" font="9">n</text>
<text top="739" left="258" width="128" height="9" font="13">What medical therapies bene</text>
<text top="738" left="386" width="191" height="12" font="13">ﬁt patients with failing Fontan physiology?</text>
<text top="750" left="244" width="6" height="10" font="9">n</text>
<text top="751" left="258" width="235" height="9" font="13">Do asymptomatic patients with ACHD with PAH bene</text>
<text top="749" left="494" width="133" height="12" font="13">ﬁt from PAH-speciﬁc therapy?</text>
<text top="761" left="244" width="6" height="10" font="9">n</text>
<text top="762" left="258" width="63" height="9" font="13">Who will bene</text>
<text top="760" left="321" width="152" height="12" font="13">ﬁt from ventricular assist devices?</text>
<text top="772" left="244" width="6" height="10" font="9">n</text>
<text top="773" left="258" width="273" height="9" font="13">What should be the threshold(s) for aortic aneurysm surgery?</text>
<text top="783" left="244" width="6" height="10" font="9">n</text>
<text top="784" left="258" width="280" height="9" font="13">What pacing and resynchronization strategies are of most bene</text>
<text top="783" left="539" width="155" height="12" font="13">ﬁt, and when should they be used?</text>
<text top="803" left="108" width="110" height="9" font="13">Outcomes/risk assessment</text>
<text top="806" left="244" width="6" height="10" font="9">n</text>
<text top="807" left="258" width="257" height="9" font="13">What criteria should determine transplantation eligibility?</text>
<text top="818" left="244" width="6" height="10" font="9">n</text>
<text top="818" left="258" width="90" height="9" font="13">Which patients bene</text>
<text top="817" left="348" width="148" height="12" font="13">ﬁt from primary prevention ICDs?</text>
<text top="829" left="244" width="6" height="10" font="9">n</text>
<text top="830" left="258" width="332" height="9" font="13">How can we risk stratify for SCD in patients with systemic right ventricles?</text>
<text top="840" left="244" width="6" height="10" font="9">n</text>
<text top="841" left="258" width="299" height="9" font="13">What operative risk score predicts outcomes in ACHD reoperations?</text>
<text top="851" left="244" width="6" height="10" font="9">n</text>
<text top="852" left="258" width="272" height="9" font="13">What HF risk score predicts outcomes in patients with ACHD?</text>
<text top="862" left="244" width="6" height="10" font="9">n</text>
<text top="863" left="258" width="228" height="9" font="13">Is there a level of exercise where risk exceeds bene</text>
<text top="862" left="486" width="14" height="12" font="13">ﬁt?</text>
<text top="874" left="244" width="6" height="10" font="9">n</text>
<text top="875" left="258" width="195" height="9" font="13">What is the rate and/or risk of endocarditis?</text>
<text top="894" left="108" width="49" height="9" font="13">Assessment</text>
<text top="897" left="244" width="6" height="10" font="9">n</text>
<text top="897" left="258" width="318" height="9" font="13">Who is at high risk of neurodevelopmental abnormalities and would bene</text>
<text top="896" left="576" width="225" height="12" font="13">ﬁt from neuropsychiatric evaluation and treatment?</text>
<text top="908" left="244" width="6" height="10" font="9">n</text>
<text top="909" left="258" width="543" height="9" font="13">Who should be screened for anxiety and depression, what treatment is most effective, and are there differences compared</text>
<text top="919" left="258" width="134" height="9" font="13">with non-patients with ACHD?</text>
<text top="929" left="244" width="6" height="10" font="9">n</text>
<text top="930" left="258" width="425" height="9" font="13">What is the standard protocol for assessing right ventricular size and function by CMR imaging?</text>
<text top="940" left="244" width="6" height="10" font="9">n</text>
<text top="941" left="258" width="267" height="9" font="13">Which biomarkers are predictive of mortality and morbidity?</text>
<text top="960" left="108" width="58" height="9" font="17">Disease-speci</text>
<text top="959" left="165" width="10" height="12" font="17">ﬁc</text>
<text top="978" left="108" width="101" height="9" font="13">Coarctation of the aorta</text>
<text top="981" left="244" width="6" height="10" font="9">n</text>
<text top="982" left="258" width="139" height="9" font="13">Which measure of hypertension</text>
<text top="980" left="398" width="262" height="12" font="13">—resting, exercise, or ambulatory—best predicts outcomes?</text>
<text top="992" left="244" width="6" height="10" font="9">n</text>
<text top="993" left="258" width="203" height="9" font="13">Is there an optimal antihypertensive regimen?</text>
<text top="1004" left="244" width="6" height="10" font="9">n</text>
<text top="1004" left="258" width="169" height="9" font="13">What should blood pressure goals be?</text>
<text top="1015" left="244" width="6" height="10" font="9">n</text>
<text top="1016" left="258" width="278" height="9" font="13">How often should patients be screened for thoracic aneurysm?</text>
<text top="1026" left="244" width="6" height="10" font="9">n</text>
<text top="1027" left="258" width="221" height="9" font="13">Should exercise-induced hypertension be treated?</text>
<text top="1037" left="244" width="6" height="10" font="9">n</text>
<text top="1038" left="258" width="237" height="9" font="13">What criteria warrant reintervention in recoarctation?</text>
<text top="1048" left="244" width="6" height="10" font="9">n</text>
<text top="1049" left="258" width="489" height="9" font="13">Is long-term outcome better with medical therapy or catheter intervention for less than severe recoarctation?</text>
<text top="1060" left="244" width="6" height="10" font="9">n</text>
<text top="1060" left="258" width="339" height="9" font="13">Should patients be screened for intracranial aneurysm, and if so, how often?</text>
<text top="1081" left="690" width="112" height="8" font="5">Continued in the next column</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="19" height="9" font="5">1542</text>
</page>
<page number="50" position="absolute" top="0" left="0" height="1160" width="864">
<text top="635" left="63" width="166" height="16" font="14">PRESIDENTS AND STAFF</text>
<text top="672" left="66" width="188" height="12" font="2">American College of Cardiology</text>
<text top="690" left="66" width="250" height="12" font="2">C. Michael Valentine, MD, FACC, President</text>
<text top="708" left="66" width="267" height="12" font="2">Cathleen C. Gates, Interim Chief Executive Of</text>
<text top="706" left="333" width="51" height="15" font="2">ﬁcer and</text>
<text top="726" left="75" width="109" height="12" font="2">Chief Operating Of</text>
<text top="724" left="184" width="25" height="15" font="2">ﬁcer</text>
<text top="744" left="66" width="299" height="12" font="2">William J. Oetgen, MD, MBA, FACC, Executive Vice</text>
<text top="762" left="75" width="310" height="12" font="2">President, Science, Education, Quality, and Publications</text>
<text top="780" left="66" width="279" height="12" font="2">MaryAnne Elma, MPH, Senior Director, Science,</text>
<text top="798" left="75" width="203" height="12" font="2">Education, Quality, and Publishing</text>
<text top="816" left="66" width="306" height="12" font="2">Amelia Scholtz, PhD, Publications Manager, Science,</text>
<text top="834" left="75" width="203" height="12" font="2">Education, Quality, and Publishing</text>
<text top="852" left="66" width="321" height="12" font="2">American College of Cardiology/American Heart Association</text>
<text top="870" left="66" width="328" height="12" font="2">Katherine A. Sheehan, PhD, Director, Guideline Strategy</text>
<text top="888" left="75" width="89" height="12" font="2">and Operations</text>
<text top="906" left="66" width="327" height="12" font="2">Abdul R. Abdullah, MD, Senior Manager, Guideline Science</text>
<text top="636" left="426" width="168" height="12" font="2">American Heart Association</text>
<text top="654" left="426" width="214" height="12" font="2">Ivor Benjamin, MD, FAHA, President</text>
<text top="672" left="426" width="195" height="12" font="2">Nancy Brown, Chief Executive Of</text>
<text top="671" left="621" width="25" height="15" font="2">ﬁcer</text>
<text top="690" left="426" width="308" height="12" font="2">Rose Marie Robertson, MD, FAHA, Chief Science and</text>
<text top="708" left="435" width="62" height="12" font="2">Medical Of</text>
<text top="706" left="498" width="25" height="15" font="2">ﬁcer</text>
<text top="726" left="426" width="318" height="12" font="2">Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice</text>
<text top="744" left="435" width="76" height="12" font="2">President, Of</text>
<text top="742" left="511" width="150" height="15" font="2">ﬁce of Science Operations</text>
<text top="762" left="426" width="283" height="12" font="2">Prashant Nedungadi, PhD, Science and Medicine</text>
<text top="780" left="435" width="66" height="12" font="2">Advisor, Of</text>
<text top="778" left="501" width="150" height="15" font="2">ﬁce of Science Operations</text>
<text top="798" left="426" width="303" height="12" font="2">Jody Hundley, Production and Operations Manager,</text>
<text top="816" left="435" width="39" height="12" font="2">Scienti</text>
<text top="814" left="475" width="261" height="15" font="2">ﬁc Publications, Ofﬁce of Science Operations</text>
<text top="148" left="67" width="53" height="10" font="15">T A B L E 3 5</text>
<text top="148" left="135" width="53" height="10" font="16">Continued</text>
<text top="169" left="63" width="69" height="9" font="13">Ebstein anomaly</text>
<text top="172" left="199" width="6" height="10" font="9">n</text>
<text top="173" left="213" width="281" height="9" font="13">What is the indication for surgery in the asymptomatic patient?</text>
<text top="183" left="199" width="6" height="10" font="9">n</text>
<text top="184" left="213" width="313" height="9" font="13">Who should have a Glenn shunt at the time of tricuspid valve surgery?</text>
<text top="195" left="199" width="6" height="10" font="9">n</text>
<text top="195" left="213" width="428" height="9" font="13">Should surgeons attempt tricuspid valve repair or routinely perform replacement in all patients?</text>
<text top="215" left="63" width="17" height="9" font="13">TOF</text>
<text top="218" left="199" width="6" height="10" font="9">n</text>
<text top="218" left="213" width="431" height="9" font="13">What is the optimal timing for pulmonary valve replacement in asymptomatic patients with TOF?</text>
<text top="229" left="199" width="6" height="10" font="9">n</text>
<text top="230" left="213" width="424" height="9" font="13">Do pulmonary valve replacement and ventricular tachycardia ablation decrease the risk of SCD?</text>
<text top="240" left="199" width="6" height="10" font="9">n</text>
<text top="241" left="213" width="348" height="9" font="13">Who needs a primary prevention ICD, and does this strategy reduce mortality?</text>
<text top="251" left="199" width="6" height="10" font="9">n</text>
<text top="252" left="213" width="180" height="9" font="13">Is there a role for PAH therapies in TOF?</text>
<text top="262" left="199" width="6" height="10" font="9">n</text>
<text top="263" left="213" width="209" height="9" font="13">Why does left ventricular dysfunction develop?</text>
<text top="282" left="63" width="119" height="9" font="13">TGA/systemic right ventricle</text>
<text top="285" left="199" width="6" height="10" font="9">n</text>
<text top="286" left="213" width="44" height="9" font="13">Who bene</text>
<text top="285" left="257" width="267" height="12" font="13">ﬁts from ACE inhibitors/ARBs/beta blockers/spironolactone?</text>
<text top="297" left="199" width="6" height="10" font="9">n</text>
<text top="297" left="213" width="352" height="9" font="13">Who needs a primary prevention ICD, and does this strategy prevent mortality?</text>
<text top="308" left="199" width="6" height="10" font="9">n</text>
<text top="309" left="213" width="61" height="9" font="13">What imaging</text>
<text top="307" left="277" width="163" height="12" font="13">ﬁndings predict mortality/morbidity?</text>
<text top="319" left="199" width="6" height="10" font="9">n</text>
<text top="320" left="213" width="513" height="9" font="13">In CCTGA with VSD/PS, does the double switch have better long-term outcomes than VSD closure and left ventricle</text>
<text top="318" left="727" width="30" height="12" font="13">–to-PA</text>
<text top="330" left="214" width="37" height="9" font="13">conduit?</text>
<text top="340" left="199" width="6" height="10" font="9">n</text>
<text top="341" left="213" width="250" height="9" font="13">When should tricuspid valve replacement be performed?</text>
<text top="352" left="199" width="6" height="10" font="9">n</text>
<text top="352" left="213" width="419" height="9" font="13">What is the role of cardiac resynchronization therapy in patients with systemic right ventricle?</text>
<text top="372" left="63" width="17" height="9" font="13">ASO</text>
<text top="375" left="199" width="6" height="10" font="9">n</text>
<text top="375" left="213" width="201" height="9" font="13">What are the long-term outcomes after ASO?</text>
<text top="386" left="199" width="6" height="10" font="9">n</text>
<text top="387" left="213" width="486" height="9" font="13">How should the possibility of asymptomatic coronary disease (ostial, compression) and ischemia be assessed?</text>
<text top="406" left="63" width="97" height="9" font="13">Single ventricle/Fontan</text>
<text top="409" left="199" width="6" height="10" font="9">n</text>
<text top="410" left="213" width="115" height="9" font="13">Is warfarin or aspirin bene</text>
<text top="408" left="329" width="139" height="12" font="13">ﬁcial in patients with a Fontan?</text>
<text top="420" left="199" width="6" height="10" font="9">n</text>
<text top="421" left="213" width="105" height="9" font="13">Are PAH therapies bene</text>
<text top="419" left="318" width="25" height="12" font="13">ﬁcial?</text>
<text top="431" left="199" width="6" height="10" font="9">n</text>
<text top="432" left="213" width="192" height="9" font="13">Is exercise capacity predictive of mortality?</text>
<text top="442" left="199" width="6" height="10" font="9">n</text>
<text top="443" left="213" width="256" height="9" font="13">What liver screening is appropriate and at what intervals?</text>
<text top="454" left="199" width="6" height="10" font="9">n</text>
<text top="454" left="213" width="259" height="9" font="13">How is protein-losing enteropathy best medically treated?</text>
<text top="465" left="199" width="6" height="10" font="9">n</text>
<text top="466" left="213" width="480" height="9" font="13">Why do some patients fail with preserved ejection fraction, whereas other have decreased ejection fraction?</text>
<text top="476" left="199" width="6" height="10" font="9">n</text>
<text top="477" left="213" width="312" height="9" font="13">What are the long-term outcomes of hypoplastic left heart syndrome?</text>
<text top="487" left="199" width="6" height="10" font="9">n</text>
<text top="488" left="213" width="529" height="9" font="13">What is ideal timing for heart transplantation in single ventricle Fontan patients, and should liver issues prompt earlier</text>
<text top="498" left="214" width="322" height="9" font="13">transplantation than might be felt necessary from a cardiac perspective?</text>
<text top="509" left="199" width="6" height="10" font="9">n</text>
<text top="509" left="213" width="399" height="9" font="13">Which has better long-term outcomes, the Fontan operation or bidirectional Glenn alone?</text>
<text top="529" left="63" width="82" height="9" font="13">Coronary anomalies</text>
<text top="532" left="199" width="6" height="10" font="9">n</text>
<text top="532" left="213" width="405" height="9" font="13">Does surgical intervention in anomalous aortic origin of coronary arteries improve survival?</text>
<text top="556" left="63" width="694" height="8" font="5">ACE indicates angiotensin-converting enzyme; ACHD, adult congenital heart disease; ARB, angiotensin-receptor blocker; ASO, arterial switch operation; CCTGA, congenitally corrected</text>
<text top="568" left="63" width="505" height="8" font="5">transposition of the great arteries; CHD, congenital heart disease; CMR, cardiac magnetic resonance; ICD, implantable cardioverter-de</text>
<text top="566" left="567" width="189" height="11" font="5">ﬁbrillator; HF, heart failure; PA, pulmonary artery;</text>
<text top="580" left="63" width="694" height="8" font="5">PAH, pulmonary artery hypertension; PS, pulmonary stenosis; SCD, sudden cardiac death; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; and VSD, ventricular septal</text>
<text top="592" left="63" width="27" height="8" font="5">defect.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="789" width="19" height="9" font="5">1543</text>
</page>
<page number="51" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="28" size="7" family="Times" color="#e3202b"/>
<text top="160" left="108" width="82" height="12" font="28">R E F E R E N C E S</text>
<text top="207" left="108" width="67" height="12" font="28">P R E A M B L E</text>
<text top="245" left="108" width="15" height="9" font="5">P-1.</text>
<text top="245" left="126" width="44" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref1">Committee</a></text>
<text top="245" left="182" width="10" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref1">on</a></text>
<text top="245" left="204" width="40" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref1">Standards</a></text>
<text top="245" left="256" width="12" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref1">for</a></text>
<text top="245" left="280" width="45" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref1">Developing</a></text>
<text top="258" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref1">Trustworthy Clinical Practice Guidelines, Institute of</a></text>
<text top="272" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref1">Medicine (U.S.). Clinical Practice Guidelines We Can</a></text>
<text top="285" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref1">Trust. Washington, DC: The National Academies</a></text>
<text top="299" left="108" width="47" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref1">Press, 2011</a></text>
<text top="299" left="155" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref1">.</a></text>
<text top="314" left="108" width="16" height="9" font="5">P-2.</text>
<text top="314" left="127" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref2">Committee on Standards for Systematic Re-</a></text>
<text top="328" left="108" width="22" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref2">views</a></text>
<text top="328" left="141" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref2">of</a></text>
<text top="328" left="161" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref2">Comparative</a></text>
<text top="328" left="222" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref2">Effectiveness</a></text>
<text top="328" left="286" width="38" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref2">Research,</a></text>
<text top="341" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref2">Institute of Medicine (U.S.). Finding What Works in</a></text>
<text top="355" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref2">Health Care: Standards for Systematic Reviews.</a></text>
<text top="368" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref2">Washington, DC: The National Academies Press,</a></text>
<text top="381" left="108" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref2">2011</a></text>
<text top="381" left="126" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref2">.</a></text>
<text top="400" left="108" width="16" height="9" font="5">P-3.</text>
<text top="400" left="127" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref3">Anderson JL, Heidenreich PA, Barnett PG, et al.</a></text>
<text top="413" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref3">ACC/AHA statement on cost/value methodology in</a></text>
<text top="427" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref3">clinical practice guidelines and performance measures:</a></text>
<text top="440" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref3">a report of the American College of Cardiology/</a></text>
<text top="454" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref3">American Heart Association Task Force on Perfor-</a></text>
<text top="467" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref3">mance Measures and Task Force on Practice Guide-</a></text>
<text top="481" left="108" width="156" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref3">lines. J Am Coll Cardiol. 2014;63:2304</a></text>
<text top="479" left="263" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref3">–22</a></text>
<text top="481" left="277" width="3" height="9" font="5">.</text>
<text top="499" left="108" width="217" height="9" font="5">P-4. ACCF/AHA Task Force on Practice Guidelines.</text>
<text top="513" left="108" width="217" height="9" font="5">Methodology Manual and Policies From the ACCF/AHA</text>
<text top="526" left="108" width="217" height="9" font="5">Task Force on Practice Guidelines. American College</text>
<text top="540" left="108" width="8" height="9" font="5">of</text>
<text top="540" left="125" width="43" height="9" font="5">Cardiology</text>
<text top="540" left="176" width="15" height="9" font="5">and</text>
<text top="540" left="200" width="37" height="9" font="5">American</text>
<text top="540" left="246" width="22" height="9" font="5">Heart</text>
<text top="540" left="277" width="48" height="9" font="5">Association,</text>
<text top="553" left="108" width="84" height="9" font="5">2010. Available at:</text>
<text top="553" left="198" width="126" height="9" font="6"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">http://assets.cardiosource.com/</a></text>
<text top="567" left="108" width="217" height="9" font="6"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">Methodology_Manual_for_ACC_AHA_Writing_Committees.</a></text>
<text top="580" left="108" width="13" height="9" font="6"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">pdf</a></text>
<text top="580" left="133" width="15" height="9" font="5">and</text>
<text top="580" left="161" width="164" height="9" font="6"><a href="http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">http://professional.heart.org/idc/groups/</a></text>
<text top="593" left="108" width="217" height="9" font="6"><a href="http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">ahamah-public/@wcm/@sop/documents/downloadable/</a></text>
<text top="607" left="108" width="63" height="9" font="6"><a href="http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">ucm_319826.pdf</a></text>
<text top="607" left="171" width="127" height="9" font="5"><a href="http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">. </a>Accessed September 15, 2017.</text>
<text top="625" left="108" width="16" height="9" font="5">P-5.</text>
<text top="625" left="127" width="34" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">Halperin</a></text>
<text top="625" left="172" width="11" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">JL,</a></text>
<text top="625" left="196" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">Levine</a></text>
<text top="625" left="233" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">GN,</a></text>
<text top="625" left="260" width="38" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">Al-Khatib</a></text>
<text top="625" left="310" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">SM,</a></text>
<text top="639" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">et al. Further evolution of the ACC/AHA clinical</a></text>
<text top="652" left="108" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">practice</a></text>
<text top="652" left="149" width="36" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">guideline</a></text>
<text top="652" left="196" width="67" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">recommendation</a></text>
<text top="652" left="274" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">classi</a></text>
<text top="651" left="295" width="30" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">ﬁcation</a></text>
<text top="666" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">system: a report of the American College of</a></text>
<text top="679" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">Cardiology/American Heart Association Task Force</a></text>
<text top="693" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">on Clinical Practice Guidelines. J Am Coll Car-</a></text>
<text top="706" left="108" width="78" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">diol. 2016;67:1572</a></text>
<text top="704" left="186" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref5">–4</a></text>
<text top="706" left="195" width="3" height="9" font="5">.</text>
<text top="725" left="108" width="17" height="9" font="5">P-6.</text>
<text top="725" left="127" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref6">Jacobs AK, Kushner FG, Ettinger SM, et al.</a></text>
<text top="738" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref6">ACCF/AHA clinical practice guideline methodology</a></text>
<text top="751" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref6">summit report: a report of the American College</a></text>
<text top="765" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref6">of Cardiology Foundation/American Heart Associa-</a></text>
<text top="778" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref6">tion Task Force on Practice Guidelines. J Am Coll</a></text>
<text top="792" left="108" width="83" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref6">Cardiol. 2013;61:213</a></text>
<text top="790" left="191" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref6">–65</a></text>
<text top="792" left="205" width="3" height="9" font="5">.</text>
<text top="810" left="108" width="16" height="9" font="5">P-7.</text>
<text top="810" left="127" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref7">Jacobs AK, Anderson JL, Halperin JL, et al. The</a></text>
<text top="824" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref7">evolution and future of ACC/AHA clinical practice</a></text>
<text top="837" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref7">guidelines: a 30-year journey: a report of the American</a></text>
<text top="851" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref7">College of Cardiology/American Heart Association Task</a></text>
<text top="864" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref7">Force on practice guidelines. J Am Coll Cardiol. 2014;</a></text>
<text top="878" left="108" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref7">64:1373</a></text>
<text top="876" left="139" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref7">–84</a></text>
<text top="878" left="154" width="3" height="9" font="5">.</text>
<text top="893" left="108" width="17" height="9" font="5">P-8.</text>
<text top="893" left="127" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref8">Arnett DK, Goodman RA, Halperin JL, et al.</a></text>
<text top="907" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref8">AHA/ACC/HHS strategies to enhance application</a></text>
<text top="920" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref8">of clinical practice guidelines in patients with</a></text>
<text top="934" left="108" width="57" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref8">cardiovascular</a></text>
<text top="934" left="173" width="29" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref8">disease</a></text>
<text top="934" left="211" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref8">and</a></text>
<text top="934" left="235" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref8">comorbid</a></text>
<text top="934" left="281" width="44" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref8">conditions:</a></text>
<text top="947" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref8">from the American Heart Association, American</a></text>
<text top="960" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref8">College of Cardiology, and US Department of</a></text>
<text top="974" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref8">Health and Human Services. J Am Coll Cardiol.</a></text>
<text top="987" left="108" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref8">2014;64:1851</a></text>
<text top="986" left="162" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref8">–6</a></text>
<text top="987" left="171" width="3" height="9" font="5">.</text>
<text top="1006" left="108" width="17" height="9" font="5">P-9.</text>
<text top="1006" left="127" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref9">Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018</a></text>
<text top="1019" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref9">AHA/ACC guideline for the management of adults with</a></text>
<text top="1033" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref9">congenital heart disease: a report of the American</a></text>
<text top="1046" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref9">College of Cardiology/American Heart Association Task</a></text>
<text top="1060" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref9">Force on Clinical Practice Guidelines. J Am Coll Cardiol.</a></text>
<text top="1073" left="108" width="145" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref9">2018 Aug 10 [E-pub ahead of print]</a></text>
<text top="1073" left="253" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref9">.</a></text>
<text top="207" left="346" width="110" height="12" font="28">1 . I N T R O D U C T I O N</text>
<text top="244" left="346" width="178" height="9" font="24">1.1. Methodology and Evidence Review</text>
<text top="258" left="346" width="25" height="9" font="5">S1.1-1.</text>
<text top="258" left="373" width="190" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref10">Zaragoza-Macias E, Zaidi A, Dendukuri N, et al.</a></text>
<text top="271" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref10">Medical therapy for systemic right ventricles: a sys-</a></text>
<text top="285" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref10">tematic review (part 1) for the 2018 AHA/ACC guide-</a></text>
<text top="298" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref10">line for the management of adults with congenital</a></text>
<text top="312" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref10">heart disease: a report of the American College of</a></text>
<text top="325" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref10">Cardiology/American Heart Association Task Force on</a></text>
<text top="339" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref10">Clinical Practice Guidelines. J Am Coll Cardiol. 2018</a></text>
<text top="352" left="346" width="118" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref10">Aug 9 [E-pub ahead of print]</a></text>
<text top="352" left="464" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref10">.</a></text>
<text top="371" left="346" width="25" height="9" font="5">S1.1-2.</text>
<text top="371" left="374" width="189" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref11">Oster M, Bhatt A, Zaragoza-Macias E, et al.</a></text>
<text top="385" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref11">Interventional therapy versus medical therapy for</a></text>
<text top="398" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref11">secundum atrial septal defect: a systematic review (part</a></text>
<text top="412" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref11">2) for the 2018 AHA/ACC guideline for the management</a></text>
<text top="425" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref11">of adults with congenital heart disease: a report of the</a></text>
<text top="439" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref11">American College of Cardiology/American Heart Asso-</a></text>
<text top="452" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref11">ciation Task Force on Clinical Practice Guidelines. J Am</a></text>
<text top="466" left="346" width="190" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref11">Coll Cardiol. 2018 Aug 9 [E-pub ahead of print]</a></text>
<text top="466" left="536" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref11">.</a></text>
<text top="488" left="346" width="122" height="9" font="24">1.4. Scope of the Guideline</text>
<text top="503" left="346" width="26" height="9" font="5">S1.4-1.</text>
<text top="503" left="375" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref12">Warnes CA, Williams RG, Bashore TM, et al.</a></text>
<text top="516" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref12">ACC/AHA 2008 guidelines for the management of</a></text>
<text top="530" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref12">adults with congenital heart disease: a report of the</a></text>
<text top="543" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref12">American College of Cardiology/American Heart As-</a></text>
<text top="556" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref12">sociation Task Force on Practice Guidelines (Writing</a></text>
<text top="570" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref12">Committee to Develop Guidelines on the Management</a></text>
<text top="583" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref12">of Adults With Congenital Heart Disease). J Am Coll</a></text>
<text top="597" left="346" width="90" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref12">Cardiol. 2008;52:e143</a></text>
<text top="595" left="435" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref12">–263</a></text>
<text top="597" left="455" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref12">.</a></text>
<text top="616" left="346" width="27" height="9" font="5">S1.4-2.</text>
<text top="616" left="376" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref13">Nishimura RA, Otto CM, Bonow RO, et al. 2014</a></text>
<text top="630" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref13">AHA/ACC guideline for the management of patients</a></text>
<text top="643" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref13">with valvular heart disease: a report of the American</a></text>
<text top="656" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref13">College of Cardiology/American Heart Association Task</a></text>
<text top="670" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref13">Force on Practice Guidelines. J Am Coll Cardiol. 2014;</a></text>
<text top="683" left="346" width="27" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref13">63:e57</a></text>
<text top="682" left="373" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref13">–185</a></text>
<text top="683" left="391" width="3" height="9" font="5">.</text>
<text top="703" left="346" width="27" height="9" font="5">S1.4-3.</text>
<text top="703" left="376" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref14">Moons P, Bovijn L, Budts W, et al. Temporal</a></text>
<text top="716" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref14">trends in survival to adulthood among patients born</a></text>
<text top="729" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref14">with congenital heart disease from 1970 to 1992 in</a></text>
<text top="743" left="346" width="146" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref14">Belgium. Circulation. 2010;122:2264</a></text>
<text top="741" left="492" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref14">–72</a></text>
<text top="743" left="505" width="3" height="9" font="5">.</text>
<text top="762" left="346" width="28" height="9" font="5">S1.4-4.</text>
<text top="762" left="377" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref15">Gilboa SM, Salemi JL, Nembhard WN, et al.</a></text>
<text top="776" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref15">Mortality resulting from congenital heart disease</a></text>
<text top="789" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref15">among children and adults in the United States, 1999</a></text>
<text top="803" left="346" width="147" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref15">to 2006. Circulation. 2010;122:2254</a></text>
<text top="801" left="493" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref15">–63</a></text>
<text top="803" left="507" width="3" height="9" font="5">.</text>
<text top="822" left="346" width="27" height="9" font="5">S1.4-5.</text>
<text top="822" left="376" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref16">van der Bom T, Bouma BJ, Meijboom FJ, et al.</a></text>
<text top="835" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref16">The prevalence of adult congenital heart disease, re-</a></text>
<text top="849" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref16">sults from a systematic review and evidence based</a></text>
<text top="862" left="346" width="155" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref16">calculation. Am Heart J. 2012;164:568</a></text>
<text top="860" left="501" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref16">–75</a></text>
<text top="862" left="514" width="3" height="9" font="5">.</text>
<text top="881" left="346" width="28" height="9" font="5">S1.4-6.</text>
<text top="881" left="377" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref17">Hoffman JIE, Kaplan S, Liberthson RR. Preva-</a></text>
<text top="895" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref17">lence of congenital heart disease. Am Heart J. 2004;</a></text>
<text top="908" left="346" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref17">147:425</a></text>
<text top="907" left="377" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref17">–39</a></text>
<text top="908" left="392" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref17">.</a></text>
<text top="927" left="346" width="27" height="9" font="5">S1.4-7.</text>
<text top="927" left="376" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref18">Lien WP, Chen JJ, Chen JH, et al. Frequency of</a></text>
<text top="941" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref18">various congenital heart diseases in Chinese adults:</a></text>
<text top="954" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref18">analysis of 926 consecutive patients over 13 years of</a></text>
<text top="968" left="346" width="129" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref18">age. Am J Cardiol. 1986;57:840</a></text>
<text top="966" left="475" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref18">–4</a></text>
<text top="968" left="484" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref18">.</a></text>
<text top="987" left="346" width="28" height="9" font="5">S1.4-8.</text>
<text top="987" left="377" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref19">Samánek M, Slavík Z, Zborilová B, et al.</a></text>
<text top="1000" left="346" width="48" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref19">Prevalence,</a></text>
<text top="1000" left="402" width="44" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref19">treatment,</a></text>
<text top="1000" left="455" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref19">and</a></text>
<text top="1000" left="479" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref19">outcome of</a></text>
<text top="1000" left="541" width="22" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref19">heart</a></text>
<text top="1014" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref19">disease in live-born children: a prospective analysis</a></text>
<text top="1027" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref19">of 91,823 live-born children. Pediatr Cardiol. 1989;</a></text>
<text top="1041" left="346" width="29" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref19">10:205</a></text>
<text top="1039" left="375" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref19">–11</a></text>
<text top="1041" left="387" width="3" height="9" font="5">.</text>
<text top="1060" left="346" width="28" height="9" font="5">S1.4-9.</text>
<text top="1060" left="377" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref20">Mylotte D, Pilote L, Ionescu-Ittu R, et al.</a></text>
<text top="1074" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref20">Specialized adult congenital heart disease care: the</a></text>
<text top="191" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref20">impact of policy on mortality. Circulation. 2014;129:</a></text>
<text top="205" left="584" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref20">1804</a></text>
<text top="203" left="605" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref20">–12</a></text>
<text top="205" left="618" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref20">.</a></text>
<text top="223" left="584" width="32" height="9" font="5">S1.4-10.</text>
<text top="223" left="620" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref21">Shen W-K, Sheldon RS, Benditt DG, et al. 2017</a></text>
<text top="237" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref21">ACC/AHA/HRS guideline for the evaluation and man-</a></text>
<text top="250" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref21">agement of patients with syncope: a report of the</a></text>
<text top="264" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref21">American College of Cardiology/American Heart As-</a></text>
<text top="277" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref21">sociation Task Force on Clinical Practice Guidelines and</a></text>
<text top="291" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref21">the Heart Rhythm Society. J Am Coll Cardiol. 2017;70:</a></text>
<text top="304" left="584" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref21">e39</a></text>
<text top="303" left="599" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref21">–110</a></text>
<text top="304" left="617" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref21">.</a></text>
<text top="323" left="584" width="30" height="9" font="5">S1.4-11.</text>
<text top="323" left="617" width="184" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref22">Page RL, Joglar JA, Caldwell MA, et al. 2015</a></text>
<text top="337" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref22">ACC/AHA/HRS guideline for the management of adult</a></text>
<text top="350" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref22">patients with supraventricular tachycardia: a report of</a></text>
<text top="363" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref22">the American College of Cardiology/American Heart</a></text>
<text top="377" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref22">Association Task Force on Clinical Practice Guidelines</a></text>
<text top="390" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref22">and the Heart Rhythm Society. J Am Coll Cardiol.</a></text>
<text top="404" left="584" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref22">2016;67:e27</a></text>
<text top="402" left="634" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref22">–115</a></text>
<text top="404" left="650" width="3" height="9" font="5">.</text>
<text top="423" left="584" width="31" height="9" font="5">S1.4-12.</text>
<text top="423" left="618" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref23">Callaway CW, Donnino MW, Fink EL, et al. Part</a></text>
<text top="436" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref23">8: post-cardiac arrest care: 2015 American Heart As-</a></text>
<text top="449" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref23">sociation guidelines update for cardiopulmonary</a></text>
<text top="463" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref23">resuscitation and emergency cardiovascular care. Cir-</a></text>
<text top="476" left="584" width="96" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref23">culation. 2015;132:S465</a></text>
<text top="475" left="680" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref23">–82</a></text>
<text top="476" left="695" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref23">.</a></text>
<text top="495" left="584" width="31" height="9" font="5">S1.4-13.</text>
<text top="495" left="618" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref24">Amsterdam EA, Wenger NK, Brindis RG, et al.</a></text>
<text top="509" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref24">2014 AHA/ACC guideline for the management of pa-</a></text>
<text top="522" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref24">tients with non-ST-elevation acute coronary syn-</a></text>
<text top="536" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref24">dromes: a report of the American College of Cardiology/</a></text>
<text top="549" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref24">American Heart Association Task Force on Practice</a></text>
<text top="562" left="584" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref24">Guidelines. J Am Coll Cardiol. 2014;64:e139</a></text>
<text top="561" left="758" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref24">–228</a></text>
<text top="562" left="777" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref24">.</a></text>
<text top="581" left="584" width="32" height="9" font="5">S1.4-14.</text>
<text top="581" left="619" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref25">Fleisher LA, Fleischmann KE, Auerbach AD,</a></text>
<text top="595" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref25">et al. 2014 ACC/AHA guideline on perioperative car-</a></text>
<text top="608" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref25">diovascular evaluation and management of patients</a></text>
<text top="622" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref25">undergoing noncardiac surgery: a report of the</a></text>
<text top="635" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref25">American College of Cardiology/American Heart As-</a></text>
<text top="649" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref25">sociation Task Force on Practice Guidelines. J Am Coll</a></text>
<text top="662" left="584" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref25">Cardiol. 2014;64:e77</a></text>
<text top="660" left="668" width="17" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref25">–137</a></text>
<text top="662" left="685" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref25">.</a></text>
<text top="681" left="584" width="31" height="9" font="5">S1.4-15.</text>
<text top="681" left="618" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref26">January CT, Wann LS, Alpert JS, et al. 2014</a></text>
<text top="694" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref26">AHA/ACC/HRS guideline for the management of pa-</a></text>
<text top="708" left="584" width="67" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref26">tients with atrial</a></text>
<text top="706" left="654" width="147" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref26">ﬁbrillation: a report of the American</a></text>
<text top="721" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref26">College of Cardiology/American Heart Association Task</a></text>
<text top="735" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref26">Force on Practice Guidelines and the Heart Rhythm</a></text>
<text top="748" left="584" width="154" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref26">Society. J Am Coll Cardiol. 2014;64:e1</a></text>
<text top="746" left="738" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref26">–76</a></text>
<text top="748" left="753" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref26">.</a></text>
<text top="767" left="584" width="32" height="9" font="5">S1.4-16.</text>
<text top="767" left="619" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref27">Fihn SD, Blankenship JC, Alexander KP, et al.</a></text>
<text top="780" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref27">2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of</a></text>
<text top="794" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref27">the guideline for the diagnosis and management of pa-</a></text>
<text top="807" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref27">tients with stable ischemic heart disease: a report of the</a></text>
<text top="821" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref27">American College of Cardiology/American Heart Associ-</a></text>
<text top="834" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref27">ation Task Force on Practice Guidelines, and the Amer-</a></text>
<text top="848" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref27">ican Association for Thoracic Surgery, Preventive</a></text>
<text top="861" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref27">Cardiovascular Nurses Association, Society for Cardio-</a></text>
<text top="874" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref27">vascular Angiography and Interventions, and Society of</a></text>
<text top="888" left="584" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref27">Thoracic Surgeons. J Am Coll Cardiol. 2014;64:1929</a></text>
<text top="886" left="784" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref27">–49</a></text>
<text top="888" left="799" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref27">.</a></text>
<text top="907" left="584" width="31" height="9" font="5">S1.4-17.</text>
<text top="907" left="618" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref28">Fihn SD, Gardin JM, Abrams J, et al. 2012</a></text>
<text top="920" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref28">ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for</a></text>
<text top="934" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref28">the diagnosis and management of patients with stable</a></text>
<text top="947" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref28">ischemic heart disease: a report of the American Col-</a></text>
<text top="961" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref28">lege of Cardiology Foundation/American Heart Asso-</a></text>
<text top="974" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref28">ciation Task Force on Practice Guidelines, and the</a></text>
<text top="987" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref28">American College of Physicians, American Association</a></text>
<text top="1001" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref28">for Thoracic Surgery, Preventive Cardiovascular Nurses</a></text>
<text top="1014" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref28">Association, Society for Cardiovascular Angiography</a></text>
<text top="1028" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref28">and Interventions, and Society of Thoracic Surgeons. J</a></text>
<text top="1041" left="584" width="120" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref28">Am Coll Cardiol. 2012;60:e44</a></text>
<text top="1040" left="704" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref28">–164</a></text>
<text top="1041" left="723" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref28">.</a></text>
<text top="1060" left="584" width="32" height="9" font="5">S1.4-18.</text>
<text top="1060" left="619" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref29">Goff DC Jr., Lloyd-Jones DM, Bennett G, et al.</a></text>
<text top="1074" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref29">2013 ACC/AHA guideline on the assessment of</a></text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="19" height="9" font="5">1544</text>
</page>
<page number="52" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref29">cardiovascular risk: a report of the American College of</a></text>
<text top="156" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref29">Cardiology/American Heart Association Task Force on</a></text>
<text top="170" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref29">Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt</a></text>
<text top="183" left="63" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref29">B):2935</a></text>
<text top="182" left="94" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref29">–59</a></text>
<text top="183" left="109" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref29">.</a></text>
<text top="203" left="63" width="32" height="9" font="5">S1.4-19.</text>
<text top="203" left="98" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref30">Stone NJ, Robinson JG, Lichtenstein AH, et al.</a></text>
<text top="216" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref30">2013 ACC/AHA guideline on the treatment of blood</a></text>
<text top="230" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref30">cholesterol to reduce atherosclerotic cardiovascular risk in</a></text>
<text top="243" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref30">adults: a report of the American College of Cardiology/</a></text>
<text top="256" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref30">American Heart Association Task Force on Practice Guide-</a></text>
<text top="270" left="63" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref30">lines. J Am Coll Cardiol. 2014;63(25 Pt B):2889</a></text>
<text top="268" left="241" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref30">–934</a></text>
<text top="270" left="259" width="3" height="9" font="5">.</text>
<text top="289" left="63" width="33" height="9" font="5">S1.4-20.</text>
<text top="289" left="99" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref31">Jensen MD, Ryan DH, Apovian CM, et al. 2013</a></text>
<text top="303" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref31">AHA/ACC/TOS guideline for the management of over-</a></text>
<text top="316" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref31">weight and obesity in adults: a report of the American</a></text>
<text top="330" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref31">College of Cardiology/American Heart Association Task</a></text>
<text top="343" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref31">Force on Practice Guidelines and The Obesity Society. J</a></text>
<text top="357" left="63" width="155" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref31">Am Coll Cardiol. 2014;63(25 Pt B):2985</a></text>
<text top="355" left="218" width="24" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref31">–3023</a></text>
<text top="357" left="242" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref31">.</a></text>
<text top="376" left="63" width="31" height="9" font="5">S1.4-21.</text>
<text top="376" left="97" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref32">Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/</a></text>
<text top="389" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref32">ACC guideline on lifestyle management to reduce</a></text>
<text top="403" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref32">cardiovascular risk: a report of the American College of</a></text>
<text top="416" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref32">Cardiology/American Heart Association Task Force on</a></text>
<text top="430" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref32">Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt</a></text>
<text top="443" left="63" width="33" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref32">B):2960</a></text>
<text top="442" left="96" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref32">–84</a></text>
<text top="443" left="111" width="3" height="9" font="5">.</text>
<text top="462" left="63" width="32" height="9" font="5">S1.4-22.</text>
<text top="462" left="98" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref33">Nishimura RA, Otto CM, Bonow RO, et al.</a></text>
<text top="476" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref33">2017 AHA/ACC focused update of the 2014 AHA/ACC</a></text>
<text top="489" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref33">guideline for the management of patients with</a></text>
<text top="503" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref33">valvular heart disease: a report of the American Col-</a></text>
<text top="516" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref33">lege of Cardiology/American Heart Association Task</a></text>
<text top="530" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref33">Force on Clinical Practice Guidelines. J Am Coll Cardiol.</a></text>
<text top="543" left="63" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref33">2017;70:252</a></text>
<text top="542" left="112" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref33">–89</a></text>
<text top="543" left="128" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref33">.</a></text>
<text top="562" left="63" width="32" height="9" font="5">S1.4-23.</text>
<text top="562" left="98" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref34">Whelton PK, Carey RM, Aronow WS, et al. 2017</a></text>
<text top="576" left="63" width="216" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref34">ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/</a></text>
<text top="589" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref34">PCNA guideline for the prevention, detection, evalua-</a></text>
<text top="603" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref34">tion, and management of high blood pressure in adults:</a></text>
<text top="616" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref34">a report of the American College of Cardiology/Amer-</a></text>
<text top="630" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref34">ican Heart Association Task Force on Clinical Practice</a></text>
<text top="643" left="63" width="169" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref34">Guidelines. J Am Coll Cardiol. 2018;71:e127</a></text>
<text top="642" left="232" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref34">–248</a></text>
<text top="643" left="252" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref34">.</a></text>
<text top="662" left="63" width="33" height="9" font="5">S1.4-24.</text>
<text top="662" left="99" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref35">Svensson LG, Adams DH, Bonow RO, et al. Aortic</a></text>
<text top="676" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref35">valve and ascending aorta guidelines for management and</a></text>
<text top="689" left="63" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref35">quality measures. Ann Thorac Surg. 2013;95:S1</a></text>
<text top="688" left="242" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref35">–66</a></text>
<text top="689" left="257" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref35">.</a></text>
<text top="709" left="63" width="32" height="9" font="5">S1.4-25.</text>
<text top="709" left="98" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref36">O</a></text>
<text top="707" left="104" width="176" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref36">’Gara PT, Kushner FG, Ascheim DD, et al.</a></text>
<text top="722" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref36">2013 ACCF/AHA guideline for the management of ST-</a></text>
<text top="736" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref36">elevation myocardial infarction: a report of the</a></text>
<text top="749" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref36">American College of Cardiology Foundation/American</a></text>
<text top="763" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref36">Heart Association Task Force on Practice Guidelines. J</a></text>
<text top="776" left="63" width="117" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref36">Am Coll Cardiol. 2013;61:e78</a></text>
<text top="774" left="180" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref36">–140</a></text>
<text top="776" left="199" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref36">.</a></text>
<text top="795" left="63" width="33" height="9" font="5">S1.4-26.</text>
<text top="795" left="99" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref37">Yancy CW, Jessup M, Bozkurt B, et al. 2017</a></text>
<text top="809" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref37">ACC/AHA/HFSA focused update of the 2013 ACCF/AHA</a></text>
<text top="822" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref37">guideline for the management of heart failure: a report</a></text>
<text top="836" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref37">of the American College of Cardiology/American Heart</a></text>
<text top="849" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref37">Association Task Force on Clinical Practice Guidelines</a></text>
<text top="863" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref37">and the Heart Failure Society of America. Circulation.</a></text>
<text top="876" left="63" width="56" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref37">2017;136:e137</a></text>
<text top="874" left="119" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref37">–61</a></text>
<text top="876" left="132" width="3" height="9" font="5">.</text>
<text top="895" left="63" width="32" height="9" font="5">S1.4-27.</text>
<text top="895" left="98" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref38">Tracy CM, Epstein AE, Darbar D, et al. 2012</a></text>
<text top="909" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref38">ACCF/AHA/HRS focused update of the 2008 guide-</a></text>
<text top="922" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref38">lines for device-based therapy of cardiac rhythm ab-</a></text>
<text top="936" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref38">normalities: a report of the American College of</a></text>
<text top="949" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref38">Cardiology Foundation/American Heart Association</a></text>
<text top="963" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref38">Task Force on Practice Guidelines and the Heart</a></text>
<text top="976" left="63" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref38">Rhythm Society. J Am Coll Cardiol. 2012;60:1297</a></text>
<text top="974" left="260" width="17" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref38">–313</a></text>
<text top="976" left="277" width="3" height="9" font="5">.</text>
<text top="995" left="63" width="33" height="9" font="5">S1.4-28.</text>
<text top="995" left="99" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref39">Hillis LD, Smith PK, Anderson JL, et al. 2011</a></text>
<text top="1009" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref39">ACCF/AHA guideline for coronary artery bypass graft</a></text>
<text top="1022" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref39">surgery: a report of the American College of Cardiol-</a></text>
<text top="1036" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref39">ogy Foundation/American Heart Association Task</a></text>
<text top="1049" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref39">Force on Practice Guidelines. J Am Coll Cardiol. 2011;</a></text>
<text top="1063" left="63" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref39">58:e123</a></text>
<text top="1061" left="94" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref39">–210</a></text>
<text top="1063" left="112" width="3" height="9" font="5">.</text>
<text top="1082" left="63" width="33" height="9" font="5">S1.4-29.</text>
<text top="1082" left="99" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref40">Levine GN, Bates ER, Blankenship JC, et al.</a></text>
<text top="1095" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref40">2011 ACCF/AHA/SCAI guideline for percutaneous</a></text>
<text top="143" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref40">coronary intervention: a report of the American Col-</a></text>
<text top="156" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref40">lege of Cardiology Foundation/American Heart Asso-</a></text>
<text top="170" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref40">ciation Task Force on Practice Guidelines and the</a></text>
<text top="183" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref40">Society for Cardiovascular Angiography and In-</a></text>
<text top="197" left="301" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref40">terventions. J Am Coll Cardiol. 2011;58:e44</a></text>
<text top="195" left="477" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref40">–122</a></text>
<text top="197" left="494" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref40">.</a></text>
<text top="215" left="301" width="33" height="9" font="5">S1.4-30.</text>
<text top="215" left="337" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref41">Smith SC Jr., Benjamin EJ, Bonow RO, et al.</a></text>
<text top="229" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref41">AHA/ACCF secondary prevention and risk reduction</a></text>
<text top="242" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref41">therapy for patients with coronary and other athero-</a></text>
<text top="256" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref41">sclerotic vascular disease: 2011 update: a guideline</a></text>
<text top="269" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref41">from the American Heart Association and American</a></text>
<text top="283" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref41">College of Cardiology Foundation. J Am Coll Cardiol.</a></text>
<text top="296" left="301" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref41">2011;58:2432</a></text>
<text top="294" left="355" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref41">–46</a></text>
<text top="296" left="370" width="3" height="9" font="5">.</text>
<text top="315" left="301" width="31" height="9" font="5">S1.4-31.</text>
<text top="315" left="335" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref42">Mosca L, Benjamin EJ, Berra K, et al. Effec-</a></text>
<text top="328" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref42">tiveness-based guidelines for the prevention of car-</a></text>
<text top="342" left="301" width="45" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref42">diovascular</a></text>
<text top="342" left="355" width="29" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref42">disease</a></text>
<text top="342" left="394" width="7" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref42">in</a></text>
<text top="342" left="410" width="29" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref42">women</a></text>
<text top="340" left="439" width="79" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref42">—2011 update: a</a></text>
<text top="355" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref42">guideline from the American Heart Association. Circu-</a></text>
<text top="368" left="301" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref42">lation. 2011;123:1243</a></text>
<text top="367" left="385" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref42">–62</a></text>
<text top="368" left="399" width="3" height="9" font="5">.</text>
<text top="387" left="301" width="32" height="9" font="5">S1.4-32.</text>
<text top="387" left="336" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref43">Baumgartner H, Bonhoeffer P, De Groot NMS,</a></text>
<text top="400" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref43">et al. ESC guidelines for the management of grown-up</a></text>
<text top="414" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref43">congenital heart disease (new version 2010). Eur Heart</a></text>
<text top="427" left="301" width="63" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref43">J. 2010;31:2915</a></text>
<text top="426" left="364" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref43">–57</a></text>
<text top="427" left="377" width="3" height="9" font="5">.</text>
<text top="446" left="301" width="32" height="9" font="5">S1.4-33.</text>
<text top="446" left="336" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">Hiratzka LF, Bakris GL, Beckman JA, et al.</a></text>
<text top="459" left="301" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">2010</a></text>
<text top="459" left="333" width="185" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/</a></text>
<text top="473" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">SVM guidelines for the diagnosis and management of</a></text>
<text top="486" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">patients with thoracic aortic disease: a report of the</a></text>
<text top="500" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">American College of Cardiology Foundation/American</a></text>
<text top="513" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">Heart Association Task Force on Practice Guidelines,</a></text>
<text top="527" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">American Association for Thoracic Surgery, American</a></text>
<text top="540" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">College of Radiology, American Stroke Association,</a></text>
<text top="554" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">Society of Cardiovascular Anesthesiologists, Society</a></text>
<text top="567" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">for Cardiovascular Angiography and Interventions,</a></text>
<text top="580" left="301" width="29" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">Society</a></text>
<text top="580" left="339" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">of</a></text>
<text top="580" left="356" width="56" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">Interventional</a></text>
<text top="580" left="421" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">Radiology,</a></text>
<text top="580" left="472" width="29" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">Society</a></text>
<text top="580" left="510" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">of</a></text>
<text top="594" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">Thoracic Surgeons, and Society for Vascular Medicine.</a></text>
<text top="607" left="301" width="125" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">J Am Coll Cardiol. 2010;55:e27</a></text>
<text top="606" left="426" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref44">–129</a></text>
<text top="607" left="444" width="3" height="9" font="5">.</text>
<text top="626" left="301" width="33" height="9" font="5">S1.4-34.</text>
<text top="626" left="337" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref45">Silversides CK, Marelli A, Beauchesne L, et al.</a></text>
<text top="639" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref45">Canadian Cardiovascular Society 2009 consensus</a></text>
<text top="653" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref45">conference on the management of adults with</a></text>
<text top="666" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref45">congenital heart disease: executive summary. Can J</a></text>
<text top="680" left="301" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref45">Cardiol. 2010;26:143</a></text>
<text top="678" left="385" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref45">–50</a></text>
<text top="680" left="400" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref45">.</a></text>
<text top="698" left="301" width="32" height="9" font="5">S1.4-35.</text>
<text top="698" left="336" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref46">Habib G, Hoen B, Tornos P, et al. Guidelines</a></text>
<text top="712" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref46">on the prevention, diagnosis, and treatment of infec-</a></text>
<text top="725" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref46">tive endocarditis (new version 2009): the Task Force</a></text>
<text top="739" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref46">on the Prevention, Diagnosis, and Treatment of</a></text>
<text top="752" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref46">Infective Endocarditis of the European Society of</a></text>
<text top="766" left="301" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref46">Cardiology (ESC). Eur Heart J. 2009;30:2369</a></text>
<text top="764" left="484" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref46">–413</a></text>
<text top="766" left="502" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref46">.</a></text>
<text top="784" left="301" width="33" height="9" font="5">S1.4-36.</text>
<text top="784" left="337" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref47">Cohen MS, Eidem BW, Cetta F, et al. Multi-</a></text>
<text top="798" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref47">modality imaging guidelines of patients with trans-</a></text>
<text top="811" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref47">position of the great arteries: a report from the</a></text>
<text top="824" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref47">American Society of Echocardiography. Developed in</a></text>
<text top="838" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref47">collaboration with the Society for Cardiovascular</a></text>
<text top="851" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref47">Magnetic Resonance and the Society of Cardiovascular</a></text>
<text top="865" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref47">Computed Tomography. J Am Soc Echocardiogr. 2016;</a></text>
<text top="878" left="301" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref47">29:571</a></text>
<text top="877" left="327" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref47">–621</a></text>
<text top="878" left="345" width="3" height="9" font="5">.</text>
<text top="897" left="301" width="32" height="9" font="5">S1.4-37.</text>
<text top="897" left="336" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref48">Lang RM, Badano LP, Mor-Avi V, et al. Rec-</a></text>
<text top="910" left="301" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref48">ommendations for cardiac chamber quanti</a></text>
<text top="909" left="475" width="43" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref48">ﬁcation by</a></text>
<text top="924" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref48">echocardiography in adults: an update from the</a></text>
<text top="937" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref48">American Society of Echocardiography and the Euro-</a></text>
<text top="951" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref48">pean Association of Cardiovascular Imaging. J Am Soc</a></text>
<text top="964" left="301" width="96" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref48">Echocardiogr. 2015;28:1</a></text>
<text top="962" left="397" width="31" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref48">–39.e14</a></text>
<text top="964" left="428" width="3" height="9" font="5">.</text>
<text top="983" left="301" width="33" height="9" font="5">S1.4-38.</text>
<text top="983" left="337" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref49">Khairy P, Van Hare GF, Balaji S, et al. PACES/</a></text>
<text top="996" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref49">HRS expert consensus statement on the recognition</a></text>
<text top="1010" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref49">and management of arrhythmias in adult congenital</a></text>
<text top="1023" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref49">heart disease. Developed in partnership between the</a></text>
<text top="1036" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref49">Pediatric and Congenital Electrophysiology Society</a></text>
<text top="1050" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref49">(PACES) and the Heart Rhythm Society (HRS). Heart</a></text>
<text top="1063" left="301" width="89" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref49">Rhythm. 2014;11:e102</a></text>
<text top="1062" left="390" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref49">–65</a></text>
<text top="1063" left="404" width="3" height="9" font="5">.</text>
<text top="1082" left="301" width="33" height="9" font="5">S1.4-39.</text>
<text top="1082" left="337" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref50">Valente AM, Cook S, Festa P, et al. Multi-</a></text>
<text top="1095" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref50">modality imaging guidelines for patients with repaired</a></text>
<text top="143" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref50">tetralogy of Fallot: a report from the American Society</a></text>
<text top="156" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref50">of Echocardiography. Developed in collaboration with</a></text>
<text top="170" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref50">the Society for Cardiovascular Magnetic Resonance</a></text>
<text top="183" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref50">and the Society for Pediatric Radiology. J Am Soc</a></text>
<text top="197" left="539" width="103" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref50">Echocardiogr. 2014;27:111</a></text>
<text top="195" left="643" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref50">–41</a></text>
<text top="197" left="656" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref50">.</a></text>
<text top="216" left="539" width="34" height="9" font="5">S1.4-40.</text>
<text top="216" left="577" width="83" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref51">Boodhwani M, Andel</a></text>
<text top="215" left="660" width="97" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref51">ﬁnger G, Leipsic J, et al.</a></text>
<text top="230" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref51">Canadian Cardiovascular Society position statement on</a></text>
<text top="243" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref51">the management of thoracic aortic disease. Can J</a></text>
<text top="257" left="539" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref51">Cardiol. 2014;30:577</a></text>
<text top="255" left="623" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref51">–89</a></text>
<text top="257" left="638" width="3" height="9" font="5">.</text>
<text top="276" left="539" width="32" height="9" font="5">S1.4-41.</text>
<text top="276" left="575" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref52">Longmuir PE, Brothers JA, de Ferranti SD,</a></text>
<text top="289" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref52">et al. Promotion of physical activity for children and</a></text>
<text top="303" left="539" width="208" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref52">adults with congenital heart disease: a scienti</a></text>
<text top="301" left="747" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref52">ﬁc</a></text>
<text top="316" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref52">statement from the American Heart Association. Cir-</a></text>
<text top="330" left="539" width="94" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref52">culation. 2013;127:2147</a></text>
<text top="328" left="633" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref52">–59</a></text>
<text top="330" left="647" width="3" height="9" font="5">.</text>
<text top="349" left="539" width="33" height="9" font="5">S1.4-42.</text>
<text top="349" left="575" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref53">Marino BS, Lipkin PH, Newburger JW, et al.</a></text>
<text top="362" left="539" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref53">Neurodevelopmental</a></text>
<text top="362" left="633" width="39" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref53">outcomes</a></text>
<text top="362" left="681" width="7" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref53">in</a></text>
<text top="362" left="697" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref53">children</a></text>
<text top="362" left="739" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref53">with</a></text>
<text top="376" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref53">congenital heart disease: evaluation and management:</a></text>
<text top="389" left="539" width="33" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref53">a scienti</a></text>
<text top="388" left="573" width="184" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref53">ﬁc statement from the American Heart Asso-</a></text>
<text top="403" left="539" width="137" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref53">ciation. Circulation. 2012;126:1143</a></text>
<text top="401" left="676" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref53">–72</a></text>
<text top="403" left="689" width="3" height="9" font="5">.</text>
<text top="422" left="539" width="33" height="9" font="5">S1.4-43.</text>
<text top="422" left="575" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref54">European Society of Gynecology (ESG), As-</a></text>
<text top="436" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref54">sociation for European Paediatric Cardiology (AEPC),</a></text>
<text top="449" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref54">German Society for Gender Medicine (DGesGM), et al.</a></text>
<text top="463" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref54">ESC guidelines on the management of cardiovascular</a></text>
<text top="476" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref54">diseases during pregnancy: the Task Force on the</a></text>
<text top="489" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref54">Management of Cardiovascular Diseases during Preg-</a></text>
<text top="503" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref54">nancy of the European Society of Cardiology (ESC). Eur</a></text>
<text top="516" left="539" width="86" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref54">Heart J. 2011;32:3147</a></text>
<text top="515" left="626" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref54">–97</a></text>
<text top="516" left="640" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref54">.</a></text>
<text top="536" left="539" width="34" height="9" font="5">S1.4-44.</text>
<text top="536" left="576" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref55">Sable C, Foster E, Uzark K, et al. Best prac-</a></text>
<text top="549" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref55">tices in managing transition to adulthood for adoles-</a></text>
<text top="563" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref55">cents with congenital heart disease: the transition</a></text>
<text top="576" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref55">process and medical and psychosocial issues: a scien-</a></text>
<text top="589" left="539" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref55">ti</a></text>
<text top="588" left="545" width="212" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref55">ﬁc statement from the American Heart Association.</a></text>
<text top="603" left="539" width="104" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref55">Circulation. 2011;123:1454</a></text>
<text top="601" left="644" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref55">–85</a></text>
<text top="603" left="658" width="3" height="9" font="5">.</text>
<text top="622" left="539" width="33" height="9" font="5">S1.4-45.</text>
<text top="622" left="575" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref56">McLaughlin VV, Archer SL, Badesch DB, et al.</a></text>
<text top="636" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref56">ACCF/AHA 2009 expert consensus document on pul-</a></text>
<text top="649" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref56">monary hypertension: a report of the American College</a></text>
<text top="663" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref56">of Cardiology Foundation Task Force on Expert</a></text>
<text top="676" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref56">Consensus Documents and the American Heart Asso-</a></text>
<text top="689" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref56">ciation. Developed in collaboration with the American</a></text>
<text top="703" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref56">College of Chest Physicians, American Thoracic Soci-</a></text>
<text top="716" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref56">ety, Inc., and the Pulmonary Hypertension Association.</a></text>
<text top="730" left="539" width="110" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref56">Circulation. 2009;119:2250</a></text>
<text top="728" left="649" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref56">–94</a></text>
<text top="730" left="664" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref56">.</a></text>
<text top="749" left="539" width="34" height="9" font="5">S1.4-46.</text>
<text top="749" left="576" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref57">Wilson W, Taubert KA, Gewitz M, et al. Pre-</a></text>
<text top="763" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref57">vention of infective endocarditis: guidelines from the</a></text>
<text top="776" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref57">American Heart Association: a guideline from the</a></text>
<text top="790" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref57">American Heart Association Rheumatic Fever, Endo-</a></text>
<text top="803" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref57">carditis, and Kawasaki Disease Committee, Council on</a></text>
<text top="816" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref57">Cardiovascular Disease in the Young, and the Council</a></text>
<text top="830" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref57">on Clinical Cardiology, Council on Cardiovascular Sur-</a></text>
<text top="843" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref57">gery and Anesthesia, and the Quality of Care and</a></text>
<text top="857" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref57">Outcomes Research Interdisciplinary Working Group.</a></text>
<text top="870" left="539" width="107" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref57">Circulation. 2007;116:1736</a></text>
<text top="869" left="646" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref57">–54</a></text>
<text top="870" left="660" width="3" height="9" font="5">.</text>
<text top="904" left="539" width="133" height="12" font="28">2 . B A C K G R O U N D A N D</text>
<text top="918" left="539" width="125" height="12" font="28">P A T H O P H Y S I O L O G Y</text>
<text top="954" left="539" width="177" height="9" font="24">2.1. Anatomic and Physiological Terms</text>
<text top="968" left="539" width="25" height="9" font="5">S2.1-1.</text>
<text top="968" left="568" width="189" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref58">Giroud JM, Jacobs JP, Spicer D, et al. Report</a></text>
<text top="982" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref58">from the International Society for Nomenclature of</a></text>
<text top="995" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref58">Paediatric and Congenital Heart Disease: creation of a</a></text>
<text top="1009" left="539" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref58">visual encyclopedia illustrating the terms and de</a></text>
<text top="1007" left="740" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref58">ﬁni-</a></text>
<text top="1022" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref58">tions of the international pediatric and congenital</a></text>
<text top="1036" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref58">cardiac code. World J Pediatr Congenit Heart Surg.</a></text>
<text top="1049" left="539" width="47" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref58">2010;1:300</a></text>
<text top="1048" left="586" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref58">–13</a></text>
<text top="1049" left="598" width="3" height="9" font="5">.</text>
<text top="1069" left="539" width="26" height="9" font="5">S2.1-2.</text>
<text top="1069" left="569" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref59">Bergersen L, Giroud JM, Jacobs JP, et al.</a></text>
<text top="1082" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref59">Report from The International Society for Nomencla-</a></text>
<text top="1095" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref59">ture of Paediatric and Congenital Heart Disease:</a></text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="789" width="19" height="9" font="5">1545</text>
</page>
<page number="53" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref59">cardiovascular catheterisation for congenital and pae-</a></text>
<text top="156" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref59">diatric cardiac disease (Part 2 - Nomenclature of</a></text>
<text top="170" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref59">complications associated with interventional cardiol-</a></text>
<text top="183" left="108" width="134" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref59">ogy). Cardiol Young. 2011;21:260</a></text>
<text top="182" left="241" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref59">–5</a></text>
<text top="183" left="250" width="3" height="9" font="5">.</text>
<text top="202" left="108" width="26" height="9" font="5">S2.1-3.</text>
<text top="202" left="137" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref60">Bergersen L, Everett AD, Giroud JM, et al.</a></text>
<text top="216" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref60">Report from the International Society for Nomencla-</a></text>
<text top="229" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref60">ture of Paediatric and Congenital Heart Disease: car-</a></text>
<text top="242" left="108" width="45" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref60">diovascular</a></text>
<text top="242" left="164" width="59" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref60">catheterisation</a></text>
<text top="242" left="234" width="12" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref60">for</a></text>
<text top="242" left="257" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref60">congenital</a></text>
<text top="242" left="310" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref60">and</a></text>
<text top="256" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref60">paediatric cardiac disease (Part 1 - Procedural</a></text>
<text top="269" left="108" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref60">nomenclature). Cardiol Young. 2011;21:252</a></text>
<text top="268" left="280" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref60">–9</a></text>
<text top="269" left="289" width="3" height="9" font="5">.</text>
<text top="288" left="108" width="27" height="9" font="5">S2.1-4.</text>
<text top="288" left="138" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref61">Franklin RCG, Jacobs JP, Krogmann ON, et al.</a></text>
<text top="301" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref61">Nomenclature for congenital and paediatric cardiac</a></text>
<text top="315" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref61">disease: historical perspectives and The International</a></text>
<text top="328" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref61">Pediatric and Congenital Cardiac Code. Cardiol Young.</a></text>
<text top="342" left="108" width="80" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref61">2008;18 suppl 2:70</a></text>
<text top="340" left="188" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref61">–80</a></text>
<text top="342" left="203" width="3" height="9" font="5">.</text>
<text top="361" left="108" width="26" height="9" font="5">S2.1-5.</text>
<text top="361" left="137" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref62">Franklin RCG, Béland MJ, Krogmann ON. Map-</a></text>
<text top="374" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref62">ping and coding of nomenclatures for paediatric</a></text>
<text top="387" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref62">and congenital heart disease. Cardiol Young. 2006;16:</a></text>
<text top="401" left="108" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref62">105</a></text>
<text top="399" left="122" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref62">–6</a></text>
<text top="401" left="132" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref62">.</a></text>
<text top="420" left="108" width="217" height="9" font="5">S2.1-6. International Society for Nomenclature of</text>
<text top="433" left="108" width="217" height="9" font="5">Paediatric and Congenital Heart Disease. International</text>
<text top="447" left="108" width="217" height="9" font="5">Paediatric and Congenital Cardiac Code. Available at:</text>
<text top="460" left="108" width="66" height="9" font="6"><a href="http://ipccc.net/">http://ipccc.net/</a></text>
<text top="460" left="173" width="106" height="9" font="5">. Accessed: May 29, 2018.</text>
<text top="483" left="108" width="98" height="9" font="24">2.2. Severity of ACHD</text>
<text top="497" left="108" width="26" height="9" font="5">S2.2-1.</text>
<text top="497" left="137" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref64">Warnes CA, Williams RG, Bashore TM, et al.</a></text>
<text top="510" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref64">ACC/AHA 2008 guidelines for the management of</a></text>
<text top="523" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref64">adults with congenital heart disease: a report of the</a></text>
<text top="537" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref64">American College of Cardiology/American Heart As-</a></text>
<text top="550" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref64">sociation Task Force on Practice Guidelines (Writing</a></text>
<text top="564" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref64">Committee to Develop Guidelines on the Management</a></text>
<text top="577" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref64">of Adults With Congenital Heart Disease). J Am Coll</a></text>
<text top="591" left="108" width="90" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref64">Cardiol. 2008;52:e143</a></text>
<text top="589" left="197" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref64">–263</a></text>
<text top="591" left="216" width="3" height="9" font="5">.</text>
<text top="609" left="108" width="27" height="9" font="5">S2.2-2.</text>
<text top="609" left="138" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref65">Nishimura RA, Otto CM, Bonow RO, et al. 2014</a></text>
<text top="623" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref65">AHA/ACC guideline for the management of patients</a></text>
<text top="636" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref65">with valvular heart disease: a report of the American</a></text>
<text top="650" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref65">College of Cardiology/American Heart Association Task</a></text>
<text top="663" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref65">Force on Practice Guidelines. J Am Coll Cardiol. 2014;</a></text>
<text top="677" left="108" width="27" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref65">63:e57</a></text>
<text top="675" left="135" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref65">–185</a></text>
<text top="677" left="153" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref65">.</a></text>
<text top="695" left="108" width="27" height="9" font="5">S2.2-3.</text>
<text top="695" left="138" width="85" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref66">Boodhwani M, Andel</a></text>
<text top="694" left="223" width="102" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref66">ﬁnger G, Leipsic J, et al.</a></text>
<text top="709" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref66">Canadian Cardiovascular Society position statement on</a></text>
<text top="722" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref66">the management of thoracic aortic disease. Can J</a></text>
<text top="736" left="108" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref66">Cardiol. 2014;30:577</a></text>
<text top="734" left="191" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref66">–89</a></text>
<text top="736" left="206" width="3" height="9" font="5">.</text>
<text top="754" left="108" width="28" height="9" font="5">S2.2-4.</text>
<text top="754" left="139" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref67">Svensson LG, Adams DH, Bonow RO, et al.</a></text>
<text top="768" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref67">Aortic valve and ascending aorta guidelines for man-</a></text>
<text top="781" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref67">agement and quality measures. Ann Thorac Surg. 2013;</a></text>
<text top="795" left="108" width="22" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref67">95:S1</a></text>
<text top="793" left="129" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref67">–66</a></text>
<text top="795" left="144" width="3" height="9" font="5">.</text>
<text top="814" left="108" width="27" height="9" font="5">S2.2-5.</text>
<text top="814" left="138" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref68">Verheugt</a></text>
<text top="814" left="184" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref68">CL,</a></text>
<text top="814" left="206" width="38" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref68">Uiterwaal</a></text>
<text top="814" left="253" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref68">CSPM,</a></text>
<text top="814" left="288" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref68">van</a></text>
<text top="814" left="312" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref68">der</a></text>
<text top="827" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref68">Velde ET, et al. Mortality in adult congenital heart</a></text>
<text top="840" left="108" width="139" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref68">disease. Eur Heart J. 2010;31:1220</a></text>
<text top="839" left="247" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref68">–9</a></text>
<text top="840" left="256" width="3" height="9" font="5">.</text>
<text top="859" left="108" width="28" height="9" font="5">S2.2-6.</text>
<text top="859" left="139" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref69">Khairy P, Aboulhosn J, Gurvitz MZ, et al.</a></text>
<text top="873" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref69">Arrhythmia burden in adults with surgically repaired</a></text>
<text top="886" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref69">tetralogy of Fallot: a multi-institutional study. Circu-</a></text>
<text top="899" left="108" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref69">lation. 2010;122:868</a></text>
<text top="898" left="192" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref69">–75</a></text>
<text top="899" left="205" width="3" height="9" font="5">.</text>
<text top="918" left="108" width="27" height="9" font="5">S2.2-7.</text>
<text top="918" left="138" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref70">Khairy P, Fernandes SM, Mayer JE Jr., et al.</a></text>
<text top="932" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref70">Long-term survival, modes of death, and predictors of</a></text>
<text top="945" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref70">mortality in patients with Fontan surgery. Circulation.</a></text>
<text top="959" left="108" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref70">2008;117:85</a></text>
<text top="957" left="158" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref70">–92</a></text>
<text top="959" left="172" width="3" height="9" font="5">.</text>
<text top="977" left="108" width="28" height="9" font="5">S2.2-8.</text>
<text top="977" left="139" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref71">Khairy P, Harris L, Landzberg MJ, et al.</a></text>
<text top="991" left="108" width="113" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref71">Implantable cardioverter-de</a></text>
<text top="989" left="221" width="104" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref71">ﬁbrillators in tetralogy of</a></text>
<text top="1004" left="108" width="132" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref71">Fallot. Circulation. 2008;117:363</a></text>
<text top="1003" left="239" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref71">–70</a></text>
<text top="1004" left="254" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref71">.</a></text>
<text top="1023" left="108" width="28" height="9" font="5">S2.2-9.</text>
<text top="1023" left="139" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref72">Dimopoulos K, Diller G-P, Koltsida E, et al.</a></text>
<text top="1036" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref72">Prevalence, predictors, and prognostic value of renal</a></text>
<text top="1050" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref72">dysfunction in adults with congenital heart disease.</a></text>
<text top="1063" left="108" width="109" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref72">Circulation. 2008;117:2320</a></text>
<text top="1062" left="216" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref72">–8</a></text>
<text top="1063" left="226" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref72">.</a></text>
<text top="1082" left="108" width="32" height="9" font="5">S2.2-10.</text>
<text top="1082" left="143" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref73">Dimopoulos K, Diller G-P, Giannakoulas G,</a></text>
<text top="1095" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref73">et al. Anemia in adults with congenital heart disease</a></text>
<text top="143" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref73">relates to adverse outcome. J Am Coll Cardiol. 2009;</a></text>
<text top="156" left="346" width="34" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref73">54:2093</a></text>
<text top="155" left="380" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref73">–100</a></text>
<text top="156" left="400" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref73">.</a></text>
<text top="176" left="346" width="30" height="9" font="5">S2.2-11.</text>
<text top="176" left="379" width="184" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref74">Dimopoulos K, Diller G-P, Petraco R, et al.</a></text>
<text top="190" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref74">Hyponatraemia: a strong predictor of mortality in</a></text>
<text top="203" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref74">adults with congenital heart disease. Eur Heart J.</a></text>
<text top="217" left="346" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref74">2010;31:595</a></text>
<text top="215" left="396" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref74">–601</a></text>
<text top="217" left="415" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref74">.</a></text>
<text top="236" left="346" width="31" height="9" font="5">S2.2-12.</text>
<text top="236" left="380" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref75">Diller G-P, Dimopoulos K, Okonko D, et al.</a></text>
<text top="250" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref75">Exercise intolerance in adult congenital heart disease:</a></text>
<text top="263" left="346" width="92" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref75">comparative severity,</a></text>
<text top="263" left="446" width="117" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref75">correlates, and prognostic</a></text>
<text top="277" left="346" width="153" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref75">implication. Circulation. 2005;112:828</a></text>
<text top="275" left="499" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref75">–35</a></text>
<text top="277" left="512" width="3" height="9" font="5">.</text>
<text top="296" left="346" width="31" height="9" font="5">S2.2-13.</text>
<text top="296" left="380" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref76">Buys R, Cornelissen V, Van De Bruaene A,</a></text>
<text top="310" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref76">et al. Measures of exercise capacity in adults with</a></text>
<text top="323" left="346" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref76">congenital heart disease. Int J Cardiol. 2011;153:26</a></text>
<text top="322" left="546" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref76">–30</a></text>
<text top="323" left="560" width="3" height="9" font="5">.</text>
<text top="343" left="346" width="32" height="9" font="5">S2.2-14.</text>
<text top="343" left="381" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref77">Gratz A, Hess J, Hager A. Self-estimated</a></text>
<text top="356" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref77">physical functioning poorly predicts actual exercise</a></text>
<text top="370" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref77">capacity in adolescents and adults with congenital</a></text>
<text top="383" left="346" width="163" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref77">heart disease. Eur Heart J. 2009;30:497</a></text>
<text top="382" left="509" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref77">–504</a></text>
<text top="383" left="530" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref77">.</a></text>
<text top="403" left="346" width="31" height="9" font="5">S2.2-15.</text>
<text top="403" left="380" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref78">Dimopoulos K, Okonko DO, Diller G-P, et al.</a></text>
<text top="417" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref78">Abnormal ventilatory response to exercise in adults</a></text>
<text top="430" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref78">with congenital heart disease relates to cyanosis and</a></text>
<text top="443" left="346" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref78">predicts survival. Circulation. 2006;113:2796</a></text>
<text top="442" left="526" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref78">–802</a></text>
<text top="443" left="546" width="3" height="9" font="5">.</text>
<text top="463" left="346" width="32" height="9" font="5">S2.2-16.</text>
<text top="463" left="381" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref79">Inuzuka R, Diller G-P, Borgia F, et al.</a></text>
<text top="477" left="346" width="61" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref79">Comprehensive</a></text>
<text top="477" left="416" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref79">use</a></text>
<text top="477" left="438" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref79">of</a></text>
<text top="477" left="455" width="108" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref79">cardiopulmonary exercise</a></text>
<text top="490" left="346" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref79">testing identi</a></text>
<text top="488" left="399" width="164" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref79">ﬁes adults with congenital heart disease</a></text>
<text top="504" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref79">at increased mortality risk in the medium term. Circu-</a></text>
<text top="517" left="346" width="82" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref79">lation. 2012;125:250</a></text>
<text top="515" left="428" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref79">–9</a></text>
<text top="517" left="438" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref79">.</a></text>
<text top="537" left="346" width="31" height="9" font="5">S2.2-17.</text>
<text top="537" left="380" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref80">Müller J, Hager A, Diller G-P, et al. Peak ox-</a></text>
<text top="550" left="346" width="111" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref80">ygen uptake, ventilatory ef</a></text>
<text top="548" left="457" width="106" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref80">ﬁciency and QRS-duration</a></text>
<text top="564" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref80">predict event free survival in patients late after sur-</a></text>
<text top="577" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref80">gical repair of tetralogy of Fallot. Int J Cardiol. 2015;</a></text>
<text top="591" left="346" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref80">196:158</a></text>
<text top="589" left="378" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref80">–64</a></text>
<text top="591" left="393" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref80">.</a></text>
<text top="610" left="346" width="32" height="9" font="5">S2.2-18.</text>
<text top="610" left="381" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref81">Kempny A, Dimopoulos K, Uebing A, et al.</a></text>
<text top="624" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref81">Reference values for exercise limitations among adults</a></text>
<text top="637" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref81">with congenital heart disease. Relation to activities of</a></text>
<text top="651" left="346" width="38" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref81">daily life</a></text>
<text top="649" left="384" width="179" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref81">—single centre experience and review of</a></text>
<text top="664" left="346" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref81">published data. Eur Heart J. 2012;33:1386</a></text>
<text top="662" left="515" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref81">–96</a></text>
<text top="664" left="531" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref81">.</a></text>
<text top="684" left="346" width="32" height="9" font="5">S2.2-19.</text>
<text top="684" left="381" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref82">New York Heart Association. In: Dolgin M,</a></text>
<text top="697" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref82">editor. Nomenclature and Criteria for Diagnosis of</a></text>
<text top="711" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref82">Diseases of the Heart and Great Vessels. 9th ed. Bos-</a></text>
<text top="724" left="346" width="147" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref82">ton, MA: Little, Brown and Co, 1994</a></text>
<text top="724" left="493" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref82">.</a></text>
<text top="744" left="346" width="33" height="9" font="5">S2.2-20.</text>
<text top="744" left="382" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref83">Hoeper MM, Bogaard HJ, Condliffe R, et al.</a></text>
<text top="757" left="346" width="11" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref83">De</a></text>
<text top="756" left="357" width="206" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref83">ﬁnitions and diagnosis of pulmonary hypertension.</a></text>
<text top="771" left="346" width="127" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref83">J Am Coll Cardiol. 2013;62:D42</a></text>
<text top="769" left="472" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref83">–50</a></text>
<text top="771" left="487" width="3" height="9" font="5">.</text>
<text top="794" left="346" width="111" height="9" font="24">2.3. The ACHD AP Classi</text>
<text top="792" left="457" width="34" height="12" font="24">ﬁcation</text>
<text top="808" left="346" width="26" height="9" font="5">S2.3-1.</text>
<text top="808" left="375" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref84">Verheugt</a></text>
<text top="808" left="422" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref84">CL,</a></text>
<text top="808" left="444" width="38" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref84">Uiterwaal</a></text>
<text top="808" left="491" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref84">CSPM,</a></text>
<text top="808" left="526" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref84">van</a></text>
<text top="808" left="550" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref84">der</a></text>
<text top="822" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref84">Velde ET, et al. Mortality in adult congenital heart</a></text>
<text top="835" left="346" width="139" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref84">disease. Eur Heart J. 2010;31:1220</a></text>
<text top="834" left="485" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref84">–9</a></text>
<text top="835" left="495" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref84">.</a></text>
<text top="855" left="346" width="27" height="9" font="5">S2.3-2.</text>
<text top="855" left="376" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref85">Diller G-P, Dimopoulos K, Okonko D, et al.</a></text>
<text top="869" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref85">Exercise intolerance in adult congenital heart disease:</a></text>
<text top="882" left="346" width="92" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref85">comparative severity,</a></text>
<text top="882" left="446" width="117" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref85">correlates, and prognostic</a></text>
<text top="895" left="346" width="153" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref85">implication. Circulation. 2005;112:828</a></text>
<text top="894" left="499" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref85">–35</a></text>
<text top="895" left="512" width="3" height="9" font="5">.</text>
<text top="915" left="346" width="27" height="9" font="5">S2.3-3.</text>
<text top="915" left="376" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref86">Dimopoulos K, Diller G-P, Koltsida E, et al.</a></text>
<text top="929" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref86">Prevalence, predictors, and prognostic value of renal</a></text>
<text top="942" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref86">dysfunction in adults with congenital heart disease.</a></text>
<text top="956" left="346" width="109" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref86">Circulation. 2008;117:2320</a></text>
<text top="954" left="454" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref86">–8</a></text>
<text top="956" left="464" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref86">.</a></text>
<text top="975" left="346" width="28" height="9" font="5">S2.3-4.</text>
<text top="975" left="377" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref87">Dimopoulos K, Okonko DO, Diller G-P, et al.</a></text>
<text top="989" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref87">Abnormal ventilatory response to exercise in adults</a></text>
<text top="1002" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref87">with congenital heart disease relates to cyanosis and</a></text>
<text top="1016" left="346" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref87">predicts survival. Circulation. 2006;113:2796</a></text>
<text top="1014" left="526" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref87">–802</a></text>
<text top="1016" left="546" width="3" height="9" font="5">.</text>
<text top="1035" left="346" width="27" height="9" font="5">S2.3-5.</text>
<text top="1035" left="376" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref88">Hebson CL, McCabe NM, Elder RW, et al. He-</a></text>
<text top="1049" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref88">modynamic phenotype of the failing Fontan in an adult</a></text>
<text top="1062" left="346" width="162" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref88">population. Am J Cardiol. 2013;112:1943</a></text>
<text top="1061" left="507" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref88">–7</a></text>
<text top="1062" left="516" width="3" height="9" font="5">.</text>
<text top="1082" left="346" width="28" height="9" font="5">S2.3-6.</text>
<text top="1082" left="377" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref89">Khairy P, Aboulhosn J, Gurvitz MZ, et al.</a></text>
<text top="1095" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref89">Arrhythmia burden in adults with surgically repaired</a></text>
<text top="143" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref89">tetralogy of Fallot: a multi-institutional study. Circu-</a></text>
<text top="156" left="584" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref89">lation. 2010;122:868</a></text>
<text top="155" left="669" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref89">–75</a></text>
<text top="156" left="682" width="3" height="9" font="5">.</text>
<text top="175" left="584" width="27" height="9" font="5">S2.3-7.</text>
<text top="175" left="614" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref90">Khairy P, Harris L, Landzberg MJ, et al. Sudden</a></text>
<text top="188" left="584" width="55" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref90">death and de</a></text>
<text top="187" left="639" width="162" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref90">ﬁbrillators in transposition of the great</a></text>
<text top="202" left="584" width="114" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref90">arteries with intra-atrial baf</a></text>
<text top="200" left="698" width="103" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref90">ﬂes: a multicenter study.</a></text>
<text top="215" left="584" width="168" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref90">Circ Arrhythm Electrophysiol. 2008;1:250</a></text>
<text top="214" left="752" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref90">–7</a></text>
<text top="215" left="761" width="3" height="9" font="5">.</text>
<text top="234" left="584" width="28" height="9" font="5">S2.3-8.</text>
<text top="234" left="615" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref91">Inuzuka R, Diller G-P, Borgia F, et al.</a></text>
<text top="247" left="584" width="61" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref91">Comprehensive</a></text>
<text top="247" left="654" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref91">use of</a></text>
<text top="247" left="694" width="108" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref91">cardiopulmonary exercise</a></text>
<text top="261" left="584" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref91">testing identi</a></text>
<text top="259" left="638" width="163" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref91">ﬁes adults with congenital heart disease</a></text>
<text top="274" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref91">at increased mortality risk in the medium term. Circu-</a></text>
<text top="288" left="584" width="82" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref91">lation. 2012;125:250</a></text>
<text top="286" left="666" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref91">–9</a></text>
<text top="288" left="676" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref91">.</a></text>
<text top="306" left="584" width="28" height="9" font="5">S2.3-9.</text>
<text top="306" left="615" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref92">Müller J, Hager A, Diller G-P, et al. Peak oxygen</a></text>
<text top="320" left="584" width="85" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref92">uptake, ventilatory ef</a></text>
<text top="318" left="669" width="132" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref92">ﬁciency and QRS-duration predict</a></text>
<text top="333" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref92">event free survival in patients late after surgical repair</a></text>
<text top="347" left="584" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref92">of tetralogy of Fallot. Int J Cardiol. 2015;196:158</a></text>
<text top="345" left="780" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref92">–64</a></text>
<text top="347" left="795" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref92">.</a></text>
<text top="365" left="584" width="32" height="9" font="5">S2.3-10.</text>
<text top="365" left="620" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref93">Stefanescu A, Macklin EA, Lin E, et al. Use-</a></text>
<text top="379" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref93">fulness of the Seattle Heart Failure Model to identify</a></text>
<text top="392" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref93">adults with congenital heart disease at high risk of</a></text>
<text top="405" left="584" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref93">poor outcome. Am J Cardiol. 2014;113:865</a></text>
<text top="404" left="756" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref93">–70</a></text>
<text top="405" left="771" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref93">.</a></text>
<text top="424" left="584" width="30" height="9" font="5">S2.3-11.</text>
<text top="424" left="617" width="184" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref94">Giannakoulas G, Dimopoulos K, Engel R, et al.</a></text>
<text top="437" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref94">Burden of coronary artery disease in adults with</a></text>
<text top="451" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref94">congenital heart disease and its relation to congenital</a></text>
<text top="464" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref94">and traditional heart risk factors. Am J Cardiol. 2009;</a></text>
<text top="478" left="584" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref94">103:1445</a></text>
<text top="476" left="621" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref94">–50</a></text>
<text top="478" left="636" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref94">.</a></text>
<text top="496" left="584" width="31" height="9" font="5">S2.3-12.</text>
<text top="496" left="618" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref95">Giannakoulas G, Dimopoulos K, Bolger AP,</a></text>
<text top="510" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref95">et al. Usefulness of natriuretic peptide levels to predict</a></text>
<text top="523" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref95">mortality in adults with congenital heart disease. Am J</a></text>
<text top="537" left="584" width="91" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref95">Cardiol. 2010;105:869</a></text>
<text top="535" left="675" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref95">–73</a></text>
<text top="537" left="688" width="3" height="9" font="5">.</text>
<text top="555" left="584" width="31" height="9" font="5">S2.3-13.</text>
<text top="555" left="618" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref96">Khairy P, Fernandes SM, Mayer JE Jr., et al.</a></text>
<text top="569" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref96">Long-term survival, modes of death, and predictors of</a></text>
<text top="582" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref96">mortality in patients with Fontan surgery. Circulation.</a></text>
<text top="596" left="584" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref96">2008;117:85</a></text>
<text top="594" left="634" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref96">–92</a></text>
<text top="596" left="649" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref96">.</a></text>
<text top="614" left="584" width="32" height="9" font="5">S2.3-14.</text>
<text top="614" left="619" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref97">Khairy P, Harris L, Landzberg MJ, et al.</a></text>
<text top="628" left="584" width="113" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref97">Implantable cardioverter-de</a></text>
<text top="626" left="697" width="104" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref97">ﬁbrillators in tetralogy of</a></text>
<text top="641" left="584" width="132" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref97">Fallot. Circulation. 2008;117:363</a></text>
<text top="639" left="716" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref97">–70</a></text>
<text top="641" left="730" width="3" height="9" font="5">.</text>
<text top="659" left="584" width="31" height="9" font="5">S2.3-15.</text>
<text top="659" left="618" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref98">Dimopoulos K, Diller G-P, Giannakoulas G,</a></text>
<text top="673" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref98">et al. Anemia in adults with congenital heart disease</a></text>
<text top="686" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref98">relates to adverse outcome. J Am Coll Cardiol. 2009;</a></text>
<text top="700" left="584" width="34" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref98">54:2093</a></text>
<text top="698" left="618" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref98">–100</a></text>
<text top="700" left="638" width="3" height="9" font="5">.</text>
<text top="718" left="584" width="32" height="9" font="5">S2.3-16.</text>
<text top="718" left="619" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref99">Dimopoulos K, Diller G-P, Petraco R, et al.</a></text>
<text top="732" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref99">Hyponatraemia: a strong predictor of mortality in</a></text>
<text top="745" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref99">adults with congenital heart disease. Eur Heart J.</a></text>
<text top="759" left="584" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref99">2010;31:595</a></text>
<text top="757" left="634" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref99">–601</a></text>
<text top="759" left="653" width="3" height="9" font="5">.</text>
<text top="777" left="584" width="31" height="9" font="5">S2.3-17.</text>
<text top="777" left="618" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref100">Yancy CW, Jessup M, Bozkurt B, et al. 2013</a></text>
<text top="791" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref100">ACCF/AHA guideline for the management of heart</a></text>
<text top="804" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref100">failure: a report of the American College of Cardiology</a></text>
<text top="818" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref100">Foundation/American Heart Association Task Force on</a></text>
<text top="831" left="584" width="189" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref100">Practice Guidelines. Circulation. 2013;128:e240</a></text>
<text top="829" left="773" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref100">–327</a></text>
<text top="831" left="791" width="3" height="9" font="5">.</text>
<text top="868" left="584" width="153" height="12" font="28">3 . G E N E R A L P R I N C I P L E S</text>
<text top="904" left="584" width="86" height="9" font="24">3.1. ACHD Program</text>
<text top="918" left="584" width="25" height="9" font="5">S3.1-1.</text>
<text top="918" left="613" width="189" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref101">Mylotte D, Pilote L, Ionescu-Ittu R, et al.</a></text>
<text top="931" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref101">Specialized adult congenital heart disease care: the</a></text>
<text top="945" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref101">impact of policy on mortality. Circulation. 2014;129:</a></text>
<text top="958" left="584" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref101">1804</a></text>
<text top="957" left="605" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref101">–12</a></text>
<text top="958" left="618" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref101">.</a></text>
<text top="981" left="584" width="85" height="9" font="24">3.2. Access to Care</text>
<text top="995" left="584" width="26" height="9" font="5">S3.2-1.</text>
<text top="995" left="614" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref102">Gurvitz M, Valente AM, Broberg C, et al.</a></text>
<text top="1008" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref102">Prevalence and predictors of gaps in care among adult</a></text>
<text top="1022" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref102">congenital heart disease patients: HEART-ACHD (The</a></text>
<text top="1035" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref102">Health, Education, and Access Research Trial). J Am</a></text>
<text top="1049" left="584" width="106" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref102">Coll Cardiol. 2013;61:2180</a></text>
<text top="1047" left="690" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref102">–4</a></text>
<text top="1049" left="700" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref102">.</a></text>
<text top="1067" left="584" width="27" height="9" font="5">S3.2-2.</text>
<text top="1067" left="614" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref103">Mackie AS, Islam S, Magill-Evans J, et al.</a></text>
<text top="1081" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref103">Healthcare transition for youth with heart disease: a</a></text>
<text top="1094" left="584" width="136" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref103">clinical trial. Heart. 2014;100:1113</a></text>
<text top="1092" left="721" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref103">–8</a></text>
<text top="1094" left="730" width="3" height="9" font="5">.</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="20" height="9" font="5">1546</text>
</page>
<page number="54" position="absolute" top="0" left="0" height="1160" width="864">
<text top="145" left="63" width="92" height="9" font="24">3.3. Delivery of Care</text>
<text top="158" left="63" width="26" height="9" font="5">S3.3-1.</text>
<text top="158" left="92" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref104">Mylotte D, Pilote L, Ionescu-Ittu R, et al.</a></text>
<text top="172" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref104">Specialized adult congenital heart disease care: the</a></text>
<text top="185" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref104">impact of policy on mortality. Circulation. 2014;129:</a></text>
<text top="199" left="63" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref104">1804</a></text>
<text top="197" left="84" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref104">–12</a></text>
<text top="199" left="96" width="3" height="9" font="5">.</text>
<text top="217" left="63" width="27" height="9" font="5">S3.3-2.</text>
<text top="217" left="93" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref105">Karamlou T, Diggs BS, Person T, et al. National</a></text>
<text top="231" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref105">practice patterns for management of adult congenital</a></text>
<text top="244" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref105">heart disease: operation by pediatric heart surgeons</a></text>
<text top="258" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref105">decreases in-hospital death. Circulation. 2008;118:</a></text>
<text top="271" left="63" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref105">2345</a></text>
<text top="269" left="83" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref105">–52</a></text>
<text top="271" left="96" width="3" height="9" font="5">.</text>
<text top="290" left="63" width="27" height="9" font="5">S3.3-3.</text>
<text top="290" left="93" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref106">Videbæk J, Laursen HB, Olsen M, et al. Long-</a></text>
<text top="303" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref106">term nationwide follow-up study of simple congenital</a></text>
<text top="316" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref106">heart disease diagnosed in otherwise healthy children.</a></text>
<text top="330" left="63" width="102" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref106">Circulation. 2016;133:474</a></text>
<text top="328" left="165" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref106">–83</a></text>
<text top="330" left="179" width="3" height="9" font="5">.</text>
<text top="348" left="63" width="28" height="9" font="5">S3.3-4.</text>
<text top="348" left="94" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref107">Karonis T, Scognamiglio G, Babu-Narayan SV,</a></text>
<text top="362" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref107">et al. Clinical course and potential complications of</a></text>
<text top="375" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref107">small ventricular septal defects in adulthood: late</a></text>
<text top="389" left="63" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref107">development of left ventricular dysfunction justi</a></text>
<text top="387" left="266" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref107">ﬁes</a></text>
<text top="402" left="63" width="167" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref107">lifelong care. Int J Cardiol. 2016;208:102</a></text>
<text top="401" left="229" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref107">–6</a></text>
<text top="402" left="239" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref107">.</a></text>
<text top="421" left="63" width="27" height="9" font="5">S3.3-5.</text>
<text top="421" left="93" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref108">Bonello B, Kilner PJ. Review of the role of</a></text>
<text top="434" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref108">cardiovascular magnetic resonance in congenital heart</a></text>
<text top="448" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref108">disease, with a focus on right ventricle assessment.</a></text>
<text top="461" left="63" width="140" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref108">Arch Cardiovasc Dis. 2012;105:605</a></text>
<text top="459" left="203" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref108">–13</a></text>
<text top="461" left="215" width="3" height="9" font="5">.</text>
<text top="480" left="63" width="28" height="9" font="5">S3.3-6.</text>
<text top="480" left="94" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref109">Kilner PJ. Imaging congenital heart disease in</a></text>
<text top="493" left="63" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref109">adults. Br J Radiol. 2011;84 Spec No 3:S258</a></text>
<text top="492" left="240" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref109">–68</a></text>
<text top="493" left="255" width="3" height="9" font="5">.</text>
<text top="512" left="63" width="27" height="9" font="5">S3.3-7.</text>
<text top="512" left="93" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref110">Cohen MS, Eidem BW, Cetta F, et al. Multi-</a></text>
<text top="525" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref110">modality imaging guidelines of patients with trans-</a></text>
<text top="539" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref110">position of the great arteries: a report from the</a></text>
<text top="552" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref110">American Society of Echocardiography. Developed in</a></text>
<text top="565" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref110">collaboration with the Society for Cardiovascular</a></text>
<text top="579" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref110">Magnetic Resonance and the Society of Cardiovascular</a></text>
<text top="592" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref110">Computed Tomography. J Am Soc Echocardiogr. 2016;</a></text>
<text top="606" left="63" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref110">29:571</a></text>
<text top="604" left="89" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref110">–621</a></text>
<text top="606" left="107" width="3" height="9" font="5">.</text>
<text top="624" left="63" width="28" height="9" font="5">S3.3-8.</text>
<text top="624" left="94" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref111">Valente AM, Cook S, Festa P, et al. Multi-</a></text>
<text top="638" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref111">modality imaging guidelines for patients with repaired</a></text>
<text top="651" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref111">tetralogy of Fallot: a report from the American Society</a></text>
<text top="665" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref111">of Echocardiography. Developed in collaboration with</a></text>
<text top="678" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref111">the Society for Cardiovascular Magnetic Resonance</a></text>
<text top="692" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref111">and the Society for Pediatric Radiology. J Am Soc</a></text>
<text top="705" left="63" width="103" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref111">Echocardiogr. 2014;27:111</a></text>
<text top="703" left="166" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref111">–41</a></text>
<text top="705" left="179" width="3" height="9" font="5">.</text>
<text top="724" left="63" width="28" height="9" font="5">S3.3-9.</text>
<text top="724" left="94" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref112">Ginde S, Bartz PJ, Hill GD, et al. Restrictive</a></text>
<text top="737" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref112">lung disease is an independent predictor of exercise</a></text>
<text top="750" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref112">intolerance in the adult with congenital heart disease.</a></text>
<text top="764" left="63" width="127" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref112">Congenit Heart Dis. 2013;8:246</a></text>
<text top="762" left="190" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref112">–54</a></text>
<text top="764" left="205" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref112">.</a></text>
<text top="782" left="63" width="32" height="9" font="5">S3.3-10.</text>
<text top="782" left="98" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref113">Alonso-Gonzalez R, Borgia F, Diller G-P, et al.</a></text>
<text top="796" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref113">Abnormal lung function in adults with congenital heart</a></text>
<text top="809" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref113">disease: prevalence, relation to cardiac anatomy, and</a></text>
<text top="823" left="63" width="213" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref113">association with survival. Circulation. 2013;127:882</a></text>
<text top="821" left="276" width="4" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref113">–</a></text>
<text top="836" left="63" width="12" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref113">90</a></text>
<text top="836" left="74" width="3" height="9" font="5">.</text>
<text top="855" left="63" width="30" height="9" font="5">S3.3-11.</text>
<text top="855" left="96" width="184" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref114">Zach KJ, Ramakrishna H, Chandrasekaran K,</a></text>
<text top="868" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref114">et al. Laparoscopic colectomy in an adult with single</a></text>
<text top="882" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref114">ventricle physiology: anesthetic implications and</a></text>
<text top="895" left="63" width="184" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref114">management. Ann Card Anaesth. 2015;18:252</a></text>
<text top="894" left="246" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref114">–6</a></text>
<text top="895" left="256" width="3" height="9" font="5">.</text>
<text top="914" left="63" width="31" height="9" font="5">S3.3-12.</text>
<text top="914" left="97" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref115">Duffels MGJ, Engelfriet PM, Berger RMF, et al.</a></text>
<text top="927" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref115">Pulmonary arterial hypertension in congenital heart</a></text>
<text top="941" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref115">disease: an epidemiologic perspective from a Dutch</a></text>
<text top="954" left="63" width="147" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref115">registry. Int J Cardiol. 2007;120:198</a></text>
<text top="952" left="209" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref115">–204</a></text>
<text top="954" left="230" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref115">.</a></text>
<text top="973" left="63" width="31" height="9" font="5">S3.3-13.</text>
<text top="973" left="97" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref116">Lowe BS, Therrien J, Ionescu-Ittu R, et al.</a></text>
<text top="986" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref116">Diagnosis of pulmonary hypertension in the congenital</a></text>
<text top="999" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref116">heart disease adult population impact on outcomes.</a></text>
<text top="1013" left="63" width="125" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref116">J Am Coll Cardiol. 2011;58:538</a></text>
<text top="1011" left="187" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref116">–46</a></text>
<text top="1013" left="202" width="3" height="9" font="5">.</text>
<text top="1031" left="63" width="32" height="9" font="5">S3.3-14.</text>
<text top="1031" left="98" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref117">Van De Bruaene A, Delcroix M, Pasquet A,</a></text>
<text top="1045" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref117">et al. The importance of pulmonary artery pressures on</a></text>
<text top="1058" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref117">late atrial arrhythmia in transcatheter and surgically</a></text>
<text top="1072" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref117">closed ASD type secundum. Int J Cardiol. 2011;152:</a></text>
<text top="1085" left="63" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref117">192</a></text>
<text top="1084" left="77" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref117">–5</a></text>
<text top="1085" left="86" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref117">.</a></text>
<text top="143" left="301" width="31" height="9" font="5">S3.3-15.</text>
<text top="143" left="335" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref118">Barst RJ, Ivy DD, Foreman AJ, et al. Four- and</a></text>
<text top="156" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref118">seven-year outcomes of patients with congenital heart</a></text>
<text top="170" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref118">disease-associated pulmonary arterial hypertension</a></text>
<text top="183" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref118">(from the REVEAL Registry). Am J Cardiol. 2014;113:</a></text>
<text top="197" left="301" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref118">147</a></text>
<text top="195" left="315" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref118">–55</a></text>
<text top="197" left="329" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref118">.</a></text>
<text top="215" left="301" width="32" height="9" font="5">S3.3-16.</text>
<text top="215" left="336" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref119">D</a></text>
<text top="214" left="342" width="176" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref119">’Alto M, Romeo E, Argiento P, et al. Therapy</a></text>
<text top="229" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref119">for pulmonary arterial hypertension due to congenital</a></text>
<text top="242" left="301" width="103" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref119">heart disease and Down</a></text>
<text top="241" left="404" width="114" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref119">’s syndrome. Int J Cardiol.</a></text>
<text top="256" left="301" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref119">2013;164:323</a></text>
<text top="254" left="355" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref119">–6</a></text>
<text top="256" left="364" width="3" height="9" font="5">.</text>
<text top="274" left="301" width="31" height="9" font="5">S3.3-17.</text>
<text top="274" left="335" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref120">Engelfriet PM, Duffels MGJ, Möller T, et al.</a></text>
<text top="288" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref120">Pulmonary arterial hypertension in adults born with a</a></text>
<text top="301" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref120">heart septal defect: the Euro Heart Survey on adult</a></text>
<text top="315" left="301" width="184" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref120">congenital heart disease. Heart. 2007;93:682</a></text>
<text top="313" left="485" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref120">–7</a></text>
<text top="315" left="493" width="3" height="9" font="5">.</text>
<text top="333" left="301" width="32" height="9" font="5">S3.3-18.</text>
<text top="333" left="336" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref121">Manes A, Palazzini M, Leci E, et al. Current era</a></text>
<text top="347" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref121">survival of patients with pulmonary arterial hyperten-</a></text>
<text top="360" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref121">sion associated with congenital heart disease: a com-</a></text>
<text top="373" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref121">parison between clinical subgroups. Eur Heart J. 2014;</a></text>
<text top="387" left="301" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref121">35:716</a></text>
<text top="385" left="327" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref121">–24</a></text>
<text top="387" left="341" width="3" height="9" font="5">.</text>
<text top="405" left="301" width="32" height="9" font="5">S3.3-19.</text>
<text top="405" left="336" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref122">O</a></text>
<text top="404" left="342" width="176" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref122">’Donnell C, Ruygrok PN, Whyte K, et al.</a></text>
<text top="419" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref122">Progressive pulmonary hypertension post atrial septal</a></text>
<text top="432" left="301" width="91" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref122">defect device closure</a></text>
<text top="431" left="392" width="126" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref122">—early symptomatic improve-</a></text>
<text top="446" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref122">ment may not predict outcome. Heart Lung Circ. 2010;</a></text>
<text top="459" left="301" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref122">19:713</a></text>
<text top="458" left="326" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref122">–6</a></text>
<text top="459" left="336" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref122">.</a></text>
<text top="478" left="301" width="33" height="9" font="5">S3.3-20.</text>
<text top="478" left="337" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref123">Van De Bruaene A, Moons P, Belmans A, et al.</a></text>
<text top="491" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref123">Predictive model for late atrial arrhythmia after</a></text>
<text top="505" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref123">closure of an atrial septal defect. Int J Cardiol. 2013;</a></text>
<text top="518" left="301" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref123">164:318</a></text>
<text top="517" left="333" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref123">–22</a></text>
<text top="518" left="346" width="3" height="9" font="5">.</text>
<text top="537" left="301" width="31" height="9" font="5">S3.3-21.</text>
<text top="537" left="335" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref124">D</a></text>
<text top="535" left="341" width="177" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref124">’Alto M, Romeo E, Argiento P, et al. Hemo-</a></text>
<text top="550" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref124">dynamics of patients developing pulmonary arterial</a></text>
<text top="564" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref124">hypertension after shunt closure. Int J Cardiol. 2013;</a></text>
<text top="577" left="301" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref124">168:3797</a></text>
<text top="575" left="338" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref124">–801</a></text>
<text top="577" left="358" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref124">.</a></text>
<text top="596" left="301" width="32" height="9" font="5">S3.3-22.</text>
<text top="596" left="336" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref125">Steele PM, Fuster V, Cohen M, et al. Isolated</a></text>
<text top="609" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref125">atrial septal defect with pulmonary vascular obstruc-</a></text>
<text top="622" left="301" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref125">tive disease</a></text>
<text top="621" left="350" width="168" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref125">—long-term follow-up and prediction of</a></text>
<text top="636" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref125">outcome after surgical correction. Circulation. 1987;</a></text>
<text top="649" left="301" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref125">76:1037</a></text>
<text top="648" left="333" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref125">–42</a></text>
<text top="649" left="347" width="3" height="9" font="5">.</text>
<text top="670" left="301" width="208" height="9" font="24">3.4. Evaluation of Suspected and Known CHD</text>
<text top="688" left="301" width="160" height="9" font="5">3.4.2. Ionizing Radiation Principles</text>
<text top="702" left="301" width="35" height="9" font="5">S3.4.2-1.</text>
<text top="702" left="339" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref126">Glatz AC, Purrington KS, Klinger A, et al.</a></text>
<text top="715" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref126">Cumulative exposure to medical radiation for children</a></text>
<text top="729" left="301" width="36" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref126">requiring</a></text>
<text top="729" left="346" width="30" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref126">surgery</a></text>
<text top="729" left="385" width="12" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref126">for</a></text>
<text top="729" left="406" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref126">congenital</a></text>
<text top="729" left="457" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref126">heart</a></text>
<text top="729" left="487" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref126">disease.</a></text>
<text top="742" left="301" width="97" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref126">J Pediatr. 2014;164:789</a></text>
<text top="740" left="398" width="32" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref126">–94.e10</a></text>
<text top="742" left="430" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref126">.</a></text>
<text top="761" left="301" width="35" height="9" font="5">S3.4.2-2.</text>
<text top="761" left="339" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref127">Johnson JN, Hornik CP, Li JS, et al. Cumula-</a></text>
<text top="774" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref127">tive radiation exposure and cancer risk estimation in</a></text>
<text top="787" left="301" width="213" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref127">children with heart disease. Circulation. 2014;130:161</a></text>
<text top="786" left="514" width="4" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref127">–</a></text>
<text top="801" left="301" width="5" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref127">7</a></text>
<text top="801" left="306" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref127">.</a></text>
<text top="819" left="301" width="35" height="9" font="5">S3.4.2-3.</text>
<text top="819" left="339" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref128">Yakoumakis E, Kostopoulou H, Makri T, et al.</a></text>
<text top="833" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref128">Estimation of radiation dose and risk to children un-</a></text>
<text top="846" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref128">dergoing cardiac catheterization for the treatment of a</a></text>
<text top="860" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref128">congenital heart disease using Monte Carlo simula-</a></text>
<text top="873" left="301" width="137" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref128">tions. Pediatr Radiol. 2013;43:339</a></text>
<text top="872" left="438" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref128">–46</a></text>
<text top="873" left="453" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref128">.</a></text>
<text top="892" left="301" width="36" height="9" font="5">S3.4.2-4.</text>
<text top="892" left="340" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref129">Andreassi MG, Ait-Ali L, Botto N, et al. Car-</a></text>
<text top="905" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref129">diac catheterization and long-term chromosomal</a></text>
<text top="919" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref129">damage in children with congenital heart disease. Eur</a></text>
<text top="932" left="301" width="92" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref129">Heart J. 2006;27:2703</a></text>
<text top="930" left="393" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref129">–8</a></text>
<text top="932" left="403" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref129">.</a></text>
<text top="955" left="301" width="110" height="9" font="5">3.4.3. Echocardiography</text>
<text top="969" left="301" width="35" height="9" font="5">S3.4.3-1.</text>
<text top="969" left="339" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref130">Randolph GR, Hagler DJ, Connolly HM, et al.</a></text>
<text top="982" left="301" width="56" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref130">Intraoperative</a></text>
<text top="982" left="370" width="65" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref130">transesophageal</a></text>
<text top="982" left="447" width="71" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref130">echocardiography</a></text>
<text top="995" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref130">during surgery for congenital heart defects. J Thorac</a></text>
<text top="1009" left="301" width="128" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref130">Cardiovasc Surg. 2002;124:1176</a></text>
<text top="1007" left="429" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref130">–82</a></text>
<text top="1009" left="443" width="3" height="9" font="5">.</text>
<text top="1032" left="301" width="90" height="9" font="5">3.4.4. CMR Imaging</text>
<text top="1045" left="301" width="35" height="9" font="5">S3.4.4-1.</text>
<text top="1045" left="339" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref131">Puchalski MD, Williams RV, Askovich B, et al.</a></text>
<text top="1059" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref131">Assessment of right ventricular size and function: echo</a></text>
<text top="1072" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref131">versus magnetic resonance imaging. Congenit Heart</a></text>
<text top="1086" left="301" width="59" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref131">Dis. 2007;2:27</a></text>
<text top="1084" left="360" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref131">–31</a></text>
<text top="1086" left="372" width="3" height="9" font="5">.</text>
<text top="143" left="539" width="36" height="9" font="5">S3.4.4-2.</text>
<text top="143" left="579" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref132">Blalock SE, Banka P, Geva T, et al. Interstudy</a></text>
<text top="156" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref132">variability in cardiac magnetic resonance imaging</a></text>
<text top="170" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref132">measurements of ventricular volume, mass, and ejec-</a></text>
<text top="183" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref132">tion fraction in repaired tetralogy of Fallot: a pro-</a></text>
<text top="197" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref132">spective observational study. J Magn Reson Imaging.</a></text>
<text top="210" left="539" width="51" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref132">2013;38:829</a></text>
<text top="209" left="590" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref132">–35</a></text>
<text top="210" left="604" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref132">.</a></text>
<text top="229" left="539" width="36" height="9" font="5">S3.4.4-3.</text>
<text top="229" left="579" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref133">Crean AM, Maredia N, Ballard G, et al. 3D</a></text>
<text top="242" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref133">Echo systematically underestimates right ventricular</a></text>
<text top="256" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref133">volumes compared to cardiovascular magnetic reso-</a></text>
<text top="269" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref133">nance in adult congenital heart disease patients with</a></text>
<text top="283" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref133">moderate or severe RV dilatation. J Cardiovasc Magn</a></text>
<text top="296" left="539" width="72" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref133">Reson. 2011;13:78</a></text>
<text top="296" left="611" width="3" height="9" font="5">.</text>
<text top="315" left="539" width="37" height="9" font="5">S3.4.4-4.</text>
<text top="315" left="580" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref134">Bonello B, Kilner PJ. Review of the role of</a></text>
<text top="328" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref134">cardiovascular magnetic resonance in congenital heart</a></text>
<text top="342" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref134">disease, with a focus on right ventricle assessment.</a></text>
<text top="355" left="539" width="140" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref134">Arch Cardiovasc Dis. 2012;105:605</a></text>
<text top="353" left="680" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref134">–13</a></text>
<text top="355" left="692" width="3" height="9" font="5">.</text>
<text top="373" left="539" width="36" height="9" font="5">S3.4.4-5.</text>
<text top="373" left="579" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref135">Kilner PJ. Imaging congenital heart disease</a></text>
<text top="387" left="539" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref135">in adults. Br J Radiol. 2011;84 Spec No 3:S258</a></text>
<text top="385" left="727" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref135">–68</a></text>
<text top="387" left="742" width="3" height="9" font="5">.</text>
<text top="405" left="539" width="37" height="9" font="5">S3.4.4-6.</text>
<text top="405" left="580" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref136">Festa P, Ait-Ali L, Cerillo AG, et al. Magnetic</a></text>
<text top="419" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref136">resonance imaging is the diagnostic tool of choice in</a></text>
<text top="432" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref136">the preoperative evaluation of patients with partial</a></text>
<text top="446" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref136">anomalous pulmonary venous return. Int J Cardiovasc</a></text>
<text top="459" left="539" width="91" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref136">Imaging. 2006;22:685</a></text>
<text top="458" left="630" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref136">–93</a></text>
<text top="459" left="645" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref136">.</a></text>
<text top="478" left="539" width="36" height="9" font="5">S3.4.4-7.</text>
<text top="478" left="579" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref137">van der Linde D, Rossi A, Yap SC, et al.</a></text>
<text top="491" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref137">Ascending aortic diameters in congenital aortic ste-</a></text>
<text top="505" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref137">nosis: cardiac magnetic resonance versus transthoracic</a></text>
<text top="518" left="539" width="213" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref137">echocardiography. Echocardiography. 2013;30:497</a></text>
<text top="517" left="752" width="4" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref137">–</a></text>
<text top="532" left="539" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref137">504</a></text>
<text top="532" left="556" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref137">.</a></text>
<text top="550" left="539" width="37" height="9" font="5">S3.4.4-8.</text>
<text top="550" left="580" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref138">Arheden H, Holmqvist C, Thilen U, et al.</a></text>
<text top="564" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref138">Left-to-right cardiac shunts: comparison of measure-</a></text>
<text top="577" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref138">ments obtained with MR velocity mapping and with</a></text>
<text top="590" left="539" width="205" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref138">radionuclide angiography. Radiology. 1999;211:453</a></text>
<text top="589" left="744" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref138">–8</a></text>
<text top="590" left="754" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref138">.</a></text>
<text top="609" left="539" width="37" height="9" font="5">S3.4.4-9.</text>
<text top="609" left="580" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref139">Brenner DJ, Hall EJ. Computed tomogra-</a></text>
<text top="622" left="539" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref139">phy</a></text>
<text top="621" left="554" width="202" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref139">—an increasing source of radiation exposure.</a></text>
<text top="636" left="539" width="120" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref139">N Engl J Med. 2007;357:2277</a></text>
<text top="634" left="659" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref139">–84</a></text>
<text top="636" left="674" width="3" height="9" font="5">.</text>
<text top="654" left="539" width="41" height="9" font="5">S3.4.4-10.</text>
<text top="654" left="584" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref140">Teo KSL, Disney PJ, Dundon BK, et al.</a></text>
<text top="668" left="539" width="47" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref140">Assessment</a></text>
<text top="668" left="595" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref140">of</a></text>
<text top="668" left="613" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref140">atrial</a></text>
<text top="668" left="643" width="24" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref140">septal</a></text>
<text top="668" left="677" width="29" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref140">defects</a></text>
<text top="668" left="715" width="7" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref140">in</a></text>
<text top="668" left="732" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref140">adults</a></text>
<text top="681" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref140">comparing cardiovascular magnetic resonance with</a></text>
<text top="695" left="539" width="70" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref140">transoesophageal</a></text>
<text top="695" left="619" width="73" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref140">echocardiography.</a></text>
<text top="695" left="701" width="4" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref140">J</a></text>
<text top="695" left="714" width="43" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref140">Cardiovasc</a></text>
<text top="708" left="539" width="100" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref140">Magn Reson. 2010;12:44</a></text>
<text top="708" left="639" width="3" height="9" font="5">.</text>
<text top="727" left="539" width="39" height="9" font="5">S3.4.4-11.</text>
<text top="727" left="582" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref141">Prasad SK, Soukias N, Hornung T, et al. Role</a></text>
<text top="740" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref141">of magnetic resonance angiography in the diagnosis of</a></text>
<text top="754" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref141">major aortopulmonary collateral arteries and partial</a></text>
<text top="767" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref141">anomalous pulmonary venous drainage. Circulation.</a></text>
<text top="780" left="539" width="59" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref141">2004;109:207</a></text>
<text top="779" left="598" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref141">–14</a></text>
<text top="780" left="611" width="3" height="9" font="5">.</text>
<text top="803" left="539" width="172" height="9" font="5">3.4.5. Cardiac Computed Tomography</text>
<text top="817" left="539" width="35" height="9" font="5">S3.4.5-1.</text>
<text top="817" left="577" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref142">Brenner DJ, Hall EJ. Computed tomography</a></text>
<text top="815" left="750" width="7" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref142">—</a></text>
<text top="830" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref142">an increasing source of radiation exposure. N Engl J</a></text>
<text top="844" left="539" width="83" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref142">Med. 2007;357:2277</a></text>
<text top="842" left="622" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref142">–84</a></text>
<text top="844" left="637" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref142">.</a></text>
<text top="862" left="539" width="35" height="9" font="5">S3.4.5-2.</text>
<text top="862" left="578" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref143">Ghoshhajra BB, Sidhu MS, El-Sherief A, et al.</a></text>
<text top="876" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref143">Adult congenital heart disease imaging with second-</a></text>
<text top="889" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref143">generation dual-source computed tomography: initial</a></text>
<text top="903" left="539" width="65" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref143">experiences and</a></text>
<text top="901" left="607" width="149" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref143">ﬁndings. Congenit Heart Dis. 2012;7:</a></text>
<text top="916" left="539" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref143">516</a></text>
<text top="915" left="554" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref143">–25</a></text>
<text top="916" left="567" width="3" height="9" font="5">.</text>
<text top="945" left="539" width="136" height="9" font="5">3.4.6. Cardiac Catheterization</text>
<text top="959" left="539" width="35" height="9" font="5">S3.4.6-1.</text>
<text top="959" left="578" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref144">Moore JW, Vincent RN, Beekman RH 3rd,</a></text>
<text top="972" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref144">et al. Procedural results and safety of common inter-</a></text>
<text top="986" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref144">ventional procedures in congenital heart disease: initial</a></text>
<text top="999" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref144">report from the National Cardiovascular Data Registry.</a></text>
<text top="1012" left="539" width="132" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref144">J Am Coll Cardiol. 2014;64:2439</a></text>
<text top="1011" left="671" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref144">–51</a></text>
<text top="1012" left="684" width="3" height="9" font="5">.</text>
<text top="1031" left="539" width="36" height="9" font="5">S3.4.6-2.</text>
<text top="1031" left="579" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref145">Learn CP, Holzer RJ, Daniels CJ, et al.</a></text>
<text top="1044" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref145">Adverse events rates and risk factors in adults under-</a></text>
<text top="1058" left="539" width="210" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref145">going cardiac catheterization at pediatric hospitals</a></text>
<text top="1056" left="750" width="7" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref145">—</a></text>
<text top="1071" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref145">results from the C3PO. Catheter Cardiovasc Interv.</a></text>
<text top="1085" left="539" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref145">2013;81:997</a></text>
<text top="1083" left="589" width="25" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref145">–1005</a></text>
<text top="1085" left="614" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref145">.</a></text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="789" width="19" height="9" font="5">1547</text>
</page>
<page number="55" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="36" height="9" font="5">S3.4.6-3.</text>
<text top="143" left="147" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref146">Sutton NJ, Greenberg MA, Menegus MA,</a></text>
<text top="156" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref146">et al. Caring for the adult with congenital heart disease</a></text>
<text top="170" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref146">in an adult catheterization laboratory by pediatric</a></text>
<text top="183" left="108" width="69" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref146">interventionalists</a></text>
<text top="182" left="177" width="148" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref146">—safety and efﬁcacy. Congenit Heart</a></text>
<text top="197" left="108" width="59" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref146">Dis. 2013;8:111</a></text>
<text top="195" left="167" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref146">–6</a></text>
<text top="197" left="176" width="3" height="9" font="5">.</text>
<text top="216" left="108" width="37" height="9" font="5">S3.4.6-4.</text>
<text top="216" left="148" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref147">Opotowsky AR, Landzberg MJ, Kimmel SE,</a></text>
<text top="230" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref147">et al. Percutaneous closure of patent foramen ovale</a></text>
<text top="243" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref147">and atrial septal defect in adults: the impact of clinical</a></text>
<text top="257" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref147">variables and hospital procedure volume on in-hospital</a></text>
<text top="270" left="108" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref147">adverse events. Am Heart J. 2009;157:867</a></text>
<text top="268" left="281" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref147">–74</a></text>
<text top="270" left="295" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref147">.</a></text>
<text top="290" left="108" width="36" height="9" font="5">S3.4.6-5.</text>
<text top="290" left="147" width="86" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref148">Reant P, Brunot S, La</a></text>
<text top="288" left="232" width="92" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref148">ﬁtte S, et al. Predictive</a></text>
<text top="303" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref148">value of noninvasive coronary angiography with mul-</a></text>
<text top="316" left="108" width="195" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref148">tidetector computed tomography to detect signi</a></text>
<text top="315" left="302" width="22" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref148">ﬁcant</a></text>
<text top="330" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref148">coronary stenosis before valve surgery. Am J Cardiol.</a></text>
<text top="343" left="108" width="58" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref148">2006;97:1506</a></text>
<text top="342" left="166" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref148">–10</a></text>
<text top="343" left="180" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref148">.</a></text>
<text top="363" left="108" width="37" height="9" font="5">S3.4.6-6.</text>
<text top="363" left="148" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref149">Gilard M, Cornily J-C, Pennec P-Y, et al.</a></text>
<text top="376" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref149">Accuracy of multislice computed tomography in the</a></text>
<text top="390" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref149">preoperative assessment of coronary disease in pa-</a></text>
<text top="403" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref149">tients with aortic valve stenosis. J Am Coll Cardiol.</a></text>
<text top="417" left="108" width="60" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref149">2006;47:2020</a></text>
<text top="415" left="167" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref149">–4</a></text>
<text top="417" left="177" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref149">.</a></text>
<text top="436" left="108" width="36" height="9" font="5">S3.4.6-7.</text>
<text top="436" left="147" width="35" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref150">Manghat</a></text>
<text top="436" left="199" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref150">NE,</a></text>
<text top="436" left="231" width="64" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref150">Morgan-Hughes</a></text>
<text top="436" left="312" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref150">GJ,</a></text>
<text top="450" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref150">Broadley AJ, et al. 16-Detector row computed tomo-</a></text>
<text top="463" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref150">graphic coronary angiography in patients undergo-</a></text>
<text top="476" left="108" width="12" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref150">ing</a></text>
<text top="476" left="131" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref150">evaluation</a></text>
<text top="476" left="184" width="12" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref150">for</a></text>
<text top="476" left="206" width="23" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref150">aortic</a></text>
<text top="476" left="240" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref150">valve</a></text>
<text top="476" left="272" width="52" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref150">replacement:</a></text>
<text top="490" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref150">comparison with catheter angiography. Clin Radiol.</a></text>
<text top="503" left="108" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref150">2006;61:749</a></text>
<text top="502" left="160" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref150">–57</a></text>
<text top="503" left="174" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref150">.</a></text>
<text top="523" left="108" width="37" height="9" font="5">S3.4.6-8.</text>
<text top="523" left="148" width="39" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref151">Meijboom</a></text>
<text top="523" left="204" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref151">WB,</a></text>
<text top="523" left="236" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref151">Mollet</a></text>
<text top="523" left="279" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref151">NR,</a></text>
<text top="523" left="310" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref151">Van</a></text>
<text top="536" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref151">Mieghem CAG, et al. Pre-operative computed tomog-</a></text>
<text top="550" left="108" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref151">raphy coronary angiography to detect signi</a></text>
<text top="548" left="283" width="42" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref151">ﬁcant cor-</a></text>
<text top="563" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref151">onary artery disease in patients referred for cardiac</a></text>
<text top="577" left="108" width="193" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref151">valve surgery. J Am Coll Cardiol. 2006;48:1658</a></text>
<text top="575" left="301" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref151">–65</a></text>
<text top="577" left="315" width="3" height="9" font="5">.</text>
<text top="596" left="108" width="37" height="9" font="5">S3.4.6-9.</text>
<text top="596" left="148" width="109" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref152">Galas A, Hryniewiecki T, Ke</a></text>
<text top="594" left="252" width="72" height="12" font="6">˛<a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref152">pka C, et al. May</a></text>
<text top="609" left="108" width="47" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref152">dual-source</a></text>
<text top="609" left="165" width="40" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref152">computed</a></text>
<text top="609" left="216" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref152">tomography</a></text>
<text top="609" left="275" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref152">angiography</a></text>
<text top="623" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref152">replace invasive coronary angiography in the evalua-</a></text>
<text top="636" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref152">tion of patients referred for valvular disease surgery?</a></text>
<text top="650" left="108" width="100" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref152">Kardiol Pol. 2012;70:877</a></text>
<text top="648" left="207" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref152">–82</a></text>
<text top="650" left="222" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref152">.</a></text>
<text top="673" left="108" width="103" height="9" font="5">3.4.7. Exercise Testing</text>
<text top="687" left="108" width="35" height="9" font="5">S3.4.7-1.</text>
<text top="687" left="145" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref153">Diller G-P, Dimopoulos K, Okonko D, et al.</a></text>
<text top="701" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref153">Exercise intolerance in adult congenital heart disease:</a></text>
<text top="714" left="108" width="92" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref153">comparative severity,</a></text>
<text top="714" left="208" width="65" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref153">correlates, and</a></text>
<text top="714" left="282" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref153">prognostic</a></text>
<text top="728" left="108" width="153" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref153">implication. Circulation. 2005;112:828</a></text>
<text top="726" left="260" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref153">–35</a></text>
<text top="728" left="274" width="3" height="9" font="5">.</text>
<text top="747" left="108" width="35" height="9" font="5">S3.4.7-2.</text>
<text top="747" left="146" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref154">Hager A, Hess J. Comparison of health</a></text>
<text top="761" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref154">related quality of life with cardiopulmonary exercise</a></text>
<text top="774" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref154">testing in adolescents and adults with congenital heart</a></text>
<text top="787" left="108" width="112" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref154">disease. Heart. 2005;91:517</a></text>
<text top="786" left="219" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref154">–20</a></text>
<text top="787" left="234" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref154">.</a></text>
<text top="807" left="108" width="35" height="9" font="5">S3.4.7-3.</text>
<text top="807" left="146" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref155">Ross RM, Murthy JN, Wollak ID, et al. The six</a></text>
<text top="820" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref155">minute walk test accurately estimates mean peak ox-</a></text>
<text top="834" left="108" width="167" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref155">ygen uptake. BMC Pulm Med. 2010;10:31</a></text>
<text top="834" left="274" width="3" height="9" font="5">.</text>
<text top="853" left="108" width="36" height="9" font="5">S3.4.7-4.</text>
<text top="853" left="147" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref156">Gungor H, Fatih Ayik M, Engin C, et al.</a></text>
<text top="867" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref156">Transthoracic echocardiographic and cardiopulmonary</a></text>
<text top="880" left="108" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref156">exercise testing parameters in Eisenmenger</a></text>
<text top="878" left="295" width="30" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref156">’s syn-</a></text>
<text top="894" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref156">drome. Association with six-minute walk test distance.</a></text>
<text top="907" left="108" width="75" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref156">Herz. 2014;39:633</a></text>
<text top="905" left="182" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref156">–7</a></text>
<text top="907" left="191" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref156">.</a></text>
<text top="930" left="108" width="115" height="9" font="24">3.5. Transition Education</text>
<text top="944" left="108" width="26" height="9" font="5">S3.5-1.</text>
<text top="944" left="137" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref157">Mackie AS, Islam S, Magill-Evans J, et al.</a></text>
<text top="958" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref157">Healthcare transition for youth with heart disease: a</a></text>
<text top="971" left="108" width="137" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref157">clinical trial. Heart. 2014;100:1113</a></text>
<text top="970" left="244" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref157">–8</a></text>
<text top="971" left="254" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref157">.</a></text>
<text top="991" left="108" width="27" height="9" font="5">S3.5-2.</text>
<text top="991" left="138" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref158">Goossens E, Van Deyk K, Zupancic N, et al.</a></text>
<text top="1004" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref158">Effectiveness of structured patient education on the</a></text>
<text top="1018" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref158">knowledge level of adolescents and adults with</a></text>
<text top="1031" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref158">congenital heart disease. Eur J Cardiovasc Nurs. 2014;</a></text>
<text top="1045" left="108" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref158">13:63</a></text>
<text top="1043" left="129" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref158">–70</a></text>
<text top="1045" left="144" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref158">.</a></text>
<text top="1067" left="108" width="109" height="9" font="24">3.6. Exercise and Sports</text>
<text top="1082" left="108" width="27" height="9" font="5">S3.6-1.</text>
<text top="1082" left="138" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref159">Pemberton VL, McCrindle BW, Barkin S, et al.</a></text>
<text top="1095" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref159">Report of the National Heart, Lung, and Blood</a></text>
<text top="143" left="346" width="34" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref159">Institute</a></text>
<text top="141" left="379" width="183" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref159">’s Working Group on obesity and other car-</a></text>
<text top="156" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref159">diovascular risk factors in congenital heart disease.</a></text>
<text top="170" left="346" width="103" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref159">Circulation. 2010;121:1153</a></text>
<text top="168" left="449" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref159">–9</a></text>
<text top="170" left="459" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref159">.</a></text>
<text top="190" left="346" width="28" height="9" font="5">S3.6-2.</text>
<text top="190" left="377" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref160">Myers J, Kaykha A, George S, et al. Fitness</a></text>
<text top="203" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref160">versus physical activity patterns in predicting mortality</a></text>
<text top="217" left="346" width="133" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref160">in men. Am J Med. 2004;117:912</a></text>
<text top="215" left="479" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref160">–8</a></text>
<text top="217" left="488" width="3" height="9" font="5">.</text>
<text top="237" left="346" width="28" height="9" font="5">S3.6-3.</text>
<text top="237" left="377" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref161">Warburton DER, Nicol CW, Bredin SSD. Health</a></text>
<text top="251" left="346" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref161">bene</a></text>
<text top="249" left="365" width="198" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref161">ﬁts of physical activity: the evidence. CMAJ.</a></text>
<text top="264" left="346" width="57" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref161">2006;174:801</a></text>
<text top="262" left="403" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref161">–9</a></text>
<text top="264" left="412" width="3" height="9" font="5">.</text>
<text top="284" left="346" width="29" height="9" font="5">S3.6-4.</text>
<text top="284" left="378" width="156" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref162">King AC, Taylor CB, Haskell WL, et al. In</a></text>
<text top="283" left="534" width="29" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref162">ﬂuence</a></text>
<text top="298" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref162">of regular aerobic exercise on psychological health: a</a></text>
<text top="311" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref162">randomized, controlled trial of healthy middle-aged</a></text>
<text top="325" left="346" width="143" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref162">adults. Health Psychol. 1989;8:305</a></text>
<text top="323" left="488" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref162">–24</a></text>
<text top="325" left="503" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref162">.</a></text>
<text top="345" left="346" width="28" height="9" font="5">S3.6-5.</text>
<text top="345" left="377" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref163">Reybrouck T, Mertens L. Physical performance</a></text>
<text top="358" left="346" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref163">and</a></text>
<text top="358" left="371" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref163">physical</a></text>
<text top="358" left="414" width="29" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref163">activity</a></text>
<text top="358" left="454" width="7" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref163">in</a></text>
<text top="358" left="471" width="39" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref163">grown-up</a></text>
<text top="358" left="521" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref163">congenital</a></text>
<text top="372" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref163">heart disease. Eur J Cardiovasc Prev Rehabil. 2005;12:</a></text>
<text top="385" left="346" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref163">498</a></text>
<text top="383" left="363" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref163">–502</a></text>
<text top="385" left="382" width="3" height="9" font="5">.</text>
<text top="405" left="346" width="29" height="9" font="5">S3.6-6.</text>
<text top="405" left="378" width="185" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref164">Duppen N, Takken T, Hopman MTE, et al.</a></text>
<text top="419" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref164">Systematic review of the effects of physical exercise</a></text>
<text top="432" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref164">training programmes in children and young adults</a></text>
<text top="446" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref164">with congenital heart disease. Int J Cardiol. 2013;168:</a></text>
<text top="459" left="346" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref164">1779</a></text>
<text top="457" left="364" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref164">–87</a></text>
<text top="459" left="379" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref164">.</a></text>
<text top="479" left="346" width="28" height="9" font="5">S3.6-7.</text>
<text top="479" left="377" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref165">Dua JS, Cooper AR, Fox KR, et al. Exercise</a></text>
<text top="493" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref165">training in adults with congenital heart disease: feasi-</a></text>
<text top="506" left="346" width="60" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref165">bility and bene</a></text>
<text top="504" left="406" width="147" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref165">ﬁts. Int J Cardiol. 2010;138:196–205</a></text>
<text top="506" left="553" width="3" height="9" font="5">.</text>
<text top="526" left="346" width="29" height="9" font="5">S3.6-8.</text>
<text top="526" left="378" width="185" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref166">Holloway TM, Chesssex C, Grace SL, et al.</a></text>
<text top="540" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref166">A call for adult congenital heart disease patient</a></text>
<text top="553" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref166">participation in cardiac rehabilitation. Int J Cardiol.</a></text>
<text top="567" left="346" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref166">2011;150:345</a></text>
<text top="565" left="399" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref166">–6</a></text>
<text top="567" left="409" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref166">.</a></text>
<text top="587" left="346" width="29" height="9" font="5">S3.6-9.</text>
<text top="587" left="378" width="185" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref167">Sandberg C, Pomeroy J, Thilén U, et al.</a></text>
<text top="600" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref167">Habitual physical activity in adults with congenital</a></text>
<text top="614" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref167">heart disease compared with age- and sex-matched</a></text>
<text top="627" left="346" width="146" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref167">controls. Can J Cardiol. 2016;32:547</a></text>
<text top="625" left="492" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref167">–53</a></text>
<text top="627" left="506" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref167">.</a></text>
<text top="647" left="346" width="33" height="9" font="5">S3.6-10.</text>
<text top="647" left="382" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref168">Diller G-P, Dimopoulos K, Okonko D, et al.</a></text>
<text top="661" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref168">Exercise intolerance in adult congenital heart disease:</a></text>
<text top="674" left="346" width="92" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref168">comparative severity,</a></text>
<text top="674" left="446" width="117" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref168">correlates, and prognostic</a></text>
<text top="688" left="346" width="153" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref168">implication. Circulation. 2005;112:828</a></text>
<text top="686" left="499" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref168">–35</a></text>
<text top="688" left="512" width="3" height="9" font="5">.</text>
<text top="708" left="346" width="31" height="9" font="5">S3.6-11.</text>
<text top="708" left="380" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref169">Kempny A, Dimopoulos K, Uebing A, et al.</a></text>
<text top="721" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref169">Reference values for exercise limitations among adults</a></text>
<text top="735" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref169">with congenital heart disease. Relation to activities of</a></text>
<text top="748" left="346" width="38" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref169">daily life</a></text>
<text top="746" left="384" width="179" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref169">—single centre experience and review of</a></text>
<text top="762" left="346" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref169">published data. Eur Heart J. 2012;33:1386</a></text>
<text top="760" left="515" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref169">–96</a></text>
<text top="762" left="531" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref169">.</a></text>
<text top="782" left="346" width="32" height="9" font="5">S3.6-12.</text>
<text top="782" left="381" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref170">Westhoff-Bleck M, Schieffer B, Tegtbur U,</a></text>
<text top="795" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref170">et al. Aerobic training in adults after atrial switch</a></text>
<text top="809" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref170">procedure for transposition of the great arteries im-</a></text>
<text top="822" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref170">proves exercise capacity without impairing systemic</a></text>
<text top="835" left="346" width="205" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref170">right ventricular function. Int J Cardiol. 2013;170:24</a></text>
<text top="834" left="551" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref170">–9</a></text>
<text top="835" left="560" width="3" height="9" font="5">.</text>
<text top="856" left="346" width="32" height="9" font="5">S3.6-13.</text>
<text top="856" left="381" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref171">Tikkanen AU, Opotowsky AR, Bhatt AB,</a></text>
<text top="869" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref171">et al. Physical activity is associated with improved</a></text>
<text top="882" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref171">aerobic exercise capacity over time in adults with</a></text>
<text top="896" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref171">congenital heart disease. Int J Cardiol. 2013;168:</a></text>
<text top="909" left="346" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref171">4685</a></text>
<text top="908" left="367" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref171">–91</a></text>
<text top="909" left="381" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref171">.</a></text>
<text top="932" left="346" width="202" height="9" font="24">3.7. Mental Health and Neurodevelopmental</text>
<text top="946" left="346" width="28" height="9" font="24">Issues</text>
<text top="961" left="346" width="26" height="9" font="5">S3.7-1.</text>
<text top="961" left="375" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref172">Kovacs AH, Saidi AS, Kuhl EA, et al. Depression</a></text>
<text top="974" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref172">and anxiety in adult congenital heart disease: pre-</a></text>
<text top="988" left="346" width="213" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref172">dictors and prevalence. Int J Cardiol. 2009;137:158</a></text>
<text top="986" left="559" width="4" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref172">–</a></text>
<text top="1001" left="346" width="11" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref172">64</a></text>
<text top="1001" left="357" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref172">.</a></text>
<text top="1021" left="346" width="27" height="9" font="5">S3.7-2.</text>
<text top="1021" left="376" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref173">Kovacs AH, Sears SF, Saidi AS. Biopsychosocial</a></text>
<text top="1035" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref173">experiences of adults with congenital heart disease:</a></text>
<text top="1048" left="346" width="213" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref173">review of the literature. Am Heart J. 2005;150:193</a></text>
<text top="1047" left="559" width="4" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref173">–</a></text>
<text top="1062" left="346" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref173">201</a></text>
<text top="1062" left="361" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref173">.</a></text>
<text top="1082" left="346" width="27" height="9" font="5">S3.7-3.</text>
<text top="1082" left="376" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref174">van</a></text>
<text top="1082" left="402" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref174">Rijen</a></text>
<text top="1082" left="433" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref174">EHM,</a></text>
<text top="1082" left="466" width="23" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref174">Utens</a></text>
<text top="1082" left="501" width="27" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref174">EMWJ,</a></text>
<text top="1082" left="540" width="23" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref174">Roos-</a></text>
<text top="1095" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref174">Hesselink JW, et al. Psychosocial functioning of the</a></text>
<text top="143" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref174">adult with congenital heart disease: a 20-33 years</a></text>
<text top="156" left="584" width="148" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref174">follow-up. Eur Heart J. 2003;24:673</a></text>
<text top="155" left="732" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref174">–83</a></text>
<text top="156" left="746" width="3" height="9" font="5">.</text>
<text top="176" left="584" width="28" height="9" font="5">S3.7-4.</text>
<text top="176" left="615" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref175">Callus E, Quadri E, Ricci C, et al. Update on</a></text>
<text top="189" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref175">psychological functioning in adults with congenital</a></text>
<text top="203" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref175">heart disease: a systematic review. Expert Rev Car-</a></text>
<text top="216" left="584" width="103" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref175">diovasc Ther. 2013;11:785</a></text>
<text top="215" left="687" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref175">–91</a></text>
<text top="216" left="701" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref175">.</a></text>
<text top="236" left="584" width="27" height="9" font="5">S3.7-5.</text>
<text top="236" left="614" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref176">Amianto F, Bergui G, Abbate-Daga G, et al.</a></text>
<text top="249" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref176">Growing up with a congenital heart disease: neuro-</a></text>
<text top="262" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref176">cognitive, psychopathological and quality of life out-</a></text>
<text top="276" left="584" width="152" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref176">comes. Panminerva Med. 2011;53:109</a></text>
<text top="274" left="736" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref176">–27</a></text>
<text top="276" left="749" width="3" height="9" font="5">.</text>
<text top="295" left="584" width="28" height="9" font="5">S3.7-6.</text>
<text top="295" left="615" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref177">Granberg M, Rydberg A, Fisher AG. Activities in</a></text>
<text top="309" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref177">daily living and schoolwork task performance in chil-</a></text>
<text top="322" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref177">dren with complex congenital heart disease. Acta</a></text>
<text top="336" left="584" width="95" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref177">Paediatr. 2008;97:1270</a></text>
<text top="334" left="680" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref177">–4</a></text>
<text top="336" left="689" width="3" height="9" font="5">.</text>
<text top="355" left="584" width="27" height="9" font="5">S3.7-7.</text>
<text top="355" left="614" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref178">Karsdorp PA, Everaerd W, Kindt M, et al. Psy-</a></text>
<text top="368" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref178">chological and cognitive functioning in children and</a></text>
<text top="382" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref178">adolescents with congenital heart disease: a meta-</a></text>
<text top="395" left="584" width="162" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref178">analysis. J Pediatr Psychol. 2007;32:527</a></text>
<text top="394" left="746" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref178">–41</a></text>
<text top="395" left="759" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref178">.</a></text>
<text top="415" left="584" width="28" height="9" font="5">S3.7-8.</text>
<text top="415" left="615" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref179">van der Rijken REA, Maassen BAM, Walk TLM,</a></text>
<text top="428" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref179">et al. Outcome after surgical repair of congenital car-</a></text>
<text top="442" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref179">diac malformations at school age. Cardiol Young.</a></text>
<text top="455" left="584" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref179">2007;17:64</a></text>
<text top="453" left="630" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref179">–71</a></text>
<text top="455" left="643" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref179">.</a></text>
<text top="474" left="584" width="28" height="9" font="5">S3.7-9.</text>
<text top="474" left="615" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref180">Kirshbom PM, Flynn TB, Clancy RR, et al. Late</a></text>
<text top="488" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref180">neurodevelopmental outcome after repair of total</a></text>
<text top="501" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref180">anomalous pulmonary venous connection. J Thorac</a></text>
<text top="515" left="584" width="130" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref180">Cardiovasc Surg. 2005;129:1091</a></text>
<text top="513" left="714" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref180">–7</a></text>
<text top="515" left="722" width="3" height="9" font="5">.</text>
<text top="537" left="584" width="130" height="9" font="24">3.8. Endocarditis Prevention</text>
<text top="552" left="584" width="27" height="9" font="5">S3.8-1.</text>
<text top="552" left="614" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref181">Nishimura RA, Otto CM, Bonow RO, et al. 2014</a></text>
<text top="565" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref181">AHA/ACC guideline for the management of patients with</a></text>
<text top="579" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref181">valvular heart disease: a report of the American College</a></text>
<text top="592" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref181">of Cardiology/American Heart Association Task Force on</a></text>
<text top="606" left="584" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref181">Practice Guidelines. Circulation. 2014;129:e521</a></text>
<text top="604" left="763" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref181">–643</a></text>
<text top="606" left="782" width="3" height="9" font="5">.</text>
<text top="625" left="584" width="28" height="9" font="5">S3.8-2.</text>
<text top="625" left="615" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref182">Verheugt</a></text>
<text top="625" left="661" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref182">CL,</a></text>
<text top="625" left="683" width="38" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref182">Uiterwaal</a></text>
<text top="625" left="730" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref182">CSPM,</a></text>
<text top="625" left="765" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref182">van</a></text>
<text top="625" left="788" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref182">der</a></text>
<text top="639" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref182">Velde ET, et al. Turning 18 with congenital heart dis-</a></text>
<text top="652" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref182">ease: prediction of infective endocarditis based on a</a></text>
<text top="665" left="584" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref182">large population. Eur Heart J. 2011;32:1926</a></text>
<text top="664" left="760" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref182">–34</a></text>
<text top="665" left="774" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref182">.</a></text>
<text top="685" left="584" width="28" height="9" font="5">S3.8-3.</text>
<text top="685" left="615" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref183">Habib G, Hoen B, Tornos P, et al. Guidelines on</a></text>
<text top="698" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref183">the prevention, diagnosis, and treatment of infective</a></text>
<text top="712" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref183">endocarditis (new version 2009): the Task Force on</a></text>
<text top="725" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref183">the Prevention, Diagnosis, and Treatment of Infective</a></text>
<text top="739" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref183">Endocarditis of the European Society of Cardiology</a></text>
<text top="752" left="584" width="137" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref183">(ESC). Eur Heart J. 2009;30:2369</a></text>
<text top="750" left="722" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref183">–413</a></text>
<text top="752" left="739" width="3" height="9" font="5">.</text>
<text top="771" left="584" width="29" height="9" font="5">S3.8-4.</text>
<text top="771" left="616" width="185" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref184">Wilson W, Taubert KA, Gewitz M, et al. Pre-</a></text>
<text top="785" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref184">vention of infective endocarditis: guidelines from the</a></text>
<text top="798" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref184">American Heart Association: a guideline from the</a></text>
<text top="812" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref184">American Heart Association Rheumatic Fever, Endo-</a></text>
<text top="825" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref184">carditis, and Kawasaki Disease Committee, Council on</a></text>
<text top="839" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref184">Cardiovascular Disease in the Young, and the Council</a></text>
<text top="852" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref184">on Clinical Cardiology, Council on Cardiovascular Sur-</a></text>
<text top="866" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref184">gery and Anesthesia, and the Quality of Care and</a></text>
<text top="879" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref184">Outcomes Research Interdisciplinary Working Group.</a></text>
<text top="892" left="584" width="107" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref184">Circulation. 2007;116:1736</a></text>
<text top="891" left="691" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref184">–54</a></text>
<text top="892" left="705" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref184">.</a></text>
<text top="912" left="584" width="28" height="9" font="5">S3.8-5.</text>
<text top="912" left="615" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref185">Allen</a></text>
<text top="912" left="645" width="9" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref185">U.</a></text>
<text top="912" left="664" width="35" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref185">Infective</a></text>
<text top="912" left="708" width="51" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref185">endocarditis:</a></text>
<text top="912" left="768" width="33" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref185">updated</a></text>
<text top="925" left="584" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref185">guidelines. Paediatr Child Health. 2010;15:205</a></text>
<text top="924" left="771" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref185">–12</a></text>
<text top="925" left="784" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref185">.</a></text>
<text top="948" left="584" width="131" height="9" font="24">3.9. Concomitant Syndromes</text>
<text top="963" left="584" width="27" height="9" font="5">S3.9-1.</text>
<text top="963" left="614" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref186">van Engelen K, Topf A, Keavney BD, et al.</a></text>
<text top="976" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref186">22q11.2 Deletion syndrome is under-recognised in</a></text>
<text top="989" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref186">adult patients with tetralogy of Fallot and pulmonary</a></text>
<text top="1003" left="584" width="111" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref186">atresia. Heart. 2010;96:621</a></text>
<text top="1001" left="695" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref186">–4</a></text>
<text top="1003" left="704" width="3" height="9" font="5">.</text>
<text top="1022" left="584" width="28" height="9" font="5">S3.9-2.</text>
<text top="1022" left="615" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref187">Fung WLA, Chow EWC, Webb GD, et al.</a></text>
<text top="1036" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref187">Extracardiac features predicting 22q11.2 deletion syn-</a></text>
<text top="1049" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref187">drome in adult congenital heart disease. Int J Cardiol.</a></text>
<text top="1063" left="584" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref187">2008;131:51</a></text>
<text top="1061" left="633" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref187">–8</a></text>
<text top="1063" left="642" width="3" height="9" font="5">.</text>
<text top="1082" left="584" width="28" height="9" font="5">S3.9-3.</text>
<text top="1082" left="615" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref188">Lin AE, Basson CT, Goldmuntz E, et al. Adults</a></text>
<text top="1095" left="584" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref188">with</a></text>
<text top="1095" left="616" width="29" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref188">genetic</a></text>
<text top="1095" left="659" width="43" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref188">syndromes</a></text>
<text top="1095" left="716" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref188">and</a></text>
<text top="1095" left="744" width="57" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref188">cardiovascular</a></text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="20" height="9" font="5">1548</text>
</page>
<page number="56" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref188">abnormalities: clinical history and management. Genet</a></text>
<text top="156" left="63" width="77" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref188">Med. 2008;10:469</a></text>
<text top="155" left="140" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref188">–94</a></text>
<text top="156" left="155" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref188">.</a></text>
<text top="175" left="63" width="29" height="9" font="5">S3.9-4.</text>
<text top="175" left="95" width="185" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref189">Richards AA, Garg V. Genetics of congenital</a></text>
<text top="189" left="63" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref189">heart disease. Curr Cardiol Rev. 2010;6:91</a></text>
<text top="187" left="233" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref189">–7</a></text>
<text top="189" left="241" width="3" height="9" font="5">.</text>
<text top="207" left="63" width="28" height="9" font="5">S3.9-5.</text>
<text top="207" left="94" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref190">Kitsiou-Tzeli S, Kolialexi A, Fryssira H, et al.</a></text>
<text top="221" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref190">Detection of 22q11.2 deletion among 139 patients with</a></text>
<text top="234" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref190">Di George/velocardiofacial syndrome features. In Vivo.</a></text>
<text top="247" left="63" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref190">2004;18:603</a></text>
<text top="246" left="116" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref190">–8</a></text>
<text top="247" left="126" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref190">.</a></text>
<text top="266" left="63" width="29" height="9" font="5">S3.9-6.</text>
<text top="266" left="95" width="185" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref191">Bassett AS, Chow EWC, Husted J, et al. Clinical</a></text>
<text top="280" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref191">features of 78 adults with 22q11 deletion syndrome.</a></text>
<text top="293" left="63" width="138" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref191">Am J Med Genet A. 2005;138:307</a></text>
<text top="291" left="201" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref191">–13</a></text>
<text top="293" left="213" width="3" height="9" font="5">.</text>
<text top="312" left="63" width="28" height="9" font="5">S3.9-7.</text>
<text top="312" left="94" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref192">Barisic I, Boban L, Greenlees R, et al. Holt Oram</a></text>
<text top="325" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref192">syndrome: a registry-based study in Europe. Orphanet</a></text>
<text top="339" left="63" width="91" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref192">J Rare Dis. 2014;9:156</a></text>
<text top="339" left="153" width="3" height="9" font="5">.</text>
<text top="357" left="63" width="29" height="9" font="5">S3.9-8.</text>
<text top="357" left="95" width="185" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref193">Pierpont MEM, Magoulas PL, Adi S, et al.</a></text>
<text top="371" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref193">Cardio-facio-cutaneous syndrome: clinical features,</a></text>
<text top="384" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref193">diagnosis, and management guidelines. Pediatrics.</a></text>
<text top="397" left="63" width="62" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref193">2014;134:e1149</a></text>
<text top="396" left="125" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref193">–62</a></text>
<text top="397" left="139" width="3" height="9" font="5">.</text>
<text top="420" left="63" width="145" height="9" font="24">3.10. Noncardiac Medical Issues</text>
<text top="434" left="63" width="31" height="9" font="5">S3.10-1.</text>
<text top="434" left="97" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref194">Wang A, Book WM, McConnell M, et al.</a></text>
<text top="447" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref194">Prevalence of hepatitis C infection in adult patients</a></text>
<text top="461" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref194">who underwent congenital heart surgery prior to</a></text>
<text top="474" left="63" width="195" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref194">screening in 1992. Am J Cardiol. 2007;100:1307</a></text>
<text top="473" left="258" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref194">–9</a></text>
<text top="474" left="267" width="3" height="9" font="5">.</text>
<text top="497" left="63" width="112" height="9" font="24">3.11. Noncardiac Surgery</text>
<text top="511" left="63" width="29" height="9" font="5">S3.11-1.</text>
<text top="511" left="95" width="185" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref195">Ammash NM, Connolly HM, Abel MD, et al.</a></text>
<text top="524" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref195">Noncardiac surgery in Eisenmenger syndrome. J Am</a></text>
<text top="538" left="63" width="102" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref195">Coll Cardiol. 1999;33:222</a></text>
<text top="536" left="165" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref195">–7</a></text>
<text top="538" left="173" width="3" height="9" font="5">.</text>
<text top="556" left="63" width="30" height="9" font="5">S3.11-2.</text>
<text top="556" left="96" width="184" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref196">Maxwell BG, Posner KL, Wong JK, et al. Fac-</a></text>
<text top="570" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref196">tors contributing to adverse perioperative events in</a></text>
<text top="583" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref196">adults with congenital heart disease: a structured</a></text>
<text top="597" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref196">analysis of cases from the closed claims project. Con-</a></text>
<text top="610" left="63" width="109" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref196">genit Heart Dis. 2015;10:21</a></text>
<text top="609" left="172" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref196">–9</a></text>
<text top="610" left="181" width="3" height="9" font="5">.</text>
<text top="629" left="63" width="30" height="9" font="5">S3.11-3.</text>
<text top="629" left="96" width="184" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref197">Maxwell BG, Wong JK, Lobato RL. Periopera-</a></text>
<text top="642" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref197">tive morbidity and mortality after noncardiac surgery</a></text>
<text top="656" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref197">in young adults with congenital or early acquired heart</a></text>
<text top="669" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref197">disease: a retrospective cohort analysis of the National</a></text>
<text top="683" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref197">Surgical Quality Improvement Program database. Am</a></text>
<text top="696" left="63" width="74" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref197">Surg. 2014;80:321</a></text>
<text top="695" left="137" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref197">–6</a></text>
<text top="696" left="146" width="3" height="9" font="5">.</text>
<text top="715" left="63" width="31" height="9" font="5">S3.11-4.</text>
<text top="715" left="97" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref198">Maxwell BG, Williams GD, Ramamoorthy C.</a></text>
<text top="728" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref198">Knowledge and attitudes of anesthesia providers</a></text>
<text top="742" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref198">about noncardiac surgery in adults with congenital</a></text>
<text top="755" left="63" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref198">heart disease. Congenit Heart Dis. 2014;9:45</a></text>
<text top="753" left="244" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref198">–53</a></text>
<text top="755" left="257" width="3" height="9" font="5">.</text>
<text top="774" left="63" width="30" height="9" font="5">S3.11-5.</text>
<text top="774" left="96" width="184" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref199">Eagle SS, Daves SM. The adult with Fontan</a></text>
<text top="787" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref199">physiology: systematic approach to perioperative</a></text>
<text top="801" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref199">management for noncardiac surgery. J Cardiothorac</a></text>
<text top="814" left="63" width="103" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref199">Vasc Anesth. 2011;25:320</a></text>
<text top="812" left="166" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref199">–34</a></text>
<text top="814" left="180" width="3" height="9" font="5">.</text>
<text top="833" left="63" width="31" height="9" font="5">S3.11-6.</text>
<text top="833" left="97" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref200">Maxwell BG, Wong JK, Kin C, et al. Perioper-</a></text>
<text top="846" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref200">ative outcomes of major noncardiac surgery in adults</a></text>
<text top="859" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref200">with congenital heart disease. Anesthesiology. 2013;</a></text>
<text top="873" left="63" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref200">119:762</a></text>
<text top="871" left="93" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref200">–9</a></text>
<text top="873" left="103" width="3" height="9" font="5">.</text>
<text top="892" left="63" width="30" height="9" font="5">S3.11-7.</text>
<text top="892" left="96" width="184" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref201">Maxwell BG, Wong JK, Sheikh AY, et al. Heart</a></text>
<text top="905" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref201">transplantation with or without prior mechanical cir-</a></text>
<text top="919" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref201">culatory support in adults with congenital heart dis-</a></text>
<text top="932" left="63" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref201">ease. Eur J Cardiothorac Surg. 2014;45:842</a></text>
<text top="930" left="238" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref201">–6</a></text>
<text top="932" left="248" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref201">.</a></text>
<text top="951" left="63" width="31" height="9" font="5">S3.11-8.</text>
<text top="951" left="97" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref202">Rabbitts JA, Groenewald CB, Mauermann WJ,</a></text>
<text top="964" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref202">et al. Outcomes of general anesthesia for noncardiac</a></text>
<text top="977" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref202">surgery in a series of patients with Fontan palliation.</a></text>
<text top="991" left="63" width="123" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref202">Paediatr Anaesth. 2013;23:180</a></text>
<text top="989" left="186" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref202">–7</a></text>
<text top="991" left="194" width="3" height="9" font="5">.</text>
<text top="1010" left="63" width="31" height="9" font="5">S3.11-9.</text>
<text top="1010" left="97" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref203">Mylotte D, Quenneville SP, Kotowycz MA,</a></text>
<text top="1023" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref203">et al. Long-term cost-effectiveness of transcatheter</a></text>
<text top="1036" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref203">versus surgical closure of secundum atrial septal</a></text>
<text top="1050" left="63" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref203">defect in adults. Int J Cardiol. 2014;172:109</a></text>
<text top="1048" left="239" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref203">–14</a></text>
<text top="1050" left="253" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref203">.</a></text>
<text top="1068" left="63" width="35" height="9" font="5">S3.11-10.</text>
<text top="1068" left="101" width="105" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref204">Warner MA, Lunn RJ, O</a></text>
<text top="1067" left="206" width="74" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref204">’Leary PW, et al.</a></text>
<text top="1082" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref204">Outcomes of noncardiac surgical procedures in chil-</a></text>
<text top="1095" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref204">dren and adults with congenital heart disease. Mayo</a></text>
<text top="143" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref204">Perioperative Outcomes Group. Mayo Clin Proc. 1998;</a></text>
<text top="156" left="301" width="27" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref204">73:728</a></text>
<text top="155" left="328" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref204">–34</a></text>
<text top="156" left="342" width="3" height="9" font="5">.</text>
<text top="181" left="301" width="217" height="9" font="24">3.12. Pregnancy, Reproduction, and Sexual</text>
<text top="199" left="301" width="30" height="9" font="24">Health</text>
<text top="217" left="301" width="78" height="9" font="5">3.12.1. Pregnancy</text>
<text top="230" left="301" width="37" height="9" font="5">S3.12.1-1.</text>
<text top="230" left="341" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref205">Balint OH, Siu SC, Mason J, et al. Cardiac</a></text>
<text top="244" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref205">outcomes after pregnancy in women with congenital</a></text>
<text top="257" left="301" width="143" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref205">heart disease. Heart. 2010;96:1656</a></text>
<text top="256" left="444" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref205">–61</a></text>
<text top="257" left="457" width="3" height="9" font="5">.</text>
<text top="276" left="301" width="37" height="9" font="5">S3.12.1-2.</text>
<text top="276" left="342" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref206">Roos-Hesselink JW, Ruys TPE, Stein JI, et al.</a></text>
<text top="289" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref206">Outcome of pregnancy in patients with structural or</a></text>
<text top="303" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref206">ischaemic heart disease: results of a registry of the</a></text>
<text top="316" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref206">European Society of Cardiology. Eur Heart J. 2013;34:</a></text>
<text top="330" left="301" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref206">657</a></text>
<text top="328" left="316" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref206">–65</a></text>
<text top="330" left="331" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref206">.</a></text>
<text top="348" left="301" width="37" height="9" font="5">S3.12.1-3.</text>
<text top="348" left="342" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref207">Ouyang DW, Khairy P, Fernandes SM, et al.</a></text>
<text top="361" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref207">Obstetric outcomes in pregnant women with congen-</a></text>
<text top="375" left="301" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref207">ital heart disease. Int J Cardiol. 2010;144:195</a></text>
<text top="373" left="484" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref207">–9</a></text>
<text top="375" left="494" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref207">.</a></text>
<text top="393" left="301" width="38" height="9" font="5">S3.12.1-4.</text>
<text top="393" left="342" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref208">Egidy Assenza G, Cassater D, Landzberg M,</a></text>
<text top="407" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref208">et al. The effects of pregnancy on right ventricular</a></text>
<text top="420" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref208">remodeling in women with repaired tetralogy of Fallot.</a></text>
<text top="434" left="301" width="113" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref208">Int J Cardiol. 2013;168:1847</a></text>
<text top="432" left="414" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref208">–52</a></text>
<text top="434" left="428" width="3" height="9" font="5">.</text>
<text top="452" left="301" width="37" height="9" font="5">S3.12.1-5.</text>
<text top="452" left="342" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref209">Chan WS, Anand S, Ginsberg JS. Anti-</a></text>
<text top="466" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref209">coagulation of pregnant women with mechanical heart</a></text>
<text top="479" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref209">valves: a systematic review of the literature. Arch</a></text>
<text top="493" left="301" width="106" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref209">Intern Med. 2000;160:191</a></text>
<text top="491" left="408" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref209">–6</a></text>
<text top="493" left="417" width="3" height="9" font="5">.</text>
<text top="511" left="301" width="38" height="9" font="5">S3.12.1-6.</text>
<text top="511" left="342" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref210">Cutts BA, Dasgupta D, Hunt BJ. New di-</a></text>
<text top="525" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref210">rections in the diagnosis and treatment of pulmonary</a></text>
<text top="538" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref210">embolism in pregnancy. Am J Obstet Gynecol. 2013;</a></text>
<text top="552" left="301" width="34" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref210">208:102</a></text>
<text top="550" left="335" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref210">–8</a></text>
<text top="552" left="344" width="3" height="9" font="5">.</text>
<text top="570" left="301" width="37" height="9" font="5">S3.12.1-7.</text>
<text top="570" left="342" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref211">Siu SC, Sermer M, Colman JM, et al. Pro-</a></text>
<text top="584" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref211">spective multicenter study of pregnancy outcomes</a></text>
<text top="597" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref211">in women with heart disease. Circulation. 2001;104:</a></text>
<text top="610" left="301" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref211">515</a></text>
<text top="609" left="314" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref211">–21</a></text>
<text top="610" left="327" width="3" height="9" font="5">.</text>
<text top="629" left="301" width="38" height="9" font="5">S3.12.1-8.</text>
<text top="629" left="342" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref212">Greutmann M, gnskipK. VK, Brooks R, et al.</a></text>
<text top="642" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref212">Pregnancy outcome in women with congenital heart</a></text>
<text top="656" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref212">disease and residual haemodynamic lesions of the</a></text>
<text top="669" left="301" width="83" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref212">right ventricular out</a></text>
<text top="668" left="384" width="134" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref212">ﬂow tract. Eur Heart J. 2010;31:</a></text>
<text top="683" left="301" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref212">1764</a></text>
<text top="681" left="320" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref212">–70</a></text>
<text top="683" left="335" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref212">.</a></text>
<text top="701" left="301" width="38" height="9" font="5">S3.12.1-9.</text>
<text top="701" left="342" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref213">Gill HK, Splitt M, Sharland GK, et al. Patterns</a></text>
<text top="715" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref213">of recurrence of congenital heart disease: an analysis</a></text>
<text top="728" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref213">of 6,640 consecutive pregnancies evaluated by</a></text>
<text top="742" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref213">detailed fetal echocardiography. J Am Coll Cardiol.</a></text>
<text top="755" left="301" width="52" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref213">2003;42:923</a></text>
<text top="754" left="353" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref213">–9</a></text>
<text top="755" left="363" width="3" height="9" font="5">.</text>
<text top="774" left="301" width="43" height="9" font="5">S3.12.1-10.</text>
<text top="774" left="347" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref214">Ohuchi H, Tanabe Y, Kamiya C, et al. Car-</a></text>
<text top="787" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref214">diopulmonary variables during exercise predict preg-</a></text>
<text top="801" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref214">nancy outcome in women with congenital heart</a></text>
<text top="814" left="301" width="112" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref214">disease. Circ J. 2013;77:470</a></text>
<text top="812" left="413" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref214">–6</a></text>
<text top="814" left="422" width="3" height="9" font="5">.</text>
<text top="833" left="301" width="40" height="9" font="5">S3.12.1-11.</text>
<text top="833" left="344" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref215">Lui GK, Silversides CK, Khairy P, et al. Heart</a></text>
<text top="846" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref215">rate response during exercise and pregnancy outcome</a></text>
<text top="859" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref215">in women with congenital heart disease. Circulation.</a></text>
<text top="873" left="301" width="52" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref215">2011;123:242</a></text>
<text top="871" left="353" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref215">–8</a></text>
<text top="873" left="363" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref215">.</a></text>
<text top="891" left="301" width="41" height="9" font="5">S3.12.1-12.</text>
<text top="891" left="345" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref216">Siu SC, Colman JM, Sorensen S, et al.</a></text>
<text top="905" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref216">Adverse neonatal and cardiac outcomes are more</a></text>
<text top="918" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref216">common in pregnant women with cardiac disease.</a></text>
<text top="932" left="301" width="109" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref216">Circulation. 2002;105:2179</a></text>
<text top="930" left="410" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref216">–84</a></text>
<text top="932" left="425" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref216">.</a></text>
<text top="950" left="301" width="41" height="9" font="5">S3.12.1-13.</text>
<text top="950" left="345" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref217">Holland BJ, Myers JA, Woods CR Jr.</a></text>
<text top="964" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref217">Prenatal diagnosis of critical congenital heart dis-</a></text>
<text top="977" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref217">ease reduces risk of death from cardiovascular</a></text>
<text top="991" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref217">compromise prior to planned neonatal cardiac sur-</a></text>
<text top="1004" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref217">gery: a meta-analysis. Ultrasound Obstet Gynecol.</a></text>
<text top="1018" left="301" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref217">2015;45:631</a></text>
<text top="1016" left="350" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref217">–8</a></text>
<text top="1018" left="360" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref217">.</a></text>
<text top="1040" left="301" width="96" height="9" font="5">3.12.2. Contraception</text>
<text top="1054" left="301" width="37" height="9" font="5">S3.12.2-1.</text>
<text top="1054" left="342" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref218">Kovacs AH, Harrison JL, Colman JM, et al.</a></text>
<text top="1067" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref218">Pregnancy and contraception in congenital heart dis-</a></text>
<text top="1081" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref218">ease: what women are not told. J Am Coll Cardiol.</a></text>
<text top="1094" left="301" width="52" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref218">2008;52:577</a></text>
<text top="1093" left="353" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref218">–8</a></text>
<text top="1094" left="362" width="3" height="9" font="5">.</text>
<text top="143" left="539" width="38" height="9" font="5">S3.12.2-2.</text>
<text top="143" left="581" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref219">Vigl M, Kaemmerer M, Seifert-Klauss V,</a></text>
<text top="156" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref219">et al. Contraception in women with congenital heart</a></text>
<text top="170" left="539" width="149" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref219">disease. Am J Cardiol. 2010;106:1317</a></text>
<text top="168" left="689" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref219">–21</a></text>
<text top="170" left="701" width="3" height="9" font="5">.</text>
<text top="189" left="539" width="38" height="9" font="5">S3.12.2-3.</text>
<text top="189" left="581" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref220">Kaemmerer M, Vigl M, Seifert-Klauss V,</a></text>
<text top="203" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref220">et al. Counseling reproductive health issues in women</a></text>
<text top="216" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref220">with congenital heart disease. Clin Res Cardiol. 2012;</a></text>
<text top="230" left="539" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref220">101:901</a></text>
<text top="228" left="571" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref220">–7</a></text>
<text top="230" left="579" width="3" height="9" font="5">.</text>
<text top="249" left="539" width="39" height="9" font="5">S3.12.2-4.</text>
<text top="249" left="582" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref221">Lidegaard Ø, Løkkegaard E, Svendsen AL,</a></text>
<text top="263" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref221">et al. Hormonal contraception and risk of venous</a></text>
<text top="276" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref221">thromboembolism: national follow-up study. BMJ.</a></text>
<text top="290" left="539" width="70" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref221">2009;339:b2890</a></text>
<text top="290" left="609" width="3" height="9" font="5">.</text>
<text top="309" left="539" width="38" height="9" font="5">S3.12.2-5.</text>
<text top="309" left="581" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref222">Pijuan-Domènech A, Baró-Mariné F, Rojas-</a></text>
<text top="323" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref222">Torrijos M, et al. Usefulness of progesterone-only</a></text>
<text top="336" left="539" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref222">components</a></text>
<text top="336" left="604" width="12" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref222">for</a></text>
<text top="336" left="631" width="55" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref222">contraception</a></text>
<text top="336" left="701" width="7" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref222">in</a></text>
<text top="336" left="724" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref222">patients</a></text>
<text top="350" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref222">with congenital heart disease. Am J Cardiol. 2013;112:</a></text>
<text top="363" left="539" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref222">590</a></text>
<text top="361" left="556" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref222">–3</a></text>
<text top="363" left="565" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref222">.</a></text>
<text top="386" left="539" width="156" height="9" font="24">3.13. Heart Failure and Transplant</text>
<text top="404" left="539" width="91" height="9" font="5">3.13.1. Heart Failure</text>
<text top="418" left="539" width="37" height="9" font="5">S3.13.1-1.</text>
<text top="418" left="579" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref223">Verheugt CL, Uiterwaal CSPM, van der</a></text>
<text top="432" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref223">Velde ET, et al. Mortality in adult congenital heart</a></text>
<text top="445" left="539" width="139" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref223">disease. Eur Heart J. 2010;31:1220</a></text>
<text top="444" left="679" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref223">–9</a></text>
<text top="445" left="688" width="3" height="9" font="5">.</text>
<text top="465" left="539" width="37" height="9" font="5">S3.13.1-2.</text>
<text top="465" left="580" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref224">Zomer AC, Vaartjes I, van der Velde ET, et al.</a></text>
<text top="478" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref224">Heart failure admissions in adults with congenital</a></text>
<text top="492" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref224">heart disease; risk factors and prognosis. Int J Cardiol.</a></text>
<text top="505" left="539" width="60" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref224">2013;168:2487</a></text>
<text top="504" left="599" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref224">–93</a></text>
<text top="505" left="614" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref224">.</a></text>
<text top="525" left="539" width="37" height="9" font="5">S3.13.1-3.</text>
<text top="525" left="580" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref225">Oechslin EN, Harrison DA, Connelly MS,</a></text>
<text top="538" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref225">et al. Mode of death in adults with congenital heart</a></text>
<text top="552" left="539" width="145" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref225">disease. Am J Cardiol. 2000;86:1111</a></text>
<text top="550" left="685" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref225">–6</a></text>
<text top="552" left="694" width="3" height="9" font="5">.</text>
<text top="571" left="539" width="38" height="9" font="5">S3.13.1-4.</text>
<text top="571" left="581" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref226">Zomer AC, Vaartjes I, Uiterwaal CSPM, et al.</a></text>
<text top="585" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref226">Circumstances of death in adult congenital heart dis-</a></text>
<text top="598" left="539" width="131" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref226">ease. Int J Cardiol. 2012;154:168</a></text>
<text top="597" left="671" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref226">–72</a></text>
<text top="598" left="684" width="3" height="9" font="5">.</text>
<text top="621" left="539" width="109" height="9" font="5">3.13.2. Heart Transplant</text>
<text top="636" left="539" width="37" height="9" font="5">S3.13.2-1.</text>
<text top="636" left="580" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref227">Everitt MD, Donaldson AE, Stehlik J, et al.</a></text>
<text top="649" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref227">Would access to device therapies improve transplant</a></text>
<text top="663" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref227">outcomes for adults with congenital heart disease?</a></text>
<text top="676" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref227">Analysis of the United Network for Organ Sharing</a></text>
<text top="689" left="539" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref227">(UNOS). J Heart Lung Transplant. 2011;30:395</a></text>
<text top="688" left="727" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref227">–401</a></text>
<text top="689" left="746" width="3" height="9" font="5">.</text>
<text top="709" left="539" width="38" height="9" font="5">S3.13.2-2.</text>
<text top="709" left="581" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref228">Davies RR, Russo MJ, Yang J, et al. Listing</a></text>
<text top="722" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref228">and transplanting adults with congenital heart disease.</a></text>
<text top="736" left="539" width="100" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref228">Circulation. 2011;123:759</a></text>
<text top="734" left="639" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref228">–67</a></text>
<text top="736" left="654" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref228">.</a></text>
<text top="755" left="539" width="38" height="9" font="5">S3.13.2-3.</text>
<text top="755" left="581" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref229">Karamlou T, Hirsch J, Welke K, et al.</a></text>
<text top="769" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref229">A United Network for Organ Sharing analysis of heart</a></text>
<text top="782" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref229">transplantation in adults with congenital heart disease:</a></text>
<text top="796" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref229">outcomes and factors associated with mortality and</a></text>
<text top="809" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref229">retransplantation. J Thorac Cardiovasc Surg. 2010;</a></text>
<text top="823" left="539" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref229">140:161</a></text>
<text top="821" left="570" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref229">–8</a></text>
<text top="823" left="580" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref229">.</a></text>
<text top="842" left="539" width="39" height="9" font="5">S3.13.2-4.</text>
<text top="842" left="582" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref230">Stout KK, Broberg CS, Book WM, et al.</a></text>
<text top="856" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref230">Chronic heart failure in congenital heart disease: a</a></text>
<text top="869" left="539" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref230">scienti</a></text>
<text top="868" left="565" width="191" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref230">ﬁc statement from the American Heart Associ-</a></text>
<text top="883" left="539" width="128" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref230">ation. Circulation. 2016;133:770</a></text>
<text top="881" left="667" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref230">–801</a></text>
<text top="883" left="686" width="3" height="9" font="5">.</text>
<text top="902" left="539" width="38" height="9" font="5">S3.13.2-5.</text>
<text top="902" left="581" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref231">Gelow JM, Song HK, Weiss JB, et al. Organ</a></text>
<text top="916" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref231">allocation in adults with congenital heart disease listed</a></text>
<text top="929" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref231">for heart transplant: impact of ventricular assist de-</a></text>
<text top="943" left="539" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref231">vices. J Heart Lung Transplant. 2013;32:1059</a></text>
<text top="941" left="722" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref231">–64</a></text>
<text top="943" left="737" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref231">.</a></text>
<text top="962" left="539" width="39" height="9" font="5">S3.13.2-6.</text>
<text top="962" left="582" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref232">Goerler H, Simon A, Gohrbandt B, et al.</a></text>
<text top="976" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref232">Heart-lung and lung transplantation in grown-up</a></text>
<text top="989" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref232">congenital heart disease: long-term single centre</a></text>
<text top="1002" left="539" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref232">experience. Eur J Cardiothorac Surg. 2007;32:926</a></text>
<text top="1001" left="741" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref232">–31</a></text>
<text top="1002" left="753" width="3" height="9" font="5">.</text>
<text top="1022" left="539" width="38" height="9" font="5">S3.13.2-7.</text>
<text top="1022" left="581" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref233">Burchill LJ, Edwards LB, Dipchand AI, et al.</a></text>
<text top="1035" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref233">Impact of adult congenital heart disease on survival</a></text>
<text top="1049" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref233">and mortality after heart transplantation. J Heart Lung</a></text>
<text top="1062" left="539" width="100" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref233">Transplant. 2014;33:1157</a></text>
<text top="1061" left="639" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref233">–63</a></text>
<text top="1062" left="653" width="3" height="9" font="5">.</text>
<text top="1082" left="539" width="39" height="9" font="5">S3.13.2-8.</text>
<text top="1082" left="582" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref234">Greutmann M, Prêtre R, Furrer L, et al.</a></text>
<text top="1095" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref234">Heart transplantation in adolescent and adult patients</a></text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="788" width="20" height="9" font="5">1549</text>
</page>
<page number="57" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref234">with congenital heart disease: a case-control study.</a></text>
<text top="156" left="108" width="125" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref234">Transplant Proc. 2009;41:3821</a></text>
<text top="155" left="232" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref234">–6</a></text>
<text top="156" left="242" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref234">.</a></text>
<text top="175" left="108" width="39" height="9" font="5">S3.13.2-9.</text>
<text top="175" left="150" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref235">Seddio F, Gorislavets N, Iacovoni A, et al. Is</a></text>
<text top="188" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref235">heart transplantation for complex congenital heart</a></text>
<text top="202" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref235">disease a good option? A 25-year single centre expe-</a></text>
<text top="215" left="108" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref235">rience. Eur J Cardiothorac Surg. 2013;43:605</a></text>
<text top="214" left="289" width="11" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref235">–11</a></text>
<text top="215" left="300" width="3" height="9" font="5">.</text>
<text top="234" left="108" width="43" height="9" font="5">S3.13.2-10.</text>
<text top="234" left="154" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref236">Alshawabkeh LI, Hu N, Carter KD, et al.</a></text>
<text top="247" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref236">Wait-list outcomes for adults with congenital heart</a></text>
<text top="261" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref236">disease listed for heart transplantation in the U.S. J Am</a></text>
<text top="274" left="108" width="106" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref236">Coll Cardiol. 2016;68:908</a></text>
<text top="273" left="213" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref236">–17</a></text>
<text top="274" left="226" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref236">.</a></text>
<text top="293" left="108" width="41" height="9" font="5">S3.13.2-11.</text>
<text top="293" left="152" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref237">Krishnamurthy Y, Cooper LB, Lu D, et al.</a></text>
<text top="306" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref237">Trends and outcomes of patients with adult congenital</a></text>
<text top="320" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref237">heart disease and pulmonary hypertension listed for</a></text>
<text top="333" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref237">orthotopic heart transplantation in the United States.</a></text>
<text top="347" left="108" width="153" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref237">J Heart Lung Transplant. 2016;35:619</a></text>
<text top="345" left="260" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref237">–24</a></text>
<text top="347" left="275" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref237">.</a></text>
<text top="365" left="108" width="42" height="9" font="5">S3.13.2-12.</text>
<text top="365" left="153" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref238">Harper AR, Crossland DS, Perri G, et al. Is</a></text>
<text top="379" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref238">alternative cardiac surgery an option in adults with</a></text>
<text top="392" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref238">congenital heart disease referred for thoracic organ</a></text>
<text top="405" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref238">transplantation? Eur J Cardiothorac Surg. 2013;43:</a></text>
<text top="419" left="108" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref238">344</a></text>
<text top="417" left="123" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref238">–51</a></text>
<text top="419" left="136" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref238">.</a></text>
<text top="442" left="108" width="90" height="9" font="24">3.14. Palliative Care</text>
<text top="455" left="108" width="31" height="9" font="5">S3.14-1.</text>
<text top="455" left="142" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref239">Greutmann M, Tobler D, Colman JM, et al.</a></text>
<text top="469" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref239">Facilitators of and barriers to advance care planning in</a></text>
<text top="482" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref239">adult congenital heart disease. Congenit Heart Dis.</a></text>
<text top="496" left="108" width="44" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref239">2013;8:281</a></text>
<text top="494" left="152" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref239">–8</a></text>
<text top="496" left="162" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref239">.</a></text>
<text top="514" left="108" width="32" height="9" font="5">S3.14-2.</text>
<text top="514" left="143" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref240">Tobler D, Greutmann M, Colman JM, et al.</a></text>
<text top="528" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref240">Knowledge of and preference for advance care plan-</a></text>
<text top="541" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref240">ning by adults with congenital heart disease. Am J</a></text>
<text top="555" left="108" width="92" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref240">Cardiol. 2012;109:1797</a></text>
<text top="553" left="200" width="22" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref240">–800</a></text>
<text top="555" left="221" width="3" height="9" font="5">.</text>
<text top="573" left="108" width="32" height="9" font="5">S3.14-3.</text>
<text top="573" left="143" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref241">Tobler D, Greutmann M, Colman JM, et al.</a></text>
<text top="587" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref241">End-of-life in adults with congenital heart disease: a</a></text>
<text top="600" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref241">call for early communication. Int J Cardiol. 2012;155:</a></text>
<text top="613" left="108" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref241">383</a></text>
<text top="612" left="123" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref241">–7</a></text>
<text top="613" left="131" width="3" height="9" font="5">.</text>
<text top="629" left="108" width="64" height="9" font="24">3.15. Cyanosis</text>
<text top="642" left="108" width="30" height="9" font="5">S3.15-1.</text>
<text top="642" left="141" width="184" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref242">Broberg CS, Van Woerkom RC, Swallow E,</a></text>
<text top="656" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref242">et al. Lung function and gas exchange in Eisenmenger</a></text>
<text top="669" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref242">syndrome and their impact on exercise capacity and</a></text>
<text top="683" left="108" width="137" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref242">survival. Int J Cardiol. 2014;171:73</a></text>
<text top="681" left="245" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref242">–7</a></text>
<text top="683" left="253" width="3" height="9" font="5">.</text>
<text top="701" left="108" width="31" height="9" font="5">S3.15-2.</text>
<text top="701" left="142" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref243">Broberg CS, Uebing A, Cuomo L, et al. Adult</a></text>
<text top="715" left="108" width="189" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref243">patients with Eisenmenger syndrome report</a></text>
<text top="713" left="302" width="23" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref243">ﬂying</a></text>
<text top="728" left="108" width="24" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref243">safely</a></text>
<text top="728" left="140" width="10" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref243">on</a></text>
<text top="728" left="159" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref243">commercial</a></text>
<text top="728" left="214" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref243">airlines.</a></text>
<text top="728" left="254" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref243">Heart.</a></text>
<text top="728" left="288" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref243">2007;93:</a></text>
<text top="742" left="108" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref243">1599</a></text>
<text top="740" left="127" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref243">–603</a></text>
<text top="742" left="148" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref243">.</a></text>
<text top="760" left="108" width="31" height="9" font="5">S3.15-3.</text>
<text top="760" left="142" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref244">Perloff JK, Child JS, Aboulhosn J, editors.</a></text>
<text top="774" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref244">Congenital Heart Disease in Adults. 3rd ed. Philadel-</a></text>
<text top="787" left="108" width="137" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref244">phia, PA: Saunders/Elsevier, 2009</a></text>
<text top="787" left="245" width="3" height="9" font="5">.</text>
<text top="810" left="108" width="185" height="9" font="24">3.16. Pharmacological Therapy for ACHD</text>
<text top="824" left="108" width="31" height="9" font="5">S3.16-1.</text>
<text top="824" left="142" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref245">Yancy CW, Jessup M, Bozkurt B, et al. 2017</a></text>
<text top="837" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref245">ACC/AHA/HFSA focused update of the 2013 ACCF/AHA</a></text>
<text top="850" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref245">guideline for the management of heart failure: a report</a></text>
<text top="864" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref245">of the American College of Cardiology/American Heart</a></text>
<text top="877" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref245">Association Task Force on Clinical Practice Guidelines</a></text>
<text top="891" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref245">and the Heart Failure Society of America. J Am Coll</a></text>
<text top="904" left="108" width="83" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref245">Cardiol. 2017;70:776</a></text>
<text top="903" left="191" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref245">–803</a></text>
<text top="904" left="211" width="3" height="9" font="5">.</text>
<text top="923" left="108" width="32" height="9" font="5">S3.16-2.</text>
<text top="923" left="143" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref246">Doughan ARK, McConnell ME, Book WM. Ef-</a></text>
<text top="936" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref246">fect of beta blockers (carvedilol or metoprolol XL) in</a></text>
<text top="950" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref246">patients with transposition of great arteries and</a></text>
<text top="963" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref246">dysfunction of the systemic right ventricle. Am J Car-</a></text>
<text top="977" left="108" width="74" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref246">diol. 2007;99:704</a></text>
<text top="975" left="182" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref246">–6</a></text>
<text top="977" left="192" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref246">.</a></text>
<text top="995" left="108" width="32" height="9" font="5">S3.16-3.</text>
<text top="995" left="143" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref247">Dos L, Pujadas S, Estruch M, et al. Eplerenone</a></text>
<text top="1009" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref247">in systemic right ventricle: double blind randomized</a></text>
<text top="1022" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref247">clinical trial. The EVEDES Study. Int J Cardiol. 2013;</a></text>
<text top="1035" left="108" width="36" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref247">168:5167</a></text>
<text top="1034" left="144" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref247">–73</a></text>
<text top="1035" left="157" width="3" height="9" font="5">.</text>
<text top="1054" left="108" width="33" height="9" font="5">S3.16-4.</text>
<text top="1054" left="144" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref248">van der Bom T, Winter MM, Bouma BJ, et al.</a></text>
<text top="1067" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref248">Effect of valsartan on systemic right ventricular func-</a></text>
<text top="1081" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref248">tion: a double-blind, randomized, placebo-controlled</a></text>
<text top="1094" left="108" width="143" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref248">pilot trial. Circulation. 2013;127:322</a></text>
<text top="1093" left="251" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref248">–30</a></text>
<text top="1094" left="265" width="3" height="9" font="5">.</text>
<text top="143" left="346" width="32" height="9" font="5">S3.16-5.</text>
<text top="143" left="381" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref249">Dore A, Houde C, Chan K-L, et al. Angiotensin</a></text>
<text top="156" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref249">receptor blockade and exercise capacity in adults with</a></text>
<text top="170" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref249">systemic right ventricles: a multicenter, randomized,</a></text>
<text top="183" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref249">placebo-controlled clinical trial. Circulation. 2005;112:</a></text>
<text top="197" left="346" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref249">2411</a></text>
<text top="195" left="364" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref249">–6</a></text>
<text top="197" left="373" width="3" height="9" font="5">.</text>
<text top="216" left="346" width="33" height="9" font="5">S3.16-6.</text>
<text top="216" left="382" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref250">Babu-Narayan SV, Uebing A, Davlouros PA,</a></text>
<text top="229" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref250">et al. Randomised trial of ramipril in repaired tetralogy</a></text>
<text top="243" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref250">of Fallot and pulmonary regurgitation: the APPRO-</a></text>
<text top="256" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref250">PRIATE study (Ace inhibitors for Potential PRevention</a></text>
<text top="270" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref250">Of the deleterious effects of Pulmonary Regurgitation</a></text>
<text top="283" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref250">In Adults with repaired TEtralogy of Fallot). Int J</a></text>
<text top="297" left="346" width="88" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref250">Cardiol. 2012;154:299</a></text>
<text top="295" left="434" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref250">–305</a></text>
<text top="297" left="454" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref250">.</a></text>
<text top="316" left="346" width="32" height="9" font="5">S3.16-7.</text>
<text top="316" left="381" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref251">Lester SJ, McElhinney DB, Viloria E, et al.</a></text>
<text top="329" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref251">Effects of losartan in patients with a systemically</a></text>
<text top="343" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref251">functioning morphologic right ventricle after atrial</a></text>
<text top="356" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref251">repair of transposition of the great arteries. Am J</a></text>
<text top="369" left="346" width="88" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref251">Cardiol. 2001;88:1314</a></text>
<text top="368" left="434" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref251">–6</a></text>
<text top="369" left="444" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref251">.</a></text>
<text top="389" left="346" width="33" height="9" font="5">S3.16-8.</text>
<text top="389" left="382" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref252">Hechter SJ, Fredriksen PM, Liu P, et al.</a></text>
<text top="402" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref252">Angiotensin-converting enzyme inhibitors in adults</a></text>
<text top="415" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref252">after the Mustard procedure. Am J Cardiol. 2001;87:</a></text>
<text top="429" left="346" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref252">660</a></text>
<text top="427" left="363" width="27" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref252">–3. A11</a></text>
<text top="429" left="391" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref252">.</a></text>
<text top="448" left="346" width="33" height="9" font="5">S3.16-9.</text>
<text top="448" left="382" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref253">Therrien J, Provost Y, Harrison J, et al. Effect</a></text>
<text top="462" left="346" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref253">of</a></text>
<text top="462" left="364" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref253">angiotensin</a></text>
<text top="462" left="420" width="34" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref253">receptor</a></text>
<text top="462" left="463" width="36" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref253">blockade</a></text>
<text top="462" left="509" width="10" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref253">on</a></text>
<text top="462" left="529" width="34" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref253">systemic</a></text>
<text top="475" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref253">right ventricular function and size: a small, random-</a></text>
<text top="488" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref253">ized, placebo-controlled study. Int J Cardiol. 2008;</a></text>
<text top="502" left="346" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref253">129:187</a></text>
<text top="500" left="377" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref253">–92</a></text>
<text top="502" left="391" width="3" height="9" font="5">.</text>
<text top="521" left="346" width="37" height="9" font="5">S3.16-10.</text>
<text top="521" left="386" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref254">Galiè N, Beghetti M, Gatzoulis MA, et al.</a></text>
<text top="534" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref254">Bosentan therapy in patients with Eisenmenger syn-</a></text>
<text top="548" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref254">drome: a multicenter, double-blind, randomized,</a></text>
<text top="561" left="346" width="76" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref254">placebo-controlled</a></text>
<text top="561" left="432" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref254">study.</a></text>
<text top="561" left="467" width="45" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref254">Circulation.</a></text>
<text top="561" left="522" width="41" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref254">2006;114:</a></text>
<text top="575" left="346" width="11" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref254">48</a></text>
<text top="573" left="357" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref254">–54</a></text>
<text top="575" left="371" width="3" height="9" font="5">.</text>
<text top="594" left="346" width="35" height="9" font="5">S3.16-11.</text>
<text top="594" left="384" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref255">Giardini A, Balducci A, Specchia S, et al. Ef-</a></text>
<text top="607" left="346" width="58" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref255">fect of sildena</a></text>
<text top="606" left="404" width="159" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref255">ﬁl on haemodynamic response to exer-</a></text>
<text top="621" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref255">cise and exercise capacity in Fontan patients. Eur Heart</a></text>
<text top="634" left="346" width="67" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref255">J. 2008;29:1681</a></text>
<text top="633" left="412" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref255">–7</a></text>
<text top="634" left="421" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref255">.</a></text>
<text top="653" left="346" width="36" height="9" font="5">S3.16-12.</text>
<text top="653" left="385" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref256">Hebert A, Mikkelsen UR, Thilen U, et al.</a></text>
<text top="667" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref256">Bosentan improves exercise capacity in adolescents</a></text>
<text top="680" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref256">and adults after Fontan operation: the TEMPO</a></text>
<text top="694" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref256">(Treatment With Endothelin Receptor Antagonist in</a></text>
<text top="707" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref256">Fontan Patients, a Randomized, Placebo-Controlled,</a></text>
<text top="721" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref256">Double-Blind Study Measuring Peak Oxygen Con-</a></text>
<text top="734" left="346" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref256">sumption) study. Circulation. 2014;130:2021</a></text>
<text top="732" left="524" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref256">–30</a></text>
<text top="734" left="539" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref256">.</a></text>
<text top="753" left="346" width="36" height="9" font="5">S3.16-13.</text>
<text top="753" left="385" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref257">Goldberg DJ, French B, McBride MG, et al.</a></text>
<text top="766" left="346" width="92" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref257">Impact of oral sildena</a></text>
<text top="765" left="438" width="125" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref257">ﬁl on exercise performance in</a></text>
<text top="780" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref257">children and young adults after the Fontan operation:</a></text>
<text top="793" left="346" width="4" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref257">a</a></text>
<text top="793" left="361" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref257">randomized,</a></text>
<text top="793" left="420" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref257">double-blind,</a></text>
<text top="793" left="484" width="78" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref257">placebo-controlled,</a></text>
<text top="807" left="346" width="165" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref257">crossover trial. Circulation. 2011;123:1185</a></text>
<text top="805" left="511" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref257">–93</a></text>
<text top="807" left="525" width="3" height="9" font="5">.</text>
<text top="841" left="346" width="132" height="12" font="28">4 . S P E C I F I C L E S I O N S</text>
<text top="877" left="346" width="83" height="9" font="24">4.1. Shunt Lesions</text>
<text top="895" left="346" width="115" height="9" font="5">4.1.1. Atrial Septal Defect</text>
<text top="909" left="346" width="33" height="9" font="5">S4.1.1-1.</text>
<text top="909" left="381" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref258">Oster M, Bhatt A, Zaragoza-Macias E, et al.</a></text>
<text top="923" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref258">Interventional therapy versus medical therapy for</a></text>
<text top="936" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref258">secundum atrial septal defect: a systematic review (part</a></text>
<text top="950" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref258">2) for the 2018 AHA/ACC guideline for the management</a></text>
<text top="963" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref258">of adults with congenital heart disease: a report of the</a></text>
<text top="977" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref258">American College of Cardiology/American Heart Asso-</a></text>
<text top="990" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref258">ciation Task Force on Clinical Practice Guidelines. J Am</a></text>
<text top="1003" left="346" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref258">Coll Cardiol. 2018 Aug 9 [E-pub ahead of print]</a></text>
<text top="1003" left="533" width="3" height="9" font="5">.</text>
<text top="1023" left="346" width="34" height="9" font="5">S4.1.1-2.</text>
<text top="1023" left="382" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref259">Ammash NM, Seward JB, Warnes CA, et al.</a></text>
<text top="1036" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref259">Partial anomalous pulmonary venous connection:</a></text>
<text top="1049" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref259">diagnosis by transesophageal echocardiography. J Am</a></text>
<text top="1063" left="346" width="104" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref259">Coll Cardiol. 1997;29:1351</a></text>
<text top="1061" left="450" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref259">–8</a></text>
<text top="1063" left="460" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref259">.</a></text>
<text top="1082" left="346" width="34" height="9" font="5">S4.1.1-3.</text>
<text top="1082" left="382" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref260">Haramati LB, Moche IE, Rivera VT, et al.</a></text>
<text top="1095" left="346" width="41" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref260">Computed</a></text>
<text top="1095" left="400" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref260">tomography</a></text>
<text top="1095" left="461" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref260">of</a></text>
<text top="1095" left="482" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref260">partial</a></text>
<text top="1095" left="520" width="43" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref260">anomalous</a></text>
<text top="143" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref260">pulmonary venous connection in adults. J Comput</a></text>
<text top="156" left="584" width="114" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref260">Assist Tomogr. 2003;27:743</a></text>
<text top="155" left="698" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref260">–9</a></text>
<text top="156" left="707" width="3" height="9" font="5">.</text>
<text top="175" left="584" width="35" height="9" font="5">S4.1.1-4.</text>
<text top="175" left="622" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref261">Nordmeyer S, Berger F, Kuehne T, et al.</a></text>
<text top="189" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref261">Flow-sensitive four-dimensional magnetic resonance</a></text>
<text top="202" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref261">imaging facilitates and improves the accurate diag-</a></text>
<text top="215" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref261">nosis of partial anomalous pulmonary venous drainage.</a></text>
<text top="229" left="584" width="109" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref261">Cardiol Young. 2011;21:528</a></text>
<text top="227" left="693" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref261">–35</a></text>
<text top="229" left="707" width="3" height="9" font="5">.</text>
<text top="248" left="584" width="34" height="9" font="5">S4.1.1-5.</text>
<text top="248" left="621" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref262">Kardon RE, Sokoloski MC, Levi DS, et al.</a></text>
<text top="261" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref262">Transthoracic echocardiographic guidance of trans-</a></text>
<text top="275" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref262">catheter atrial septal defect closure. Am J Cardiol.</a></text>
<text top="288" left="584" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref262">2004;94:256</a></text>
<text top="286" left="638" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref262">–60</a></text>
<text top="288" left="654" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref262">.</a></text>
<text top="307" left="584" width="34" height="9" font="5">S4.1.1-6.</text>
<text top="307" left="622" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref263">Zanchetta M, Rigatelli G, Pedon L, et al.</a></text>
<text top="320" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref263">Transcatheter atrial septal defect closure assisted by</a></text>
<text top="334" left="584" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref263">intracardiac</a></text>
<text top="334" left="641" width="73" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref263">echocardiography:</a></text>
<text top="334" left="724" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref263">3-year</a></text>
<text top="334" left="759" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref263">follow-up.</a></text>
<text top="347" left="584" width="113" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref263">J Interv Cardiol. 2004;17:95</a></text>
<text top="345" left="698" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref263">–8</a></text>
<text top="347" left="707" width="3" height="9" font="5">.</text>
<text top="366" left="584" width="34" height="9" font="5">S4.1.1-7.</text>
<text top="366" left="621" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref264">Attie F, Rosas M, Granados N, et al. Surgical</a></text>
<text top="379" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref264">treatment for secundum atrial septal defects in pa-</a></text>
<text top="393" left="584" width="23" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref264">tients</a></text>
<text top="391" left="610" width="192" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref264">&gt;40 years old. A randomized clinical trial. J Am</a></text>
<text top="406" left="584" width="109" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref264">Coll Cardiol. 2001;38:2035</a></text>
<text top="404" left="693" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref264">–42</a></text>
<text top="406" left="707" width="3" height="9" font="5">.</text>
<text top="425" left="584" width="34" height="9" font="5">S4.1.1-8.</text>
<text top="425" left="622" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref265">Brochu M-C, Baril J-F, Dore A, et al.</a></text>
<text top="438" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref265">Improvement in exercise capacity in asymptomatic and</a></text>
<text top="451" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref265">mildly symptomatic adults after atrial septal defect</a></text>
<text top="465" left="584" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref265">percutaneous closure. Circulation. 2002;106:1821</a></text>
<text top="463" left="783" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref265">–6</a></text>
<text top="465" left="793" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref265">.</a></text>
<text top="484" left="584" width="34" height="9" font="5">S4.1.1-9.</text>
<text top="484" left="622" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref266">Shah D, Azhar M, Oakley CM, et al. Natural</a></text>
<text top="497" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref266">history of secundum atrial septal defect in adults after</a></text>
<text top="510" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref266">medical or surgical treatment: a historical prospective</a></text>
<text top="524" left="584" width="123" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref266">study. Br Heart J. 1994;71:224</a></text>
<text top="522" left="707" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref266">–7</a></text>
<text top="524" left="716" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref266">.</a></text>
<text top="543" left="584" width="39" height="9" font="5">S4.1.1-10.</text>
<text top="543" left="626" width="61" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref267">Roos-Hesselink</a></text>
<text top="543" left="703" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref267">JW,</a></text>
<text top="543" left="734" width="39" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref267">Meijboom</a></text>
<text top="543" left="790" width="11" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref267">FJ,</a></text>
<text top="556" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref267">Spitaels SEC, et al. Excellent survival and low incidence</a></text>
<text top="570" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref267">of arrhythmias, stroke and heart failure long-term af-</a></text>
<text top="583" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref267">ter surgical ASD closure at young age. A prospective</a></text>
<text top="596" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref267">follow-up study of 21-33 years. Eur Heart J. 2003;24:</a></text>
<text top="610" left="584" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref267">190</a></text>
<text top="608" left="600" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref267">–7</a></text>
<text top="610" left="608" width="3" height="9" font="5">.</text>
<text top="629" left="584" width="37" height="9" font="5">S4.1.1-11.</text>
<text top="629" left="624" width="12" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref268">Alt</a></text>
<text top="627" left="635" width="166" height="12" font="6">ı<a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref268">ndag T, Roos-Hesselink JW, Cuypers JA,</a></text>
<text top="642" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref268">et al. Transcatheter device closure of atrial septal de-</a></text>
<text top="655" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref268">fects in patients aged 40 years and older. Neth Heart</a></text>
<text top="669" left="584" width="59" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref268">J. 2010;18:537</a></text>
<text top="667" left="643" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref268">–42</a></text>
<text top="669" left="657" width="3" height="9" font="5">.</text>
<text top="688" left="584" width="37" height="9" font="5">S4.1.1-12.</text>
<text top="688" left="625" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref269">Varma C, Benson LN, Silversides C, et al.</a></text>
<text top="701" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref269">Outcomes and alternative techniques for device</a></text>
<text top="714" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref269">closure of the large secundum atrial septal defect.</a></text>
<text top="728" left="584" width="161" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref269">Catheter Cardiovasc Interv. 2004;61:131</a></text>
<text top="726" left="745" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref269">–9</a></text>
<text top="728" left="755" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref269">.</a></text>
<text top="747" left="584" width="37" height="9" font="5">S4.1.1-13.</text>
<text top="747" left="625" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref270">Du Z-D, Cao Q-L, Rhodes J, et al. Choice of</a></text>
<text top="760" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref270">device size and results of transcatheter closure of</a></text>
<text top="773" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref270">atrial septal defect using the amplatzer septal</a></text>
<text top="787" left="584" width="157" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref270">occluder. J Interv Cardiol. 2002;15:287</a></text>
<text top="785" left="741" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref270">–92</a></text>
<text top="787" left="756" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref270">.</a></text>
<text top="806" left="584" width="38" height="9" font="5">S4.1.1-14.</text>
<text top="806" left="626" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref271">Gajjar TP, Hiremath CS, Desai NB. Surgical</a></text>
<text top="819" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref271">closure of sinus venosus atrial septal defect using a</a></text>
<text top="832" left="584" width="48" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref271">single patch</a></text>
<text top="831" left="633" width="169" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref271">—transcaval repair technique. J Card Surg.</a></text>
<text top="846" left="584" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref271">2011;26:429</a></text>
<text top="844" left="634" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref271">–34</a></text>
<text top="846" left="648" width="3" height="9" font="5">.</text>
<text top="865" left="584" width="37" height="9" font="5">S4.1.1-15.</text>
<text top="865" left="625" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref272">Du Z-D, Hijazi ZM, Kleinman CS, et al.</a></text>
<text top="878" left="584" width="47" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref272">Comparison</a></text>
<text top="878" left="640" width="35" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref272">between</a></text>
<text top="878" left="684" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref272">transcatheter</a></text>
<text top="878" left="747" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref272">and</a></text>
<text top="878" left="771" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref272">surgical</a></text>
<text top="891" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref272">closure of secundum atrial septal defect in children</a></text>
<text top="905" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref272">and adults: results of a multicenter nonrandomized</a></text>
<text top="918" left="584" width="154" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref272">trial. J Am Coll Cardiol. 2002;39:1836</a></text>
<text top="917" left="738" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref272">–44</a></text>
<text top="918" left="753" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref272">.</a></text>
<text top="937" left="584" width="38" height="9" font="5">S4.1.1-16.</text>
<text top="937" left="625" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref273">Du Z-D, Koenig P, Cao Q-L, et al. Compari-</a></text>
<text top="950" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref273">son of transcatheter closure of secundum atrial septal</a></text>
<text top="964" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref273">defect using the Amplatzer septal occluder associated</a></text>
<text top="977" left="584" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref273">with de</a></text>
<text top="976" left="617" width="185" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref273">ﬁcient versus sufﬁcient rims. Am J Cardiol.</a></text>
<text top="991" left="584" width="55" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref273">2002;90:865</a></text>
<text top="989" left="639" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref273">–9</a></text>
<text top="991" left="649" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref273">.</a></text>
<text top="1009" left="584" width="37" height="9" font="5">S4.1.1-17.</text>
<text top="1009" left="625" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref274">Lopez K, Dalvi BV, Balzer D, et al. Trans-</a></text>
<text top="1023" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref274">catheter closure of large secundum atrial septal de-</a></text>
<text top="1036" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref274">fects using the 40 mm Amplatzer septal occluder:</a></text>
<text top="1050" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref274">results of an international registry. Catheter Car-</a></text>
<text top="1063" left="584" width="116" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref274">diovasc Interv. 2005;66:580</a></text>
<text top="1062" left="700" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref274">–4</a></text>
<text top="1063" left="710" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref274">.</a></text>
<text top="1082" left="584" width="38" height="9" font="5">S4.1.1-18.</text>
<text top="1082" left="625" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref275">Amin Z, Hijazi ZM, Bass JL, et al. Erosion of</a></text>
<text top="1095" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref275">Amplatzer septal occluder device after closure of</a></text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="20" height="9" font="5">1550</text>
</page>
<page number="58" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref275">secundum atrial septal defects: review of registry of</a></text>
<text top="156" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref275">complications and recommendations to minimize</a></text>
<text top="170" left="63" width="213" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref275">future risk. Catheter Cardiovasc Interv. 2004;63:496</a></text>
<text top="168" left="276" width="4" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref275">–</a></text>
<text top="183" left="63" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref275">502</a></text>
<text top="183" left="78" width="3" height="9" font="5">.</text>
<text top="202" left="63" width="38" height="9" font="5">S4.1.1-19.</text>
<text top="202" left="104" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref276">Bradley EA, Chakinala M, Billadello JJ.</a></text>
<text top="216" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref276">Usefulness of medical therapy for pulmonary hyper-</a></text>
<text top="229" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref276">tension and delayed atrial septal defect closure. Am J</a></text>
<text top="243" left="63" width="88" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref276">Cardiol. 2013;112:1471</a></text>
<text top="241" left="151" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref276">–6</a></text>
<text top="243" left="160" width="3" height="9" font="5">.</text>
<text top="262" left="63" width="40" height="9" font="5">S4.1.1-20.</text>
<text top="262" left="105" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref277">Cho YH, Jun T-G, Yang J-H, et al. Surgical</a></text>
<text top="275" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref277">strategy in patients with atrial septal defect and severe</a></text>
<text top="289" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref277">pulmonary hypertension. Heart Surg Forum. 2012;15:</a></text>
<text top="302" left="63" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref277">E111</a></text>
<text top="300" left="79" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref277">–5</a></text>
<text top="302" left="88" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref277">.</a></text>
<text top="321" left="63" width="37" height="9" font="5">S4.1.1-21.</text>
<text top="321" left="103" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref278">Kouchoukos NT, Blackstone EH, Kirklin JW.</a></text>
<text top="334" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref278">Surgical implications of pulmonary hypertension in</a></text>
<text top="348" left="63" width="192" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref278">congenital heart disease. Adv Cardiol. 1978:225</a></text>
<text top="346" left="254" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref278">–31</a></text>
<text top="348" left="267" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref278">.</a></text>
<text top="367" left="63" width="38" height="9" font="5">S4.1.1-22.</text>
<text top="367" left="104" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref279">Shohtsu A, Takeuchi S, Inoue T. Surgical in-</a></text>
<text top="380" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref279">dications and results for congenital cardiac anomalies</a></text>
<text top="394" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref279">associated with left to right shunt and severe pulmo-</a></text>
<text top="407" left="63" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref279">nary hypertension. Jpn Circ J. 1976;40:629</a></text>
<text top="406" left="237" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref279">–32</a></text>
<text top="407" left="251" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref279">.</a></text>
<text top="430" left="63" width="24" height="9" font="5">4.1.2.</text>
<text top="430" left="106" width="51" height="9" font="5">Anomalous</text>
<text top="430" left="177" width="50" height="9" font="5">Pulmonary</text>
<text top="430" left="246" width="34" height="9" font="5">Venous</text>
<text top="443" left="63" width="56" height="9" font="5">Connections</text>
<text top="458" left="63" width="34" height="9" font="5">S4.1.2-1.</text>
<text top="458" left="99" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref280">Festa P, Ait-Ali L, Cerillo AG, et al. Magnetic</a></text>
<text top="471" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref280">resonance imaging is the diagnostic tool of choice in</a></text>
<text top="484" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref280">the preoperative evaluation of patients with partial</a></text>
<text top="498" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref280">anomalous pulmonary venous return. Int J Cardiovasc</a></text>
<text top="511" left="63" width="91" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref280">Imaging. 2006;22:685</a></text>
<text top="510" left="154" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref280">–93</a></text>
<text top="511" left="168" width="3" height="9" font="5">.</text>
<text top="530" left="63" width="35" height="9" font="5">S4.1.2-2.</text>
<text top="530" left="100" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref281">Nordmeyer S, Berger F, Kuehne T, et al.</a></text>
<text top="544" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref281">Flow-sensitive four-dimensional magnetic resonance</a></text>
<text top="557" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref281">imaging facilitates and improves the accurate diag-</a></text>
<text top="571" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref281">nosis of partial anomalous pulmonary venous drainage.</a></text>
<text top="584" left="63" width="109" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref281">Cardiol Young. 2011;21:528</a></text>
<text top="582" left="172" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref281">–35</a></text>
<text top="584" left="186" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref281">.</a></text>
<text top="603" left="63" width="35" height="9" font="5">S4.1.2-3.</text>
<text top="603" left="100" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref282">Dyme JL, Prakash A, Printz BF, et al. Physi-</a></text>
<text top="616" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref282">ology of isolated anomalous pulmonary venous</a></text>
<text top="630" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref282">connection of a single pulmonary vein as determined</a></text>
<text top="643" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref282">by cardiac magnetic resonance imaging. Am J Cardiol.</a></text>
<text top="657" left="63" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref282">2006;98:107</a></text>
<text top="655" left="116" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref282">–10</a></text>
<text top="657" left="130" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref282">.</a></text>
<text top="676" left="63" width="35" height="9" font="5">S4.1.2-4.</text>
<text top="676" left="101" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref283">Haramati LB, Moche IE, Rivera VT, et al.</a></text>
<text top="689" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref283">Computed tomography of partial anomalous pulmo-</a></text>
<text top="703" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref283">nary venous connection in adults. J Comput Assist</a></text>
<text top="716" left="63" width="88" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref283">Tomogr. 2003;27:743</a></text>
<text top="714" left="150" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref283">–9</a></text>
<text top="716" left="160" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref283">.</a></text>
<text top="735" left="63" width="35" height="9" font="5">S4.1.2-5.</text>
<text top="735" left="100" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref284">Majdalany DS, Phillips SD, Dearani JA, et al.</a></text>
<text top="749" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref284">Isolated partial anomalous pulmonary venous con-</a></text>
<text top="762" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref284">nections in adults: twenty-year experience. Congenit</a></text>
<text top="775" left="63" width="88" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref284">Heart Dis. 2010;5:537</a></text>
<text top="774" left="150" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref284">–45</a></text>
<text top="775" left="165" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref284">.</a></text>
<text top="794" left="63" width="35" height="9" font="5">S4.1.2-6.</text>
<text top="794" left="101" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref285">Sachweh JS, Daebritz SH, Hermanns B, et al.</a></text>
<text top="808" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref285">Hypertensive pulmonary vascular disease in adults</a></text>
<text top="821" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref285">with secundum or sinus venosus atrial septal defect.</a></text>
<text top="835" left="63" width="125" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref285">Ann Thorac Surg. 2006;81:207</a></text>
<text top="833" left="188" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref285">–13</a></text>
<text top="835" left="200" width="3" height="9" font="5">.</text>
<text top="854" left="63" width="35" height="9" font="5">S4.1.2-7.</text>
<text top="854" left="100" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref286">Jemielity M, Perek B, Paluszkiewicz L, et al.</a></text>
<text top="867" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref286">Results of repair of partial anomalous pulmonary</a></text>
<text top="881" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref286">venous connection and sinus venosus atrial septal</a></text>
<text top="894" left="63" width="189" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref286">defect in adults. J Heart Valve Dis. 1998;7:410</a></text>
<text top="892" left="251" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref286">–4</a></text>
<text top="894" left="261" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref286">.</a></text>
<text top="913" left="63" width="35" height="9" font="5">S4.1.2-8.</text>
<text top="913" left="101" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref287">Dusenbery SM, Geva T, Seale A, et al.</a></text>
<text top="926" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref287">Outcome predictors and implications for management</a></text>
<text top="940" left="63" width="195" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref287">of scimitar syndrome. Am Heart J. 2013;165:770</a></text>
<text top="938" left="258" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref287">–7</a></text>
<text top="940" left="266" width="3" height="9" font="5">.</text>
<text top="959" left="63" width="35" height="9" font="5">S4.1.2-9.</text>
<text top="959" left="101" width="78" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref288">Brink J, Yong MS, d</a></text>
<text top="957" left="179" width="101" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref288">’Udekem Y, et al. Surgery</a></text>
<text top="972" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref288">for scimitar syndrome: the Melbourne experience.</a></text>
<text top="986" left="63" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref288">Interact Cardiovasc Thorac Surg. 2015;20:31</a></text>
<text top="984" left="240" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref288">–4</a></text>
<text top="986" left="249" width="3" height="9" font="5">.</text>
<text top="1009" left="63" width="142" height="9" font="5">4.1.3. Ventricular Septal Defect</text>
<text top="1023" left="63" width="34" height="9" font="5">S4.1.3-1.</text>
<text top="1023" left="99" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref289">Corone P, Doyon F, Gaudeau S, et al. Natural</a></text>
<text top="1036" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref289">history of ventricular septal defect. A study involving</a></text>
<text top="1050" left="63" width="145" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref289">790 cases. Circulation. 1977;55:908</a></text>
<text top="1048" left="207" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref289">–15</a></text>
<text top="1050" left="220" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref289">.</a></text>
<text top="1069" left="63" width="35" height="9" font="5">S4.1.3-2.</text>
<text top="1069" left="100" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref290">Yoshimura N, Hori Y, Horii Y, et al. Compari-</a></text>
<text top="1082" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref290">son of magnetic resonance imaging with transthoracic</a></text>
<text top="1095" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref290">echocardiography in the diagnosis of ventricular septal</a></text>
<text top="143" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref290">defect-associated coronary cusp prolapse. J Magn</a></text>
<text top="156" left="301" width="121" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref290">Reson Imaging. 2010;32:1099</a></text>
<text top="155" left="422" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref290">–103</a></text>
<text top="156" left="441" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref290">.</a></text>
<text top="175" left="301" width="35" height="9" font="5">S4.1.3-3.</text>
<text top="175" left="339" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref291">Wu M-H, Wang J-K, Lin M-T, et al. Ventric-</a></text>
<text top="189" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref291">ular septal defect with secondary left ventricular-to-</a></text>
<text top="202" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref291">right atrial shunt is associated with a higher risk for</a></text>
<text top="216" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref291">infective endocarditis and a lower late chance of</a></text>
<text top="229" left="301" width="138" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref291">closure. Pediatrics. 2006;117:e262</a></text>
<text top="228" left="439" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref291">–7</a></text>
<text top="229" left="448" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref291">.</a></text>
<text top="248" left="301" width="35" height="9" font="5">S4.1.3-4.</text>
<text top="248" left="339" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref292">D</a></text>
<text top="247" left="346" width="173" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref292">’Alto M, Romeo E, Argiento P, et al. He-</a></text>
<text top="262" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref292">modynamics of patients developing pulmonary arterial</a></text>
<text top="275" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref292">hypertension after shunt closure. Int J Cardiol. 2013;</a></text>
<text top="289" left="301" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref292">168:3797</a></text>
<text top="287" left="338" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref292">–801</a></text>
<text top="289" left="358" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref292">.</a></text>
<text top="307" left="301" width="35" height="9" font="5">S4.1.3-5.</text>
<text top="307" left="339" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref293">Janjua AM, Saleem K, Khan I, et al. Double</a></text>
<text top="319" left="301" width="217" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref293">ﬂap patch closure of VSD with elevated pulmonary</a></text>
<text top="334" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref293">vascular resistance: an experience at AFIC/NIHD. J Coll</a></text>
<text top="348" left="301" width="130" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref293">Physicians Surg Pak. 2011;21:197</a></text>
<text top="346" left="431" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref293">–201</a></text>
<text top="348" left="450" width="3" height="9" font="5">.</text>
<text top="367" left="301" width="35" height="9" font="5">S4.1.3-6.</text>
<text top="367" left="339" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref294">Talwar S, Keshri VK, Choudhary SK, et al.</a></text>
<text top="380" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref294">Unidirectional valved patch closure of ventricular</a></text>
<text top="394" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref294">septal defects with severe pulmonary arterial hyper-</a></text>
<text top="407" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref294">tension: hemodynamic outcomes. J Thorac Cardiovasc</a></text>
<text top="421" left="301" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref294">Surg. 2014;148:2570</a></text>
<text top="419" left="385" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref294">–5</a></text>
<text top="421" left="394" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref294">.</a></text>
<text top="440" left="301" width="35" height="9" font="5">S4.1.3-7.</text>
<text top="440" left="339" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref295">Kouchoukos NT, Blackstone EH, Kirklin JW.</a></text>
<text top="453" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref295">Surgical implications of pulmonary hypertension in</a></text>
<text top="466" left="301" width="192" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref295">congenital heart disease. Adv Cardiol. 1978:225</a></text>
<text top="465" left="493" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref295">–31</a></text>
<text top="466" left="505" width="3" height="9" font="5">.</text>
<text top="485" left="301" width="35" height="9" font="5">S4.1.3-8.</text>
<text top="485" left="339" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref296">Shohtsu A, Takeuchi S, Inoue T. Surgical in-</a></text>
<text top="499" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref296">dications and results for congenital cardiac anomalies</a></text>
<text top="512" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref296">associated with left to right shunt and severe pulmo-</a></text>
<text top="526" left="301" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref296">nary hypertension. Jpn Circ J. 1976;40:629</a></text>
<text top="524" left="476" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref296">–32</a></text>
<text top="526" left="489" width="3" height="9" font="5">.</text>
<text top="545" left="301" width="35" height="9" font="5">S4.1.3-9.</text>
<text top="545" left="339" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref297">Cartmill TB, DuShane JW, McGoon DC, et al.</a></text>
<text top="558" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref297">Results of repair of ventricular septal defect. J Thorac</a></text>
<text top="572" left="301" width="121" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref297">Cardiovasc Surg. 1966;52:486</a></text>
<text top="570" left="422" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref297">–501</a></text>
<text top="572" left="441" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref297">.</a></text>
<text top="594" left="301" width="164" height="9" font="5">4.1.4. Atrioventricular Septal Defect</text>
<text top="609" left="301" width="35" height="9" font="5">S4.1.4-1.</text>
<text top="609" left="339" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref298">Nishimura RA, Otto CM, Bonow RO, et al.</a></text>
<text top="622" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref298">2014 AHA/ACC guideline for the management of pa-</a></text>
<text top="635" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref298">tients with valvular heart disease: a report of the</a></text>
<text top="649" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref298">American College of Cardiology/American Heart As-</a></text>
<text top="662" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref298">sociation Task Force on Practice Guidelines. Circula-</a></text>
<text top="676" left="301" width="79" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref298">tion. 2014;129:e521</a></text>
<text top="674" left="380" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref298">–643</a></text>
<text top="676" left="400" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref298">.</a></text>
<text top="695" left="301" width="35" height="9" font="5">S4.1.4-2.</text>
<text top="695" left="339" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref299">Bianchi G, Bevilacqua S, Solinas M, et al. In</a></text>
<text top="708" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref299">adult patients undergoing redo surgery for left atrio-</a></text>
<text top="722" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref299">ventricular valve regurgitation after atrioventricular</a></text>
<text top="735" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref299">septal defect correction, is replacement superior to</a></text>
<text top="749" left="301" width="205" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref299">repair? Interact Cardiovasc Thorac Surg. 2011;12:1033</a></text>
<text top="747" left="506" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref299">–9</a></text>
<text top="749" left="516" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref299">.</a></text>
<text top="767" left="301" width="35" height="9" font="5">S4.1.4-3.</text>
<text top="767" left="339" width="48" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref300">Hoohenkerk</a></text>
<text top="767" left="404" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref300">GJF,</a></text>
<text top="767" left="439" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref300">Bruggemans</a></text>
<text top="767" left="506" width="12" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref300">EF,</a></text>
<text top="781" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref300">Koolbergen DR, et al. Long-term results of reoperation</a></text>
<text top="794" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref300">for left atrioventricular valve regurgitation after</a></text>
<text top="808" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref300">correction of atrioventricular septal defects. Ann</a></text>
<text top="821" left="301" width="105" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref300">Thorac Surg. 2012;93:849</a></text>
<text top="820" left="406" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref300">–55</a></text>
<text top="821" left="420" width="3" height="9" font="5">.</text>
<text top="840" left="301" width="36" height="9" font="5">S4.1.4-4.</text>
<text top="840" left="340" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref301">Stulak JM, Burkhart HM, Dearani JA. Reop-</a></text>
<text top="854" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref301">erations after repair of partial and complete atrioven-</a></text>
<text top="867" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref301">tricular septal defect. World J Pediatr Congenit Heart</a></text>
<text top="881" left="301" width="63" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref301">Surg. 2010;1:97</a></text>
<text top="879" left="364" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref301">–104</a></text>
<text top="881" left="384" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref301">.</a></text>
<text top="900" left="301" width="35" height="9" font="5">S4.1.4-5.</text>
<text top="900" left="339" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref302">Kouchoukos NT, Blackstone EH, Kirklin JW.</a></text>
<text top="913" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref302">Surgical implications of pulmonary hypertension in</a></text>
<text top="926" left="301" width="192" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref302">congenital heart disease. Adv Cardiol. 1978:225</a></text>
<text top="925" left="493" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref302">–31</a></text>
<text top="926" left="505" width="3" height="9" font="5">.</text>
<text top="945" left="301" width="36" height="9" font="5">S4.1.4-6.</text>
<text top="945" left="340" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref303">Shohtsu A, Takeuchi S, Inoue T. Surgical in-</a></text>
<text top="959" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref303">dications and results for congenital cardiac anomalies</a></text>
<text top="972" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref303">associated with left to right shunt and severe pulmo-</a></text>
<text top="986" left="301" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref303">nary hypertension. Jpn Circ J. 1976;40:629</a></text>
<text top="984" left="476" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref303">–32</a></text>
<text top="986" left="489" width="3" height="9" font="5">.</text>
<text top="1008" left="301" width="141" height="9" font="5">4.1.5. Patent Ductus Arteriosus</text>
<text top="1023" left="301" width="34" height="9" font="5">S4.1.5-1.</text>
<text top="1023" left="338" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref304">Yan C, Zhao S, Jiang S, et al. Transcatheter</a></text>
<text top="1036" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref304">closure of patent ductus arteriosus with severe pul-</a></text>
<text top="1050" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref304">monary arterial hypertension in adults. Heart. 2007;</a></text>
<text top="1063" left="301" width="27" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref304">93:514</a></text>
<text top="1061" left="328" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref304">–8</a></text>
<text top="1063" left="338" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref304">.</a></text>
<text top="1082" left="301" width="35" height="9" font="5">S4.1.5-2.</text>
<text top="1082" left="339" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref305">Gamboa R, Rios-Méndez RE, Mollón FP, et al.</a></text>
<text top="1095" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref305">Percutaneous closure of patent ductus arteriosus in</a></text>
<text top="143" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref305">adults using different devices. Rev Esp Cardiol. 2010;</a></text>
<text top="156" left="539" width="28" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref305">63:726</a></text>
<text top="155" left="567" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref305">–9</a></text>
<text top="156" left="577" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref305">.</a></text>
<text top="176" left="539" width="35" height="9" font="5">S4.1.5-3.</text>
<text top="176" left="577" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref306">Jeong Y-H, Yun T-J, Song J-M, et al. Left</a></text>
<text top="190" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref306">ventricular remodeling and change of systolic function</a></text>
<text top="203" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref306">after closure of patent ductus arteriosus in adults:</a></text>
<text top="217" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref306">device and surgical closure. Am Heart J. 2007;154:</a></text>
<text top="230" left="539" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref306">436</a></text>
<text top="228" left="555" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref306">–40</a></text>
<text top="230" left="571" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref306">.</a></text>
<text top="250" left="539" width="35" height="9" font="5">S4.1.5-4.</text>
<text top="250" left="578" width="22" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref307">Zabal</a></text>
<text top="250" left="610" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref307">C,</a></text>
<text top="250" left="629" width="58" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref307">García-Montes</a></text>
<text top="250" left="698" width="12" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref307">JA,</a></text>
<text top="250" left="721" width="36" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref307">Buendía-</a></text>
<text top="263" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref307">Hernández A, et al. Percutaneous closure of hyper-</a></text>
<text top="277" left="539" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref307">tensive ductus arteriosus. Heart. 2010;96:625</a></text>
<text top="275" left="725" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref307">–9</a></text>
<text top="277" left="734" width="3" height="9" font="5">.</text>
<text top="297" left="539" width="35" height="9" font="5">S4.1.5-5.</text>
<text top="297" left="577" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref308">Kouchoukos NT, Blackstone EH, Kirklin JW.</a></text>
<text top="310" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref308">Surgical implications of pulmonary hypertension in</a></text>
<text top="324" left="539" width="191" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref308">congenital heart disease. Adv Cardiol. 1978:225</a></text>
<text top="322" left="731" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref308">–31</a></text>
<text top="324" left="743" width="3" height="9" font="5">.</text>
<text top="346" left="539" width="160" height="9" font="24">4.2. Left-Sided Obstructive Lesions</text>
<text top="364" left="539" width="98" height="9" font="5">4.2.1. Cor Triatriatum</text>
<text top="379" left="539" width="34" height="9" font="5">S4.2.1-1.</text>
<text top="379" left="576" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref309">Ozyuksel A, Yildirim O, Avsar M, et al. Surgi-</a></text>
<text top="393" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref309">cal correction of cor triatriatum sinister in the paedi-</a></text>
<text top="406" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref309">atric population: mid-term results in 15 cases. Eur J</a></text>
<text top="420" left="539" width="126" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref309">Cardiothorac Surg. 2015;47:e25</a></text>
<text top="418" left="666" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref309">–8</a></text>
<text top="420" left="675" width="3" height="9" font="5">.</text>
<text top="440" left="539" width="35" height="9" font="5">S4.2.1-2.</text>
<text top="440" left="577" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref310">Yaroglu Kazanci S, Emani S, McElhinney DB.</a></text>
<text top="453" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref310">Outcome after repair of cor triatriatum. Am J Cardiol.</a></text>
<text top="466" left="539" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref310">2012;109:412</a></text>
<text top="465" left="593" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref310">–6</a></text>
<text top="466" left="603" width="3" height="9" font="5">.</text>
<text top="486" left="539" width="35" height="9" font="5">S4.2.1-3.</text>
<text top="486" left="577" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref311">Saxena P, Burkhart HM, Schaff HV, et al.</a></text>
<text top="500" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref311">Surgical repair of cor triatriatum sinister: the Mayo</a></text>
<text top="513" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref311">Clinic 50-year experience. Ann Thorac Surg. 2014;97:</a></text>
<text top="527" left="539" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref311">1659</a></text>
<text top="525" left="559" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref311">–63</a></text>
<text top="527" left="574" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref311">.</a></text>
<text top="549" left="539" width="148" height="9" font="5">4.2.2. Congenital Mitral Stenosis</text>
<text top="564" left="539" width="35" height="9" font="5">S4.2.2-1.</text>
<text top="564" left="577" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref312">Schaverien MV, Freedom RM, McCrindle BW.</a></text>
<text top="578" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref312">Independent factors associated with outcomes of</a></text>
<text top="591" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref312">parachute mitral valve in 84 patients. Circulation.</a></text>
<text top="605" left="539" width="64" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref312">2004;109:2309</a></text>
<text top="603" left="604" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref312">–13</a></text>
<text top="605" left="616" width="3" height="9" font="5">.</text>
<text top="625" left="539" width="35" height="9" font="5">S4.2.2-2.</text>
<text top="625" left="578" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref313">Marino BS, Kruge LE, Cho CJ, et al. Parachute</a></text>
<text top="638" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref313">mitral valve: morphologic descriptors, associated le-</a></text>
<text top="652" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref313">sions, and outcomes after biventricular repair. J Thorac</a></text>
<text top="665" left="539" width="125" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref313">Cardiovasc Surg. 2009;137:385</a></text>
<text top="663" left="664" width="27" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref313">–93.e4</a></text>
<text top="665" left="691" width="3" height="9" font="5">.</text>
<text top="688" left="539" width="111" height="9" font="5">4.2.3. Subaortic Stenosis</text>
<text top="703" left="539" width="35" height="9" font="5">S4.2.3-1.</text>
<text top="703" left="577" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref314">Diller G-P, Dimopoulos K, Okonko D, et al.</a></text>
<text top="716" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref314">Exercise intolerance in adult congenital heart disease:</a></text>
<text top="730" left="539" width="92" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref314">comparative severity,</a></text>
<text top="730" left="640" width="117" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref314">correlates, and prognostic</a></text>
<text top="743" left="539" width="153" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref314">implication. Circulation. 2005;112:828</a></text>
<text top="742" left="692" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref314">–35</a></text>
<text top="743" left="706" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref314">.</a></text>
<text top="763" left="539" width="35" height="9" font="5">S4.2.3-2.</text>
<text top="763" left="578" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref315">Diller G-P, Dimopoulos K, Okonko D, et al.</a></text>
<text top="776" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref315">Heart rate response during exercise predicts survival in</a></text>
<text top="790" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref315">adults with congenital heart disease. J Am Coll Cardiol.</a></text>
<text top="803" left="539" width="58" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref315">2006;48:1250</a></text>
<text top="802" left="598" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref315">–6</a></text>
<text top="803" left="607" width="3" height="9" font="5">.</text>
<text top="823" left="539" width="35" height="9" font="5">S4.2.3-3.</text>
<text top="823" left="578" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref316">Trinchero R, Demarie D, Orzan F, et al. Fixed</a></text>
<text top="837" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref316">subaortic stenosis. Natural history of patients with</a></text>
<text top="850" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref316">mild obstruction and follow-up of operated patients.</a></text>
<text top="863" left="539" width="108" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref316">G Ital Cardiol. 1988;18:738</a></text>
<text top="862" left="648" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref316">–44</a></text>
<text top="863" left="663" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref316">.</a></text>
<text top="883" left="539" width="36" height="9" font="5">S4.2.3-4.</text>
<text top="883" left="579" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref317">Oliver JM, González A, Gallego P, et al.</a></text>
<text top="897" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref317">Discrete subaortic stenosis in adults: increased preva-</a></text>
<text top="910" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref317">lence and slow rate of progression of the obstruction</a></text>
<text top="924" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref317">and aortic regurgitation. J Am Coll Cardiol. 2001;38:</a></text>
<text top="937" left="539" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref317">835</a></text>
<text top="936" left="555" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref317">–42</a></text>
<text top="937" left="569" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref317">.</a></text>
<text top="957" left="539" width="35" height="9" font="5">S4.2.3-5.</text>
<text top="957" left="578" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref318">Brauner R, Laks H, Drinkwater DCJ, et al.</a></text>
<text top="970" left="539" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref318">Bene</a></text>
<text top="969" left="559" width="197" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref318">ﬁts of early surgical repair in ﬁxed subaortic ste-</a></text>
<text top="984" left="539" width="155" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref318">nosis. J Am Coll Cardiol. 1997;30:1835</a></text>
<text top="982" left="695" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref318">–42</a></text>
<text top="984" left="709" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref318">.</a></text>
<text top="1004" left="539" width="36" height="9" font="5">S4.2.3-6.</text>
<text top="1004" left="579" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref319">Parry AJ, Kovalchin JP, Suda K, et al.</a></text>
<text top="1017" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref319">Resection of subaortic stenosis; can a more aggressive</a></text>
<text top="1031" left="539" width="70" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref319">approach be justi</a></text>
<text top="1029" left="609" width="147" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref319">ﬁed? Eur J Cardiothorac Surg. 1999;</a></text>
<text top="1044" left="539" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref319">15:631</a></text>
<text top="1042" left="565" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref319">–8</a></text>
<text top="1044" left="574" width="3" height="9" font="5">.</text>
<text top="1067" left="539" width="191" height="9" font="5">4.2.4. Congenital Valvular Aortic Stenosis</text>
<text top="1082" left="539" width="35" height="9" font="5">S4.2.4-1.</text>
<text top="1082" left="578" width="41" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref320">Fernandes</a></text>
<text top="1082" left="628" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref320">SM,</a></text>
<text top="1082" left="652" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref320">Sanders</a></text>
<text top="1082" left="693" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref320">SP,</a></text>
<text top="1082" left="714" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref320">Khairy</a></text>
<text top="1082" left="749" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref320">P,</a></text>
<text top="1095" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref320">et al. Morphology of bicuspid aortic valve in</a></text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="790" width="17" height="9" font="5">1551</text>
</page>
<page number="59" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref320">children and adolescents. J Am Coll Cardiol. 2004;</a></text>
<text top="156" left="108" width="34" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref320">44:1648</a></text>
<text top="155" left="141" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref320">–51</a></text>
<text top="156" left="154" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref320">.</a></text>
<text top="175" left="108" width="36" height="9" font="5">S4.2.4-2.</text>
<text top="175" left="147" width="43" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref321">Biner S, Ra</a></text>
<text top="173" left="190" width="134" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref321">ﬁque AM, Ray I, et al. Aortopathy</a></text>
<text top="189" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref321">is prevalent in relatives of bicuspid aortic valve pa-</a></text>
<text top="202" left="108" width="162" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref321">tients. J Am Coll Cardiol. 2009;53:2288</a></text>
<text top="200" left="269" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref321">–95</a></text>
<text top="202" left="284" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref321">.</a></text>
<text top="221" left="108" width="36" height="9" font="5">S4.2.4-3.</text>
<text top="221" left="147" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref322">Tutar E, Ekici F, Atalay S, et al. The preva-</a></text>
<text top="234" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref322">lence of bicuspid aortic valve in newborns by echo-</a></text>
<text top="247" left="108" width="206" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref322">cardiographic screening. Am Heart J. 2005;150:513</a></text>
<text top="246" left="313" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref322">–5</a></text>
<text top="247" left="322" width="3" height="9" font="5">.</text>
<text top="266" left="108" width="37" height="9" font="5">S4.2.4-4.</text>
<text top="266" left="148" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref323">Huntington</a></text>
<text top="266" left="203" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref323">K,</a></text>
<text top="266" left="221" width="28" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref323">Hunter</a></text>
<text top="266" left="258" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref323">AG,</a></text>
<text top="266" left="282" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref323">Chan</a></text>
<text top="266" left="312" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref323">KL.</a></text>
<text top="280" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref323">A prospective study to assess the frequency of familial</a></text>
<text top="293" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref323">clustering of congenital bicuspid aortic valve. J Am</a></text>
<text top="306" left="108" width="109" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref323">Coll Cardiol. 1997;30:1809</a></text>
<text top="305" left="216" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref323">–12</a></text>
<text top="306" left="229" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref323">.</a></text>
<text top="325" left="108" width="36" height="9" font="5">S4.2.4-5.</text>
<text top="325" left="147" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref324">Nishimura RA, Otto CM, Bonow RO, et al.</a></text>
<text top="338" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref324">2014 AHA/ACC guideline for the management of pa-</a></text>
<text top="352" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref324">tients with valvular heart disease: a report of the</a></text>
<text top="365" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref324">American College of Cardiology/American Heart As-</a></text>
<text top="379" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref324">sociation Task Force on Practice Guidelines. Circula-</a></text>
<text top="392" left="108" width="79" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref324">tion. 2014;129:e521</a></text>
<text top="391" left="186" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref324">–643</a></text>
<text top="392" left="206" width="3" height="9" font="5">.</text>
<text top="411" left="108" width="37" height="9" font="5">S4.2.4-6.</text>
<text top="411" left="148" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref325">Arora R, Jolly N, Bhat A, et al. Follow-up of</a></text>
<text top="424" left="108" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref325">balloon aortic valvuloplasty in young adults</a></text>
<text top="423" left="289" width="35" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref325">—a com-</a></text>
<text top="438" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref325">bined hemodynamic and Doppler echocardiographic</a></text>
<text top="451" left="108" width="138" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref325">study. Indian Heart J. 1989;41:314</a></text>
<text top="450" left="246" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref325">–7</a></text>
<text top="451" left="254" width="3" height="9" font="5">.</text>
<text top="474" left="108" width="116" height="9" font="5">4.2.4.1. Turner Syndrome</text>
<text top="488" left="108" width="42" height="9" font="5">S4.2.4.1-1.</text>
<text top="488" left="152" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref326">Sybert VP. Cardiovascular malformations</a></text>
<text top="501" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref326">and complications in Turner syndrome. Pediatrics.</a></text>
<text top="515" left="108" width="52" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref326">1998;101:E11</a></text>
<text top="515" left="159" width="3" height="9" font="5">.</text>
<text top="533" left="108" width="43" height="9" font="5">S4.2.4.1-2.</text>
<text top="533" left="153" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref327">Carlson M, Airhart N, Lopez L, et al. Mod-</a></text>
<text top="547" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref327">erate aortic enlargement and bicuspid aortic valve are</a></text>
<text top="560" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref327">associated with aortic dissection in Turner syndrome:</a></text>
<text top="574" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref327">report of the International Turner Syndrome Aortic</a></text>
<text top="587" left="108" width="189" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref327">Dissection Registry. Circulation. 2012;126:2220</a></text>
<text top="585" left="297" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref327">–6</a></text>
<text top="587" left="306" width="3" height="9" font="5">.</text>
<text top="610" left="108" width="163" height="9" font="5">4.2.5. Supravalvular Aortic Stenosis</text>
<text top="624" left="108" width="35" height="9" font="5">S4.2.5-1.</text>
<text top="624" left="145" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref328">Tani LY, Minich LL, Pagotto LT, et al. Use-</a></text>
<text top="637" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref328">fulness of doppler echocardiography to determine the</a></text>
<text top="650" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref328">timing of surgery for supravalvar aortic stenosis. Am J</a></text>
<text top="664" left="108" width="86" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref328">Cardiol. 2000;86:114</a></text>
<text top="662" left="193" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref328">–6</a></text>
<text top="664" left="203" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref328">.</a></text>
<text top="683" left="108" width="35" height="9" font="5">S4.2.5-2.</text>
<text top="683" left="146" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref329">Thiene G, Ho SY. Aortic root pathology and</a></text>
<text top="696" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref329">sudden death in youth: review of anatomical varieties.</a></text>
<text top="709" left="108" width="98" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref329">Appl Pathol. 1986;4:237</a></text>
<text top="708" left="206" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref329">–45</a></text>
<text top="709" left="220" width="3" height="9" font="5">.</text>
<text top="728" left="108" width="35" height="9" font="5">S4.2.5-3.</text>
<text top="728" left="146" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref330">Stamm C, Li J, Ho SY, et al. The aortic root in</a></text>
<text top="741" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref330">supravalvular aortic stenosis: the potential surgical</a></text>
<text top="755" left="108" width="101" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref330">relevance of morphologic</a></text>
<text top="753" left="211" width="114" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref330">ﬁndings. J Thorac Cardiovasc</a></text>
<text top="768" left="108" width="70" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref330">Surg. 1997;114:16</a></text>
<text top="767" left="178" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref330">–24</a></text>
<text top="768" left="192" width="3" height="9" font="5">.</text>
<text top="787" left="108" width="36" height="9" font="5">S4.2.5-4.</text>
<text top="787" left="147" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref331">Martin MM, Lemmer JH Jr., Shaffer E, et al.</a></text>
<text top="800" left="108" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref331">Obstruction to left coronary artery blood</a></text>
<text top="799" left="286" width="39" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref331">ﬂow sec-</a></text>
<text top="814" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref331">ondary to obliteration of the coronary ostium in</a></text>
<text top="827" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref331">supravalvular aortic stenosis. Ann Thorac Surg. 1988;</a></text>
<text top="841" left="108" width="22" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref331">45:16</a></text>
<text top="839" left="130" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref331">–20</a></text>
<text top="841" left="145" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref331">.</a></text>
<text top="859" left="108" width="35" height="9" font="5">S4.2.5-5.</text>
<text top="859" left="146" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref332">Bruno E, Rossi N, Thüer O, et al. Cardiovas-</a></text>
<text top="873" left="108" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref332">cular</a></text>
<text top="871" left="132" width="192" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref332">ﬁndings, and clinical course, in patients with</a></text>
<text top="886" left="108" width="193" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref332">Williams syndrome. Cardiol Young. 2003;13:532</a></text>
<text top="885" left="300" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref332">–6</a></text>
<text top="886" left="310" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref332">.</a></text>
<text top="905" left="108" width="36" height="9" font="5">S4.2.5-6.</text>
<text top="905" left="147" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref333">Wren C, Oslizlok P, Bull C. Natural history of</a></text>
<text top="918" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref333">supravalvular aortic stenosis and pulmonary artery</a></text>
<text top="932" left="108" width="167" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref333">stenosis. J Am Coll Cardiol. 1990;15:1625</a></text>
<text top="930" left="274" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref333">–30</a></text>
<text top="932" left="289" width="3" height="9" font="5">.</text>
<text top="950" left="108" width="35" height="9" font="5">S4.2.5-7.</text>
<text top="950" left="146" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref334">Eronen M, Peippo M, Hiippala A, et al. Car-</a></text>
<text top="964" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref334">diovascular manifestations in 75 patients with Williams</a></text>
<text top="977" left="108" width="154" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref334">syndrome. J Med Genet. 2002;39:554</a></text>
<text top="976" left="261" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref334">–8</a></text>
<text top="977" left="271" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref334">.</a></text>
<text top="996" left="108" width="36" height="9" font="5">S4.2.5-8.</text>
<text top="996" left="147" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref335">Greutmann M, Tobler D, Sharma NC, et al.</a></text>
<text top="1009" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref335">Cardiac outcomes in adults with supravalvar aortic</a></text>
<text top="1023" left="108" width="143" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref335">stenosis. Eur Heart J. 2012;33:2442</a></text>
<text top="1021" left="251" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref335">–50</a></text>
<text top="1023" left="266" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref335">.</a></text>
<text top="1041" left="108" width="36" height="9" font="5">S4.2.5-9.</text>
<text top="1041" left="147" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref336">Doty DB, Eastham CL, Hiratzka LF, et al.</a></text>
<text top="1055" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref336">Determination of coronary reserve in patients with</a></text>
<text top="143" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref336">supravalvular aortic stenosis. Circulation. 1982;66:</a></text>
<text top="156" left="346" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref336">I186</a></text>
<text top="155" left="363" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref336">–92</a></text>
<text top="156" left="378" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref336">.</a></text>
<text top="179" left="346" width="139" height="9" font="5">4.2.6. Coarctation of the Aorta</text>
<text top="193" left="346" width="35" height="9" font="5">S4.2.6-1.</text>
<text top="193" left="384" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref337">Qureshi AM, McElhinney DB, Lock JE, et al.</a></text>
<text top="207" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref337">Acute and intermediate outcomes, and evaluation of</a></text>
<text top="220" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref337">injury to the aortic wall, as based on 15 years experi-</a></text>
<text top="233" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref337">ence of implanting stents to treat aortic coarctation.</a></text>
<text top="247" left="346" width="112" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref337">Cardiol Young. 2007;17:307</a></text>
<text top="245" left="458" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref337">–18</a></text>
<text top="247" left="471" width="3" height="9" font="5">.</text>
<text top="266" left="346" width="36" height="9" font="5">S4.2.6-2.</text>
<text top="266" left="385" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref338">Hager A, Kanz S, Kaemmerer H, et al.</a></text>
<text top="279" left="346" width="208" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref338">Coarctation Long-term Assessment (COALA): signi</a></text>
<text top="277" left="554" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref338">ﬁ-</a></text>
<text top="293" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref338">cance of arterial hypertension in a cohort of 404 pa-</a></text>
<text top="306" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref338">tients up to 27 years after surgical repair of isolated</a></text>
<text top="319" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref338">coarctation of the aorta, even in the absence of</a></text>
<text top="333" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref338">restenosis and prosthetic material. J Thorac Cardiovasc</a></text>
<text top="346" left="346" width="79" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref338">Surg. 2007;134:738</a></text>
<text top="345" left="425" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref338">–45</a></text>
<text top="346" left="439" width="3" height="9" font="5">.</text>
<text top="365" left="346" width="36" height="9" font="5">S4.2.6-3.</text>
<text top="365" left="385" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref339">Forbes TJ, Garekar S, Amin Z, et al. Proce-</a></text>
<text top="378" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref339">dural results and acute complications in stenting</a></text>
<text top="392" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref339">native and recurrent coarctation of the aorta in pa-</a></text>
<text top="405" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref339">tients over 4 years of age: a multi-institutional study.</a></text>
<text top="419" left="346" width="164" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref339">Catheter Cardiovasc Interv. 2007;70:276</a></text>
<text top="417" left="510" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref339">–85</a></text>
<text top="419" left="525" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref339">.</a></text>
<text top="438" left="346" width="37" height="9" font="5">S4.2.6-4.</text>
<text top="438" left="386" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref340">Morgan GJ, Lee KJ, Chaturvedi R, et al.</a></text>
<text top="451" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref340">Systemic blood pressure after stent management for</a></text>
<text top="464" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref340">arch coarctation implications for clinical care. J Am</a></text>
<text top="478" left="346" width="115" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref340">Coll Cardiol Intv. 2013;6:192</a></text>
<text top="476" left="461" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref340">–201</a></text>
<text top="478" left="480" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref340">.</a></text>
<text top="497" left="346" width="36" height="9" font="5">S4.2.6-5.</text>
<text top="497" left="385" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref341">Cook SC, Hickey J, Maul TM, et al. Assess-</a></text>
<text top="510" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref341">ment of the cerebral circulation in adults with coarc-</a></text>
<text top="523" left="346" width="213" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref341">tation of the aorta. Congenit Heart Dis. 2013;8:289</a></text>
<text top="522" left="559" width="4" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref341">–</a></text>
<text top="537" left="346" width="10" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref341">95</a></text>
<text top="537" left="356" width="3" height="9" font="5">.</text>
<text top="556" left="346" width="37" height="9" font="5">S4.2.6-6.</text>
<text top="556" left="386" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref342">Connolly HM, Huston J 3rd, Brown RD Jr.,</a></text>
<text top="569" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref342">et al. Intracranial aneurysms in patients with coarcta-</a></text>
<text top="582" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref342">tion of the aorta: a prospective magnetic resonance</a></text>
<text top="596" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref342">angiographic study of 100 patients. Mayo Clin Proc.</a></text>
<text top="609" left="346" width="56" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref342">2003;78:1491</a></text>
<text top="608" left="401" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref342">–9</a></text>
<text top="609" left="411" width="3" height="9" font="5">.</text>
<text top="628" left="346" width="36" height="9" font="5">S4.2.6-7.</text>
<text top="628" left="385" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref343">Correia AS, Gonçalves A, Paiva M, et al.</a></text>
<text top="642" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref343">Long-term follow-up after aortic coarctation repair:</a></text>
<text top="655" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref343">the unsolved issue of exercise-induced hypertension.</a></text>
<text top="668" left="346" width="121" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref343">Rev Port Cardiol. 2013;32:879</a></text>
<text top="667" left="467" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref343">–83</a></text>
<text top="668" left="481" width="3" height="9" font="5">.</text>
<text top="687" left="346" width="37" height="9" font="5">S4.2.6-8.</text>
<text top="687" left="386" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref344">Holzer R, Qureshi S, Ghasemi A, et al.</a></text>
<text top="701" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref344">Stenting of aortic coarctation: acute, intermediate, and</a></text>
<text top="714" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref344">long-term results of a prospective multi-institutional</a></text>
<text top="727" left="346" width="30" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref344">registry</a></text>
<text top="726" left="376" width="187" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref344">—Congenital Cardiovascular Interventional</a></text>
<text top="741" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref344">Study Consortium (CCISC). Catheter Cardiovasc Interv.</a></text>
<text top="754" left="346" width="51" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref344">2010;76:553</a></text>
<text top="753" left="396" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref344">–63</a></text>
<text top="754" left="411" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref344">.</a></text>
<text top="773" left="346" width="37" height="9" font="5">S4.2.6-9.</text>
<text top="773" left="386" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref345">Chessa M, Carrozza M, Butera G, et al. Re-</a></text>
<text top="787" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref345">sults and mid-long-term follow-up of stent implanta-</a></text>
<text top="800" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref345">tion for native and recurrent coarctation of the aorta.</a></text>
<text top="813" left="346" width="108" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref345">Eur Heart J. 2005;26:2728</a></text>
<text top="812" left="454" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref345">–32</a></text>
<text top="813" left="468" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref345">.</a></text>
<text top="832" left="346" width="41" height="9" font="5">S4.2.6-10.</text>
<text top="832" left="390" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref346">Toro-Salazar OH, Steinberger J, Thomas W,</a></text>
<text top="846" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref346">et al. Long-term follow-up of patients after coarcta-</a></text>
<text top="859" left="346" width="206" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref346">tion of the aorta repair. Am J Cardiol. 2002;89:541</a></text>
<text top="857" left="552" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref346">–7</a></text>
<text top="859" left="560" width="3" height="9" font="5">.</text>
<text top="878" left="346" width="39" height="9" font="5">S4.2.6-11.</text>
<text top="878" left="388" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref347">Carr JA. The results of catheter-based</a></text>
<text top="891" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref347">therapy compared with surgical repair of adult aortic</a></text>
<text top="905" left="346" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref347">coarctation. J Am Coll Cardiol. 2006;47:1101</a></text>
<text top="903" left="526" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref347">–7</a></text>
<text top="905" left="535" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref347">.</a></text>
<text top="923" left="346" width="40" height="9" font="5">S4.2.6-12.</text>
<text top="923" left="389" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref348">Brown JW, Ruzmetov M, Hoyer MH, et al.</a></text>
<text top="937" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref348">Recurrent coarctation: is surgical repair of recurrent</a></text>
<text top="950" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref348">coarctation of the aorta safe and effective? Ann Thorac</a></text>
<text top="964" left="346" width="82" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref348">Surg. 2009;88:1923</a></text>
<text top="962" left="427" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref348">–30</a></text>
<text top="964" left="442" width="3" height="9" font="5">.</text>
<text top="982" left="346" width="40" height="9" font="5">S4.2.6-13.</text>
<text top="982" left="389" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref349">Chobanian AV, Bakris GL, Black HR, et al.</a></text>
<text top="996" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref349">Seventh report of the Joint National Committee on</a></text>
<text top="1009" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref349">Prevention, Detection, Evaluation, and Treatment of</a></text>
<text top="1023" left="346" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref349">High Blood Pressure. Hypertension. 2003;42:1206</a></text>
<text top="1021" left="547" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref349">–52</a></text>
<text top="1023" left="560" width="3" height="9" font="5">.</text>
<text top="1041" left="346" width="41" height="9" font="5">S4.2.6-14.</text>
<text top="1041" left="390" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref350">Suárez de Lezo J, Pan M, Romero M, et al.</a></text>
<text top="1055" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref350">Percutaneous interventions on severe coarctation of</a></text>
<text top="143" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref350">the aorta: a 21-year experience. Pediatr Cardiol. 2005;</a></text>
<text top="156" left="584" width="27" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref350">26:176</a></text>
<text top="155" left="611" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref350">–89</a></text>
<text top="156" left="626" width="3" height="9" font="5">.</text>
<text top="179" left="584" width="110" height="9" font="24">4.3. Right-Sided Lesions</text>
<text top="197" left="584" width="159" height="9" font="5">4.3.1. Valvular Pulmonary Stenosis</text>
<text top="212" left="584" width="34" height="9" font="5">S4.3.1-1.</text>
<text top="212" left="621" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref351">Voet A, Rega F, de Bruaene AV, et al. Long-</a></text>
<text top="225" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref351">term outcome after treatment of isolated pulmonary</a></text>
<text top="238" left="584" width="162" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref351">valve stenosis. Int J Cardiol. 2012;156:11</a></text>
<text top="237" left="747" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref351">–5</a></text>
<text top="238" left="755" width="3" height="9" font="5">.</text>
<text top="258" left="584" width="35" height="9" font="5">S4.3.1-2.</text>
<text top="258" left="622" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref352">Kaul UA, Singh B, Tyagi S, et al. Long-term</a></text>
<text top="271" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref352">results after balloon pulmonary valvuloplasty in</a></text>
<text top="285" left="584" width="137" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref352">adults. Am Heart J. 1993;126:1152</a></text>
<text top="283" left="721" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref352">–5</a></text>
<text top="285" left="730" width="3" height="9" font="5">.</text>
<text top="304" left="584" width="35" height="9" font="5">S4.3.1-3.</text>
<text top="304" left="622" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref353">Chen CR, Cheng TO, Huang T, et al. Percu-</a></text>
<text top="317" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref353">taneous balloon valvuloplasty for pulmonic stenosis in</a></text>
<text top="331" left="584" width="206" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref353">adolescents and adults. N Engl J Med. 1996;335:21</a></text>
<text top="329" left="790" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref353">–5</a></text>
<text top="331" left="799" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref353">.</a></text>
<text top="350" left="584" width="35" height="9" font="5">S4.3.1-4.</text>
<text top="350" left="623" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref354">Taggart NW, Cetta F, Cabalka AK, et al.</a></text>
<text top="363" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref354">Outcomes for balloon pulmonary valvuloplasty in</a></text>
<text top="377" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref354">adults: comparison with a concurrent pediatric cohort.</a></text>
<text top="390" left="584" width="160" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref354">Catheter Cardiovasc Interv. 2013;82:811</a></text>
<text top="389" left="744" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref354">–5</a></text>
<text top="390" left="753" width="3" height="9" font="5">.</text>
<text top="410" left="584" width="35" height="9" font="5">S4.3.1-5.</text>
<text top="410" left="622" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref355">Kopecky SL, Gersh BJ, McGoon MD, et al.</a></text>
<text top="423" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref355">Long-term outcome of patients undergoing surgical</a></text>
<text top="437" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref355">repair of isolated pulmonary valve stenosis. Follow-up</a></text>
<text top="450" left="584" width="168" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref355">at 20-30 years. Circulation. 1988;78:1150</a></text>
<text top="448" left="752" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref355">–6</a></text>
<text top="450" left="762" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref355">.</a></text>
<text top="469" left="584" width="35" height="9" font="5">S4.3.1-6.</text>
<text top="469" left="622" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref356">Hayes CJ, Gersony WM, Driscoll DJ, et al.</a></text>
<text top="483" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref356">Second natural history study of congenital heart de-</a></text>
<text top="496" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref356">fects. Results of treatment of patients with pulmonary</a></text>
<text top="510" left="584" width="161" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref356">valvar stenosis. Circulation. 1993;87:I28</a></text>
<text top="508" left="745" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref356">–37</a></text>
<text top="510" left="758" width="3" height="9" font="5">.</text>
<text top="529" left="584" width="35" height="9" font="5">S4.3.1-7.</text>
<text top="529" left="622" width="61" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref357">Roos-Hesselink</a></text>
<text top="529" left="700" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref357">JW,</a></text>
<text top="529" left="733" width="39" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref357">Meijboom</a></text>
<text top="529" left="790" width="11" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref357">FJ,</a></text>
<text top="542" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref357">Spitaels SEC, et al. Long-term outcome after surgery</a></text>
<text top="556" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref357">for pulmonary stenosis (a longitudinal study of 22-33</a></text>
<text top="569" left="584" width="134" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref357">years). Eur Heart J. 2006;27:482</a></text>
<text top="568" left="718" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref357">–8</a></text>
<text top="569" left="727" width="3" height="9" font="5">.</text>
<text top="588" left="584" width="35" height="9" font="5">S4.3.1-8.</text>
<text top="588" left="622" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref358">Earing MG, Connolly HM, Dearani JA, et al.</a></text>
<text top="602" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref358">Long-term follow-up of patients after surgical treat-</a></text>
<text top="615" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref358">ment for isolated pulmonary valve stenosis. Mayo Clin</a></text>
<text top="629" left="584" width="76" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref358">Proc. 2005;80:871</a></text>
<text top="627" left="660" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref358">–6</a></text>
<text top="629" left="670" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref358">.</a></text>
<text top="652" left="584" width="24" height="9" font="5">4.3.2.</text>
<text top="652" left="620" width="32" height="9" font="5">Branch</text>
<text top="652" left="664" width="17" height="9" font="5">and</text>
<text top="652" left="693" width="47" height="9" font="5">Peripheral</text>
<text top="652" left="752" width="50" height="9" font="5">Pulmonary</text>
<text top="665" left="584" width="38" height="9" font="5">Stenosis</text>
<text top="679" left="584" width="35" height="9" font="5">S4.3.2-1.</text>
<text top="679" left="622" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref359">Hallbergson A, Lock JE, Marshall AC. Fre-</a></text>
<text top="693" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref359">quency and risk of in-stent stenosis following pulmo-</a></text>
<text top="706" left="584" width="193" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref359">nary artery stenting. Am J Cardiol. 2014;113:541</a></text>
<text top="705" left="778" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref359">–5</a></text>
<text top="706" left="786" width="3" height="9" font="5">.</text>
<text top="725" left="584" width="35" height="9" font="5">S4.3.2-2.</text>
<text top="725" left="623" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref360">Gonzalez I, Kenny D, Slyder S, et al. Medium</a></text>
<text top="739" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref360">and long-term outcomes after bilateral pulmonary</a></text>
<text top="752" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref360">artery stenting in children and adults with congenital</a></text>
<text top="766" left="584" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref360">heart disease. Pediatr Cardiol. 2013;34:179</a></text>
<text top="764" left="756" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref360">–84</a></text>
<text top="766" left="771" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref360">.</a></text>
<text top="785" left="584" width="35" height="9" font="5">S4.3.2-3.</text>
<text top="785" left="623" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref361">Kenny D, Amin Z, Slyder S, et al. Medium-</a></text>
<text top="799" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref361">term outcomes for peripheral pulmonary artery</a></text>
<text top="812" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref361">stenting in adults with congenital heart disease.</a></text>
<text top="825" left="584" width="115" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref361">J Interv Cardiol. 2011;24:373</a></text>
<text top="824" left="699" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref361">–7</a></text>
<text top="825" left="708" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref361">.</a></text>
<text top="848" left="584" width="187" height="9" font="5">4.3.3. Double-Chambered Right Ventricle</text>
<text top="863" left="584" width="35" height="9" font="5">S4.3.3-1.</text>
<text top="863" left="622" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref362">Hachiro Y, Takagi N, Koyanagi T, et al. Repair</a></text>
<text top="876" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref362">of double-chambered right ventricle: surgical results</a></text>
<text top="890" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref362">and long-term follow-up. Ann Thorac Surg. 2001;72:</a></text>
<text top="903" left="584" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref362">1520</a></text>
<text top="901" left="604" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref362">–2</a></text>
<text top="903" left="613" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref362">.</a></text>
<text top="922" left="584" width="35" height="9" font="5">S4.3.3-2.</text>
<text top="922" left="623" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref363">Kveselis D, Rosenthal A, Ferguson P, et al.</a></text>
<text top="936" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref363">Long-term prognosis after repair of double-chamber</a></text>
<text top="949" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref363">right ventricle with ventricular septal defect. Am J</a></text>
<text top="963" left="584" width="88" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref363">Cardiol. 1984;54:1292</a></text>
<text top="961" left="672" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref363">–5</a></text>
<text top="963" left="681" width="3" height="9" font="5">.</text>
<text top="982" left="584" width="35" height="9" font="5">S4.3.3-3.</text>
<text top="982" left="623" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref364">Said SM, Burkhart HM, Dearani JA, et al.</a></text>
<text top="995" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref364">Outcomes of surgical repair of double-chambered right</a></text>
<text top="1009" left="584" width="161" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref364">ventricle. Ann Thorac Surg. 2012;93:197</a></text>
<text top="1007" left="746" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref364">–200</a></text>
<text top="1009" left="767" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref364">.</a></text>
<text top="1028" left="584" width="36" height="9" font="5">S4.3.3-4.</text>
<text top="1028" left="624" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref365">Kahr PC, Alonso-Gonzalez R, Kempny A,</a></text>
<text top="1041" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref365">et al. Long-term natural history and postoperative</a></text>
<text top="1055" left="584" width="35" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref365">outcome</a></text>
<text top="1055" left="629" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref365">of</a></text>
<text top="1055" left="647" width="75" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref365">double-chambered</a></text>
<text top="1055" left="731" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref365">right</a></text>
<text top="1055" left="760" width="35" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref365">ventricle</a></text>
<text top="1053" left="795" width="7" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref365">—</a></text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="18" height="9" font="5">1552</text>
</page>
<page number="60" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref365">experience from two tertiary adult congenital heart</a></text>
<text top="156" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref365">centres and review of the literature. Int J Cardiol.</a></text>
<text top="170" left="63" width="55" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref365">2014;174:662</a></text>
<text top="168" left="118" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref365">–8</a></text>
<text top="170" left="127" width="3" height="9" font="5">.</text>
<text top="193" left="63" width="106" height="9" font="5">4.3.4. Ebstein Anomaly</text>
<text top="206" left="63" width="35" height="9" font="5">S4.3.4-1.</text>
<text top="206" left="101" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref366">Bharucha T, Anderson RH, Lim ZS, et al.</a></text>
<text top="220" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref366">Multiplanar review of three-dimensional echocardiog-</a></text>
<text top="233" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref366">raphy gives new insights into the morphology of</a></text>
<text top="247" left="63" width="29" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref366">Ebstein</a></text>
<text top="245" left="92" width="188" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref366">’s malformation. Cardiol Young. 2010;20:49–</a></text>
<text top="260" left="63" width="10" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref366">53</a></text>
<text top="260" left="72" width="3" height="9" font="5">.</text>
<text top="279" left="63" width="36" height="9" font="5">S4.3.4-2.</text>
<text top="279" left="102" width="44" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref367">Attenhofer</a></text>
<text top="279" left="159" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref367">Jost</a></text>
<text top="279" left="188" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref367">CH,</a></text>
<text top="279" left="215" width="35" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref367">Edmister</a></text>
<text top="279" left="263" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref367">WD,</a></text>
<text top="292" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref367">Julsrud PR, et al. Prospective comparison of echocar-</a></text>
<text top="306" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref367">diography versus cardiac magnetic resonance imaging</a></text>
<text top="319" left="63" width="100" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref367">in patients with Ebstein</a></text>
<text top="318" left="162" width="118" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref367">’s anomaly. Int J Cardiovasc</a></text>
<text top="333" left="63" width="90" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref367">Imaging. 2012;28:1147</a></text>
<text top="331" left="153" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref367">–59</a></text>
<text top="333" left="167" width="3" height="9" font="5">.</text>
<text top="351" left="63" width="36" height="9" font="5">S4.3.4-3.</text>
<text top="351" left="102" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref368">Wei W, Zhan X, Xue Y, et al. Features of</a></text>
<text top="365" left="63" width="146" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref368">accessory pathways in adult Ebstein</a></text>
<text top="363" left="209" width="71" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref368">’s anomaly. Euro-</a></text>
<text top="378" left="63" width="77" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref368">pace. 2014;16:1619</a></text>
<text top="377" left="140" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref368">–25</a></text>
<text top="378" left="154" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref368">.</a></text>
<text top="397" left="63" width="37" height="9" font="5">S4.3.4-4.</text>
<text top="397" left="103" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref369">Iturralde P, Nava S, Sálica G, et al. Electro-</a></text>
<text top="410" left="63" width="211" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref369">cardiographic characteristics of patients with Ebstein</a></text>
<text top="409" left="274" width="6" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref369">’s</a></text>
<text top="424" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref369">anomaly before and after ablation of an accessory</a></text>
<text top="437" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref369">atrioventricular pathway. J Cardiovasc Electrophysiol.</a></text>
<text top="451" left="63" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref369">2006;17:1332</a></text>
<text top="449" left="117" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref369">–6</a></text>
<text top="451" left="127" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref369">.</a></text>
<text top="469" left="63" width="36" height="9" font="5">S4.3.4-5.</text>
<text top="469" left="102" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref370">Shivapour JKL, Sherwin ED, Alexander ME,</a></text>
<text top="483" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref370">et al. Utility of preoperative electrophysiologic studies</a></text>
<text top="496" left="63" width="103" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref370">in patients with Ebstein</a></text>
<text top="494" left="165" width="115" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref370">’s anomaly undergoing the</a></text>
<text top="510" left="63" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref370">cone procedure. Heart Rhythm. 2014;11:182</a></text>
<text top="508" left="239" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref370">–6</a></text>
<text top="510" left="249" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref370">.</a></text>
<text top="528" left="63" width="37" height="9" font="5">S4.3.4-6.</text>
<text top="528" left="103" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref371">Raju V, Dearani JA, Burkhart HM, et al. Right</a></text>
<text top="542" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref371">ventricular unloading for heart failure related to Ebstein</a></text>
<text top="555" left="63" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref371">malformation. Ann Thorac Surg. 2014;98:167</a></text>
<text top="553" left="243" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref371">–73</a></text>
<text top="555" left="256" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref371">.</a></text>
<text top="574" left="63" width="36" height="9" font="5">S4.3.4-7.</text>
<text top="574" left="102" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref372">Brown ML, Dearani JA, Danielson GK, et al.</a></text>
<text top="587" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref372">The outcomes of operations for 539 patients with</a></text>
<text top="601" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref372">Ebstein anomaly. J Thorac Cardiovasc Surg. 2008;135:</a></text>
<text top="614" left="63" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref372">1120</a></text>
<text top="612" left="81" width="37" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref372">–36. e1-7</a></text>
<text top="614" left="118" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref372">.</a></text>
<text top="633" left="63" width="37" height="9" font="5">S4.3.4-8.</text>
<text top="633" left="103" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref373">Dearani JA, Said SM, Burkhart HM, et al.</a></text>
<text top="646" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref373">Strategies for tricuspid re-repair in Ebstein malforma-</a></text>
<text top="660" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref373">tion using the cone technique. Ann Thorac Surg. 2013;</a></text>
<text top="673" left="63" width="30" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref373">96:202</a></text>
<text top="671" left="92" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref373">–8</a></text>
<text top="673" left="102" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref373">.</a></text>
<text top="692" left="63" width="37" height="9" font="5">S4.3.4-9.</text>
<text top="692" left="103" width="103" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref374">Dearani JA, Said SM, O</a></text>
<text top="690" left="206" width="74" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref374">’Leary PW, et al.</a></text>
<text top="705" left="63" width="115" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref374">Anatomic repair of Ebstein</a></text>
<text top="703" left="177" width="102" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref374">’s malformation: lessons</a></text>
<text top="718" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref374">learned with cone reconstruction. Ann Thorac Surg.</a></text>
<text top="732" left="63" width="51" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref374">2013;95:220</a></text>
<text top="730" left="114" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref374">–6</a></text>
<text top="732" left="123" width="3" height="9" font="5">.</text>
<text top="751" left="63" width="41" height="9" font="5">S4.3.4-10.</text>
<text top="751" left="107" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref375">Badiu CC, Schreiber C, Hörer J, et al. Early</a></text>
<text top="764" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref375">timing of surgical intervention in patients with</a></text>
<text top="778" left="63" width="29" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref375">Ebstein</a></text>
<text top="776" left="92" width="188" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref375">’s anomaly predicts superior long-term</a></text>
<text top="791" left="63" width="191" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref375">outcome. Eur J Cardiothorac Surg. 2010;37:186</a></text>
<text top="789" left="254" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref375">–92</a></text>
<text top="791" left="268" width="3" height="9" font="5">.</text>
<text top="810" left="63" width="39" height="9" font="5">S4.3.4-11.</text>
<text top="810" left="105" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref376">Khositseth A, Danielson GK, Dearani JA,</a></text>
<text top="823" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref376">et al. Supraventricular tachyarrhythmias in Ebstein</a></text>
<text top="836" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref376">anomaly: management and outcome. J Thorac Car-</a></text>
<text top="850" left="63" width="114" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref376">diovasc Surg. 2004;128:826</a></text>
<text top="848" left="177" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref376">–33</a></text>
<text top="850" left="190" width="3" height="9" font="5">.</text>
<text top="869" left="63" width="40" height="9" font="5">S4.3.4-12.</text>
<text top="869" left="106" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref377">Zachariah JP, Walsh EP, Triedman JK, et al.</a></text>
<text top="882" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref377">Multiple accessory pathways in the young: the impact of</a></text>
<text top="895" left="63" width="195" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref377">structural heart disease. Am Heart J. 2013;165:87</a></text>
<text top="894" left="258" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref377">–92</a></text>
<text top="895" left="272" width="3" height="9" font="5">.</text>
<text top="914" left="63" width="40" height="9" font="5">S4.3.4-13.</text>
<text top="914" left="106" width="85" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref378">Chauvaud S. Ebstein</a></text>
<text top="912" left="191" width="89" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref378">’s malformation. Sur-</a></text>
<text top="927" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref378">gical treatment and results. Thorac Cardiovasc Surg.</a></text>
<text top="941" left="63" width="55" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref378">2000;48:220</a></text>
<text top="939" left="118" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref378">–3</a></text>
<text top="941" left="127" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref378">.</a></text>
<text top="959" left="63" width="41" height="9" font="5">S4.3.4-14.</text>
<text top="959" left="107" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref379">Chen JM, Mosca RS, Altmann K, et al. Early</a></text>
<text top="973" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref379">and medium-term results for repair of Ebstein anom-</a></text>
<text top="986" left="63" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref379">aly. J Thorac Cardiovasc Surg. 2004;127:990</a></text>
<text top="985" left="244" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref379">–8</a></text>
<text top="986" left="254" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref379">.</a></text>
<text top="1005" left="63" width="40" height="9" font="5">S4.3.4-15.</text>
<text top="1005" left="106" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref380">Malhotra SP, Petrossian E, Reddy VM, et al.</a></text>
<text top="1019" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref380">Selective right ventricular unloading and novel tech-</a></text>
<text top="1032" left="63" width="100" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref380">nical concepts in Ebstein</a></text>
<text top="1030" left="162" width="117" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref380">’s anomaly. Ann Thorac Surg.</a></text>
<text top="1045" left="63" width="58" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref380">2009;88:1975</a></text>
<text top="1044" left="121" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref380">–81</a></text>
<text top="1045" left="134" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref380">.</a></text>
<text top="1068" left="63" width="113" height="9" font="5">4.3.5. Tetralogy of Fallot</text>
<text top="1082" left="63" width="35" height="9" font="5">S4.3.5-1.</text>
<text top="1082" left="100" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref381">Knauth AL, Gauvreau K, Powell AJ, et al.</a></text>
<text top="1095" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref381">Ventricular size and function assessed by cardiac</a></text>
<text top="143" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref381">MRI predict major adverse clinical outcomes late</a></text>
<text top="156" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref381">after tetralogy of Fallot repair. Heart. 2008;94:</a></text>
<text top="170" left="301" width="12" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref381">211</a></text>
<text top="168" left="313" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref381">–6</a></text>
<text top="170" left="323" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref381">.</a></text>
<text top="190" left="301" width="35" height="9" font="5">S4.3.5-2.</text>
<text top="190" left="339" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref382">Morray BH, McElhinney DB, Cheatham JP,</a></text>
<text top="203" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref382">et al. Risk of coronary artery compression among pa-</a></text>
<text top="217" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref382">tients referred for transcatheter pulmonary valve im-</a></text>
<text top="230" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref382">plantation: a multicenter experience. Circ Cardiovasc</a></text>
<text top="244" left="301" width="74" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref382">Interv. 2013;6:535</a></text>
<text top="242" left="375" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref382">–42</a></text>
<text top="244" left="389" width="3" height="9" font="5">.</text>
<text top="264" left="301" width="35" height="9" font="5">S4.3.5-3.</text>
<text top="264" left="339" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref383">Khairy P, Van Hare GF, Balaji S, et al. PACES/</a></text>
<text top="277" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref383">HRS expert consensus statement on the recognition</a></text>
<text top="291" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref383">and management of arrhythmias in adult congenital</a></text>
<text top="304" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref383">heart disease. Developed in partnership between the</a></text>
<text top="318" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref383">Pediatric and Congenital Electrophysiology Society</a></text>
<text top="331" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref383">(PACES) and the Heart Rhythm Society (HRS). Heart</a></text>
<text top="344" left="301" width="89" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref383">Rhythm. 2014;11:e102</a></text>
<text top="343" left="390" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref383">–65</a></text>
<text top="344" left="404" width="3" height="9" font="5">.</text>
<text top="364" left="301" width="36" height="9" font="5">S4.3.5-4.</text>
<text top="364" left="340" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref384">Dietl CA, Cazzaniga ME, Dubner SJ, et al.</a></text>
<text top="378" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref384">Life-threatening arrhythmias and RV dysfunction after</a></text>
<text top="391" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref384">surgical repair of tetralogy of Fallot. Comparison be-</a></text>
<text top="405" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref384">tween transventricular and transatrial approaches.</a></text>
<text top="418" left="301" width="95" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref384">Circulation. 1994;90:II7</a></text>
<text top="417" left="396" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref384">–12</a></text>
<text top="418" left="409" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref384">.</a></text>
<text top="438" left="301" width="35" height="9" font="5">S4.3.5-5.</text>
<text top="438" left="339" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref385">Khairy P, Landzberg MJ, Gatzoulis MA, et al.</a></text>
<text top="452" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref385">Value of programmed ventricular stimulation after</a></text>
<text top="465" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref385">tetralogy of Fallot repair: a multicenter study. Circu-</a></text>
<text top="479" left="301" width="92" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref385">lation. 2004;109:1994</a></text>
<text top="477" left="393" width="27" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref385">–2000</a></text>
<text top="479" left="420" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref385">.</a></text>
<text top="499" left="301" width="36" height="9" font="5">S4.3.5-6.</text>
<text top="499" left="340" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref386">Tsai SF, Chan DP, Ro PS, et al. Rate of</a></text>
<text top="512" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref386">inducible ventricular arrhythmia in adults with</a></text>
<text top="525" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref386">congenital heart disease. Am J Cardiol. 2010;106:</a></text>
<text top="539" left="301" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref386">730</a></text>
<text top="537" left="317" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref386">–6</a></text>
<text top="539" left="327" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref386">.</a></text>
<text top="559" left="301" width="35" height="9" font="5">S4.3.5-7.</text>
<text top="559" left="339" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref387">Khairy P. Programmed ventricular stimula-</a></text>
<text top="572" left="301" width="71" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref387">tion for risk strati</a></text>
<text top="571" left="372" width="146" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref387">ﬁcation in patients with tetralogy of</a></text>
<text top="586" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref387">Fallot: a Bayesian perspective. Nat Clin Pract Car-</a></text>
<text top="599" left="301" width="103" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref387">diovasc Med. 2007;4:292</a></text>
<text top="598" left="404" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref387">–3</a></text>
<text top="599" left="413" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref387">.</a></text>
<text top="619" left="301" width="36" height="9" font="5">S4.3.5-8.</text>
<text top="619" left="340" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref388">Lucron H, Marçon F, Bosser G, et al. Induc-</a></text>
<text top="633" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref388">tion of sustained ventricular tachycardia after surgical</a></text>
<text top="646" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref388">repair of tetralogy of Fallot. Am J Cardiol. 1999;83:</a></text>
<text top="660" left="301" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref388">1369</a></text>
<text top="658" left="321" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref388">–73</a></text>
<text top="660" left="334" width="3" height="9" font="5">.</text>
<text top="680" left="301" width="36" height="9" font="5">S4.3.5-9.</text>
<text top="680" left="340" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref389">Ferraz Cavalcanti PE, Sá MPBO, Santos CA,</a></text>
<text top="693" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref389">et al. Pulmonary valve replacement after operative</a></text>
<text top="706" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref389">repair of tetralogy of Fallot: meta-analysis and meta-</a></text>
<text top="720" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref389">regression of 3,118 patients from 48 studies. J Am</a></text>
<text top="733" left="301" width="106" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref389">Coll Cardiol. 2013;62:2227</a></text>
<text top="732" left="407" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref389">–43</a></text>
<text top="733" left="421" width="3" height="9" font="5">.</text>
<text top="753" left="301" width="40" height="9" font="5">S4.3.5-10.</text>
<text top="753" left="344" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref390">Gengsakul A, Harris L, Bradley TJ, et al. The</a></text>
<text top="767" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref390">impact of pulmonary valve replacement after tetralogy</a></text>
<text top="780" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref390">of Fallot repair: a matched comparison. Eur J Car-</a></text>
<text top="794" left="301" width="117" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref390">diothorac Surg. 2007;32:462</a></text>
<text top="792" left="418" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref390">–8</a></text>
<text top="794" left="427" width="3" height="9" font="5">.</text>
<text top="814" left="301" width="38" height="9" font="5">S4.3.5-11.</text>
<text top="814" left="342" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref391">Discigil B, Dearani JA, Puga FJ, et al. Late</a></text>
<text top="827" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref391">pulmonary valve replacement after repair of tetralogy</a></text>
<text top="841" left="301" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref391">of Fallot. J Thorac Cardiovasc Surg. 2001;121:344</a></text>
<text top="839" left="501" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref391">–51</a></text>
<text top="841" left="513" width="3" height="9" font="5">.</text>
<text top="861" left="301" width="39" height="9" font="5">S4.3.5-12.</text>
<text top="861" left="343" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref392">Oosterhof T, van Straten A, Vliegen HW,</a></text>
<text top="874" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref392">et al. Preoperative thresholds for pulmonary valve</a></text>
<text top="887" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref392">replacement in patients with corrected tetralogy of</a></text>
<text top="901" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref392">Fallot using cardiovascular magnetic resonance. Cir-</a></text>
<text top="914" left="301" width="92" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref392">culation. 2007;116:545</a></text>
<text top="913" left="393" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref392">–51</a></text>
<text top="914" left="406" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref392">.</a></text>
<text top="934" left="301" width="39" height="9" font="5">S4.3.5-13.</text>
<text top="934" left="343" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref393">Lee C, Kim YM, Lee C-H, et al. Outcomes of</a></text>
<text top="948" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref393">pulmonary valve replacement in 170 patients with</a></text>
<text top="961" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref393">chronic pulmonary regurgitation after relief of right</a></text>
<text top="975" left="301" width="60" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref393">ventricular out</a></text>
<text top="973" left="361" width="158" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref393">ﬂow tract obstruction: implications for</a></text>
<text top="988" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref393">optimal timing of pulmonary valve replacement. J Am</a></text>
<text top="1002" left="301" width="109" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref393">Coll Cardiol. 2012;60:1005</a></text>
<text top="1000" left="410" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref393">–14</a></text>
<text top="1002" left="423" width="3" height="9" font="5">.</text>
<text top="1022" left="301" width="40" height="9" font="5">S4.3.5-14.</text>
<text top="1022" left="344" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref394">Geva T. Indications for pulmonary valve</a></text>
<text top="1035" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref394">replacement in repaired tetralogy of Fallot: the quest</a></text>
<text top="1048" left="301" width="150" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref394">continues. Circulation. 2013;128:1855</a></text>
<text top="1047" left="451" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref394">–7</a></text>
<text top="1048" left="459" width="3" height="9" font="5">.</text>
<text top="1068" left="301" width="39" height="9" font="5">S4.3.5-15.</text>
<text top="1068" left="343" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref395">Koyak Z, de Groot JR, Bouma BJ, et al.</a></text>
<text top="1082" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref395">Symptomatic but not asymptomatic non-sustained</a></text>
<text top="1095" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref395">ventricular tachycardia is associated with appropriate</a></text>
<text top="143" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref395">implantable cardioverter therapy in tetralogy of Fallot.</a></text>
<text top="156" left="539" width="111" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref395">Int J Cardiol. 2013;167:1532</a></text>
<text top="155" left="651" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref395">–5</a></text>
<text top="156" left="659" width="3" height="9" font="5">.</text>
<text top="177" left="539" width="40" height="9" font="5">S4.3.5-16.</text>
<text top="177" left="583" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref396">Khairy P, Harris L, Landzberg MJ, et al.</a></text>
<text top="190" left="539" width="113" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref396">Implantable cardioverter-de</a></text>
<text top="188" left="652" width="104" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref396">ﬁbrillators in tetralogy of</a></text>
<text top="203" left="539" width="132" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref396">Fallot. Circulation. 2008;117:363</a></text>
<text top="202" left="671" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref396">–70</a></text>
<text top="203" left="686" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref396">.</a></text>
<text top="224" left="539" width="39" height="9" font="5">S4.3.5-17.</text>
<text top="224" left="582" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref397">Witte KK, Pepper CB, Cowan JC, et al.</a></text>
<text top="237" left="539" width="112" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref397">Implantable cardioverter-de</a></text>
<text top="235" left="652" width="105" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref397">ﬁbrillator therapy in adult</a></text>
<text top="251" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref397">patients with tetralogy of Fallot. Europace. 2008;10:</a></text>
<text top="264" left="539" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref397">926</a></text>
<text top="262" left="555" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref397">–30</a></text>
<text top="264" left="570" width="3" height="9" font="5">.</text>
<text top="287" left="539" width="25" height="9" font="5">4.3.6.</text>
<text top="287" left="574" width="24" height="9" font="5">Right</text>
<text top="287" left="609" width="41" height="9" font="5">Ventricle</text>
<text top="285" left="650" width="106" height="12" font="5">–to-Pulmonary Artery</text>
<text top="300" left="539" width="36" height="9" font="5">Conduit</text>
<text top="316" left="539" width="35" height="9" font="5">S4.3.6-1.</text>
<text top="316" left="578" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref398">Morray BH, McElhinney DB, Cheatham JP,</a></text>
<text top="329" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref398">et al. Risk of coronary artery compression among pa-</a></text>
<text top="342" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref398">tients referred for transcatheter pulmonary valve im-</a></text>
<text top="356" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref398">plantation: a multicenter experience. Circ Cardiovasc</a></text>
<text top="369" left="539" width="74" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref398">Interv. 2013;6:535</a></text>
<text top="368" left="613" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref398">–42</a></text>
<text top="369" left="627" width="3" height="9" font="5">.</text>
<text top="389" left="539" width="36" height="9" font="5">S4.3.6-2.</text>
<text top="389" left="579" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref399">Fraisse A, Assaidi A, Mauri L, et al. Coronary</a></text>
<text top="403" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref399">artery compression during intention to treat right</a></text>
<text top="416" left="539" width="51" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref399">ventricle out</a></text>
<text top="415" left="591" width="166" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref399">ﬂow with percutaneous pulmonary valve</a></text>
<text top="430" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref399">implantation: incidence, diagnosis, and outcome.</a></text>
<text top="443" left="539" width="169" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref399">Catheter Cardiovasc Interv. 2014;83:E260</a></text>
<text top="442" left="709" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref399">–8</a></text>
<text top="443" left="718" width="3" height="9" font="5">.</text>
<text top="463" left="539" width="36" height="9" font="5">S4.3.6-3.</text>
<text top="463" left="579" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref400">McElhinney DB, Benson LN, Eicken A,</a></text>
<text top="477" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref400">et al. Infective endocarditis after transcatheter pul-</a></text>
<text top="490" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref400">monary valve replacement using the Melody valve:</a></text>
<text top="504" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref400">combined results of 3 prospective North American</a></text>
<text top="517" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref400">and European studies. Circ Cardiovasc Interv. 2013;</a></text>
<text top="531" left="539" width="24" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref400">6:292</a></text>
<text top="529" left="563" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref400">–300</a></text>
<text top="531" left="584" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref400">.</a></text>
<text top="551" left="539" width="37" height="9" font="5">S4.3.6-4.</text>
<text top="551" left="580" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref401">McElhinney DB, Cheatham JP, Jones TK,</a></text>
<text top="564" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref401">et al. Stent fracture, valve dysfunction, and right</a></text>
<text top="578" left="539" width="61" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref401">ventricular out</a></text>
<text top="576" left="600" width="156" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref401">ﬂow tract reintervention after trans-</a></text>
<text top="591" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref401">catheter pulmonary valve implantation: patient-</a></text>
<text top="605" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref401">related and procedural risk factors in the US</a></text>
<text top="618" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref401">Melody Valve Trial. Circ Cardiovasc Interv. 2011;4:</a></text>
<text top="632" left="539" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref401">602</a></text>
<text top="630" left="556" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref401">–14</a></text>
<text top="632" left="569" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref401">.</a></text>
<text top="652" left="539" width="36" height="9" font="5">S4.3.6-5.</text>
<text top="652" left="579" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref402">Mainwaring RD, Pirolli T, Punn R, et al. Late</a></text>
<text top="665" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref402">repair of the native pulmonary valve in patients with</a></text>
<text top="679" left="539" width="65" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref402">pulmonary insuf</a></text>
<text top="677" left="605" width="152" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref402">ﬁciency after surgery for tetralogy of</a></text>
<text top="692" left="539" width="151" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref402">Fallot. Ann Thorac Surg. 2012;93:677</a></text>
<text top="690" left="690" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref402">–9</a></text>
<text top="692" left="700" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref402">.</a></text>
<text top="712" left="539" width="37" height="9" font="5">S4.3.6-6.</text>
<text top="712" left="579" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref403">Bauer BS, Zachariah S, Levi D, et al. Evalu-</a></text>
<text top="726" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref403">ation of peak pressure gradients in patients after</a></text>
<text top="739" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref403">Melody valve implantation: a comparison of cardiac</a></text>
<text top="753" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref403">catheterization and doppler echocardiography. Echo-</a></text>
<text top="766" left="539" width="89" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref403">cardiography. 2015;32</a></text>
<text top="766" left="628" width="3" height="9" font="5">.</text>
<text top="786" left="539" width="36" height="9" font="5">S4.3.6-7.</text>
<text top="786" left="579" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref404">McElhinney DB, Hellenbrand WE, Zahn EM,</a></text>
<text top="800" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref404">et al. Short- and medium-term outcomes after trans-</a></text>
<text top="813" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref404">catheter pulmonary valve placement in the expanded</a></text>
<text top="826" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref404">multicenter US Melody valve trial. Circulation. 2010;</a></text>
<text top="840" left="539" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref404">122:507</a></text>
<text top="838" left="571" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref404">–16</a></text>
<text top="840" left="584" width="3" height="9" font="5">.</text>
<text top="860" left="539" width="37" height="9" font="5">S4.3.6-8.</text>
<text top="860" left="579" width="69" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref405">Niemantsverdriet</a></text>
<text top="860" left="660" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref405">MBA,</a></text>
<text top="860" left="693" width="45" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref405">Ottenkamp</a></text>
<text top="860" left="750" width="7" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref405">J,</a></text>
<text top="874" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref405">Gauvreau K, et al. Determinants of right ventricular</a></text>
<text top="887" left="539" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref405">out</a></text>
<text top="885" left="553" width="204" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref405">ﬂow tract conduit longevity: a multinational anal-</a></text>
<text top="900" left="539" width="148" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref405">ysis. Congenit Heart Dis. 2008;3:176</a></text>
<text top="899" left="687" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref405">–84</a></text>
<text top="900" left="702" width="3" height="9" font="5">.</text>
<text top="921" left="539" width="37" height="9" font="5">S4.3.6-9.</text>
<text top="921" left="579" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref406">Batra AS, McElhinney DB, Wang W, et al.</a></text>
<text top="934" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref406">Cardiopulmonary exercise function among patients</a></text>
<text top="948" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref406">undergoing transcatheter pulmonary valve implanta-</a></text>
<text top="961" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref406">tion in the US Melody valve investigational trial. Am</a></text>
<text top="974" left="539" width="90" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref406">Heart J. 2012;163:280</a></text>
<text top="973" left="629" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref406">–7</a></text>
<text top="974" left="638" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref406">.</a></text>
<text top="995" left="539" width="41" height="9" font="5">S4.3.6-10.</text>
<text top="995" left="584" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref407">Zahn EM, Hellenbrand WE, Lock JE, et al.</a></text>
<text top="1008" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref407">Implantation of the Melody transcatheter pulmonary</a></text>
<text top="1021" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref407">valve in patients with a dysfunctional right ven-</a></text>
<text top="1035" left="539" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref407">tricular out</a></text>
<text top="1033" left="585" width="171" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref407">ﬂow tract conduit early results from the</a></text>
<text top="1048" left="539" width="213" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref407">U.S. clinical trial. J Am Coll Cardiol. 2009;54:1722</a></text>
<text top="1047" left="752" width="4" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref407">–</a></text>
<text top="1062" left="539" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref407">9</a></text>
<text top="1062" left="545" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref407">.</a></text>
<text top="1082" left="539" width="39" height="9" font="5">S4.3.6-11.</text>
<text top="1082" left="582" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref408">Brown JW, Ruzmetov M, Rodefeld MD, et al.</a></text>
<text top="1095" left="539" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref408">Right ventricular out</a></text>
<text top="1094" left="623" width="133" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref408">ﬂow tract reconstruction in Ross</a></text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="789" width="18" height="9" font="5">1553</text>
</page>
<page number="61" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref408">patients: does the homograft fare better? Ann Thorac</a></text>
<text top="156" left="108" width="83" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref408">Surg. 2008;86:1607</a></text>
<text top="155" left="190" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref408">–12</a></text>
<text top="156" left="203" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref408">.</a></text>
<text top="177" left="108" width="40" height="9" font="5">S4.3.6-12.</text>
<text top="177" left="151" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref409">Frigiola A, Tsang V, Nordmeyer J, et al.</a></text>
<text top="191" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref409">Current approaches to pulmonary regurgitation. Eur J</a></text>
<text top="204" left="108" width="130" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref409">Cardiothorac Surg. 2008;34:576</a></text>
<text top="202" left="238" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref409">–80</a></text>
<text top="204" left="254" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref409">.</a></text>
<text top="225" left="108" width="40" height="9" font="5">S4.3.6-13.</text>
<text top="225" left="151" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref410">Lurz P, Nordmeyer J, Giardini A, et al. Early</a></text>
<text top="238" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref410">versus late functional outcome after successful</a></text>
<text top="252" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref410">percutaneous pulmonary valve implantation: are the</a></text>
<text top="265" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref410">acute effects of altered right ventricular loading all we</a></text>
<text top="279" left="108" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref410">can expect? J Am Coll Cardiol. 2011;57:724</a></text>
<text top="277" left="281" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref410">–31</a></text>
<text top="279" left="293" width="3" height="9" font="5">.</text>
<text top="299" left="108" width="41" height="9" font="5">S4.3.6-14.</text>
<text top="299" left="152" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref411">Coats L, Khambadkone S, Derrick G, et al.</a></text>
<text top="313" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref411">Physiological and clinical consequences of relief of</a></text>
<text top="326" left="108" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref411">right ventricular out</a></text>
<text top="325" left="191" width="133" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref411">ﬂow tract obstruction late after</a></text>
<text top="340" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref411">repair of congenital heart defects. Circulation. 2006;</a></text>
<text top="353" left="108" width="35" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref411">113:2037</a></text>
<text top="351" left="143" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref411">–44</a></text>
<text top="353" left="157" width="3" height="9" font="5">.</text>
<text top="376" left="108" width="98" height="9" font="24">4.4. Complex Lesions</text>
<text top="394" left="108" width="188" height="9" font="5">4.4.1. Transposition of the Great Arteries</text>
<text top="412" left="108" width="217" height="9" font="5">4.4.1.1. Transposition of the Great Arteries With</text>
<text top="425" left="108" width="59" height="9" font="5">Atrial Switch</text>
<text top="441" left="108" width="41" height="9" font="5">S4.4.1.1-1.</text>
<text top="441" left="151" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref412">Khairy P, Landzberg MJ, Gatzoulis MA,</a></text>
<text top="455" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref412">et al. Transvenous pacing leads and systemic throm-</a></text>
<text top="468" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref412">boemboli in patients with intracardiac shunts: a</a></text>
<text top="481" left="108" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref412">multicenter study. Circulation. 2006;113:2391</a></text>
<text top="480" left="291" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref412">–7</a></text>
<text top="481" left="300" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref412">.</a></text>
<text top="502" left="108" width="42" height="9" font="5">S4.4.1.1-2.</text>
<text top="502" left="152" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref413">Khairy P, Harris L, Landzberg MJ, et al.</a></text>
<text top="516" left="108" width="85" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref413">Sudden death and de</a></text>
<text top="514" left="192" width="132" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref413">ﬁbrillators in transposition of the</a></text>
<text top="529" left="108" width="141" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref413">great arteries with intra-atrial baf</a></text>
<text top="527" left="249" width="76" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref413">ﬂes: a multicenter</a></text>
<text top="542" left="108" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref413">study. Circ Arrhythm Electrophysiol. 2008;1:250</a></text>
<text top="541" left="303" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref413">–7</a></text>
<text top="542" left="312" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref413">.</a></text>
<text top="565" left="108" width="217" height="9" font="5">4.4.1.2. Transposition of the Great Arteries With</text>
<text top="579" left="108" width="68" height="9" font="5">Arterial Switch</text>
<text top="595" left="108" width="42" height="9" font="5">S4.4.1.2-1.</text>
<text top="595" left="152" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref414">Khairy P, Clair M, Fernandes SM, et al.</a></text>
<text top="608" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref414">Cardiovascular outcomes after the arterial switch</a></text>
<text top="621" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref414">operation for D-transposition of the great arteries.</a></text>
<text top="635" left="108" width="99" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref414">Circulation. 2013;127:331</a></text>
<text top="633" left="207" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref414">–9</a></text>
<text top="635" left="216" width="3" height="9" font="5">.</text>
<text top="656" left="108" width="43" height="9" font="5">S4.4.1.2-2.</text>
<text top="656" left="153" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref415">Kempny A, Wustmann K, Borgia F, et al.</a></text>
<text top="669" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref415">Outcome in adult patients after arterial switch opera-</a></text>
<text top="683" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref415">tion for transposition of the great arteries. Int J Car-</a></text>
<text top="696" left="108" width="80" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref415">diol. 2013;167:2588</a></text>
<text top="694" left="187" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref415">–93</a></text>
<text top="696" left="202" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref415">.</a></text>
<text top="717" left="108" width="43" height="9" font="5">S4.4.1.2-3.</text>
<text top="717" left="153" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref416">Lim H-G, Kim W-H, Lee JR, et al. Long-</a></text>
<text top="730" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref416">term results of the arterial switch operation for</a></text>
<text top="744" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref416">ventriculo-arterial discordance. Eur J Cardiothorac</a></text>
<text top="757" left="108" width="73" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref416">Surg. 2013;43:325</a></text>
<text top="755" left="180" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref416">–34</a></text>
<text top="757" left="195" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref416">.</a></text>
<text top="778" left="108" width="44" height="9" font="5">S4.4.1.2-4.</text>
<text top="778" left="154" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref417">Ou P, Khraiche D, Celermajer DS, et al.</a></text>
<text top="791" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref417">Mechanisms of coronary complications after the arte-</a></text>
<text top="805" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref417">rial switch for transposition of the great arteries.</a></text>
<text top="818" left="108" width="164" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref417">J Thorac Cardiovasc Surg. 2013;145:1263</a></text>
<text top="816" left="271" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref417">–9</a></text>
<text top="818" left="281" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref417">.</a></text>
<text top="839" left="108" width="43" height="9" font="5">S4.4.1.2-5.</text>
<text top="839" left="153" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref418">Legendre A, Losay J, Touchot-Koné A,</a></text>
<text top="852" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref418">et al. Coronary events after arterial switch operation</a></text>
<text top="866" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref418">for transposition of the great arteries. Circulation.</a></text>
<text top="879" left="108" width="94" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref418">2003;108 suppl 1:II186</a></text>
<text top="878" left="201" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref418">–90</a></text>
<text top="879" left="217" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref418">.</a></text>
<text top="900" left="108" width="43" height="9" font="5">S4.4.1.2-6.</text>
<text top="900" left="154" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref419">Nishimura RA, Otto CM, Bonow RO, et al.</a></text>
<text top="913" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref419">2014 AHA/ACC guideline for the management of pa-</a></text>
<text top="927" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref419">tients with valvular heart disease: a report of the</a></text>
<text top="940" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref419">American College of Cardiology/American Heart As-</a></text>
<text top="954" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref419">sociation Task Force on Practice Guidelines. Circula-</a></text>
<text top="967" left="108" width="79" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref419">tion. 2014;129:e521</a></text>
<text top="965" left="186" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref419">–643</a></text>
<text top="967" left="206" width="3" height="9" font="5">.</text>
<text top="988" left="108" width="43" height="9" font="5">S4.4.1.2-7.</text>
<text top="988" left="153" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref420">Fihn SD, Gardin JM, Abrams J, et al. 2012</a></text>
<text top="1001" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref420">ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for</a></text>
<text top="1015" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref420">the diagnosis and management of patients with stable</a></text>
<text top="1028" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref420">ischemic heart disease: a report of the American Col-</a></text>
<text top="1042" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref420">lege of Cardiology Foundation/American Heart Asso-</a></text>
<text top="1055" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref420">ciation Task Force on Practice Guidelines, and the</a></text>
<text top="1069" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref420">American College of Physicians, American Association</a></text>
<text top="1082" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref420">for Thoracic Surgery, Preventive Cardiovascular Nurses</a></text>
<text top="1095" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref420">Association, Society for Cardiovascular Angiography</a></text>
<text top="143" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref420">and Interventions, and Society of Thoracic Surgeons.</a></text>
<text top="156" left="346" width="107" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref420">Circulation. 2012;126:e354</a></text>
<text top="155" left="452" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref420">–471</a></text>
<text top="156" left="470" width="3" height="9" font="5">.</text>
<text top="175" left="346" width="43" height="9" font="5">S4.4.1.2-8.</text>
<text top="175" left="392" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref421">Fihn SD, Blankenship JC, Alexander KP,</a></text>
<text top="188" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref421">et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused</a></text>
<text top="202" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref421">update of the guideline for the diagnosis and man-</a></text>
<text top="215" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref421">agement of patients with stable ischemic heart dis-</a></text>
<text top="229" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref421">ease: a report of the American College of Cardiology/</a></text>
<text top="242" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref421">American Heart Association Task Force on Practice</a></text>
<text top="256" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref421">Guidelines, and the American Association for Thoracic</a></text>
<text top="269" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref421">Surgery, Preventive Cardiovascular Nurses Association,</a></text>
<text top="283" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref421">Society for Cardiovascular Angiography and In-</a></text>
<text top="296" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref421">terventions, and Society of Thoracic Surgeons. J Am</a></text>
<text top="310" left="346" width="108" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref421">Coll Cardiol. 2014;64:1929</a></text>
<text top="308" left="454" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref421">–49</a></text>
<text top="310" left="469" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref421">.</a></text>
<text top="332" left="346" width="217" height="9" font="5">4.4.1.3. Congenitally Corrected Transposition of</text>
<text top="346" left="346" width="82" height="9" font="5">the Great Arteries</text>
<text top="359" left="346" width="42" height="9" font="5">S4.4.1.3-1.</text>
<text top="359" left="391" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref422">Lewis M, Ginns J, Rosenbaum M. Is sys-</a></text>
<text top="373" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref422">temic right ventricular function by cardiac MRI related</a></text>
<text top="386" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref422">to the degree of tricuspid regurgitation in congenitally</a></text>
<text top="400" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref422">corrected transposition of the great arteries? Int J</a></text>
<text top="413" left="346" width="89" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref422">Cardiol. 2014;174:586</a></text>
<text top="412" left="434" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref422">–9</a></text>
<text top="413" left="444" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref422">.</a></text>
<text top="432" left="346" width="43" height="9" font="5">S4.4.1.3-2.</text>
<text top="432" left="392" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref423">Grewal J, Crean A, Garceau P, et al. Sub-</a></text>
<text top="445" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref423">aortic right ventricular characteristics and relationship</a></text>
<text top="459" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref423">to exercise capacity in congenitally corrected trans-</a></text>
<text top="472" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref423">position of the great arteries. J Am Soc Echocardiogr.</a></text>
<text top="486" left="346" width="52" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref423">2012;25:1215</a></text>
<text top="484" left="397" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref423">–21</a></text>
<text top="486" left="410" width="3" height="9" font="5">.</text>
<text top="504" left="346" width="43" height="9" font="5">S4.4.1.3-3.</text>
<text top="504" left="392" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref424">Mongeon F-P, Connolly HM, Dearani JA,</a></text>
<text top="518" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref424">et al. Congenitally corrected transposition of the great</a></text>
<text top="531" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref424">arteries ventricular function at the time of systemic</a></text>
<text top="544" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref424">atrioventricular valve replacement predicts long-term</a></text>
<text top="558" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref424">ventricular function. J Am Coll Cardiol. 2011;57:</a></text>
<text top="571" left="346" width="23" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref424">2008</a></text>
<text top="570" left="368" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref424">–17</a></text>
<text top="571" left="381" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref424">.</a></text>
<text top="590" left="346" width="44" height="9" font="5">S4.4.1.3-4.</text>
<text top="590" left="392" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref425">Prieto LR, Hordof AJ, Secic M, et al. Pro-</a></text>
<text top="603" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref425">gressive tricuspid valve disease in patients with</a></text>
<text top="617" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref425">congenitally corrected transposition of the great ar-</a></text>
<text top="630" left="346" width="128" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref425">teries. Circulation. 1998;98:997</a></text>
<text top="629" left="474" width="25" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref425">–1005</a></text>
<text top="630" left="499" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref425">.</a></text>
<text top="649" left="346" width="43" height="9" font="5">S4.4.1.3-5.</text>
<text top="649" left="392" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref426">Buber J, McElhinney DB, Valente AM, et al.</a></text>
<text top="662" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref426">Tricuspid valve regurgitation in congenitally corrected</a></text>
<text top="676" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref426">transposition of the great arteries and a left ventricle</a></text>
<text top="689" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref426">to pulmonary artery conduit. Ann Thorac Surg. 2015;</a></text>
<text top="703" left="346" width="33" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref426">99:1348</a></text>
<text top="701" left="379" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref426">–56</a></text>
<text top="703" left="394" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref426">.</a></text>
<text top="731" left="346" width="217" height="9" font="5">4.4.2. Fontan Palliation of Single Ventricle</text>
<text top="745" left="346" width="217" height="9" font="5">Physiology (Including Tricuspid Atresia and</text>
<text top="758" left="346" width="126" height="9" font="5">Double Inlet Left Ventricle)</text>
<text top="772" left="346" width="35" height="9" font="5">S4.4.2-1.</text>
<text top="772" left="384" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref427">Khairy P, Fernandes SM, Mayer JE Jr., et al.</a></text>
<text top="785" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref427">Long-term survival, modes of death, and predictors of</a></text>
<text top="799" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref427">mortality in patients with Fontan surgery. Circulation.</a></text>
<text top="812" left="346" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref427">2008;117:85</a></text>
<text top="811" left="396" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref427">–92</a></text>
<text top="812" left="411" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref427">.</a></text>
<text top="831" left="346" width="36" height="9" font="5">S4.4.2-2.</text>
<text top="831" left="385" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref428">Gatzoulis MA, Munk MD, Williams WG, et al.</a></text>
<text top="844" left="346" width="11" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref428">De</a></text>
<text top="843" left="357" width="206" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref428">ﬁnitive palliation with cavopulmonary or aorto-</a></text>
<text top="858" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref428">pulmonary shunts for adults with single ventricle</a></text>
<text top="871" left="346" width="124" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref428">physiology. Heart. 2000;83:51</a></text>
<text top="869" left="469" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref428">–7</a></text>
<text top="871" left="478" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref428">.</a></text>
<text top="890" left="346" width="36" height="9" font="5">S4.4.2-3.</text>
<text top="890" left="385" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref429">Cordina R, O</a></text>
<text top="888" left="434" width="129" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref429">’Meagher S, Gould H, et al. Skel-</a></text>
<text top="903" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref429">etal muscle abnormalities and exercise capacity in adults</a></text>
<text top="917" left="346" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref429">with a Fontan circulation. Heart. 2013;99:1530</a></text>
<text top="915" left="528" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref429">–4</a></text>
<text top="917" left="537" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref429">.</a></text>
<text top="935" left="346" width="37" height="9" font="5">S4.4.2-4.</text>
<text top="935" left="386" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref430">Dulfer K, Duppen N, Blom NA, et al. Effects</a></text>
<text top="949" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref430">of exercise training on behavioral and emotional</a></text>
<text top="962" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref430">problems in adolescents with tetralogy of Fallot or a</a></text>
<text top="975" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref430">Fontan circulation: a randomized controlled trial. Int J</a></text>
<text top="989" left="346" width="92" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref430">Cardiol. 2014;172:e425</a></text>
<text top="987" left="438" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref430">–7</a></text>
<text top="989" left="446" width="3" height="9" font="5">.</text>
<text top="1007" left="346" width="36" height="9" font="5">S4.4.2-5.</text>
<text top="1007" left="385" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref431">Inai K, Saita Y, Takeda S, et al. Skeletal</a></text>
<text top="1021" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref431">muscle hemodynamics and endothelial function in</a></text>
<text top="1034" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref431">patients after Fontan operation. Am J Cardiol. 2004;</a></text>
<text top="1048" left="346" width="28" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref431">93:792</a></text>
<text top="1046" left="374" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref431">–7</a></text>
<text top="1048" left="382" width="3" height="9" font="5">.</text>
<text top="1066" left="346" width="37" height="9" font="5">S4.4.2-6.</text>
<text top="1066" left="386" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref432">Kiesewetter CH, Sheron N, Vettukattill JJ,</a></text>
<text top="1080" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref432">et al. Hepatic changes in the failing Fontan circulation.</a></text>
<text top="1093" left="346" width="80" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref432">Heart. 2007;93:579</a></text>
<text top="1092" left="426" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref432">–84</a></text>
<text top="1093" left="441" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref432">.</a></text>
<text top="143" left="584" width="36" height="9" font="5">S4.4.2-7.</text>
<text top="143" left="624" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref433">Seddio F, Gorislavets N, Iacovoni A, et al. Is</a></text>
<text top="156" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref433">heart transplantation for complex congenital heart</a></text>
<text top="170" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref433">disease a good option? A 25-year single centre expe-</a></text>
<text top="183" left="584" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref433">rience. Eur J Cardiothorac Surg. 2013;43:605</a></text>
<text top="182" left="766" width="11" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref433">–11</a></text>
<text top="183" left="777" width="3" height="9" font="5">.</text>
<text top="202" left="584" width="37" height="9" font="5">S4.4.2-8.</text>
<text top="202" left="624" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref434">Hebson CL, McCabe NM, Elder RW, et al.</a></text>
<text top="215" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref434">Hemodynamic phenotype of the failing Fontan in an</a></text>
<text top="229" left="584" width="185" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref434">adult population. Am J Cardiol. 2013;112:1943</a></text>
<text top="227" left="769" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref434">–7</a></text>
<text top="229" left="778" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref434">.</a></text>
<text top="247" left="584" width="37" height="9" font="5">S4.4.2-9.</text>
<text top="247" left="624" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref435">Davies RR, Sorabella RA, Yang J, et al. Out-</a></text>
<text top="261" left="584" width="135" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref435">comes after transplantation for</a></text>
<text top="259" left="725" width="77" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref435">“failed” Fontan: a</a></text>
<text top="274" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref435">single-institution experience. J Thorac Cardiovasc</a></text>
<text top="288" left="584" width="80" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref435">Surg. 2012;143:1183</a></text>
<text top="286" left="664" width="37" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref435">–1192, e4</a></text>
<text top="288" left="702" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref435">.</a></text>
<text top="306" left="584" width="41" height="9" font="5">S4.4.2-10.</text>
<text top="306" left="629" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref436">Gamba A, Merlo M, Fiocchi R, et al. Heart</a></text>
<text top="320" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref436">transplantation in patients with previous Fontan op-</a></text>
<text top="333" left="584" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref436">erations. J Thorac Cardiovasc Surg. 2004;127:555</a></text>
<text top="331" left="783" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref436">–62</a></text>
<text top="333" left="798" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref436">.</a></text>
<text top="352" left="584" width="39" height="9" font="5">S4.4.2-11.</text>
<text top="352" left="627" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref437">Jayakumar</a></text>
<text top="352" left="678" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref437">KA,</a></text>
<text top="352" left="701" width="40" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref437">Addonizio</a></text>
<text top="352" left="750" width="11" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref437">LJ,</a></text>
<text top="352" left="771" width="30" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref437">Kichuk-</a></text>
<text top="365" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref437">Chrisant MR, et al. Cardiac transplantation after the</a></text>
<text top="379" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref437">Fontan or Glenn procedure. J Am Coll Cardiol. 2004;</a></text>
<text top="392" left="584" width="35" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref437">44:2065</a></text>
<text top="390" left="619" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref437">–72</a></text>
<text top="392" left="632" width="3" height="9" font="5">.</text>
<text top="410" left="584" width="40" height="9" font="5">S4.4.2-12.</text>
<text top="410" left="627" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref438">Backer CL, Russell HM, Pahl E, et al. Heart</a></text>
<text top="424" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref438">transplantation for the failing Fontan. Ann Thorac</a></text>
<text top="437" left="584" width="77" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref438">Surg. 2013;96:1413</a></text>
<text top="436" left="661" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref438">–9</a></text>
<text top="437" left="671" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref438">.</a></text>
<text top="456" left="584" width="40" height="9" font="5">S4.4.2-13.</text>
<text top="456" left="627" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref439">Triedman JK. Arrhythmias in adults with</a></text>
<text top="469" left="584" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref439">congenital heart disease. Heart. 2002;87:383</a></text>
<text top="468" left="767" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref439">–9</a></text>
<text top="469" left="777" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref439">.</a></text>
<text top="488" left="584" width="41" height="9" font="5">S4.4.2-14.</text>
<text top="488" left="628" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref440">Yap S-C, Harris L, Silversides CK, et al.</a></text>
<text top="501" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref440">Outcome of intra-atrial re-entrant tachycardia catheter</a></text>
<text top="515" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref440">ablation in adults with congenital heart disease:</a></text>
<text top="528" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref440">negative impact of age and complex atrial surgery.</a></text>
<text top="542" left="584" width="131" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref440">J Am Coll Cardiol. 2010;56:1589</a></text>
<text top="540" left="716" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref440">–96</a></text>
<text top="542" left="731" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref440">.</a></text>
<text top="560" left="584" width="40" height="9" font="5">S4.4.2-15.</text>
<text top="560" left="627" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref441">de Groot NMS, Atary JZ, Blom NA, et al.</a></text>
<text top="574" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref441">Long-term outcome after ablative therapy of post-</a></text>
<text top="587" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref441">operative atrial tachyarrhythmia in patients with</a></text>
<text top="601" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref441">congenital heart disease and characteristics of atrial</a></text>
<text top="614" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref441">tachyarrhythmia recurrences. Circ Arrhythm Electro-</a></text>
<text top="628" left="584" width="79" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref441">physiol. 2010;3:148</a></text>
<text top="626" left="663" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref441">–54</a></text>
<text top="628" left="678" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref441">.</a></text>
<text top="646" left="584" width="41" height="9" font="5">S4.4.2-16.</text>
<text top="646" left="628" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref442">Aboulhosn J, Williams R, Shivkumar K, et al.</a></text>
<text top="659" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref442">Arrhythmia recurrence in adult patients with single</a></text>
<text top="673" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref442">ventricle physiology following surgical Fontan con-</a></text>
<text top="686" left="584" width="163" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref442">version. Congenit Heart Dis. 2010;5:430</a></text>
<text top="685" left="747" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref442">–4</a></text>
<text top="686" left="756" width="3" height="9" font="5">.</text>
<text top="705" left="584" width="40" height="9" font="5">S4.4.2-17.</text>
<text top="705" left="627" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref443">Mavroudis C, Deal BJ, Backer CL, et al. J.</a></text>
<text top="718" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref443">Maxwell Chamberlain Memorial Paper for congenital</a></text>
<text top="732" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref443">heart surgery. 111 Fontan conversions with arrhythmia</a></text>
<text top="745" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref443">surgery: surgical lessons and outcomes. Ann Thorac</a></text>
<text top="759" left="584" width="80" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref443">Surg. 2007;84:1457</a></text>
<text top="757" left="664" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref443">–65</a></text>
<text top="759" left="679" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref443">.</a></text>
<text top="777" left="584" width="41" height="9" font="5">S4.4.2-18.</text>
<text top="777" left="628" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref444">Takahashi K, Fynn-Thompson F, Cecchin F,</a></text>
<text top="791" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref444">et al. Clinical outcomes of Fontan conversion surgery</a></text>
<text top="804" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref444">with and without associated arrhythmia intervention.</a></text>
<text top="818" left="584" width="112" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref444">Int J Cardiol. 2009;137:260</a></text>
<text top="816" left="696" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref444">–6</a></text>
<text top="818" left="706" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref444">.</a></text>
<text top="836" left="584" width="41" height="9" font="5">S4.4.2-19.</text>
<text top="836" left="628" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref445">Hebert A, Mikkelsen UR, Thilen U, et al.</a></text>
<text top="850" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref445">Bosentan improves exercise capacity in adolescents</a></text>
<text top="863" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref445">and adults after Fontan operation: the TEMPO</a></text>
<text top="876" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref445">(Treatment With Endothelin Receptor Antagonist in</a></text>
<text top="890" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref445">Fontan Patients, a Randomized, Placebo-Controlled,</a></text>
<text top="903" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref445">Double-Blind Study Measuring Peak Oxygen Con-</a></text>
<text top="917" left="584" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref445">sumption) study. Circulation. 2014;130:2021</a></text>
<text top="915" left="762" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref445">–30</a></text>
<text top="917" left="777" width="3" height="9" font="5">.</text>
<text top="935" left="584" width="42" height="9" font="5">S4.4.2-20.</text>
<text top="935" left="630" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref446">Giardini A, Balducci A, Specchia S, et al.</a></text>
<text top="949" left="584" width="67" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref446">Effect of sildena</a></text>
<text top="947" left="651" width="151" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref446">ﬁl on haemodynamic response to ex-</a></text>
<text top="962" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref446">ercise and exercise capacity in Fontan patients. Eur</a></text>
<text top="976" left="584" width="92" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref446">Heart J. 2008;29:1681</a></text>
<text top="974" left="676" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref446">–7</a></text>
<text top="976" left="684" width="3" height="9" font="5">.</text>
<text top="994" left="584" width="40" height="9" font="5">S4.4.2-21.</text>
<text top="994" left="627" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref447">Goldberg DJ, French B, McBride MG, et al.</a></text>
<text top="1008" left="584" width="92" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref447">Impact of oral sildena</a></text>
<text top="1006" left="676" width="125" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref447">ﬁl on exercise performance in</a></text>
<text top="1021" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref447">children and young adults after the Fontan operation:</a></text>
<text top="1035" left="584" width="4" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref447">a</a></text>
<text top="1035" left="599" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref447">randomized,</a></text>
<text top="1035" left="659" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref447">double-blind,</a></text>
<text top="1035" left="723" width="78" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref447">placebo-controlled,</a></text>
<text top="1048" left="584" width="165" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref447">crossover trial. Circulation. 2011;123:1185</a></text>
<text top="1046" left="749" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref447">–93</a></text>
<text top="1048" left="764" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref447">.</a></text>
<text top="1067" left="584" width="41" height="9" font="5">S4.4.2-22.</text>
<text top="1067" left="628" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref448">Ovaert C, Thijs D, Dewolf D, et al. The ef-</a></text>
<text top="1080" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref448">fect of bosentan in patients with a failing Fontan cir-</a></text>
<text top="1093" left="584" width="149" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref448">culation. Cardiol Young. 2009;19:331</a></text>
<text top="1092" left="734" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref448">–9</a></text>
<text top="1093" left="743" width="3" height="9" font="5">.</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="19" height="9" font="5">1554</text>
</page>
<page number="62" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="41" height="9" font="5">S4.4.2-23.</text>
<text top="143" left="107" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref449">Bowater SE, Weaver RA, Thorne SA, et al.</a></text>
<text top="156" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref449">The safety and effects of bosentan in patients with a</a></text>
<text top="170" left="63" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref449">Fontan circulation. Congenit Heart Dis. 2012;7:243</a></text>
<text top="168" left="266" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref449">–9</a></text>
<text top="170" left="276" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref449">.</a></text>
<text top="190" left="63" width="42" height="9" font="5">S4.4.2-24.</text>
<text top="190" left="108" width="139" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref450">Derk G, Houser L, Miner P, et al. Ef</a></text>
<text top="189" left="246" width="33" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref450">ﬁcacy of</a></text>
<text top="204" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref450">endothelin blockade in adults with Fontan physiology.</a></text>
<text top="217" left="63" width="128" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref450">Congenit Heart Dis. 2015;10:E11</a></text>
<text top="215" left="191" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref450">–6</a></text>
<text top="217" left="201" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref450">.</a></text>
<text top="237" left="63" width="41" height="9" font="5">S4.4.2-25.</text>
<text top="237" left="107" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref451">Schuuring MJ, Vis JC, van Dijk APJ, et al.</a></text>
<text top="251" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref451">Impact of bosentan on exercise capacity in adults after</a></text>
<text top="264" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref451">the Fontan procedure: a randomized controlled trial.</a></text>
<text top="278" left="63" width="118" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref451">Eur J Heart Fail. 2013;15:690</a></text>
<text top="276" left="181" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref451">–8</a></text>
<text top="278" left="191" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref451">.</a></text>
<text top="298" left="63" width="42" height="9" font="5">S4.4.2-26.</text>
<text top="298" left="108" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref452">Potter BJ, Leong-Sit P, Fernandes SM,</a></text>
<text top="312" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref452">et al. Effect of aspirin and warfarin therapy on</a></text>
<text top="325" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref452">thromboembolic events in patients with univentricular</a></text>
<text top="338" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref452">hearts and Fontan palliation. Int J Cardiol. 2013;168:</a></text>
<text top="352" left="63" width="22" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref452">3940</a></text>
<text top="350" left="85" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref452">–3</a></text>
<text top="352" left="93" width="3" height="9" font="5">.</text>
<text top="372" left="63" width="41" height="9" font="5">S4.4.2-27.</text>
<text top="372" left="107" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref453">Harper AR, Crossland DS, Perri G, et al. Is</a></text>
<text top="386" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref453">alternative cardiac surgery an option in adults with</a></text>
<text top="399" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref453">congenital heart disease referred for thoracic organ</a></text>
<text top="413" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref453">transplantation? Eur J Cardiothorac Surg. 2013;43:</a></text>
<text top="426" left="63" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref453">344</a></text>
<text top="424" left="78" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref453">–51</a></text>
<text top="426" left="91" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref453">.</a></text>
<text top="449" left="63" width="213" height="9" font="5">4.4.4. Severe PAH and Eisenmenger Syndrome</text>
<text top="467" left="63" width="89" height="9" font="5">4.4.4.1. Severe PAH</text>
<text top="482" left="63" width="43" height="9" font="5">S4.4.4.1-1.</text>
<text top="482" left="108" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref454">D</a></text>
<text top="481" left="114" width="165" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref454">’Alto M, Romeo E, Argiento P, et al. He-</a></text>
<text top="496" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref454">modynamics of patients developing pulmonary arterial</a></text>
<text top="509" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref454">hypertension after shunt closure. Int J Cardiol. 2013;</a></text>
<text top="523" left="63" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref454">168:3797</a></text>
<text top="521" left="100" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref454">–801</a></text>
<text top="523" left="119" width="3" height="9" font="5">.</text>
<text top="543" left="63" width="44" height="9" font="5">S4.4.4.1-2.</text>
<text top="543" left="109" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref455">Barst RJ, Ivy DD, Foreman AJ, et al. Four-</a></text>
<text top="556" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref455">and seven-year outcomes of patients with congenital</a></text>
<text top="570" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref455">heart disease-associated pulmonary arterial hyper-</a></text>
<text top="583" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref455">tension (from the REVEAL Registry). Am J Cardiol.</a></text>
<text top="597" left="63" width="51" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref455">2014;113:147</a></text>
<text top="595" left="114" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref455">–55</a></text>
<text top="597" left="128" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref455">.</a></text>
<text top="617" left="63" width="44" height="9" font="5">S4.4.4.1-3.</text>
<text top="617" left="109" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref456">Duffels MGJ, Engelfriet PM, Berger RMF,</a></text>
<text top="630" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref456">et al. Pulmonary arterial hypertension in congenital</a></text>
<text top="644" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref456">heart disease: an epidemiologic perspective from a</a></text>
<text top="657" left="63" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref456">Dutch registry. Int J Cardiol. 2007;120:198</a></text>
<text top="656" left="236" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref456">–204</a></text>
<text top="657" left="256" width="3" height="9" font="5">.</text>
<text top="678" left="63" width="44" height="9" font="5">S4.4.4.1-4.</text>
<text top="678" left="110" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref457">Engelfriet PM, Duffels MGJ, Möller T, et al.</a></text>
<text top="691" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref457">Pulmonary arterial hypertension in adults born with a</a></text>
<text top="705" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref457">heart septal defect: the Euro Heart Survey on adult</a></text>
<text top="718" left="63" width="184" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref457">congenital heart disease. Heart. 2007;93:682</a></text>
<text top="716" left="246" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref457">–7</a></text>
<text top="718" left="255" width="3" height="9" font="5">.</text>
<text top="738" left="63" width="44" height="9" font="5">S4.4.4.1-5.</text>
<text top="738" left="109" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref458">Lowe BS, Therrien J, Ionescu-Ittu R, et al.</a></text>
<text top="752" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref458">Diagnosis of pulmonary hypertension in the congenital</a></text>
<text top="765" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref458">heart disease adult population impact on outcomes.</a></text>
<text top="779" left="63" width="125" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref458">J Am Coll Cardiol. 2011;58:538</a></text>
<text top="777" left="187" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref458">–46</a></text>
<text top="779" left="202" width="3" height="9" font="5">.</text>
<text top="799" left="63" width="44" height="9" font="5">S4.4.4.1-6.</text>
<text top="799" left="110" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref459">Manes A, Palazzini M, Leci E, et al. Current</a></text>
<text top="812" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref459">era survival of patients with pulmonary arterial hy-</a></text>
<text top="826" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref459">pertension associated with congenital heart disease: a</a></text>
<text top="839" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref459">comparison between clinical subgroups. Eur Heart J.</a></text>
<text top="853" left="63" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref459">2014;35:716</a></text>
<text top="851" left="111" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref459">–24</a></text>
<text top="853" left="126" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref459">.</a></text>
<text top="873" left="63" width="44" height="9" font="5">S4.4.4.1-7.</text>
<text top="873" left="109" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref460">Gabriels C, De Meester P, Pasquet A, et al.</a></text>
<text top="887" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref460">A different view on predictors of pulmonary hyper-</a></text>
<text top="900" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref460">tension in secundum atrial septal defect. Int J Cardiol.</a></text>
<text top="913" left="63" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref460">2014;176:833</a></text>
<text top="912" left="117" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref460">–40</a></text>
<text top="913" left="132" width="3" height="9" font="5">.</text>
<text top="934" left="63" width="44" height="9" font="5">S4.4.4.1-8.</text>
<text top="934" left="110" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref461">O</a></text>
<text top="932" left="116" width="163" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref461">’Donnell C, Ruygrok PN, Whyte K, et al.</a></text>
<text top="947" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref461">Progressive pulmonary hypertension post atrial septal</a></text>
<text top="961" left="63" width="91" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref461">defect device closure</a></text>
<text top="959" left="154" width="126" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref461">—early symptomatic improve-</a></text>
<text top="974" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref461">ment may not predict outcome. Heart Lung Circ. 2010;</a></text>
<text top="987" left="63" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref461">19:713</a></text>
<text top="986" left="88" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref461">–6</a></text>
<text top="987" left="97" width="3" height="9" font="5">.</text>
<text top="1008" left="63" width="44" height="9" font="5">S4.4.4.1-9.</text>
<text top="1008" left="110" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref462">Van De Bruaene A, Delcroix M, Pasquet A,</a></text>
<text top="1021" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref462">et al. The importance of pulmonary artery pressures on</a></text>
<text top="1035" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref462">late atrial arrhythmia in transcatheter and surgically</a></text>
<text top="1048" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref462">closed ASD type secundum. Int J Cardiol. 2011;152:</a></text>
<text top="1062" left="63" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref462">192</a></text>
<text top="1060" left="77" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref462">–5</a></text>
<text top="1062" left="86" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref462">.</a></text>
<text top="1082" left="63" width="49" height="9" font="5">S4.4.4.1-10.</text>
<text top="1082" left="114" width="166" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref463">Van De Bruaene A, Moons P, Belmans A,</a></text>
<text top="1095" left="63" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref463">et al. Predictive model for late atrial arrhythmia after</a></text>
<text top="143" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref463">closure of an atrial septal defect. Int J Cardiol. 2013;</a></text>
<text top="156" left="301" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref463">164:318</a></text>
<text top="155" left="333" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref463">–22</a></text>
<text top="156" left="346" width="3" height="9" font="5">.</text>
<text top="175" left="301" width="47" height="9" font="5">S4.4.4.1-11.</text>
<text top="175" left="351" width="167" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref464">Berner M, Beghetti M, Spahr-Schopfer I,</a></text>
<text top="188" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref464">et al. Inhaled nitric oxide to test the vasodilator ca-</a></text>
<text top="202" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref464">pacity of the pulmonary vascular bed in children with</a></text>
<text top="215" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref464">long-standing pulmonary hypertension and congenital</a></text>
<text top="229" left="301" width="164" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref464">heart disease. Am J Cardiol. 1996;77:532</a></text>
<text top="227" left="465" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref464">–5</a></text>
<text top="229" left="474" width="3" height="9" font="5">.</text>
<text top="247" left="301" width="47" height="9" font="5">S4.4.4.1-12.</text>
<text top="247" left="352" width="167" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref465">Balint OH, Samman A, Haberer K, et al.</a></text>
<text top="261" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref465">Outcomes in patients with pulmonary hypertension</a></text>
<text top="274" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref465">undergoing percutaneous atrial septal defect closure.</a></text>
<text top="288" left="301" width="85" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref465">Heart. 2008;94:1189</a></text>
<text top="286" left="386" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref465">–93</a></text>
<text top="288" left="400" width="3" height="9" font="5">.</text>
<text top="306" left="301" width="47" height="9" font="5">S4.4.4.1-13.</text>
<text top="306" left="352" width="24" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref466">Goren</a></text>
<text top="305" left="375" width="143" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref466">ﬂo M, Gu H, Xu Z. Peri-operative</a></text>
<text top="320" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref466">pulmonary hypertension in paediatric patients: current</a></text>
<text top="333" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref466">strategies in children with congenital heart disease.</a></text>
<text top="347" left="301" width="97" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref466">Cardiology. 2010;116:10</a></text>
<text top="345" left="398" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref466">–7</a></text>
<text top="347" left="407" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref466">.</a></text>
<text top="365" left="301" width="48" height="9" font="5">S4.4.4.1-14.</text>
<text top="365" left="352" width="166" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref467">Huang J-B, Liu Y-L, Yu C-T, et al. Lung</a></text>
<text top="379" left="301" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref467">biopsy</a></text>
<text top="377" left="330" width="188" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref467">ﬁndings in previously inoperable patients with</a></text>
<text top="392" left="301" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref467">severe</a></text>
<text top="392" left="336" width="43" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref467">pulmonary</a></text>
<text top="392" left="388" width="52" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref467">hypertension</a></text>
<text top="392" left="450" width="41" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref467">associated</a></text>
<text top="392" left="501" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref467">with</a></text>
<text top="405" left="301" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref467">congenital heart disease. Int J Cardiol. 2011;151:76</a></text>
<text top="404" left="501" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref467">–83</a></text>
<text top="405" left="516" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref467">.</a></text>
<text top="424" left="301" width="47" height="9" font="5">S4.4.4.1-15.</text>
<text top="424" left="352" width="167" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref468">Neutze JM, Ishikawa T, Clarkson PM, et al.</a></text>
<text top="437" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref468">Assessment and follow-up of patients with ventricular</a></text>
<text top="451" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref468">septal defect and elevated pulmonary vascular resis-</a></text>
<text top="464" left="301" width="134" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref468">tance. Am J Cardiol. 1989;63:327</a></text>
<text top="463" left="435" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref468">–31</a></text>
<text top="464" left="448" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref468">.</a></text>
<text top="483" left="301" width="48" height="9" font="5">S4.4.4.1-16.</text>
<text top="483" left="352" width="166" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref469">Steele PM, Fuster V, Cohen M, et al. Iso-</a></text>
<text top="496" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref469">lated atrial septal defect with pulmonary vascular</a></text>
<text top="510" left="301" width="77" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref469">obstructive disease</a></text>
<text top="508" left="378" width="140" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref469">—long-term follow-up and predic-</a></text>
<text top="523" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref469">tion of outcome after surgical correction. Circulation.</a></text>
<text top="537" left="301" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref469">1987;76:1037</a></text>
<text top="535" left="355" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref469">–42</a></text>
<text top="537" left="369" width="3" height="9" font="5">.</text>
<text top="555" left="301" width="47" height="9" font="5">S4.4.4.1-17.</text>
<text top="555" left="352" width="167" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref470">Yong G, Khairy P, De Guise P, et al. Pul-</a></text>
<text top="569" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref470">monary arterial hypertension in patients with trans-</a></text>
<text top="582" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref470">catheter closure of secundum atrial septal defects: a</a></text>
<text top="596" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref470">longitudinal study. Circ Cardiovasc Interv. 2009;2:</a></text>
<text top="609" left="301" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref470">455</a></text>
<text top="607" left="316" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref470">–62</a></text>
<text top="609" left="331" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref470">.</a></text>
<text top="628" left="301" width="48" height="9" font="5">S4.4.4.1-18.</text>
<text top="628" left="352" width="166" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref471">Balzer DT, Kort HW, Day RW, et al.</a></text>
<text top="641" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref471">Inhaled nitric oxide as a preoperative test (INOP Test</a></text>
<text top="654" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref471">I): the INOP Test Study Group. Circulation. 2002;106:</a></text>
<text top="668" left="301" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref471">I76</a></text>
<text top="666" left="314" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref471">–81</a></text>
<text top="668" left="327" width="3" height="9" font="5">.</text>
<text top="692" left="301" width="145" height="9" font="5">4.4.4.2. Eisenmenger Syndrome</text>
<text top="706" left="301" width="44" height="9" font="5">S4.4.4.2-1.</text>
<text top="706" left="348" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref472">Dimopoulos K, Inuzuka R, Goletto S, et al.</a></text>
<text top="719" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref472">Improved survival among patients with Eisenmenger</a></text>
<text top="733" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref472">syndrome receiving advanced therapy for pulmonary</a></text>
<text top="746" left="301" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref472">arterial hypertension. Circulation. 2010;121:20</a></text>
<text top="745" left="487" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref472">–5</a></text>
<text top="746" left="496" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref472">.</a></text>
<text top="765" left="301" width="44" height="9" font="5">S4.4.4.2-2.</text>
<text top="765" left="348" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref473">Gatzoulis MA, Beghetti M, Galiè N, et al.</a></text>
<text top="778" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref473">Longer-term bosentan therapy improves functional</a></text>
<text top="792" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref473">capacity in Eisenmenger syndrome: results of the</a></text>
<text top="805" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref473">BREATHE-5 open-label extension study. Int J Cardiol.</a></text>
<text top="819" left="301" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref473">2008;127:27</a></text>
<text top="817" left="351" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref473">–32</a></text>
<text top="819" left="365" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref473">.</a></text>
<text top="837" left="301" width="44" height="9" font="5">S4.4.4.2-3.</text>
<text top="837" left="348" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref474">Galiè N, Beghetti M, Gatzoulis MA, et al.</a></text>
<text top="850" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref474">Bosentan therapy in patients with Eisenmenger syn-</a></text>
<text top="864" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref474">drome: a multicenter, double-blind, randomized,</a></text>
<text top="877" left="301" width="213" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref474">placebo-controlled study. Circulation. 2006;114:48</a></text>
<text top="876" left="514" width="4" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref474">–</a></text>
<text top="891" left="301" width="10" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref474">54</a></text>
<text top="891" left="311" width="3" height="9" font="5">.</text>
<text top="909" left="301" width="45" height="9" font="5">S4.4.4.2-4.</text>
<text top="909" left="349" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref475">Diller</a></text>
<text top="909" left="389" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref475">G-P,</a></text>
<text top="909" left="425" width="67" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref475">Alonso-Gonzalez</a></text>
<text top="909" left="510" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref475">R,</a></text>
<text top="923" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref475">Dimopoulos K, et al. Disease targeting therapies in</a></text>
<text top="936" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref475">patients with Eisenmenger syndrome: response to</a></text>
<text top="950" left="301" width="121" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref475">treatment and long-term ef</a></text>
<text top="948" left="422" width="96" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref475">ﬁciency. Int J Cardiol.</a></text>
<text top="963" left="301" width="56" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref475">2013;167:840</a></text>
<text top="962" left="357" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref475">–7</a></text>
<text top="963" left="365" width="3" height="9" font="5">.</text>
<text top="982" left="301" width="44" height="9" font="5">S4.4.4.2-5.</text>
<text top="982" left="348" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref476">D</a></text>
<text top="980" left="355" width="164" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref476">’Alto M, Romeo E, Argiento P, et al.</a></text>
<text top="995" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref476">Therapy for pulmonary arterial hypertension due to</a></text>
<text top="1009" left="301" width="144" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref476">congenital heart disease and Down</a></text>
<text top="1007" left="445" width="74" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref476">’s syndrome. Int J</a></text>
<text top="1022" left="301" width="87" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref476">Cardiol. 2013;164:323</a></text>
<text top="1020" left="388" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref476">–6</a></text>
<text top="1022" left="398" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref476">.</a></text>
<text top="1041" left="301" width="45" height="9" font="5">S4.4.4.2-6.</text>
<text top="1041" left="349" width="169" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref477">Iversen K, Jensen AS, Jensen TV, et al.</a></text>
<text top="1054" left="301" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref477">Combination therapy with bosentan and sildena</a></text>
<text top="1052" left="499" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref477">ﬁl in</a></text>
<text top="1067" left="301" width="51" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref477">Eisenmenger</a></text>
<text top="1067" left="361" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref477">syndrome:</a></text>
<text top="1067" left="412" width="4" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref477">a</a></text>
<text top="1067" left="425" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref477">randomized,</a></text>
<text top="1067" left="483" width="35" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref477">placebo-</a></text>
<text top="1081" left="301" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref477">controlled, double-blinded trial. Eur Heart J. 2010;</a></text>
<text top="1094" left="301" width="29" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref477">31:1124</a></text>
<text top="1093" left="330" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref477">–31</a></text>
<text top="1094" left="342" width="3" height="9" font="5">.</text>
<text top="143" left="539" width="44" height="9" font="5">S4.4.4.2-7.</text>
<text top="143" left="587" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref478">Baptista R, Castro G, da Silva AM, et al.</a></text>
<text top="156" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref478">Long-term effect of bosentan in pulmonary hyper-</a></text>
<text top="170" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref478">tension associated with complex congenital heart</a></text>
<text top="183" left="539" width="153" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref478">disease. Rev Port Cardiol. 2013;32:123</a></text>
<text top="182" left="692" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref478">–9</a></text>
<text top="183" left="702" width="3" height="9" font="5">.</text>
<text top="202" left="539" width="45" height="9" font="5">S4.4.4.2-8.</text>
<text top="202" left="588" width="169" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref479">Crepaz R, Romeo C, Montanaro D, et al.</a></text>
<text top="215" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref479">Long-term results of treatment with bosentan in adult</a></text>
<text top="229" left="539" width="51" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref479">Eisenmenger</a></text>
<text top="227" left="591" width="166" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref479">’s syndrome patients with Down’s syn-</a></text>
<text top="242" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref479">drome related to congenital heart disease. BMC Car-</a></text>
<text top="256" left="539" width="107" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref479">diovasc Disord. 2013;13:74</a></text>
<text top="256" left="646" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref479">.</a></text>
<text top="274" left="539" width="45" height="9" font="5">S4.4.4.2-9.</text>
<text top="274" left="588" width="169" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref480">Duffels MGJ, Vis JC, van Loon RLE, et al.</a></text>
<text top="288" left="539" width="23" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref480">Down</a></text>
<text top="288" left="571" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref480">patients</a></text>
<text top="288" left="613" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref480">with</a></text>
<text top="288" left="639" width="51" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref480">Eisenmenger</a></text>
<text top="288" left="700" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref480">syndrome:</a></text>
<text top="288" left="750" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref480">is</a></text>
<text top="301" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref480">bosentan treatment an option? Int J Cardiol. 2009;</a></text>
<text top="315" left="539" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref480">134:378</a></text>
<text top="313" left="571" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref480">–83</a></text>
<text top="315" left="585" width="3" height="9" font="5">.</text>
<text top="333" left="539" width="50" height="9" font="5">S4.4.4.2-10.</text>
<text top="333" left="592" width="165" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref481">Serino G, Guazzi M, Micheletti A, et al.</a></text>
<text top="347" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref481">Effect of bosentan on exercise capacity and clinical</a></text>
<text top="360" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref481">worsening in patients with dual Down and Eisen-</a></text>
<text top="373" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref481">menger syndrome. Clin Med Insights Cardiol. 2013;7:</a></text>
<text top="387" left="539" width="10" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref481">29</a></text>
<text top="385" left="550" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref481">–34</a></text>
<text top="387" left="564" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref481">.</a></text>
<text top="405" left="539" width="47" height="9" font="5">S4.4.4.2-11.</text>
<text top="405" left="590" width="167" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref482">Zhang Z-N, Jiang X, Zhang R, et al. Oral</a></text>
<text top="419" left="539" width="28" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref482">sildena</a></text>
<text top="417" left="567" width="189" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref482">ﬁl treatment for Eisenmenger syndrome: a</a></text>
<text top="432" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref482">prospective, open-label, multicentre study. Heart.</a></text>
<text top="446" left="539" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref482">2011;97:1876</a></text>
<text top="444" left="593" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref482">–81</a></text>
<text top="446" left="606" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref482">.</a></text>
<text top="464" left="539" width="48" height="9" font="5">S4.4.4.2-12.</text>
<text top="464" left="591" width="166" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref483">Garg N, Tripathy N, Sinha N. Comparative</a></text>
<text top="478" left="539" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref483">ef</a></text>
<text top="476" left="547" width="209" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref483">ﬁcacy of sildenaﬁl in Eisenmenger’s syndrome sec-</a></text>
<text top="491" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref483">ondary to atrial septal defect versus ventricular septal</a></text>
<text top="505" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref483">defect: a cardiac catheterisation follow-up study.</a></text>
<text top="518" left="539" width="108" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref483">Cardiol Young. 2011;21:631</a></text>
<text top="517" left="647" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref483">–8</a></text>
<text top="518" left="657" width="3" height="9" font="5">.</text>
<text top="537" left="539" width="48" height="9" font="5">S4.4.4.2-13.</text>
<text top="537" left="591" width="166" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref484">Tay ELW, Papaphylactou M, Diller G-P,</a></text>
<text top="550" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref484">et al. Quality of life and functional capacity can be</a></text>
<text top="564" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref484">improved in patients with Eisenmenger syndrome with</a></text>
<text top="577" left="539" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref484">oral sildena</a></text>
<text top="575" left="586" width="163" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref484">ﬁl therapy. Int J Cardiol. 2011;149:372–6</a></text>
<text top="577" left="749" width="3" height="9" font="5">.</text>
<text top="596" left="539" width="49" height="9" font="5">S4.4.4.2-14.</text>
<text top="596" left="592" width="142" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref485">Bharani A, Patel A, Saraf J, et al. Ef</a></text>
<text top="594" left="734" width="23" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref485">ﬁcacy</a></text>
<text top="609" left="539" width="151" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref485">and safety of PDE-5 inhibitor tadala</a></text>
<text top="607" left="690" width="66" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref485">ﬁl in pulmonary</a></text>
<text top="622" left="539" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref485">arterial hypertension. Indian Heart J. 2007;59:323</a></text>
<text top="621" left="742" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref485">–8</a></text>
<text top="622" left="751" width="3" height="9" font="5">.</text>
<text top="641" left="539" width="48" height="9" font="5">S4.4.4.2-15.</text>
<text top="641" left="591" width="60" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref486">Mukhopadhyay</a></text>
<text top="641" left="671" width="7" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref486">S,</a></text>
<text top="641" left="697" width="30" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref486">Sharma</a></text>
<text top="641" left="746" width="10" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref486">M,</a></text>
<text top="654" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref486">Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in</a></text>
<text top="668" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref486">Eisenmenger syndrome: a preliminary observational</a></text>
<text top="681" left="539" width="136" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref486">study. Circulation. 2006;114:1807</a></text>
<text top="680" left="676" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref486">–10</a></text>
<text top="681" left="689" width="3" height="9" font="5">.</text>
<text top="700" left="539" width="49" height="9" font="5">S4.4.4.2-16.</text>
<text top="700" left="592" width="165" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref487">Singh TP, Rohit M, Grover A, et al.</a></text>
<text top="713" left="539" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref487">A</a></text>
<text top="713" left="555" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref487">randomized,</a></text>
<text top="713" left="614" width="78" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref487">placebo-controlled,</a></text>
<text top="713" left="703" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref487">double-blind,</a></text>
<text top="727" left="539" width="145" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref487">crossover study to evaluate the ef</a></text>
<text top="725" left="685" width="72" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref487">ﬁcacy of oral sil-</a></text>
<text top="740" left="539" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref487">dena</a></text>
<text top="739" left="559" width="198" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref487">ﬁl therapy in severe pulmonary artery hyperten-</a></text>
<text top="754" left="539" width="140" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref487">sion. Am Heart J. 2006;151. 851.e1</a></text>
<text top="752" left="680" width="30" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref487">–851.e5</a></text>
<text top="754" left="710" width="3" height="9" font="5">.</text>
<text top="778" left="539" width="121" height="9" font="5">4.4.5. Coronary Anomalies</text>
<text top="792" left="539" width="35" height="9" font="5">S4.4.5-1.</text>
<text top="792" left="578" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref488">Eckart RE, Shry EA, Burke AP, et al. Sudden</a></text>
<text top="805" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref488">death in young adults: an autopsy-based series of a</a></text>
<text top="818" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref488">population undergoing active surveillance. J Am Coll</a></text>
<text top="832" left="539" width="86" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref488">Cardiol. 2011;58:1254</a></text>
<text top="830" left="626" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref488">–61</a></text>
<text top="832" left="639" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref488">.</a></text>
<text top="850" left="539" width="36" height="9" font="5">S4.4.5-2.</text>
<text top="850" left="579" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref489">Krasuski RA, Magyar D, Hart S, et al. Long-</a></text>
<text top="864" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref489">term outcome and impact of surgery on adults with</a></text>
<text top="877" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref489">coronary arteries originating from the opposite coro-</a></text>
<text top="891" left="539" width="143" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref489">nary cusp. Circulation. 2011;123:154</a></text>
<text top="889" left="682" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref489">–62</a></text>
<text top="891" left="697" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref489">.</a></text>
<text top="909" left="539" width="36" height="9" font="5">S4.4.5-3.</text>
<text top="909" left="579" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref490">Angelini P, Uribe C, Monge J, et al. Origin of</a></text>
<text top="923" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref490">the right coronary artery from the opposite sinus of</a></text>
<text top="936" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref490">Valsalva in adults: characterization by intravascular</a></text>
<text top="950" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref490">ultrasonography at baseline and after stent angio-</a></text>
<text top="963" left="539" width="192" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref490">plasty. Catheter Cardiovasc Interv. 2015;86:199</a></text>
<text top="962" left="732" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref490">–208</a></text>
<text top="963" left="752" width="3" height="9" font="5">.</text>
<text top="982" left="539" width="37" height="9" font="5">S4.4.5-4.</text>
<text top="982" left="580" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref491">Opolski MP, Pregowski J, Kruk M, et al.</a></text>
<text top="995" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref491">Prevalence and characteristics of coronary anomalies</a></text>
<text top="1009" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref491">originating from the opposite sinus of Valsalva in</a></text>
<text top="1022" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref491">8,522 patients referred for coronary computed to-</a></text>
<text top="1035" left="539" width="206" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref491">mography angiography. Am J Cardiol. 2013;111:1361</a></text>
<text top="1034" left="745" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref491">–7</a></text>
<text top="1035" left="754" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref491">.</a></text>
<text top="1054" left="539" width="36" height="9" font="5">S4.4.5-5.</text>
<text top="1054" left="579" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref492">Lee H-J, Hong YJ, Kim HY, et al. Anomalous</a></text>
<text top="1067" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref492">origin of the right coronary artery from the left coro-</a></text>
<text top="1081" left="539" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref492">nary sinus with an interarterial course: subtypes and</a></text>
<text top="1094" left="539" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref492">clinical importance. Radiology. 2012;262:101</a></text>
<text top="1093" left="719" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref492">–8</a></text>
<text top="1094" left="728" width="3" height="9" font="5">.</text>
<text top="54" left="63" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="54" left="710" width="47" height="9" font="13">Stout et al.</text>
<text top="69" left="63" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="155" width="21" height="10" font="9">– 5 6 3</text>
<text top="69" left="579" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="53" left="789" width="18" height="9" font="5">1555</text>
</page>
<page number="63" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="37" height="9" font="5">S4.4.5-6.</text>
<text top="143" left="148" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref493">Kaushal S, Backer CL, Popescu AR, et al.</a></text>
<text top="156" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref493">Intramural coronary length correlates with symptoms</a></text>
<text top="170" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref493">in patients with anomalous aortic origin of the coro-</a></text>
<text top="183" left="108" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref493">nary artery. Ann Thorac Surg. 2011;92:986</a></text>
<text top="182" left="280" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref493">–91</a></text>
<text top="183" left="293" width="3" height="9" font="5">.</text>
<text top="202" left="108" width="36" height="9" font="5">S4.4.5-7.</text>
<text top="202" left="147" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref494">Maron BJ, Doerer JJ, Haas TS, et al. Sudden</a></text>
<text top="215" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref494">deaths in young competitive athletes: analysis of 1866</a></text>
<text top="229" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref494">deaths in the United States, 1980-2006. Circulation.</a></text>
<text top="242" left="108" width="61" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref494">2009;119:1085</a></text>
<text top="241" left="169" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref494">–92</a></text>
<text top="242" left="183" width="3" height="9" font="5">.</text>
<text top="261" left="108" width="37" height="9" font="5">S4.4.5-8.</text>
<text top="261" left="148" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref495">Eckart RE, Scoville SL, Campbell CL, et al.</a></text>
<text top="274" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref495">Sudden death in young adults: a 25-year review of</a></text>
<text top="288" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref495">autopsies in military recruits. Ann Intern Med. 2004;</a></text>
<text top="301" left="108" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref495">141:829</a></text>
<text top="299" left="139" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref495">–34</a></text>
<text top="301" left="153" width="3" height="9" font="5">.</text>
<text top="320" left="108" width="37" height="9" font="5">S4.4.5-9.</text>
<text top="320" left="148" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref496">Frescura C, Basso C, Thiene G, et al. Anoma-</a></text>
<text top="333" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref496">lous origin of coronary arteries and risk of sudden death:</a></text>
<text top="347" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref496">a study based on an autopsy population of congenital</a></text>
<text top="360" left="108" width="162" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref496">heart disease. Hum Pathol. 1998;29:689</a></text>
<text top="358" left="270" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref496">–95</a></text>
<text top="360" left="284" width="3" height="9" font="5">.</text>
<text top="379" left="108" width="41" height="9" font="5">S4.4.5-10.</text>
<text top="379" left="152" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref497">Basso C, Maron BJ, Corrado D, et al. Clinical</a></text>
<text top="392" left="108" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref497">pro</a></text>
<text top="390" left="121" width="204" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref497">ﬁle of congenital coronary artery anomalies with</a></text>
<text top="405" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref497">origin from the wrong aortic sinus leading to sudden</a></text>
<text top="419" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref497">death in young competitive athletes. J Am Coll Cardiol.</a></text>
<text top="432" left="108" width="57" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref497">2000;35:1493</a></text>
<text top="431" left="165" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref497">–501</a></text>
<text top="432" left="184" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref497">.</a></text>
<text top="451" left="108" width="39" height="9" font="5">S4.4.5-11.</text>
<text top="451" left="150" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref498">Davies JE, Burkhart HM, Dearani JA, et al.</a></text>
<text top="464" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref498">Surgical management of anomalous aortic origin of a</a></text>
<text top="478" left="108" width="195" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref498">coronary artery. Ann Thorac Surg. 2009;88:844</a></text>
<text top="476" left="302" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref498">–7</a></text>
<text top="478" left="311" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref498">.</a></text>
<text top="496" left="108" width="40" height="9" font="5">S4.4.5-12.</text>
<text top="496" left="151" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref499">Kragel AH, Roberts WC. Anomalous origin</a></text>
<text top="510" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref499">of either the right or left main coronary artery from the</a></text>
<text top="523" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref499">aorta with subsequent coursing between aorta and</a></text>
<text top="537" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref499">pulmonary trunk: analysis of 32 necropsy cases. Am J</a></text>
<text top="550" left="108" width="83" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref499">Cardiol. 1988;62:771</a></text>
<text top="548" left="190" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref499">–7</a></text>
<text top="550" left="199" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref499">.</a></text>
<text top="569" left="108" width="40" height="9" font="5">S4.4.5-13.</text>
<text top="569" left="151" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref500">Donaldson RM, Raphael M, Radley-Smith R,</a></text>
<text top="582" left="108" width="103" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref500">et al. Angiographic identi</a></text>
<text top="580" left="211" width="114" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref500">ﬁcation of primary coronary</a></text>
<text top="596" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref500">anomalies causing impaired myocardial perfusion.</a></text>
<text top="609" left="108" width="148" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref500">Cathet Cardiovasc Diagn. 1983;9:237</a></text>
<text top="607" left="255" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref500">–49</a></text>
<text top="609" left="271" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref500">.</a></text>
<text top="628" left="108" width="41" height="9" font="5">S4.4.5-14.</text>
<text top="628" left="152" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref501">Brothers JA, McBride MG, Seliem MA, et al.</a></text>
<text top="641" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref501">Evaluation of myocardial ischemia after surgical repair</a></text>
<text top="654" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref501">of anomalous aortic origin of a coronary artery in a</a></text>
<text top="668" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref501">series of pediatric patients. J Am Coll Cardiol. 2007;</a></text>
<text top="681" left="108" width="35" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref501">50:2078</a></text>
<text top="680" left="142" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref501">–82</a></text>
<text top="681" left="157" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref501">.</a></text>
<text top="700" left="108" width="40" height="9" font="5">S4.4.5-15.</text>
<text top="700" left="151" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref502">Sharma V, Burkhart HM, Dearani JA, et al.</a></text>
<text top="713" left="108" width="60" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref502">Surgical unroo</a></text>
<text top="712" left="168" width="157" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref502">ﬁng of anomalous aortic origin of a</a></text>
<text top="727" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref502">coronary artery: a single-center experience. Ann</a></text>
<text top="740" left="108" width="105" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref502">Thorac Surg. 2014;98:941</a></text>
<text top="739" left="212" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref502">–5</a></text>
<text top="740" left="221" width="3" height="9" font="5">.</text>
<text top="759" left="108" width="41" height="9" font="5">S4.4.5-16.</text>
<text top="759" left="152" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref503">Frommelt PC, Sheridan DC, Berger S, et al.</a></text>
<text top="772" left="108" width="185" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref503">Ten-year experience with surgical unroo</a></text>
<text top="771" left="292" width="32" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref503">ﬁng of</a></text>
<text top="786" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref503">anomalous aortic origin of a coronary artery from the</a></text>
<text top="799" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref503">opposite sinus with an interarterial course. J Thorac</a></text>
<text top="813" left="108" width="128" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref503">Cardiovasc Surg. 2011;142:1046</a></text>
<text top="811" left="235" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref503">–51</a></text>
<text top="813" left="248" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref503">.</a></text>
<text top="833" left="108" width="40" height="9" font="5">S4.4.5-17.</text>
<text top="833" left="151" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref504">Mainwaring RD, Reddy VM, Reinhartz O,</a></text>
<text top="846" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref504">et al. Anomalous aortic origin of a coronary artery:</a></text>
<text top="859" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref504">medium-term results after surgical repair in 50 pa-</a></text>
<text top="873" left="108" width="149" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref504">tients. Ann Thorac Surg. 2011;92:691</a></text>
<text top="871" left="257" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref504">–7</a></text>
<text top="873" left="266" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref504">.</a></text>
<text top="891" left="108" width="41" height="9" font="5">S4.4.5-18.</text>
<text top="891" left="152" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref505">Mumtaz MA, Lorber RE, Arruda J, et al.</a></text>
<text top="905" left="108" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref505">Surgery for anomalous aortic origin of the coronary</a></text>
<text top="918" left="108" width="147" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref505">artery. Ann Thorac Surg. 2011;91:811</a></text>
<text top="917" left="255" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref505">–4</a></text>
<text top="918" left="264" width="3" height="9" font="5">.</text>
<text top="145" left="346" width="216" height="9" font="5">4.4.5.1. Anomalous Coronary Artery Evaluation</text>
<text top="158" left="346" width="42" height="9" font="5">S4.4.5.1-1.</text>
<text top="158" left="391" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref506">Basso C, Maron BJ, Corrado D, et al. Clinical</a></text>
<text top="172" left="346" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref506">pro</a></text>
<text top="170" left="359" width="204" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref506">ﬁle of congenital coronary artery anomalies with</a></text>
<text top="185" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref506">origin from the wrong aortic sinus leading to sudden</a></text>
<text top="199" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref506">death in young competitive athletes. J Am Coll Cardiol.</a></text>
<text top="212" left="346" width="57" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref506">2000;35:1493</a></text>
<text top="211" left="403" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref506">–501</a></text>
<text top="212" left="422" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref506">.</a></text>
<text top="231" left="346" width="43" height="9" font="5">S4.4.5.1-2.</text>
<text top="231" left="392" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref507">Davies JE, Burkhart HM, Dearani JA, et al.</a></text>
<text top="244" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref507">Surgical management of anomalous aortic origin of a</a></text>
<text top="258" left="346" width="195" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref507">coronary artery. Ann Thorac Surg. 2009;88:844</a></text>
<text top="256" left="541" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref507">–7</a></text>
<text top="258" left="549" width="3" height="9" font="5">.</text>
<text top="276" left="346" width="43" height="9" font="5">S4.4.5.1-3.</text>
<text top="276" left="392" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref508">Sharma V, Burkhart HM, Dearani JA, et al.</a></text>
<text top="290" left="346" width="60" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref508">Surgical unroo</a></text>
<text top="288" left="406" width="157" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref508">ﬁng of anomalous aortic origin of a</a></text>
<text top="303" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref508">coronary artery: a single-center experience. Ann</a></text>
<text top="316" left="346" width="105" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref508">Thorac Surg. 2014;98:941</a></text>
<text top="315" left="451" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref508">–5</a></text>
<text top="316" left="459" width="3" height="9" font="5">.</text>
<text top="335" left="346" width="44" height="9" font="5">S4.4.5.1-4.</text>
<text top="335" left="392" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref509">Eckart RE, Shry EA, Burke AP, et al. Sudden</a></text>
<text top="348" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref509">death in young adults: an autopsy-based series of a</a></text>
<text top="362" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref509">population undergoing active surveillance. J Am Coll</a></text>
<text top="375" left="346" width="86" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref509">Cardiol. 2011;58:1254</a></text>
<text top="374" left="432" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref509">–61</a></text>
<text top="375" left="446" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref509">.</a></text>
<text top="394" left="346" width="43" height="9" font="5">S4.4.5.1-5.</text>
<text top="394" left="392" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref510">Angelini P, Uribe C, Monge J, et al. Origin</a></text>
<text top="407" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref510">of the right coronary artery from the opposite sinus of</a></text>
<text top="421" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref510">Valsalva in adults: characterization by intravascular</a></text>
<text top="434" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref510">ultrasonography at baseline and after stent angio-</a></text>
<text top="448" left="346" width="192" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref510">plasty. Catheter Cardiovasc Interv. 2015;86:199</a></text>
<text top="446" left="538" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref510">–208</a></text>
<text top="448" left="559" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref510">.</a></text>
<text top="466" left="346" width="43" height="9" font="5">S4.4.5.1-6.</text>
<text top="466" left="392" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref511">Opolski MP, Pregowski J, Kruk M, et al.</a></text>
<text top="480" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref511">Prevalence and characteristics of coronary anomalies</a></text>
<text top="493" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref511">originating from the opposite sinus of Valsalva in</a></text>
<text top="507" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref511">8,522 patients referred for coronary computed to-</a></text>
<text top="520" left="346" width="206" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref511">mography angiography. Am J Cardiol. 2013;111:1361</a></text>
<text top="518" left="552" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref511">–7</a></text>
<text top="520" left="560" width="3" height="9" font="5">.</text>
<text top="539" left="346" width="43" height="9" font="5">S4.4.5.1-7.</text>
<text top="539" left="392" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref512">Lee H-J, Hong YJ, Kim HY, et al. Anoma-</a></text>
<text top="552" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref512">lous origin of the right coronary artery from the left</a></text>
<text top="565" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref512">coronary sinus with an interarterial course: subtypes</a></text>
<text top="579" left="346" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref512">and clinical importance. Radiology. 2012;262:101</a></text>
<text top="577" left="543" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref512">–8</a></text>
<text top="579" left="553" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref512">.</a></text>
<text top="597" left="346" width="43" height="9" font="5">S4.4.5.1-8.</text>
<text top="597" left="392" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref513">Kaushal S, Backer CL, Popescu AR, et al.</a></text>
<text top="611" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref513">Intramural coronary length correlates with symptoms</a></text>
<text top="624" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref513">in patients with anomalous aortic origin of the coro-</a></text>
<text top="638" left="346" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref513">nary artery. Ann Thorac Surg. 2011;92:986</a></text>
<text top="636" left="518" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref513">–91</a></text>
<text top="638" left="532" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref513">.</a></text>
<text top="656" left="346" width="43" height="9" font="5">S4.4.5.1-9.</text>
<text top="656" left="392" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref514">Frescura C, Basso C, Thiene G, et al.</a></text>
<text top="670" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref514">Anomalous origin of coronary arteries and risk of</a></text>
<text top="683" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref514">sudden death: a study based on an autopsy population</a></text>
<text top="697" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref514">of congenital heart disease. Hum Pathol. 1998;29:</a></text>
<text top="710" left="346" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref514">689</a></text>
<text top="708" left="363" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref514">–95</a></text>
<text top="710" left="377" width="3" height="9" font="5">.</text>
<text top="734" left="346" width="217" height="9" font="5">4.4.5.2. Anomalous Aortic Origin of Coronary</text>
<text top="748" left="346" width="29" height="9" font="5">Artery</text>
<text top="762" left="346" width="43" height="9" font="5">S4.4.5.2-1.</text>
<text top="762" left="392" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref515">Basso C, Maron BJ, Corrado D, et al. Clinical</a></text>
<text top="775" left="346" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref515">pro</a></text>
<text top="773" left="359" width="204" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref515">ﬁle of congenital coronary artery anomalies with</a></text>
<text top="788" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref515">origin from the wrong aortic sinus leading to sudden</a></text>
<text top="802" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref515">death in young competitive athletes. J Am Coll Cardiol.</a></text>
<text top="815" left="346" width="57" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref515">2000;35:1493</a></text>
<text top="814" left="403" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref515">–501</a></text>
<text top="815" left="422" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref515">.</a></text>
<text top="834" left="346" width="44" height="9" font="5">S4.4.5.2-2.</text>
<text top="834" left="392" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref516">Davies JE, Burkhart HM, Dearani JA, et al.</a></text>
<text top="847" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref516">Surgical management of anomalous aortic origin of a</a></text>
<text top="861" left="346" width="195" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref516">coronary artery. Ann Thorac Surg. 2009;88:844</a></text>
<text top="859" left="541" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref516">–7</a></text>
<text top="861" left="549" width="3" height="9" font="5">.</text>
<text top="879" left="346" width="44" height="9" font="5">S4.4.5.2-3.</text>
<text top="879" left="392" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref517">Sharma V, Burkhart HM, Dearani JA, et al.</a></text>
<text top="893" left="346" width="60" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref517">Surgical unroo</a></text>
<text top="891" left="406" width="157" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref517">ﬁng of anomalous aortic origin of a</a></text>
<text top="906" left="346" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref517">coronary artery: a single-center experience. Ann</a></text>
<text top="920" left="346" width="105" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref517">Thorac Surg. 2014;98:941</a></text>
<text top="918" left="451" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref517">–5</a></text>
<text top="920" left="459" width="3" height="9" font="5">.</text>
<text top="143" left="584" width="44" height="9" font="5">S4.4.5.2-4.</text>
<text top="143" left="632" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref518">Frommelt PC, Sheridan DC, Berger S, et al.</a></text>
<text top="156" left="584" width="185" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref518">Ten-year experience with surgical unroo</a></text>
<text top="155" left="769" width="32" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref518">ﬁng of</a></text>
<text top="170" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref518">anomalous aortic origin of a coronary artery from the</a></text>
<text top="183" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref518">opposite sinus with an interarterial course. J Thorac</a></text>
<text top="197" left="584" width="128" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref518">Cardiovasc Surg. 2011;142:1046</a></text>
<text top="195" left="712" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref518">–51</a></text>
<text top="197" left="724" width="3" height="9" font="5">.</text>
<text top="215" left="584" width="44" height="9" font="5">S4.4.5.2-5.</text>
<text top="215" left="631" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref519">Gulati R, Reddy VM, Culbertson C, et al.</a></text>
<text top="229" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref519">Surgical management of coronary artery arising from</a></text>
<text top="242" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref519">the wrong coronary sinus, using standard and</a></text>
<text top="256" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref519">novel approaches. J Thorac Cardiovasc Surg. 2007;</a></text>
<text top="269" left="584" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref519">134:1171</a></text>
<text top="268" left="616" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref519">–8</a></text>
<text top="269" left="626" width="3" height="9" font="5">.</text>
<text top="288" left="584" width="44" height="9" font="5">S4.4.5.2-6.</text>
<text top="288" left="632" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref520">Mainwaring RD, Reddy VM, Reinhartz O,</a></text>
<text top="301" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref520">et al. Anomalous aortic origin of a coronary artery:</a></text>
<text top="315" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref520">medium-term results after surgical repair in 50 pa-</a></text>
<text top="328" left="584" width="149" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref520">tients. Ann Thorac Surg. 2011;92:691</a></text>
<text top="326" left="734" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref520">–7</a></text>
<text top="328" left="742" width="3" height="9" font="5">.</text>
<text top="351" left="584" width="217" height="9" font="5">4.4.5.3. Anomalous Coronary Artery Arising</text>
<text top="364" left="584" width="57" height="9" font="5">From the PA</text>
<text top="378" left="584" width="43" height="9" font="5">S4.4.5.3-1.</text>
<text top="378" left="630" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref521">Cochrane AD, Coleman DM, Davis AM, et al.</a></text>
<text top="391" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref521">Excellent long-term functional outcome after an</a></text>
<text top="405" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref521">operation for anomalous left coronary artery from the</a></text>
<text top="418" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref521">pulmonary artery. J Thorac Cardiovasc Surg. 1999;117:</a></text>
<text top="432" left="584" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref521">332</a></text>
<text top="430" left="599" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref521">–42</a></text>
<text top="432" left="613" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref521">.</a></text>
<text top="450" left="584" width="44" height="9" font="5">S4.4.5.3-2.</text>
<text top="450" left="631" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref522">Paridon SM, Farooki ZQ, Kuhns LR, et al.</a></text>
<text top="464" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref522">Exercise performance after repair of anomalous origin</a></text>
<text top="477" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref522">of the left coronary artery from the pulmonary artery.</a></text>
<text top="491" left="584" width="102" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref522">Circulation. 1990;81:1287</a></text>
<text top="489" left="687" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref522">–92</a></text>
<text top="491" left="701" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref522">.</a></text>
<text top="509" left="584" width="44" height="9" font="5">S4.4.5.3-3.</text>
<text top="509" left="631" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref523">Lange R, Vogt M, Hörer J, et al. Long-term</a></text>
<text top="523" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref523">results of repair of anomalous origin of the left coro-</a></text>
<text top="536" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref523">nary artery from the pulmonary artery. Ann Thorac</a></text>
<text top="550" left="584" width="80" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref523">Surg. 2007;83:1463</a></text>
<text top="548" left="664" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref523">–71</a></text>
<text top="550" left="677" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref523">.</a></text>
<text top="568" left="584" width="44" height="9" font="5">S4.4.5.3-4.</text>
<text top="568" left="632" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref524">el-Said GM, Ruzyllo W, Williams RL, et al.</a></text>
<text top="581" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref524">Early and late result of saphenous vein graft for</a></text>
<text top="595" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref524">anomalous origin of left coronary artery from pulmo-</a></text>
<text top="608" left="584" width="145" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref524">nary artery. Circulation. 1973;48:III2</a></text>
<text top="607" left="729" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref524">–6</a></text>
<text top="608" left="739" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref524">.</a></text>
<text top="627" left="584" width="44" height="9" font="5">S4.4.5.3-5.</text>
<text top="627" left="631" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref525">Wilson CL, Dlabal PW, McGuire SA. Surgical</a></text>
<text top="640" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref525">treatment of anomalous left coronary artery from</a></text>
<text top="654" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref525">pulmonary artery: follow-up in teenagers and adults.</a></text>
<text top="667" left="584" width="104" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref525">Am Heart J. 1979;98:440</a></text>
<text top="666" left="688" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref525">–6</a></text>
<text top="667" left="697" width="3" height="9" font="5">.</text>
<text top="686" left="584" width="44" height="9" font="5">S4.4.5.3-6.</text>
<text top="686" left="632" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref526">Yau JM, Singh R, Halpern EJ, et al.</a></text>
<text top="699" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref526">Anomalous origin of the left coronary artery from</a></text>
<text top="713" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref526">the pulmonary artery in adults: a comprehensive</a></text>
<text top="726" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref526">review of 151 adult cases and a new diagnosis in</a></text>
<text top="740" left="584" width="4" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref526">a</a></text>
<text top="740" left="600" width="47" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref526">53-year-old</a></text>
<text top="740" left="657" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref526">woman.</a></text>
<text top="740" left="700" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref526">Clin</a></text>
<text top="740" left="726" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref526">Cardiol.</a></text>
<text top="740" left="767" width="34" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref526">2011;34:</a></text>
<text top="753" left="584" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref526">204</a></text>
<text top="751" left="601" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref526">–10</a></text>
<text top="753" left="614" width="3" height="9" font="5">.</text>
<text top="772" left="584" width="44" height="9" font="5">S4.4.5.3-7.</text>
<text top="772" left="631" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref527">Rajbanshi BG, Burkhart HM, Schaff HV,</a></text>
<text top="785" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref527">et al. Surgical strategies for anomalous origin of cor-</a></text>
<text top="798" left="584" width="217" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref527">onary artery from pulmonary artery in adults. J Thorac</a></text>
<text top="812" left="584" width="125" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref527">Cardiovasc Surg. 2014;148:220</a></text>
<text top="810" left="709" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(18)36845-1/sref527">–4</a></text>
<text top="812" left="718" width="3" height="9" font="5">.</text>
<text top="864" left="584" width="62" height="12" font="24">KEY WORDS</text>
<text top="866" left="652" width="115" height="9" font="5">ACC/AHA Clinical Practice</text>
<text top="879" left="584" width="217" height="9" font="5">Guidelines, arrhythmias, cardiac catheterization,</text>
<text top="893" left="584" width="185" height="9" font="5">cardiac defects, congenital heart disease,</text>
<text top="906" left="584" width="208" height="9" font="5">congenital heart surgery, unoperated/repaired</text>
<text top="919" left="584" width="55" height="9" font="5">heart defect</text>
<text top="53" left="108" width="47" height="9" font="13">Stout et al.</text>
<text top="54" left="671" width="130" height="7" font="9">J A C C V O L . 7 3 , N O . 1 2 , 2 0 1 9</text>
<text top="68" left="108" width="178" height="9" font="13">2018 ACHD Guideline: Executive Summary</text>
<text top="69" left="689" width="90" height="7" font="9">A P R I L 2 , 2 0 1 9 : 1 4 9 4</text>
<text top="67" left="780" width="21" height="10" font="9">– 5 6 3</text>
<text top="53" left="57" width="19" height="9" font="5">1556</text>
</page>
<page number="64" position="absolute" top="0" left="0" height="864" width="1160">
	<fontspec id="29" size="9" family="Times" color="#e3202b"/>
	<fontspec id="30" size="9" family="Times" color="#327eb1"/>
	<fontspec id="31" size="7" family="Times" color="#000000"/>
	<fontspec id="32" size="7" family="Times" color="#327eb1"/>
	<fontspec id="33" size="5" family="Times" color="#000000"/>
	<fontspec id="34" size="6" family="Times" color="#000000"/>
<text top="78" left="59" width="959" height="16" font="29">APPENDIX 1. AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (RELEVANT)—2018 AHA/ACC GUIDELINE FOR THE MANAGEMENT</text>
<text top="96" left="59" width="325" height="16" font="29">OF ADULTS WITH CONGENITAL HEART DISEASE</text>
<text top="96" left="385" width="5" height="16" font="30"><a href="1-s2.0-S0735109718368451-main.html#65">*</a></text>
<text top="96" left="395" width="120" height="16" font="29">(FEBRUARY 2018)</text>
<text top="173" left="60" width="91" height="9" font="31">Committee Member</text>
<text top="173" left="248" width="58" height="9" font="31">Employment</text>
<text top="173" left="400" width="50" height="9" font="31">Consultant</text>
<text top="161" left="484" width="42" height="9" font="31">Speakers</text>
<text top="173" left="489" width="32" height="9" font="31">Bureau</text>
<text top="149" left="549" width="53" height="9" font="31">Ownership/</text>
<text top="161" left="547" width="59" height="9" font="31">Partnership/</text>
<text top="173" left="556" width="41" height="9" font="31">Principal</text>
<text top="161" left="626" width="40" height="9" font="31">Personal</text>
<text top="173" left="626" width="42" height="9" font="31">Research</text>
<text top="137" left="716" width="60" height="9" font="31">Institutional,</text>
<text top="149" left="710" width="71" height="9" font="31">Organizational,</text>
<text top="161" left="704" width="83" height="9" font="31">or Other Financial</text>
<text top="173" left="729" width="23" height="9" font="31">Bene</text>
<text top="172" left="752" width="10" height="12" font="31">ﬁt</text>
<text top="161" left="842" width="31" height="9" font="31">Expert</text>
<text top="173" left="839" width="37" height="9" font="31">Witness</text>
<text top="161" left="921" width="88" height="9" font="31">Voting Recusals by</text>
<text top="173" left="946" width="34" height="9" font="31">Section</text>
<text top="172" left="980" width="5" height="12" font="32"><a href="1-s2.0-S0735109718368451-main.html#65">†</a></text>
<text top="193" left="60" width="92" height="9" font="31">Karen K. Stout (Chair)</text>
<text top="193" left="190" width="106" height="9" font="31">University of Washington</text>
<text top="191" left="296" width="69" height="12" font="31">—Director, Adult</text>
<text top="204" left="212" width="146" height="9" font="31">Congenital Heart Disease Program,</text>
<text top="216" left="217" width="136" height="9" font="31">Professor, Internal Medicine and</text>
<text top="228" left="265" width="40" height="9" font="31">Pediatrics</text>
<text top="193" left="414" width="22" height="9" font="31">None</text>
<text top="193" left="494" width="22" height="9" font="31">None</text>
<text top="193" left="565" width="22" height="9" font="31">None</text>
<text top="193" left="625" width="22" height="9" font="31">None</text>
<text top="193" left="735" width="22" height="9" font="31">None</text>
<text top="193" left="847" width="22" height="9" font="31">None</text>
<text top="193" left="954" width="22" height="9" font="31">None</text>
<text top="248" left="60" width="108" height="9" font="31">Curt J. Daniels (Vice Chair)</text>
<text top="248" left="188" width="179" height="9" font="31">The Ohio State University Heart Center and</text>
<text top="260" left="217" width="85" height="9" font="31">Nationwide Children</text>
<text top="258" left="302" width="51" height="12" font="31">’s Hospital—</text>
<text top="272" left="217" width="136" height="9" font="31">Director, Adult Congenital Heart</text>
<text top="283" left="207" width="155" height="9" font="31">Disease and Pulmonary Hypertension</text>
<text top="295" left="206" width="158" height="9" font="31">Program, Professor, Internal Medicine</text>
<text top="307" left="256" width="59" height="9" font="31">and Pediatrics</text>
<text top="248" left="414" width="22" height="9" font="31">None</text>
<text top="248" left="494" width="22" height="9" font="31">None</text>
<text top="248" left="565" width="22" height="9" font="31">None</text>
<text top="248" left="625" width="22" height="9" font="31">None</text>
<text top="251" left="692" width="6" height="10" font="33">n</text>
<text top="251" left="707" width="36" height="9" font="31">Actelion</text>
<text top="250" left="743" width="5" height="12" font="32"><a href="1-s2.0-S0735109718368451-main.html#65">‡</a></text>
<text top="248" left="847" width="22" height="9" font="31">None</text>
<text top="248" left="916" width="98" height="9" font="31">4.1.1, 4.1.2, 4.1.3, 4.1.4,</text>
<text top="260" left="920" width="90" height="9" font="31">4.1.5, 4.4.6.1, 4.4.6.2</text>
<text top="327" left="60" width="81" height="9" font="31">Jamil A. Aboulhosn</text>
<text top="327" left="199" width="157" height="9" font="31">UCLA Adult Congenital Heart Disease</text>
<text top="339" left="251" width="27" height="9" font="31">Center</text>
<text top="337" left="278" width="40" height="12" font="31">—Director</text>
<text top="330" left="391" width="6" height="10" font="33">n</text>
<text top="330" left="405" width="36" height="9" font="31">Actelion</text>
<text top="345" left="391" width="6" height="10" font="33">n</text>
<text top="346" left="405" width="49" height="9" font="31">GE Medical</text>
<text top="361" left="391" width="6" height="10" font="33">n</text>
<text top="362" left="405" width="33" height="9" font="31">Edward</text>
<text top="378" left="405" width="53" height="9" font="31">Lifesciences</text>
<text top="378" left="458" width="5" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#65">§</a></text>
<text top="393" left="391" width="6" height="10" font="33">n</text>
<text top="394" left="405" width="44" height="9" font="31">Medtronic</text>
<text top="327" left="494" width="22" height="9" font="31">None</text>
<text top="327" left="565" width="22" height="9" font="31">None</text>
<text top="330" left="629" width="6" height="10" font="33">n</text>
<text top="330" left="644" width="21" height="9" font="31">Gore</text>
<text top="330" left="692" width="6" height="10" font="33">n</text>
<text top="330" left="707" width="89" height="9" font="31">United Therapeutics</text>
<text top="345" left="692" width="6" height="10" font="33">n</text>
<text top="346" left="707" width="36" height="9" font="31">Actelion</text>
<text top="361" left="692" width="6" height="10" font="33">n</text>
<text top="362" left="707" width="44" height="9" font="31">Medtronic</text>
<text top="377" left="692" width="6" height="10" font="33">n</text>
<text top="377" left="707" width="35" height="9" font="31">St. Jude</text>
<text top="392" left="692" width="6" height="10" font="33">n</text>
<text top="393" left="707" width="89" height="9" font="31">Edward Lifesciences</text>
<text top="327" left="847" width="22" height="9" font="31">None</text>
<text top="327" left="916" width="98" height="9" font="31">4.1.1, 4.1.2, 4.1.3, 4.1.4,</text>
<text top="339" left="924" width="82" height="9" font="31">4.1.5, 4.2.6, 4.3.1.1,</text>
<text top="350" left="923" width="85" height="9" font="31">4.3.2, 4.3.5, 4.4.6.1,</text>
<text top="362" left="950" width="30" height="9" font="31">4.4.6.2</text>
<text top="413" left="60" width="65" height="9" font="31">Biykem Bozkurt</text>
<text top="413" left="192" width="113" height="9" font="31">Baylor College of Medicine</text>
<text top="411" left="305" width="58" height="12" font="31">—Professor of</text>
<text top="425" left="266" width="37" height="9" font="31">Medicine</text>
<text top="413" left="414" width="22" height="9" font="31">None</text>
<text top="413" left="494" width="22" height="9" font="31">None</text>
<text top="413" left="565" width="22" height="9" font="31">None</text>
<text top="413" left="625" width="22" height="9" font="31">None</text>
<text top="416" left="692" width="6" height="10" font="33">n</text>
<text top="417" left="707" width="36" height="9" font="31">Novartis</text>
<text top="413" left="847" width="22" height="9" font="31">None</text>
<text top="413" left="954" width="22" height="9" font="31">None</text>
<text top="444" left="60" width="68" height="9" font="31">Craig S. Broberg</text>
<text top="444" left="195" width="158" height="9" font="31">Oregon Health and Science University</text>
<text top="442" left="353" width="7" height="12" font="31">—</text>
<text top="456" left="218" width="133" height="9" font="31">Associate Professor of Medicine</text>
<text top="444" left="414" width="22" height="9" font="31">None</text>
<text top="444" left="494" width="22" height="9" font="31">None</text>
<text top="444" left="565" width="22" height="9" font="31">None</text>
<text top="444" left="625" width="22" height="9" font="31">None</text>
<text top="447" left="692" width="6" height="10" font="33">n</text>
<text top="448" left="707" width="36" height="9" font="31">Actelion</text>
<text top="444" left="847" width="22" height="9" font="31">None</text>
<text top="444" left="916" width="98" height="9" font="31">4.1.1, 4.1.2, 4.1.3, 4.1.4,</text>
<text top="456" left="920" width="90" height="9" font="31">4.1.5, 4.4.6.1, 4.4.6.2</text>
<text top="475" left="60" width="66" height="9" font="31">Jack M. Colman</text>
<text top="475" left="204" width="90" height="9" font="31">University of Toronto</text>
<text top="473" left="293" width="58" height="12" font="31">—Professor of</text>
<text top="487" left="203" width="164" height="9" font="31">Medicine and Obstetrics &amp; Gynecology,</text>
<text top="499" left="205" width="160" height="9" font="31">Toronto Congenital Cardiac Centre for</text>
<text top="511" left="217" width="136" height="9" font="31">Adults and Pregnancy and Heart</text>
<text top="523" left="211" width="148" height="9" font="31">Disease Program; University Health</text>
<text top="535" left="209" width="144" height="9" font="31">Network and Mount Sinai Hospital</text>
<text top="533" left="353" width="7" height="12" font="31">—</text>
<text top="547" left="223" width="123" height="9" font="31">Senior Attending Cardiologist</text>
<text top="475" left="414" width="22" height="9" font="31">None</text>
<text top="475" left="494" width="22" height="9" font="31">None</text>
<text top="475" left="565" width="22" height="9" font="31">None</text>
<text top="475" left="625" width="22" height="9" font="31">None</text>
<text top="475" left="735" width="22" height="9" font="31">None</text>
<text top="475" left="847" width="22" height="9" font="31">None</text>
<text top="475" left="954" width="22" height="9" font="31">None</text>
<text top="566" left="60" width="76" height="9" font="31">Stephen R. Crumb</text>
<text top="566" left="198" width="85" height="9" font="31">Nationwide Children</text>
<text top="564" left="282" width="75" height="12" font="31">’s Hospital—Nurse</text>
<text top="578" left="207" width="155" height="9" font="31">Practitioner and Coordinator, COACH</text>
<text top="590" left="203" width="164" height="9" font="31">and Pulmonary Hypertension Programs</text>
<text top="566" left="414" width="22" height="9" font="31">None</text>
<text top="566" left="494" width="22" height="9" font="31">None</text>
<text top="566" left="565" width="22" height="9" font="31">None</text>
<text top="566" left="625" width="22" height="9" font="31">None</text>
<text top="566" left="735" width="22" height="9" font="31">None</text>
<text top="566" left="847" width="22" height="9" font="31">None</text>
<text top="566" left="954" width="22" height="9" font="31">None</text>
<text top="609" left="60" width="75" height="9" font="31">Joseph A. Dearani</text>
<text top="609" left="198" width="48" height="9" font="31">Mayo Clinic</text>
<text top="607" left="246" width="111" height="12" font="31">—Professor of Surgery and</text>
<text top="621" left="218" width="134" height="9" font="31">Chair, Division of Cardiovascular</text>
<text top="633" left="269" width="32" height="9" font="31">Surgery</text>
<text top="609" left="414" width="22" height="9" font="31">None</text>
<text top="609" left="494" width="22" height="9" font="31">None</text>
<text top="609" left="565" width="22" height="9" font="31">None</text>
<text top="609" left="625" width="22" height="9" font="31">None</text>
<text top="612" left="692" width="6" height="10" font="33">n</text>
<text top="613" left="707" width="73" height="9" font="31">Sorin (LivaNova)</text>
<text top="613" left="780" width="5" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#65">§</a></text>
<text top="611" left="785" width="5" height="12" font="32"><a href="1-s2.0-S0735109718368451-main.html#65">k</a></text>
<text top="628" left="692" width="6" height="10" font="33">n</text>
<text top="629" left="707" width="43" height="9" font="31">Cormat<a href="1-s2.0-S0735109718368451-main.html#65">rix</a></text>
<text top="627" left="750" width="5" height="12" font="32"><a href="1-s2.0-S0735109718368451-main.html#65">k</a></text>
<text top="609" left="847" width="22" height="9" font="31">None</text>
<text top="609" left="954" width="22" height="9" font="31">None</text>
<text top="651" left="60" width="68" height="9" font="31">Stephanie Fuller</text>
<text top="651" left="201" width="153" height="9" font="31">University of Pennsylvania Perelman</text>
<text top="663" left="222" width="80" height="9" font="31">School of Medicine</text>
<text top="661" left="302" width="46" height="12" font="31">—Associate</text>
<text top="675" left="226" width="119" height="9" font="31">Professor of Clinical Surgery</text>
<text top="651" left="414" width="22" height="9" font="31">None</text>
<text top="651" left="494" width="22" height="9" font="31">None</text>
<text top="651" left="565" width="22" height="9" font="31">None</text>
<text top="651" left="625" width="22" height="9" font="31">None</text>
<text top="651" left="735" width="22" height="9" font="31">None</text>
<text top="651" left="847" width="22" height="9" font="31">None</text>
<text top="651" left="954" width="22" height="9" font="31">None</text>
<text top="695" left="914" width="105" height="8" font="34">Continued on the next page</text>
<text top="57" left="1102" width="0" height="7" font="9">J</text>
<text top="63" left="1102" width="0" height="7" font="9">A</text>
<text top="69" left="1102" width="0" height="7" font="9">C</text>
<text top="76" left="1102" width="0" height="7" font="9">C</text>
<text top="86" left="1102" width="0" height="7" font="9">V</text>
<text top="92" left="1102" width="0" height="7" font="9">O</text>
<text top="99" left="1102" width="0" height="7" font="9">L</text>
<text top="105" left="1102" width="0" height="7" font="9">.</text>
<text top="112" left="1102" width="0" height="7" font="9">7</text>
<text top="117" left="1102" width="0" height="7" font="9">3</text>
<text top="123" left="1102" width="0" height="7" font="9">,N</text>
<text top="137" left="1102" width="0" height="7" font="9">O</text>
<text top="144" left="1102" width="0" height="7" font="9">.</text>
<text top="151" left="1102" width="0" height="7" font="9">1</text>
<text top="155" left="1102" width="0" height="7" font="9">2</text>
<text top="161" left="1102" width="0" height="7" font="9">,2</text>
<text top="173" left="1102" width="0" height="7" font="9">0</text>
<text top="180" left="1102" width="0" height="7" font="9">1</text>
<text top="184" left="1102" width="0" height="7" font="9">9</text>
<text top="703" left="1100" width="0" height="9" font="13">Stout</text>
<text top="728" left="1100" width="0" height="9" font="13">et</text>
<text top="739" left="1100" width="0" height="9" font="13">al</text>
<text top="747" left="1100" width="0" height="9" font="13">.</text>
<text top="57" left="1087" width="0" height="7" font="9">AP</text>
<text top="70" left="1087" width="0" height="7" font="9">RI</text>
<text top="80" left="1087" width="0" height="7" font="9">L</text>
<text top="89" left="1087" width="0" height="7" font="9">2</text>
<text top="95" left="1087" width="0" height="7" font="9">,</text>
<text top="102" left="1087" width="0" height="7" font="9">2</text>
<text top="108" left="1087" width="0" height="7" font="9">01</text>
<text top="118" left="1087" width="0" height="7" font="9">9</text>
<text top="124" left="1087" width="0" height="7" font="9">:</text>
<text top="127" left="1087" width="0" height="7" font="9">1</text>
<text top="131" left="1087" width="0" height="7" font="9">4</text>
<text top="137" left="1087" width="0" height="7" font="9">9</text>
<text top="143" left="1087" width="0" height="7" font="9">4</text>
<text top="148" left="1087" width="0" height="10" font="9">–</text>
<text top="155" left="1087" width="0" height="7" font="9">563</text>
<text top="572" left="1085" width="0" height="9" font="13">2018</text>
<text top="596" left="1085" width="0" height="9" font="13">ACHD</text>
<text top="623" left="1085" width="0" height="9" font="13">Guideline:</text>
<text top="668" left="1085" width="0" height="9" font="13">Executive</text>
<text top="711" left="1085" width="0" height="9" font="13">Summary</text>
<text top="783" left="1101" width="0" height="9" font="5">1557</text>
</page>
<page number="65" position="absolute" top="0" left="0" height="864" width="1160">
<text top="59" left="59" width="156" height="16" font="29">APPENDIX 1. CONTINUED</text>
<text top="150" left="59" width="91" height="9" font="31">Committee Member</text>
<text top="150" left="247" width="58" height="9" font="31">Employment</text>
<text top="150" left="398" width="50" height="9" font="31">Consultant</text>
<text top="138" left="483" width="42" height="9" font="31">Speakers</text>
<text top="150" left="487" width="32" height="9" font="31">Bureau</text>
<text top="126" left="548" width="53" height="9" font="31">Ownership/</text>
<text top="138" left="546" width="59" height="9" font="31">Partnership/</text>
<text top="150" left="555" width="41" height="9" font="31">Principal</text>
<text top="138" left="625" width="40" height="9" font="31">Personal</text>
<text top="150" left="625" width="42" height="9" font="31">Research</text>
<text top="114" left="714" width="60" height="9" font="31">Institutional,</text>
<text top="126" left="709" width="71" height="9" font="31">Organizational,</text>
<text top="138" left="703" width="84" height="9" font="31">or Other Financial</text>
<text top="150" left="728" width="23" height="9" font="31">Bene</text>
<text top="148" left="751" width="10" height="12" font="31">ﬁt</text>
<text top="138" left="841" width="31" height="9" font="31">Expert</text>
<text top="150" left="838" width="37" height="9" font="31">Witness</text>
<text top="138" left="920" width="88" height="9" font="31">Voting Recusals by</text>
<text top="150" left="945" width="34" height="9" font="31">Section</text>
<text top="148" left="979" width="5" height="12" font="32"><a href="1-s2.0-S0735109718368451-main.html#65">†</a></text>
<text top="169" left="59" width="68" height="9" font="31">Michelle Gurvitz</text>
<text top="169" left="197" width="157" height="9" font="31">Harvard Medical School; Brigham and</text>
<text top="181" left="216" width="31" height="9" font="31">Women</text>
<text top="179" left="248" width="103" height="12" font="31">’s Hospital—Instructor of</text>
<text top="193" left="221" width="126" height="9" font="31">Pediatrics, Assistant Professor</text>
<text top="169" left="413" width="22" height="9" font="31">None</text>
<text top="169" left="493" width="22" height="9" font="31">None</text>
<text top="169" left="564" width="22" height="9" font="31">None</text>
<text top="169" left="634" width="22" height="9" font="31">None</text>
<text top="169" left="734" width="22" height="9" font="31">None</text>
<text top="169" left="845" width="22" height="9" font="31">None</text>
<text top="169" left="953" width="22" height="9" font="31">None</text>
<text top="212" left="59" width="47" height="9" font="31">Paul Khairy</text>
<text top="212" left="188" width="175" height="9" font="31">Montreal Heart Institute Adult Congenital</text>
<text top="224" left="194" width="27" height="9" font="31">Center</text>
<text top="223" left="221" width="137" height="12" font="31">—Director; Professor of Medicine</text>
<text top="212" left="413" width="22" height="9" font="31">None</text>
<text top="212" left="493" width="22" height="9" font="31">None</text>
<text top="212" left="564" width="22" height="9" font="31">None</text>
<text top="212" left="634" width="22" height="9" font="31">None</text>
<text top="215" left="691" width="6" height="10" font="33">n</text>
<text top="216" left="705" width="48" height="9" font="31">Boehringer</text>
<text top="232" left="701" width="43" height="9" font="31">Ingelheim</text>
<text top="232" left="745" width="5" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#65">§</a></text>
<text top="247" left="691" width="6" height="10" font="33">n</text>
<text top="248" left="705" width="73" height="9" font="31">St. Jude Medic<a href="1-s2.0-S0735109718368451-main.html#65">al</a></text>
<text top="248" left="778" width="5" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#65">§</a></text>
<text top="263" left="691" width="6" height="10" font="33">n</text>
<text top="264" left="705" width="44" height="9" font="31">Medtronic</text>
<text top="264" left="750" width="5" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#65">§</a></text>
<text top="278" left="691" width="6" height="10" font="33">n</text>
<text top="279" left="705" width="36" height="9" font="31">Actelion</text>
<text top="279" left="742" width="5" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#65">§</a></text>
<text top="212" left="845" width="22" height="9" font="31">None</text>
<text top="212" left="915" width="98" height="9" font="31">4.1.1, 4.1.2, 4.1.3, 4.1.4,</text>
<text top="224" left="923" width="82" height="9" font="31">4.1.5, 4.2.6, 4.3.1.1,</text>
<text top="236" left="922" width="85" height="9" font="31">4.3.2, 4.3.5, 4.4.6.1,</text>
<text top="248" left="949" width="30" height="9" font="31">4.4.6.2</text>
<text top="298" left="59" width="89" height="9" font="31">Michael J. Landzberg</text>
<text top="298" left="186" width="66" height="9" font="31">Boston Children</text>
<text top="297" left="252" width="113" height="12" font="31">’s Hospital— Director, Adult</text>
<text top="310" left="213" width="142" height="9" font="31">Congenital Heart Service; Harvard</text>
<text top="322" left="202" width="63" height="9" font="31">Medical School</text>
<text top="321" left="265" width="100" height="12" font="31">—Associate Professor of</text>
<text top="334" left="265" width="37" height="9" font="31">Medicine</text>
<text top="298" left="413" width="22" height="9" font="31">None</text>
<text top="298" left="493" width="22" height="9" font="31">None</text>
<text top="298" left="564" width="22" height="9" font="31">None</text>
<text top="298" left="634" width="22" height="9" font="31">None</text>
<text top="301" left="691" width="6" height="10" font="33">n</text>
<text top="302" left="705" width="27" height="9" font="31">Gilead</text>
<text top="317" left="691" width="6" height="10" font="33">n</text>
<text top="318" left="705" width="36" height="9" font="31">Actelion</text>
<text top="298" left="845" width="22" height="9" font="31">None</text>
<text top="298" left="915" width="98" height="9" font="31">4.1.1, 4.1.2, 4.1.3, 4.1.4,</text>
<text top="310" left="919" width="90" height="9" font="31">4.1.5, 4.4.6.1, 4.4.6.2</text>
<text top="354" left="59" width="44" height="9" font="31">Arwa Saidi</text>
<text top="354" left="187" width="171" height="9" font="31">University of Florida College of Medicine</text>
<text top="352" left="358" width="7" height="12" font="31">—</text>
<text top="366" left="210" width="146" height="9" font="31">Professor, Congenital Heart Center</text>
<text top="354" left="413" width="22" height="9" font="31">None</text>
<text top="354" left="493" width="22" height="9" font="31">None</text>
<text top="354" left="564" width="22" height="9" font="31">None</text>
<text top="354" left="634" width="22" height="9" font="31">None</text>
<text top="356" left="691" width="6" height="10" font="33">n</text>
<text top="357" left="705" width="36" height="9" font="31">Actelion</text>
<text top="357" left="742" width="5" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#65">§</a></text>
<text top="354" left="845" width="22" height="9" font="31">None</text>
<text top="354" left="915" width="98" height="9" font="31">4.1.1, 4.1.2, 4.1.3, 4.1.4,</text>
<text top="366" left="919" width="90" height="9" font="31">4.1.5, 4.4.6.1, 4.4.6.2</text>
<text top="385" left="59" width="82" height="9" font="31">Anne Marie Valente</text>
<text top="385" left="197" width="67" height="9" font="31">Boston Children</text>
<text top="383" left="264" width="102" height="12" font="31">’s Hospital, Brigham and</text>
<text top="397" left="201" width="31" height="9" font="31">Women</text>
<text top="395" left="233" width="133" height="12" font="31">’s Hospital—Outpatient Director,</text>
<text top="409" left="202" width="163" height="9" font="31">Boston Adult Congenital Heart Disease</text>
<text top="421" left="205" width="157" height="9" font="31">and Pulmonary Hypertension Service;</text>
<text top="433" left="211" width="99" height="9" font="31">Harvard Medical School</text>
<text top="431" left="310" width="46" height="12" font="31">—Associate</text>
<text top="444" left="207" width="153" height="9" font="31">Professor of Medicine and Pediatrics</text>
<text top="385" left="413" width="22" height="9" font="31">None</text>
<text top="385" left="493" width="22" height="9" font="31">None</text>
<text top="385" left="564" width="22" height="9" font="31">None</text>
<text top="385" left="634" width="22" height="9" font="31">None</text>
<text top="385" left="734" width="22" height="9" font="31">None</text>
<text top="385" left="845" width="22" height="9" font="31">None</text>
<text top="385" left="953" width="22" height="9" font="31">None</text>
<text top="464" left="59" width="82" height="9" font="31">George F. Van Hare</text>
<text top="464" left="208" width="136" height="9" font="31">Washington University School of</text>
<text top="476" left="224" width="37" height="9" font="31">Medicine</text>
<text top="474" left="261" width="82" height="12" font="31">—Director, Pediatric</text>
<text top="488" left="217" width="124" height="9" font="31">Cardiology; St. Louis Children</text>
<text top="486" left="341" width="9" height="12" font="31">’s,</text>
<text top="500" left="205" width="151" height="9" font="31">Washington University Heart Center</text>
<text top="498" left="355" width="7" height="12" font="31">—</text>
<text top="512" left="260" width="48" height="9" font="31">Co-Director</text>
<text top="464" left="413" width="22" height="9" font="31">None</text>
<text top="464" left="493" width="22" height="9" font="31">None</text>
<text top="464" left="564" width="22" height="9" font="31">None</text>
<text top="464" left="634" width="22" height="9" font="31">None</text>
<text top="464" left="734" width="22" height="9" font="31">None</text>
<text top="464" left="845" width="22" height="9" font="31">None</text>
<text top="464" left="953" width="22" height="9" font="31">None</text>
<text top="535" left="59" width="959" height="8" font="34">This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls</text>
<text top="547" left="59" width="396" height="8" font="34">of the writing committee during the document development process. The table does not necessarily re</text>
<text top="546" left="455" width="563" height="11" font="34">ﬂect relationships with industry at the time of publication. A person is deemed to have a signiﬁcant interest in a business if the interest represents</text>
<text top="559" left="59" width="50" height="8" font="34">ownership of</text>
<text top="558" left="111" width="907" height="11" font="34">$5% of the voting stock or share of the business entity, or ownership of $$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the</text>
<text top="571" left="59" width="177" height="8" font="34">previous year. Relationships that exist with no</text>
<text top="570" left="239" width="779" height="11" font="34">ﬁnancial beneﬁt are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. According to the ACC/AHA, a person has a relevant relationship IF: a) the</text>
<text top="583" left="59" width="959" height="8" font="34">relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the</text>
<text top="595" left="59" width="461" height="8" font="34">document or makes a competing drug or device addressed in the document; or c) the person or a member of the person</text>
<text top="593" left="520" width="498" height="11" font="34">’s household, has a reasonable potential for ﬁnancial, professional or other personal gain or loss as a result of the issues/content</text>
<text top="607" left="59" width="106" height="8" font="34">addressed in the document.</text>
<text top="619" left="59" width="959" height="8" font="34">*The ACHD Guideline began in March 2014. Over the initial years of the CMS Open Payment System, understandably, there have been issues related to accurate reporting of food and beverage payments. For this reason, the ACC and AHA have not</text>
<text top="631" left="59" width="264" height="8" font="34">considered these minor charges relevant relationships with industry.</text>
<text top="641" left="59" width="883" height="11" font="34">†Writing committee members are required to recuse themselves from voting on sections to which their speciﬁc relationships with industry and other entities may apply. Section numbers pertain to those in the full-text guideline.</text>
<text top="653" left="59" width="82" height="11" font="34">‡No ﬁnancial beneﬁt.</text>
<text top="667" left="59" width="23" height="8" font="34">§Signi</text>
<text top="665" left="82" width="72" height="11" font="34">ﬁcant relationship.</text>
<text top="677" left="59" width="959" height="11" font="34"><a href="1-s2.0-S0735109718368451-main.html#65">k</a>CMS reported payments to Dr. Dearani in 2016 related to research for the Sorin Group and Cormatrix; however, he disagrees with this report. The sections authored by Dr. Dearani have been reviewed, and it was afﬁrmed that there was no implication of</text>
<text top="691" left="59" width="23" height="8" font="34">any in</text>
<text top="689" left="82" width="75" height="11" font="34">ﬂuence of industry.</text>
<text top="705" left="67" width="876" height="8" font="34">ACC indicates American College of Cardiology; AHA, American Heart Association; CMS, Centers for Medicare &amp; Medicaid Services; COACH, Columbus Ohio Adult Congenital Heart; and UCLA, University of California, Los Angeles.</text>
<text top="100" left="1100" width="0" height="9" font="13">Stout</text>
<text top="126" left="1100" width="0" height="9" font="13">et</text>
<text top="137" left="1100" width="0" height="9" font="13">al</text>
<text top="145" left="1100" width="0" height="9" font="13">.</text>
<text top="665" left="1102" width="0" height="7" font="9">JA</text>
<text top="677" left="1102" width="0" height="7" font="9">C</text>
<text top="684" left="1102" width="0" height="7" font="9">C</text>
<text top="694" left="1102" width="0" height="7" font="9">V</text>
<text top="700" left="1102" width="0" height="7" font="9">O</text>
<text top="707" left="1102" width="0" height="7" font="9">L</text>
<text top="713" left="1102" width="0" height="7" font="9">.</text>
<text top="720" left="1102" width="0" height="7" font="9">73</text>
<text top="731" left="1102" width="0" height="7" font="9">,</text>
<text top="738" left="1102" width="0" height="7" font="9">N</text>
<text top="745" left="1102" width="0" height="7" font="9">O</text>
<text top="752" left="1102" width="0" height="7" font="9">.</text>
<text top="759" left="1102" width="0" height="7" font="9">1</text>
<text top="763" left="1102" width="0" height="7" font="9">2</text>
<text top="769" left="1102" width="0" height="7" font="9">,</text>
<text top="776" left="1102" width="0" height="7" font="9">2</text>
<text top="781" left="1102" width="0" height="7" font="9">01</text>
<text top="792" left="1102" width="0" height="7" font="9">9</text>
<text top="100" left="1085" width="0" height="9" font="13">2018</text>
<text top="125" left="1085" width="0" height="9" font="13">ACHD</text>
<text top="152" left="1085" width="0" height="9" font="13">Guideline:</text>
<text top="197" left="1085" width="0" height="9" font="13">Executive</text>
<text top="240" left="1085" width="0" height="9" font="13">Summary</text>
<text top="683" left="1087" width="0" height="7" font="9">APR</text>
<text top="702" left="1087" width="0" height="7" font="9">I</text>
<text top="706" left="1087" width="0" height="7" font="9">L</text>
<text top="715" left="1087" width="0" height="7" font="9">2</text>
<text top="721" left="1087" width="0" height="7" font="9">,</text>
<text top="728" left="1087" width="0" height="7" font="9">2</text>
<text top="733" left="1087" width="0" height="7" font="9">0</text>
<text top="740" left="1087" width="0" height="7" font="9">1</text>
<text top="744" left="1087" width="0" height="7" font="9">9:</text>
<text top="753" left="1087" width="0" height="7" font="9">1494</text>
<text top="773" left="1087" width="0" height="10" font="9">–</text>
<text top="780" left="1087" width="0" height="7" font="9">563</text>
<text top="50" left="1101" width="0" height="9" font="5">1558</text>
</page>
<page number="66" position="absolute" top="0" left="0" height="864" width="1160">
<text top="78" left="59" width="931" height="16" font="29">APPENDIX 2. REVIEWER RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (COMPREHENSIVE)—2018 AHA/ACC GUIDELINE FOR THE</text>
<text top="96" left="59" width="552" height="16" font="29">MANAGEMENT OF ADULTS WITH CONGENITAL HEART DISEASE (FEBRUARY 2018)</text>
<text top="177" left="59" width="43" height="9" font="31">Reviewer</text>
<text top="177" left="189" width="71" height="9" font="31">Representation</text>
<text top="177" left="344" width="58" height="9" font="31">Employment</text>
<text top="177" left="495" width="50" height="9" font="31">Consultant</text>
<text top="165" left="585" width="42" height="9" font="31">Speakers</text>
<text top="177" left="590" width="32" height="9" font="31">Bureau</text>
<text top="153" left="642" width="53" height="9" font="31">Ownership/</text>
<text top="165" left="639" width="59" height="9" font="31">Partnership/</text>
<text top="177" left="648" width="40" height="9" font="31">Principal</text>
<text top="165" left="728" width="40" height="9" font="31">Personal</text>
<text top="177" left="727" width="42" height="9" font="31">Research</text>
<text top="141" left="831" width="60" height="9" font="31">Institutional,</text>
<text top="153" left="819" width="84" height="9" font="31">Organizational, or</text>
<text top="165" left="826" width="71" height="9" font="31">Other Financial</text>
<text top="177" left="845" width="23" height="9" font="31">Bene</text>
<text top="175" left="868" width="10" height="12" font="31">ﬁt</text>
<text top="165" left="958" width="31" height="9" font="31">Expert</text>
<text top="177" left="955" width="37" height="9" font="31">Witness</text>
<text top="196" left="59" width="90" height="9" font="31">Samuel J. Asirvatham</text>
<text top="196" left="171" width="10" height="9" font="31">Of</text>
<text top="195" left="181" width="86" height="12" font="31">ﬁcial Reviewer—AHA</text>
<text top="196" left="291" width="48" height="9" font="31">Mayo Clinic</text>
<text top="195" left="339" width="116" height="12" font="31">—Professor of Medicine and</text>
<text top="208" left="353" width="40" height="9" font="31">Pediatrics</text>
<text top="199" left="472" width="6" height="10" font="33">n</text>
<text top="200" left="486" width="39" height="9" font="31">Abiomed</text>
<text top="212" left="472" width="6" height="10" font="33">n</text>
<text top="213" left="486" width="36" height="9" font="31">AtriCure</text>
<text top="225" left="472" width="6" height="10" font="33">n</text>
<text top="225" left="486" width="78" height="9" font="31">Biosense Webster</text>
<text top="237" left="472" width="6" height="10" font="33">n</text>
<text top="238" left="486" width="40" height="9" font="31">Biotronik</text>
<text top="253" left="472" width="6" height="10" font="33">n</text>
<text top="254" left="486" width="63" height="9" font="31">Boston Scienti</text>
<text top="252" left="550" width="10" height="12" font="31">ﬁc</text>
<text top="254" left="560" width="4" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">*</a></text>
<text top="266" left="472" width="6" height="10" font="33">n</text>
<text top="267" left="486" width="44" height="9" font="31">Medtronic</text>
<text top="279" left="472" width="6" height="10" font="33">n</text>
<text top="279" left="486" width="21" height="9" font="31">Sano</text>
<text top="278" left="508" width="41" height="12" font="31">ﬁ-aventis</text>
<text top="291" left="472" width="6" height="10" font="33">n</text>
<text top="292" left="486" width="73" height="9" font="31">St. Jude Medical</text>
<text top="196" left="595" width="22" height="9" font="31">None</text>
<text top="196" left="658" width="22" height="9" font="31">None</text>
<text top="196" left="737" width="22" height="9" font="31">None</text>
<text top="196" left="850" width="22" height="9" font="31">None</text>
<text top="196" left="962" width="22" height="9" font="31">None</text>
<text top="311" left="59" width="66" height="9" font="31">Wendy M. Book</text>
<text top="311" left="171" width="10" height="9" font="31">Of</text>
<text top="310" left="181" width="86" height="12" font="31">ﬁcial Reviewer—AHA</text>
<text top="311" left="289" width="71" height="9" font="31">Emory University</text>
<text top="310" left="360" width="98" height="12" font="31">—Professor of Medicine</text>
<text top="323" left="298" width="164" height="9" font="31">and Director of Emory Adult Congenital</text>
<text top="335" left="300" width="161" height="9" font="31">Heart Center, Department of Medicine</text>
<text top="311" left="509" width="22" height="9" font="31">None</text>
<text top="311" left="595" width="22" height="9" font="31">None</text>
<text top="311" left="658" width="22" height="9" font="31">None</text>
<text top="311" left="737" width="22" height="9" font="31">None</text>
<text top="314" left="803" width="6" height="10" font="33">n</text>
<text top="315" left="817" width="36" height="9" font="31">Actelion</text>
<text top="314" left="933" width="6" height="10" font="33">n</text>
<text top="315" left="947" width="49" height="9" font="31">Defendant,</text>
<text top="328" left="946" width="72" height="9" font="31">congenital heart</text>
<text top="341" left="946" width="59" height="9" font="31">disease, 2015</text>
<text top="358" left="59" width="76" height="9" font="31">Samuel S. Gidding</text>
<text top="358" left="176" width="10" height="9" font="31">Of</text>
<text top="356" left="186" width="88" height="12" font="31">ﬁcial Reviewer—ACC/</text>
<text top="370" left="193" width="80" height="9" font="31">AHA Task Force on</text>
<text top="382" left="199" width="66" height="9" font="31">Clinical Practice</text>
<text top="393" left="211" width="43" height="9" font="31">Guidelines</text>
<text top="358" left="287" width="172" height="9" font="31">Nemours Cardiac Center DuPont Hospital</text>
<text top="370" left="298" width="49" height="9" font="31">for Children</text>
<text top="368" left="348" width="115" height="12" font="31">—Chief, Division of Pediatric</text>
<text top="382" left="358" width="45" height="9" font="31">Cardiology</text>
<text top="358" left="509" width="22" height="9" font="31">None</text>
<text top="358" left="595" width="22" height="9" font="31">None</text>
<text top="358" left="658" width="22" height="9" font="31">None</text>
<text top="358" left="737" width="22" height="9" font="31">None</text>
<text top="358" left="850" width="22" height="9" font="31">None</text>
<text top="358" left="962" width="22" height="9" font="31">None</text>
<text top="413" left="59" width="46" height="9" font="31">Yuli Y. Kim</text>
<text top="413" left="171" width="10" height="9" font="31">Of</text>
<text top="411" left="181" width="86" height="12" font="31">ﬁcial Reviewer—AHA</text>
<text top="413" left="296" width="110" height="9" font="31">University of Pennsylvania</text>
<text top="411" left="406" width="44" height="12" font="31">—Assistant</text>
<text top="425" left="312" width="131" height="9" font="31">Professor of Medicine; Children</text>
<text top="423" left="443" width="6" height="12" font="31">’s</text>
<text top="437" left="311" width="100" height="9" font="31">Hospital of Philadelphia</text>
<text top="435" left="411" width="39" height="12" font="31">—Medical</text>
<text top="449" left="299" width="163" height="9" font="31">Director, Philadelphia Adult Congenital</text>
<text top="461" left="354" width="54" height="9" font="31">Heart Center</text>
<text top="413" left="509" width="22" height="9" font="31">None</text>
<text top="413" left="595" width="22" height="9" font="31">None</text>
<text top="413" left="658" width="22" height="9" font="31">None</text>
<text top="413" left="737" width="22" height="9" font="31">None</text>
<text top="413" left="850" width="22" height="9" font="31">None</text>
<text top="413" left="962" width="22" height="9" font="31">None</text>
<text top="480" left="59" width="77" height="9" font="31">Geetha Raghuveer</text>
<text top="480" left="178" width="10" height="9" font="31">Of</text>
<text top="478" left="188" width="84" height="12" font="31">ﬁcial Reviewer—ACC</text>
<text top="492" left="184" width="82" height="9" font="31">Board of Governors</text>
<text top="480" left="298" width="35" height="9" font="31">Children</text>
<text top="478" left="333" width="115" height="12" font="31">’s Mercy Hospital—Pediatric</text>
<text top="492" left="306" width="149" height="9" font="31">Cardiologist; University of Missouri,</text>
<text top="504" left="312" width="130" height="9" font="31">Kansas City School of Medicine</text>
<text top="502" left="442" width="7" height="12" font="31">—</text>
<text top="516" left="334" width="94" height="9" font="31">Professor of Pediatrics</text>
<text top="480" left="509" width="22" height="9" font="31">None</text>
<text top="480" left="595" width="22" height="9" font="31">None</text>
<text top="480" left="658" width="22" height="9" font="31">None</text>
<text top="480" left="737" width="22" height="9" font="31">None</text>
<text top="480" left="850" width="22" height="9" font="31">None</text>
<text top="480" left="962" width="22" height="9" font="31">None</text>
<text top="535" left="59" width="72" height="9" font="31">Carole A. Warnes</text>
<text top="535" left="178" width="10" height="9" font="31">Of</text>
<text top="533" left="188" width="84" height="12" font="31">ﬁcial Reviewer—ACC</text>
<text top="547" left="188" width="74" height="9" font="31">Board of Trustees</text>
<text top="535" left="300" width="48" height="9" font="31">Mayo Clinic</text>
<text top="533" left="348" width="98" height="12" font="31">—Professor of Medicine</text>
<text top="535" left="509" width="22" height="9" font="31">None</text>
<text top="535" left="595" width="22" height="9" font="31">None</text>
<text top="535" left="658" width="22" height="9" font="31">None</text>
<text top="535" left="737" width="22" height="9" font="31">None</text>
<text top="535" left="850" width="22" height="9" font="31">None</text>
<text top="535" left="962" width="22" height="9" font="31">None</text>
<text top="566" left="59" width="57" height="9" font="31">Peter J. Bartz</text>
<text top="566" left="171" width="95" height="9" font="31">Organizational Reviewer</text>
<text top="564" left="266" width="7" height="12" font="31">—</text>
<text top="578" left="186" width="16" height="9" font="31">ASE</text>
<text top="566" left="284" width="35" height="9" font="31">Children</text>
<text top="564" left="318" width="145" height="12" font="31">’s Hospital of Wisconsin—Associate</text>
<text top="578" left="298" width="164" height="9" font="31">Professor, Medical College of Wisconsin</text>
<text top="566" left="509" width="22" height="9" font="31">None</text>
<text top="566" left="595" width="22" height="9" font="31">None</text>
<text top="566" left="658" width="22" height="9" font="31">None</text>
<text top="566" left="737" width="22" height="9" font="31">None</text>
<text top="566" left="850" width="22" height="9" font="31">None</text>
<text top="566" left="962" width="22" height="9" font="31">None</text>
<text top="597" left="59" width="71" height="9" font="31">Mitchell I. Cohen</text>
<text top="597" left="171" width="101" height="9" font="31">Organizational Reviewer</text>
<text top="595" left="272" width="7" height="12" font="31">—</text>
<text top="609" left="216" width="17" height="9" font="31">HRS</text>
<text top="597" left="295" width="91" height="9" font="31">Inova Fairfax Children</text>
<text top="595" left="386" width="65" height="12" font="31">’s Hospital—Co-</text>
<text top="609" left="299" width="164" height="9" font="31">Director of the Heart Center and Chief,</text>
<text top="621" left="339" width="84" height="9" font="31">Pediatric Cardiology</text>
<text top="597" left="509" width="22" height="9" font="31">None</text>
<text top="597" left="595" width="22" height="9" font="31">None</text>
<text top="597" left="658" width="22" height="9" font="31">None</text>
<text top="597" left="737" width="22" height="9" font="31">None</text>
<text top="597" left="850" width="22" height="9" font="31">None</text>
<text top="597" left="962" width="22" height="9" font="31">None</text>
<text top="640" left="59" width="77" height="9" font="31">Marshall L. Jacobs</text>
<text top="640" left="171" width="101" height="9" font="31">Organizational Reviewer</text>
<text top="639" left="272" width="7" height="12" font="31">—</text>
<text top="652" left="214" width="22" height="9" font="31">AATS</text>
<text top="640" left="298" width="143" height="9" font="31">Johns Hopkins School of Medicine</text>
<text top="639" left="441" width="7" height="12" font="31">—</text>
<text top="652" left="309" width="143" height="9" font="31">Professor of Surgery and Director,</text>
<text top="664" left="310" width="142" height="9" font="31">Pediatric Heart Surgery Outcomes</text>
<text top="676" left="362" width="37" height="9" font="31">Research</text>
<text top="640" left="509" width="22" height="9" font="31">None</text>
<text top="640" left="595" width="22" height="9" font="31">None</text>
<text top="640" left="658" width="22" height="9" font="31">None</text>
<text top="640" left="737" width="22" height="9" font="31">None</text>
<text top="640" left="850" width="22" height="9" font="31">None</text>
<text top="640" left="962" width="22" height="9" font="31">None</text>
<text top="694" left="59" width="64" height="9" font="31">Larry A. Latson</text>
<text top="694" left="171" width="101" height="9" font="31">Organizational Reviewer</text>
<text top="692" left="272" width="7" height="12" font="31">—</text>
<text top="706" left="215" width="19" height="9" font="31">SCAI</text>
<text top="694" left="291" width="94" height="9" font="31">Joe DiMaggio Children</text>
<text top="692" left="385" width="70" height="12" font="31">’s Hospital Heart</text>
<text top="706" left="305" width="35" height="9" font="31">Institute</text>
<text top="704" left="340" width="117" height="12" font="31">—Medical Director, Pediatric</text>
<text top="718" left="318" width="124" height="9" font="31">and Congenital Interventional</text>
<text top="730" left="358" width="45" height="9" font="31">Cardiology</text>
<text top="697" left="472" width="6" height="10" font="33">n</text>
<text top="698" left="486" width="58" height="9" font="31">Gore Medical</text>
<text top="694" left="577" width="22" height="9" font="31">None</text>
<text top="694" left="639" width="22" height="9" font="31">None</text>
<text top="694" left="703" width="22" height="9" font="31">None</text>
<text top="697" left="803" width="6" height="10" font="33">n</text>
<text top="698" left="817" width="73" height="9" font="31">St. Jude Medical</text>
<text top="694" left="962" width="22" height="9" font="31">None</text>
<text top="750" left="913" width="105" height="8" font="34">Continued on the next page</text>
<text top="57" left="1102" width="0" height="7" font="9">J</text>
<text top="63" left="1102" width="0" height="7" font="9">A</text>
<text top="69" left="1102" width="0" height="7" font="9">C</text>
<text top="76" left="1102" width="0" height="7" font="9">C</text>
<text top="86" left="1102" width="0" height="7" font="9">V</text>
<text top="92" left="1102" width="0" height="7" font="9">O</text>
<text top="99" left="1102" width="0" height="7" font="9">L</text>
<text top="105" left="1102" width="0" height="7" font="9">.</text>
<text top="112" left="1102" width="0" height="7" font="9">7</text>
<text top="117" left="1102" width="0" height="7" font="9">3</text>
<text top="123" left="1102" width="0" height="7" font="9">,N</text>
<text top="137" left="1102" width="0" height="7" font="9">O</text>
<text top="144" left="1102" width="0" height="7" font="9">.</text>
<text top="151" left="1102" width="0" height="7" font="9">1</text>
<text top="155" left="1102" width="0" height="7" font="9">2</text>
<text top="161" left="1102" width="0" height="7" font="9">,2</text>
<text top="173" left="1102" width="0" height="7" font="9">0</text>
<text top="180" left="1102" width="0" height="7" font="9">1</text>
<text top="184" left="1102" width="0" height="7" font="9">9</text>
<text top="703" left="1100" width="0" height="9" font="13">Stout</text>
<text top="728" left="1100" width="0" height="9" font="13">et</text>
<text top="739" left="1100" width="0" height="9" font="13">al</text>
<text top="747" left="1100" width="0" height="9" font="13">.</text>
<text top="57" left="1087" width="0" height="7" font="9">AP</text>
<text top="70" left="1087" width="0" height="7" font="9">RI</text>
<text top="80" left="1087" width="0" height="7" font="9">L</text>
<text top="89" left="1087" width="0" height="7" font="9">2</text>
<text top="95" left="1087" width="0" height="7" font="9">,</text>
<text top="102" left="1087" width="0" height="7" font="9">2</text>
<text top="108" left="1087" width="0" height="7" font="9">01</text>
<text top="118" left="1087" width="0" height="7" font="9">9</text>
<text top="124" left="1087" width="0" height="7" font="9">:</text>
<text top="127" left="1087" width="0" height="7" font="9">1</text>
<text top="131" left="1087" width="0" height="7" font="9">4</text>
<text top="137" left="1087" width="0" height="7" font="9">9</text>
<text top="143" left="1087" width="0" height="7" font="9">4</text>
<text top="148" left="1087" width="0" height="10" font="9">–</text>
<text top="155" left="1087" width="0" height="7" font="9">563</text>
<text top="572" left="1085" width="0" height="9" font="13">2018</text>
<text top="596" left="1085" width="0" height="9" font="13">ACHD</text>
<text top="623" left="1085" width="0" height="9" font="13">Guideline:</text>
<text top="668" left="1085" width="0" height="9" font="13">Executive</text>
<text top="711" left="1085" width="0" height="9" font="13">Summary</text>
<text top="782" left="1101" width="0" height="9" font="5">1559</text>
</page>
<page number="67" position="absolute" top="0" left="0" height="864" width="1160">
<text top="59" left="59" width="158" height="16" font="29">APPENDIX 2. CONTINUED</text>
<text top="147" left="60" width="43" height="9" font="31">Reviewer</text>
<text top="147" left="190" width="71" height="9" font="31">Representation</text>
<text top="147" left="345" width="58" height="9" font="31">Employment</text>
<text top="147" left="495" width="50" height="9" font="31">Consultant</text>
<text top="135" left="585" width="42" height="9" font="31">Speakers</text>
<text top="147" left="590" width="32" height="9" font="31">Bureau</text>
<text top="123" left="642" width="53" height="9" font="31">Ownership/</text>
<text top="135" left="640" width="58" height="9" font="31">Partnership/</text>
<text top="147" left="649" width="41" height="9" font="31">Principal</text>
<text top="135" left="729" width="40" height="9" font="31">Personal</text>
<text top="147" left="728" width="42" height="9" font="31">Research</text>
<text top="111" left="831" width="60" height="9" font="31">Institutional,</text>
<text top="123" left="820" width="84" height="9" font="31">Organizational, or</text>
<text top="135" left="826" width="71" height="9" font="31">Other Financial</text>
<text top="147" left="845" width="23" height="9" font="31">Bene</text>
<text top="146" left="868" width="10" height="12" font="31">ﬁt</text>
<text top="135" left="958" width="31" height="9" font="31">Expert</text>
<text top="147" left="955" width="36" height="9" font="31">Witness</text>
<text top="166" left="60" width="95" height="9" font="31">Constantine Mavroudis</text>
<text top="166" left="172" width="101" height="9" font="31">Organizational Reviewer</text>
<text top="165" left="272" width="7" height="12" font="31">—</text>
<text top="178" left="218" width="15" height="9" font="31">STS</text>
<text top="166" left="295" width="119" height="9" font="31">Florida Hospital for Children</text>
<text top="165" left="414" width="39" height="12" font="31">—Medical</text>
<text top="178" left="299" width="164" height="9" font="31">Director, Pediatric and Congenital Heart</text>
<text top="190" left="367" width="27" height="9" font="31">Center</text>
<text top="166" left="510" width="22" height="9" font="31">None</text>
<text top="166" left="595" width="22" height="9" font="31">None</text>
<text top="166" left="658" width="22" height="9" font="31">None</text>
<text top="166" left="738" width="22" height="9" font="31">None</text>
<text top="166" left="851" width="22" height="9" font="31">None</text>
<text top="166" left="963" width="22" height="9" font="31">None</text>
<text top="210" left="60" width="81" height="9" font="31">Doff B. McElhinney</text>
<text top="210" left="172" width="101" height="9" font="31">Organizational Reviewer</text>
<text top="208" left="272" width="7" height="12" font="31">—</text>
<text top="221" left="216" width="19" height="9" font="31">SCAI</text>
<text top="210" left="309" width="81" height="9" font="31">Stanford University</text>
<text top="208" left="390" width="49" height="12" font="31">—Professor,</text>
<text top="221" left="299" width="164" height="9" font="31">Cardiothoracic Surgery and of Pediatrics</text>
<text top="212" left="473" width="6" height="10" font="33">n</text>
<text top="213" left="487" width="44" height="9" font="31"><a href="1-s2.0-S0735109718368451-main.html#70">Medtronic</a></text>
<text top="213" left="531" width="4" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">*</a></text>
<text top="210" left="595" width="22" height="9" font="31">None</text>
<text top="210" left="658" width="22" height="9" font="31">None</text>
<text top="210" left="738" width="22" height="9" font="31">None</text>
<text top="210" left="851" width="22" height="9" font="31">None</text>
<text top="210" left="963" width="22" height="9" font="31">None</text>
<text top="241" left="60" width="74" height="9" font="31">Erwin N. Oechslin</text>
<text top="241" left="172" width="101" height="9" font="31">Organizational Reviewer</text>
<text top="239" left="272" width="7" height="12" font="31">—</text>
<text top="253" left="209" width="32" height="9" font="31">ISACHD</text>
<text top="241" left="300" width="90" height="9" font="31">University of Toronto</text>
<text top="239" left="390" width="58" height="12" font="31">—Professor of</text>
<text top="253" left="300" width="155" height="9" font="31">Medicine; Peter Munk Cardiac Centre</text>
<text top="251" left="455" width="7" height="12" font="31">—</text>
<text top="265" left="313" width="136" height="9" font="31">Director, Adult Congenital Heart</text>
<text top="277" left="346" width="70" height="9" font="31">Disease Program</text>
<text top="244" left="473" width="6" height="10" font="33">n</text>
<text top="244" left="487" width="36" height="9" font="31">Actelion</text>
<text top="241" left="595" width="22" height="9" font="31">None</text>
<text top="241" left="658" width="22" height="9" font="31">None</text>
<text top="241" left="738" width="22" height="9" font="31">None</text>
<text top="241" left="851" width="22" height="9" font="31">None</text>
<text top="241" left="963" width="22" height="9" font="31">None</text>
<text top="296" left="60" width="73" height="9" font="31">John K. Triedman</text>
<text top="296" left="172" width="101" height="9" font="31">Organizational Reviewer</text>
<text top="294" left="272" width="7" height="12" font="31">—</text>
<text top="308" left="217" width="17" height="9" font="31">HRS</text>
<text top="296" left="302" width="67" height="9" font="31">Boston Children</text>
<text top="294" left="369" width="76" height="12" font="31">’s Hospital—Senior</text>
<text top="308" left="313" width="136" height="9" font="31">Associate in Cardiology; Harvard</text>
<text top="320" left="299" width="63" height="9" font="31">Medical School</text>
<text top="318" left="362" width="101" height="12" font="31">—Professor of Pediatrics</text>
<text top="299" left="473" width="6" height="10" font="33">n</text>
<text top="299" left="487" width="78" height="9" font="31">Biosense Webster</text>
<text top="296" left="595" width="22" height="9" font="31">None</text>
<text top="296" left="658" width="22" height="9" font="31">None</text>
<text top="296" left="738" width="22" height="9" font="31">None</text>
<text top="296" left="851" width="22" height="9" font="31">None</text>
<text top="296" left="963" width="22" height="9" font="31">None</text>
<text top="339" left="60" width="76" height="9" font="31">Sana M. Al-Khatib</text>
<text top="339" left="174" width="74" height="9" font="31">Content Reviewer</text>
<text top="337" left="249" width="27" height="12" font="31">—ACC/</text>
<text top="351" left="193" width="80" height="9" font="31">AHA Task Force on</text>
<text top="363" left="200" width="66" height="9" font="31">Clinical Practice</text>
<text top="375" left="211" width="43" height="9" font="31">Guidelines</text>
<text top="339" left="285" width="131" height="9" font="31">Duke University Medical Center</text>
<text top="337" left="416" width="46" height="12" font="31">—Professor</text>
<text top="351" left="357" width="49" height="9" font="31">of Medicine</text>
<text top="339" left="510" width="22" height="9" font="31">None</text>
<text top="339" left="595" width="22" height="9" font="31">None</text>
<text top="339" left="658" width="22" height="9" font="31">None</text>
<text top="339" left="738" width="22" height="9" font="31">None</text>
<text top="339" left="851" width="22" height="9" font="31">None</text>
<text top="339" left="963" width="22" height="9" font="31">None</text>
<text top="394" left="60" width="62" height="9" font="31">Naser Ammash</text>
<text top="394" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="394" left="301" width="48" height="9" font="31">Mayo Clinic</text>
<text top="392" left="349" width="98" height="12" font="31">—Professor of Medicine</text>
<text top="394" left="510" width="22" height="9" font="31">None</text>
<text top="394" left="595" width="22" height="9" font="31">None</text>
<text top="394" left="658" width="22" height="9" font="31">None</text>
<text top="394" left="738" width="22" height="9" font="31">None</text>
<text top="394" left="851" width="22" height="9" font="31">None</text>
<text top="394" left="963" width="22" height="9" font="31">None</text>
<text top="413" left="60" width="88" height="9" font="31">Helmut Baumgartner</text>
<text top="413" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="413" left="297" width="96" height="9" font="31">University of Muenster</text>
<text top="411" left="393" width="58" height="12" font="31">—Professor of</text>
<text top="425" left="300" width="162" height="9" font="31">Cardiology and Adult Congenital Heart</text>
<text top="437" left="299" width="158" height="9" font="31">Disease; University Hospital Muenster</text>
<text top="435" left="456" width="7" height="12" font="31">—</text>
<text top="449" left="303" width="157" height="9" font="31">Director, Division of Adult Congenital</text>
<text top="461" left="299" width="164" height="9" font="31">and Valvular Heart Disease, Department</text>
<text top="473" left="325" width="112" height="9" font="31">of Cardiovascular Medicine</text>
<text top="413" left="510" width="22" height="9" font="31">None</text>
<text top="413" left="595" width="22" height="9" font="31">None</text>
<text top="413" left="658" width="22" height="9" font="31">None</text>
<text top="413" left="738" width="22" height="9" font="31">None</text>
<text top="413" left="851" width="22" height="9" font="31">None</text>
<text top="413" left="963" width="22" height="9" font="31">None</text>
<text top="492" left="60" width="90" height="9" font="31">James C. Blankenship</text>
<text top="492" left="176" width="74" height="9" font="31">Content Reviewer</text>
<text top="490" left="251" width="24" height="12" font="31">—ACC</text>
<text top="504" left="187" width="92" height="9" font="31">Interventional Section</text>
<text top="516" left="194" width="79" height="9" font="31">Leadership Council</text>
<text top="492" left="288" width="104" height="9" font="31">Geisinger Medical Center</text>
<text top="490" left="392" width="68" height="12" font="31">—Staff Physician</text>
<text top="504" left="304" width="154" height="9" font="31">and Director, Cardiac Catheterization</text>
<text top="516" left="359" width="45" height="9" font="31">Laboratory</text>
<text top="492" left="510" width="22" height="9" font="31">None</text>
<text top="492" left="595" width="22" height="9" font="31">None</text>
<text top="492" left="658" width="22" height="9" font="31">None</text>
<text top="492" left="738" width="22" height="9" font="31">None</text>
<text top="495" left="804" width="6" height="10" font="33">n</text>
<text top="496" left="818" width="71" height="9" font="31">Abbott Vascular</text>
<text top="494" left="889" width="5" height="12" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">†</a></text>
<text top="508" left="804" width="6" height="10" font="33">n</text>
<text top="509" left="818" width="63" height="9" font="31">Boston Scienti</text>
<text top="507" left="881" width="10" height="12" font="31">ﬁc</text>
<text top="507" left="892" width="5" height="12" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">†</a></text>
<text top="520" left="804" width="6" height="10" font="33">n</text>
<text top="521" left="818" width="72" height="9" font="31">GlaxoSmithKline</text>
<text top="520" left="890" width="5" height="12" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">†</a></text>
<text top="533" left="804" width="6" height="10" font="33">n</text>
<text top="534" left="818" width="101" height="9" font="31">Takeda Pharmaceutical</text>
<text top="532" left="919" width="5" height="12" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">†</a></text>
<text top="492" left="963" width="22" height="9" font="31">None</text>
<text top="553" left="60" width="67" height="9" font="31">Ralph G. Brindis</text>
<text top="553" left="174" width="74" height="9" font="31">Content Reviewer</text>
<text top="551" left="249" width="27" height="12" font="31">—ACC/</text>
<text top="565" left="193" width="80" height="9" font="31">AHA Task Force on</text>
<text top="577" left="200" width="66" height="9" font="31">Clinical Practice</text>
<text top="589" left="211" width="43" height="9" font="31">Guidelines</text>
<text top="553" left="290" width="161" height="9" font="31">Northern California Kaiser Permanente</text>
<text top="551" left="451" width="7" height="12" font="31">—</text>
<text top="565" left="300" width="163" height="9" font="31">Senior Advisor, Cardiovascular Disease;</text>
<text top="577" left="299" width="158" height="9" font="31">University of California, San Francisco</text>
<text top="575" left="456" width="7" height="12" font="31">—</text>
<text top="589" left="319" width="124" height="9" font="31">Clinical Professor of Medicine</text>
<text top="553" left="510" width="22" height="9" font="31">None</text>
<text top="553" left="595" width="22" height="9" font="31">None</text>
<text top="553" left="658" width="22" height="9" font="31">None</text>
<text top="553" left="738" width="22" height="9" font="31">None</text>
<text top="553" left="851" width="22" height="9" font="31">None</text>
<text top="553" left="963" width="22" height="9" font="31">None</text>
<text top="608" left="60" width="84" height="9" font="31">Robert M. Campbell</text>
<text top="608" left="172" width="74" height="9" font="31">Content Reviewer</text>
<text top="608" left="295" width="157" height="9" font="31">Emory University School of Medicine,</text>
<text top="620" left="313" width="129" height="9" font="31">Sibley Heart Center Cardiology</text>
<text top="619" left="442" width="7" height="12" font="31">—</text>
<text top="632" left="334" width="94" height="9" font="31">Professor of Pediatrics</text>
<text top="608" left="510" width="22" height="9" font="31">None</text>
<text top="608" left="595" width="22" height="9" font="31">None</text>
<text top="608" left="658" width="22" height="9" font="31">None</text>
<text top="608" left="738" width="22" height="9" font="31">None</text>
<text top="608" left="851" width="22" height="9" font="31">None</text>
<text top="608" left="963" width="22" height="9" font="31">None</text>
<text top="650" left="60" width="66" height="9" font="31">Lesley H. Curtis</text>
<text top="650" left="174" width="74" height="9" font="31">Content Reviewer</text>
<text top="648" left="249" width="27" height="12" font="31">—ACC/</text>
<text top="662" left="193" width="80" height="9" font="31">AHA Task Force on</text>
<text top="674" left="200" width="66" height="9" font="31">Clinical Practice</text>
<text top="686" left="211" width="43" height="9" font="31">Guidelines</text>
<text top="650" left="296" width="148" height="9" font="31">Duke University School of Medicine</text>
<text top="648" left="444" width="7" height="12" font="31">—</text>
<text top="662" left="336" width="91" height="9" font="31">Professor of Medicine</text>
<text top="650" left="510" width="22" height="9" font="31">None</text>
<text top="650" left="595" width="22" height="9" font="31">None</text>
<text top="650" left="658" width="22" height="9" font="31">None</text>
<text top="650" left="738" width="22" height="9" font="31">None</text>
<text top="653" left="804" width="6" height="10" font="33">n</text>
<text top="654" left="818" width="63" height="9" font="31">Boston Scienti</text>
<text top="652" left="881" width="10" height="12" font="31">ﬁc</text>
<text top="654" left="892" width="4" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">*</a></text>
<text top="665" left="804" width="6" height="10" font="33">n</text>
<text top="666" left="818" width="63" height="9" font="31">GE Healthcare</text>
<text top="666" left="881" width="4" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">*</a></text>
<text top="678" left="804" width="6" height="10" font="33">n</text>
<text top="679" left="818" width="72" height="9" font="31">GlaxoSmithKline</text>
<text top="679" left="890" width="4" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">*</a></text>
<text top="691" left="804" width="6" height="10" font="33">n</text>
<text top="692" left="818" width="44" height="9" font="31">Medtronic</text>
<text top="692" left="863" width="4" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">*</a></text>
<text top="704" left="804" width="6" height="10" font="33">n</text>
<text top="704" left="818" width="37" height="9" font="31">Novartis</text>
<text top="704" left="855" width="4" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">*</a></text>
<text top="650" left="963" width="22" height="9" font="31">None</text>
<text top="744" left="904" width="115" height="9" font="31">Continued on the next page</text>
<text top="100" left="1100" width="0" height="9" font="13">Stout</text>
<text top="126" left="1100" width="0" height="9" font="13">et</text>
<text top="137" left="1100" width="0" height="9" font="13">al</text>
<text top="145" left="1100" width="0" height="9" font="13">.</text>
<text top="665" left="1102" width="0" height="7" font="9">JA</text>
<text top="677" left="1102" width="0" height="7" font="9">C</text>
<text top="684" left="1102" width="0" height="7" font="9">C</text>
<text top="694" left="1102" width="0" height="7" font="9">V</text>
<text top="700" left="1102" width="0" height="7" font="9">O</text>
<text top="707" left="1102" width="0" height="7" font="9">L</text>
<text top="713" left="1102" width="0" height="7" font="9">.</text>
<text top="720" left="1102" width="0" height="7" font="9">73</text>
<text top="731" left="1102" width="0" height="7" font="9">,</text>
<text top="738" left="1102" width="0" height="7" font="9">N</text>
<text top="745" left="1102" width="0" height="7" font="9">O</text>
<text top="752" left="1102" width="0" height="7" font="9">.</text>
<text top="759" left="1102" width="0" height="7" font="9">1</text>
<text top="763" left="1102" width="0" height="7" font="9">2</text>
<text top="769" left="1102" width="0" height="7" font="9">,</text>
<text top="776" left="1102" width="0" height="7" font="9">2</text>
<text top="781" left="1102" width="0" height="7" font="9">01</text>
<text top="792" left="1102" width="0" height="7" font="9">9</text>
<text top="100" left="1085" width="0" height="9" font="13">2018</text>
<text top="125" left="1085" width="0" height="9" font="13">ACHD</text>
<text top="152" left="1085" width="0" height="9" font="13">Guideline:</text>
<text top="197" left="1085" width="0" height="9" font="13">Executive</text>
<text top="240" left="1085" width="0" height="9" font="13">Summary</text>
<text top="683" left="1087" width="0" height="7" font="9">APR</text>
<text top="702" left="1087" width="0" height="7" font="9">I</text>
<text top="706" left="1087" width="0" height="7" font="9">L</text>
<text top="715" left="1087" width="0" height="7" font="9">2</text>
<text top="721" left="1087" width="0" height="7" font="9">,</text>
<text top="728" left="1087" width="0" height="7" font="9">2</text>
<text top="733" left="1087" width="0" height="7" font="9">0</text>
<text top="740" left="1087" width="0" height="7" font="9">1</text>
<text top="744" left="1087" width="0" height="7" font="9">9:</text>
<text top="753" left="1087" width="0" height="7" font="9">1494</text>
<text top="773" left="1087" width="0" height="10" font="9">–</text>
<text top="780" left="1087" width="0" height="7" font="9">563</text>
<text top="50" left="1101" width="0" height="9" font="5">1560</text>
</page>
<page number="68" position="absolute" top="0" left="0" height="864" width="1160">
<text top="60" left="59" width="158" height="16" font="29">APPENDIX 2. CONTINUED</text>
<text top="148" left="59" width="42" height="9" font="31">Reviewer</text>
<text top="148" left="190" width="71" height="9" font="31">Representation</text>
<text top="148" left="344" width="58" height="9" font="31">Employment</text>
<text top="148" left="495" width="50" height="9" font="31">Consultant</text>
<text top="136" left="585" width="42" height="9" font="31">Speakers</text>
<text top="148" left="590" width="32" height="9" font="31">Bureau</text>
<text top="124" left="642" width="53" height="9" font="31">Ownership/</text>
<text top="136" left="639" width="58" height="9" font="31">Partnership/</text>
<text top="148" left="649" width="40" height="9" font="31">Principal</text>
<text top="136" left="728" width="40" height="9" font="31">Personal</text>
<text top="148" left="728" width="42" height="9" font="31">Research</text>
<text top="112" left="831" width="60" height="9" font="31">Institutional,</text>
<text top="124" left="820" width="84" height="9" font="31">Organizational, or</text>
<text top="136" left="826" width="71" height="9" font="31">Other Financial</text>
<text top="148" left="845" width="23" height="9" font="31">Bene</text>
<text top="146" left="868" width="10" height="12" font="31">ﬁt</text>
<text top="136" left="958" width="31" height="9" font="31">Expert</text>
<text top="148" left="955" width="37" height="9" font="31">Witness</text>
<text top="167" left="59" width="77" height="9" font="31">Kristi K. Fitzgerald</text>
<text top="167" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="167" left="287" width="173" height="9" font="31">Nemours Cardiac Center DuPont Hospital</text>
<text top="179" left="313" width="50" height="9" font="31">for Children</text>
<text top="177" left="363" width="85" height="12" font="31">—Genetic Counselor,</text>
<text top="191" left="316" width="131" height="9" font="31">Division of Pediatric Cardiology</text>
<text top="167" left="509" width="22" height="9" font="31">None</text>
<text top="167" left="595" width="22" height="9" font="31">None</text>
<text top="167" left="658" width="22" height="9" font="31">None</text>
<text top="167" left="738" width="22" height="9" font="31">None</text>
<text top="167" left="850" width="22" height="9" font="31">None</text>
<text top="167" left="962" width="22" height="9" font="31">None</text>
<text top="210" left="59" width="62" height="9" font="31">Lee A. Fleisher</text>
<text top="210" left="174" width="74" height="9" font="31">Content Reviewer</text>
<text top="208" left="249" width="27" height="12" font="31">—ACC/</text>
<text top="222" left="193" width="80" height="9" font="31">AHA Task Force on</text>
<text top="234" left="200" width="66" height="9" font="31">Clinical Practice</text>
<text top="246" left="211" width="43" height="9" font="31">Guidelines</text>
<text top="210" left="286" width="174" height="9" font="31">University of Pennsylvania Health System</text>
<text top="222" left="308" width="146" height="9" font="31">Department of Anesthesiology and</text>
<text top="234" left="305" width="50" height="9" font="31">Critical Care</text>
<text top="232" left="355" width="103" height="12" font="31">—Robert Dunning Dripps</text>
<text top="246" left="322" width="117" height="9" font="31">Professor of Anesthesiology</text>
<text top="210" left="509" width="22" height="9" font="31">None</text>
<text top="210" left="595" width="22" height="9" font="31">None</text>
<text top="210" left="658" width="22" height="9" font="31">None</text>
<text top="210" left="738" width="22" height="9" font="31">None</text>
<text top="210" left="850" width="22" height="9" font="31">None</text>
<text top="210" left="962" width="22" height="9" font="31">None</text>
<text top="265" left="59" width="68" height="9" font="31">Federico Gentile</text>
<text top="265" left="174" width="74" height="9" font="31">Content Reviewer</text>
<text top="263" left="249" width="27" height="12" font="31">—ACC/</text>
<text top="277" left="193" width="80" height="9" font="31">AHA Task Force on</text>
<text top="289" left="200" width="66" height="9" font="31">Clinical Practice</text>
<text top="301" left="211" width="43" height="9" font="31">Guidelines</text>
<text top="265" left="294" width="115" height="9" font="31">Centro Cardiologico Gentile</text>
<text top="263" left="410" width="43" height="12" font="31">—Director,</text>
<text top="277" left="334" width="94" height="9" font="31">Cardiovascular Disease</text>
<text top="265" left="509" width="22" height="9" font="31">None</text>
<text top="265" left="595" width="22" height="9" font="31">None</text>
<text top="265" left="658" width="22" height="9" font="31">None</text>
<text top="265" left="738" width="22" height="9" font="31">None</text>
<text top="265" left="850" width="22" height="9" font="31">None</text>
<text top="265" left="962" width="22" height="9" font="31">None</text>
<text top="320" left="59" width="54" height="9" font="31">Louise Harris</text>
<text top="320" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="320" left="292" width="106" height="9" font="31">Toronto General Hospital</text>
<text top="319" left="398" width="58" height="12" font="31">—Professor of</text>
<text top="332" left="363" width="37" height="9" font="31">Medicine</text>
<text top="323" left="473" width="6" height="10" font="33">n</text>
<text top="324" left="487" width="73" height="9" font="31">St. Jude Medical</text>
<text top="320" left="595" width="22" height="9" font="31">None</text>
<text top="320" left="658" width="22" height="9" font="31">None</text>
<text top="320" left="738" width="22" height="9" font="31">None</text>
<text top="320" left="850" width="22" height="9" font="31">None</text>
<text top="320" left="962" width="22" height="9" font="31">None</text>
<text top="351" left="59" width="62" height="9" font="31">Mark A. Hlatky</text>
<text top="351" left="174" width="74" height="9" font="31">Content Reviewer</text>
<text top="350" left="249" width="27" height="12" font="31">—ACC/</text>
<text top="363" left="193" width="80" height="9" font="31">AHA Task Force on</text>
<text top="375" left="200" width="66" height="9" font="31">Clinical Practice</text>
<text top="387" left="211" width="43" height="9" font="31">Guidelines</text>
<text top="351" left="289" width="163" height="9" font="31">Stanford University School of Medicine</text>
<text top="350" left="452" width="7" height="12" font="31">—</text>
<text top="363" left="311" width="140" height="9" font="31">Professor of Health Research and</text>
<text top="375" left="301" width="161" height="9" font="31">Policy, and of Cardiovascular Medicine</text>
<text top="351" left="509" width="22" height="9" font="31">None</text>
<text top="351" left="595" width="22" height="9" font="31">None</text>
<text top="351" left="658" width="22" height="9" font="31">None</text>
<text top="351" left="738" width="22" height="9" font="31">None</text>
<text top="351" left="850" width="22" height="9" font="31">None</text>
<text top="351" left="962" width="22" height="9" font="31">None</text>
<text top="406" left="59" width="67" height="9" font="31">Craig T. January</text>
<text top="406" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="406" left="284" width="179" height="9" font="31">University of Wisconsin School of Medicine</text>
<text top="418" left="302" width="74" height="9" font="31">and Public Health</text>
<text top="417" left="376" width="84" height="12" font="31">—Professor, Division</text>
<text top="430" left="325" width="112" height="9" font="31">of Cardiovascular Medicine</text>
<text top="406" left="509" width="22" height="9" font="31">None</text>
<text top="406" left="595" width="22" height="9" font="31">None</text>
<text top="406" left="658" width="22" height="9" font="31">None</text>
<text top="406" left="738" width="22" height="9" font="31">None</text>
<text top="406" left="850" width="22" height="9" font="31">None</text>
<text top="406" left="962" width="22" height="9" font="31">None</text>
<text top="450" left="59" width="59" height="9" font="31">José A. Joglar</text>
<text top="450" left="174" width="74" height="9" font="31">Content Reviewer</text>
<text top="448" left="249" width="27" height="12" font="31">—ACC/</text>
<text top="461" left="193" width="80" height="9" font="31">AHA Task Force on</text>
<text top="473" left="200" width="66" height="9" font="31">Clinical Practice</text>
<text top="485" left="211" width="43" height="9" font="31">Guidelines</text>
<text top="450" left="284" width="138" height="9" font="31">UT Southwestern Medical Center</text>
<text top="448" left="422" width="7" height="12" font="31">—</text>
<text top="461" left="299" width="126" height="9" font="31">Professor of Internal Medicine</text>
<text top="450" left="509" width="22" height="9" font="31">None</text>
<text top="450" left="595" width="22" height="9" font="31">None</text>
<text top="450" left="658" width="22" height="9" font="31">None</text>
<text top="450" left="738" width="22" height="9" font="31">None</text>
<text top="450" left="850" width="22" height="9" font="31">None</text>
<text top="450" left="962" width="22" height="9" font="31">None</text>
<text top="505" left="59" width="70" height="9" font="31">Thomas K. Jones</text>
<text top="505" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="505" left="284" width="67" height="9" font="31">Seattle Children</text>
<text top="503" left="351" width="102" height="12" font="31">’s Hospital—Professor of</text>
<text top="517" left="299" width="131" height="9" font="31">Pediatrics and Director, Cardiac</text>
<text top="528" left="299" width="118" height="9" font="31">Catheterization Laboratories</text>
<text top="508" left="473" width="6" height="10" font="33">n</text>
<text top="508" left="487" width="58" height="9" font="31">Gore Medical</text>
<text top="508" left="545" width="4" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">*</a></text>
<text top="523" left="473" width="6" height="10" font="33">n</text>
<text top="524" left="487" width="44" height="9" font="31">Medtr<a href="1-s2.0-S0735109718368451-main.html#70">onic</a></text>
<text top="524" left="531" width="4" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">*</a></text>
<text top="505" left="595" width="22" height="9" font="31">None</text>
<text top="505" left="658" width="22" height="9" font="31">None</text>
<text top="505" left="738" width="22" height="9" font="31">None</text>
<text top="508" left="804" width="6" height="10" font="33">n</text>
<text top="508" left="818" width="58" height="9" font="31">Gore Medical</text>
<text top="508" left="876" width="4" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">*</a></text>
<text top="523" left="804" width="6" height="10" font="33">n</text>
<text top="524" left="818" width="44" height="9" font="31"><a href="1-s2.0-S0735109718368451-main.html#70">Medtronic</a></text>
<text top="524" left="862" width="4" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">*</a></text>
<text top="539" left="804" width="6" height="10" font="33">n</text>
<text top="540" left="818" width="73" height="9" font="31">St. Jude Medical</text>
<text top="540" left="891" width="4" height="9" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">*</a></text>
<text top="505" left="962" width="22" height="9" font="31">None</text>
<text top="559" left="59" width="62" height="9" font="31">Brian E. Kogon</text>
<text top="559" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="559" left="293" width="154" height="9" font="31">Emory University School of Medicine</text>
<text top="557" left="447" width="7" height="12" font="31">—</text>
<text top="571" left="312" width="137" height="9" font="31">Associate Professor, Surgery and</text>
<text top="583" left="313" width="137" height="9" font="31">Surgical Director of Emory Adult</text>
<text top="595" left="303" width="156" height="9" font="31">Congenital Heart Center and Chief of</text>
<text top="607" left="329" width="104" height="9" font="31">Pediatric Cardiac Surgery</text>
<text top="559" left="509" width="22" height="9" font="31">None</text>
<text top="559" left="595" width="22" height="9" font="31">None</text>
<text top="559" left="658" width="22" height="9" font="31">None</text>
<text top="559" left="738" width="22" height="9" font="31">None</text>
<text top="559" left="850" width="22" height="9" font="31">None</text>
<text top="559" left="962" width="22" height="9" font="31">None</text>
<text top="626" left="59" width="62" height="9" font="31">Gautam Kumar</text>
<text top="626" left="176" width="74" height="9" font="31">Content Reviewer</text>
<text top="624" left="251" width="24" height="12" font="31">—ACC</text>
<text top="638" left="187" width="92" height="9" font="31">Interventional Section</text>
<text top="650" left="193" width="79" height="9" font="31">Leadership Council</text>
<text top="626" left="295" width="157" height="9" font="31">Emory University School of Medicine,</text>
<text top="638" left="312" width="92" height="9" font="31">Division of Cardiology</text>
<text top="636" left="404" width="46" height="12" font="31">—Associate</text>
<text top="650" left="336" width="91" height="9" font="31">Professor of Medicine</text>
<text top="629" left="473" width="6" height="10" font="33">n</text>
<text top="630" left="487" width="38" height="9" font="31">Abiomed</text>
<text top="626" left="595" width="22" height="9" font="31">None</text>
<text top="626" left="658" width="22" height="9" font="31">None</text>
<text top="626" left="738" width="22" height="9" font="31">None</text>
<text top="629" left="804" width="6" height="10" font="33">n</text>
<text top="630" left="818" width="87" height="9" font="31">OrbusNeich Medical</text>
<text top="626" left="962" width="22" height="9" font="31">None</text>
<text top="669" left="59" width="60" height="9" font="31">Eric V. Krieger</text>
<text top="669" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="669" left="298" width="106" height="9" font="31">University of Washington</text>
<text top="667" left="403" width="46" height="12" font="31">—Associate</text>
<text top="681" left="305" width="151" height="9" font="31">Professor of Medicine and Associate</text>
<text top="693" left="313" width="136" height="9" font="31">Director, Adult Congenital Heart</text>
<text top="705" left="366" width="29" height="9" font="31">Service</text>
<text top="672" left="473" width="6" height="10" font="33">n</text>
<text top="673" left="487" width="36" height="9" font="31">Actelion</text>
<text top="669" left="595" width="22" height="9" font="31">None</text>
<text top="669" left="658" width="22" height="9" font="31">None</text>
<text top="669" left="738" width="22" height="9" font="31">None</text>
<text top="669" left="850" width="22" height="9" font="31">None</text>
<text top="669" left="962" width="22" height="9" font="31">None</text>
<text top="723" left="59" width="67" height="9" font="31">Glenn N. Levine</text>
<text top="723" left="174" width="74" height="9" font="31">Content Reviewer</text>
<text top="721" left="249" width="27" height="12" font="31">—ACC/</text>
<text top="735" left="193" width="80" height="9" font="31">AHA Task Force on</text>
<text top="747" left="200" width="66" height="9" font="31">Clinical Practice</text>
<text top="759" left="211" width="43" height="9" font="31">Guidelines</text>
<text top="723" left="288" width="113" height="9" font="31">Baylor College of Medicine</text>
<text top="721" left="401" width="58" height="12" font="31">—Professor of</text>
<text top="735" left="311" width="139" height="9" font="31">Medicine; Michael E. DeBakey VA</text>
<text top="747" left="301" width="63" height="9" font="31">Medical Center</text>
<text top="745" left="363" width="98" height="12" font="31">—Director, Cardiac Care</text>
<text top="759" left="372" width="17" height="9" font="31">Unit</text>
<text top="723" left="509" width="22" height="9" font="31">None</text>
<text top="723" left="595" width="22" height="9" font="31">None</text>
<text top="723" left="658" width="22" height="9" font="31">None</text>
<text top="723" left="738" width="22" height="9" font="31">None</text>
<text top="723" left="850" width="22" height="9" font="31">None</text>
<text top="723" left="962" width="22" height="9" font="31">None</text>
<text top="779" left="913" width="105" height="8" font="34">Continued on the next page</text>
<text top="57" left="1102" width="0" height="7" font="9">J</text>
<text top="63" left="1102" width="0" height="7" font="9">A</text>
<text top="69" left="1102" width="0" height="7" font="9">C</text>
<text top="76" left="1102" width="0" height="7" font="9">C</text>
<text top="86" left="1102" width="0" height="7" font="9">V</text>
<text top="92" left="1102" width="0" height="7" font="9">O</text>
<text top="99" left="1102" width="0" height="7" font="9">L</text>
<text top="105" left="1102" width="0" height="7" font="9">.</text>
<text top="112" left="1102" width="0" height="7" font="9">7</text>
<text top="117" left="1102" width="0" height="7" font="9">3</text>
<text top="123" left="1102" width="0" height="7" font="9">,N</text>
<text top="137" left="1102" width="0" height="7" font="9">O</text>
<text top="144" left="1102" width="0" height="7" font="9">.</text>
<text top="151" left="1102" width="0" height="7" font="9">1</text>
<text top="155" left="1102" width="0" height="7" font="9">2</text>
<text top="161" left="1102" width="0" height="7" font="9">,2</text>
<text top="173" left="1102" width="0" height="7" font="9">0</text>
<text top="180" left="1102" width="0" height="7" font="9">1</text>
<text top="184" left="1102" width="0" height="7" font="9">9</text>
<text top="703" left="1100" width="0" height="9" font="13">Stout</text>
<text top="728" left="1100" width="0" height="9" font="13">et</text>
<text top="739" left="1100" width="0" height="9" font="13">al</text>
<text top="747" left="1100" width="0" height="9" font="13">.</text>
<text top="57" left="1087" width="0" height="7" font="9">AP</text>
<text top="70" left="1087" width="0" height="7" font="9">RI</text>
<text top="80" left="1087" width="0" height="7" font="9">L</text>
<text top="89" left="1087" width="0" height="7" font="9">2</text>
<text top="95" left="1087" width="0" height="7" font="9">,</text>
<text top="102" left="1087" width="0" height="7" font="9">2</text>
<text top="108" left="1087" width="0" height="7" font="9">01</text>
<text top="118" left="1087" width="0" height="7" font="9">9</text>
<text top="124" left="1087" width="0" height="7" font="9">:</text>
<text top="127" left="1087" width="0" height="7" font="9">1</text>
<text top="131" left="1087" width="0" height="7" font="9">4</text>
<text top="137" left="1087" width="0" height="7" font="9">9</text>
<text top="143" left="1087" width="0" height="7" font="9">4</text>
<text top="148" left="1087" width="0" height="10" font="9">–</text>
<text top="155" left="1087" width="0" height="7" font="9">563</text>
<text top="572" left="1085" width="0" height="9" font="13">2018</text>
<text top="596" left="1085" width="0" height="9" font="13">ACHD</text>
<text top="623" left="1085" width="0" height="9" font="13">Guideline:</text>
<text top="668" left="1085" width="0" height="9" font="13">Executive</text>
<text top="711" left="1085" width="0" height="9" font="13">Summary</text>
<text top="783" left="1101" width="0" height="9" font="5">1561</text>
</page>
<page number="69" position="absolute" top="0" left="0" height="864" width="1160">
<text top="59" left="58" width="158" height="16" font="29">APPENDIX 2. CONTINUED</text>
<text top="139" left="59" width="43" height="9" font="31">Reviewer</text>
<text top="139" left="190" width="71" height="9" font="31">Representation</text>
<text top="139" left="344" width="58" height="9" font="31">Employment</text>
<text top="139" left="495" width="50" height="9" font="31">Consultant</text>
<text top="127" left="585" width="42" height="9" font="31">Speakers</text>
<text top="139" left="590" width="32" height="9" font="31">Bureau</text>
<text top="115" left="642" width="53" height="9" font="31">Ownership/</text>
<text top="127" left="639" width="59" height="9" font="31">Partnership/</text>
<text top="139" left="648" width="41" height="9" font="31">Principal</text>
<text top="127" left="728" width="40" height="9" font="31">Personal</text>
<text top="139" left="728" width="42" height="9" font="31">Research</text>
<text top="103" left="831" width="60" height="9" font="31">Institutional,</text>
<text top="115" left="819" width="84" height="9" font="31">Organizational, or</text>
<text top="127" left="826" width="71" height="9" font="31">Other Financial</text>
<text top="139" left="845" width="23" height="9" font="31">Bene</text>
<text top="137" left="868" width="10" height="12" font="31">ﬁt</text>
<text top="127" left="958" width="31" height="9" font="31">Expert</text>
<text top="139" left="955" width="37" height="9" font="31">Witness</text>
<text top="158" left="59" width="46" height="9" font="31">C. Huie Lin</text>
<text top="158" left="175" width="74" height="9" font="31">Content Reviewer</text>
<text top="157" left="249" width="189" height="12" font="31">—SCAI Houston Methodist DeBakey Heart &amp;</text>
<text top="170" left="299" width="65" height="9" font="31">Vascular Center</text>
<text top="169" left="364" width="56" height="12" font="31">—Cardiologist</text>
<text top="161" left="472" width="6" height="10" font="33">n</text>
<text top="162" left="487" width="58" height="9" font="31">Gore Medical</text>
<text top="177" left="472" width="6" height="10" font="33">n</text>
<text top="178" left="487" width="86" height="9" font="31">ACI Clinical (DSMB)</text>
<text top="161" left="582" width="6" height="10" font="33">n</text>
<text top="162" left="596" width="39" height="9" font="31">Abiomed</text>
<text top="158" left="658" width="22" height="9" font="31">None</text>
<text top="161" left="707" width="6" height="10" font="33">n</text>
<text top="162" left="721" width="73" height="9" font="31">St. Jude Medical</text>
<text top="158" left="850" width="22" height="9" font="31">None</text>
<text top="158" left="962" width="22" height="9" font="31">None</text>
<text top="197" left="59" width="77" height="9" font="31">Massimo Mancone</text>
<text top="197" left="176" width="74" height="9" font="31">Content Reviewer</text>
<text top="195" left="250" width="24" height="12" font="31">—ACC</text>
<text top="209" left="225" width="15" height="9" font="31">AIG</text>
<text top="197" left="288" width="120" height="9" font="31">Sapienza University of Rome</text>
<text top="195" left="407" width="51" height="12" font="31">—Cardiology</text>
<text top="209" left="358" width="45" height="9" font="31">Consultant</text>
<text top="197" left="509" width="22" height="9" font="31">None</text>
<text top="197" left="595" width="22" height="9" font="31">None</text>
<text top="197" left="658" width="22" height="9" font="31">None</text>
<text top="197" left="737" width="22" height="9" font="31">None</text>
<text top="197" left="850" width="22" height="9" font="31">None</text>
<text top="197" left="962" width="22" height="9" font="31">None</text>
<text top="228" left="59" width="58" height="9" font="31">Ariane Marelli</text>
<text top="228" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="228" left="284" width="132" height="9" font="31">McGill University Health Center</text>
<text top="226" left="416" width="46" height="12" font="31">—Professor</text>
<text top="240" left="300" width="162" height="9" font="31">of Medicine and Director, MAUDE Unit</text>
<text top="228" left="509" width="22" height="9" font="31">None</text>
<text top="228" left="595" width="22" height="9" font="31">None</text>
<text top="228" left="658" width="22" height="9" font="31">None</text>
<text top="228" left="737" width="22" height="9" font="31">None</text>
<text top="228" left="850" width="22" height="9" font="31">None</text>
<text top="228" left="962" width="22" height="9" font="31">None</text>
<text top="259" left="59" width="57" height="9" font="31">Koichiro Niwa</text>
<text top="259" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="259" left="285" width="34" height="9" font="31">St. Luke</text>
<text top="257" left="319" width="143" height="12" font="31">’s International Hospital—Director,</text>
<text top="271" left="326" width="109" height="9" font="31">Department of Cardiology</text>
<text top="259" left="509" width="22" height="9" font="31">None</text>
<text top="259" left="595" width="22" height="9" font="31">None</text>
<text top="259" left="658" width="22" height="9" font="31">None</text>
<text top="259" left="737" width="22" height="9" font="31">None</text>
<text top="259" left="850" width="22" height="9" font="31">None</text>
<text top="259" left="962" width="22" height="9" font="31">None</text>
<text top="290" left="59" width="62" height="9" font="31">Matthew Oster</text>
<text top="290" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="290" left="293" width="154" height="9" font="31">Emory University School of Medicine</text>
<text top="289" left="447" width="7" height="12" font="31">—</text>
<text top="302" left="317" width="122" height="9" font="31">Associate Professor; Children</text>
<text top="301" left="438" width="6" height="12" font="31">’s</text>
<text top="314" left="314" width="90" height="9" font="31">Healthcare of Atlanta</text>
<text top="313" left="404" width="43" height="12" font="31">—Director,</text>
<text top="326" left="301" width="35" height="9" font="31">Children</text>
<text top="325" left="336" width="125" height="12" font="31">’s Cardiac Outcomes Research</text>
<text top="338" left="315" width="131" height="9" font="31">Program at Sibley Heart Center</text>
<text top="290" left="509" width="22" height="9" font="31">None</text>
<text top="290" left="595" width="22" height="9" font="31">None</text>
<text top="290" left="658" width="22" height="9" font="31">None</text>
<text top="290" left="737" width="22" height="9" font="31">None</text>
<text top="290" left="850" width="22" height="9" font="31">None</text>
<text top="290" left="962" width="22" height="9" font="31">None</text>
<text top="357" left="59" width="75" height="9" font="31">Catherine M. Otto</text>
<text top="357" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="357" left="299" width="148" height="9" font="31">University of Washington School of</text>
<text top="369" left="312" width="37" height="9" font="31">Medicine</text>
<text top="368" left="349" width="100" height="12" font="31">—Professor of Medicine,</text>
<text top="381" left="306" width="149" height="9" font="31">Division of Cardiology and Director,</text>
<text top="393" left="344" width="74" height="9" font="31">Heart Valve Clinic</text>
<text top="357" left="509" width="22" height="9" font="31">None</text>
<text top="357" left="595" width="22" height="9" font="31">None</text>
<text top="357" left="658" width="22" height="9" font="31">None</text>
<text top="357" left="737" width="22" height="9" font="31">None</text>
<text top="357" left="850" width="22" height="9" font="31">None</text>
<text top="357" left="962" width="22" height="9" font="31">None</text>
<text top="412" left="59" width="65" height="9" font="31">Richard L. Page</text>
<text top="412" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="412" left="284" width="179" height="9" font="31">University of Wisconsin School of Medicine</text>
<text top="424" left="302" width="74" height="9" font="31">and Public Health</text>
<text top="423" left="376" width="83" height="12" font="31">—Chair, Department</text>
<text top="436" left="356" width="49" height="9" font="31">of Medicine</text>
<text top="412" left="509" width="22" height="9" font="31">None</text>
<text top="412" left="595" width="22" height="9" font="31">None</text>
<text top="412" left="658" width="22" height="9" font="31">None</text>
<text top="412" left="737" width="22" height="9" font="31">None</text>
<text top="412" left="850" width="22" height="9" font="31">None</text>
<text top="412" left="962" width="22" height="9" font="31">None</text>
<text top="456" left="59" width="51" height="9" font="31">James Perry</text>
<text top="456" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="456" left="293" width="58" height="9" font="31">Rady Children</text>
<text top="454" left="351" width="103" height="12" font="31">’s Hospital; University of</text>
<text top="468" left="308" width="87" height="9" font="31">California, San Diego</text>
<text top="466" left="395" width="58" height="12" font="31">—Professor of</text>
<text top="479" left="314" width="55" height="9" font="31">Pediatrics, Af</text>
<text top="478" left="370" width="77" height="12" font="31">ﬁliate Professor of</text>
<text top="491" left="320" width="122" height="9" font="31">Bioengineering, and Director,</text>
<text top="503" left="299" width="164" height="9" font="31">Electrophysiology and Adult Congenital</text>
<text top="515" left="348" width="66" height="9" font="31">Heart Programs</text>
<text top="456" left="509" width="22" height="9" font="31">None</text>
<text top="456" left="595" width="22" height="9" font="31">None</text>
<text top="456" left="658" width="22" height="9" font="31">None</text>
<text top="456" left="737" width="22" height="9" font="31">None</text>
<text top="456" left="850" width="22" height="9" font="31">None</text>
<text top="456" left="962" width="22" height="9" font="31">None</text>
<text top="535" left="59" width="70" height="9" font="31">Susan J. Pressler</text>
<text top="535" left="174" width="74" height="9" font="31">Content Reviewer</text>
<text top="533" left="248" width="27" height="12" font="31">—ACC/</text>
<text top="547" left="193" width="80" height="9" font="31">AHA Task Force on</text>
<text top="558" left="200" width="66" height="9" font="31">Clinical Practice</text>
<text top="570" left="211" width="43" height="9" font="31">Guidelines</text>
<text top="535" left="294" width="152" height="9" font="31">Indiana University School of Nursing</text>
<text top="533" left="446" width="7" height="12" font="31">—</text>
<text top="547" left="310" width="142" height="9" font="31">Professor and Director, Center for</text>
<text top="558" left="305" width="151" height="9" font="31">Enhancing Quality of Life in Chronic</text>
<text top="570" left="368" width="26" height="9" font="31">Illness</text>
<text top="535" left="509" width="22" height="9" font="31">None</text>
<text top="535" left="595" width="22" height="9" font="31">None</text>
<text top="535" left="658" width="22" height="9" font="31">None</text>
<text top="535" left="737" width="22" height="9" font="31">None</text>
<text top="537" left="803" width="6" height="10" font="33">n</text>
<text top="538" left="817" width="5" height="9" font="31">P</text>
<text top="537" left="823" width="19" height="12" font="31">ﬁze<a href="1-s2.0-S0735109718368451-main.html#70">r</a></text>
<text top="537" left="842" width="5" height="12" font="32"><a href="1-s2.0-S0735109718368451-main.html#70">†</a></text>
<text top="535" left="962" width="22" height="9" font="31">None</text>
<text top="590" left="59" width="90" height="9" font="31">Candice K. Silversides</text>
<text top="590" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="590" left="284" width="90" height="9" font="31">University of Toronto</text>
<text top="588" left="374" width="88" height="12" font="31">—Associate Professor</text>
<text top="590" left="509" width="22" height="9" font="31">None</text>
<text top="590" left="595" width="22" height="9" font="31">None</text>
<text top="590" left="658" width="22" height="9" font="31">None</text>
<text top="590" left="737" width="22" height="9" font="31">None</text>
<text top="590" left="850" width="22" height="9" font="31">None</text>
<text top="590" left="962" width="22" height="9" font="31">None</text>
<text top="607" left="59" width="107" height="9" font="31">Duminda N. Wijeysundera</text>
<text top="607" left="176" width="72" height="9" font="31">Content Reviewer</text>
<text top="606" left="247" width="27" height="12" font="31">—ACC/</text>
<text top="619" left="194" width="77" height="9" font="31">AHA Task Force on</text>
<text top="631" left="201" width="63" height="9" font="31">Clinical Practice</text>
<text top="643" left="212" width="41" height="9" font="31">Guidelines</text>
<text top="607" left="284" width="90" height="9" font="31">University of Toronto</text>
<text top="606" left="374" width="89" height="12" font="31">—Assistant Professor,</text>
<text top="619" left="299" width="164" height="9" font="31">Department of Anesthesia and Institute</text>
<text top="631" left="309" width="143" height="9" font="31">of Health Policy Management and</text>
<text top="643" left="359" width="44" height="9" font="31">Evaluation</text>
<text top="607" left="509" width="22" height="9" font="31">None</text>
<text top="607" left="595" width="22" height="9" font="31">None</text>
<text top="607" left="658" width="22" height="9" font="31">None</text>
<text top="607" left="737" width="22" height="9" font="31">None</text>
<text top="607" left="850" width="22" height="9" font="31">None</text>
<text top="607" left="962" width="22" height="9" font="31">None</text>
<text top="682" left="904" width="115" height="9" font="31">Continued on the next page</text>
<text top="100" left="1100" width="0" height="9" font="13">Stout</text>
<text top="126" left="1100" width="0" height="9" font="13">et</text>
<text top="137" left="1100" width="0" height="9" font="13">al</text>
<text top="145" left="1100" width="0" height="9" font="13">.</text>
<text top="665" left="1102" width="0" height="7" font="9">JA</text>
<text top="677" left="1102" width="0" height="7" font="9">C</text>
<text top="684" left="1102" width="0" height="7" font="9">C</text>
<text top="694" left="1102" width="0" height="7" font="9">V</text>
<text top="700" left="1102" width="0" height="7" font="9">O</text>
<text top="707" left="1102" width="0" height="7" font="9">L</text>
<text top="713" left="1102" width="0" height="7" font="9">.</text>
<text top="720" left="1102" width="0" height="7" font="9">73</text>
<text top="731" left="1102" width="0" height="7" font="9">,</text>
<text top="738" left="1102" width="0" height="7" font="9">N</text>
<text top="745" left="1102" width="0" height="7" font="9">O</text>
<text top="752" left="1102" width="0" height="7" font="9">.</text>
<text top="759" left="1102" width="0" height="7" font="9">1</text>
<text top="763" left="1102" width="0" height="7" font="9">2</text>
<text top="769" left="1102" width="0" height="7" font="9">,</text>
<text top="776" left="1102" width="0" height="7" font="9">2</text>
<text top="781" left="1102" width="0" height="7" font="9">01</text>
<text top="792" left="1102" width="0" height="7" font="9">9</text>
<text top="100" left="1085" width="0" height="9" font="13">2018</text>
<text top="125" left="1085" width="0" height="9" font="13">ACHD</text>
<text top="152" left="1085" width="0" height="9" font="13">Guideline:</text>
<text top="197" left="1085" width="0" height="9" font="13">Executive</text>
<text top="240" left="1085" width="0" height="9" font="13">Summary</text>
<text top="683" left="1087" width="0" height="7" font="9">APR</text>
<text top="702" left="1087" width="0" height="7" font="9">I</text>
<text top="706" left="1087" width="0" height="7" font="9">L</text>
<text top="715" left="1087" width="0" height="7" font="9">2</text>
<text top="721" left="1087" width="0" height="7" font="9">,</text>
<text top="728" left="1087" width="0" height="7" font="9">2</text>
<text top="733" left="1087" width="0" height="7" font="9">0</text>
<text top="740" left="1087" width="0" height="7" font="9">1</text>
<text top="744" left="1087" width="0" height="7" font="9">9:</text>
<text top="753" left="1087" width="0" height="7" font="9">1494</text>
<text top="773" left="1087" width="0" height="10" font="9">–</text>
<text top="780" left="1087" width="0" height="7" font="9">563</text>
<text top="50" left="1101" width="0" height="9" font="5">1562</text>
</page>
<page number="70" position="absolute" top="0" left="0" height="864" width="1160">
	<fontspec id="35" size="6" family="Times" color="#327eb1"/>
<text top="147" left="60" width="43" height="9" font="31">Reviewer</text>
<text top="147" left="190" width="71" height="9" font="31">Representation</text>
<text top="147" left="345" width="58" height="9" font="31">Employment</text>
<text top="147" left="495" width="50" height="9" font="31">Consultant</text>
<text top="135" left="585" width="42" height="9" font="31">Speakers</text>
<text top="147" left="590" width="32" height="9" font="31">Bureau</text>
<text top="123" left="642" width="53" height="9" font="31">Ownership/</text>
<text top="135" left="640" width="59" height="9" font="31">Partnership/</text>
<text top="147" left="649" width="41" height="9" font="31">Principal</text>
<text top="135" left="729" width="40" height="9" font="31">Personal</text>
<text top="147" left="728" width="42" height="9" font="31">Research</text>
<text top="111" left="831" width="60" height="9" font="31">Institutional,</text>
<text top="123" left="820" width="84" height="9" font="31">Organizational, or</text>
<text top="135" left="826" width="71" height="9" font="31">Other Financial</text>
<text top="147" left="845" width="23" height="9" font="31">Bene</text>
<text top="146" left="868" width="10" height="12" font="31">ﬁt</text>
<text top="135" left="958" width="31" height="9" font="31">Expert</text>
<text top="147" left="955" width="37" height="9" font="31">Witness</text>
<text top="166" left="60" width="46" height="9" font="31">Ali N. Zaidi</text>
<text top="166" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="166" left="288" width="27" height="9" font="31">Monte</text>
<text top="165" left="315" width="145" height="12" font="31">ﬁore Einstein Center for Heart and</text>
<text top="178" left="307" width="56" height="9" font="31">Vascular Care</text>
<text top="177" left="363" width="92" height="12" font="31">—Director, Monteﬁore</text>
<text top="190" left="316" width="131" height="9" font="31">Adult Congenital Heart Disease</text>
<text top="202" left="307" width="149" height="9" font="31">Program; Albert Einstein College of</text>
<text top="214" left="300" width="37" height="9" font="31">Medicine</text>
<text top="213" left="337" width="126" height="12" font="31">—Associate Professor, Internal</text>
<text top="226" left="332" width="99" height="9" font="31">Medicine and Pediatrics</text>
<text top="166" left="510" width="22" height="9" font="31">None</text>
<text top="166" left="595" width="22" height="9" font="31">None</text>
<text top="166" left="658" width="22" height="9" font="31">None</text>
<text top="166" left="738" width="22" height="9" font="31">None</text>
<text top="166" left="851" width="22" height="9" font="31">None</text>
<text top="166" left="963" width="22" height="9" font="31">None</text>
<text top="245" left="60" width="91" height="9" font="31">Elisa Zaragoza-Macias</text>
<text top="245" left="188" width="74" height="9" font="31">Content Reviewer</text>
<text top="245" left="289" width="163" height="9" font="31">PeaceHealth North Cascade Cardiology</text>
<text top="244" left="452" width="7" height="12" font="31">—</text>
<text top="257" left="356" width="50" height="9" font="31">Cardiologist</text>
<text top="245" left="510" width="22" height="9" font="31">None</text>
<text top="245" left="595" width="22" height="9" font="31">None</text>
<text top="245" left="658" width="22" height="9" font="31">None</text>
<text top="245" left="738" width="22" height="9" font="31">None</text>
<text top="245" left="851" width="22" height="9" font="31">None</text>
<text top="245" left="963" width="22" height="9" font="31">None</text>
<text top="281" left="60" width="783" height="8" font="34">This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant to this document. It does not necessarily re</text>
<text top="279" left="843" width="176" height="11" font="34">ﬂect relationships with industry at the time of</text>
<text top="293" left="60" width="177" height="8" font="34">publication. A person is deemed to have a signi</text>
<text top="291" left="237" width="781" height="11" font="34">ﬁcant interest in a business if the interest represents ownership of $5% of the voting stock or share of the business entity, or ownership of $$5,000 of the fair market value of the business entity; or if funds</text>
<text top="305" left="60" width="279" height="8" font="34">received by the person from the business entity exceed 5% of the person</text>
<text top="303" left="338" width="680" height="11" font="34">’s gross income for the previous year. A relationship is considered to be modest if it is less than signiﬁcant under the preceding deﬁnition. Relationships that exist with no ﬁnancial</text>
<text top="317" left="60" width="19" height="8" font="34">bene</text>
<text top="315" left="78" width="791" height="11" font="34">ﬁt are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Please refer to</text>
<text top="317" left="872" width="146" height="8" font="35"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">http://www.acc.org/guidelines/about-</a></text>
<text top="329" left="60" width="265" height="8" font="35"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">guidelines-and-clinical-documents/relationships-with-industry-policy</a></text>
<text top="329" left="328" width="23" height="8" font="34">for de</text>
<text top="327" left="351" width="466" height="11" font="34">ﬁnitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.</text>
<text top="341" left="60" width="26" height="8" font="34">**Signi</text>
<text top="339" left="86" width="72" height="11" font="34">ﬁcant relationship.</text>
<text top="351" left="60" width="86" height="11" font="34">††No ﬁnancial beneﬁt.</text>
<text top="367" left="68" width="951" height="8" font="34">AATS indicates American Association for Thoracic Surgery; ACC, American College of Cardiology; AHA, American Heart Association; AIG, Assembly of International Governors; ASE, American Society of Echocardiography; DSMB, Data Safety Monitoring</text>
<text top="379" left="60" width="959" height="8" font="34">Board; HRS, Heart Rhythm Society; ISACHD, International Society for Adult Congenital Heart Disease; MAUDE, McGill Adult Unit for Congenital Heart Disease Excellence; SCAI, Society for Cardiovascular Angiography and Interventions; and STS, Society of</text>
<text top="391" left="60" width="184" height="8" font="34">Thoracic Surgeons; and UT, University of Texas.</text>
<text top="60" left="59" width="158" height="16" font="29">APPENDIX 2. CONTINUED</text>
<text top="57" left="1102" width="0" height="7" font="9">J</text>
<text top="63" left="1102" width="0" height="7" font="9">A</text>
<text top="69" left="1102" width="0" height="7" font="9">C</text>
<text top="76" left="1102" width="0" height="7" font="9">C</text>
<text top="86" left="1102" width="0" height="7" font="9">V</text>
<text top="92" left="1102" width="0" height="7" font="9">O</text>
<text top="99" left="1102" width="0" height="7" font="9">L</text>
<text top="105" left="1102" width="0" height="7" font="9">.</text>
<text top="112" left="1102" width="0" height="7" font="9">7</text>
<text top="117" left="1102" width="0" height="7" font="9">3</text>
<text top="123" left="1102" width="0" height="7" font="9">,N</text>
<text top="137" left="1102" width="0" height="7" font="9">O</text>
<text top="144" left="1102" width="0" height="7" font="9">.</text>
<text top="151" left="1102" width="0" height="7" font="9">1</text>
<text top="155" left="1102" width="0" height="7" font="9">2</text>
<text top="161" left="1102" width="0" height="7" font="9">,2</text>
<text top="173" left="1102" width="0" height="7" font="9">0</text>
<text top="180" left="1102" width="0" height="7" font="9">1</text>
<text top="184" left="1102" width="0" height="7" font="9">9</text>
<text top="703" left="1100" width="0" height="9" font="13">Stout</text>
<text top="728" left="1100" width="0" height="9" font="13">et</text>
<text top="739" left="1100" width="0" height="9" font="13">al</text>
<text top="747" left="1100" width="0" height="9" font="13">.</text>
<text top="57" left="1087" width="0" height="7" font="9">AP</text>
<text top="70" left="1087" width="0" height="7" font="9">RI</text>
<text top="80" left="1087" width="0" height="7" font="9">L</text>
<text top="89" left="1087" width="0" height="7" font="9">2</text>
<text top="95" left="1087" width="0" height="7" font="9">,</text>
<text top="102" left="1087" width="0" height="7" font="9">2</text>
<text top="108" left="1087" width="0" height="7" font="9">01</text>
<text top="118" left="1087" width="0" height="7" font="9">9</text>
<text top="124" left="1087" width="0" height="7" font="9">:</text>
<text top="127" left="1087" width="0" height="7" font="9">1</text>
<text top="131" left="1087" width="0" height="7" font="9">4</text>
<text top="137" left="1087" width="0" height="7" font="9">9</text>
<text top="143" left="1087" width="0" height="7" font="9">4</text>
<text top="148" left="1087" width="0" height="10" font="9">–</text>
<text top="155" left="1087" width="0" height="7" font="9">563</text>
<text top="572" left="1085" width="0" height="9" font="13">2018</text>
<text top="596" left="1085" width="0" height="9" font="13">ACHD</text>
<text top="623" left="1085" width="0" height="9" font="13">Guideline:</text>
<text top="668" left="1085" width="0" height="9" font="13">Executive</text>
<text top="711" left="1085" width="0" height="9" font="13">Summary</text>
<text top="782" left="1101" width="0" height="9" font="5">1563</text>
</page>
<outline>
<item page="1">2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary</item>
<outline>
<item page="2">Table of Contents</item>
<item page="3">Preamble</item>
<outline>
<item page="3">Intended Use</item>
<item page="3">Clinical Implementation</item>
<item page="3">Methodology and Modernization</item>
<item page="4">Selection of Writing Committee Members</item>
<item page="4">Relationships With Industry and Other Entities</item>
<item page="4">Evidence Review and Evidence Review Committees</item>
<item page="4">Guideline-Directed Management and Therapy</item>
<item page="4">Class of Recommendation and Level of Evidence</item>
</outline>
<item page="5">1. Introduction</item>
<outline>
<item page="5">1.1. Methodology and Evidence Review</item>
<item page="6">1.2. Organization of the Writing Committee</item>
<item page="6">1.3. Document Review and Approval</item>
<item page="6">1.4. Scope of the Guideline</item>
<item page="7">1.5. Abbreviations</item>
</outline>
<item page="9">2. Background and Pathophysiology</item>
<outline>
<item page="9">2.1. Anatomic and Physiological Terms</item>
<item page="9">2.2. Severity of ACHD</item>
<item page="9">2.3. The ACHD AP Classification</item>
</outline>
<item page="11">3. General Principles</item>
<outline>
<item page="11">3.1. ACHD Program</item>
<item page="12">3.2. Access to Care</item>
<item page="12">3.3. Delivery of Care</item>
<item page="14">3.4. Evaluation of Suspected and Known CHD</item>
<outline>
<item page="14">3.4.1. Electrocardiogram</item>
<item page="15">3.4.2. Ionizing Radiation Principles</item>
<item page="15">3.4.3. Echocardiography</item>
<item page="15">3.4.4. CMR Imaging</item>
<item page="16">3.4.5. Cardiac Computed Tomography</item>
<item page="16">3.4.6. Cardiac Catheterization</item>
<item page="17">3.4.7. Exercise Testing</item>
</outline>
<item page="17">3.5. Transition Education</item>
<item page="17">3.6. Exercise and Sports</item>
<item page="17">3.7. Mental Health and Neurodevelopmental Issues</item>
<item page="18">3.8. Endocarditis Prevention</item>
<item page="18">3.9. Concomitant Syndromes</item>
<item page="19">3.10. Noncardiac Medical Issues</item>
<item page="19">3.11. Noncardiac Surgery</item>
<item page="20">3.12. Pregnancy, Reproduction, and Sexual Health</item>
<outline>
<item page="20">3.12.1. Pregnancy</item>
<item page="20">3.12.2. Contraception</item>
</outline>
<item page="20">3.13. Heart Failure and Transplant</item>
<outline>
<item page="20">3.13.1. Heart Failure</item>
<item page="21">3.13.2. Heart Transplant</item>
</outline>
<item page="21">3.14. Palliative Care</item>
<item page="21">3.15. Cyanosis</item>
<item page="22">3.16. Pharmacological Therapy for ACHD</item>
</outline>
<item page="22">4. Specific Lesions</item>
<outline>
<item page="22">4.1. Shunt Lesions</item>
<outline>
<item page="22">4.1.1. Atrial Septal Defect</item>
<item page="24">4.1.2. Anomalous Pulmonary Venous Connections</item>
<item page="25">4.1.3. Ventricular Septal Defect</item>
<item page="27">4.1.4. Atrioventricular Septal Defect</item>
<item page="27">4.1.5. Patent Ductus Arteriosus</item>
</outline>
<item page="28">4.2. Left-Sided Obstructive Lesions</item>
<outline>
<item page="28">4.2.1. Cor Triatriatum</item>
<item page="29">4.2.2. Congenital Mitral Stenosis</item>
<item page="29">4.2.3. Subaortic Stenosis</item>
<item page="30">4.2.4. Congenital Valvular Aortic Stenosis</item>
<item page="30">4.2.4.1. Turner Syndrome</item>
<item page="31">4.2.5. Supravalvular Aortic Stenosis</item>
<item page="32">4.2.6. Coarctation of the Aorta</item>
</outline>
<item page="33">4.3. Right-Sided Lesions</item>
<outline>
<item page="33">4.3.1. Valvular Pulmonary Stenosis</item>
<item page="33">4.3.1.1. Isolated PR After Repair of PS</item>
<item page="35">4.3.2. Branch and Peripheral Pulmonary Stenosis</item>
<item page="35">4.3.3. Double-Chambered Right Ventricle</item>
<item page="36">4.3.4. Ebstein Anomaly</item>
<item page="37">4.3.5. Tetralogy of Fallot</item>
<item page="40">4.3.6. Right Ventricle–to-Pulmonary Artery Conduit</item>
</outline>
<item page="41">4.4. Complex Lesions</item>
<outline>
<item page="41">4.4.1. Transposition of the Great Arteries</item>
<item page="41">4.4.1.1. Transposition of the Great Arteries With Atrial Switch</item>
<item page="42">4.4.1.2. Transposition of the Great Arteries With Arterial Switch</item>
<item page="43">4.4.1.3. Congenitally Corrected Transposition of the Great Arteries</item>
<item page="44">4.4.2. Fontan Palliation of Single Ventricle Physiology (Including Tricuspid Atresia and Double Inlet Left Ventricle)</item>
<item page="45">4.4.3. Double Outlet Right Ventricle</item>
<item page="45">4.4.4. Severe PAH and Eisenmenger Syndrome</item>
<item page="45">4.4.4.1. Severe PAH</item>
<item page="46">4.4.4.2. Eisenmenger Syndrome</item>
<item page="47">4.4.5. Coronary Anomalies</item>
<item page="47">4.4.5.1. Anomalous Coronary Artery Evaluation</item>
<item page="48">4.4.5.2. Anomalous Aortic Origin of Coronary Artery</item>
<item page="49">4.4.5.3. Anomalous Coronary Artery Arising From the PA</item>
</outline>
</outline>
<item page="49">5. Evidence Gaps and Future Directions</item>
<item page="50">Presidents and Staff</item>
<item page="51">References</item>
<item page="51">Preamble</item>
<item page="51">1. Introduction</item>
<item page="52">2. Background and Pathophysiology</item>
<item page="53">3. General Principles</item>
<item page="57">4. Specific Lesions</item>
</outline>
</outline>
</pdf2xml>
